

**Funding Opportunities Monthly Edition
February 2021 Due Dates**

Introduction

This funding opportunity packet contains information on funding opportunities with deadlines in February 2021. The opportunities are organized in the following order:

1. [National Institutes of Health \(NIH\)](#)
2. [National Science Foundation \(NSF\)](#)
3. [Other Federal](#)
4. [Non Federal](#)

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
097362	RFA-RM-20-015 -- Harnessing Data Science for Health Discovery and Innovation in Africa (DS-I Africa) Research Hubs (U54–Clinical Trial Optional)	Fogarty International Center/NIH/DHHS	RFA-RM-20-015	08-Feb-2021	6,500,000 USD
	<p>Contact Name Brad Newsome, Ph.D.</p> <p>Contact Telephone 301-480-8389</p> <p>Contact Email brad.newsome@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Feb-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) seeks applications for Research Hubs as part of a broader initiative entitled Harnessing Data Science for Health Discovery and Innovation in Africa (DS-I Africa). The goal of DS-I Africa is to spur new health discoveries and catalyze innovation in healthcare, public health, and health research on the continent through application of data science. DS-I Africa Research Hubs will be funded to advance data science health research and innovation in Africa and support new African and global partnerships that enhance the impact of data science health research. Hubs will engage government, industry, or other organizations, including diverse departments from academic institutions, that can partner to provide synergistic expertise, collaborate on research, and support data science linked to new technologies and solutions. Applicants must propose at least 2 distinct research projects and a system for soliciting, evaluating, and awarding smaller pilots projects, all focused on a central health theme that addresses priorities in an African country or region. Applications must be submitted from African academic or other non-profit organizations. Proposed partnerships with organizations outside the applicant institution are required and can include all types of organizations in Africa, the U.S., or other countries.</p>				
077911	Mechanisms of Disparities in Etiology and Outcomes of Lung Cancer in the U.S.: The Role of Risk and Protective Factors (R21 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PA-19-019	04-Feb-2021 [Optional][LOI/Pre-App]	275,000 USD
	<p>Contact Name Crystal Wolfrey</p> <p>Contact Telephone 240-276-6277</p> <p>Contact Email Crystal.wolfrey@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 04-Feb-2021 [Optional][LOI/Pre-App], 04-Mar-2021</p> <p>Synopsis National Cancer Institute (NCI) invites applications that will support exploratory and developmental multidisciplinary research to understand the underlying causal factors and mechanisms that result in lung cancer disparities in U.S. health disparity populations. This FOA will use the NIH Exploratory/Development Research Grant (R21) award mechanism. The purpose of this initiative is to promote multidisciplinary research to understand the underlying causal factors and mechanisms that result in lung cancer disparities in U.S. health disparity populations.</p>				
077905	Mechanisms of Disparities in Etiology and Outcomes of Lung Cancer in the U.S.: The Role of Risk and Protective Factors (R01 - Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PA-19-018	04-Feb-2021 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Crystal Wolfrey</p> <p>Contact Telephone 240-276-6277</p> <p>Contact Email Crystal.wolfrey@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 04-Feb-2021 [Optional][LOI/Pre-App], 04-Mar-2021</p> <p>Synopsis National Cancer Institute (NCI) invites applications that will support multidisciplinary research to understand the underlying causal factors and mechanisms that result in lung cancer disparities in U.S. health disparity populations. This FOA will use the NIH Research Project (R01) award mechanism. The purpose of this initiative is to promote multidisciplinary research to understand the underlying causal factors and mechanisms that result in lung cancer disparities in U.S. health disparity populations.</p>				
099075	Clinical Translation of Activated Optical Fluorescence Methods and Technologies for Sensitive Cancer Detection in Vivo (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-20-295	10-Feb-2021	2,500,000 USD
	<p>Contact Name Pushpa Tandon, PhD</p> <p>Contact Telephone 240 276 5971</p> <p>Contact Email tandonp@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Deadline Dates (ALL) | 10-Feb-2021 , 13-Oct-2021

Synopsis

The purpose of this Funding Opportunity Announcement (FOA) is to bring a highly sensitive imaging technology capable of detecting very small (1-3 mm³) tumors in vivo to clinical utility. Through this FOA, the National Cancer Institute (NCI) solicits innovative concepts that propose a path to clinical validation for in vivo ‘intelligent’ or activated optical fluorescence agents or probes with previously demonstrated capabilities for the detection of small tumors. Current imaging techniques are in use for non-invasive cancer detection, but clinical methods are limited to detecting masses several millimeters to centimeters in size. To image small primary or metastatic tumor sites composed of 10⁶ -10⁷ cells, imaging sensitivity must be improved. This can be achieved without significant hardware advances by improving the contrast between diseased and healthy tissue captured in the image. Thus, there is a clinical need for techniques that improve image contrast between tumors and surrounding normal tissue. There are several novel optical fluorescence methods that rely on the use of specialized agents that are activated when coupled to a tumor target. These activated agents dramatically increase the contrast between small tumor cell masses and surrounding tissue. Efforts to develop activated fluorescence imaging agents have been ongoing for over a decade. These developmental successes now need to be translated for clinical use. This FOA thus supports translation of novel activated optical fluorescence agents for sensitive cancer detection in vivo. Clinical translation and validation should be the primary goals of the proposed research. The bulk of the proposed research must focus on translating improvements in imaging sensitivity to a clinical environment with the goal of demonstrating that tumor cell aggregates on the order of 1 mm³ in volume can be visualized in vivo. However, minimal research toward development of the probe in preparation for clinical validation will be accepted under this FOA. This FOA thus supports translation of already developed technologies for small tumor detection in vivo. It is not intended to support continued development of novel agents or preclinical studies. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer Moonshot SM Initiative that is intended to accelerate cancer research. Specifically, this FOA falls under the scientific priority designated by the Blue-Ribbon Panel (BRP) as “Developing Cancer Technologies” (see <https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/implementation/new-technologies>).

079769	Biology of Bladder Cancer (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-184	05-Feb-2021	275,000 USD
--------	---	------------------------------------	------------	-------------	-------------

Contact Name | Ron Johnson, Ph. D.
 Contact Telephone | 240-276-6250
 Contact Email | rjohnso2@mail.nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	<p>Synopsis</p>	<p>This Funding Opportunity Announcement (FOA) seeks applications investigating the biology and underlying mechanisms of bladder cancer. Bladder cancer is a significant health problem both in the United States and globally. Because of the high incidence and frequent tumor recurrence, bladder cancer exacts an outsized medical burden. While recent progress has been made in the molecular profiling of bladder cancers and identification of mutated genes, relatively little is known regarding the molecular mechanisms driving initiation, progression, and malignancy of bladder cancer. Furthermore, our understanding of biological processes of the normal bladder at the molecular, cell and organ levels is limited. Fundamental knowledge of how molecular and cellular functions of the bladder are altered in cancer will aid our understanding of bladder cancer biology and interventions. Applications that involve multidisciplinary teams and use clinical specimens or investigate both normal and cancer processes are encouraged.</p>			
--	-----------------	---	--	--	--

070179	Using Information Technology to Support Systematic Screening and Treatment of Depression in Oncology Practices (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PA-18-493	05-Feb-2021	Not Specified
--------	--	------------------------------------	-----------	-------------	---------------

	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Gurvaneet S. Randhawa, M.D., MPH</p> <p>240-276-6940</p> <p>gurvaneet.randhawa@nih.gov</p> <p></p> <p>Link to program URL</p> <p>05-Feb-2021</p> <p>National Cancer Institute (NCI) invites applications to: identify new, information technology (IT)-enabled delivery models that support systematic screening and treatment of depression in cancer patients; test the feasibility of implementing these new delivery models in a variety of oncology practice settings, especially those serving under-served populations; test the effectiveness of these new delivery models, and their components, in a variety of oncology practice settings, especially those serving under-served populations; and evaluate the sustainability and scalability of these new delivery models. This FOA will use the NIH Research Project (R01) award mechanism.</p>			
--	---	---	--	--	--

079767	Biology of Bladder Cancer (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-183	05-Feb-2021	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p>	<p>Ron Johnson, Ph. D.</p> <p>240-276-6250</p> <p>rjohnso2@mail.nih.gov</p>			
--	---	--	--	--	--

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages applications investigating the biology and underlying mechanisms of bladder cancer. Bladder cancer is a significant health problem both in the United States and globally. Because of the high incidence and frequent tumor recurrence, bladder cancer exacts an outsized medical burden. While recent progress has been made in the molecular profiling of bladder cancers and identification of mutated genes, relatively little is known regarding the molecular mechanisms driving initiation, progression, and malignancy of bladder cancer. Furthermore, our understanding of biological processes of the normal bladder at the molecular, cell and organ levels is limited. Fundamental knowledge of how molecular and cellular functions of the bladder are altered in cancer will aid our understanding of bladder cancer biology and interventions. Applications that involve multidisciplinary teams and use clinical specimens or investigate both normal and cancer processes are encouraged.</p>				
097239	<p>Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)</p>	National Cancer Institute/NIH/DHHS	PAR-20-276	05-Feb-2021	1,750,000 USD
	<p>Contact Name Melissa Rotunno, Ph.D.</p> <p>Contact Telephone 240-276-7245</p> <p>Contact Email rotunnom@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022</p> <p>Synopsis Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) along with the National Human Genome Research Institute (NHGRI) and National Institute of Dental and Craniofacial Research (NIDCR) encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate the genetic architecture of cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.). The goal of this initiative is to address key scientific questions relevant to cancer genomics and epidemiology by supporting the analysis of existing genetic or genomic datasets, in combination with other omics and environmental, clinical, behavioral, lifestyle, and molecular profiles data. Applicants are encouraged to leverage existing genetic data and perform innovative analyses of the existing data.</p>				
073406	<p>Age-related Microbiota Changes and their Implications in Chronic</p>	National Cancer	PA-18-738	05-Feb-2021	Not

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Disease Prevention, Treatment and Progression (R01 Clinical Trial Optional)	Institute/NIH/DHHS			Specified
	<p>Contact Name: Gabriela Riscuta MD, CNS, MS</p> <p>Contact Telephone:</p> <p>Contact Email:</p> <p>Sponsor Website:</p> <p>Program URL: Link to program URL</p> <p>Deadline Dates (ALL): 05-Feb-2021</p> <p>Synopsis: National Institutes of Health (NIH) and its participating Institutes and Centers invite applications to assess the role of the microbiome in health and disease during aging. This initiative will support research projects designed to evaluate changes in the microbiota during lifetime and its influence in health and disease status in the elderly, including those from racial/ethnic minority and underserved populations and understand the underlying mechanisms of microbiota interactions in aged subjects as related to health and disease. This FOA will support basic mechanistic, preclinical studies in animal models and human clinical trial proposals in accordance with the state of the science. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
079077	Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-113	05-Feb-2021	2,000,000 USD
	<p>Contact Name: Nastaran Z. Kuhn, Ph.D.</p> <p>Contact Telephone: 240-276-7610</p> <p>Contact Email: nas.zahir@nih.gov</p> <p>Sponsor Website:</p> <p>Program URL: Link to program URL</p> <p>Deadline Dates (ALL): 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021</p> <p>Synopsis: This Funding Opportunity Announcement (FOA) will support the development and characterization of state-of-the-art biomimetic tissue-engineered technologies for cancer research. Collaborative, multidisciplinary projects that engage the fields of regenerative medicine, tissue engineering, biomaterials, and bioengineering with cancer biology will be essential for generating novel experimental models that mimic cancer pathophysiology in the context of a testable cancer research hypothesis. The projects supported by this FOA will collectively participate in the Cancer Tissue Engineering Collaborative</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>(TEC) Research Program. The Cancer TEC Program will (1) catalyze the advancement of innovative, well characterized in vitro and ex vivo systems available for cancer research, (2) expand the breadth of these systems to several cancer types, and (3) promote the exploration of cancer phenomena with biomimetic tissue-engineered systems.</p>				
090364	Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-20-131	05-Feb-2021	1,350,000 USD
	<p>Contact Name: Joanna Watson, Ph.D. Contact Telephone: 240-276-6230 Contact Email: Joanna.Watson@nih.gov Sponsor Website: Program URL: Link to program URL Deadline Dates (ALL): 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023</p> <p>Synopsis: The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for projects to expand, improve, or transform the utility of mammalian cancer and tumor models for translational research. With this FOA, the NCI intends to encourage submission of projects devoted to demonstrating that mammalian models or their derivatives used for translational research are robust representations of human biology, are appropriate to test questions of clinical importance, and provide reliable information for patients' benefit. These practical goals contrast with the goals of many mechanistic, NCI-supported R01 projects that use mammals, or develop and use mammalian cancer models, transplantation tumor models, or models derived from mammalian or human tissues or cells for hypothesis-testing, non-clinical research. Among many other possible endeavors, applicants in response to this FOA could propose demonstrations of how to overcome translational deficiencies of mammalian oncology models, define new uses of mammalian models or their genetics for unexplored translational challenges, advance standard practices for use of translational models, test approaches to validate and credential models, or challenge current practices for how models are used translationally.</p>				
084505	Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-325	11-Feb-2021	Not Specified
	<p>Contact Name: Kelly Filipski PhD, MPH Contact Telephone: 240-276-6841 Contact Email: Filipskikk@mail.nih.gov Sponsor Website:</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-Feb-2021 , 20-Sep-2021 , 11-Feb-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative research projects designed to address adverse sequelae of cancer therapies that persist and become chronic comorbidities or develop as delayed posttreatment effects. This FOA supports basic, translational, and/or clinical research projects that seek to identify the mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, or translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae. Research projects should focus on 1) mechanistic studies with translational endpoints; and/or 2) longitudinal clinical phenotyping to identify and validate clinical endpoints (biomarkers, imaging, patient-reported outcomes, or combined elements) for future use in clinical trials that will evaluate the efficacy of interventions designed to prevent or reduce specific adverse sequelae.</p>				
087000	Program to Assess the Rigor and Reproducibility of Extracellular Vesicle-Derived Analytes for Cancer Detection (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-20-053	05-Feb-2021	Not Specified
	<p>Contact Name Sudhir Srivastava, Ph.D., M.P.H.</p> <p>Contact Telephone 240-276-7028</p> <p>Contact Email svrivasts@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022 , 05-Oct-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages research projects that focus on innovative research in the isolation and characterization of extracellular vesicles (EVs) and their cargo for discovery of predictive biomarkers for risk assessment, detection, diagnosis and prognosis of early cancer. This FOA will promote rigor and reproducibility research in both the isolation of EVs as well as the computational analysis of the cargo carried in these vesicles.</p>				
086487	Fundamental Mechanisms of Affective and Decisional Processes in Cancer Control (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-20-034	05-Feb-2021	Not Specified
	<p>Contact Name Rebecca A Ferrer, Ph.D.</p> <p>Contact Telephone 240-276-6963</p> <p>Contact Email ferrerra@mail.nih.gov</p> <p>Sponsor Website</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022 , 05-Oct-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage projects to generate fundamental knowledge of affective processes. Basic affective science projects should have key consequences for single (e.g., cancer screening) and multiple (e.g., adherence to oral chemotherapy regimen) event decisions and behaviors across the cancer prevention and control continuum. The FOA is expected to encourage collaboration among cancer control researchers and those from scientific disciplines not traditionally connected to cancer control applications (e.g., affective and cognitive neuroscience, decision science, consumer science) to elucidate perplexing and understudied problems in affective and decision sciences with downstream implications for cancer prevention and control.</p>				
086149	Perception and Cognition Research to Inform Cancer Image Interpretation (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-387	05-Feb-2021	Not Specified
	<p>Contact Name Todd S. Horowitz, Ph.D.</p> <p>Contact Telephone 240-276-6963</p> <p>Contact Email todd.horowitz@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022 , 05-Oct-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to facilitate research on the perceptual and cognitive processes underlying the performance of cancer image observers in radiology and pathology, in order to improve the accuracy of cancer detection and diagnosis.</p>				
072431	Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 - Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PA-18-677	05-Feb-2021	Not Specified
	<p>Contact Name Tram Kim Lam, Ph.D., MPH</p> <p>Contact Telephone 240-276-6967</p> <p>Contact Email Tram.Lam@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	National Cancer Institute (NCI) invites applications for epidemiologic research investigating novel and innovative hypotheses on emerging risk factors (biological, environmental, and social) and their interplay with established risk factors (e.g., viral hepatitis) associated with the development of liver cancer (hepatocellular carcinoma and other histological subtypes) in the United States. This FOA will use the NIH Research Project (R01) award mechanism.			
085330	Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-360	05-Feb-2021	Not Specified
	Contact Name	Sarah Kobrin, Ph.D., MPH			
	Contact Telephone	240-276-6931			
	Contact Email	kobrins@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022			
	Synopsis	This Funding Opportunity Announcement (FOA) encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting, can all affect whether a provider makes a recommendation, and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare delivery.			
085257	Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-352	05-Feb-2021	Not Specified
	Contact Name	Michelle Mollica, PhD, MPH, RN, OCN			
	Contact Telephone	240-276-7621			
	Contact Email	michelle.mollica@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022			
	Synopsis	This Funding Opportunity Announcement (FOA) invites applications for intervention research designed to support caregivers of adult cancer patients. Interventions supported by this FOA are intended to provide caregivers with care training, promote			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>coping skills, and ultimately help them manage care. Outcomes of such interventions are expected to (1) optimize patient health care utilization, (2) improve caregiver well-being, and (3) improve patient physical health and psychosocial outcomes.</p>			
100261	Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-20-313	18-Feb-2021	1,025,000 USD
	Contact Name	Tracy G. Lively, Ph.D.			
	Contact Telephone	240-276-5944			
	Contact Email	livelyt@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	18-Feb-2021 , 09-Jul-2021 , 08-Oct-2021 , 14-Feb-2022 , 11-Jun-2022 , 11-Oct-2022 , 14-Feb-2023 , 10-Jul-2023 , 10-Oct-2023			
	Synopsis	<p>Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications to support the validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA will support investigator-initiated research for both analytical, and clinical validation of assays to be used in cancer treatment, control, or prevention trials supported by the NCI. This FOA will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants should have assays that work on human samples and whose importance is well justified for development into clinical assays. As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance durability of anti-cancer responses, assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously. The UH2 phase of this FOA supports analytical validation of assays for these molecular/cellular/imaging markers, which must be achieved within 2 years before assays may undergo clinical validation. The UH3 phase of this FOA supports clinical validation of analytically validated assays for up to 3 years using well-annotated biospecimens from retrospective or prospective clinical trials or studies. This FOA may be used to validate existing assays for use in other cancer clinical trials, observational studies, or population studies. Efforts to harmonize clinical laboratory tests, including investigation into the performance and reproducibility of assays across multiple clinical laboratories, are also appropriate for this funding opportunity. Projects proposed for this FOA will require multi-disciplinary interaction and collaboration among scientific investigators, oncologists, statisticians, and clinical laboratory scientists. This FOA is not intended to support early-stage development of technology or the conduct of clinical trials but is intended for validation of assays to the point where they could be integrated into clinical trials/studies as investigational assays. Investigators responding to this FOA must address both UH2 and UH3 phases. Milestones to be accomplished in the UH2 phase for transition to the UH3 phase must be proposed by the investigators.</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
100262	Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-20-314	18-Feb-2021	750,000 USD
	<p>Contact Name Tracy G. Lively, Ph.D.</p> <p>Contact Telephone 240-276-5944</p> <p>Contact Email livelyt@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 18-Feb-2021 , 09-Jul-2021 , 08-Oct-2021 , 14-Feb-2022 , 11-Jun-2022 , 11-Oct-2022 , 14-Feb-2023 , 10-Jul-2023 , 10-Oct-2023</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the adoption and validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants to this FOA must have an assay(s) whose performance has been analytically validated in specimens similar to those for the intended clinical use of the marker(s) and assay(s). As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance the durability of anti-cancer responses, assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously. The UH3 mechanism will support the clinical validation of established assays for up to 3 years using specimens from retrospective or prospective clinical trials or studies. This FOA may be used to validate existing assays for use in other trials, observational studies, or population studies. Efforts to harmonize clinical laboratory tests, including investigation into the performance and reproducibility of assays across multiple clinical laboratories, are also appropriate for this funding opportunity. Projects proposed for this FOA will require multi-disciplinary interaction and collaboration among scientific investigators, oncologists, statisticians, and clinical laboratory scientists. This FOA is not intended to support early-stage development of technology or the conduct of clinical trials but is intended for validation of assays to the point where they could be integrated into clinical trials/studies as investigational assays.</p>				
086150	Perception and Cognition Research to Inform Cancer Image Interpretation (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-389	16-Feb-2021	400,000 USD
	<p>Contact Name Todd S. Horowitz, Ph.D.</p> <p>Contact Telephone 240-276-6963</p> <p>Contact Email todd.horowitz@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022 , 16-Oct-2022			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to facilitate research on the perceptual and cognitive processes underlying the performance of cancer image observers in radiology and pathology, in order to improve the accuracy of cancer detection and diagnosis.			
070181	Using Information Technology to Support Systematic Screening and Treatment of Depression in Oncology Practices (R21Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PA-18-492	16-Feb-2021	275,000 USD
	Contact Name	Gurvaneet S. Randhawa, M.D., MPH			
	Contact Telephone	240-276-6940			
	Contact Email	gurvaneet.randhawa@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Feb-2021			
	Synopsis	National Cancer Institute (NCI) invites applications to: identify new, information technology (IT)-enabled delivery models that support systematic screening and treatment of depression in cancer patients; test the feasibility of implementing these new delivery models in a variety of oncology practice settings, especially those serving under-served populations; and test the usability and potential effectiveness of the IT-specific components of these new delivery models. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.			
070114	NCI Transition Career Development Award (K22 Independent Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-18-467	12-Feb-2021	450,000 USD
	Contact Name	Sonia Jakowlew, Ph.D., Program Director			
	Contact Telephone	240-276-5630			
	Contact Email	jakowles@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	12-Feb-2021			
	Synopsis	National Cancer Institute (NCI) provides support to facilitate the transition of investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions. This goal is achieved by providing protected time			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

through salary and research support for the initial 3 years of the first independent tenure-track faculty position, or its equivalent, beginning at the time when the candidate starts a tenure-track faculty position. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. This program will use the NIH K22 Career Transition Award mechanism.

085337	Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-358	16-Feb-2021	275,000 USD
--------	--	------------------------------------	------------	-------------	-------------

Contact Name	Sarah Kobrin, Ph.D., MPH
Contact Telephone	240-276-6931
Contact Email	kobrins@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022
Synopsis	This Funding Opportunity Announcement (FOA) encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting, can all affect whether a provider makes a recommendation, and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare delivery.

085343	Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R03 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-359	16-Feb-2021	100,000 USD
--------	--	------------------------------------	------------	-------------	-------------

Contact Name	Sarah Kobrin, Ph.D., MPH
Contact Telephone	240-276-6931
Contact Email	kobrins@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022
Synopsis	This Funding Opportunity Announcement (FOA) encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine.

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		Characteristics of the provider, parent/patient, and clinical setting, can all affect whether a provider makes a recommendation and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare delivery.			
085275	Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-355	16-Feb-2021	275,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Michelle Mollica, PhD, MPH, RN, OCN 240-276-7621 michelle.mollica@nih.gov Link to program URL 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022 This Funding Opportunity Announcement (FOA) invites applications for intervention research designed to support caregivers of adult cancer patients. Interventions supported by this FOA are intended to provide caregivers with care training, promote coping skills, and ultimately help them manage care. Outcomes of such interventions are expected to (1) optimize patient health care utilization, (2) improve caregiver well-being, and (3) improve patient physical health and psychosocial outcomes			
072031	Exploratory/Developmental Grants Program for Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-18-655	18-Feb-2021	275,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Jennifer Isaacs, Ph.D. 240-276-6251 jennifer.isaacs@nih.gov Link to program URL 18-Feb-2021 National Cancer Institute (NCI) invites applications from investigators interested in conducting basic research studies into the biological/genetic causes and mechanisms of cancer health disparities. These awards will support pilot and feasibility studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, (2) the development and testing of new methodologies and models, and (3) secondary			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>data analyses. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models and methods that are necessary to conduct basic research in cancer health disparities. In addition, the FOA will further the development of scientific areas, providing support for early-stage exploratory projects that lead to future in-depth mechanistic studies (such as R01 projects) of the biology of cancer health disparities. This FOA will use the NIH R21 Exploratory/Developmental Research award mechanism.</p>				
072029	Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-18-654	08-Feb-2021	Not Specified
	<p>Contact Name Jennifer Isaacs, Ph.D. Contact Telephone 240-276-6251 Contact Email jennifer.isaacs@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 08-Feb-2021</p> <p>Synopsis National Cancer Institute (NCI) invites applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants (R01) will support innovative studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models, and methods that are necessary to conduct basic research in cancer health disparities. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
100707	National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)	National Cancer Institute/NIH/DHHS	PAR-21-033	05-Feb-2021	2,499,995 USD
	<p>Contact Name Lori A. Henderson, Ph.D. Contact Telephone 240-276-5930 Contact Email hendersonlori@mail.nih.gov</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to seek research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of the National Cancer Institute's (NCI) Division of Cancer Treatment and Diagnosis (DCTD) and the Office of HIV and AIDS Malignancies (OHAM, Office of the Director). Applicants are strongly encouraged to consult the NCI DCTD website and/or the OHAM website to learn more about the various program goals, research priorities, and strategies developed to fight cancer. Applications submitted to this FOA must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trial information as described in this FOA. This FOA does not accept phase III clinical trials in any area of cancer research; therefore, applications that propose phase III clinical trials will be deemed non-responsive and will not be reviewed.			
100708	Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)	National Cancer Institute/NIH/DHHS	PAR-21-035	05-Feb-2021	Not Specified
	Contact Name	Brandy Heckman-Stoddard, Ph.D., M.P.H.			
	Contact Telephone	240-276-7048			
	Contact Email	heckmanbm@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024			
	Synopsis	Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for support of investigator-initiated clinical trials related to the programmatic interests of the NCI Division of Cancer Prevention and/or the NCI Division of Cancer Control and Population Sciences that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health. Applications submitted to this FOA must include studies that meet the National Institutes of			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Health (NIH) definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trial information as described in this FOA and the application instructions. This FOA does not and will not support clinical trials for studies of cancer diagnosis and/or oncologic therapy in patients.

100855	RFA-CA-21-004 -- Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	RFA-CA-21-004	23-Jan-2021 [Optional][LOI/Pre-App]	900,000 USD
--------	---	------------------------------------	---------------	--	----------------

Contact Name	Tony Dickherber, Ph.D., Program Director
Contact Telephone	301-547-9980
Contact Email	dickherberaj@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	23-Jan-2021 [Optional][LOI/Pre-App], 22-Feb-2021 , 27-Apr-2021 [Optional][LOI/Pre-App], 27-May-2021 , 30-Aug-2021 [Optional][LOI/Pre-App], 29-Sep-2021
Synopsis	This Funding Opportunity Announcement (FOA) invites grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic or clinical cancer research. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

100854	RFA-CA-21-003 -- Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	RFA-CA-21-003	23-Jan-2021 [Optional][LOI/Pre-App]	400,000 USD
--------	--	------------------------------------	---------------	--	----------------

Contact Name	Tony Dickherber, Ph.D., Program Director
Contact Telephone	301-547-9980

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email dickherberaj@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 23-Jan-2021 [Optional][LOI/Pre-App], 22-Feb-2021 , 27-Apr-2021 [Optional][LOI/Pre-App], 27-May-2021 , 30-Aug-2021 [Optional][LOI/Pre-App], 29-Sep-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic or clinical cancer research. The emphasis of this FOA is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer biology. Projects proposing the application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.</p>				
099631	Tobacco Control Policies to Promote Health Equity (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-20-303	16-Feb-2021	275,000 USD
	<p>Contact Name Bob Vollinger, DrPH, MSPH</p> <p>Contact Telephone 240-276-6919</p> <p>Contact Email Bob.Vollinger@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022 , 16-Oct-2022 , 16-Feb-2023 , 16-Jun-2023</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support observational or intervention research focused on reducing disparities in tobacco use and secondhand smoke (SHS) exposure in the U.S. Specifically, this FOA aims to stimulate scientific inquiry focused on innovative state and local level tobacco prevention and control policies. The long-term goal of this FOA is to reduce disparities in tobacco-related cancers, and in doing so, to promote health equity among all populations. Applicants submitting applications related to health economics are encouraged to consult NOT-OD-16-025 to ensure that the research projects align with NIH mission priorities in health economics research.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
099622	Tobacco Control Policies to Promote Health Equity (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-20-302	05-Feb-2021	Not Specified
	Contact Name	Bob Vollinger, DrPH, MSPH			
	Contact Telephone	240-276-6919			
	Contact Email	Bob.Vollinger@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023			
	Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to support observational or intervention research focused on reducing disparities in tobacco use and secondhand smoke (SHS) exposure in the U.S. Specifically, this FOA aims to stimulate scientific inquiry focused on innovative state and local level tobacco prevention and control policies. The long-term goal of this FOA is to reduce disparities in tobacco-related cancers, and in doing so, to promote health equity among all populations. Applicants submitting applications related to health economics are encouraged to consult NOT-OD-16-025 to ensure that the research projects align with NIH mission priorities in health economics research.</p>			
100856	RFA-CA-21-005 -- Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R21 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	RFA-CA-21-005	23-Jan-2021 [Optional][LOI/Pre-App]	400,000 USD
	Contact Name	Tony Dickherber, Ph.D., Program Director			
	Contact Telephone	301-547-9980			
	Contact Email	dickherberaj@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	23-Jan-2021 [Optional][LOI/Pre-App], 22-Feb-2021 , 27-Apr-2021 [Optional][LOI/Pre-App], 27-May-2021 , 30-Aug-2021 [Optional][LOI/Pre-App], 29-Sep-2021			
	Synopsis	<p>This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices,</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection, and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.			
100859	RFA-CA-21-006 -- Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	RFA-CA-21-006	23-Jan-2021 [Optional][LOI/Pre-App]	900,000 USD
	Contact Name	Tony Dickherber, Ph.D., Program Director			
	Contact Telephone	301-547-9980			
	Contact Email	dickherberaj@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	23-Jan-2021 [Optional][LOI/Pre-App], 22-Feb-2021 , 27-Apr-2021 [Optional][LOI/Pre-App], 27-May-2021 , 30-Aug-2021 [Optional][LOI/Pre-App], 29-Sep-2021			
	Synopsis	This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still require further development and rigorous validation to encourage adoption by the research community. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. Projects proposing to use existing technologies where the novelty resides in the application of the technology or the biological or clinical question being pursued, and not the technical capabilities			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

being developed, are not appropriate for this FOA and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

100903	RFA-CA-21-007 -- Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-CA-21-007	23-Jan-2021 [Optional][LOI/Pre-App]	150,000 USD
--------	--	------------------------------------	---------------	--	----------------

Contact Name	Tony Dickherber, Ph.D.
Contact Telephone	301-547-9980
Contact Email	dickherberaj@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	23-Jan-2021 [Optional][LOI/Pre-App], 22-Feb-2021 , 27-Apr-2021 [Optional][LOI/Pre-App], 27-May-2021 , 30-Aug-2021 [Optional][LOI/Pre-App], 29-Sep-2021
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI R01 research projects. The applicants should propose to expand upon the original research question(s) or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the adoption of these emerging technologies by appropriate research communities. As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.

100905	RFA-CA-21-008 -- Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-CA-21-008	23-Jan-2021 [Optional][LOI/Pre-App]	150,000 USD
--------	--	------------------------------------	---------------	--	----------------

Contact Name	Tony Dickherber, Ph.D.
Contact Telephone	301-547-9980
Contact Email	dickherberaj@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	23-Jan-2021 [Optional][LOI/Pre-App], 22-Feb-2021 , 27-Apr-2021 [Optional][LOI/Pre-App], 27-May-2021 , 30-Aug-2021

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	<p>Synopsis</p>	<p>[Optional][LOI/Pre-App], 29-Sep-2021</p> <p>The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI U01 research projects. The applicants should propose to expand upon the original research question(s) or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities. As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.</p>			
100913	<p>RFA-CA-21-010 -- Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U2C Clinical Trial Optional)</p>	<p>National Cancer Institute/NIH/DHHS</p>	<p>RFA-CA-21-010</p>	<p>23-Jan-2021 [Optional][LOI/Pre-App]</p>	<p>150,000 USD</p>

	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Tony Dickherber, Ph.D.</p> <p>301-547-9980</p> <p>dickherberaj@mail.nih.gov</p> <p></p> <p>Link to program URL</p> <p>23-Jan-2021 [Optional][LOI/Pre-App], 22-Feb-2021 , 27-Apr-2021 [Optional][LOI/Pre-App], 27-May-2021 , 30-Aug-2021 [Optional][LOI/Pre-App], 29-Sep-2021</p> <p>The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI U2C Resource-Related Multi-Component Projects and Centers proposing to expand upon original research question(s) from specific projects or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities. As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.</p>			
--	---	--	--	--	--

079067	<p>Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R01 Clinical Trial Optional)</p>	<p>National Cancer Institute/NIH/DHHS</p>	<p>PA-19-112</p>	<p>05-Feb-2021</p>	<p>Not Specified</p>
	<p>Contact Name</p>	<p>Nonniekaye Shelburne, MS, CRNP, AOCN</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 240-276-6897</p> <p>Contact Email nshelburne@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages collaborative applications that will contribute to the identification and characterization of patients at risk of developing cancer treatment-related cardiotoxicity. The primary intent is to mitigate cardiovascular dysfunction while optimizing cancer outcomes. To accomplish this, methods that evaluate cardiovascular risk prior to treatment and integrate evidence-based cancer treatment regimens with cardiovascular screening, diagnostic, and/or management strategies are sought. Research applications should focus on mitigation/management of adverse effects associated with anti-cancer treatments including: cytotoxic chemotherapies, targeted agents, immunomodulatory therapies and radiation (that occur during cancer treatment and/or long-term survivorship) as defined by cardiac and/or vascular specific common terminology criteria for adverse events (CTCAE).</p>				
087228	Co-infection and Cancer (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-20-062	05-Feb-2021	Not Specified
	<p>Contact Name Tram Kim Lam, Ph.D., MPH</p> <p>Contact Telephone 240-276-6967</p> <p>Contact Email lamt@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022 , 05-Oct-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents – either concurrently or sequentially – and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and of co-infections that engender novel opportunities for prevention and treatment</p>				
087229	Co-infection and Cancer (R21 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-20-061	16-Feb-2021	275,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Tram Kim Lam, Ph.D., MPH</p> <p>Contact Telephone 240-276-6967</p> <p>Contact Email lamt@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022 , 16-Oct-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents – either concurrently or sequentially – and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and of co-infections that engender novel opportunities for prevention and treatment.</p>				
077311	<p>Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)</p>	National Cancer Institute/NIH/DHHS	PAR-18-913	11-Feb-2021	Not Specified
	<p>Contact Name Claire Zhu, Ph.D.</p> <p>Contact Telephone 240-276-7013</p> <p>Contact Email zhucla@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-Feb-2021 , 11-Aug-2021</p> <p>Synopsis National Cancer Institute (NCI) invites applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO screened arm participants, and a onetime collection of buccal cells from the control arm participants. Available data associated with the biospecimens includes demographic, diet, lifestyle, smoking, screening results, and clinical data. This FOA supports a wide range of cancer research including, but not limited to, biochemical and genetic analyses of cancer risk, as well as discovery and validation of early detection biomarkers. The proposed research project must involve use of PLCO biospecimens; additionally, it should also take advantage of the unique characteristics of</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

the PLCO biospecimens. Research projects that do not involve the use of PLCO biospecimens will not be supported under this FOA. This program will use the NIH U01 Research Project Cooperative Agreements award mechanism.

080137	Tobacco Regulatory Science (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-OD-19-019	13-Feb-2021	900,000 USD
--------	--	------------------------------------	---------------	-------------	-------------

Contact Name | Rachel Grana Mayne, PhD
 Contact Telephone | 240-276-5899
 Contact Email | granar@nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 13-Feb-2021

Synopsis | The purpose of this Funding Opportunity Announcement (FOA) is to invite R01 applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). The awards under this FOA will be administered by NIH using funds that have been made available through FDA CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health.

101128	RFA-CA-21-002 -- Cellular Cancer Biology Imaging Research (CCBIR) Program (U54, Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	RFA-CA-21-002	16-Feb-2021 [Optional][LOI/Pre-App]	6,250,000 USD
--------	---	------------------------------------	---------------	-------------------------------------	---------------

Contact Name | Nastaran Zahir, Ph.D.
 Contact Telephone | 240-276-6333
 Contact Email | nas.zahir@nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 16-Feb-2021 [Optional][LOI/Pre-App], 18-Mar-2021

Synopsis | The National Cancer Institute (NCI) invites applications for Cellular Cancer Biology Imaging Research (CCBIR) Centers. The Centers will develop and test enabling imaging technologies at the cellular and organ scales driven by specific fundamental questions in cancer biology. The overall purpose of the CCBIR initiative is to facilitate innovation in advanced imaging

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

technologies that could be applied to fundamental basic and pre-clinical research problems in cancer biology. CCBIR Centers are structured to operate collaboratively between technology developers and cancer biologists at the forefront of their respective fields. CCBIR Centers will increase in experimental sophistication over time to ultimately produce an interoperable suite of state-of-the-art imaging technologies with transformative potential to study the cancer biology process(es) that defines the Center. The cadre of CCBIR Centers will form a consortium that will be expected to engage with the broader cancer research community.

086016	RFA-OD-19-028--Tobacco Regulatory Science (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-OD-19-028	13-Feb-2021	900,000 USD
--------	---	------------------------------------	---------------	-------------	-------------

Contact Name	Rachel Grana Mayne, PhD
Contact Telephone	240-276-5899
Contact Email	granar@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	13-Feb-2021
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to invite R01 applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). The awards under this FOA will be administered by NIH using funds that have been made available through FDA CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health.

100482	RFA-CA-20-056 -- NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	RFA-CA-20-056	26-Feb-2021	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name	Sergey Radaev, PhD
Contact Telephone	240-276-5630
Contact Email	sradaev@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 26-Feb-2021</p> <p>Synopsis The purpose of the NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Fellows (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of data science and cancer control science are especially encouraged to apply. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA (RFA-CA-20-057).</p>				
100483	RFA-CA-20-057 -- NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Required)	National Cancer Institute/NIH/DHHS	RFA-CA-20-057	26-Feb-2021	Not Specified
	<p>Contact Name Sergey Radaev, PhD</p> <p>Contact Telephone 240-276-5630</p> <p>Contact Email sradaev@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 26-Feb-2021</p> <p>Synopsis The purpose of the NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of data science and cancer control science are especially encouraged to apply. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (RFA-CA-20-056).			
100481	RFA-CA-20-055 -- NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Basic Experimental Studies with Humans Required)	National Cancer Institute/NIH/DHHS	RFA-CA-20-055	26-Feb-2021	Not Specified
	Contact Name	Sergey Radaev, PhD			
	Contact Telephone	240-276-5630			
	Contact Email	sradaev@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	26-Feb-2021			
	Synopsis	<p>The purpose of the NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research career development beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of data science and cancer control science are especially encouraged to apply. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this Funding Opportunity Announcement (FOA) include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA, RFA-CA-20-056</p>			
101162	Notice of Special Interest (NOSI): Tailoring Follow-up Care for	National Cancer	NOT-CA-21-019	05-Feb-2021	Not

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Survivors Using Risk-Stratified Pathways	Institute/NIH/DHHS			Specified
	<p>Contact Name Michelle Mollica, PhD, MPH, RN, OCN</p> <p>Contact Telephone 240-276-7621</p> <p>Contact Email michelle.mollica@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023</p> <p>Synopsis The purpose of this Notice is to highlight the NCI Division of Cancer Control and Population Sciences' interest in receiving applications focused on identifying important factors for defining risk-stratified survivorship care or developing and testing approaches to improve the clinical management and outcomes for adult cancer survivors using risk-stratified survivorship care pathways. Risk-stratified survivorship care describes a personalized approach to care in which cancer survivors are triaged or stratified to distinct care pathways based on the complexity of their needs and the types of providers their care requires.</p>				
100910	RFA-CA-21-009 -- Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U54 Clinical Trials Optional)	National Cancer Institute/NIH/DHHS	RFA-CA-21-009	23-Jan-2021 [Optional][LOI/Pre-App]	150,000 USD
	<p>Contact Name Tony Dickherber, Ph.D.</p> <p>Contact Telephone 301-547-9980</p> <p>Contact Email dickherberaj@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 23-Jan-2021 [Optional][LOI/Pre-App], 22-Feb-2021 , 27-Apr-2021 [Optional][LOI/Pre-App], 27-May-2021 , 30-Aug-2021 [Optional][LOI/Pre-App], 29-Sep-2021</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI U54 Resource-Related Research Projects proposing to expand upon original research question(s) from specific projects or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

emerging technologies for appropriate research communities. As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.

100914	RFA-CA-21-011 -- Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-CA-21-011	23-Jan-2021 [Optional][LOI/Pre-App]	150,000 USD
--------	--	------------------------------------	---------------	--	----------------

Contact Name	Tony Dickherber, Ph.D.
Contact Telephone	301-547-9980
Contact Email	dickherberaj@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	23-Jan-2021 [Optional][LOI/Pre-App], 22-Feb-2021 , 27-Apr-2021 [Optional][LOI/Pre-App], 27-May-2021 , 30-Aug-2021 [Optional][LOI/Pre-App], 29-Sep-2021
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI P01 program projects proposing to expand upon original research question(s) from specific projects or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities. As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.

100916	RFA-CA-21-012 -- Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-CA-21-012	23-Jan-2021 [Optional][LOI/Pre-App]	150,000 USD
--------	--	------------------------------------	---------------	--	----------------

Contact Name	Tony Dickherber, Ph.D.
Contact Telephone	301-547-9980
Contact Email	dickherberaj@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 23-Jan-2021 [Optional][LOI/Pre-App], 22-Feb-2021 , 27-Apr-2021 [Optional][LOI/Pre-App], 27-May-2021 , 30-Aug-2021 [Optional][LOI/Pre-App], 29-Sep-2021</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI P50 specialized centers proposing to expand upon original research question(s) from specific projects or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities. As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.</p>				
098641	NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-20-292	19-Feb-2021	275,000 USD
	<p>Contact Name William C. Timmer, Ph.D</p> <p>Contact Telephone 240-276-6130</p> <p>Contact Email william.timmer@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 19-Feb-2021 , 19-Mar-2021 , 21-Jun-2021 , 20-Jul-2021 , 20-Oct-2021 , 17-Dec-2021 , 22-Feb-2022 , 21-Jun-2022 , 21-Jun-2022 , 20-Jul-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) supports preclinical and early phase clinical research, as well as correlative studies, directly related to advancements in cancer treatment, diagnosis, prevention, symptom management, or reduction of cancer health disparities. This includes (but is not limited to) development and testing of the following: new molecular agents or biologics for cancer treatment; management strategies for cancer-related symptoms or treatment-related toxicity; cancer screening or diagnostic tools, such as imaging techniques; cancer preventive agents or approaches; predictive and prognostic biomarkers for patient selection or stratification; clinically relevant in vivo or in vitro tumor models (including genetically engineered mouse models, patient-derived xenograft models, organoids, and cell lines); and strategies to address therapeutic outcome disparities among diverse racial/ethnic populations. In addition to novel agents, new treatment strategies may involve repurposed agents or novel combinations of interventions (including radiation), based on established mechanisms of action. Comparative oncology studies in dogs investigating strategies for treatment and diagnosis of human disease are supported as well. This FOA does not support research that focuses on basic cancer biology (such as studies of cancer-related pathways or molecular mechanisms), late-stage clinical trials, risk assessment studies, epidemiological studies, or studies of</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

behavioral interventions. These applications will be deemed not responsive to this FOA and will not be reviewed (see below for a more detailed description of studies that are not responsive for this FOA). The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to breakthroughs in particular areas, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on cancer research (preclinical or clinical).

068218	NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08 No Independent Clinical Trials)	National Cancer Institute/NIH/DHHS	PAR-18-337	12-Feb-2021	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name | John O. Ojeifo, MD, PhD, MBA.
 Contact Telephone | 240-276-6186
 Contact Email | ojeifojo@mail.nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 12-Feb-2021

Synopsis | National Cancer Institute (NCI) invites applications for the NCI Mentored Clinical Scientist Research Career Development Awards (K08). The purpose of the NCI Mentored Clinical Scientist Career Development Award (K08) program is to prepare individuals for careers that have a significant impact on the health-related research needs of the nation. This program represents the continuation of a long-standing NIH program that provides support and protected time to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. The NCI-sponsored K08 award is specifically designed to promote career development of clinical scientists from backgrounds that have been shown to be nationally underrepresented in health-related science and for those who are committed to a career in basic biomedical, behavioral or translational cancer research, including research on cancer health disparities. The expectation is that through this sustained period of research career development and training, awardees will develop enhanced research capabilities for cancer research careers and be better prepared to compete for research project grants (e.g. R03, R21, or R01) funding. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. This Funding Opportunity Announcement (FOA) will utilize the NIH K08 Clinical Investigator Award (CIA) mechanism.

070100	NCI Transition Career Development Award (K22 Independent Clinical	National Cancer	PAR-18-466	12-Feb-2021	450,000
--------	---	-----------------	------------	-------------	---------

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Trial Required	Institute/NIH/DHHS			USD
	Contact Name	Sonia Jakowlew, Ph.D., Program Director			
	Contact Telephone	240-276-5630			
	Contact Email	jakowles@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	12-Feb-2021			
	Synopsis	National Cancer Institute (NCI) provides support to facilitate the transition of investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions. This goal is achieved by providing protected time through salary and research support for the initial 3 years of the first independent tenure-track faculty position, or its equivalent, beginning at the time when the candidate starts a tenure-track faculty position. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. This program will use the NIH K22 Career Transition Award mechanism.			
079076	Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PA-19-111	16-Feb-2021	275,000 USD
	Contact Name	Nonniekaye Shelburne, MS, CRNP, AOCN			
	Contact Telephone	240-276-6897			
	Contact Email	nshelburne@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021			
	Synopsis	This Funding Opportunity Announcement (FOA) encourages collaborative applications that will contribute to the identification and characterization of patients at risk of developing cancer treatment-related cardiotoxicity. The primary intent is to mitigate cardiovascular dysfunction while optimizing cancer outcomes. To accomplish this, methods that evaluate cardiovascular risk prior to treatment and integrate evidence-based cancer treatment regimens with cardiovascular screening, diagnostic, and/or management strategies are sought. Research applications should focus on mitigation/management of adverse effects associated with anti-cancer treatments including: cytotoxic chemotherapies, targeted agents, immunomodulatory therapies and radiation (that occur during cancer treatment and/or long-term			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

| survivorship) as defined by cardiac and/or vascular specific common terminology criteria for adverse events (CTCAE).

069612	NCI Transition Career Development Award to Promote Diversity (K22 No Independent Clinical Trials)	National Cancer Institute/NIH/DHHS	PAR-18-366	12-Feb-2021	450,000 USD
--------	---	------------------------------------	------------	-------------	-------------

Contact Name	Abigail Soyombo, Ph.D., M.B.A.
Contact Telephone	240-276-6553
Contact Email	abigail.soyombo@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	12-Feb-2021
Synopsis	National Cancer Institute (NCI) invites applications for the National Cancer Institute (NCI) Career Transition Award. The purpose of the award is to assist postdoctoral fellows or individuals in equivalent positions to transition to positions of assistant professor or equivalent and initiate a successful biomedical career as an independent research scientist. To this end, the Diversity Training Branch (DTB), within the Center to Reduce Cancer Health Disparities (CRCHD) (http://crchd.cancer.gov/) invites applications from research scientists in postdoctoral positions or equivalent who are from backgrounds nationally underrepresented in biomedical, behavioral, clinical, and/or social sciences. This award will provide "protected time" through salary and research support for 3 years beginning at the time when the candidate starts a tenure-track faculty position. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by another investigator. This program will use the NIH Transition Career Development Award (K22) mechanism.

069610	NCI Transition Career Development Award to Promote Diversity (K22 Clinical Trial Required)	National Cancer Institute/NIH/DHHS	PAR-18-367	12-Feb-2021	450,000 USD
--------	--	------------------------------------	------------	-------------	-------------

Contact Name	Abigail Soyombo, Ph.D., M.B.A.
Contact Telephone	240-276-6553
Contact Email	abigail.soyombo@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	12-Feb-2021

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>National Cancer Institute (NCI) invites applications for the National Cancer Institute (NCI) Career Transition Award. The purpose of the award is to assist postdoctoral fellows or individuals in equivalent positions to transition to positions of assistant professor or equivalent and initiate a successful biomedical career as an independent research scientist. To this end, the Diversity Training Branch (DTB), within the Center to Reduce Cancer Health Disparities (CRCHD) (http://crchd.cancer.gov/) invites applications from research scientists in postdoctoral positions or equivalent who are from backgrounds nationally underrepresented in biomedical, behavioral, clinical, and/or social sciences. This award will provide "protected time" through salary and research support for 3 years beginning at the time when the candidate starts a tenure-track faculty position. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. This program will use the NIH Transition Career Development Award (K22) mechanism.</p>			
073410	Age-related Microbiota Changes and their Implications in Chronic Disease Prevention, Treatment and Progression (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PA-18-739	16-Feb-2021	275,000 USD
	Contact Name	Gabriela Riscuta MD, CNS, MS			
	Contact Telephone				
	Contact Email				
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Feb-2021			
	Synopsis	<p>National Institutes of Health (NIH) and its participating Institutes and Centers invite applications to assess the role of the microbiome in health and disease during aging. This initiative will support research projects designed to evaluate changes in the microbiota during lifetime and its influence in health and disease status in the elderly, including those from racial/ethnic minority and underserved populations and understand the underlying mechanisms of microbiota interactions in aged subjects as related to health and disease. This FOA will support basic mechanistic, preclinical studies in animal models and human clinical trial proposals in accordance with the state of the science. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</p>			
097241	Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-20-277	16-Feb-2021	400,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Melissa Rotunno, Ph.D.</p> <p>Contact Telephone 240-276-7245</p> <p>Contact Email rotunnom@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022</p> <p>Synopsis Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) along with the National Human Genome Research Institute (NHGRI) and National Institute of Dental and Craniofacial Research (NIDCR) encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate the genetic architecture of cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.). The goal of this initiative is to address key scientific questions relevant to cancer genomic and epidemiology by supporting the analysis of existing genetic or genomic datasets, in combination with other omics and environmental, clinical, behavioral, lifestyle, and molecular profiles data. Applicants are encouraged to leverage existing genetic data and perform innovative analyses of the existing data.</p>				
069273	NCI Mentored Research Scientist Development Award to Promote Diversity (Parent K01 -Independent Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-18-364	12-Feb-2021	650,000 USD
	<p>Contact Name Abigail Soyombo, Ph.D., M.B.A.</p> <p>Contact Telephone 240-276-6553</p> <p>Contact Email Abigail.Soyombo@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Feb-2021</p> <p>Synopsis National Cancer Institute (NCI) invites applications for the Mentored Research Scientist Development Award. The purpose of the award is to enhance the diversity of the pool of the NCI-funded cancer research workforce by supporting eligible individuals from groups that have been shown to be nationally underrepresented in the biomedical, behavioral, social and clinical sciences. This FOA provides salary and research support for a sustained period of "protected time" for intensive research career development under the guidance of an experienced mentor. The Diversity Training Branch (DTB) of the Center to Reduce Cancer Health Disparities (CRCHD), at the National Cancer Institute (NCI), invites career development award applications (K01) from individuals from backgrounds that have been shown to be nationally underrepresented in health-</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>related sciences. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. This Funding Opportunity Announcement (FOA) will utilize the NIH Mentored Research Scientist Development Award (K01) mechanism.</p>			
069282	NCI Mentored Research Scientist Development Award to Promote Diversity (Parent K01 - Clinical Trial Required)	National Cancer Institute/NIH/DHHS	PAR-18-365	12-Feb-2021	650,000 USD
	Contact Name	Abigail Soyombo, Ph.D., M.B.A.			
	Contact Telephone	240-276-6553			
	Contact Email	Abigail.Soyombo@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	12-Feb-2021			
	Synopsis	<p>National Cancer Institute (NCI) invites applications for the Mentored Research Scientist Development Award. The purpose of the award is to enhance the diversity of the pool of the NCI-funded cancer research workforce by supporting eligible individuals from groups that have been shown to be nationally underrepresented in the biomedical, behavioral, social and clinical sciences. This FOA provides salary and research support for a sustained period of "protected time" for intensive research career development under the guidance of an experienced mentor. The Diversity Training Branch (DTB) of the Center to Reduce Cancer Health Disparities (CRCHD), at the National Cancer Institute (NCI), invites career development award applications (K01) from individuals from backgrounds that have been shown to be nationally underrepresented in health-related sciences. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. This Funding Opportunity Announcement (FOA) will utilize the NIH Mentored Research Scientist Development Award (K01) mechanism.</p>			
072438	Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R21 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PA-18-678	16-Feb-2021	275,000 USD
	Contact Name	Tram Kim Lam, Ph.D., MPH			
	Contact Telephone	240-276-6967			
	Contact Email	Tram.Lam@nih.gov			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021</p> <p>Synopsis National Cancer Institute (NCI) invites applications for epidemiologic research investigating novel and innovative hypotheses on emerging risk factors (biological, environmental, and social) and their interplay with established risk factors (e.g., viral hepatitis) associated with the development of liver cancer (hepatocellular carcinoma and other histological subtypes) in the United States. This FOA will use the NIH R21 Exploratory/Developmental Grant award mechanism.</p>				
087537	Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-20-074	26-Feb-2021	450,000 USD
	<p>Contact Name Sumana Dey, Ph.D.</p> <p>Contact Telephone 240-276-5748</p> <p>Contact Email sumana.dey@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 26-Feb-2021 , 13-Jul-2021 , 26-Oct-2021 , 28-Feb-2022 , 11-Jul-2022 , 28-Oct-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI R01 research projects. The applicants should propose projects that are expected to accelerate the pace of translation of NCI-supported methods/assays/technologies (referred to as "assays") to the clinic. Specifically, the focus of applications submitted in response to this FOA should be on the adaption and clinical validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") for cancer detection, diagnosis, prognosis, monitoring, and prediction of response in treatment, as well as markers for cancer prevention and control. Applications may support the acquisition of well-annotated specimens from NCI-supported or other clinical trials or observational cohorts/consortia for the purpose of clinical validation of the assay. Research projects proposed in response to this FOA encourage multi-disciplinary interaction among scientific investigators, assay developers, clinicians, statisticians, and clinical laboratory staff. Clinical laboratory scientist(s) and statistical experts are highly encouraged to comprise integral parts of the application. This FOA is not intended to support early-stage development of technology or the conduct of clinical trials, but rather the adaption and validation of assays to the point where they could be integrated into clinical trials as investigational assays/tools/devices.</p>				
101460	Notice of Special Interest (NOSI): New Approaches to Identify	National Cancer	NOT-CA-21-025	22-Feb-2021	Not

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Neurogenesis and Study its Dynamics in Brain Aging and AD/ADRD (R01 Clinical Trial Not Allowed)	Institute/NIH/DHHS			Specified
	<p>Contact Name Paul C. Pearlman, Ph.D.</p> <p>Contact Telephone 240-276-6429</p> <p>Contact Email paul.pearlman@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 22-Feb-2021 , 27-May-2021 , 29-Sep-2021</p> <p>Synopsis This Notice of Special Interest (NOSI) is to alert the community that the National Cancer Institute (NCI) Center for Global Health (CGH) is seeking to leverage ongoing Innovative Molecular Analysis Technologies (IMAT) program activities to stimulate exploratory research on technology platforms relevant for global oncology and appropriate for use in low-resource settings globally. NCI CGH is prepared to support highly meritorious R21 applications submitted to either RFA-CA-21-003 or RFA-CA-21-005, with the goal of helping drive innovation in this field and enrich the pool of investigators participating in the NCI-sponsored Affordable Cancer Technologies (ACTs) Program.</p>				
101459	Notice of Special Interest (NOSI): Leveraging Population-based Cancer Registry Data to Study Health Disparities	National Cancer Institute/NIH/DHHS	NOT-CA-21-020	05-Feb-2021	Not Specified
	<p>Contact Name Kathy Cronin, Ph.D.</p> <p>Contact Telephone 240-276-6836</p> <p>Contact Email cronink@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 16-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023</p> <p>Synopsis The National Cancer Institute (NCI) is issuing this Notice of Special Interest (NOSI) to encourage applications that efficiently use the existing cancer registry infrastructure by augmenting existing data with additional information not routinely collected by registries to study observed health disparities such as those that exist by race, ethnicity, socioeconomic status, income, insurance status, age, education level, or geographic area. The Surveillance, Epidemiology, and End Results (SEER) Program and the National Program of Cancer Registries (NPCR) are uniquely positioned to support research to assess health disparities</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>in the United States (US) population because they contain information on all cases diagnosed within geographically defined areas. The goal of these hypothesis-driven studies should be to understand why disparities in cancer treatment and outcomes persist by identifying factors contributing to disparities and their relative importance.</p>			
070540	Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-18-530	05-Feb-2021	Not Specified
	<p>Contact Name Miguel Ossandon MS</p> <p>Contact Telephone 240-276-5714</p> <p>Contact Email ossandom@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021</p>	<p>Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invite applications to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes. This FOA specifies a partnership structure that is expected to help bridge gaps in knowledge and experience by engaging the strengths of academic, industrial, and other investigators. The partners on each application should establish an inter-disciplinary, multi-institutional research team to work in strategic alliance to implement a coherent strategy to develop and translate a solution to their chosen problem. They are expected to plan, design, and validate that the solution will be suitable for end users. Each partnership should include at least one academic and one industrial organization. Each partnership should plan to transition a technology, method, assay, device, and/or system from a demonstration of possibility to a status useful in the chosen setting. Funding may be requested to enhance, adapt, optimize, validate, and otherwise translate technologies that address problems in biology, pathology, risk assessment, diagnosis, treatment, and/or monitoring of disease status. This FOA defines innovation as likelihood to deliver a new capability to end users. This FOA will support clinical trials that test functionality, or validate performance in the chosen setting. This FOA is not intended to support commercial production, basic research projects, or straight clinical trials that lack translation as the primary motivation. This FOA will use the NIH Research Project (R01) award mechanism.</p>			
071800	Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PA-18-629	05-Feb-2021	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Anne Menkens, Ph.D.</p> <p>Contact Telephone 240-276-6510</p> <p>Contact Email menkensa@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021</p> <p>Synopsis National Cancer Institute (NCI) invites applications for research projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
076909	Advancing Translational and Clinical Probiotic/Prebiotic and Human Microbiome Research (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PA-18-902	05-Feb-2021	Not Specified
	<p>Contact Name Gabriela Riscuta, MD, CNS</p> <p>Contact Telephone 240-276-7118</p> <p>Contact Email gabriela.riscuta@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021</p> <p>Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for interdisciplinary collaborations across scientific disciplines engaged in microbiome and pro/prebiotic research including, but not limited to: nutritional science, microbiology, virology, microecology and microbiome, genomics, immunology, computational biology, chemistry, bioengineering, as well as integration of omics and computational approaches in DNA technologies. The purpose of this funding opportunity announcement (FOA) is twofold: 1) to accelerate translational and clinical Phase I and II a/b safety and efficacy studies for substantiating measurable functional benefits of probiotic/prebiotic components and/or their combinations; and; 2) to understand the underlying mechanisms of their action(s), and variability in responses to these interventions. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
086964	NCI Small Grants Program for Cancer Research for Years 2020, 2021, and 2022 (NCI Omnibus R03 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-20-052	24-Feb-2021	100,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 24-Feb-2021 , 07-May-2021 , 24-Jun-2021 , 07-Sep-2021 , 20-Oct-2021 , 07-Jan-2022 , 24-Feb-2022 , 07-May-2022 , 24-Jun-2022 , 07-Sep-2022 , 20-Oct-2022 , 07-Jan-2023</p> <p>Synopsis This funding opportunity announcement (FOA) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.</p>				
100927	AMENDMENT -- Computing and Data Management Services for the National Cancer Institute (NCI)	National Cancer Institute/NIH/DHHS	75N91019R00007-R	12-Feb-2021	Not Specified
	<p>Contact Name Rachel Weiszer</p> <p>Contact Telephone 240-276-5389</p> <p>Contact Email rweiszer@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Feb-2021</p> <p>Synopsis Pre-Solicitation Notice Request for Proposals (RFP) 75N91019R00007 TITLE IS CHANGED TO: Biomedical Computing, Analytic and Data Management Services Set Aside Status: This potential acquisition will be competed through FULL AND OPEN COMPETITION. Only qualified businesses under the size classification relative to the North American Industry Classification System (NAICS) code 541511 – Custom Computer Programming Services need apply. The Government anticipates making two (2) indefinite delivery indefinite quantity (IDIQ) contract awards under which fixed price and cost-reimbursement type task orders will be issued. The Government anticipates that at least one task order will be awarded with each base contract. Background: The National Cancer Institute (NCI) conducts and supports science to identify a person’s risk of developing cancer and to find ways to reduce that risk. Years of research have shown that the diseases of cancer occur not as a single, catastrophic event, but rather as the result of a complex and long-evolving process. The process of carcinogenesis can take decades to complete, proving time and opportunities to retard, stop, or reverse its progress. The NCI advances</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

cancer research by generating new information about molecular processes that are vulnerable to interventions, developing effective chemoprevention agents; discovering early detection biomarkers; pinpointing mechanistically targeted nutrients; testing new screening methods and technologies; and conducting clinical trials through national networks and at the community level. The NCI studies cancer through structural, functional and computational genomics, collecting data from tissue samples from research studies, and making the data publicly available for research. Project Requirements: The goal of this acquisition is to provide non-research and development (R&D) technical support and data management services to NCI, to support a wide variety of NCI studies and projects. These services include systems design, computer programming, system documentation, and operational support to the National Cancer Institute. Computer-related support is required in eleven (11) main areas. Area 1: Project Management/Core Services Area 2: Data Management Area 3: Computer Programming Area 4: Computing Infrastructure Services Area 5: Website Development Area 6: Systems Design and Development Area 7: Reports and Manuscripts Preparation Area 8: Management of NCI Data Area 9: Evaluation of NCI Data and Projects Area 10: Technical and Administrative Support Area 11: Statistical Methodology and Program Support The NCI intends to award two (2) Indefinite Delivery Indefinite Quantity (IDIQ) contracts with a five year ordering period. Sample Task Order #1, "Contract Initiation/Kick-Off" will be solicited as part of the Request for Proposal for the base IDIQ contracts and awarded concurrently with all base IDIQ contracts. Sample Task Order #2, "Data Computing Services" will be awarded following the award of the base IDIQ contract to one awardee. Place of Performance: The place of performance will be the Contractor's work site. Additional Information: Request for Proposal Number 75N91019R0007 will be available on or about December 16, 2020 with a due date for receipt of proposals on or about February 16, 2020. The RFP is only available electronically and must be accessed through "Contract Opportunities" at the <https://beta.sam.gov/> website and the National Cancer Institute homepage at <http://rcb.cancer.gov/rcb-internet/index.jsp> . All information required for submission of a proposal must be contained in the electronic RFP package. It is the Offeror's responsibility to monitor the above websites for the release of this RFP and amendments, if any. All responsible sources may submit a proposal, which shall be considered by the agency. This notice does not commit the Government to award a contract. Offerors are required to submit their proposals online at the NIH electronic Contract Proposal Submission (eCPS) website (<https://ecps.nih.gov/NCI/home/>) ONLY. Proposals submitted in hard copy (paper) will not be accepted. Proposals submitted by email will not be accepted. Collect calls will not be accepted. Facsimile transmissions will not be accepted. This notice does not commit the Government to award a contract. **POTENTIAL OFFERORS ARE RESPONSIBLE FOR DOWNLOADING THEIR OWN COPY OF THE SOLICITATION AND ANY POSSIBLE AMENDMENTS. ALL INQUIRIES SHALL BE SUBMITTED ELECTRONICALLY TO THE POINTS OF CONTACTS LISTED HEREIN.**

085422	Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-363	05-Feb-2021	499,999 USD
--------	---	------------------------------------	------------	-------------	-------------

Contact Name	Anne Menkens, Ph.D.
Contact Telephone	240-276-6510

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email menkensa@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021</p> <p>Synopsis National Cancer Institute (NCI) invites applications for research projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
092626	RFA-CA-20-031 -- Strengthening Institutional Capacity to Conduct Global Cancer Research in Low- and Middle-Income Countries (D43 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	RFA-CA-20-031	05-Feb-2021	1,250,000 USD
	<p>Contact Name Sudha Sivaram, DrPH, MPH</p> <p>Contact Telephone 240-276-5804</p> <p>Contact Email nciglobaltraining@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to establish an institutional program for mentored training in global cancer research. This program will support research training led by the United States (U.S.)-based cancer research-intensive institutions working in collaboration with institutions in low and middle-income countries (LMICs). These training programs will be built upon the US institutions' pre-existing training infrastructure and research collaborations with LMICs and will leverage these resources to expand the global cancer research workforce both in the US and in LMICs. The overarching goal of this initiative is to build capacity to conduct innovative and collaborative global research projects that will contribute to the advancement of basic, clinical, translational, and population-based cancer research in LMICs. This FOA does not allow appointed trainees to lead an independent clinical trial but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.</p>				
067494	Testing Interventions for Health-Enhancing Physical Activity (R01 - Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-18-324	05-Feb-2021	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Frank Perna, Ed.D., Ph.D.</p> <p>Contact Telephone 240-276-6782</p> <p>Contact Email pernafm@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021</p> <p>Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for highly innovative and promising research that tests multi-level physical activity intervention programs acting on at least two levels of the socioecological model and designed to increase health-enhancing physical activity: 1) in persons or groups that can benefit from such activity; and 2) that could be made scalable and sustainable for broad use across the nation. This program will use the NIH R01 Research Project Grant award mechanism.</p>				
067401	Developing Interventions for Health-Enhancing Physical Activity (R21/R33 - Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-18-307	16-Feb-2021	1,025,000 USD
	<p>Contact Name Frank Perna, Ed.D., Ph.D.</p> <p>Contact Telephone 240-276-6782</p> <p>Contact Email pernafm@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 07-May-2021</p> <p>Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for highly innovative and promising research aimed at developing multi-level physical activity intervention programs acting on at least two levels of the socioecological model and designed to increase health-enhancing physical activity: 1) in persons or groups that can benefit from such activity; and 2) that could be made scalable and sustainable for broad use across the nation. This FOA provides support for up to two years (R21 phase) for research planning activities and feasibility studies, followed by a possible transition to expanded research support (R33 phase) for optimizing the intervention and conducting larger-scale feasibility studies. Transition to the R33 depends on the completion of applicant-defined milestones, as well as program priorities and the availability of funds. This program will use the NIH R21/R33 Phased Innovation Award award mechanism.</p>				
076579	Advancing Mechanistic Probiotic/Prebiotic and Human Microbiome Research (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PA-18-876	05-Feb-2021	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Dr. Roberto Flores</p> <p>Contact Telephone 240-276-7119</p> <p>Contact Email floresr2@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021</p> <p>Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for basic and mechanistic science that facilitates the development of effective probiotics or pre-/probiotic combinations of relevance to human health and disease; and (2) determine biological outcomes for the evaluation of efficacy of pre/probiotics in appropriate test systems and animal models. This FOA encourages basic and mechanistic studies using in vitro, in vivo, ex vivo, and in silico models that focus on prebiotic/probiotic strain selectivity, interaction, and function. It will also encourage inter and multidisciplinary collaborations among scientists in a wide range of disciplines including nutritional science, immunology, microbiomics, genomics, other '-omic' sciences, biotechnology, and bioinformatics. This FOA will use the NIH Research Project (R01) award mechanism.</p>				

076806	Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-18-892	16-Feb-2021	275,000 USD
--------	--	------------------------------------	------------	-------------	-------------

	<p>Contact Name Frank M. Perna, Ed.D., Ph.D.</p> <p>Contact Telephone 240-276-6782</p> <p>Contact Email pernafm@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021</p> <p>Synopsis National Cancer Institute (NCI) invites applications for transdisciplinary and translational research that will identify the specific biological or biobehavioral pathways through which physical activity and/or weight control (either weight loss or avoidance of weight gain) may affect cancer prognosis and survival. Research applications should test the effects of physical activity, alone or in combination with weight control (either weight loss or avoidance of weight gain), on biomarkers of cancer prognosis among cancer survivors identified by previous animal or observational research on established biomarkers other than insulin/glucose metabolism, especially those obtained from tumor tissue sourced from repeat biopsies where available.</p>				
--	--	--	--	--	--

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Because many cancer survivor populations will not experience recurrence but will die of comorbid diseases or may experience early effects of aging, inclusion of biomarkers of comorbid diseases (e.g., cardiovascular disease) and of the aging process are also sought. Applications should use experimental designs (e.g., randomized controlled clinical trials (RCTs), fractional factorial designs), and will include transdisciplinary approaches that bring together behavioral intervention expertise, cancer biology, and other basic and clinical science disciplines relevant to the pathways being studied. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.

076805	Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-18-893	05-Feb-2021	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

Contact Name	Frank M. Perna, Ed.D., Ph.D.
Contact Telephone	240-276-6782
Contact Email	pernafm@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021

Synopsis
 National Cancer Institute (NCI) invites applications for transdisciplinary and translational research that will identify the specific biological or biobehavioral pathways through which physical activity and/or weight control (either weight loss or avoidance of weight gain) may affect cancer prognosis and survival. Research applications should test the effects of physical activity, alone or in combination with weight control (either weight loss or avoidance of weight gain), on biomarkers of cancer prognosis among cancer survivors identified by previous animal or observational research on established biomarkers other than insulin/glucose metabolism, especially those obtained from tumor tissue sourced from repeat biopsies where available. Because many cancer survivor populations will not experience recurrence but will die of comorbid diseases or may experience early effects of aging, inclusion of biomarkers of comorbid diseases (e.g., cardiovascular disease) and of the aging process are also sought. Applications should use experimental designs (e.g., randomized controlled clinical trials (RCTs), fractional factorial designs), and will include transdisciplinary approaches that bring together behavioral intervention expertise, cancer biology, and other basic and clinical science disciplines relevant to the pathways being studied. This FOA will use the NIH R01 Research Project Grant award mechanism.

082214	Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-274	05-Feb-2021	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name	Gila Neta, Ph.D.
--------------	------------------

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 240-276-6785</p> <p>Contact Email gila.neta@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based interventions, tools, policies, and guidelines. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of interventions that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. All applications must be within the scope of the mission of one of the Institutes/Centers listed above.</p>				
077667	Increasing Uptake of Evidence-Based Screening in Diverse Adult Populations (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PA-18-932	05-Feb-2021	Not Specified
	<p>Contact Name Erica S. Breslau, PhD, MPH</p> <p>Contact Telephone 240-276-6773</p> <p>Contact Email breslaue@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022</p> <p>Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invite applications that seek to understand strategies to reduce disparities in the uptake of evidence-based screening (e.g. screening recommendations proven to be effective based on rigorous systematic review of scientific evidence by authoritative committees) across the adult lifespan. In this program announcement, screening is defined as a preventive service focused on detection of an undiagnosed disease in asymptomatic populations. Research supported by this initiative should enhance the screening process related to use: (1) in diverse populations, (2) in diverse clinical and community settings, and/or (3) with traditional, non-traditional and/or allied health care providers. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
079335	Exploratory/Developmental Bioengineering Research Grants(EBRG) (R21 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-19-149	16-Feb-2021	275,000 USD
	Contact Name Miguel R. Ossandon, Ph.D.				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 240-276-5714</p> <p>Contact Email ossandom@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022</p> <p>Synopsis The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility.</p>				
079333	Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-150	16-Feb-2021	275,000 USD
	<p>Contact Name Miguel R. Ossandon, Ph.D.</p> <p>Contact Telephone 240-276-5714</p> <p>Contact Email ossandom@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022</p> <p>Synopsis The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of Exploratory/Developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility.</p>				
082215	Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-275	16-Feb-2021	275,000 USD
	<p>Contact Name Gila Neta, Ph.D.</p> <p>Contact Telephone 240-276-6785</p> <p>Contact Email gila.neta@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based interventions, tools, policies, and guidelines. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of interventions that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. All applications must be within scope of the mission of one of the Institutes/Centers listed above.			
082216	Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-19-276	16-Feb-2021	50,000 USD
	Contact Name	Gila Neta, Ph.D.			
	Contact Telephone	240-276-6785			
	Contact Email	gila.neta@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based interventions, tools, policies, and guidelines. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of interventions that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. All applications must be within scope of the mission of one of the Institutes/Centers listed above.			
083680	Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-309	16-Feb-2021	275,000 USD
	Contact Name	Tanya Agurs-Collins, Ph.D			
	Contact Telephone	240-276-6956			
	Contact Email	collinsta@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to provide support for the development of innovative interventions that improve cancer-related health behaviors across diverse racial/ethnic populations. Specifically, this FOA is intended to stimulate research aimed at 1) testing new theories and conceptual frameworks; 2) developing and evaluating novel strategies to improve cancer-related health behaviors; 3) investigating multi-level and multi-behavioral approaches; and 4) utilizing innovative research designs, methodologies, and technologies. The cancer-related health behaviors to be targeted are diet, obesity, physical activity and sedentary behavior, smoking, sleep and circadian dysfunction, alcohol use, and/or adherence to cancer-related medical regimens. Research can involve several stages of the cancer continuum and any phase of the translational spectrum.</p>				
080314	<p>Mechanisms Underlying the Contribution of Sleep Disturbances to Pain (R01 Clinical Trial Optional)</p>	National Center for Complementary and Integrative Health/NIH/DHHS	PA-19-200	05-Feb-2021	Not Specified
	<p>Contact Name Inna Belfer, M.D., Ph.D.</p> <p>Contact Telephone 301-435-1573</p> <p>Contact Email inna.belfer@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022</p> <p>Synopsis The purpose of this FOA is to encourage mechanistic research to investigate the impact of sleep disturbances on pain. The mechanisms and processes underlying the contribution of sleep and sleep disturbances to pain perception and the development and maintenance of chronic pain may be very broad. This FOA encourages interdisciplinary research collaborations by experts from multiple fields—neuroscientists, psychologists, endocrinologists, immunologists, geneticists, pharmacologists, chemists, physicists, behavioral scientists, clinicians, caregivers, and others in relevant fields of inquiry. Applications proposing to study the impact of pain on sleep will be considered low priority and are unlikely to be funded under this FOA.</p>				
094929	<p>Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Natural Products (Collaborative UG3/UH3 Clinical Trial Required)</p>	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-20-215	01-Feb-2021	Not Specified
	<p>Contact Name Wendy Weber, N.D., Ph.D, M.P.H.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-402-1272</p> <p>Contact Email weberwj@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Feb-2021 , 07-May-2021 , 01-Oct-2021 , 07-Jan-2022 , 01-Jun-2022 , 07-Sep-2022 , 01-Feb-2023 , 07-May-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages cooperative agreement applications for investigator-initiated, multi-site, clinical trials (Phase III and beyond) to study the effects of natural products in NCCIH designated areas of high research priority. Applicants should describe plans for a Clinical Coordinating Center to develop and implement the proposed multi-site clinical trial. The objective of the Clinical Coordinating Center is to provide the design scientific rationale and a comprehensive scientific and operational plan for the clinical trial. The Clinical Coordinating Center is expected to be responsible for project management, participant recruitment and retention strategies, performance milestones, scientific conduct, and dissemination of results. Clinical Coordinating Center applications submitted under this FOA will utilize a two-phase, milestone-driven, cooperative agreement (UG3/UH3) funding mechanism. In addition, an accompanying Data Coordinating Center application, submitted under PAR-20-219, proposing a data analysis and data management plan for the clinical project is required. Both a Clinical Coordinating Center application and a corresponding Data Coordinating Center (DCC) application need to be submitted simultaneously for consideration by NCCIH.</p>				
094930	NCCIH Natural Product Mid Phase Clinical Trial Cooperative Agreement (U01 Clinical Trial Required)	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-20-216	01-Feb-2021	1,750,000 USD
	<p>Contact Name Wendy Weber, N.D., Ph.D, M.P.H.</p> <p>Contact Telephone 301-402-1272</p> <p>Contact Email weberwj@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Feb-2021 , 07-May-2021 , 01-Oct-2021 , 07-Jan-2022 , 01-Jun-2022 , 07-Sep-2022 , 01-Feb-2023 , 07-May-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites cooperative agreement applications for investigator-initiated mid-phase clinical trials of natural products. All applications submitted under this FOA must be supported by sufficient preliminary data of bioavailability and documentation that the natural product produces a replicable and measurable impact on a biological signature (i.e., measure of the mechanism of action). Only in cases when it is not possible/practical to measure a biological signature in the patient population of interest or when there is a fundamental understanding of the product's</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>mechanism of action will this preliminary data requirement be waived. Applications submitted to this FOA should propose a mid-phase clinical trial to do the following: determine the optimal dose or formulation of a given natural product for use in a future multi-site clinical trial; or determine which patient phenotypes will be responders versus non-responders to the natural product to inform inclusion/exclusion criteria of a future efficacy study. Clinical trials submitted under this FOA are expected to be hypothesis based, milestone-driven, and directly related to the research priorities and mission of NCCIH. This FOA will not support single-site or multi-site efficacy or effectiveness trials, nor will it support trials to test natural products for the treatment or prevention of cancer. Applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this FOA.</p>			
094934	Natural Product Multi-Site Clinical Trial Data Coordinating Center (Collaborative U24 Clinical Trial Required)	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-20-219	01-Feb-2021	Not Specified
	Contact Name	Wendy Weber, N.D., Ph.D, M.P.H.			
	Contact Telephone	301-402-1272			
	Contact Email	weberwj@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Feb-2021 , 07-May-2021 , 01-Oct-2021 , 07-Jan-2022 , 01-Jun-2022 , 07-Sep-2022 , 01-Feb-2023 , 07-May-2023			
	Synopsis	<p>This Funding Opportunity Announcement (FOA), utilizing the U24 grant funding mechanism, encourages applications for a collaborating Data Coordinating Center (DCC) application that accompanies an investigator-initiated multi-site clinical trial (Phase III and beyond) application submitted under PAR-20-215 The DCC application must be specific to the collaborating Clinical Coordinating Center (CCC) application. The objective of the DCC application is to propose a comprehensive plan that provides overall project coordination, and administrative, data management, and biostatistical support for the proposed clinical trial. Both a DCC application and a corresponding CCC application need to be submitted simultaneously for consideration by NCCIH. Trials for which this FOA applies must be relevant to the research mission of the NCCIH and considered a high priority by the Center. For additional information about the mission, strategic vision, and research priorities of the NCCIH, applicants are encouraged to consult the NCCIH website: (http://www.nccih.nih.gov). Applicants are strongly encouraged to contact the appropriate Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this FOA.</p>			
080324	Mechanisms Underlying the Contribution of Sleep Disturbances to Pain (R21 Clinical Trial Optional)	National Center for Complementary and Integrative	PA-19-201	16-Feb-2021	275,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Health/NIH/DHHS					
	<p>Contact Name Inna Belfer, M.D., Ph.D.</p> <p>Contact Telephone 301-435-1573</p> <p>Contact Email inna.belfer@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022</p> <p>Synopsis The purpose of this FOA is to encourage mechanistic research to investigate the impact of sleep disturbances on pain. The mechanisms and processes underlying the contribution of sleep and sleep disturbances to pain perception and the development and maintenance of chronic pain may be very broad. This FOA encourages interdisciplinary research collaborations by experts from multiple fields—neuroscientists, psychologists, endocrinologists, immunologists, geneticists, pharmacologists, chemists, physicists, behavioral scientists, clinicians, caregivers, and others in relevant fields of inquiry. Applications proposing to study the impact of pain on sleep will be considered low priority and are unlikely to be funded under this FOA.</p>				
091405	<p>Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)</p>	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-20-154	05-Feb-2021	Not Specified
	<p>Contact Name Lanay Mudd, Ph.D</p> <p>Contact Telephone 301-594-9346</p> <p>Contact Email lanay.mudd@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages applications for investigator-initiated fully remotely delivered and conducted clinical trials to assess the efficacy or effectiveness of complementary and integrative health interventions in NCCIH designated areas of high research priority. Applications submitted under this FOA are expected to propose a remotely delivered and conducted clinical trial with no in-person contact between research staff and study participants and may utilize mHealth tools or technologies. To justify the proposed remotely delivered efficacy or effectiveness clinical trial, applications</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

must have sufficient preliminary data that includes: demonstration of feasibility of remote recruitment and accrual of participants; demonstration of participant adherence to the intervention as well as retention of participants throughout the study; completion of final data collection from any related studies; demonstration of the safety of the intervention; and evidence that the intervention has promise of clinical benefit. Applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this FOA.

067449	Fundamental Science Research on Mind and Body Approaches (R21 Clinical Trial Optional)	National Center for Complementary and Integrative Health/NIH/DHHS	PA-18-322	16-Feb-2021	275,000 USD
--------	--	---	-----------	-------------	-------------

Contact Name	Wen G. Chen, PhD
Contact Telephone	301-451-3989
Contact Email	chenw@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	16-Feb-2021 , 07-May-2021
Synopsis	National Center for Complementary and Integrative Health (NCCIH) invites applications to investigate the fundamental science of mind and body approaches, including mind/brain-focused practices (e.g., meditation, hypnosis), body-based approaches (e.g., acupuncture, massage, spinal manipulation/mobilization), meditative exercise (e.g., yoga, tai chi, qi gong), art and music therapies, or integrative approaches combining several components. Studies of pharmacologic approaches exclusively are not included in the scope of this FOA. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.

067448	Fundamental Science Research on Mind and Body Approaches (R01 Clinical Trial Optional)	National Center for Complementary and Integrative Health/NIH/DHHS	PA-18-323	05-Feb-2021	Not Specified
--------	--	---	-----------	-------------	---------------

Contact Name	Wen G. Chen, PhD
Contact Telephone	301-451-3989
Contact Email	chenw@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021</p> <p>Synopsis National Center for Complementary and Integrative Health (NCCIH) invites applications to investigate the fundamental science of mind and body approaches, including mind/brain-focused practices (e.g., meditation, hypnosis), body-based approaches (e.g., acupuncture, massage, spinal manipulation/mobilization), meditative exercise (e.g., yoga, tai chi, qi gong), art and music therapies, or integrative approaches combining several components. Studies of pharmacologic approaches exclusively are not included in the scope of this FOA. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
101324	<p>Notice of Special Interest (NOSI): NEI Anterior Segment Initiative (ASI): Identification and Development of New Biomarkers and Effective Methods to Diagnose Dry Eye Disease.</p>	National Eye Institute/NIH/DHHS	NOT-EY-21-007	05-Feb-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 16-Feb-2021 , 05-Apr-2021 , 07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 05-Sep-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 05-Jan-2022 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 05-Apr-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 05-Sep-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 05-Jan-2023 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 05-Apr-2023 , 07-May-2023</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants of the special interest of the NEI in research to identify new biomarkers and develop effective methods that can be used for the early diagnosis of dry eye disease (DED) and its subtypes, prognosis of disease progression, and monitoring of treatment response.</p>				
081084	<p>NEI Clinical Research Study Planning Grant Program (R34 Clinical Trial Not Allowed)</p>	National Eye Institute/NIH/DHHS	PAR-19-231	16-Feb-2021	300,000 USD
	<p>Contact Name Donald Everett, MA</p> <p>Contact Telephone 301-451-2020</p> <p>Contact Email everettd@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022</p> <p>Synopsis The National Eye Institute (NEI) supports large-scale clinical vision research projects, including randomized clinical trials and epidemiologic studies. At the time of submission, applications requesting support for these activities are expected to provide detailed information regarding the study rationale, design, analytic techniques, protocols and procedures, facilities and environment, organizational structure, and collaborative arrangements. This information is best conveyed in a well-documented Manual of Procedures (MOP), the development of which represents a costly and time-consuming activity. This FOA is designed to facilitate activities central to the refinement of a study protocol and procedures and the development of a detailed MOP. The NEI Clinical Study Planning Grant may be used to support the development of a MOP, as well as to conduct preliminary studies to refine study procedures or document recruitment potential. The grant must not be used to generate data on the effects of a proposed intervention. This NEI FOA is applicable to both epidemiologic and clinical trial research studies.</p>				
081744	NEI Research Grant for Vision-Related Secondary Data Analysis (R21 Clinical Trial Not Allowed)	National Eye Institute/NIH/DHHS	PAR-19-260	16-Feb-2021	275,000 USD
	<p>Contact Name Donald Everett, M.A.</p> <p>Contact Telephone 301-451-2020</p> <p>Contact Email everettd@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022</p> <p>Synopsis This FOA encourages applications from institutions/organizations that propose to conduct vision-related secondary data analyses utilizing existing database resources. Applications may be related to, but must be distinct from, the specific aims of the original data collection. The NEI supports an extensive portfolio of clinical trials and large-scale epidemiologic research projects wherein numerous data collection activities are required to meet each project's specific aims. The resultant wealth of data generated by these studies often provides unique, cost-effective opportunities to investigate additional research questions or develop new analytical approaches secondary to a project's originally-intended purpose. Data are not limited to those collected under NEI support, but such data are of the highest programmatic interest. The purpose of this FOA is for secondary data analysis using existing data sets from vision-related clinical trials, epidemiologic, and other clinical research studies. This FOA may be used to develop new statistical methodologies or test hypotheses using existing data, but this FOA must not be used to support the collection of new data.</p>				
092824	RFA-HL-22-006 -- Implementation Research to Improve Case Finding	National Heart, Lung, and Blood	RFA-HL-22-006	08-Feb-2021	2,060,000

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Cascade Screening, and Treatment for Familial Hypercholesterolemia (FH) (R61/R33 Clinical Trial Required)	Institute/NIH/DHHS		[Optional][LOI/Pre-App]	USD
	<p>Contact Name Cheryl Anne Boyce, Ph.D.</p> <p>Contact Telephone 301-496-1051</p> <p>Contact Email cheryl.boyce@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Feb-2021 [Optional][LOI/Pre-App], 08-Mar-2021 , 07-May-2021</p> <p>Synopsis This milestone-driven Funding Opportunity Announcement (FOA) invites applications for single site clinical trials to: (1) address barriers that impede population-level implementation of case finding and cascade screening (i.e., blood relatives of familial hypercholesterolemia (FH) index cases are systematically contacted based on their risk according to the pattern of inheritance); (2) explore implementation science methodologies to assess the uptake, cost-effectiveness, feasibility, and scalability of family-based cascade screening programs for FH; (3) develop or improve machine learning algorithms and data mining techniques to find high-risk individuals using Electronic Health Records (EHRs); and (4) optimize treatment strategies and health outcomes.</p>				
074136	RFA-HL-19-023 -- T32 Training Program for Institutions That Promote Diversity (T32 – Clinical Trial Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-19-023	26-Feb-2021	1,155,000 USD
	<p>Contact Name Henry Chang, MD</p> <p>Contact Telephone 301-827-8263</p> <p>Contact Email Henry.Chang@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 26-Feb-2021</p> <p>Synopsis National Heart, Lung, and Blood Institute (NHLBI) invites applications to enhance the participation of individuals from nationally underrepresented backgrounds in cardiovascular, pulmonary, hematologic and sleep disorders research across the career development continuum by providing support to institutions that promote diversity. The NHLBI's T32 Training Program for Institutions That Promote Diversity is a Ruth L. Kirschstein National Research Service Award Program intended to support training of predoctoral and health professional students and individuals in postdoctoral training institutions with an institutional mission focused on serving health disparity populations not well represented in scientific research, or institutions</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

that have been identified by federal legislation as having an institutional mission focused on these populations, with the potential to develop meritorious training programs in cardiovascular, pulmonary, and hematologic diseases, and sleep disorders. These institutions are uniquely positioned to engage minority and other health disparity populations in research, translation, and implementation of research advances that impact health outcomes, as well as provide health care for these populations. This FOA does not allow appointed trainees to lead an independent clinical trial but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor. This FOA will utilize the NIH T32 Institutional National Research Service Award (NRSA) mechanism.

074239	RFA-HL-19-024 -- Short-Term Research Education Program to Increase Diversity in Health-Related Research (R25 Clinical Trial Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-19-024	27-Jan-2021 [Optional][LOI/Pre-App]	595,000 USD
--------	--	--	---------------	--	----------------

Contact Name	Xenia Tigno, Ph.D.
Contact Telephone	301-435-0202
Contact Email	xenia.tigno@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	27-Jan-2021 [Optional][LOI/Pre-App], 26-Feb-2021
Synopsis	National Heart, Lung, and Blood Institute (NHLBI) invites applications to support research education activities in the mission areas of the NIH. The over-arching goal of this NHLBI R25 program is to support educational activities that enhance the diversity of the biomedical, behavioral and clinical research workforce by providing research experiences and related opportunities that enrich the pool of individuals from nationally underrepresented groups who will be available to compete for research opportunities in the mission areas of importance to NHLBI. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Research Experiences. This FOA will utilize the NIH R25 Education Projects award mechanism.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
085482	RFA-HL-20-024 -- Catalyze: Product Definition – Device Prototype Design and Testing, Diagnostic Disease Target Identification and Assay Development, and Research Tool Development (R61/R33 - Clinical Trial Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-20-024	09-Feb-2021 [Optional][LOI/Pre-App]	500,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Kathleen Rousche, Ph.D.</p> <p>Contact Telephone 301-827-7981</p> <p>Contact Email kathleen.rousche@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 09-Feb-2021 [Optional][LOI/Pre-App], 09-Mar-2021 , 11-May-2021 , 09-Jun-2021 [Optional][LOI/Pre-App], 09-Jul-2021 , 11-Aug-2021</p> <p>Synopsis This Catalyze Product Definition Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to develop and test device prototype designs, identify diagnostic disease targets and develop associated assays, and develop research tools for use in the treatment of HLBS diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical product optimization and characterization.</p>				

085480	RFA-HL-20-022 -- Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-20-022	09-Feb-2021 [Optional][LOI/Pre-App]	600,000 USD
--------	---	--	---------------	-------------------------------------	-------------

	<p>Contact Name Margaret Ochocinska, PhD</p> <p>Contact Telephone 301-827-8285</p> <p>Contact Email ochocinm@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 09-Feb-2021 [Optional][LOI/Pre-App], 09-Mar-2021 , 11-May-2021 , 09-Jun-2021 [Optional][LOI/Pre-App], 09-Jul-2021 , 11-Aug-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) solicits grant applications to further develop enabling technologies and transformative platforms to catalyze next-generation predictive, diagnostic and therapeutic products to address heart, lung, blood, and sleep (HLBS)-related disorders and diseases. This FOA solicits R33 applications where major feasibility gaps for the enabling technology or transformative platform have already been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage downstream demonstration, utilization and adoption.</p>				
--	---	--	--	--	--

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
085481	RFA-HL-20-023 -- Catalyze: Product Definition for Small Molecules and Biologics - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 – Clinical Trials Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-20-023	09-Feb-2021 [Optional][LOI/Pre-App]	700,000 USD
	<p>Contact Name Kathleen Rousche, Ph.D.</p> <p>Contact Telephone 301-827-7981</p> <p>Contact Email kathleen.rousche@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 09-Feb-2021 [Optional][LOI/Pre-App], 09-Mar-2021 , 11-May-2021 , 09-Jun-2021 [Optional][LOI/Pre-App], 09-Jul-2021 , 11-Aug-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to identify and characterize potential therapeutic candidates (compound and lead series) to treat heart, lung, blood, and sleep diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical optimization and development of therapeutic candidates.</p>				
085485	RFA-HL-20-028 -- Catalyze: Product Definition – Device Prototype Testing and Design Modification, Diagnostic Disease Target Assay Development and Design Characterization, and Research Tool Testing and Validation (R33 - Clinical Trials Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-20-028	09-Feb-2021 [Optional][LOI/Pre-App]	500,000 USD
	<p>Contact Name Kathleen Rousche, Ph.D.</p> <p>Contact Telephone 301-827-7981</p> <p>Contact Email kathleen.rousche@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 09-Feb-2021 [Optional][LOI/Pre-App], 09-Mar-2021 , 11-May-2021 , 09-Jun-2021 [Optional][LOI/Pre-App], 09-Jul-2021 , 11-Aug-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed for prototype testing/design modification, assay development for diagnostic disease targets, and development of research tools for use in</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

the treatment of HLBS diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical product optimization and characterization.

085483	RFA-HL-20-027 -- Catalyze: Product Definition for Small Molecules and Biologics - Preliminary Product/Lead Series Identification (R33 - Clinical Trial Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-20-027	09-Feb-2021 [Optional][LOI/Pre-App]	700,000 USD
--------	---	--	---------------	--	----------------

Contact Name	Kathleen Rousche, Ph.D.
Contact Telephone	301-827-7981
Contact Email	kathleen.rousche@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	09-Feb-2021 [Optional][LOI/Pre-App], 09-Mar-2021 , 11-May-2021 , 09-Jun-2021 [Optional][LOI/Pre-App], 09-Jul-2021 , 11-Aug-2021
Synopsis	This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to identify a lead compound series toward development of potential therapeutic agents to treat heart, lung, blood, and sleep diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical optimization and development of therapeutic agents.

093741	RFA-HL-21-013 -- Disease Modifying Therapies for Chronic Lung Disease (R61/R33 Clinical Trial Required)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-21-013	17-Feb-2021 [Optional][LOI/Pre-App]	1,000,000 USD
--------	---	--	---------------	--	------------------

Contact Name	Antonello Punturieri, MD, PhD
Contact Telephone	301-435-0233
Contact Email	punturiera@nhlbi.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	17-Feb-2021 [Optional][LOI/Pre-App], 19-Mar-2021 , 02-May-2022 [Optional][LOI/Pre-App], 01-Jun-2022
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support multiple Protocol Leadership Groups (PLGs) that

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>will conduct phase II trials within the NHLBI Pulmonary Trials Cooperative (PTC) clinical trials network. The PTC will include multiple Protocol Leadership Groups (PLGs) and a single Network Management Core (NEMO) and will conduct multiple simultaneous phase II clinical trials that test innovative disease modifying therapies (DMT) for chronic lung diseases. A companion FOA (RFA-HL-21-012) seeks applications for the Network Management Core (NEMO).</p>				
100811	NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-21-079	16-Feb-2021	450,000 USD
	Contact Name	Patrice Desvigne-Nickens, MD			
	Contact Telephone	301-435-0504			
	Contact Email	gweinmann@nih.gov			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023 , 16-Oct-2023 , 07-Jan-2024			
	Synopsis	<p>This Funding Opportunity Announcement (FOA) supports studies that are both necessary and sufficient to inform the planning of a Phase II-IV clinical trial within NHLBI's mission. The NHLBI expects that applications to this FOA will describe the planned clinical trial and in so doing demonstrate that the proposed (R34) research is scientifically necessary to design or plan the subsequent trial. Furthermore, this FOA will support research projects that are designed to provide results that will be sufficient to inform the future trial without further studies. The planned Phase II, III, or IV trial must be primarily intended to test the efficacy, safety, clinical management, or implementation of intervention(s) in the prevention and/or treatment of heart, lung, blood, and sleep disorders. In contrast to the study start up or preparation phase of NHLBI funding opportunities for clinical trials (as described at https://www.nhlbi.nih.gov/grants-and-training/funding-opportunities-and-contacts/clinical-trials-optimization), the R34 mechanism is intended to provide new information that answers a scientific or operational question(s) which may be pragmatic in nature and, therefore, informs the final development of a Phase II-IV clinical trial. Regardless of the results of the R34, support of the proposed future clinical trial will require a new application.</p>			
087786	Secondary Analysis of Existing Datasets in Heart, Lung, and Blood Diseases and Sleep Disorders (R21 Clinical Trial Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-20-078	26-Feb-2021	150,000 USD
	Contact Name	Ruth Kirby, BS			
	Contact Telephone	301-435-0401			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email kirbyr@nhlbi.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 26-Feb-2021 , 20-Apr-2021 , 28-Oct-2021 , 26-Nov-2021 , 26-Feb-2022 , 21-Apr-2022 , 28-Oct-2022 , 25-Nov-2022</p> <p>Synopsis The goal of this funding opportunity is to stimulate the use of existing human datasets for well-focused secondary analyses to investigate novel scientific ideas or new models, systems, tools, methods, or technologies that have the potential for significant impact on biomedical or biobehavioral research in areas relevant to the NHLBI mission. This FOA actively supports the use of existing database resources to conduct additional analyses secondary to a project's originally-intended primary purpose. Applications may be related to, but must be distinct from, the specific aims of the original data collection. It will not support the collection of new data.</p>				
079586	RFA-HL-20-011 -- NHLBI Outstanding Investigator Award (OIA) (R35 Clinical Trial Optional)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-20-011	15-Feb-2021	4,200,000 USD
	<p>Contact Name Narasimhan Danthi, Ph.D.</p> <p>Contact Telephone 301-451-5170</p> <p>Contact Email ndanthi@nhlbi.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Feb-2021 , 15-Apr-2021</p> <p>Synopsis The purpose of the NHLBI Outstanding Investigator Award (OIA) is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program Directors/Principal Investigators (PD/PIs) who are currently PD/PIs on at least two NHLBI R01-equivalent awards and whose outstanding record of research demonstrates their ability to make major contributions to heart, lung, blood and sleep (HLBS) research. The OIA is intended to support a research program, rather than a research project, by providing the primary and most likely sole source of NHLBI funding on individual grant awards. The OIA will support the research program of NHLBI-funded investigators for up to seven years. The OIA will provide investigators increased freedom to conduct research that breaks new ground or extends previous discoveries in new directions. It will also allow PD/PIs to take greater risks and to pursue research that requires a longer timeframe. Research supported by the OIA must be within the scope of the NHLBI mission (https://www.nhlbi.nih.gov/about/mission-statement). It is anticipated that the OIA will: Provide a stable funding environment, thereby improving productivity and facilitating nimble, ambitious, creative research; Accelerate scientific innovation by enabling flexibility in pursuing new research directions as they arise, since PD/PIs will not be bound to specific aims proposed in advance of the studies; Reduce</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		the time researchers spend writing grant applications and managing multiple grant awards, thereby allowing more time to be devoted to conducting research; Facilitate PD/PIs' commitment to research through increased stability of funding; and Enable PD/PIs to devote more time and energy to mentoring students and junior scientists and providing scientific service.			
079587	RFA-HL-20-012 -- NHLBI Emerging Investigator Award (EIA) (R35 Clinical Trial Optional)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-20-012	15-Feb-2021	4,200,000 USD
	Contact Name	Narasimhan Danthi, Ph.D.			
	Contact Telephone	301-451-5170			
	Contact Email	ndanthi@nhlbi.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Feb-2021 , 15-Apr-2021			
	Synopsis	The purpose of the NHLBI Emerging Investigator Award (EIA) is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program Directors/Principal Investigators (PD/PIs) who are currently PD/PIs on at least two NHLBI R01-equivalent awards and whose outstanding record of research demonstrate their ability to make major contributions to heart, lung, blood and sleep (HLBS) research. The EIA is intended to support a research program, rather than a research project, by providing the primary and most likely sole source of NHLBI funding on individual grant awards. The EIA will support the research program of NHLBI-funded investigators for up to seven years. The EIA will provide investigators increased freedom to conduct research that breaks new ground or extends previous discoveries in new directions. It will also allow PD/PIs to take greater risks and to pursue research that requires a longer timeframe. Research supported by the EIA must be within the scope of the NHLBI mission (https://www.nhlbi.nih.gov/about/mission-statement). It is anticipated that the EIA will: Provide a stable funding environment, thereby improving productivity and facilitating nimble, ambitious, creative research; Accelerate scientific innovation by enabling flexibility in pursuing new research directions as they arise, since PD/PIs will not be bound to specific aims proposed in advance of the studies; Reduce the time researchers spend writing grant applications and managing multiple grant awards, thereby allowing more time to be devoted to conducting research; Facilitate PD/PIs' commitment to research through increased stability of funding; and Enable PD/PIs to devote more time and energy to mentoring students and junior scientists and providing scientific service			
084646	Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-19-330	14-Jan-2021	Not Specified
	Contact Name	Nancy DiFronzo, PhD			
	Contact Telephone	301-435-0065			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email difronzon@nhlbi.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 14-Jan-2021 , 11-Feb-2021 , 11-May-2021 , 10-Jun-2021 , 08-Sep-2021 , 14-Oct-2021 , 14-Jan-2022 , 11-Feb-2022 , 11-May-2022 , 10-Jun-2022 , 08-Sep-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) supports applications for a collaborating Data Coordinating Center (DCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a cooperative agreement mechanism of award and runs in parallel with a companion FOA (PAR-19-329) that encourages applications for a collaborating Clinical Coordinating Center (CCC). The objective of the DCC application is to present a comprehensive plan to provide overall project coordination, administration, data management, and biostatistical support for the clinical trial proposed in the collaborating CCC application. Both a DCC application and a collaborating CCC application must be submitted on the same application due date for consideration by NHLBI.</p>				
084638	<p>Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)</p>	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-19-329	14-Jan-2021	Not Specified
	<p>Contact Name Nancy DiFronzo, PhD</p> <p>Contact Telephone 301-435-0065</p> <p>Contact Email difronzon@nhlbi.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 14-Jan-2021 , 11-Feb-2021 , 11-May-2021 , 10-Jun-2021 , 08-Sep-2021 , 14-Oct-2021 , 14-Jan-2022 , 11-Feb-2022 , 11-May-2022 , 10-Jun-2022 , 08-Sep-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) supports applications to develop and implement a Clinical Coordinating Center (CCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015) . For additional information about the mission, strategic vision, and</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a bi-phasic, milestone-driven cooperative agreement mechanism of award and runs in parallel with a companion FOA that encourages applications for a collaborating Data Coordinating Center (DCC) (PAR-19-330). The objective of the CCC application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. Both a CCC application and a collaborating DCC application must be submitted on the same application due date for consideration by NHLBI.</p>			
084637	Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-19-328	14-Jan-2021	Not Specified
	Contact Name	Nahed El Kassar, MD			
	Contact Telephone	301-435-0065			
	Contact Email	nahed.elkassar@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	14-Jan-2021 , 11-Feb-2021 , 11-May-2021 , 10-Jun-2021 , 08-Sep-2021 , 14-Oct-2021 , 14-Jan-2022 , 11-Feb-2022 , 11-May-2022 , 10-Jun-2022 , 08-Sep-2022			
	Synopsis	<p>This Funding Opportunity Announcement (FOA) supports applications to develop and implement investigator-initiated single site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a bi-phasic, milestone-driven mechanism of award. The objective of the application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. The multiple PD/PI model is strongly encouraged but not required. Applicants are encouraged to include a PD/PI with expertise in biostatistics, clinical trial design, and coordination.</p>			
078369	New Research Directions that Advance the NHLBI Strategic Vision Normal Biology (R21 - Clinical Trial Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	PA-19-049	16-Feb-2021	275,000 USD
	Contact Name	Ravi Chandra Balijepalli, Ph.D.			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Telephone	301-435-0504
Contact Email	ravi.balijepalli@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021
Synopsis	The development of more effective means for diagnosing and treating heart, lung, blood, and sleep (HLBS) disorders is often aided by a detailed understanding of normal biology, specifically the nature and operations of the molecular systems and cells that are affected by those diseases. Areas of research interest include studies of fundamental processes that explain “resilience” – the capability of some individuals to maintain or restore normal function despite aging or exposure that causes disease in others. This Funding Opportunity Announcement (FOA) will support pilot studies by R01-funded investigators in areas of research that advance high priority studies of normal biology and resilience as described by Objective 1 of the NHLBI Strategic Vision.

100447	Notice of Special Interest (NOSI): Use of Predictive Analytics to Accelerate Late-Stage Implementation Research to Address Heart, Lung, Blood, and Sleep Disorders	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-20-815	05-Feb-2021	Not Specified
--------	--	--	---------------	-------------	---------------

Contact Name	Rebecca A. Roper, MS, MPH
Contact Telephone	301-496-1051
Contact Email	Rebecca.Roper@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024
Synopsis	NHLBI is issuing this Notice of Special Interest (NOSI) to leverage existing data resources using Predictive Analytics Implementation Research (PAIR) that utilizes complex and innovative methodologies and modeling techniques to rely on integration of existing data to inform the designs (and often test) implementation strategies for heart, lung, blood, and sleep (HLBS) conditions. NHLBI also encourages applications which focus on the development of advance modeling techniques and data reporting, which would be publicly available and could be used to inform subsequent implementation strategies to address HLBS conditions.

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
074657	The Mechanistic Role of the Microbiome in the Pathobiology of Heart, Lung, Blood, and Sleep Diseases (R01 - Clinical Trial Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	PA-18-784	05-Feb-2021	Not Specified
	<p>Contact Name Lis Caler, Ph.D.</p> <p>Contact Telephone 301-435-0222</p> <p>Contact Email lis.caler@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021</p> <p>Synopsis National Heart, Lung, and Blood Institute (NHLBI) invites applications for functional microbiome research focused on understanding the molecular, immunological and physiological mechanisms by which the microbiota (gut, lung, oral, including bacteria, viral and fungal microflora) and its derived factors modulate heart, lung, blood and sleep (HLBS) biology and physiology to promote health or contribute to disease. This FOA encourages mechanistic studies using in vitro, in vivo and/or ex vivo models that focus on the mechanistic and functional involvement of the microbiome and their components in the modulation or activation of host pathways. The goal is to provide the critical knowledge to guide early translational approaches for better understanding and treatment of HLBS conditions in adults and children. This FOA encourages multidisciplinary collaborations among scientists in a wide range of disciplines including (but not limited to) cardiology, pulmonology, hematology, sleep science, circadian biology, immunology, '-omic' sciences, microbiology, microbial ecology, biotechnology, and bioinformatics. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
086465	RFA-HL-20-029 -- Limited Competition: Small Grant Program for NHLBI K01/K08/K23 Recipients (R03 - Clinical Trial Optional)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-20-029	08-Feb-2021	100,000 USD
	<p>Contact Name Roya Kalantari, PhD</p> <p>Contact Telephone 301-480-1989</p> <p>Contact Email roya.kalantari@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Feb-2021 , 10-May-2021 , 08-Jun-2021 , 08-Sep-2021 , 08-Oct-2021 , 10-Jan-2022</p> <p>Synopsis The purpose of this FOA is to solicit current or recently completed NHLBI K01, K08, and K23 awardees for grant support to expand their current research objectives or to branch out to a study that resulted from the research conducted under the K award. Active NHLBI K01, K08, and K23 awardees may apply for R03 support to run concurrently with the final two years of</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>their K award. Recently completed NHLBI K01, K08, and K23 awardees are eligible to apply for the R03 if the earliest possible R03 start date falls within 2 years of their prior NHLBI K award Project Period end date. Thus, this FOA is intended to enhance the capability of NHLBI K01, K08, and K23 award recipients to conduct research as they complete their transition to fully independent investigator status. The R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. For current and previous K23 awardees, research proposed in the R03 application may or may not include patient-oriented research. The R03 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that provide preliminary data to support a subsequent R01, or equivalent, application.</p>			
074423	NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22 Independent Clinical Trial Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-18-772	12-Feb-2021	Not Specified
	Contact Name	Herbert M. Geller, Ph.D.			
	Contact Telephone	301-451-9440			
	Contact Email	direducation@nhlbi.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	12-Feb-2021 , 07-May-2021			
	Synopsis	<p>National Heart, Lung, and Blood Institute (NHLBI) provides highly qualified postdoctoral fellows and other doctoral-level researchers still in training in the NHLBI Division of Intramural Research the opportunity to transition their research programs to extramural institutions as junior investigators. To achieve these objectives, the NHLBI Career Transition Award will support two phases of research: a mentored intramural phase (up to two years) and an extramural phase (three years), for a total of five years of combined support. Transition from the intramural phase of support to the extramural phase is not automatic. Approval of the transition will be based on the success of the awardee's research program during the mentored phase as determined by an NHLBI progress review, which will include an evaluation of a research plan to be carried out at the extramural institution. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. This Funding Opportunity Announcement (FOA) will utilize the NIH K22 Career Transition Award mechanism.</p>			
074422	NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22 Clinical Trial Required)	National Heart, Lung, and Blood Institute/NIH/DHHS	PAR-18-771	12-Feb-2021	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name	Herbert M. Geller, Ph.D.
Contact Telephone	301-451-9440
Contact Email	direducation@nhlbi.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	12-Feb-2021 , 07-May-2021
Synopsis	National Heart, Lung, and Blood Institute (NHLBI) provides highly qualified postdoctoral fellows and other doctoral-level researchers still in training in the NHLBI Division of Intramural Research the opportunity to transition their research programs to extramural institutions as junior investigators. To achieve these objectives, the NHLBI Career Transition Award will support two phases of research: a mentored intramural phase (up to two years) and an extramural phase (three years), for a total of five years of combined support. Transition from the intramural phase of support to the extramural phase is not automatic. Approval of the transition will be based on the success of the awardee's research program during the mentored phase as determined by an NHLBI progress review, which will include an evaluation of a research plan to be carried out at the extramural institution. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. This Funding Opportunity Announcement (FOA) will utilize the NIH K22 Career Transition Award mechanism.

076311	RFA-HL-19-026 -- Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research (K01 Independent Clinical Trial Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-19-026	11-Feb-2021	750,000 USD
--------	---	--	---------------	-------------	-------------

Contact Name	Jane D. Scott, ScD, MSN, FAHA
Contact Telephone	301-435-0535
Contact Email	scottj2@nhlbi.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	11-Feb-2021 , 06-May-2021
Synopsis	National Heart, Lung, and Blood Institute (NHLBI) invites applications to enhance the pool of highly trained investigators from diverse backgrounds, including those from groups underrepresented in research areas of interest to the NHLBI. The career development will take place under the guidance of an experienced mentor in the biomedical, behavioral or clinical sciences

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

leading to research independence. It is targeted toward individuals whose basic, clinical, and translational research interests are grounded in the advanced methods and experimental approaches needed to solve problems related to cardiovascular, pulmonary, and hematologic diseases and sleep disorders in the general and health disparities populations. This FOA invites applications from institutions with eligible faculty members to undertake special study and supervised research under a mentor who is an accomplished investigator in the research area proposed and has experience in developing independent investigators. This FOA is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. This FOA will utilize the NIH K01 Research Scientist Development Award - Research & Training award mechanism.

076292	RFA-HL-19-025 -- Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research (K01 Independent Clinical Trial Required)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-19-025	11-Feb-2021	750,000 USD
--------	--	--	---------------	-------------	-------------

Contact Name | Jane D. Scott, ScD, MSN, FAHA
 Contact Telephone | 301-435-0535
 Contact Email | scottj2@nhlbi.nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 11-Feb-2021 , 06-May-2021

Synopsis | National Heart, Lung, and Blood Institute (NHLBI) invites applications to enhance the pool of highly trained investigators from diverse backgrounds, including those from groups underrepresented in research areas of interest to the NHLBI. The career development will take place under the guidance of an experienced mentor in the biomedical, behavioral or clinical sciences leading to research independence. It is targeted toward individuals whose basic, clinical, and translational research interests are grounded in the advanced methods and experimental approaches needed to solve problems related to cardiovascular, pulmonary, and hematologic diseases and sleep disorders in the general and health disparities populations. This FOA invites applications from institutions with eligible faculty members to undertake special study and supervised research under a mentor who is an accomplished investigator in the research area proposed and has experience in developing independent investigators. This FOA is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. This FOA will utilize the NIH K01 Research Scientist Development Award - Research & Training award mechanism.

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
079552	Implementation of Shared Decision Making for HLBS Diseases and Conditions (R01 Clinical Trial Optional)	National Heart, Lung, and Blood Institute/NIH/DHHS	PA-19-166	05-Feb-2021	2,499,995 USD
	<p>Contact Name: Susan T. Shero, BSN, MS</p> <p>Contact Telephone: 301-496-1051</p> <p>Contact Email: sheros@nih.gov</p> <p>Sponsor Website:</p> <p>Program URL: Link to program URL</p> <p>Deadline Dates (ALL): 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022</p> <p>Synopsis: The purpose of this initiative is to support research that uses evidence-based, practical approaches to increase the uptake of shared decision making (SDM) into routine clinical practice. Objectives are to improve patient-centered care for heart, lung, blood, and sleep (HLBS) diseases and conditions; and to address barriers and facilitators related to SDM strategies used to improve quality of care, adherence, and informed consent; reduce health disparities; and deliver treatments best suited for individual patients. Investigators and multidisciplinary research teams with expertise in clinical implementation research, health information technology, behavioral science, behavioral economics, workflow design, and organizational engineering are encouraged to apply.</p>				
100825	Notice of Special Interest (NOSI): Integrative Omics Analysis of NHLBI TOPMed Data (Parent R01 Clinical Trial Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-20-823	05-Feb-2021	Not Specified
	<p>Contact Name: Weiniu Gan, Ph.D.</p> <p>Contact Telephone: 301-435-0202</p> <p>Contact Email: ganw2@mail.nih.gov</p> <p>Sponsor Website:</p> <p>Program URL: Link to program URL</p> <p>Deadline Dates (ALL): 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023</p> <p>Synopsis: The symptom-based diagnosis and treatment of heart, lung, blood, and sleep (HLBS) diseases has vastly improved in recent years, yet an understanding of the molecular mechanisms underlying many of these diseases has remained elusive. Furthermore, in most cases the impact of genetic variation on severity of disease and treatment outcomes remains unknown. Therefore, the NHLBI has recently created the Trans Omics for Precision Medicine (TOPMed) program, which aims to utilize high throughput omics to characterize a variety of HLBS diseases. TOPMed is well on its way to collecting whole genome</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
099803	Notice of Special Interest (NOSI): Palliative Care in Heart, Lung, Blood, and Sleep Diseases	National Heart, Lung, and Blood Institute/NIH/DHHS	NOT-HL-20-737	05-Feb-2021	Not Specified

sequence from over 130,000 well-phenotyped individuals and is currently generating high-throughput expression and other “omics” data (e.g. RNA, DNA methylation, metabolites, and proteins) from many of these individuals to complement whole genome sequence information. Having produced an unprecedented volume of high-throughput data, TOPMed now seeks to turn its attention to effectively leveraging this resource through novel systems biology analyses to uncover disease pathobiology. Although lower costs and technological improvements in sequencing technology have vastly expanded our ability to generate large volumes of omics data, the ability to analyze such large datasets to extract biologically meaningful insights from them remains challenging. Systems level models incorporating trans-omics analyses will be an important step in uncovering the underlying biological networks, gene-gene and gene-environment interactions influencing disease and treatment outcomes. Thus, advanced analyses that incorporate genotype and phenotype datasets from thousands to tens of thousands of individuals are required to move TOPMed to the next phase of discovery.

Contact Name	Lora Reineck, MD, MS
Contact Telephone	301-435-0222
Contact Email	lora.reineck@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023
Synopsis	<p>Providing care that is consistent with a patient’s values, preferences, and goals is a cornerstone of palliative care, an interdisciplinary patient-centered approach that aims to improve quality of life for persons with advanced illness and their families. Palliative care focuses on several objectives including relief of symptoms and suffering, communication of prognosis and treatment options in the context of patients’ goals, and coordination of care within and across healthcare settings. Palliative care is not synonymous with hospice or end-of-life care. Rather, palliative care addresses the spectrum of care for serious illness from diagnosis through terminal stages of diseases. Moreover, palliative care does not necessarily entail withholding or curbing treatment. Relief of symptoms, enhancing quality of life, and many other specific aspects of goal-concordant care may, in fact, involve optimal medical or surgical treatment of diseases. The expected outcome of integrating palliative care into the management of the patient’s disease is a better quality of life, a realistic understanding of risks and benefits of treatment and interventions, and medical treatment decisions that align with the patient’s goals, preferences, and values. Many heart, lung, blood, and sleep (HLBS) diseases, including heart failure, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, pulmonary hypertension, cystic fibrosis, myelodysplastic syndromes, and aplastic anemia are life-</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

limiting, non-curable illnesses. These and other HLBS diseases may benefit from care focused on improvement of symptoms and quality of life, in addition to care focused on slowing or halting progression of diseases. Integration of palliative care into cardiology, pulmonary, hematology, and critical care practice is recommended by multiple professional societies. Additionally, symptoms of HLBS diseases such as cough, shortness of breath, and fatigue may be especially burdensome, even in diseases that are not life-limiting. Research to improve burdensome symptoms has the potential to greatly improve the quality of life for all patients with HLBS diseases, not just those with life-limiting disease.

076415	Novel Approaches for Relating Genetic Variation to Function and Disease (R01 Clinical Trial Not Allowed)	National Human Genome Research Institute/NIH/DHHS	PA-18-868	05-Feb-2021	Not Specified
--------	--	---	-----------	-------------	---------------

Contact Name	Lisa D. Brooks, Ph.D.
Contact Telephone	301-547-1387
Contact Email	Lisa.Brooks@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Feb-2021 , 05-Jun-2021
Synopsis	National Human Genome Research Institute (NHGRI) invites applications for the development of novel and generalizable approaches to study how genetic variants lead to differences in function and to study how such functional differences affect human health and disease processes or how this knowledge can be used clinically. This FOA will use the NIH Research Project (R01) award mechanism.

090720	RFA-HG-20-016 -- Novel Synthetic Nucleic Acid Technology Development (R43/R44) (Clinical Trial Not Allowed)	National Human Genome Research Institute/NIH/DHHS	RFA-HG-20-016	07-Feb-2021 [Optional][LOI/Pre-App]	Not Specified
--------	---	---	---------------	-------------------------------------	---------------

Contact Name	Michael W. Smith, Ph.D.
Contact Telephone	301-480-3413
Contact Email	smithmw@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	07-Feb-2021 [Optional][LOI/Pre-App], 09-Mar-2021 , 05-Jan-2022 [Optional][LOI/Pre-App], 04-Feb-2022
Synopsis	This Funding Opportunity Announcement (FOA) solicits R43/R44 grant applications to develop novel technologies that will

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		enable substantive (no less than one order of magnitude) improvement in commercial synthetic nucleic acids. The goal is to improve the quality, capabilities and efficiency of commercial nucleic acid synthesis and synthetic constructs at reasonable and decreased costs. Applicants may propose to develop novel complete synthesis and/or synthetic constructs systems, investigate challenges underlying key novel system components, or propose substantive improvements of at least an order of magnitude improvement to existing commercial systems. Exploration of methods other than those currently commercially in use is highly encouraged.			
090708	RFA-HG-20-014 -- Novel Synthetic Nucleic Acid Technology Development (R01 Clinical Trial not allowed)	National Human Genome Research Institute/NIH/DHHS	RFA-HG-20-014	07-Feb-2021 [Optional][LOI/Pre-App]	2,100,000 USD
	Contact Name	Michael W. Smith, Ph.D.			
	Contact Telephone	301-480-3413			
	Contact Email	smithmw@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-Feb-2021 [Optional][LOI/Pre-App], 09-Mar-2021 , 05-Jan-2022 [Optional][LOI/Pre-App], 04-Feb-2022			
	Synopsis	This Funding Opportunity Announcement (FOA) solicits R01 grant applications to develop novel technologies that will enable substantive (no less than one order of magnitude) improvement in synthetic nucleic acids. The goal is to improve the quality, capabilities and efficiency of nucleic acid synthesis and synthetic constructs at reasonable and decreased costs. Large progress in this area has the potential to catalyze scientific advances relevant to the mission of NIH, NHGRI and the field of genomics.			
090719	RFA-HG-20-015 -- Novel Synthetic Nucleic Acid Technology Development (R21) (Clinical Trial not allowed)	National Human Genome Research Institute/NIH/DHHS	RFA-HG-20-015	07-Feb-2021 [Optional][LOI/Pre-App]	400,000 USD
	Contact Name	Michael W. Smith, Ph.D.			
	Contact Telephone	301-480-3413			
	Contact Email	smithmw@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-Feb-2021 [Optional][LOI/Pre-App], 09-Mar-2021 , 05-Jan-2022 [Optional][LOI/Pre-App], 04-Feb-2022			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p>	<p>This Funding Opportunity Announcement (FOA) solicits R21 grant applications to develop novel technologies that will enable substantive (no less than one order of magnitude) improvement in synthetic nucleic acids. The goal is to improve the quality, capabilities and efficiency of nucleic acid synthesis and synthetic constructs at reasonable and decreased costs. Applicants may propose to develop novel complete synthesis and/or synthetic constructs systems, investigate challenges underlying key novel system components, or propose substantive improvements of at least an order of magnitude improvement to existing systems. Exploration of methods other than those currently in use is highly encouraged. High-risk/high-payoff applications are appropriate to achieve the goals of this FOA.</p>			
095566	<p>RFA-HG-20-037 -- Advancing Genomic Medicine Research (R21 Clinical Trial Optional)</p>	National Human Genome Research Institute/NIH/DHHS	RFA-HG-20-037	06-Feb-2021 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Ms. Christine Chang</p> <p>301-480-2255</p> <p>christine.chang2@nih.gov</p> <p></p> <p>Link to program URL</p> <p>06-Feb-2021 [Optional][LOI/Pre-App], 08-Mar-2021 , 03-Oct-2021 [Optional][LOI/Pre-App], 02-Nov-2021 , 02-Jul-2022 [Optional][LOI/Pre-App], 01-Aug-2022 , 11-Feb-2023 [Optional][LOI/Pre-App], 13-Aug-2023</p> <p>This Funding Opportunity Announcement (FOA) encourages applications that stimulate innovation and advance understanding of when, where, and how best to implement the use of genomic information and technologies in clinical care. Proposed projects should be broadly applicable to genomic medicine as a field, and yield findings of significance beyond a single disease, gene, or setting. Projects are strongly encouraged to include ancestrally diverse and underrepresented participants and populations.</p>			
095564	<p>RFA-HG-20-036 -- Advancing Genomic Medicine Research (R01 Clinical Trial Optional)</p>	National Human Genome Research Institute/NIH/DHHS	RFA-HG-20-036	06-Feb-2021 [Optional][LOI/Pre-App]	3,000,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p>	<p>Ms. Christine Chang</p> <p>301-480-2255</p> <p>christine.chang2@nih.gov</p> <p></p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 06-Feb-2021 [Optional][LOI/Pre-App], 08-Mar-2021 , 03-Oct-2021 [Optional][LOI/Pre-App], 02-Nov-2021 , 02-Jul-2022 [Optional][LOI/Pre-App], 01-Aug-2022 , 11-Feb-2023 [Optional][LOI/Pre-App], 13-Aug-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages applications that stimulate innovation and advance understanding of when, where, and how best to implement the use of genomic information and technologies in clinical care. Proposed projects should be broadly applicable to genomic medicine as a field, and yield findings of significance beyond a single disease, gene, or setting. Projects are strongly encouraged to include ancestrally diverse and underrepresented participants and populations.</p>				
076417	Novel Approaches for Relating Genetic Variation to Function and Disease (R21 Clinical Trial Not Allowed)	National Human Genome Research Institute/NIH/DHHS	PA-18-867	16-Feb-2021	275,000 USD
	<p>Contact Name Lisa D. Brooks, Ph.D.</p> <p>Contact Telephone 301-547-1387</p> <p>Contact Email Lisa.Brooks@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 16-Jun-2021</p> <p>Synopsis National Human Genome Research Institute (NHGRI) invites applications for the development of novel and generalizable approaches to study how genetic variants lead to differences in function and to study how such functional differences affect human health and disease processes or how this knowledge can be used clinically. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</p>				
101030	Notice of Special Interest (NOSI): Clone Program (Defunct)	National Human Genome Research Institute/NIH/DHHS	NOT-HG-21-004	05-Feb-2021	Not Specified
	<p>Contact Name Colin Fletcher, Ph.D.</p> <p>Contact Telephone 301-496-7531</p> <p>Contact Email fletcher2@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 16-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 08-Jan-</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	2022 , 05-Feb-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 05-Oct-2023 , 07-Jan-2024 The National Human Genome Research Institute (NHGRI) is issuing this Notice of Special Interest (NOSI) to encourage applications focused on developing novel methods to perform high-throughput molecular and cellular phenotyping in order to elucidate the functional consequences of DNA variation.			
101174	Notice of Special Interest (NOSI): Advancing Genomic Technology Development for Research and Clinical Application	National Human Genome Research Institute/NIH/DHHS	NOT-HG-21-018	05-Feb-2021	Not Specified
	Contact Name	Michael W. Smith, Ph.D.			
	Contact Telephone	301-480-3413			
	Contact Email	smithmw@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Feb-2021 , 16-Feb-2021 , 05-Apr-2021 , 07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 05-Jan-2022 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 05-Apr-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 05-Sep-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 05-Jan-2023 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 05-Apr-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 05-Sep-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 05-Jan-2024 , 07-Jan-2024			
	Synopsis	The National Human Genome Research Institute (NHGRI) is issuing this Notice of Special Interest (NOSI) to encourage applications focused on developing novel laboratory-focused tools and technologies that enable new lines of scientific inquiry and clinical applications in human genomics.			
100014	RFA-AI-20-055 -- Understanding Evolutionary Dynamics of Influenza to Inform and Improve Vaccine Strain Selection (R01 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-20-055	11-Jan-2021 [Optional][LOI/Pre-App]	Not Specified
	Contact Name	Brooke Bozick, Ph.D.			
	Contact Telephone	301-761-6710			
	Contact Email	brooke.bozick@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
<p>Deadline Dates (ALL) 11-Jan-2021 [Optional][LOI/Pre-App], 11-Feb-2021</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support research to improve understanding of the evolutionary dynamics of seasonal influenza to increase our capacity to predict the emergence of new antigenic variants and more accurately select strains for use in the seasonal influenza vaccine.</p>					
100046	RFA-AI-20-057 -- Understanding the Role of the M. Tuberculosis Granuloma in Tuberculosis (TB) Disease and Treatment Outcomes (R01 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-20-057	22-Jan-2021 [Optional][LOI/Pre-App]	Not Specified
<p>Contact Name Karen A. Lacourciere, Ph.D.</p> <p>Contact Telephone 240-627-3297</p> <p>Contact Email lacourcierek@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 22-Jan-2021 [Optional][LOI/Pre-App], 22-Feb-2021</p> <p>Synopsis To support research to better define the role of the granuloma, the hallmark structure of pulmonary tuberculosis (TB), in TB disease and disease outcomes. Improved understanding of the granuloma will provide a much-needed knowledge base for the development of improved therapeutic approaches.</p>					
076258	Advancing Research Needed to Develop a Universal Influenza Vaccine (R01 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-18-859	05-Feb-2021	Not Specified
<p>Contact Name Diane Post, Ph.D.</p> <p>Contact Telephone 240-627-3348</p> <p>Contact Email postd@niaid.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 05-Jun-2021</p> <p>Synopsis National Institute of Allergy and Infectious Diseases (NIAID) invites applications for research activities that will advance NIAID's mission to develop a universal influenza vaccine providing durable protection against multiple influenza strains, including efforts to: 1) improve understanding of transmission, natural history and pathogenesis of influenza virus infection; 2) characterize influenza immunity and correlates of immune protection; and 3) support rational design of universal influenza</p>					

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

| vaccines. This FOA will use the NIH Research Project (R01) award mechanism.

078788	Control of Sexually Transmitted Infections (STIs) Through a Comprehensive Understanding of the Natural History of Infection (R01 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-19-096	05-Feb-2021	Not Specified
--------	--	--	-----------	-------------	---------------

Contact Name	Leah R. Vincent, Ph.D.
Contact Telephone	301-761-7365
Contact Email	leah.vincent@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to encourage research to advance the understanding of natural history of infection for three sexually transmitted infections (STIs): gonorrhea, syphilis, and chlamydia. This research opportunity encourages studies that address the natural history of infection in the context of either: 1) correlates of protection, 2) host response to infection, 3) clinical endpoints of disease, or 4) biological and clinical factors that influence clearance rather than persistence of infection.

073273	Generating New Insights and Mechanistic Understanding of Antibiotic Resistance Development (R01 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-18-725	05-Feb-2021	Not Specified
--------	---	--	-----------	-------------	---------------

Contact Name	Ryan Ranallo, Ph.D.
Contact Telephone	240-627-3351
Contact Email	ryan.ranallo@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Feb-2021
Synopsis	National Institute of Allergy and Infectious Diseases (NIAID) invites applications for select areas of research recognized as critical in the National Action Plan for Combating Antibiotic-Resistant Bacteria (CARB), including research focused on understanding the nature of microbial communities, how antibiotics affect them, and how they can be harnessed to prevent disease, as well as research exploring combination therapies to address the emergence of resistance. This FOA will use the NIH Research Project (R01) award mechanism.

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
072905	Investigations on Primary Immunodeficiency Diseases/Inborn Errors of Immunity (R01 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-18-712	05-Feb-2021	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>Frosso Voulgaropoulou, Ph.D.</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td>240-627-3205</td> </tr> <tr> <td style="padding-right: 5px;">Contact Email</td> <td>fvoulgaropoulou@niaid.nih.gov</td> </tr> <tr> <td style="padding-right: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="padding-right: 5px;">Deadline Dates (ALL)</td> <td>05-Feb-2021</td> </tr> <tr> <td style="padding-right: 5px;">Synopsis</td> <td>National Institute of Allergy and Infectious Diseases (NIAID) invites applications for the discovery and characterization of primary immunodeficiency diseases, also referred to as inborn errors of immunity, to understand the causes and mechanisms of disease, to enable early detection and molecular diagnosis, and to support the development of strategies to treat and eventually cure these disorders. This FOA will use the NIH Research Project (R01) award mechanism.</td> </tr> </table>					Contact Name	Frosso Voulgaropoulou, Ph.D.	Contact Telephone	240-627-3205	Contact Email	fvoulgaropoulou@niaid.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	05-Feb-2021	Synopsis	National Institute of Allergy and Infectious Diseases (NIAID) invites applications for the discovery and characterization of primary immunodeficiency diseases, also referred to as inborn errors of immunity, to understand the causes and mechanisms of disease, to enable early detection and molecular diagnosis, and to support the development of strategies to treat and eventually cure these disorders. This FOA will use the NIH Research Project (R01) award mechanism.
Contact Name	Frosso Voulgaropoulou, Ph.D.																		
Contact Telephone	240-627-3205																		
Contact Email	fvoulgaropoulou@niaid.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	05-Feb-2021																		
Synopsis	National Institute of Allergy and Infectious Diseases (NIAID) invites applications for the discovery and characterization of primary immunodeficiency diseases, also referred to as inborn errors of immunity, to understand the causes and mechanisms of disease, to enable early detection and molecular diagnosis, and to support the development of strategies to treat and eventually cure these disorders. This FOA will use the NIH Research Project (R01) award mechanism.																		
076260	Advancing Research Needed to Develop a Universal Influenza Vaccine (R01 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-18-858	16-Feb-2021	275,000 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>Diane Post, Ph.D.</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td>240-627-3348</td> </tr> <tr> <td style="padding-right: 5px;">Contact Email</td> <td>postd@niaid.nih.gov</td> </tr> <tr> <td style="padding-right: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="padding-right: 5px;">Deadline Dates (ALL)</td> <td>16-Feb-2021 , 16-Jun-2021</td> </tr> <tr> <td style="padding-right: 5px;">Synopsis</td> <td>National Institute of Allergy and Infectious Diseases (NIAID) invites applications for research activities that will advance NIAID's mission to develop a universal influenza vaccine providing durable protection against multiple influenza strains, including efforts to: 1) improve understanding of transmission, natural history and pathogenesis of influenza virus infection; 2) characterize influenza immunity and correlates of immune protection; and 3) support rational design of universal influenza vaccines. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</td> </tr> </table>					Contact Name	Diane Post, Ph.D.	Contact Telephone	240-627-3348	Contact Email	postd@niaid.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	16-Feb-2021 , 16-Jun-2021	Synopsis	National Institute of Allergy and Infectious Diseases (NIAID) invites applications for research activities that will advance NIAID's mission to develop a universal influenza vaccine providing durable protection against multiple influenza strains, including efforts to: 1) improve understanding of transmission, natural history and pathogenesis of influenza virus infection; 2) characterize influenza immunity and correlates of immune protection; and 3) support rational design of universal influenza vaccines. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.
Contact Name	Diane Post, Ph.D.																		
Contact Telephone	240-627-3348																		
Contact Email	postd@niaid.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	16-Feb-2021 , 16-Jun-2021																		
Synopsis	National Institute of Allergy and Infectious Diseases (NIAID) invites applications for research activities that will advance NIAID's mission to develop a universal influenza vaccine providing durable protection against multiple influenza strains, including efforts to: 1) improve understanding of transmission, natural history and pathogenesis of influenza virus infection; 2) characterize influenza immunity and correlates of immune protection; and 3) support rational design of universal influenza vaccines. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.																		
100208	RFA-AI-20-056 -- Coccidioidomycosis Collaborative Research Centers (U19 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-20-056	19-Jan-2021 [Optional][LOI/Pre-App]	6,000,000 USD														

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Dona Love, Ph.D.</p> <p>Contact Telephone 240-695-7097</p> <p>Contact Email dona.love@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 19-Jan-2021 [Optional][LOI/Pre-App], 18-Feb-2021</p> <p>Synopsis The purpose of the Funding Opportunity announcement (FOA) is to solicit applications for a Coccidioidomycosis Collaborative Research Centers (CCRC) program. This new initiative will establish highly collaborative, multi-disciplinary research teams to conduct translational and clinical research for the improved diagnosis, treatment and prevention of coccidioidomycosis (Valley fever).</p>				
078712	Advancing Development of Rapid Fungal Diagnostics (R01 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-19-080	05-Feb-2021	Not Specified
	<p>Contact Name Dona Love, Ph.D.</p> <p>Contact Telephone 301-761-7788</p> <p>Contact Email dona.love@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021</p> <p>Synopsis The purpose of this Funding Opportunity Announcement is to support the development of rapid, sensitive, specific, simple, and cost-effective diagnostics for primary health-care settings (hospitals and point-of-care).</p>				
078715	Novel Approaches to Understand, Prevent, Treat, and Diagnose coccidioidomycosis (Valley Fever) and Other Select Endemic Fungal Infections (R01 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-19-082	05-Feb-2021	Not Specified
	<p>Contact Name Dona Love, Ph.D.</p> <p>Contact Telephone 301-761-7788</p> <p>Contact Email dona.love@nih.gov</p> <p>Sponsor Website </p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021</p> <p>Synopsis The purpose of this Funding Opportunity Announcement is to support research activities that will contribute to the overall understanding of coccidioidomycosis, commonly known as Valley Fever, and other select endemic fungal diseases including histoplasmosis and blastomycosis. This research opportunity encourages studies that address diverse scientific areas such as: 1) pathogenesis; 2) host response; 3) disease transmission; 4) natural history and environmental factors contributing to disease; 5) vaccines; 6) diagnostics; and 7) therapeutics; with the ultimate goal of advancing the field towards solutions for the improved detection, prevention and treatment of select endemic mycoses.</p>				
098066	Notice of Special Interest (NOSI): Availability of Emergency Awards for Limited Clinical Trials to Evaluate Therapeutic and Vaccine Candidates Against SARS-CoV-2	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-20-065	14-Jan-2021	Not Specified
	<p>Contact Name Diane Post, Ph.D.</p> <p>Contact Telephone 240-627-3348</p> <p>Contact Email NIAIDCOVIDIICTNOSI@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 14-Jan-2021 , 14-Feb-2021 , 14-Mar-2021 , 14-Apr-2021 , 14-May-2021 , 14-Jun-2021 , 14-Jul-2021 , 14-Aug-2021 , 14-Sep-2021</p> <p>Synopsis This Notice of Special Interest encourages cooperative agreement applications for implementation of investigator-initiated high-risk clinical trials, as defined by NIAID in PAR-18-633 and NOT-AI-16-084, that will augment ongoing and planned clinical trials of therapeutic and vaccine candidates directed against SARS-CoV-2 to evaluate: SARS-CoV-2 candidate vaccines non-vaccine biomedical prevention of SARS-CoV-2 infection and/or COVID-19 therapeutic approaches to treat COVID-19</p>				
078718	Molecular and Genetic Characterization of Inborn Errors of Immunity (RO1 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-19-078	05-Feb-2021	Not Specified
	<p>Contact Name Frosso Voulgaropoulou, PhD</p> <p>Contact Telephone 240-627-3205</p> <p>Contact Email fvoulgaropoulou@niaid.nih.gov</p> <p>Sponsor Website</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to advance the experimental validation and functional characterization of genetic variants in coding or non-coding genomic regions that result in inborn errors of immunity/primary immunodeficiency diseases and to elucidate the molecular, cellular, and immunological mechanisms of these disorders. Understanding the genetic basis of primary immunodeficiency disorders is essential for their diagnosis, prognosis, and the development of precision therapeutics.</p>				
078710	Accelerating Malaria Vaccine Discovery (R01 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-19-077	05-Feb-2021	Not Specified
	<p>Contact Name Annie Mo, Ph.D.</p> <p>Contact Telephone 240-627-3320</p> <p>Contact Email moa@niaid.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support early phase translational research that will generate new malaria vaccine candidates suitable for further downstream development and clinical evaluation. This research opportunity encourages studies that will lead to discovery of new vaccine candidates that prevent infection, ameliorate disease, and/or interrupt transmission caused by human malaria parasites, especially P. falciparum and P. vivax.</p>				
078719	Molecular and Genetic Characterization of Inborn Errors of Immunity (R21 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-19-079	16-Feb-2021	275,000 USD
	<p>Contact Name Frosso Voulgaropoulou, PhD</p> <p>Contact Telephone 240-627-3205</p> <p>Contact Email fvoulgaropoulou@niaid.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to advance the experimental validation and functional</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

characterization of genetic variants in coding or non-coding genomic regions that result in inborn errors of immunity/primary immunodeficiency diseases and to elucidate the molecular, cellular, and immunological mechanisms of these disorders. Understanding the genetic basis of primary immunodeficiency disorders is essential for their diagnosis, prognosis, and the development of precision therapeutics.

078717	Novel Approaches to Understand, Prevent, Treat, and Diagnose coccidioidomycosis (Valley Fever) and Other Select Endemic Fungal Infections (R21 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-19-083	16-Feb-2021	275,000 USD
--------	--	--	-----------	-------------	-------------

Contact Name | Dona Love, Ph.D.
 Contact Telephone | 301-761-7788
 Contact Email | dona.love@nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021

Synopsis | The purpose of this Funding Opportunity Announcement is to support research activities that will contribute to the overall understanding of coccidioidomycosis, commonly known as Valley Fever, and other select endemic fungal diseases including histoplasmosis and blastomycosis. This research opportunity encourages studies that address diverse scientific areas such as: 1) pathogenesis; 2) host response; 3) disease transmission; 4) natural history and environmental factors contributing to disease; 5) vaccines; 6) diagnostics; and 7) therapeutics; with the ultimate goal of advancing the field towards solutions for the improved detection, prevention and treatment of select endemic mycoses.

078714	Advancing Development of Rapid Fungal Diagnostics (R01 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-19-081	16-Feb-2021	275,000 USD
--------	--	--	-----------	-------------	-------------

Contact Name | Dona Love, Ph.D.
 Contact Telephone | 301-761-7788
 Contact Email | dona.love@nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021

Synopsis | The purpose of this Funding Opportunity Announcement is to support the development of rapid, sensitive, specific, simple,

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		and cost-effective diagnostics for primary health-care settings (hospitals and point-of-care).			
073282	Generating New Insights and Mechanistic Understanding of Antibiotic Resistance Development (R21 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-18-724	16-Feb-2021	275,000 USD
	Contact Name	Ryan Ranallo, Ph.D.			
	Contact Telephone	240-627-3351			
	Contact Email	ryan.ranallo@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Feb-2021			
	Synopsis	National Institute of Allergy and Infectious Diseases (NIAID) invites applications for select areas of research recognized as critical in the National Action Plan for Combating Antibiotic-Resistant Bacteria (CARB), including research focused on understanding the nature of microbial communities, how antibiotics affect them, and how they can be harnessed to prevent disease, as well as research exploring combination therapies to address the emergence of resistance. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.			
084965	Investigations on Primary Immunodeficiency Diseases/Inborn Errors of Immunity (R03 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-19-347	16-Feb-2021	100,000 USD
	Contact Name	Frosso Voulgaropoulou, Ph.D.			
	Contact Telephone	240-627-3205			
	Contact Email	fvoulgaropoulou@niaid.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support the discovery and characterization of primary immunodeficiency diseases, also referred to as inborn errors of immunity, to understand the causes and mechanisms of disease, to enable early detection and molecular diagnosis, and to support the development of strategies to treat and eventually cure these disorders.			
084962	Investigations on Primary Immunodeficiency Diseases/Inborn Errors of Immunity (R21 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-19-346	16-Feb-2021	275,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Frosso Voulgaropoulou, Ph.D.</p> <p>Contact Telephone 240-627-3205</p> <p>Contact Email fvoulgaropoulou@niaid.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support the discovery and characterization of primary immunodeficiency diseases, also referred to as inborn errors of immunity, to understand the causes and mechanisms of disease, to enable early detection and molecular diagnosis, and to support the development of strategies to treat and eventually cure these disorders.</p>				
078569	Secondary Analysis of Existing Datasets for Advancing Infectious Disease Research (R21 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-19-068	16-Feb-2021	275,000 USD
	<p>Contact Name Ishwar Chandramouliswaran M.S., M.B.A.</p> <p>Contact Telephone 301-761-7822</p> <p>Contact Email ishwar.chandramouliswaran@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support projects that utilize open-access data, alone or in combination with other datasets, to address knowledge gaps in basic and/or clinical research in infectious diseases.</p>				
100061	RFA-AI-20-060 -- Cohort Studies To Improve Our Understanding of Influenza Immunity, Vaccine Response and Effectiveness in Older Adults (65 years and older) (U01 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-20-060	02-Feb-2021	Not Specified
	<p>Contact Name Mercy PrabhuDas, PhD, MBA</p> <p>Contact Telephone 240-627-3534</p> <p>Contact Email mprabhudas@niaid.nih.gov</p> <p>Sponsor Website </p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Program URL	Link to program URL
Deadline Dates (ALL)	02-Feb-2021
Synopsis	This initiative will support the use of longitudinal cohorts to develop greater understanding of important elements of influenza immunity that impact vaccine response and vaccine effectiveness in older adults (those 65 and older). In addition, this work will increase our understanding of how these elements relate to severe outcomes from influenza virus infection in older adults (i.e., hospitalization and death).

076435	Research to Advance Vaccine Safety (R21 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-18-872	16-Feb-2021	275,000 USD
--------	---	--	-----------	-------------	-------------

Contact Name	Barbara Mulach, Ph.D.
Contact Telephone	240-627-3322
Contact Email	bmulach@niaid.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	16-Feb-2021 , 16-Jun-2021 , 07-Sep-2021
Synopsis	The National Institutes of Health (NIH) and Centers for Disease Control and Prevention (CDC) and their participating Institutes and Centers invite applications to support research that will contribute to the overall understanding of vaccine safety. This research opportunity encourages studies that address scientific areas potentially relevant to vaccine safety, such as: 1) characterization of physiological and immunological responses to vaccines and vaccine components, including different adjuvants; 2) how genetic variations affect immune/physiological responses that may impact vaccine safety; 3) identification of risk factors e.g., infection history, predisposition to or presence of allergic and/or autoimmune disease and biological markers that may be used to assess whether there is a relationship between certain diseases or disorders and licensed vaccines; 4) creation/evaluation of statistical methodologies for analyzing data on vaccine safety, including data available from existing data sources, such as passive reporting systems or healthcare databases; or 5) the application of genomic/molecular technologies and systems biology approaches to evaluate vaccine safety. This FOA aligns with the research goals and objectives outlined in the U.S. National Vaccine Plan. This program will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.

076434	Research to Advance Vaccine Safety (R01 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-18-873	05-Feb-2021	Not Specified
--------	---	--	-----------	-------------	---------------

Contact Name	Barbara Mulach, Ph.D.
--------------	-----------------------

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 240-627-3322</p> <p>Contact Email bmulach@niaid.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 05-Jun-2021 , 07-Sep-2021</p> <p>Synopsis The National Institutes of Health (NIH) and Centers for Disease Control and Prevention (CDC) and their participating Institutes and Centers invite applications to support research that will contribute to the overall understanding of vaccine safety. This research opportunity encourages studies that address scientific areas potentially relevant to vaccine safety, such as: 1) characterization of physiological and immunological responses to vaccines and vaccine components, including different adjuvants; 2) how genetic variations affect immune/physiological responses that may impact vaccine safety; 3) identification of risk factors e.g., infection history, predisposition to or presence of allergic and/or autoimmune disease and biological markers that may be used to assess whether there is a relationship between certain diseases or disorders and licensed vaccines; 4) creation/evaluation of statistical methodologies for analyzing data on vaccine safety, including data available from existing data sources, such as passive reporting systems or healthcare databases; or 5) the application of genomic/molecular technologies and systems biology approaches to evaluate vaccine safety. This FOA aligns with the research goals and objectives outlined in the U.S. National Vaccine Plan. This program will use the NIH Research Project (R01) award mechanism.</p>				
081206	Novel RNAs in Virology (including HIV) and Immune Regulation: Basic Science and Therapeutic Discovery (R21 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PA-19-237	16-Feb-2021	275,000 USD
	<p>Contact Name Chao Jiang, Ph.D.</p> <p>Contact Telephone 301-761-7802</p> <p>Contact Email chao.jiang@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support basic science research, from early exploratory studies to therapeutic discovery and development, in novel biologically active viral and/or host RNAs involved in virology (including HIV biology) and immune regulation.</p>				
085477	NIAID Career Transition Award (K22 Independent Clinical Trial Not	National Institute of Allergy and	PAR-19-	12-Feb-2021	Not

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	Allowed)		Infectious Diseases/NIH/DHHS	371	Specified	
	<p>Contact Name Shawn Drew Gaillard, Ph.D.</p> <p>Contact Telephone 240-627-3857</p> <p>Contact Email Shawn.Gaillard@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Feb-2021 , 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022</p> <p>Synopsis National Institute of Allergy and Infectious Diseases (NIAID) provides support for the NIAID Research Scholar Development Award (RSDA), which is intended to assist postdoctoral fellows' transition to positions of assistant professor or equivalent and initiate a successful biomedical career as an independent research scientist. This Funding Opportunity Announcement (FOA) will utilize the NIH Career Transition Award (K22) mechanism.</p>					
094380	NIAID Physician-Scientist Pathway to Independence Award (K99/R00 Independent Clinical Trial Not Allowed)		National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-20-210	12-Feb-2021	Not Specified
	<p>Contact Name Shawn Drew Gaillard, Ph.D.</p> <p>Contact Telephone 301-761-7776</p> <p>Contact Email AITrainingHelpDesk@niaid.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Feb-2021 , 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</p> <p>Synopsis The purpose of the NIAID Physician-Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent physician-scientists. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIAID research support during this transition to help awardees launch competitive, independent research careers in biomedical fields and thereby help to address the national physician-scientist workforce shortage. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary study to an ongoing</p>					

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
	clinical trial as lead investigator, should apply to the companion FOA (PAR-20-209).																		
094378	NIAID Physician-Scientist Pathway to Independence Award (K99/R00 Clinical Trial Required)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-20-209	12-Feb-2021	Not Specified														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Deborah Philip, Ph.D.</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>301-761-7776</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>AITrainingHelpDesk@niaid.nih.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>12-Feb-2021 , 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>The purpose of the NIAID Physician-Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent physician-scientists. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIAID research support during this transition to help awardees launch competitive, independent research careers in biomedical fields and thereby help to address the national physician-scientist workforce shortage. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-20-210).</td> </tr> </table>					Contact Name	Deborah Philip, Ph.D.	Contact Telephone	301-761-7776	Contact Email	AITrainingHelpDesk@niaid.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	12-Feb-2021 , 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023	Synopsis	The purpose of the NIAID Physician-Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent physician-scientists. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIAID research support during this transition to help awardees launch competitive, independent research careers in biomedical fields and thereby help to address the national physician-scientist workforce shortage. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-20-210).
Contact Name	Deborah Philip, Ph.D.																		
Contact Telephone	301-761-7776																		
Contact Email	AITrainingHelpDesk@niaid.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	12-Feb-2021 , 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023 , 12-Feb-2023 , 07-May-2023																		
Synopsis	The purpose of the NIAID Physician-Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent physician-scientists. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIAID research support during this transition to help awardees launch competitive, independent research careers in biomedical fields and thereby help to address the national physician-scientist workforce shortage. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-20-210).																		
099832	Limited Competition: Exploratory and Developmental Research Grant Program for NIAID K01/K08/K23 Recipients (R21 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-20-291	16-Feb-2021	275,000 USD														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Timothy A. Gondré-Lewis, Ph.D.</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>240-627-3566</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>tglewis@mail.nih.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-</td> </tr> </table>					Contact Name	Timothy A. Gondré-Lewis, Ph.D.	Contact Telephone	240-627-3566	Contact Email	tglewis@mail.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-		
Contact Name	Timothy A. Gondré-Lewis, Ph.D.																		
Contact Telephone	240-627-3566																		
Contact Email	tglewis@mail.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-																		

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p> <p>2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023</p> <p>The National Institute of Allergy and Infectious Diseases (NIAID) announces a program that provides NIAID-supported K01, K08, and K23 recipients with the opportunity to apply for Exploratory and Developmental Research Grant (R21) support at some point during the final two years of their K award. Through the use of this mechanism, NIAID seeks to enhance the capability of its K01, K08, and K23 award recipients to conduct research as they complete their transition to fully independent investigator status (e.g., R01 support). The R21 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R21 is, therefore, intended to support research projects that may provide preliminary data to support a subsequent R01, or equivalent, application.</p>				
099831	<p>Limited Competition: Small Research Grant Program for NIAID K01/K08/K23 Recipients (R03 Clinical Trial Not Allowed)</p>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-20-290	16-Feb-2021	100,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Stacy E. Ferguson, Ph.D.</p> <p>240-627-3504</p> <p>fergusont@niaid.nih.gov</p> <p></p> <p>Link to program URL</p> <p>16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023</p> <p>The National Institute of Allergy and Infectious Diseases (NIAID) announces a program that provides NIAID-supported K01, K08, and K23 recipients with the opportunity to apply for Small Research Grant (R03) support at some point during the final two years of their K award. Through the use of this mechanism, NIAID seeks to enhance the capability of its K01, K08, and K23 award recipients to conduct research as they complete their transition to fully independent investigator status (e.g., R01 support). The R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that may provide preliminary data to support a subsequent R01, or equivalent, application.</p>			
100195	<p>RFA-AI-20-064 -- A Multidisciplinary Approach to Study Vaccine-elicited Immunity and Efficacy against Malaria (U01 Clinical Trial Not Allowed)</p>	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-20-064	08-Feb-2021	3,750,000 USD
	<p>Contact Name</p>	<p>Annie Mo, Ph.D.</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 240-627-3320</p> <p>Contact Email moa@niaid.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Feb-2021</p> <p>Synopsis The purpose of this initiative is to support research to advance understanding of the underlying immune mechanisms that contribute to malaria vaccine-elicited protection or vaccine hypo-responsiveness in endemic regions by capitalizing on recent research advances in systems vaccinology and systems immunology as well as emerging opportunities in data science and informatics. Multidisciplinary science and collaboration among investigators from the malaria vaccine research field and other relevant scientific areas are highly encouraged. The goal is to identify host signatures and mechanistic factors that influence malaria vaccine performance in endemic regions to guide and improve future vaccine design and evaluation.</p>				
073320	Accelerating Basic and Translational Research in Hidradenitis Suppurativa (R01 Clinical Trial Not Allowed)	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	PA-18-719	05-Feb-2021	Not Specified
	<p>Contact Name Ricardo R. Cibotti, Ph.D.</p> <p>Contact Telephone 301-451-5888</p> <p>Contact Email ricardo.cibotti@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 05-Jun-2021</p> <p>Synopsis National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) invites applications for basic and translational studies aimed at understanding the etiology, and the cellular and molecular mechanisms, including the environmental, genetic, epigenetic, biologic, and immunologic factors causing and/or associated with Hidradenitis Suppurativa. The purpose is to accelerate discovery in this field of research and to apply new knowledge to improve patients' condition and ultimately better control disease. This FOA intends to support a broad range of mechanistic studies using animal and human models, with an emphasis on multidisciplinary collaboration for rapid bench-to-bedside exchange of information and therapy development. This FOA is not intended to support applications proposing epidemiology studies and/or clinical trials. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
100388	Mechanistic Ancillary Studies to Ongoing Clinical Projects (R01 Clinical	National Institute of Arthritis and	PAR-21-	18-Feb-2021	1,200,000

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	Trial Not Allowed		Musculoskeletal and Skin Diseases/NIH/DHHS	055 [Optional][LOI/Pre-App]	USD	
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Heiyoung Park, Ph.D.</p> <p>301-594-5032</p> <p>parkh1@mail.nih.gov</p>				
				<p>Link to program URL</p> <p>18-Feb-2021 [Optional][LOI/Pre-App], 18-Mar-2021 , 20-Jun-2021 [Optional][LOI/Pre-App], 20-Jul-2021 , 18-Oct-2021 [Optional][LOI/Pre-App], 18-Nov-2021 , 18-Feb-2022 [Optional][LOI/Pre-App], 18-Mar-2022 , 20-Jun-2022 [Optional][LOI/Pre-App], 20-Jul-2022 , 18-Oct-2022 [Optional][LOI/Pre-App], 18-Nov-2022</p> <p>This Funding Opportunity Announcement (FOA) solicits applications that propose to conduct time-sensitive mechanistic ancillary studies related to the NIAMS mission in conjunction with privately or publicly funded, ongoing clinical projects. The ongoing “parent” clinical project can be an interventional clinical trial, or a clinical study such as an observational study that will be actively collecting patient samples or clinical data. The “parent” project(s) should provide a cohort of well-characterized patients, infrastructure, data, and biological samples for the ancillary study. Applications submitted in response to this FOA will undergo an accelerated review and award process. The objective of this FOA is to provide a flexible mechanism to leverage established resources and maximize the return on existing investments in parent projects. Successful ancillary studies will enhance the scientific content and value of the parent projects, improve the research community’s understanding of a disease or organ system in the NIAMS portfolio, and thus may identify novel targets for diagnosis, treatment, and prevention of disease.</p>		
081513	Limited Competition: Small Grant Program for NIAMS K08 and K23 Recipients (R03)		National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	PAR-19-257 19-Feb-2021	100,000 USD	
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p>	<p>Su-Yau Mao, Ph.D.</p> <p>301-594-5032</p> <p>maos2@mail.nih.gov</p>				
				<p>Link to program URL</p> <p>19-Feb-2021 , 21-Jun-2021 , 19-Oct-2021 , 21-Feb-2022</p>		

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	Synopsis	<p>The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) announces a program that provides NIAMS-supported K08 and K23 recipients the opportunity to apply for Small Grant (R03) support at an appropriate point during the second to fourth year of their K award. Through the use of this mechanism, which allows up to \$50,000 direct costs per year for each of two years, the NIAMS is seeking to enhance the capability of its clinical scientists to conduct research as they complete their transition to fully independent investigator status. The R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that provide preliminary data to support a subsequent R01, or equivalent, application. Clinical trials of any phase will not be supported by this FOA.</p>			
--	----------	--	--	--	--

100387	Mechanistic Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed)	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	PAR-21-054	18-Feb-2021 [Optional][LOI/Pre-App]	400,000 USD
--------	---	--	------------	--	----------------

	Contact Name	Heiyoung Park, Ph.D.		
	Contact Telephone	301-594-5032		
	Contact Email	parkh1@mail.nih.gov		
	Sponsor Website			
	Program URL	Link to program URL		
	Deadline Dates (ALL)	18-Feb-2021 [Optional][LOI/Pre-App], 18-Mar-2021 , 20-Jun-2021 [Optional][LOI/Pre-App], 20-Jul-2021 , 18-Oct-2021 [Optional][LOI/Pre-App], 18-Nov-2021 , 18-Feb-2022 [Optional][LOI/Pre-App], 18-Mar-2022 , 20-Jun-2022 [Optional][LOI/Pre-App], 20-Jul-2022 , 18-Oct-2022 [Optional][LOI/Pre-App], 18-Nov-2022		
	Synopsis	<p>This Funding Opportunity Announcement (FOA) solicits applications that propose to conduct time-sensitive mechanistic ancillary studies related to the NIAMS mission in conjunction with privately or publicly funded, ongoing clinical projects. The ongoing “parent” clinical project can be an interventional clinical trial, or a clinical study such as an observational study that will be actively collecting patient samples or clinical data. The “parent” project(s) should provide a cohort of well-characterized patients, infrastructure, data, and biological samples for the ancillary study. Applications submitted in response to this FOA will undergo an accelerated review and award process. The objective of this FOA is to provide a flexible mechanism to leverage established resources and maximize the return on existing investments in parent projects. Successful ancillary studies will enhance the scientific content and value of the parent projects, improve the research community’s understanding of a disease or organ system in the NIAMS portfolio, and thus may identify novel targets for diagnosis, treatment, and prevention of disease.</p>		

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
073322	Accelerating Basic and Translational Research in Hidradenitis Suppurativa (R21 Clinical Trial Not Allowed)		National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	PA-18-718	16-Feb-2021	275,000 USD
	Contact Name	Ricardo R. Cibotti, Ph.D.				
	Contact Telephone	301-451-5888				
	Contact Email	ricardo.cibotti@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	16-Feb-2021 , 16-Jun-2021				
	Synopsis	<p>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) invites applications for basic and translational studies aimed at understanding the etiology, and the cellular and molecular mechanisms, including the environmental, genetic, epigenetic, biologic, and immunologic factors causing and/or associated with Hidradenitis Suppurativa. The purpose is to accelerate discovery in this field of research and to apply new knowledge to improve patients' condition and ultimately better control disease. This FOA intends to support a broad range of mechanistic studies using animal and human models, with an emphasis on multidisciplinary collaboration for rapid bench-to-bedside exchange of information and therapy development. This FOA is not intended to support applications proposing epidemiology studies and/or clinical trials. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</p>				
101494	Notice of Special Interest (NOSI): Promoting Research on COVID-19 and Rheumatic, Musculoskeletal and Skin Diseases		National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	NOT-AR-21-012	05-Feb-2021	Not Specified
	Contact Name	Marie Mancini, Ph.D.				
	Contact Telephone	301-594-5032				
	Contact Email	mancinim2@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Feb-2021 , 16-Feb-2021 , 07-May-2021 , 15-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021				
	Synopsis	<p>The purpose of this Notice is to announce to potential applicants to the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) an interest in research on the impact of COVID-19 as related to diseases and conditions within the NIAMS mission.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
067950	Research Grants Using the Resources from the Osteoarthritis Initiative (OAI) (R21 Clinical Trial Not Allowed)	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	PA-18-408	16-Feb-2021	275,000 USD
	<p>Contact Name Gayle E. Lester, Ph.D.</p> <p>Contact Telephone 301-594-3511</p> <p>Contact Email lester1@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 07-May-2021</p> <p>Synopsis National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and National Institute on Aging (NIA) invite applications for research awards that are focused on the use of the Osteoarthritis Initiative (OAI) database, clinical data and images. This FOA seeks to expand the use of these resources by investigators in the broader research community. The publication of this FOA to the research community indicates to investigators and peer reviewers the importance that the NIAMS and others have placed on the use of the OAI resources. This FOA will use the NIH Exploratory/Developmental (R21) grant mechanism.</p>				
067972	Research Grants Using the Resources from the Osteoarthritis Initiative (OAI) (R01 Clinical Trial Not Allowed)	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	PA-18-409	05-Feb-2021	275,000 USD
	<p>Contact Name Gayle E. Lester, Ph.D.</p> <p>Contact Telephone 301-594-3511</p> <p>Contact Email lester1@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021</p> <p>Synopsis National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and National Institute on Aging (NIA) invite applications for research awards that are focused on the use of the Osteoarthritis Initiative (OAI) database, clinical data and images. This FOA seeks to expand the use of these resources by investigators in the broader research community. The publication of this FOA to the research community indicates to investigators and peer reviewers the importance that the NIAMS and others have placed on the use of the OAI resources. This FOA will use the NIH R01 Research Project Grant award</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

mechanism.

088092	NIBIB Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional)	National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS	PAR-20-084	16-Feb-2021	400,000 USD
--------	---	--	------------	-------------	-------------

Contact Name	Randy King, Ph.D.
Contact Telephone	301-451-0707
Contact Email	Randy.King@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023
Synopsis	This Trailblazer Award is an opportunity for NIH-defined New and Early Stage Investigators (https://grants.nih.gov/policy/early-investigators/index.htm) to pursue research programs of high interest to the NIBIB that integrate engineering and the physical sciences with the life and/or biomedical sciences. A Trailblazer project may be exploratory, developmental, proof of concept, or high risk-high impact, and may be technology design-directed, discovery-driven, or hypothesis-driven. Importantly, applicants must propose research approaches for which there are minimal or no preliminary data. A distinct feature for this FOA is that no preliminary data are required, expected, or encouraged. However, if available, minimal preliminary data are allowed. Preliminary data are defined as material which the applicant has independently produced and not yet published in a peer-reviewed journal. All preliminary data should be clearly marked and limited to one-half page, which may include one figure. Applications including data more than one-half page or more than one figure will be considered noncompliant with the FOA instructions and will not go forward to review.

079361	Bioengineering Research Grants (BRG) (R01 Clinical Trial Not Allowed)	National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS	PAR-19-158	05-Feb-2021	Not Specified
--------	---	--	------------	-------------	---------------

Contact Name	Seila Selimovic, Ph.D. Program Director
Contact Telephone	301-451-4577
Contact Email	seila.selimovic@nih.gov
Sponsor Website	
Program URL	Link to program URL

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021</p> <p>Synopsis The purpose of this funding opportunity announcement is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical or translational science.</p>				
079367	Bioengineering Research Partnerships (U01 Clinical Trial Not Allowed)	National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS	PAR-19-156	05-Feb-2021	Not Specified
	<p>Contact Name Seila Selimovic, Ph.D. Program Director</p> <p>Contact Telephone 301-451-4577</p> <p>Contact Email seila.selimovic@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages bioengineering applications that will accelerate the development and adoption of promising tools and technologies that can address important biomedical problems. The objectives are to establish these tools and technologies as robust, well-characterized solutions that fulfill an unmet need and are capable of enhancing our understanding of life science processes or the practice of medicine. Awards will focus on supporting multidisciplinary teams that apply an integrative, quantitative bioengineering approach to developing technologies, and engage biomedical researchers or clinicians throughout the project. The goal of the program is to support projects that can realize meaningful solutions within 5 – 10 years.</p>				
079366	Bioengineering Research Partnerships (U01 Clinical Trial Required)	National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS	PAR-19-157	05-Feb-2021	Not Specified
	<p>Contact Name Seila Selimovic, Ph.D. Program Director</p> <p>Contact Telephone 301-451-4577</p> <p>Contact Email seila.selimovic@nih.gov</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages bioengineering applications that will accelerate the development and adoption of promising tools and technologies that can address important biomedical problems. The objectives are to establish these tools and technologies as robust, well-characterized solutions that fulfill an unmet need and are capable of enhancing our understanding of life science processes or the practice of medicine. Awards will focus on supporting multidisciplinary teams that apply an integrative, quantitative bioengineering approach to developing technologies, and engage biomedical researchers or clinicians throughout the project. The goal of the program is to support projects that can realize meaningful solutions within 5 – 10 years.</p>				
079360	Bioengineering Research Grants (BRG) (R01 Clinical Trial Required)	National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS	PAR-19-159	05-Feb-2021	Not Specified
	<p>Contact Name Seila Selimovic, Ph.D. Program Director</p> <p>Contact Telephone 301-451-4577</p> <p>Contact Email seila.selimovic@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021</p> <p>Synopsis The purpose of this funding opportunity announcement is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical or translational science.</p>				
087243	Small Research Grants for Establishing Basic Science-Clinical Collaborations to Understand Structural Birth Defects (R03 Clinical Trial Not Allowed)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-20-065	16-Feb-2021	150,000 USD
	Contact Name Reiko Toyama, PhD				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-435-2723</p> <p>Contact Email toyamar@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022 , 16-Oct-2022</p> <p>Synopsis The purpose of this funding opportunity announcement (FOA) is to promote initial establishment of basic science-clinical collaborations by providing small grants to teams of basic scientists, physician scientists, and/or clinicians. These interdisciplinary teams may include but are not limited to the following: developmental biologists, cell biologists, geneticists, genomicists, physician-scientists including individuals with DVM/VMD degrees, clinicians, epidemiologists, biostatisticians, and/or bioinformaticists. Applications must include at least one scientist with expertise from the basic science side of the spectrum as well as one from the clinical side. The multiple PD/PI model is strongly encouraged but not required. The goal is to facilitate the gathering of preliminary data to support future, larger research grant applications that will combine expertise and integrate basic, translational, and/or clinical approaches to understanding the developmental biology, genetics, and/or environmental basis of structural birth defects.</p>				
101233	<p>Notice of Special Interest (NOSI): Discovery of the Genetic Basis of Conditions Associated with Down Syndrome for the INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE) Project (X01)</p>	National Institute of Child Health and Human Development/NIH/DHHS	NOT-HD-20-039	19-Feb-2021	Not Specified
	<p>Contact Name Valerie Cotton</p> <p>Contact Telephone 301-594-1519</p> <p>Contact Email valerie.cotton@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 19-Feb-2021</p> <p>Synopsis The INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project was developed in response to Fiscal Year 2018 and 2019 Omnibus Appropriations Reports, which encouraged the NIH to expand its current efforts on Down syndrome (DS) and common co-occurring conditions also seen in the general population while increasing the pipeline of DS investigators. Information about projects that were funded in 2018-2020, as well as the INCLUDE Project Research Plan, is available on the INCLUDE Project website. Individuals with DS face significant and changing health challenges but have often been excluded from participation in research that could improve their health outcomes and quality</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>of life. This population is understudied even though DS is the most common genetic cause of intellectual and developmental disabilities (IDD) and, in the past 25 years, the average lifespan has doubled from 30 to 60 years. In addition to intellectual disability, DS is associated with an increased prevalence of autism and epilepsy. About 75% of individuals with DS experience cognitive decline in a syndrome that resembles Alzheimer’s disease, but with onset a decade or two earlier than typical Alzheimer’s disease. Individuals with DS also have high rates of hearing loss, eye abnormalities, congenital heart defects, sleep apnea, pulmonary hypertension, gastrointestinal malformations, thyroid disease, leukemia, and other autoimmune or immune dysregulation disorders including celiac disease. However, people with DS infrequently develop solid tumors such as breast or prostate cancer. Despite multiple risk factors for coronary artery disease and high rates of obesity, sleep apnea, and type 1 diabetes, people with DS rarely develop atherosclerosis or have myocardial infarctions. Understanding this unique combination of risk and resiliencies will inform medical advances for individuals with DS and for individuals who do not have DS but who share these co-occurring conditions.</p>				
099263	Notice of Special Interest (NOSI): Emerging Viral Infections and their Impact on the Male and Female Reproductive Tract	National Institute of Child Health and Human Development/NIH/DHHS	NOT-HD-20-021	05-Feb-2021	Not Specified
	<p>Contact Name: Stuart B. Moss, PhD Contact Telephone: 301-435-6979 Contact Email: mossstua@mail.nih.gov Sponsor Website: Program URL: Link to program URL Deadline Dates (ALL): 05-Feb-2021 , 16-Feb-2021 , 05-Jun-2021 , 16-Jun-2021 , 05-Oct-2021 , 16-Oct-2021 , 05-Feb-2022 , 16-Feb-2022 , 05-Jun-2022 , 16-Jun-2022 , 05-Oct-2022 , 16-Oct-2022 , 05-Feb-2023 , 16-Feb-2023 , 05-Jun-2023 , 16-Jun-2023 Synopsis: The purpose of this Notice is to invite applications proposing cutting-edge research on emerging viral infections that are thought to primarily impact non-reproductive sites, at least at initial presentation, but may also affect the male and/or female reproductive tract. The recent global outbreak of the novel coronavirus, SARS-CoV-2, is not an anomaly and will most likely not be the last virus occurrence. Today, infectious diseases are emerging and reemerging more quickly than ever before. In the last four-five years alone, two viral infections, one caused by the Zika virus (ZIKV) and the other caused by a SARS-CoV-2 (Covid19), have spread world-wide, resulting in death, severe disease with yet, unknown, long-term morbidities., or severe birth defects to the new-born. Both ZIKV and SARS-CoV-2 infections may affect male and/or female reproductive systems in addition to other non-reproductive sites. Therefore, it becomes essential to investigate possible effects of emerging viruses on reproductive tissues and cells to better understand potential impacts on fertility that may be sex specific.</p>				
100458	Discovery of the Genetic Basis of Childhood Cancers and of Structural	National Institute of Child Health and	PAR-21-	19-Feb-2021	Not

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Birth Defects: Gabriella Miller Kids First Pediatric Research Program (X01 Clinical Trial Not Allowed)	Human Development/NIH/DHHS	040		Specified
	<p>Contact Name James Coulombe, Ph.D.</p> <p>Contact Telephone 301-451-1390</p> <p>Contact Email CoulombeJ@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 19-Feb-2021</p> <p>Synopsis As part of the Gabriella Miller Kids First Pediatric Research Program (Kids First), the NIH invites applications to submit samples from pediatric cohorts for whole genome sequencing at a Kids First-supported sequencing center. Applicants are encouraged to propose sequencing of existing pediatric cancer cohorts to elucidate the genetic contribution to childhood cancers, or to expand the range of disorders included within the Kids First Data Resource to investigate the genetic etiology of structural birth defects. Whole genome, exome, and transcriptome sequencing may be available for tumor or affected tissue when justified. These data, and associated clinical and phenotypic data, will become part of the Gabriella Miller Kids First Pediatric Data Resource (Kids First Data Resource) for the pediatric research community.</p>				
070064	NICHD Small Grant Program (R03 Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	PA-18-481	16-Feb-2021	100,000 USD
	<p>Contact Name NICHD Referral Office</p> <p>Contact Telephone</p> <p>Contact Email NICHDReferral@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 07-May-2021</p> <p>Synopsis National Institute of Child Health and Human Development (NICHD) invites applications for small research projects that can be carried out in a short period of time with limited resources. The R03 activity code supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. This FOA will use the NIH R03 Small Grant Program award mechanism.</p>				
075836	Role of Gut Microbiome in Regulating Reproduction and Its Impact on	National Institute of Child Health and	PA-18-	05-Feb-2021	2,499,995

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Fertility Status in Women Living with and Without HIV (R01 Clinical Trial Optional)	Human Development/NIH/DHHS	838		USD
	<p>Contact Name Ravi Ravindranath, PhD</p> <p>Contact Telephone 301-435-6889</p> <p>Contact Email ravindr@nmail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021</p> <p>Synopsis National Institute of Child Health and Human Development (NICHD) invites applications for research related to the role of the gut microbiome in regulating metabolism and reproduction, and its impact on fertility status. The overarching goal is to gain fundamental insight into the possible role of the gut microbiome in regulating reproduction through hypothalamo-pituitary-gonadal (HPG), hypothalamo-pituitary-adrenal (HPA), and hypothalamo-pituitary-thyroid (HPT) axes in the brain. The results of the study could lead to development of diagnostic markers (signature microbiomes) for reproductive and metabolic failure. The project is pertinent to multiple portfolios in the Fertility and Infertility Branch, e.g., basic ovarian biology, fertility preservation, assisted reproductive technology, spermatogenesis and sperm function, and therapeutic interventions to infertility. The emphasis on the gut microbiome and its impact on reproduction through its effects on HPG, HPA, and HPT axes leading to obesity, metabolic syndrome, stress disorders, infection and anxiety is also of interest to the Maternal and Pediatric infectious disease Branch, Pediatric Growth and Nutrition Branch and Intellectual and Developmental Disabilities Branch. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
074839	Patient Safety in the Context of Perinatal, Neonatal, and Pediatric Care (R03 - Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	PA-18-791	16-Feb-2021	100,000 USD
	<p>Contact Name Marion Koso-Thomas, M.D, MPH</p> <p>Contact Telephone 301-435-6873</p> <p>Contact Email kosomari@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021</p> <p>Synopsis National Institute of Child Health and Human Development (NICHD) invites applications for a wide range of collaborative research projects related to patient safety in the context of perinatal, neonatal and pediatric care both in routine hospital</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

settings and in intensive care units. The FOA welcomes applications related to (but not limited to): the epidemiology of various domains of medical errors and consequent patient harm; assessing the factors at various levels that contribute to such errors; and intervention strategies at individual, systems, and institutional-levels to help reduce and eliminate medical errors. It is anticipated that knowledge gained from these projects will help develop strategies to deliver highest quality of healthcare to all newborn infants and children with utmost safety and effectiveness. This FOA will use the NIH R03 Small Grant Program award mechanism.

074832	Patient Safety in the Context of Perinatal, Neonatal, and Pediatric Care (R01 - Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	PA-18-790	05-Feb-2021	Not Specified
--------	--	---	-----------	-------------	---------------

Contact Name | Marion Koso-Thomas, M.D, MPH
 Contact Telephone | 301-435-6873
 Contact Email | kosomari@mail.nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021

Synopsis | National Institute of Child Health and Human Development (NICHD) invites applications for a wide range of collaborative research projects related to patient safety in the context of perinatal, neonatal and pediatric care both in routine hospital settings and in intensive care units. The FOA welcomes applications related to (but not limited to): the epidemiology of various domains of medical errors and consequent patient harm; assessing the factors at various levels that contribute to such errors; and intervention strategies at individual, systems, and institutional-levels to help reduce and eliminate medical errors. It is anticipated that knowledge gained from these projects will help develop strategies to deliver highest quality of healthcare to all newborn infants and children with utmost safety and effectiveness. This FOA will use the NIH Research Project (R01) award mechanism.

070412	Drug Repurposing for Conditions Affecting Neonates and Pregnant Women (R01 Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-18-506	05-Feb-2021	Not Specified
--------	---	---	------------	-------------	---------------

Contact Name | Ekaterini Tsilou. MD
 Contact Telephone | 301-496-6287
 Contact Email | tsiloue@mail.nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021</p> <p>Synopsis National Institute of Child Health and Human Development (NICHD) invites applications to repurpose already FDA approved drugs for new neonatal and obstetric indications, in order to overcome the difficulties associated with the traditional development of drugs appropriate for use in neonates and pregnant women and facilitate treatment of these vulnerable populations. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
072577	Innovative Therapies and Tools for Screenable Disorders in Newborns (R01 - Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-18-689	05-Feb-2021	Not Specified
	<p>Contact Name Melissa Parisi, MD, PhD</p> <p>Contact Telephone 301-435-6880</p> <p>Contact Email parisima@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021</p> <p>Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for research relevant to the development of therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as "high priority" genetic conditions where screening may be possible in the near future. Demonstrating the benefits of treatment is often a primary criterion for including a condition on a newborn screening panel; therefore, for this FOA, a "high priority" condition is one where screening is not currently recommended but would significantly benefit from early identification and treatment. This program will use the NIH Research Project (R01) award mechanism.</p>				
072586	Innovative Therapies and Tools for Screenable Disorders in Newborns (R21 Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-18-691	16-Feb-2021	275,000 USD
	<p>Contact Name Melissa Parisi, MD, PhD</p> <p>Contact Telephone 301-435-6880</p> <p>Contact Email parisima@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 07-May-2021</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for research relevant to the development of therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as "high priority" genetic conditions where screening may be possible in the near future. Demonstrating the benefits of treatment is often a primary criterion for including a condition on a newborn screening panel; therefore, for this FOA, a "high priority" condition is one where screening is not currently recommended but would significantly benefit from early identification and treatment. This program will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.			
072588	Innovative Therapies and Tools for Screenable Disorders in Newborns (R03 Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-18-690	16-Feb-2021	100,000 USD
	Contact Name	Melissa Parisi, MD, PhD			
	Contact Telephone	301-435-6880			
	Contact Email	parisima@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Feb-2021 , 07-May-2021			
	Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for research relevant to the development of therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as "high priority" genetic conditions where screening may be possible in the near future. Demonstrating the benefits of treatment is often a primary criterion for including a condition on a newborn screening panel; therefore, for this FOA, a "high priority" condition is one where screening is not currently recommended but would significantly benefit from early identification and treatment. This program will use the NIH R03 Small Grant Program award mechanism.			
072575	Developmental Pharmacodynamics and Models of Drug Effects in Pediatrics (R01 Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	PA-18-688	05-Feb-2021	Not Specified
	Contact Name	George P. Giacoia MD			
	Contact Telephone	301-496-5589			
	Contact Email	giacoia@exchange.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021</p> <p>Synopsis National Institute of Child Health and Human Development (NICHD) and National Institute of Mental Health (NIMH) invite applications for multidisciplinary, investigator-initiated basic translational and clinical research in developmental pharmacodynamics. This FOA seeks grant applications that propose studies to increase and establish data on developmental pharmacodynamics in the pediatric age groups and allows the determination of pharmacokinetic-pharmacodynamic relationship of drugs used in this population. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
072576	Developmental Pharmacodynamics and Models of Drug Effects in Pediatrics (R03 Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	PA-18-687	16-Feb-2021	100,000 USD
	<p>Contact Name George P. Giacoia MD</p> <p>Contact Telephone 301-496-5589</p> <p>Contact Email giacoia@exchange.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 07-May-2021</p> <p>Synopsis National Institute of Child Health and Human Development (NICHD) and National Institute of Mental Health (NIMH) invite applications for multidisciplinary, investigator-initiated basic translational and clinical research in developmental pharmacodynamics. This FOA seeks grant applications that propose studies to increase and establish data on developmental pharmacodynamics in the pediatric age groups and allows the determination of pharmacokinetic-pharmacodynamic relationship of drugs used in this population. This FOA will use the NIH R03 Small Grant Program award mechanism.</p>				
075841	Role of Gut Microbiome in Regulating Reproduction and Its Impact on Fertility Status in Women Living with and Without HIV (R21 Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	PA-18-839	16-Feb-2021	275,000 USD
	<p>Contact Name Ravi Ravindranath, PhD</p> <p>Contact Telephone 301-435-6889</p> <p>Contact Email ravindr@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis National Institute of Child Health and Human Development (NICHD) invites applications for research related to the role of the gut microbiome in regulating metabolism and reproduction, and its impact on fertility status. The overarching goal is to gain fundamental insight into the possible role of the gut microbiome in regulating reproduction through hypothalamo-pituitary-gonadal (HPG), hypothalamo-pituitary-adrenal (HPA), and hypothalamo-pituitary-thyroid (HPT) axes in the brain. The results of the study could lead to development of diagnostic markers (signature microbiomes) for reproductive and metabolic failure. The project is pertinent to multiple portfolios in the Fertility and Infertility Branch, e.g., basic ovarian biology, fertility preservation, assisted reproductive technology, spermatogenesis and sperm function, and therapeutic interventions to infertility. The emphasis on the gut microbiome and its impact on reproduction through its effects on HPG, HPA, and HPT axes leading to obesity, metabolic syndrome, stress disorders, infection and anxiety is also of interest to the Maternal and Pediatric infectious disease Branch, Pediatric Growth and Nutrition Branch and Intellectual and Developmental Disabilities Branch. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</p>				
070059	NICHD Research Project Grant (R01 - Clinical Trial Required)	National Institute of Child Health and Human Development/NIH/DHHS	PA-18-480	05-Feb-2021	Not Specified
	<p>Contact Name NICHD Referral Office</p> <p>Contact Telephone</p> <p>Contact Email NICHDReferral@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021</p> <p>Synopsis National Institute of Child Health and Human Development (NICHD) invites applications for clinical trials that fall within the NICHD mission. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
074138	Identification and Management of Behavioral Symptoms and Mental Health Conditions in Individuals with Intellectual Disabilities (R01 - Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-18-766	05-Feb-2021	Not Specified
	<p>Contact Name Tracy King, MD, MPH</p> <p>Contact Telephone 301-402-1822</p> <p>Contact Email tracy.king@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021			
	Synopsis	National Institute of Child Health and Human Development (NICHD) invites applications focusing on identification and management of behavioral symptoms and mental health conditions in individuals with intellectual disabilities (ID). Specific areas of interest for this funding opportunity are (1) applications to develop and validate assessment tools that reliably identify behavioral symptoms or diagnose mental health conditions in individuals with ID, and (2) applications studying the pharmacokinetics, safety and efficacy of specific psychotropic medications for treatment of behavioral symptoms or mental health conditions in individuals with ID. This FOA will use the NIH Research Project (R01) award mechanism.			
079181	Academic Research Enhancement Award for Undergraduate-Focused Institutions (R15 - Clinical Trial Required)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-19-133	25-Feb-2021	300,000 USD
	Contact Name	Mahua Mukhopadhyay, PhD			
	Contact Telephone	301-435-6886			
	Contact Email	mukhopam@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	25-Feb-2021 , 07-May-2021 , 25-Jun-2021 , 07-Sep-2021 , 25-Oct-2021 , 07-Jan-2022			
	Synopsis	The purpose of this Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences for undergraduate students and enhancing the research environment at these applicant institutions. Eligible institutions must award baccalaureate science degrees and have received less than 6 million dollars per year of NIH support (total costs) in 4 of the last 7 fiscal years. This funding opportunity announcement (FOA) supports investigator-initiated mechanistic and/or minimal risk clinical trials addressing the mission and research interests of the participating NIH institutes. Minimal risk clinical trials are defined as those that do not require FDA oversight, do not intend to formally establish efficacy, and have low risks to potentially cause physical or psychological harm.			
085590	Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03 Clinical Trial Not Allowed)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-19-375	16-Feb-2021	200,000 USD
	Contact Name	James N. Coulombe, Ph.D.			
	Contact Telephone	301-451-1390			
	Contact Email	CoulombeJ@mail.nih.gov			
	Sponsor Website				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023</p> <p>Synopsis The NIH Common Fund has established the Gabriella Miller Kids First Pediatric Research Program (Kids First) to develop a pediatric research data resource populated by genome sequence and phenotype data that will be of high value for the communities of investigators who study the genetics of childhood cancers and/or structural birth defects. The goal of the Gabriella Miller Kids First Pediatric Data Resource is to build a collection of curated genomic and phenotypic data from childhood cancer and birth defects cohorts and provide a central portal where data and analysis tools will be readily accessible to the research community. Access to these data will promote comprehensive and cross-cutting research and collaboration leading to more refined diagnostic capabilities and ultimately more targeted therapies. This FOA is intended to support meritorious small research projects focused on the development and analyses of childhood cancer and/or structural birth defects datasets that are part of the Kids First Data Resource or could be included in the Kids First Data Resource. Development of statistical methodology appropriate for analyzing genome-wide data relevant to childhood cancer and/or structural birth defects may also be proposed.</p>				
087240	Archiving and Documenting Child Health and Human Development Data Sets (R03 Clinical Trial Not Allowed)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-20-064	16-Feb-2021	100,000 USD
	<p>Contact Name Regina Bures, Ph.D.</p> <p>Contact Telephone 301-496-9485</p> <p>Contact Email regina.bures@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023</p> <p>Synopsis The purpose of this funding opportunity announcement (FOA) is to support the archiving and documentation of existing data sets within the scientific mission of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) in order to enable secondary analysis of these data by the scientific community. The highest priority is to archive original data collected with NICHD funding.</p>				
100064	Notice of Special Interest (NOSI): Small Grants for Secondary Analyses of Existing Data Sets and Stored Biospecimens	National Institute of Child Health and Human Development/NIH/DHHS	NOT-HD-20-022	16-Feb-2021	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name	Regina Bures, PhD
Contact Telephone	301-496-9485
Contact Email	regina.bures@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023
Synopsis	This Notice of Special Interest (NOSI) encourages applications that propose to conduct secondary analyses using publicly available NICHD-funded data sets or stored biospecimens. The goal of this program is to facilitate innovative yet cost-effective research utilizing data and biospecimens collected with NICHD resources.

079632	Achieving Tissue Robustness Through Harnessing Immune System Plasticity (R01 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19-172	05-Feb-2021	Not Specified
--------	--	---	------------	-------------	---------------

Contact Name	Preethi Chander, PhD
Contact Telephone	301-827-4620
Contact Email	preethi.chander@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022
Synopsis	This funding opportunity announcement (FOA) encourages state-of-the-art, systematic research approaches to elucidate the role of immune system plasticity in health and in the pathogenesis of dental, oral, and craniofacial (DOC) diseases. This FOA encourages applications that will seek to determine mechanisms underlying the ability or inability of the immune system to dynamically maintain its functional role against internal and external perturbations. The expectation is that new knowledge derived from this research will facilitate development of novel, personalized immunomodulatory-based therapies that shift the balance between degenerative and regenerative processes toward regeneration disease management in a patient-specific manner across the lifespan.

100931	NIDCR Small Grant Program for New Investigators (R03 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-21-084	16-Feb-2021	200,000 USD
--------	--	---	------------	-------------	-------------

Contact Name | Preethi Chander, PhD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-827-4620</p> <p>Contact Email preethi.chander@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023 , 16-Oct-2023 , 07-Jan-2024</p> <p>Synopsis This NIDCR Small Grant Program for New Investigators supports basic and clinical research conducted by scientists who are in the early stages of establishing an independent research career in oral, dental and craniofacial research. This R03 program supports pilot or feasibility studies and developmental research projects with the intention of obtaining sufficient preliminary data for a subsequent investigator- initiated Research Project Grant (R01) or equivalent application.</p>				
100635	<p>RFA-RM-21-007 -- Pilot Projects Enhancing Utility and Usage of Common Fund Data Sets (R03 Clinical Trial Not Allowed)</p>	National Institute of Dental and Craniofacial Research/NIH/DHHS	RFA-RM-21-007	20-Jan-2021 [Optional][LOI/Pre-App]	200,000 USD
	<p>Contact Name Haluk Resat, Ph.D.</p> <p>Contact Telephone 301-827-6671</p> <p>Contact Email haluk.resat@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 20-Jan-2021 [Optional][LOI/Pre-App], 19-Feb-2021</p> <p>Synopsis Several valuable and widely available data sets have been generated by multiple Common Fund programs. The purpose of this funding opportunity announcement (FOA) is to announce the availability of funding to demonstrate and enhance the utility of selected Common Fund (https://commonfund.nih.gov/) data sets, including generating hypotheses and catalyzing discoveries. Award recipients are asked to provide feedback on the utility of the Common Fund data resources. This Funding Opportunity Announcement (FOA) is developed as a Common Fund initiative (http://commonfund.nih.gov/) through the Office of the NIH Director, Office of Strategic Coordination (https://dpcpsi.nih.gov/). All NIH Institutes and Centers participate in Common Fund initiatives. The awards issued in response to this FOA will be administered by the National Institute of Dental and Craniofacial Research (NIDCR) on behalf of the NIH.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
101189	RFA-DE-21-002 -- Engaging the Dental Workforce to End the HIV Epidemic in the U.S. (UG3/UH3 Clinical Trial Required)	National Institute of Dental and Craniofacial Research/NIH/DHHS	RFA-DE-21-002	10-Jan-2021 [Optional][LOI/Pre-App]	Not Specified
	Contact Name	Melissa Riddle, PhD			
	Contact Telephone	301-451-3888			
	Contact Email	riddleme@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	10-Feb-2021			
	Synopsis	<p>The purpose of this initiative is to support intervention research aimed at equipping the dental workforce in meeting the unique needs of people living with HIV (PLWH) or at risk of contracting HIV. This initiative aligns with the United States Department of Health and Human Services (DHHS) plan, "Ending the HIV Epidemic: A Plan for America," which identifies four broad goals: 1) Diagnose individuals infected with HIV as soon as possible after infection; 2) Treat HIV infection rapidly and effectively to achieve sustained viral suppression; 3) Protect people at risk for HIV using potent and proven prevention strategies, including Pre-exposure Prophylaxis (PrEP); and 4) Respond rapidly to detect growing HIV clusters and to prevent new HIV infections. Dental care providers may have unique opportunities to contribute to these efforts, but there are also significant challenges. Among the most commonly-cited challenges are concerns about patient acceptability, the need for appropriate provider training and support, fitting HIV-related services into the dental clinic workflow, complex and variable laws related to HIV service-provision, and billing and reimbursement systems necessary for sustainability. Applications in response to this FOA must propose to develop, adapt, and/or test interventions to equip dental care providers to participate in and/or to provide HIV-related services, consistent with those identified in the DHHS plan. Proposed interventions are expected to address one or more challenges currently preventing greater participation by dental care providers, and may aim to overcome barriers at any relevant socioecological level (e.g., individual patient or provider, community, clinic, care organization). Awards made under this Funding Opportunity Announcement (FOA) will initially support a milestone-driven planning phase (UG3) for up to 2 years, with possible transition to a clinical trial implementation phase of up to five years (UH3). Only UG3 projects that have met the scientific milestones and feasibility requirements may transition to the UH3 phase.</p>			
079633	Achieving Tissue Robustness Through Harnessing Immune System Plasticity (R21 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19-173	16-Feb-2021	275,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	Contact Name	Preethi Chander, PhD			
	Contact Telephone	301-827-4620			
	Contact Email	preethi.chander@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022			
	Synopsis	<p>This funding opportunity announcement (FOA) encourages state-of-the-art, systematic research approaches to elucidate the role of immune system plasticity in health and in the pathogenesis of dental, oral, and craniofacial (DOC) diseases. This FOA encourages applications that will seek to determine mechanisms underlying the ability or inability of the immune system to dynamically maintain its functional role against internal and external perturbations. The expectation is that new knowledge derived from this research will facilitate development of novel, personalized immunomodulatory-based therapies that shift the balance between degenerative and regenerative processes toward regeneration disease management in a patient-specific manner across the lifespan.</p>			

074728	Precision Imaging of Oral Lesions (R01- Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-18-787	05-Feb-2021	Not Specified
--------	---	---	------------	-------------	---------------

	Contact Name	Chiayeng Wang, Ph.D.			
	Contact Telephone	301-827-4647			
	Contact Email	chiayeng.wang@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021			
	Synopsis	<p>National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for the development, adaptation, optimization, and validation of accurate, reproducible, specific, and sensitive imaging approaches to improve diagnosis, treatment, and treatment monitoring for diseases and conditions in the oral cavity and oropharynx. This FOA will use the NIH Research Project (R01) award mechanism.</p>			

072035	NIDCR Behavioral and Social Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-18-656	09-Feb-2021	Not Specified
--------	---	---	------------	-------------	---------------

Contact Name | Melissa W. Riddle, PhD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Telephone | 301-451-3888
 Contact Email | riddleme@mail.nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 09-Feb-2021 , 07-May-2021

Synopsis | National Institute of Dental and Craniofacial Research (NIDCR) invites research applications to plan and implement behavioral and social intervention clinical trials. Studies appropriate for this announcement include traditional clinical trials to develop and test behavior change interventions for preventing and treating dental, oral, or craniofacial conditions, as well as interventions that are used as tools to understand mechanisms of behavior change. Awards made under this FOA will initially support a milestone-driven planning phase (UG3) for up to 2 years, with possible transition to a clinical trial implementation phase of up to five years (UH3). Only UG3 projects that have met the scientific milestones and feasibility requirements may transition to the UH3 phase. The UG3/UH3 application must be submitted as a single application, following the instructions described in this FOA. The UG3 phase for behavioral and social intervention clinical trials will permit both scientific and operational planning activities. Scientific planning activities include small-scale data collection to assess the feasibility and/or acceptability of a planned behavioral or social intervention and associated study procedures (e.g., acceptability of study content or mode of delivery; feasibility of proposed data collection procedures; preliminary testing of intervention training and fidelity monitoring procedures). Operational planning activities include, at a minimum, development of: the final clinical protocol; the intervention manual or equivalent; the data management system and other tools for data and quality management, safety and operational oversight plans; recruitment and retention strategies; and other essential documents such as the Manual of Procedures for the subsequent clinical trial in the UH3 phase. The UH3 phase of the award will support the conduct of investigator-initiated intervention research at all stages, from early mechanistic research and intervention development (e.g., Stage 0 & I) through implementation and cost-effectiveness research (Stages IV/V). This FOA will use the NIH UG3/UH3 Exploratory/Developmental Phased Award Cooperative Agreement award mechanism.

087115	Improving Oral Health and Reducing Disparities in Adolescents (R21 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-20-059	16-Feb-2021	275,000 USD
--------	--	---	------------	-------------	-------------

Contact Name | Darien Weatherspoon, DDS, MPH
 Contact Telephone | 301-594-5394
 Contact Email | darien.weatherspoon@nih.gov
 Sponsor Website |

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage exploratory or developmental research to improve the oral health of adolescents in the United States, and to reduce observed oral health disparities and inequities in this population. This FOA defines “adolescents” as those individuals between the ages of 10 and 19.</p>				
087114	Improving Oral Health and Reducing Disparities in Adolescents (R01 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-20-058	05-Feb-2021	Not Specified
	<p>Contact Name Darien Weatherspoon, DDS, MPH</p> <p>Contact Telephone 301-594-5394</p> <p>Contact Email darien.weatherspoon@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research to improve the oral health of adolescents in the United States, and to reduce observed oral health disparities and inequities in this population. This FOA defines “adolescents” as those individuals between the ages of 10 and 19.</p>				
086959	NIDCR Research Grants for Analyses of Existing Genomics Data (R01 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-20-045	05-Feb-2021	Not Specified
	<p>Contact Name Lu Wang, Ph.D.</p> <p>Contact Telephone 301-594-4846</p> <p>Contact Email wanglu@nidcr.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023</p> <p>Synopsis The purpose of this FOA is to announce support for meritorious research projects that address research questions relevant to</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

human dental, oral, or craniofacial (DOC) conditions or traits through analysis of existing and publicly available genomics data using statistical and computational approaches. Data analysis for each project can be performed using existing and/or novel methods to be developed in the same project, including machine learning-based methods (ML). In addition to analysis of existing data, experimental or in silico work is required to validate data analysis results, or to validate a newly developed analytic method. Work that tackles causal mechanisms of action for onset and progression of disease for identified candidate causal genetic variants is highly encouraged.

086963	NIDCR Small Research Grants for Analyses of Existing Genomics Data (R03 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-20-046	16-Feb-2021	200,000 USD
--------	---	---	------------	-------------	-------------

Contact Name	Lu Wang, Ph.D.
Contact Telephone	301-594-4846
Contact Email	wanglu@nidcr.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023
Synopsis	The purpose of this FOA is to announce support for meritorious research projects that address research questions relevant to human dental, oral, or craniofacial (DOC) conditions or traits through analysis of existing and publicly available genomics data using statistical and computational approaches. Data analysis for each project can be performed using existing and/or novel methods to be developed in the same project, including machine learning-based methods (ML).

053538	Precision Imaging of Oral Lesions (R21-Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-18-788	16-Feb-2021	275,000 USD
--------	--	---	------------	-------------	-------------

Contact Name	Chiayeng Wang, Ph.D.
Contact Telephone	301-827-4647
Contact Email	chiayeng.wang@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021
Synopsis	National Institute of Dental and Craniofacial Research (NIDCR) invites applications for the development, adaptation,

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		optimization, and validation of accurate, reproducible, specific, and sensitive imaging approaches to improve diagnosis, treatment, and treatment monitoring for diseases and conditions in the oral cavity and oropharynx. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.			
069107	NIDCR Mentored Career Development Award to Promote Diversity in the Dental, Oral and Craniofacial Research Workforce (K01-Clinical Trial Required)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-18-359	12-Feb-2021	625,000 USD
	Contact Name	Lynn Mertens King, PhD			
	Contact Telephone	301-594-5006			
	Contact Email	lynn.king@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	12-Feb-2021 , 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022			
	Synopsis	National Institute of Dental and Craniofacial Research (NIDCR) invites applications for the NIDCR Mentored Career Development Award. The award is designed to enhance the diversity of the independently funded dental, oral and craniofacial research workforce by providing a mentored research experience for eligible postdoctoral fellows and junior faculty who are from groups that have been shown to be nationally underrepresented in the basic and clinical biomedical, behavioral, and social sciences. This award provides salary and research support for a sustained period of protected time for intensive research career development under the guidance of an experienced mentor. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. This FOA will use the NIH K01 Research Scientist Development Award - Research & Training award mechanism.			
069114	NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22 Clinical Trial Required)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-18-360	12-Feb-2021	Not Specified
	Contact Name	Leslie A. Frieden, PhD			
	Contact Telephone	301-496-4263			
	Contact Email	leslie.frieden@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	12-Feb-2021 , 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	National Institute of Dental and Craniofacial Research (NIDCR) invites applications for the NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22) program. provide highly qualified dentists in NIH Intramural postdoctoral fellowship positions with an opportunity to receive further mentored research experience in the NIH Intramural program, and then to provide them with independent funding to facilitate the transition of their research programs as new investigators at extramural institutions. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. This FOA will utilize the NIH K22 Career Transition Award mechanism.			
076575	Biologic Factors Underlying Dental, Oral, and Craniofacial Health Disparities (R21 - Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PA-18-874	16-Feb-2021	275,000 USD
	Contact Name	Darlen Weatherspoon, DDS, MPH			
	Contact Telephone	301-594-5394			
	Contact Email	darien.weatherspoon@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021			
	Synopsis	National Institute of Dental and Craniofacial Research (NIDCR) and National Institute on Minority Health and Health Disparities (NIMHD) invite applications for investigator-initiated studies designed to identify and understand biologic factors (microbial, immune, genetic) that contribute to disparities in dental, oral, and craniofacial disease onset, progression, and persistence. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.			
076575	Biologic Factors Underlying Dental, Oral, and Craniofacial Health Disparities (R01 - Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-18-875	05-Feb-2021	Not Specified
	Contact Name	Darlen Weatherspoon, DDS, MPH			
	Contact Telephone	301-594-5394			
	Contact Email	darien.weatherspoon@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	National Institute of Dental and Craniofacial Research (NIDCR) and National Institute on Minority Health and Health Disparities (NIMHD) invite applications for investigator-initiated studies designed to identify and understand biologic factors (microbial, immune, genetic) that contribute to disparities in dental, oral, and craniofacial disease onset, progression, and persistence. This FOA will use the NIH Research Project (R01) award mechanism.			
079369	NIDCR Mentored Career Development Award to Promote Diversity in the Dental, Oral and Craniofacial Workforce (K01 Independent Basic Experimental Studies with Humans Required)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19-161	12-Feb-2021	Not Specified
	Contact Name	Lynn Mertens King, Ph.D.			
	Contact Telephone	301-594-5006			
	Contact Email	lynn.king@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	12-Feb-2021 , 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022			
	Synopsis	The purpose of this NIDCR Mentored Career Development Award is to enhance the diversity of the independently funded dental, oral and craniofacial research workforce by providing a mentored research experience for eligible postdoctoral fellows and early career faculty from diverse backgrounds, including those who are from groups underrepresented in the biomedical and behavioral sciences. This award provides salary and research support for a sustained period of protected time for intensive research career development under the guidance of an experienced mentor. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate ‘Clinical Trial Required’ NIDCR K01 PAR-18-359). Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NIDCR K01 PAR-19-160 Clinical Trial Not Allowed.			
079378	NIDCR Mentored Career Development Award to Promote Diversity in the Dental, Oral and Craniofacial Workforce (K01 Independent Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19-160	12-Feb-2021	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Lynn Mertens King, Ph.D.</p> <p>Contact Telephone 301-594-5006</p> <p>Contact Email lynn.king@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Feb-2021 , 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022</p> <p>Synopsis The purpose of this NIDCR Mentored Career Development Award is to enhance the diversity of the independently funded dental, oral and craniofacial research workforce by providing a mentored research experience for eligible postdoctoral fellows and early career faculty from diverse backgrounds, including those who are from groups underrepresented in the biomedical and behavioral sciences. This award provides salary and research support for a sustained period of protected time for intensive research career development under the guidance of an experienced mentor . This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA (PAR-18-359).</p>				
079343	<p>NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22 Independent Clinical Trial Not Allowed)</p>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19-152	12-Feb-2021	Not Specified
	<p>Contact Name Leslie A. Frieden, PhD</p> <p>Contact Telephone 301-496-4263</p> <p>Contact Email leslie.frieden@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Feb-2021 , 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022</p> <p>Synopsis The purpose of the NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22) program is to provide highly qualified dentists in NIH Intramural postdoctoral fellowship positions with opportunity to transition from mentored research experiences in the NIH Intramural program to extramural institutions as new investigators with independent research funding. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion 'Clinical Trial Required' FOA (PAR-18-360). Applicants proposing basic experimental studies in humans referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants" should apply to the companion Basic Experimental Studies with Humans FOA (PAR-19-151).

081212	Short-term Mentored Career Enhancement Award in Dental, Oral and Craniofacial Research for Mid-Career and Senior Investigators (K18 Independent Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19-238	12-Feb-2021	Not Specified
--------	---	---	------------	-------------	---------------

Contact Name	Lynn Mertens King, PhD
Contact Telephone	301-594-5006
Contact Email	Lynn.King@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	12-Feb-2021 , 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022
Synopsis	This Funding Opportunity Announcement (FOA) encourages applications for short-term mentored career enhancement (K18) awards in dental, oral and craniofacial (DOC) research with a focus on behavioral and social sciences, and on genetics, genomics, bioinformatics and computational biology research. The intent of this program is to provide mid-career and senior investigators with short-term training in the theories, tools, methods or approaches of another scientific area, in order to enhance their existing research program. Two categories of candidates are targeted: (a) established DOC research investigators who seek training with investigators from another field, in order to enrich their existing DOC research program; and (b) established investigators in other fields who seek training with DOC research investigators in order to facilitate the introduction of DOC research into an existing research program. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.

081268	Clinical Research to Improve the Oral Health of Older Adults (R01 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19-239	05-Feb-2021	Not Specified
--------	---	---	------------	-------------	---------------

Contact Name	Darien Weatherspoon, DDS, MPH
Contact Telephone	301-594-5394
Contact Email	darien.weatherspoon@mail.nih.gov

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research to address gaps in our knowledge related to the risk factors, access to care barriers, oral health promotion and disease prevention strategies, and clinical management of dental, oral, and craniofacial (DOC) diseases more commonly experienced by older adults. This FOA defines "older adults" as those individuals age 65 years and older.			
081272	Clinical Research to Improve the Oral Health of Older Adults (R21 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19-240	16-Feb-2021	275,000 USD
	Contact Name	Darlen Weatherspoon, DDS, MPH			
	Contact Telephone	301-594-5394			
	Contact Email	darien.weatherspoon@mail.nih			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to encourage exploratory or developmental research to address risk factors, access to care barriers, oral health promotion and disease prevention strategies, and clinical management of dental, oral, and craniofacial (DOC) diseases more commonly experienced by older adults. This FOA defines "older adults" as those individuals age 65 years and older.			
079222	NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00 Independent Basic Experimental Studies with Humans Required)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19-141	12-Feb-2021	Not Specified
	Contact Name	Leslie A. Frieden, PhD			
	Contact Telephone	301-496-4263			
	Contact Email	leslie.frieden@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 12-Feb-2021 , 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022</p> <p>Synopsis The purpose of the NIDCR Dentist Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent dual degree dentist scientists. This program is designed to facilitate a timely transition of outstanding dual degree dentist scientists from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions by providing support for two years of mentored training and three to five years of independent research. The option for five years of independent (R00) support is available to accommodate clinical training in an advanced specialty education program at no more than 3 person-months effort (25% effort) in any year of the R00 phase. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate 'Clinical Trials Required' FOA (PAR-18-432). Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-19-144).</p>				
079225	<p>NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00 Independent Clinical Trial Not Allowed)</p>	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19-144	12-Feb-2021	Not Specified
	<p>Contact Name Leslie A. Frieden, PhD</p> <p>Contact Telephone 301-496-4263</p> <p>Contact Email leslie.frieden@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Feb-2021 , 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (PAR-18-432). Applicants proposing basic experimental studies in humans referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants" should apply to the companion Basic Experimental Studies with Humans FOA (PAR-19- 141). The purpose of the NIDCR Dentist Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

new and talented independent dual degree dentist scientists. This program is designed to facilitate a timely transition of outstanding dual degree dentist scientists from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions by providing support for two years of mentored training and three to five years of independent research. The option for five years of independent (R00) support is available to accommodate clinical training in an advanced specialty education program at no more than 3 person-months effort (25% effort) in any year of the R00 phase.

079337	NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22 Independent Basic Experimental Studies with Humans Required)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19-151	12-Feb-2021	Not Specified
--------	--	---	------------	-------------	---------------

Contact Name	Leslie A. Frieden, PhD
Contact Telephone	301-496-4263
Contact Email	leslie.frieden@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	12-Feb-2021 , 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022
Synopsis	<p>The purpose of the NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22) program is to provide highly qualified dentists in NIH Intramural postdoctoral fellowship positions with opportunity to transition from mentored research experiences in the NIH Intramural program to extramural institutions as new investigators with independent research funding. This Funding Opportunity Announcement (FOA) is designed specifically for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should apply to the companion ‘Clinical Trial Required’ FOA (PAR-18-360). Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-19-152).</p>

079322	NIDCR Small Research Grants for Oral Health Data Analysis and Statistical Methodology Development (R03 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19-145	16-Feb-2021	200,000 USD
--------	--	---	------------	-------------	-------------

Contact Name	Darien Weatherspoon, DDS, MPH
Contact Telephone	301-594-5394

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email darien.weatherspoon@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022</p> <p>Synopsis The goal of this funding opportunity announcement is to support meritorious research projects that involve secondary data analyses of existing oral or craniofacial database resources, or to develop needed statistical methodology for analyzing oral and craniofacial data using existing oral or craniofacial databases. The R03 grant mechanism supports research limited in time and amount for studies in categorical program areas.</p>				
083076	Mechanistic Studies of Gene-Environment Interplay in Dental, Oral, Craniofacial, and Other Diseases and Conditions (R01 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19-292	05-Feb-2021	Not Specified
	<p>Contact Name Kathryn Stein, Ph.D.</p> <p>Contact Telephone 301-827-4653</p> <p>Contact Email kathryn.stein@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) is intended to foster research towards a better understanding of the biological mechanisms of gene-environment interplay in human diseases and conditions. Through this FOA, the NIDCR, NIEHS, and NICHD solicit applications that use animal models, in vitro systems, or ex vivo approaches to conduct mechanistic investigation of the interplay of genes/gene networks and environmental factors in dental, oral, craniofacial (DOC), and other diseases and conditions.</p>				
083077	Development of Novel and Robust Systems for Mechanistic Studies of Gene-Environment Interplay in Dental, Oral, Craniofacial, and Other Diseases and Conditions (R21 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-19-293	16-Feb-2021	275,000 USD
	<p>Contact Name Kathryn Stein, Ph.D.</p> <p>Contact Telephone 301-827-4653</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email kathryn.stein@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) is intended to foster research towards a better understanding of the biological mechanisms of gene-environment interplay in human diseases and conditions. Through this FOA, the NIDCR, NIEHS, and NICHD solicit applications to develop novel and robust experimental systems that offer approaches complementary to human epidemiologic or in vivo studies to facilitate mechanistic investigation of gene-environment interplay in dental, oral, craniofacial, and other diseases and conditions.</p>				
087123	NIDCR Prospective Observational or Biomarker Validation Study Cooperative Agreement (U01 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-20-060	05-Feb-2021	Not Specified
	<p>Contact Name Dena Fischer, DDS, MSD, MS</p> <p>Contact Telephone 301-594-4876</p> <p>Contact Email dena.fischer@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) will support, through the cooperative agreement mechanism, investigator-initiated observational studies or biomarker validation studies that require prospective collection of data/biospecimens or continued analysis of data/biospecimens collected as part of a previous NIDCR award.</p>				
096097	Enabling Technologies to Accelerate Development of Oral Biodevices (R01 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-20-233	05-Feb-2021	Not Specified
	<p>Contact Name Orlando Lopez, PhD</p> <p>Contact Telephone 301-402-4243</p> <p>Contact Email orlando.lopez@nih.gov</p> <p>Sponsor Website</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites applications that propose transformative engineering solutions to technical challenges associated with new development, substantial optimization of existing technologies and clinical translation of intraoral biodevices. Proposed technologies are expected to advance development of oral biodevices for clinical use, including but not limited to: precision medicine-based detection, diagnosis and treatment of oral and overall health conditions, and measurement of patient functional status and clinical outcome assessment. Areas of interest in this FOA include engineering approaches that allow integration of electronic, physical, and biological systems into functional biodevices that are safe and effective for detection, diagnosis and treatment of oral and systemic disease. Products of this research will be functional biodevices and integrated approaches thoroughly characterized to demonstrate preclinical safety and effective performance in support of specific intended clinical applications. To streamline the development of oral biodevices that advance precision medicine-based approaches in clinical practice, this FOA encourages interdisciplinary collaborations across engineering, multifunctional sensors, pharmacology, chemistry, medicine, and dentistry, as well as between academia and industry.</p>				
096105	Enabling Technologies to Accelerate Development of Oral Biodevices (R21 Clinical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-20-232	16-Feb-2021	Not Specified
	<p>Contact Name Orlando Lopez, PhD</p> <p>Contact Telephone 301-402-4243</p> <p>Contact Email orlando.lopez@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites exploratory/developmental applications that propose transformative engineering solutions to technical challenges associated with meaningful development, substantial optimization of existing technologies and clinical translation of intraoral biodevices. Proposed technologies are expected to advance development of oral biodevices to clinical use, including but not limited to: precision medicine-based detection, diagnosis and treatment of oral and overall health conditions, and measurement of patient functional status and clinical outcome assessment. Areas of interest in this FOA include engineering approaches that allow integration of electronic, physical, and biological systems</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>essential to the development of functional biodevices that are safe and effective for detection, diagnosis and treatment of oral and systemic disease. Products of this research will be proof-of-concept prototype biodevices, dedicated biosensors and associated core technologies that enable development of safe and effective intra-oral biodevices intended for specific clinical applications. To streamline the development of oral biodevices that advance precision medicine-based approaches in clinical practice, this FOA encourages interdisciplinary collaborations across engineering, multifunctional sensors, pharmacology, chemistry, medicine, and dentistry, as well as between academia and industry.</p>				
100184	National Dental Practice-Based Research Network Clinical Trial or Observational Study Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Optional)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-20-306	09-Feb-2021	Not Specified
	<p>Contact Name: Dena Fischer, DDS, MSD, MS Contact Telephone: 301-594-4876 Contact Email: dena.fischer@nih.gov Sponsor Website: Program URL: Link to program URL Deadline Dates (ALL): 09-Feb-2021 , 07-May-2021 , 09-Jun-2021 , 07-Sep-2021 , 08-Oct-2021 , 09-Feb-2022 , 07-May-2022 , 09-Jun-2022 , 07-Jul-2022 , 07-Sep-2022 , 07-Oct-2022 , 07-Jan-2023 , 09-Feb-2023 , 07-May-2023 , 09-Jun-2023 , 07-Sep-2023</p> <p>Synopsis: The National Institute of Dental and Craniofacial Research (NIDCR) is continuing support for research conducted within a dental Practice-Based Research Network (PBRN). The National Dental PBRN Administrative and Resource Center and National Coordinating Center support the infrastructure for and implementation of multiple observational studies and clinical trials. This Funding Opportunity Announcement (FOA) is soliciting applications for clinical trials and large clinical observational studies to be conducted in the National Dental PBRN through a milestone-driven UG3/UH3 cooperative agreement mechanism. Each UG3/UH3 award will support an individual project which will utilize the National Dental PBRN infrastructure and resources for study planning and implementation. This FOA supports a UG3 clinical study planning phase and potential transition to a UH3 implementation phase. Progression to the UH3 phase is based on an administrative review and is dependent on success in meeting UG3 milestones, consideration of the dental PBRN as an appropriate venue for conduct of the research, NIDCR program priorities, and availability of funds. The main goals of the dental PBRN are to streamline the implementation of national oral health research studies in dental practices on topics of importance to practitioners and their patients, to provide evidence useful in daily patient care, and to facilitate the translation of research findings into clinical practice. This FOA encourages applications proposing research studies that align with the goals of the dental PBRN.</p>				
081339	Stimulating Urology Interdisciplinary Team Opportunity Research (SUITOR)	National Institute of Diabetes	PAS-19-	05-Feb-2021	Not

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	(R01 Clinical Trial Optional)		and Digestive and Kidney Diseases/NIH/DHHS	241	Specified	
	<p>Contact Name Tamara G. Bavendam, MD, MS</p> <p>Contact Telephone 301-594-4733</p> <p>Contact Email tamara.bavendam@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022</p> <p>Synopsis The Stimulating Urology Interdisciplinary Team Opportunity Research (SUITOR) program is intended to promote innovative, high quality, interdisciplinary research relevant to the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The NIDDK invites investigator-initiated research project grant applications (R01s) in specific areas of basic, translational and clinical research in specific benign urologic conditions and diseases where needs and opportunities for progress are particularly timely. Specific research topic areas supported by the SUITOR program, as outlined below, will change over time and will be updated annually through the NIH Guide to Grants and Contracts.</p>					
079079	Stimulating Hematology Investigation: New Endeavors (SHINE) (R01 Clinical Trial Not Allowed)		National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAS-19-105	05-Feb-2021	Not Specified
	<p>Contact Name Terry Rogers Bishop, Ph.D.</p> <p>Contact Telephone 301-594-7726</p> <p>Contact Email terry.bishop@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021</p> <p>Synopsis The Stimulating Hematology Investigation: New Endeavors (SHINE) program is intended to promote innovative, high-quality nonmalignant hematology research relevant to the missions of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Aging (NIA), and the National Heart, Lung, and Blood Institute (NHLBI). Investigator-initiated research project grant applications (R01s) in specific areas of basic and early translational hematology research are invited to this program that supports growth in the nonmalignant hematology research domain. Specific emerging topics that are at the leading edge of the field will change over time and will be updated annually through the NIH Guide to Grants</p>					

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

and Contracts and hyperlinked to this FOA.

098427	Notice of Special Interest (NOSI): Administrative Supplements to Support Emerging Physician-Scientists to Develop Research Expertise in Diabetes, Endocrinology and Metabolic Diseases	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	NOT-DK-20-040	03-Feb-2021	Not Specified
--------	--	---	---------------	-------------	---------------

Contact Name	Carol R. Haft, PhD
Contact Telephone	301-594-7789
Contact Email	haftc@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	03-Feb-2021 , 03-Feb-2022 , 03-Feb-2023
Synopsis	The purpose of the NIDDK's Division of Diabetes, Endocrinology and Metabolic Diseases (DDEMD) Administrative Supplement Program is to enable additional clinical perspectives to be brought to on-going research projects within the Division's mission and to enhance the research expertise of selected physicians. The program will provide supplementary funds to support advanced research opportunities for exceptional emerging physician-scientists (hereafter, "candidates") holding the MD or equivalent or MD/PhD degrees, and who are early in their research careers. The supplement is intended to allow candidates to expand their research experience to help them transition beyond their clinical training to the next stage of their research careers as physician-scientists.

100782	RFA-DK-20-033 -- Exploratory Centers for Interdisciplinary Research in Benign Urology (P20 Clinical Trial Optional)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK-20-033	18-Feb-2021 [Optional][LOI/Pre-App]	400,000 USD
--------	---	---	---------------	-------------------------------------	-------------

Contact Name	Tamara G. Bavendam, MD, MS
Contact Telephone	301-594-4733
Contact Email	tamara.bavendam@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	18-Feb-2021 [Optional][LOI/Pre-App], 18-Mar-2021
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to seek applications for Exploratory Centers for Interdisciplinary Research in Benign Urology (P20). A major goal of this program is to build interdisciplinary research teams.

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>The program seeks innovative, high-risk–high-reward Research Projects that utilize integrative approaches to address questions relevant to benign genitourinary diseases or disorders bringing together investigators with complementary expertise. Studies involving human subjects or tissues and small, innovative, pilot and feasibility clinical studies are encouraged. The following expertise must be included in the proposed Research Project: 1) researchers new to the investigation of benign genitourinary diseases or disorders and 2) clinical urology expertise. Additional expertise may also be included, as needed. In addition to the scientific Research Project, each Exploratory Center must include an Administrative Core with an Educational Enrichment Program. As part of the NIDDK's efforts to expand and enhance benign urology research and the base of urologic researchers, the Exploratory Centers Program will work in partnership with the George M. O'Brien Urology Cooperative Research Centers Program (U54), the Urology Centers Program Interactions Core (U24), and the Multidisciplinary K12 Urologic Research (KURe and UroEpi) Career Development Programs.</p>				
100737	RFA-DK-20-030 -- Understanding the Cellular and Molecular Mechanisms of Gastroparesis in Adults and Children (R01 Clinical Trial Not Allowed)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK-20-030	03-Feb-2021 [Optional][LOI/Pre-App]	1,250,000 USD
	<p>Contact Name: Frank A. Hamilton, M.D., MPH Contact Telephone: 301-594-8877 Contact Email: hamiltonf@mail.nih.gov Sponsor Website: Program URL: Deadline Dates (ALL): 03-Feb-2021 [Optional][LOI/Pre-App], 03-Mar-2021</p> <p>Synopsis: Since its establishment in 2006, the Gastroparesis Clinical Research Consortium (GpCRC), a multi-center coalition created and funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has made major advances to our understanding of the pathophysiology of Gastroparesis (Gp). Through the establishment of the largest gastroparesis tissue repository in the United States, combined with detailed phenotypic data, the GpCRC is ideally suited to accelerate insights into the underlying cellular and molecular pathophysiology of the gastroparesis with the ultimate goal of developing therapeutic target(s). This RFA invites investigators from several disciplines, including basic and translational research in areas of neurosciences, immunology, microbiology and physiology, to contribute new insights into the cellular and molecular mechanisms of Gastroparesis.</p>				
100881	RFA-DK-20-013 -- GenitoUrinary Development Molecular Anatomy Project (GUDMAP) - Atlas Projects (U01 Clinical Trial Not Allowed)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK-20-013	18-Jan-2021 [Optional][LOI/Pre-App]	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Deborah K. Hoshizaki, Ph.D.</p> <p>Contact Telephone 301-594-7712</p> <p>Contact Email dkhosh@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 18-Jan-2021 [Optional][LOI/Pre-App], 18-Feb-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) requests applications for GUDMAP Atlas Projects to generate data for the GUDMAP database. The scope of Atlas Projects is limited to molecular and anatomical development of human and mouse (1) lower urinary tract, including ureters, bladder, urethra, prostate, and external male genitalia; and (2) kidney and lower urinary tract vasculature, nerves, and lymphatics. The GUDMAP Atlas Projects will be part of the GUDMAP consortium which was established to generate a molecular anatomy atlas of the developing mouse and human kidney and lower urinary tract. The GUDMAP consortium is expected to be a continuing resource for the research community and its long-term objective is to establish a comprehensive understanding of kidney and lower urinary tract development and maturation to inform the study of tissue maturation and aging, organ dysgenesis and disease, and ultimately organ repair and regeneration. A separate FOA seeks applications for the Data Hub (RFA-DK-20-014).</p>				
100880	<p>RFA-DK-20-014 -- Reconfiguration of GenitoUrinary Development Molecular Anatomy Project (GUDMAP) / (Re)Building A Kidney (RBK) Data Hub (U24 Clinical Trial Not Allowed)</p>	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK-20-014	18-Jan-2021 [Optional][LOI/Pre-App]	3,750,000 USD
	<p>Contact Name Deborah K. Hoshizaki, Ph.D.</p> <p>Contact Telephone 301-594-7712</p> <p>Contact Email dkhosh@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 18-Jan-2021 [Optional][LOI/Pre-App], 18-Feb-2021</p> <p>Synopsis This Funding Opportunity Announcement invites applications for a consolidated Data Hub for the GenitoUrinary Development Molecular Anatomy Project (GUDMAP) and the (Re)Building a Kidney (RBK) consortium. The GUDMAP/RBK Data Hub will have both scientific and administrative responsibilities, including the operation of a searchable web-based data repository. The Data Hub will implement FAIR (Findable, Accessible, Interoperable, and Reusable) principles and have appropriate domain expertise, such as in bioinformatics, website and software development, biocuration and ontology</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	development (including specific expertise in appropriate organ anatomy and physiology), and workshop planning and administration. The Data Hub will also oversee an Opportunity Pool Program that will allow the consortium to proactively adapt to a changing scientific landscape and identify gaps within the RBK and GUDMAP consortia.				
098645	RFA-DK-20-022 -- Toward Elucidating Mechanisms of HIV Pathogenesis within the Mission of the NIDDK (Pathogenesis TEAMS) (R01 Clinical Trial Optional)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK-20-022	03-Feb-2021 [Optional][LOI/Pre-App]	2,500,000 USD
	Contact Name	Peter J. Perrin, Ph.D.			
	Contact Telephone	301-451-3759			
	Contact Email	Peter.Perrin@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	03-Feb-2021 [Optional][LOI/Pre-App], 03-Mar-2021 , 17-Oct-2021 [Optional][LOI/Pre-App], 17-Nov-2021			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support multidisciplinary research teams with complementary expertise in HIV and pathobiology, pathophysiology, and/or metabolism in organs, tissues, and/or biological systems of specific interest to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). These teams will comprehensively interrogate fundamental mechanisms underlying HIV-associated comorbidities, coinfections, and complications relevant to the mission of the NIDDK and advance progress toward alleviating them.			
076166	Time-Sensitive Obesity Policy and Program Evaluation (R01 Clinical Trial Not Allowed)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-18-854	11-Jan-2021	Not Specified
	Contact Name	Mary Evans, Ph.D.			
	Contact Telephone	301-594-4578			
	Contact Email	evansmary@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	11-Jan-2021 , 10-Feb-2021 , 10-Mar-2021 , 09-Apr-2021 , 10-May-2021 , 11-Jun-2021 , 09-Jul-2021 , 10-Aug-2021 , 10-Sep-2021			
	Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for time-sensitive research to			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

evaluate a new policy or program that is likely to influence obesity related behaviors (e.g., dietary intake, physical activity, or sedentary behavior) and/or weight outcomes in an effort to prevent or reduce obesity. This FOA is intended to support research where opportunities for empirical study are, by their very nature, only available through expedited review and funding. All applications submitted to this FOA must demonstrate that the evaluation of an obesity related policy and /or program offers an uncommon and scientifically compelling research opportunity that will only be available if the research is initiated with minimum delay. For these reasons, applications submitted to this time-sensitive FOA are not eligible for re-submission. It is intended that eligible applications selected for funding will be awarded within 4 months of the application due date. However, administrative requirements and other unforeseen circumstances may delay issuance dates beyond that timeline. This FOA will utilize the NIH R01 Research Project Grant award mechanism.

101372	NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-21-102	05-Feb-2021	Not Specified
--------	---	---	------------	-------------	---------------

Contact Name	Tracy Rankin, Ph.D., M.P.H.
Contact Telephone	301-594-4748
Contact Email	rankint@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024
Synopsis	This FOA invites applications for investigator-initiated, high-risk multi-center clinical trials involving more than one clinical center. Proposed trials should be hypothesis-driven, have the potential to change clinical practice and/or public health, and focus on a disease relevant to the mission of NIDDK. Planning activities must be completed prior to submission and are not permitted under this FOA. Applicants who require a planning phase may first apply for an implementation planning cooperative agreement (U34; see PAR-21-101). Consultation with NIDDK Scientific/Research staff is strongly encouraged prior to the submission of either a U34 or U01 application.

101373	NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Not Allowed)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-21-103	05-Feb-2021	Not Specified
--------	--	---	------------	-------------	---------------

Contact Name	Tracy Rankin, Ph.D., M.P.H.
--------------	-----------------------------

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Telephone	301-594-4748
Contact Email	rankint@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024
Synopsis	This FOA invites applications for investigator-initiated, high-risk multi-center observational studies involving more than one clinical center. Proposed studies should be hypothesis-driven and focus on a disease relevant to the mission of NIDDK. Planning activities must be completed prior to submission and are not permitted under this FOA. Applicants who require a planning phase may first apply for an implementation planning cooperative agreement (U34; see PAR-21-101). Consultation with NIDDK Scientific/Research staff is strongly encouraged prior to the submission of either a U34 or U01 application.

076238	Diet and Physical Activity Assessment Methodology (R01 Clinical Trial Not Allowed)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PA-18-856	05-Feb-2021	Not Specified
--------	--	---	-----------	-------------	---------------

Contact Name	Mary Evans, Ph.D.
Contact Telephone	301-594-4578
Contact Email	evansmary@nidk.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021
Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for innovative research to enhance the quality of measurements of dietary intake and physical activity. Applications submitted to this FOA may include development of: novel assessment approaches; better methods to evaluate instruments; assessment tools for culturally diverse populations or various age groups, including children and older adults; improved technology or applications of existing technology; statistical methods/modeling to improve assessment and/or to correct for measurement errors or biases; methods to investigate the multidimensionality of diet and physical activity behavior through pattern analysis; or integrated measurement of diet and physical activity along with the environmental context of such behaviors. This FOA will use the NIH Research Project (R01) award mechanism.

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
076246	Diet and Physical Activity Assessment Methodology (R21 Clinical Trial Not Allowed)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-18-857	16-Feb-2021	275,000 USD
	<p>Contact Name Mary Evans, Ph.D.</p> <p>Contact Telephone 301-594-4578</p> <p>Contact Email evansmary@niddk.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021</p> <p>Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for innovative research to enhance the quality of measurements of dietary intake and physical activity. Applications submitted to this FOA may include development of: novel assessment approaches; better methods to evaluate instruments; assessment tools for culturally diverse populations or various age groups, including children and older adults; improved technology or applications of existing technology; statistical methods/modeling to improve assessment and/or to correct for measurement errors or biases; methods to investigate the multidimensionality of diet and physical activity behavior through pattern analysis; or integrated measurement of diet and physical activity along with the environmental context of such behaviors. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</p>				
085472	Limited Competition: Small Grant Program for NIDDK K01/K08/K23/K25 Recipients (R03 Clinical Trial Optional)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-19-365	16-Feb-2021	150,000 USD
	<p>Contact Name Lisa M. Spain, Ph.D.</p> <p>Contact Telephone 301-451-9871</p> <p>Contact Email SpainL@niddk.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022</p> <p>Synopsis National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites applications to provide NIDDK-supported K01, K08, K23, and K25 recipients the opportunity to apply for Small Grant (R03) support at some point during the final two</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

years of their K award. Through the use of this mechanism, the NIDDK is seeking to enhance the capability of its K01, K08, K23, and K25 award recipients to conduct research as they complete their transition to fully independent investigator status. The R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that may provide preliminary data to support a subsequent R01, or equivalent, application. This program will use the NIH Small Research Grant (R03) award mechanism.

091518	Small R01s for Clinical Trials Targeting Diseases within the Mission of NIDDK (R01 Clinical Trial Required)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAS-20-160	05-Feb-2021	600,000 USD
--------	---	---	------------	-------------	-------------

Contact Name	Susan Mendley, M.D.
Contact Telephone	301- 827-1861
Contact Email	susan.mendley@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023
Synopsis	This Funding Opportunity Announcement encourages the submission of pilot and feasibility clinical trials conducted in humans that will lay the foundation for larger clinical trials related to the prevention and/or treatment of diseases and conditions within the mission of NIDDK. The program will support small, short-term clinical trials in humans to acquire preliminary data regarding the effects of the intervention, as well as feasibility data related to recruitment and retention, and study conduct. Applications for clinical trials submitted under this FOA should have clearly described aims and objectives, and have a high likelihood that the trial findings will lead to more definitive, hypothesis-driven trials to improve understanding, diagnosis, prevention or treatment of the diseases studied and have the potential to impact clinical practice and/or public health. Preliminary data regarding intervention efficacy are not required.

073411	Secondary Analyses in Obesity, Diabetes and Digestive and Kidney Diseases (R21 Clinical Trial Not Allowed)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PA-18-741	16-Feb-2021	275,000 USD
--------	--	---	-----------	-------------	-------------

Contact Name	Aynur Unalp-Arida, MD, MSc, PhD
Contact Telephone	301-594-8879

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email aynur.unalp-arida@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 07-May-2021</p> <p>Synopsis National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites applications that propose to conduct secondary analyses of existing data sets relevant to diabetes and selected endocrine and metabolic diseases including thyroid, parathyroid and Cushing's diseases and acromegaly; and genetic metabolic disease including cystic fibrosis, lysosomal storage diseases, and disorders of the urea cycle, amino acid metabolism and metal transport where the focus is on peripheral metabolism or organ function; obesity, liver diseases, alimentary GI tract diseases and nutrition; kidney, urologic, and hematologic diseases. The goal of this program is to facilitate research that explores innovative hypotheses through the use of existing data sets or data, for which the primary goal is data analysis and not preparation/presentation of data. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.</p>				
073342	New Directions in Hematology Research (SHINE-II) (R01 Clinical Trial Optional)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAS-18-730	05-Feb-2021	600,000 USD
	<p>Contact Name Terry Rogers Bishop, Ph.D.</p> <p>Contact Telephone 301-594-7726</p> <p>Contact Email terry.bishop@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021</p> <p>Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invite applications in nonmalignant hematology research. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute on Aging (NIA) have joined together to build and promote research activities in nonmalignant hematology. Innovative research project applications that will steer the field in new directions are invited. Each project will propose proof of principle research that is tightly focused into one specific aim and is directed at validating novel concepts and approaches that promise to open up new pathways for discovery. Research applications submitted under this FOA should be more limited in scope (a single central aim) and duration (1-3 years) than typical R01 grant applications. This FOA will use the NIH Research Project (R01) award mechanism.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
080703	Small Grants for New Investigators to Promote Diversity in Health-Related Research (R21 Clinical Trial Optional)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-19-222	16-Feb-2021	375,000 USD
	<p>Contact Name Lawrence Agodoa, M.D.</p> <p>Contact Telephone 301-594-1932</p> <p>Contact Email SmallGrant4Diversity@niddk.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 07-May-2021</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to provide support for New Investigators: (1) from diverse backgrounds, including from groups nationally underrepresented in biomedical and behavioral research to conduct small research projects in the scientific mission areas of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Human Genome Research Institute (NHGRI) and (2) who at the time of award under this FOA will have/have had less than \$125,000 direct cost of combined research funding (excluding NIH training and NIH career awards). This R21 will support small research projects that can be carried out in a short period of time with limited resources and seeks to facilitate the transition to research independence of diverse New Investigators. The R21 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.</p>				
090534	Catalytic Tool and Technology Development in Kidney, Urologic, and Hematologic Diseases (R21 Clinical Trial Not Allowed)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-20-140	16-Feb-2021	275,000 USD
	<p>Contact Name Daniel Gossett, Ph.D.</p> <p>Contact Telephone 301-594-7723</p> <p>Contact Email daniel.gossett@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023</p> <p>Synopsis The purpose of this Funding Opportunity Announcement is to promote development of innovative, enabling tools and</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		technologies in the areas of kidney, urologic, and hematologic diseases.			
078518	Medical Simulators for Practicing Patient Care Providers Skill Acquisition, Outcomes Assessment and Technology Development (R01 Clinical Trial Not Allowed)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PA-19-065	05-Feb-2021	Not Specified
	<p>Contact Name Jose Serrano, M.D., Ph.D.</p> <p>Contact Telephone 301-594-8871</p> <p>Contact Email serranoj@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022</p> <p>Synopsis The purpose of the Funding Opportunity Announcement (FOA) is to promote the assessment and further development of simulation technologies intended to improve patient safety and healthcare outcomes provided by practicing patient care providers and experienced (not trainee) physicians. The FOA seeks applications directed toward three areas of research: 1) Skill Acquisition: to evaluate strategies and protocols for simulation-based methods for skill acquisition and maintenance by experienced clinicians; 2) Outcomes Assessment: to assess the relationship of simulation-based assessments of skills demonstrated by experienced clinicians with the quality of clinical care delivered by those clinicians, and to identify strategies to increase the quality of simulation-based assessments of skills; and 3) Technology Development: to develop “virtual coaches” by incorporating intelligent technologies into existing simulators to provide adaptive, cognitive assistance to coach experienced practitioners in retaining, retraining and improving performance levels in the context of the user environment (and physiological system as appropriate).</p>				
099798	RFA-DK-20-506 -- Limited Competition for the Continuation of the Urinary Stone Disease Research Network (USDNRN) Clinical Centers (U01 Clinical Trial Required)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK-20-506	09-Feb-2021	1,200,000 USD
	<p>Contact Name Ziya Kirkali, MD</p> <p>Contact Telephone 301-594-7717</p> <p>Contact Email kirkaliz@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 09-Feb-2021</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)'s Urinary Stone Disease Research Network (USDRN) is conducting a multi-center randomized clinical trial and an observational clinical study to: a) provide evidence on the effects of increased fluid intake and urine output on urinary stone disease recurrence through innovative adherence strategies, b) understand and mitigate ureteral stent-associated pain and urinary symptoms, and c) collect data and biological samples for future investigations. The purpose of this Limited Competition Funding Opportunity Announcement (FOA) is to invite applications from current USDRN Clinical Centers to complete these clinical investigations.			
099799	RFA-DK-20-507 -- Limited Competition for the Continuation of the Urinary Stone Disease Research Network (USDRN) Scientific Data Research Center (U24 Clinical Trial Required)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK-20-507	09-Feb-2021	2,100,000 USD
	Contact Name	Ziya Kirkali, MD			
	Contact Telephone	301-594-7717			
	Contact Email	kirkaliz@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	09-Feb-2021			
	Synopsis	The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)'s Urinary Stone Disease Research Network (USDRN) is conducting a multi-center randomized clinical trial and an observational clinical study to: a) provide evidence on the effects of increased fluid intake and urine output on urinary stone disease recurrence through innovative adherence strategies, b) understand and mitigate ureteral stent-associated pain and urinary symptoms, and c) collect data and biological samples for future investigations. The purpose of this Limited Competition Funding Opportunity Announcement (FOA) is to invite an application from the current USDRN Scientific Data Research Center to complete these clinical investigations.			
099941	RFA-DK-20-509 -- Limited Competition for Continuation of the Integrated Islet Distribution Program (U24 Clinical Trial Not Allowed)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA-DK-20-509	09-Feb-2021	2,000,000 USD
	Contact Name	Sheryl M. Sato, Ph.D.			
	Contact Telephone	301-594-8811			
	Contact Email	Sheryl.sato@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 09-Feb-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites one application from the Program Director(s)/Principal Investigator(s) of the current Integrated Islet Distribution Program (IIDP) to renew the program and maintain support for its continuing mission to provide the scientific community with important islet resources for diabetes research. The IIDP facilitates the distribution of human islets to biomedical researchers by establishing partnerships with qualified islet isolation facilities to prepare and distribute human islets. The program manages an application process to establish investigator eligibility to receive islet shipments, informs investigators of islet availability, manages a cost recovery system through fees collected from islet recipients, and oversees standardized phenotypic and genotypic analyses of islet preparations distributed throughout the IIDP network. Human islets remain an essential resource for diabetes research to advance our understanding of human islet cell biology, and to promote the development of new therapies for the prevention and treatment of diabetes.</p>				
098653	RFA-ES-20-013 -- RESolution of InflammaTion in EnvirOnmentally Related diseasE (RESTORE) (R01 Clinical Trial Not Allowed)	National Institute of Environmental Health Sciences/NIH/DHHS	RFA-ES-20-013	11-Jan-2021 [Optional][LOI/Pre-App]	1,750,000 USD
	<p>Contact Name Srikanth S. Nadadur, PhD</p> <p>Contact Telephone 984-287-3296</p> <p>Contact Email nadadurs@niehs.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-Jan-2021 [Optional][LOI/Pre-App], 11-Feb-2021</p> <p>Synopsis The purpose of the RESTORE program is to advance understanding of the role of inflammation resolution pathways at the cellular and molecular level and how exposure to environmental pollutants interferes with these pathways resulting in exposure-induced chronic systemic inflammation and ultimately chronic disease conditions. The initial phase of this program is focused on understanding how chronic exposure to air pollution interferes with resolution of inflammation in pulmonary, cardiovascular, and metabolic systems and diseases.</p>				
099384	RFA-ES-20-014 -- Superfund Hazardous Substance Research and Training Program (P42 Clinical Trial Optional)	National Institute of Environmental Health Sciences/NIH/DHHS	RFA-ES-20-014	15-Jan-2021 [Optional][LOI/Pre-App]	1,750,000 USD
	<p>Contact Name Heather Henry, PhD</p> <p>Contact Telephone 984-287-3268</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email heather.henry@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Jan-2021 [Optional][LOI/Pre-App], 15-Feb-2021</p> <p>Synopsis National Institute of Environmental Health Sciences (NIEHS) invites applications for the continuation of the Superfund Hazardous Substance Research and Training Program, referred to as Superfund Research Program (SRP) Centers. SRP Center grants will support problem-based, solution-oriented research Centers that consist of multiple, integrated projects representing both the biomedical and environmental science and engineering disciplines; as well as cores tasked with administrative (which includes research translation), data management and analysis, community engagement, research experience and training coordination, and research support functions. The scope of the SRP Centers is taken directly from the Superfund Amendments and Reauthorization Act of 1986, and includes: (1) advanced techniques for the detection, assessment, and evaluation of the effect on human health of hazardous substances; (2) methods to assess the risks to human health presented by hazardous substances; (3) methods and technologies to detect hazardous substances in the environment; and (4) basic biological, chemical, and physical methods to reduce the amount and toxicity of hazardous substances. This FOA will utilize the NIH P42 Hazardous Substances Basic Research Grants Program award mechanism.</p>				
068838	<p>Transition to Independent Environmental Health Research (TIEHR) Career Award (K01 Clinical Trial Not Allowed)</p>	National Institute of Environmental Health Sciences/NIH/DHHS	PAR-18-291	12-Feb-2021	375,000 USD
	<p>Contact Name Carol Shreffler, Ph.D.</p> <p>Contact Telephone 919-541-1445</p> <p>Contact Email Shreffl1@niehs.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Feb-2021</p> <p>Synopsis National Institute of Environmental Health Sciences (NIEHS) invites applications for the Transitions to Independent Environmental Health Research (TIEHR) Career Development Award. This award is a 3-year bridge scholar development program for newly independent faculty who intend to pursue research careers in environmental health sciences. At the conclusion of the career development period the candidates are expected to demonstrate they can successfully compete for research funding in the environmental health sciences. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. This FOA will utilize the NIH K01 Research Scientist Development Award - Research & Training mechanism.			
068837	Transition to Independent Environmental Health Research (TIEHR) Career Award (K01 Clinical Trial Required)	National Institute of Environmental Health Sciences/NIH/DHHS	PAR-18-261	12-Feb-2021	375,000 USD
	Contact Name	Carol Shreffler, Ph.D.			
	Contact Telephone	919-541-1445			
	Contact Email	Shreffl1@niehs.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	12-Feb-2021			
	Synopsis	National Institute of Environmental Health Sciences (NIEHS) invites applications for the Transitions to Independent Environmental Health Research (TIEHR) Career Development Award. This award is a 3-year bridge scholar development program for newly independent faculty who intend to pursue research careers in environmental health sciences. At the conclusion of the career development period the candidates are expected to demonstrate they can successfully compete for research funding in the environmental health sciences. his Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial a feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. This FOA will utilize the NIH K01 Research Scientist Development Award - Research & Training mechanism.			
100822	RFA-ES-21-001 -- Outstanding New Environmental Scientist (ONES) Award (R01 Clinical Trial Optional)	National Institute of Environmental Health Sciences/NIH/DHHS	RFA-ES-21-001	27-Jan-2021 [Optional][LOI/Pre-App]	2,375,000 USD
	Contact Name	Carol Shreffler, PhD			
	Contact Telephone	948-287-3322			
	Contact Email	shreffl1@niehs.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	27-Jan-2021 [Optional][LOI/Pre-App], 26-Feb-2021 , 25-Jan-2022 [Optional][LOI/Pre-App], 24-Feb-2022 , 25-Jan-2023			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p>	<p>[Optional][LOI/Pre-App], 24-Feb-2023</p> <p>The Outstanding New Environmental Scientist (ONES) Award is intended to identify the most talented Early Stage Investigators (ESIs) who intend to make a long-term commitment to research in the Environmental Health Sciences and assist them in launching an innovative research program focused on understanding the effects of environmental exposure on people's health.</p>			
101131	<p>RFA-ES-21-002 -- Application of Artificial Intelligence and Machine Learning for Advancing Environmental Health Sciences (R43 Clinical Trial Not Allowed)</p>	National Institute of Environmental Health Sciences/NIH/DHHS	RFA-ES-21-002	28-Feb-2021 [Optional][LOI/Pre-App]	256,580 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Lingamanaidu Ravichandran, PhD</p> <p>948-287-3309</p> <p>lingamanaidu.ravichandran@nih.gov</p> <p></p> <p>Link to program URL</p> <p>28-Feb-2021 [Optional][LOI/Pre-App], 29-Mar-2021</p> <p>This Funding Opportunity Announcement (FOA) solicits Phase I (R43) SBIR grant applications from small business concerns (SBCs) to develop promising methodologies using Artificial Intelligence (AI) and Machine Learning (ML) approaches to advance environmental health research and decisions. When further developed and validated, these methodologies or approaches should improve the accuracy of toxicity prediction, help in prioritizing chemicals for more relevant or targeted testing, identify and/or fill data or knowledge gaps in toxicity assessment, and promote more comprehensive understanding of human exposure effects, susceptibility and adverse health outcomes.</p>			
101133	<p>RFA-ES-21-003 -- Application of Artificial Intelligence and Machine Learning for Advancing Environmental Health Sciences (R41 Clinical Trial Not Allowed)</p>	National Institute of Environmental Health Sciences/NIH/DHHS	RFA-ES-21-003	28-Feb-2021 [Optional][LOI/Pre-App]	256,580 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p>	<p>Lingamanaidu Ravichandran, PhD</p> <p>948-287-3309</p> <p>lingamanaidu.ravichandran@nih.gov</p> <p></p> <p>Link to program URL</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 28-Feb-2021 [Optional][LOI/Pre-App], 29-Mar-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) solicits Phase I (R41) STTR grant applications from small business concerns (SBCs) to develop promising methodologies using Artificial Intelligence (AI) and Machine Learning (ML) approaches to advance environmental health research and decisions. When further developed and validated, these methodologies or approaches should improve the accuracy of toxicity prediction, help in prioritizing chemicals for more relevant or targeted testing, identify and/or fill data or knowledge gaps in toxicity assessment, and promote more comprehensive understanding of human exposure effects, susceptibility and adverse health outcomes.</p>				
084593	RFA-ES-19-011 -- Mechanism for Time-Sensitive Research Opportunities in Environmental Health Sciences (R21 Clinical Trial Not Allowed)	National Institute of Environmental Health Sciences/NIH/DHHS	RFA-ES-19-011	01-Feb-2021	275,000 USD
	<p>Contact Name Martha I. Barnes, MS</p> <p>Contact Telephone 919-541-3335</p> <p>Contact Email barnes@niehs.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Feb-2021 , 01-Mar-2021 , 01-Apr-2021 , 03-May-2021 , 01-Jun-2021 , 01-Jul-2021 , 02-Aug-2021 , 01-Sep-2021 , 01-Oct-2021 , 01-Nov-2021 , 01-Dec-2021 , 03-Jan-2022 , 01-Feb-2022 , 01-Mar-2022 , 01-Apr-2022 , 02-May-2022 , 01-Jun-2022 , 01-Jul-2022 , 01-Aug-2022 , 01-Sep-2022 , 03-Oct-2022</p> <p>Synopsis This funding opportunity announcement (FOA) is intended to support novel environmental health research in which an unpredictable event or policy change provides a limited window of opportunity to collect human biological samples or environmental exposure data. The primary motivation of the FOA is to understand the consequences of natural and human-made disasters, emerging environmental public health threats, and policy changes in the U.S. and abroad. A distinguishing feature of an appropriate study is the need for rapid review and funding, substantially shorter than the typical NIH grant review/award cycle, for the research question to be addressed and swiftly implemented. The shortened timeframe will be achieved by more frequent application due dates and expediting peer review, council concurrence and award issuance. The entire cycle, from submission to award, is expected to be within 3-4 months.</p>				
100259	Notice of Special Interest (NOSI): NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19)	National Institute of Environmental Health Sciences/NIH/DHHS	NOT-ES-20-015	01-Feb-2021	Not Specified
	Contact Name Anika Dzierlenga, Ph.D.				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 984-287-3125</p> <p>Contact Email anika.dzierlenga@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Feb-2021 , 01-Mar-2021 , 01-Apr-2021 , 03-May-2021</p> <p>Synopsis NIEHS is issuing this Notice of Special Interest (NOSI) to address the urgent need for mission-relevant research to understand the impact of environmental exposures on Coronavirus Disease 2019 (COVID-19) and its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2). NIEHS is particularly interested in applications that will provide insight into the role of environmental exposures in pathogenicity, transmission, individual susceptibility, or prevention and intervention strategies.</p>				
100252	Notice of Special Interest (NOSI): NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19)	National Institute of Environmental Health Sciences/NIH/DHHS	NOT-ES-20-020	01-Feb-2021	Not Specified
	<p>Contact Name Anika Dzierlenga, Ph.D.</p> <p>Contact Telephone 984-287-3125</p> <p>Contact Email anika.dzierlenga@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Feb-2021 , 01-Mar-2021 , 01-Apr-2021 , 03-May-2021</p> <p>Synopsis NIEHS is issuing this Notice of Special Interest (NOSI) to address the urgent need for mission-relevant research to understand the impact of environmental exposures on Coronavirus Disease 2019 (COVID-19) and its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2). NIEHS is particularly interested in applications that will provide insight into the role of environmental exposures in pathogenicity, transmission, individual susceptibility, or prevention and intervention strategies.</p>				
080739	Transition to Independent Environmental Health Research (TIEHR) Career Award (K01 Independent Basic Experimental Studies with Humans Required)	National Institute of Environmental Health Sciences/NIH/DHHS	PAR-19-225	12-Feb-2021	375,000 USD
	Contact Name Carol Shreffler, PhD				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 984-287-3322</p> <p>Contact Email shreffl1@niehs.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Feb-2021 , 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022</p> <p>Synopsis The Transition to Independent Environmental Health (TIEHR) Career Award is a 3-year bridge scholar development program for newly independent faculty who intend to pursue research careers in environmental health sciences. At the conclusion of the career development period the candidates are expected to demonstrate they can successfully compete for research funding in the environmental health sciences. Note: This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to inNOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the companion ‘Independent Clinical Trial Required’ PAR 18-261.</p>				
081442	Focused Technology Research and Development (R01 - Clinical Trial Not Allowed)	National Institute of General Medical Sciences/NIH/DHHS	PAR-19-253	05-Feb-2021	Not Specified
	<p>Contact Name Paul Sammak, Ph.D.</p> <p>Contact Telephone </p> <p>Contact Email paul.sammak@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) will support projects that focus solely on development of technologies with the potential to enable acquisition of basic biomedical knowledge. Projects should be justified in terms of technical innovation, and utility for future biomedical impact. The products of this research will be functioning prototype instruments, methods, synthetic approaches, biological products, etc., characterized adequately to be ready for first application to the type of biomedical research questions that provide the rationale for their development, but application of the proposed technology to specific biomedical questions is considered beyond the scope of the program, should not be included, and</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>would not be funded. Proof of concept for the technology must have already been demonstrated, but there should still be significant technical challenges. Applications should include preliminary data. Projects that have significant remaining risk but are supported by early feasibility studies might be appropriate for a three-year R01 application with reduced budget to better manage risk and investment. Projects that are well supported by feasibility studies and propose to develop fully functional prototypes might require higher budgets and a four-year duration (five years for Early Stage Investigators). Projects that primarily focus on optimization, hardening, or obvious extrapolations of established technology might be less competitive.</p>			
100852	Initiative for Maximizing Student Development (IMSD) (T32 - Clinical Trial Not Allowed)	National Institute of General Medical Sciences/NIH/DHHS	PAR-21-025	26-Feb-2021	Not Specified
	Contact Name	Sydella Blatch, Ph.D.			
	Contact Telephone				
	Contact Email	sydella.blatch@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	26-Feb-2021 , 28-Jan-2022 , 30-Jan-2023			
	Synopsis	<p>The goal of the Initiative for Maximizing Student Development (IMSD) program is to develop a diverse pool of scientists earning a Ph.D., who have the skills to successfully transition into careers in the biomedical research workforce. This funding opportunity announcement (FOA) provides support to eligible, domestic institutions to develop and implement effective, evidence-informed approaches to biomedical graduate training and mentoring that will keep pace with the rapid evolution of the biomedical research enterprise. NIGMS expects that the proposed research training programs will incorporate didactic, research, mentoring, and career development elements to prepare trainees for careers that will have a significant impact on the health-related research needs of the Nation. This program is limited to applications from training programs at research-intensive institutions (i.e., those with NIH Research Project Grant funding averaging greater than or equal to \$7.5 million in total costs (direct and F&A/indirect) per year over the last three fiscal years). This FOA does not allow appointed trainees to lead an independent clinical trial but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.</p>			
100853	Graduate Research Training Initiative for Student Enhancement (G-RISE) (T32 - Clinical Trial Not Allowed)	National Institute of General Medical Sciences/NIH/DHHS	PAR-21-026	26-Feb-2021	Not Specified
	Contact Name	Sydella Blatch, Ph.D.			
	Contact Telephone				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email sydella.blatch@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 26-Feb-2021 , 28-Jan-2022 , 30-Jan-2023</p> <p>Synopsis The goal of the Graduate Research Training Initiative for Student Enhancement (G-RISE) program is to develop a diverse pool of scientists earning a Ph.D., who have the skills to successfully transition into careers in the biomedical research workforce. This funding opportunity announcement (FOA) provides support to eligible, domestic institutions to develop and implement effective, evidence-informed approaches to biomedical graduate training and mentoring that will keep pace with the rapid evolution of the biomedical research enterprise. NIGMS expects that the proposed research training programs will incorporate didactic, research, mentoring, and career development elements to prepare trainees for careers that will have a significant impact on the health-related research needs of the Nation. This program is limited to applications from training programs at research-active institutions (i.e., those with NIH Research Project Grant funding averaging less than \$7.5 million in total costs (direct and F&A/indirect) per year over the last three fiscal years). This FOA does not allow appointed trainees to lead an independent clinical trial but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.</p>				
081443	Exploratory Research for Technology Development (R21 - Clinical Trial Not Allowed)	National Institute of General Medical Sciences/NIH/DHHS	PAR-19-254	16-Feb-2021	275,000 USD
	<p>Contact Name Paul Sammak, Ph.D.</p> <p>Contact Telephone</p> <p>Contact Email paul.sammak@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) will support exploratory research leading to the development of innovative technologies for biomedical research. The program will recognize and reward high-risk approaches with potential for significant impact. Projects should entail a high degree of risk or novelty, which will be offset by a correspondingly high potential impact. However, the possible impact is likely to be far off. Application of the proposed technology to specific biomedical questions is considered beyond the scope of the program, should not be included, and would not be funded. The goal of this FOA is to support proof of concept studies for feasibility and exploratory technology development. Feasibility must not have already been developed in the literature or with preliminary data. Published data can be used to establish the</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

current state of the art but cannot forecast or predict project outcomes. Preliminary data for any purpose might appear to forecast the likelihood of success. Therefore, no unpublished data is allowed. While unpublished data are not permitted, references and data from widely-available preprints that have a Digital Object Identifier (DOI) are acceptable.

072936	Academic Research Enhancement Award for Undergraduate-Focused Institutions (R15 - Clinical Trial Not Allowed)	National Institute of General Medical Sciences/NIH/DHHS	PAR-18-714	25-Feb-2021	300,000 USD
--------	---	---	------------	-------------	-------------

Contact Name	Alexandra M. Ainsztein, PhD.
Contact Telephone	301-594-0943
Contact Email	Alexandra.Ainsztein@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	25-Feb-2021 , 07-May-2021
Synopsis	National Institute of General Medical Sciences (NIGMS) invites applications for the Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions. The purpose of the award is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for undergraduate students, and enhancing the research environment at these applicant institutions. Eligible institutions must award baccalaureate science degrees, and have received less than 6 million dollars per year of NIH support (total costs) in 4 of the last 7 fiscal years. This FOA will use the NIH R15 Academic Research Enhancement Award (AREA) mechanism.

081132	Reducing the Duration of Untreated Psychosis in the United States (R01 Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-19-236	05-Feb-2021	Not Specified
--------	---	--	------------	-------------	---------------

Contact Name	Susan T. Azrin, Ph.D.
Contact Telephone	301-443-3267
Contact Email	susan.azrin@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022
Synopsis	Approximately 100,000 adolescents and young adults in the United States experience a first episode of psychosis (FEP) every year. The early phase of psychotic illness is widely viewed as a critical opportunity for indicated prevention, and a chance to

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

alter the downward trajectory and poor outcomes associated with schizophrenia and related psychotic disorders. Unfortunately, numerous studies find a substantial delay between the onset of psychotic symptoms and the initiation of FEP care; in the U.S. treatment is typically delayed between one and three years. Early identification of FEP, rapid referral to evidence-based Coordinated Specialty Care (CSC) for early psychosis, and effective engagement in CSC services are essential to shortening the duration of untreated psychosis (DUP) and pre-empting the functional deterioration common in psychotic disorders. The World Health Organization advocates reducing DUP to 3 months or less. Accordingly, this Funding Opportunity Announcement (FOA) seeks research project grant applications that test practical, reproducible strategies for substantially reducing DUP among persons with FEP in the U.S. by eliminating bottlenecks or closing gaps in the pathway to CSC services. Alternatively, applicants whose work in this area is at a developmental stage should consider applying to the companion R34 FOA PAR-19-235.

078784	Emotion Regulation, Aging and Mental Disorder (R01 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PA-19-094	05-Feb-2021	Not Specified
--------	--	--	-----------	-------------	---------------

Contact Name	Jovier Evans, PhD
Contact Telephone	301-443-1369
Contact Email	jevans1@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021
Synopsis	<p>This Funding Opportunity Announcement (FOA) encourages applications for mechanistic research on age-related changes in emotion regulation and how they may contribute to mental disorders in middle-aged and older adults. In particular, research is sought that will advance understanding of irregularities in the integrative neural-behavioral mechanisms of emotion regulation in adult mood and anxiety disorders, and that will examine whether the irregularities are associated with typical or atypical maturational trajectories of emotion processing. Currently, it is not known whether older adults who suffer episodes of affective dysregulation share the same patterns of improved emotional function with age as have been found to be typical of the older adult population in general. Research that helps to clarify whether they do or do not manifest typical emotion processing trajectories may lead to very different understandings of the irregularities involved in their dysregulation. It is anticipated that such studies may identify novel targets for mental health interventions or prevention efforts, or provide clues as to which available intervention strategies might be optimally applied to normalize emotion dysregulation or to strengthen emotional resilience at particular stages of the adult life cycle.</p>

076937	Leveraging Electronic Medical Records for Psychiatric Genetic Research (R01)	National Institute of Mental	PAR-18-	05-Feb-2021	Not
--------	--	------------------------------	---------	-------------	-----

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	(Collab) Clinical Trial Not Allowed		Health/NIH/DHHS	905	Specified	
	<p>Contact Name Anjené Addington</p> <p>Contact Telephone 301-443-6653</p> <p>Contact Email anjene.addinton@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 05-Jun-2021</p> <p>Synopsis National Institute of Mental Health (NIMH) invites applications for collaborative R01 projects from multidisciplinary teams that implement creative, efficient molecular epidemiologic approaches that incorporate individual genetic information, including polygenic as well as specific genetic risk variants, in existing large, population-based cohorts, registries and/or health systems to conduct analyses that advance our understanding of the complex etiology of severe mental disorders. The ultimate objective of this funding opportunity is the elucidation of the complex interplays of genetic (e.g., polygenic) risk, in addition to specific risk loci and networks, and environmental factors, in human populations, which will lead to better understanding, diagnosis, and ultimately treatment of mental disorders. For a linked set of collaborative R01s, each site has its own Program Director(s)/Principal Investigator(s), and the program provides a mechanism for cross-site coordination and communication. Collaborative studies are appropriate to address research projects that go beyond the capacity of a single-site investigation, particularly to accommodate collaborations among sites with diverse expertise, perspectives, and contributions. This FOA will use the NIH Research Project (R01) award mechanism.</p>					
076934	Leveraging Electronic Medical Records for Psychiatric Genetic Research (R01 Clinical Trial Not Allowed)		National Institute of Mental Health/NIH/DHHS	PAR-18-904	05-Feb-2021	Not Specified
	<p>Contact Name Anjené Addington</p> <p>Contact Telephone 301-443-6653</p> <p>Contact Email anjene.addinton@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 05-Jun-2021</p> <p>Synopsis National Institute of Mental Health (NIMH) invites applications for projects that implement creative, efficient molecular epidemiologic approaches that incorporate individual genetic information, including polygenic as well as specific genetic risk variants, in existing large, population-based cohorts, registries and/or health systems to conduct analyses that advance our</p>					

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>understanding of the complex etiology of severe mental disorders. The ultimate objective of this funding opportunity is the elucidation of the complex interplays of genetic (e.g., polygenic) risk, in addition to specific risk loci and networks, and environmental factors, in human populations, which will lead to better understanding, diagnosis, and ultimately treatment of mental disorders. This FOA will use the NIH Research Project (R01) award mechanism.</p>			
082860	Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-19-289	05-Feb-2021	Not Specified
	<p>Contact Name Lois Winsky, Ph.D.</p> <p>Contact Telephone 301-443-5288</p> <p>Contact Email lwinsky@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022</p>	<p>Synopsis The overall goal of this Funding Opportunity Announcement (FOA) is to identify, in animals, in vivo neurophysiological and behavioral measures for use as assays in the early screening phase of treatment development. The FOA will support efforts to optimize and evaluate measures of neurophysiological and behavioral processes that may serve as surrogate markers of neural processes of clinical interest based on available knowledge of the neurobiology of mental illnesses. The screening assays thus developed from this FOA are expected to build upon systems neurobiology and clinical neuroscience to enhance the scientific value of preclinical animal data contributing to a therapeutic development pipeline by assessing the impact of therapeutic targets and treatment candidates on neurobiological mechanisms of clinical relevance to mental illnesses. The objectives of the FOA will be accomplished by supporting basic and translational neuroscientists who are committed to improving the efficiency and scientific value of the therapeutic development pipeline by advancing the discovery of in vivophysiological and behavioral measures reflecting circuit engagement as tools for early phase target validation and therapeutic screening for mental illness treatment development. The efforts supported by this initiative focus on measures in animals as a first step in generating translational assay measures that are adaptable across early therapeutic screens in animals to evaluation in humans. As such, this FOA may be considered a prequel to build a suite of assays that are evaluated in future projects for coherence of assay performance between the preclinical species and healthy humans. In summary, this FOA will support efforts to improve the tool kit of assays available for early phase testing of novel therapeutic agents by incorporating measures proximal to neural systems that impact mental health.</p>			
097908	Cellular and Molecular Biology of Complex Brain Disorders (R01 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-20-263	05-Feb-2021	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	Contact Name	David Panchision			
	Contact Telephone	301-443-5288			
	Contact Email	panchisiond@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023			
	Synopsis	<p>This Funding Opportunity Announcement (FOA) encourages research on the biology of high confidence risk factors associated with complex brain disorders, with a focus on the intracellular, transcellular and circuit substrates of neural function. For the purposes of this FOA, the term “complex” can refer to a multifactorial contribution to risk (e.g., polygenic and/or environmental) and/or highly distributed functional features of the brain disorder. Studies may be either hypothesis-generating (unbiased discovery) or hypothesis-testing in design and may utilize in vivo, in situ or in vitro experimental paradigms, e.g., model organisms or human cell-based assays. While behavioral paradigms and outcome measures can be incorporated into the research design to facilitate the characterization of intracellular, transcellular and circuit mechanisms, these are neither required nor expected. Studies should not attempt to “model” disorders but instead should aim to elucidate the neurobiological impact of individual or combined risk factor(s), such as the affected molecular and cellular components and their relationships within defined biological process(es). This can include the fundamental biology of these factors, components and processes. The resulting paradigms, component pathways and biological processes should be disseminated with sufficient detail to enrich common and/or federated data resources (e.g., those contributing to the Gene Ontology, Synaptic Gene Ontology, FAIR Data Informatics) in order to bridge the gap between disease risk factors, biological mechanism and therapeutic target identification. The present announcement (R01 activity code) can be used for applications to further develop lines of inquiry where feasibility or proof-of-concept has been established.</p>			

077725	Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R01 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-18-942	05-Feb-2021	Not Specified
--------	--	--	------------	-------------	---------------

	Contact Name	David McMullen, M.D.			
	Contact Telephone	301-451-0180			
	Contact Email	david.mcmullen@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Feb-2021 , 05-Jun-2021			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Synopsis</p>	<p>The purpose of this funding opportunity announcement (FOA) is to encourage applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are sought that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently U.S. Food and Drug Administration (FDA)-approved or cleared. Novel devices should move beyond existing electrical/magnetic stimulation and develop new stimulation techniques capable of increased spatiotemporal precision as well as multi-focal, closed-loop approaches. Applications seeking to develop new capabilities should focus on significant enhancement of the spatial resolution, depth of delivery, and/or precision of the device. Incremental changes to existing devices (e.g., software updates) are not within the scope of this announcement. Applications should be submitted by multi-disciplinary teams with diverse expertise including systems neuroscience, engineering, clinical, and regulatory affairs. Applications submitted to this FOA should promote the development or significant enhancement of novel tools (hardware/software) for brain stimulation in humans. Although the application should focus on the engineering development and bench top testing of the tool, animal and limited human testing necessary to demonstrate initial proof of concept is allowable. Applications to this FOA may propose hypothesis-driven research , but should propose design-directed, developmental, or discovery-driven technology research using integrative approaches. Applications that seek to study scientific or clinical hypotheses that simply utilize devices are outside the scope of this FOA.</p>			
077665	<p>Development and Optimization of Tasks and Measures for Functional Domains of Behavior (R01 Clinical Trial Not Allowed)</p>	National Institute of Mental Health/NIH/DHHS	PAR-18-930	05-Feb-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Sarah Morris, Ph.D.</p> <p>301-443-9233</p> <p>sarah.morris@nih.gov</p> <p></p> <p>Link to program URL</p> <p>05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021</p> <p>National Institute of Mental Health (NIMH) and National Institute on Alcohol Abuse and Alcoholism (NIAAA) invite applications for the development and optimization of tasks and/or measures for constructs pertaining to functional aspects of behavior or cognitive/affective processes, for use in laboratory or population-based studies, clinical trials outcomes, or related research. This FOA encourages research that will result in the availability of tasks and measures that demonstrate: (1) good validity as a measure of a specific construct; (2) robust measurement properties; and (3) suitability for use across diverse participants. This FOA will use the NIH Research Project (R01) award mechanism.</p>			
077664	<p>High-Priority Areas for Research Leveraging EHR and Large-Scale Data (R01)</p>	National Institute of Mental	PAR-18-	05-Feb-2021	Not

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	Clinical Trial Not Allowed		Health/NIH/DHHS	929	Specified	
	<p>Contact Name Farris Tuma, ScD</p> <p>Contact Telephone 301-443-9232</p> <p>Contact Email ftuma@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 05-Jun-2021</p> <p>Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers, along with Department of Veterans Affairs (VA) invite applications to leverage large-scale, real-world data from electronic health records (EHRs) from a variety of systems (e.g., the Department of Defense (DOD), Department of Veterans Affairs (VA), Centers for Medicare and Medicaid Services administrative claims, as well as public or private health care systems and networks) to understand risk, onset, course, and impact of treatments and services for mental and neurological disorders and to identify promising new mental health and neurological disorders research. There is particular interest in leveraging EHRs and administrative data to 1) understand and improve the treatment of post traumatic psychopathology, including posttraumatic stress disorder, depression, traumatic brain injury (TBI), and risk for suicide; and 2) characterize post-trauma multi-symptom recovery trajectory patterns of TBI, that may include post traumatic stress disorder, depression, cognitive impairment, pain, substance abuse disorder and risk for suicide. NIMH also invites innovative approaches to use EHR and administrative data to understand risk, onset, course, and impact of treatments and services for mental disorders more broadly. This FOA will use the NIH Research Project (R01) award mechanism.</p>					
076230	RFA-MH-19-147 -- BRAIN Initiative: Integration and Analysis of BRAIN Initiative Data (R01 Clinical Trial Not Allowed)		National Institute of Mental Health/NIH/DHHS	RFA-MH-19-147	02-Feb-2021 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Ming Zhan, Ph.D.</p> <p>Contact Telephone 301-827-3678</p> <p>Contact Email ming.zhan@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 02-Feb-2021 [Optional][LOI/Pre-App], 04-Mar-2021</p> <p>Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invite applications to develop informatics tools</p>					

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

for analyzing, visualizing, and integrating data related to the BRAIN Initiative or to enhance our understanding of the brain. This FOA will use the NIH R01 Research Project Grant award mechanism.

068980	RFA-MH-18-704--Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33- Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	RFA-MH-18-704	19-Jan-2021 [Optional][LOI/Pre-App]	Not Specified
--------	---	--	---------------	--	---------------

Contact Name	Ann Wagner, Ph.D.
Contact Telephone	301-443-3633
Contact Email	awagner@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	19-Jan-2021 [Optional][LOI/Pre-App], 18-Feb-2021
Synopsis	<p>National Institute of Mental Health (NIMH) invites applications to support the efficient pilot testing of novel psychosocial therapeutic and preventive interventions for mental disorders in adults and children, using an experimental therapeutics approach. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support "go/no-go" decisions about further development or testing of the intervention. This FOA supports the development and testing of innovative psychosocial intervention approaches where the target and/or the intervention strategy is novel. Targets might include, but are not limited to, potentially modifiable behavioral, cognitive, affective and/or interpersonal factors or processes, neural circuits or neural activity subserving specific behaviors or cognitive processes, and/or other neurobiological mechanisms associated with risk for, causation of, or maintenance of a mental disorder. Eligible psychosocial intervention strategies might include in-person or technology-assisted delivery, provided the target and/or the intervention strategy is novel. This FOA supports the development and testing of novel psychosocial interventions, as defined above, as monotherapies or as augmentations to standard treatment. Support will be provided for up to two years (R61 phase) for preliminary milestone-driven testing of the intervention's impact on a target (a process or mechanism associated with risk for, causation, or maintenance of a clinical condition), that is, its target engagement. Contingent on meeting "go/no-go" milestones in the R61 phase, up to 3 years of additional support (R33 phase) may be provided for studies to replicate target engagement and relate change in the intervention target/mechanism to clinical benefit. Ultimately, this R61/R33 FOA is intended to speed the translation of emerging basic science findings of mechanisms and processes underlying mental disorders into novel interventions that can be efficiently tested for their promise in restoring function and reducing symptoms for those living with mental disorders, or for preventing mental disorders among those at risk. This FOA will use the NIH R61/R33 Exploratory/Developmental Phased Award mechanism.</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
068982	RFA-MH-18-706 -- Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34- Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	RFA-MH-18-706	19-Jan-2021 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Joel Sherrill, Ph.D.</p> <p>Contact Telephone 301-443-2477</p> <p>Contact Email jsherril@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 19-Jan-2021 [Optional][LOI/Pre-App], 18-Feb-2021</p> <p>Synopsis National Institute of Mental Health (NIMH) invites applications for pilot research consistent with NIMH's priorities for: 1) effectiveness research on preventive and therapeutic interventions with previously demonstrated efficacy, for use with broader target populations or for use in community practice settings, and 2) research on the development and preliminary testing of innovative services interventions. Applications should provide resources for evaluating the feasibility, tolerability, acceptability and safety of approaches to improve mental health/functional outcomes, to modify risk factors, or to improve service delivery, and for obtaining the preliminary data needed as a pre-requisite to a larger-scale intervention trial (e.g., comparative effectiveness study, practical trial) or large-scale services study. In this pilot phase of effectiveness research, NIMH places highest priority on approaches that can be justified in terms of their potential to substantially impact practice and public health and approaches that are empirically grounded. Adaptations or augmentations of efficacious interventions should only be undertaken if there is an empirical rationale for the adaptation target and for the corresponding mechanism by which the adapted intervention or augmentation is expected to substantially enhance outcomes. This FOA is intended to support pilot effectiveness trials that are designed to explicitly address whether the intervention engages the target(s)/mechanism(s) presumed to underlie the intervention effects. This FOA will use the NIH R34 Planning Grant award mechanism.</p>				
068981	RFA-MH-18-705--Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	RFA-MH-18-705	19-Jan-2021 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Ann Wagner, Ph.D.</p> <p>Contact Telephone 301-443-3633</p> <p>Contact Email awagner@mail.nih.gov</p> <p>Sponsor Website </p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 19-Jan-2021 [Optional][LOI/Pre-App], 18-Feb-2021</p> <p>Synopsis National Institute of Mental Health (NIMH) invites applications to support the efficient pilot testing of novel psychosocial therapeutic and preventive interventions for mental disorders in adults and children, using an experimental therapeutics approach. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support "go/no-go" decisions about further development or testing of the intervention. This FOA supports the development and testing of innovative psychosocial intervention approaches where the target and/or the intervention strategy are novel. Targets might include, but are not limited to, potentially modifiable behavioral, cognitive, affective and/or interpersonal factors or processes, neural circuits or neural activity subserving specific behaviors or cognitive processes, and/or other neurobiological mechanisms associated with risk for, causation of, or maintenance of a mental disorder. Eligible psychosocial intervention strategies might include in-person or technology-assisted delivery, provided the target and/or the intervention strategy is novel. This FOA supports the development and testing of novel psychosocial interventions, as defined above, as monotherapies or as augmentations to standard treatment. Support will be provided for up to 3 years for studies to replicate previous target engagement findings, and relate change in the intervention target/mechanism to clinical benefit. Ultimately, this FOA is intended to speed the translation of emerging basic science findings of mechanisms and processes underlying mental disorders into novel interventions that can be efficiently tested for their promise in restoring function and reducing symptoms for those living with mental disorders, or for preventing mental disorders among those at risk. This FOA will use the NIH R33 Exploratory/Developmental Grants Phase II award mechanism.</p>				
100293	<p>RFA-MH-21-165 -- From Genomic Association to Causation: A Convergent Neuroscience Approach for Integrating Levels of Analysis to Delineate Brain Function in Neuropsychiatric Disorders (U19 Clinical Trial Optional)</p>	National Institute of Mental Health/NIH/DHHS	RFA-MH-21-165	15-Feb-2021 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name David M. Panchision, Ph.D.</p> <p>Contact Telephone 301-443-5288</p> <p>Contact Email panchisiond@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Feb-2021 [Optional][LOI/Pre-App], 17-Mar-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) supports research to understand causal linkages across different scales (e.g., molecular, cellular, circuit, behavioral, clinical) relevant to neuropsychiatric disorders. The Convergent Neuroscience (CN) program goal is to establish theoretical models to show how specific constituent processes at one level of analysis contribute</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

to quantifiable properties at other levels, either directly or as emergent phenomenon. Studies should incorporate four key features: (1) a premise on identifying the causal and disease-relevant relationships between objective genetic/biological/clinical criteria at two or more contiguous levels of analysis, whether involving human subjects or experimentally tractable in vivo or in vitro paradigms (genetic variation can be one of the contiguous levels of analysis or can be the context in which other, higher levels of analysis are linked); (2) use of the large and diverse datasets existing or generated at these levels of analysis to develop testable theoretical models within three years of award; (3) experimental testing of the model-based predictions to confirm or reject their validity, (4) preferential utilization of scalable approaches to maximize analytic throughput, content, sensitivity, selectivity, spatiotemporal resolution and robustness. Results should yield causal linkages between levels of analysis and mechanistically explain key functional dimension(s) relevant to mental illness pathophysiology. Leadership of research teams will include expertise in experimental neurobiology or clinical research paired with orthogonal theoretical disciplines (e.g., mathematics, computation, physics). This endeavor will be facilitated by active participation in a community-driven manner through the CN Consortium. Groups will manage their data and analysis methods using a harmonized framework with other U19 awardees through a CN Consortium Data Commons structure.

068963	RFA-MH-18-700 -- Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01 - Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	RFA-MH-18-700	19-Jan-2021 [Optional][LOI/Pre-App]	Not Specified
--------	---	--	---------------	-------------------------------------	---------------

Contact Name	Joel Sherrill, Ph.D.
Contact Telephone	301-443-2477
Contact Email	jsherril@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	19-Jan-2021 [Optional][LOI/Pre-App], 18-Feb-2021

Synopsis National Institute of Mental Health (NIMH) invites applications to support clinical trials to establish the effectiveness of interventions and to test hypotheses regarding moderators, mediators, and mechanisms of action of these interventions. This FOA supports clinical trials designed to test the therapeutic value of treatment and preventive interventions for which there is already evidence of efficacy, for use in community and practice settings. Applications might include research to evaluate the effectiveness or increase the clinical impact of pharmacologic, somatic, psychosocial (psychotherapeutic, behavioral), device-based, rehabilitative and combination interventions to prevent or treat mental illness. This FOA also supports clinical trials to test patient-, provider-, organizational-, or systems-level services interventions to improve access, continuity, quality, equity, and/or value of services. The intervention research covered under this announcement is explicitly focused on practice-relevant questions. This FOA supports trials that require participation of two or more collaborative sites for

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

completion of the study. Accordingly, the collaborating studies share a specific protocol across the sites and are organized as such in order to increase sample size, accelerate recruitment, or increase sample diversity and representation. Each site has its own Program Director/Principal Investigator (PD/PI) and the program provides a mechanism for cross-site coordination, quality control, database management, statistical analysis, and reporting. This FOA will use the NIH R01 Research Project Grant award mechanism.

068973	RFA-MH-18-701 -- Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01 Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	RFA-MH-18-701	19-Jan-2021 [Optional][LOI/Pre-App]	Not Specified
--------	---	--	---------------	-------------------------------------	---------------

Contact Name | Joel Sherrill, Ph.D.
 Contact Telephone | 301-443-2477
 Contact Email | jsherril@mail.nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 19-Jan-2021 [Optional][LOI/Pre-App], 18-Feb-2021

Synopsis | National Institute of Mental Health (NIMH) invites applications to support clinical trials to establish the effectiveness of interventions and to test hypotheses regarding moderators, mediators, and mechanisms of action of these interventions. This FOA supports clinical trials designed to test the therapeutic value of treatment and preventive interventions for which there is already evidence of efficacy, for use in community and practice settings. Applications might include research to evaluate the effectiveness or increase the clinical impact of pharmacologic, somatic, psychosocial (psychotherapeutic, behavioral), device-based, rehabilitative and combination interventions to prevent or treat mental illness. This FOA also supports clinical trials to test patient-, provider-, organizational-, or systems-level services interventions to improve access, continuity, quality, equity, and/or value of services. The intervention research covered under this announcement is explicitly focused on practice-relevant questions. This FOA will use the NIH R01 Research Project Grant award mechanism.

068977	RFA-MH-18-702 -- Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33- Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	RFA-MH-18-702	19-Jan-2021 [Optional][LOI/Pre-App]	Not Specified
--------	--	--	---------------	-------------------------------------	---------------

Contact Name | Margaret Grabb, Ph.D.
 Contact Telephone | 301-443-3563
 Contact Email | mgrabb@mail.nih.gov

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 19-Jan-2021 [Optional][LOI/Pre-App], 18-Feb-2021</p> <p>Synopsis National Institute of Mental Health (NIMH) invites applications to support the early stage testing of pharmacologic interventions with novel mechanisms of action, or device-based interventions, for the treatment of symptoms or domains of altered functions in individuals with mental illness (e.g., schizophrenia, depression, autism, obsessive compulsive disorder, anxiety, bipolar disorder). Early intervention studies are also encouraged where symptoms of a disorder have been identified in subjects (a prodromal phase), prior to full diagnostic criteria being met. Ultimately, this FOA is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a dose-dependent neurophysiological/clinical/behavioral effect. The R61/R33 FOAs are intended to support biphasic high risk applications. This FOA will use the NIH R61/R33 Exploratory/Developmental Phased Award mechanism.</p>				
068979	<p>RFA-MH-18-703 -- Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required)</p>	National Institute of Mental Health/NIH/DHHS	RFA-MH-18-703	19-Jan-2021 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Margaret Grabb, Ph.D.</p> <p>Contact Telephone 301-443-3563</p> <p>Contact Email mgrabb@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 19-Jan-2021 [Optional][LOI/Pre-App], 18-Feb-2021</p> <p>Synopsis National Institute of Mental Health (NIMH) invites applications to support the early stage testing of pharmacologic interventions with novel mechanisms of action or device-based interventions, for the treatment of symptoms or domains of altered functions in individuals with mental illness (e.g., schizophrenia, depression, autism, obsessive compulsive disorder, anxiety, bipolar disorder). Early intervention studies are also encouraged where symptoms of a disorder have been identified in subjects (a prodromal phase), prior to full diagnostic criteria being met. Ultimately, this FOA is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a dose-dependent neurophysiological/clinical/behavioral effect. Pediatric, adult and geriatric focused interventions are appropriate for this FOA. This R33 FOA supports single phased clinical trial awards. This FOA will use the NIH R33</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

| Exploratory/Developmental Grants Phase II award mechanism.

100747	RFA-MH-21-110 -- Service-Ready Tools for Identification, Prevention, and Treatment of Individuals at Risk for Suicide (R01 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	RFA-MH-21-110	18-Feb-2021	Not Specified
--------	---	--	---------------	-------------	---------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Stephen O'Connor, Ph.D.</p> <p>301-480-8366</p> <p>stephen.o'connor2@nih.gov</p> <p></p> <p>Link to program URL</p> <p>18-Feb-2021 , 15-Oct-2021 , 15-Jun-2022</p> <p>NIMH seeks applications for research projects to evaluate the effectiveness of service-ready tools and technologies that can be used to advance training, quality monitoring, and quality improvement efforts and ultimately improve the availability of evidence-based suicide prevention services. Specifically, this initiative encourages research on the effectiveness-implementation continuum aimed at (1) developing and testing the effectiveness of optimized, service-ready suicide prevention tools for identification, prevention, and treatment of individuals at risk for suicide; and (2) testing strategies to improve adoption, implementation fidelity, and sustained use of these tools, guided by an implementation science framework. Given the focus on practice-ready accessible resources and products that could be readily integrated into practice, NIMH encourages the use of technology and other design features that make the tools scalable and robust against implementation drift, and a deployment-focused approach that takes into account the perspectives of key stakeholders (e.g., service users, providers, administrators) and system-level factors, such as workforce capacity that influence potential integration of tools into clinical workflows. This Funding Opportunity Announcement (FOA) is intended to support effectiveness research of service-ready tools and technologies for suicide prevention that are statistically powered to provide a definitive answer regarding the study tool's effectiveness. Support for pilot effectiveness research to evaluate the initial feasibility, tolerability, acceptability, safety, and preliminary indications of effectiveness of service-ready tools and technologies for suicide prevention is provided via the R34 in RFA-MH-21-111. Support for SBIR studies focused on service-ready tools and technologies or suicide prevention is provided via the R43/R44 in RFA-MH-21-112.</p>
---	--

100751	RFA-MH-21-112 -- Service-Ready Tools for Identification, Prevention, and Treatment of Individuals at Risk for Suicide (R43/R44 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	RFA-MH-21-112	18-Feb-2021	Not Specified
--------	---	--	---------------	-------------	---------------

<p>Contact Name</p> <p>Contact Telephone</p>	<p>Stephen O'Connor, Ph.D.</p> <p>301-480-8366</p>
--	--

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email stephen.o'connor2@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 18-Feb-2021 , 15-Oct-2021 , 15-Jun-2022</p> <p>Synopsis This SBIR Funding Opportunity Announcement (FOA) is intended to support small businesses to develop and test service-ready, commercially viable tools and technologies for suicide prevention, including technologies that can be used to advance training, quality monitoring, and quality improvement efforts and ultimately improve the availability of evidence-based suicide prevention services. Specifically, this initiative encourages research on the effectiveness-implementation continuum aimed at (1) developing and testing the effectiveness of optimized, service-ready suicide prevention tools for identification, prevention, and treatment of individuals at risk for suicide; and (2) testing strategies to improve adoption, implementation fidelity, and sustained use of these tools, guided by an implementation science framework. Given the focus on practice-ready accessible resources and products that could be readily integrated into practice, NIMH encourages the use of technology and other design features that make the tools scalable and robust against implementation drift, and a deployment-focused approach that takes into account the perspectives of key stakeholders (e.g., service users, providers, administrators) and system-level factors, such as workforce capacity that influence potential integration of tools into clinical workflows.</p>				
100749	RFA-MH-21-111 -- Service-Ready Tools for Identification, Prevention, and Treatment of Individuals at Risk for Suicide (R34 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	RFA-MH-21-111	18-Feb-2021	450,000 USD
	<p>Contact Name Stephen O'Connor, Ph.D.</p> <p>Contact Telephone 301-480-8366</p> <p>Contact Email stephen.o'connor2@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 18-Feb-2021 , 15-Oct-2021 , 15-Jun-2022</p> <p>Synopsis NIMH seeks applications for pilot effectiveness projects to evaluate the preliminary effectiveness of service-ready tools and technologies that can be used to advance training, quality monitoring, and quality improvement efforts and ultimately improve the availability of evidence-based suicide prevention services. Specifically, this initiative encourages research on the effectiveness-implementation continuum aimed at (1) developing and testing the effectiveness of optimized, service-ready suicide prevention tools for identification, prevention, and treatment of individuals at risk for suicide; and (2) testing strategies to improve adoption, implementation fidelity, and sustained use of these tools, guided by an implementation science framework. Given the focus on practice-ready accessible resources and products that could be readily integrated into</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>practice, NIMH encourages the use of technology and other design features that make the tools scalable and robust against implementation drift, and a deployment-focused approach that takes into account the perspectives of key stakeholders (e.g., service users, providers, administrators) and system-level factors, such as workforce capacity that influence potential integration of tools into clinical workflows. This Funding Opportunity Announcement (FOA) supports pilot effectiveness research to evaluate the feasibility, tolerability, acceptability, safety and preliminary indications of effectiveness of service-ready tools and technologies for suicide prevention and inform the design of definitive effectiveness trials. Support for fully-powered, definitive effectiveness studies focused on service-ready tools and technologies or suicide prevention is provided via the R01 in RFA-MH-21-110. Support for SBIR studies focused on service-ready tools and technologies or suicide prevention is provided via the R43/R44 in RFA-MH-21-112.</p>			
100788	RFA-MH-21-160 -- Social Drivers of Mental Illnesses in Low- & Middle-Income Countries: Mechanisms and Pathways of Interventions for Youth (R01 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	RFA-MH-21-160	18-Feb-2021 [Optional][LOI/Pre-App]	2,500,000 USD
	<p>Contact Name Stacia Friedman-Hill, PhD</p> <p>Contact Telephone 301-443-8458</p> <p>Contact Email friedmans@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 18-Feb-2021 [Optional][LOI/Pre-App], 18-Mar-2021</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to solicit research that will help to identify and explain the mechanisms and pathways by which interventions targeting social drivers of mental illnesses affect the mental health and functioning of children and/or adolescents (ages 5-24 years) living in World Bank designated low- and middle-income countries (LMICs) and previously designated LMICs re-categorized as high income on or after January 1, 2021. Studies should use innovative approaches to capture as much real-world complexity as possible in identifying and elucidating mechanisms and pathways that reduce risk for mental illnesses or improve mental health in children and/or adolescents. NIMH welcomes applicants from LMICs and strongly encourages applicants from the United States or upper middle income countries to partner with sites in LMICs.</p>				
100375	RFA-MH-21-140 -- BRAIN Initiative Cell Census Network (BICCN) Scalable Technologies and Tools for Brain Cell Census (R01 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	RFA-MH-21-140	10-Feb-2021 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Yong Yao, Ph.D.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-443-6102</p> <p>Contact Email yyao@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-Feb-2021 [Optional][LOI/Pre-App], 10-Mar-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) intends to accelerate the use of scalable technologies and tools to enhance brain cell census research, including the development of technology platforms and/or resources and the generation of spatiotemporal cell census data and/or resources. Applications are expected to address limitations and gaps of existing technologies/tools as a benchmark against which the improvements or competitive advantages of the proposed ones will be measured. The improvements include throughput, sensitivity, selectivity, scalability, spatiotemporal resolution and reproducibility in cell atlas analyses. The projects funded under this FOA will align with the overarching goals of the BRAIN Initiative Cell Census Network (BICCN) and are expected to enable the generation of a large amount of cell census data using the proposed technologies or via collaboration with the BICCN.</p>				
078787	Emotion Regulation, Aging and Mental Disorder (R21 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PA-19-095	16-Feb-2021	275,000 USD
	<p>Contact Name Jovier Evans, PhD</p> <p>Contact Telephone 301-443-1369</p> <p>Contact Email jevans1@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages applications for mechanistic research on age-related changes in emotion regulation and how they may contribute to mental disorders in middle-aged and older adults. In particular, research is sought that will advance understanding of irregularities in the integrative neural-behavioral mechanisms of emotion regulation in adult mood and anxiety disorders, and that will examine whether the irregularities are associated with typical or atypical maturational trajectories of emotion processing. Currently, it is not known whether older adults who suffer episodes of affective dysregulation share the same patterns of improved emotional function with age as have been found to be typical of the older adult population in general. Research that helps to clarify whether they do or do not manifest typical emotion processing trajectories may lead to very different understandings of the irregularities involved in their dysregulation. It is anticipated that such studies may identify novel targets for mental health interventions or prevention efforts, or provide</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
					clues as to which available intervention strategies might be optimally applied to normalize emotion dysregulation or to strengthen emotional resilience at particular stages of the adult life cycle.
078030	Basic Neurodevelopmental Biology of Circuits and Behavior (R01 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-19-027	05-Feb-2021	2,500,000 USD
	Contact Name	Bettina Buhring			
	Contact Telephone	301-443-1576			
	Contact Email	neurodevelopmentpar@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021			
	Synopsis	This Funding Opportunity Announcement (FOA) encourages research projects focused on the dynamic and mechanistic links between the maturation of brain circuits and behaviors across development in rodents and non-human primates. The goal is to build a foundation for understanding how interactions within and among brain regions change over pre- and post-natal development, allowing for the emergence of cognitive, affective and social behaviors. To this end, projects supported will focus on neurodevelopmental trajectories and investigate questions using in vivo neural measures in awake, behaving animals. This FOA uses the R01 grant mechanism, whereas its companion funding opportunity seeks shorter, higher-risk R21 grant applications.			
101117	RFA-MH-21-116 -- Mood Disorders in People Living with HIV: Mechanisms and Pathways (R01 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	RFA-MH-21-116	10-Feb-2021 [Optional][LOI/Pre-App]	Not Specified
	Contact Name	Vasudev R Rao, MBBS, MS.			
	Contact Telephone	301-825-3259			
	Contact Email	vasudev.rao@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	10-Feb-2021 [Optional][LOI/Pre-App], 10-Mar-2021			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support studies to better understand the underlying mechanisms and interplay of biological, psychosocial and structural factors contributing to mood disorders in people living			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		with HIV. Applications testing a fully conceptualized and hypothesis-based solid premise founded with adequate preliminary data are appropriate for this FOA. Exploratory and high-risk research projects should consider applying to the companion R21 announcement RFA-MH-21-117. Basic and preclinical research in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required.			
101119	RFA-MH-21-117 -- Mood Disorders in People Living with HIV: Mechanisms and Pathways (R21 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	RFA-MH-21-117	10-Feb-2021 [Optional][LOI/Pre-App]	275,000 USD
	Contact Name	Vasudev R Rao, MBBS, MS.			
	Contact Telephone	301-825-3259			
	Contact Email	vasudev.rao@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	10-Feb-2021 [Optional][LOI/Pre-App], 10-Mar-2021			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support studies to better understand the underlying mechanisms and interplay of biological, psychosocial and structural factors contributing to mood disorders in people living with HIV. Exploratory and high-risk research projects are appropriate for this FOA. Applications testing a fully conceptualized and hypothesis-based solid premise founded with adequate preliminary data should consider applying to the companion R01 announcement RFA-MH-21-116. Basic and preclinical research in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required.			
070086	Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R01 Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-18-430	05-Feb-2021	Not Specified
	Contact Name	Adam Haim, Ph.D.			
	Contact Telephone	301-435-3593			
	Contact Email	haima@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Feb-2021			
	Synopsis	National Institute of Mental Health (NIMH) invites applications for research projects to evaluate the effectiveness of			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		therapeutic and service delivery interventions for the post-acute management of mental health conditions affecting youth, adults, and older adults. This FOA encourages clinical trials to establish the effectiveness and test hypotheses regarding moderators, mediators, and mechanisms of action of post-acute phase therapeutic and services interventions that are matched to the stage of illness in terms of both their focus (e.g., consolidating and maintaining gains from initial treatment, managing residual symptoms/impairment, preventing relapse, promoting adherence and appropriate service use) and intensity/burden for promoting optimal longer-term outcomes. This FOA will use the NIH Research Project (R01) award mechanism.			
073671	NIMH Career Transition Award for Tenure-Track Intramural Investigators (K22 Independent Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-18-755	12-Feb-2021	900,000 USD
	Contact Name	Ashlee Van't Veer, PhD			
	Contact Telephone	301-443-3107			
	Contact Email	dnbbstrainingbranch@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	12-Feb-2021			
	Synopsis	National Institute of Mental Health (NIMH) provides support for career intramural investigators at NIMH who aim to transition from the Division of Intramural Research Programs (DIRP) to an independent research faculty position in the extramural community. Applicants should have a demonstrated record of meritorious research in mental health-related fields. This FOA will utilize the NIH Career Transition (K22) award mechanism.			
080474	Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-19-214	19-Feb-2021	Not Specified
	Contact Name	Lois Winsky, Ph.D.			
	Contact Telephone	301-443-5288			
	Contact Email	lwinsky@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	19-Feb-2021 , 21-Jun-2021 , 20-Oct-2021 , 21-Feb-2022			
	Synopsis	The overall goal of this initiative is to identify neurophysiological measures as potential assays for treatment development			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
077729	Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R21 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-18-941	16-Feb-2021	275,000 USD

research. The funding opportunity announcement (FOA) will support efforts to optimize and evaluate measures of neurophysiological processes that are disrupted within or across mental disorders in both healthy humans and in another species relevant to the therapeutic development pipeline. The initiative will support initial proof of concept studies aimed at identifying measures for potential development as preclinical assays for evaluating potential new drug and device therapies and their targets. Data will also reveal assay measures where the performance between preclinical animal species and humans is dissimilar, thus establishing a firm basis for limiting speculative extrapolations of preclinical animal findings to humans. The ultimate practical goal of this FOA is to improve the efficiency of the therapeutic development process by identifying coherence of measures and inconsistencies between the preclinical screening pipeline and clinical evaluation of new treatment candidates and thereby hasten the development of more effective treatments for mental disorders. The objectives of the FOA will be accomplished by supporting partnerships among basic and translational neuroscientists who are committed to advancing the discovery of in vivo physiological measures as tools for target validation and therapeutic development. Groups will be tasked with developing and optimizing in vivo assays of brain processes in both animals and in healthy humans. Groups will evaluate assay performance across both species in response to specific chemical, physiological, or behavioral manipulations. In this way, projects will reveal the potential of specific assays to translate from animals to humans, suggesting assays for further development as tools in the treatment development pipeline.

Contact Name David McMullen, M.D.
 Contact Telephone 301-451-0180
 Contact Email david.mcmullen@nih.gov
 Sponsor Website
 Program URL [Link to program URL](#)
 Deadline Dates (ALL) 16-Feb-2021 , 16-Jun-2021

Synopsis National Institute of Mental Health (NIMH) invites applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are sought that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently U.S. Food and Drug Administration (FDA)-approved or cleared. Novel devices should move beyond existing electrical/magnetic stimulation and develop new stimulation techniques capable of increased spatiotemporal precision as well as multi-focal, closed-loop approaches. Applications seeking to develop new capabilities should focus on significant enhancement of the spatial resolution, depth of delivery, and/or precision of the device. Incremental changes to existing devices (e.g., software updates) are not within the scope of this announcement. Applications should be submitted by

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

multi-disciplinary teams with diverse expertise including systems neuroscience, engineering, clinical, and regulatory affairs. Applications submitted in response to this FOA should promote the development or significant enhancement of novel tools (hardware/software) for brain stimulation in humans. Although the application should focus on the engineering development and bench top testing of the tool, animals and limited human testing necessary to demonstrate initial proof of concept is allowable. Applications to this FOA are not expected to be hypothesis-driven, but should propose design-directed, developmental, or discovery-driven technology research using integrative approaches. Applications that seek to study scientific or clinical hypotheses that simply utilize devices are outside the scope of this FOA. This FOA will utilize the NIH R21 Exploratory/Developmental Research Grant award mechanism.

078035	Basic Neurodevelopmental Biology of Brain Circuits and Behavior (R21 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-19-028	16-Feb-2021	275,000 USD
--------	--	--	------------	-------------	-------------

Contact Name | Bettina Buhring
 Contact Telephone | 301-443-1576
 Contact Email | neurodevelopmentpar@mail.nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021

Synopsis | This Funding Opportunity Announcement (FOA) invites research projects focused on the dynamic and mechanistic links between the maturation of brain circuits and behaviors across development in rodents and non-human primates. The goal is to build a foundation for understanding how interactions within and among brain regions change during pre- and post-natal development, allowing for the emergence of cognitive, affective and social behaviors. To this end, projects supported will focus on neurodevelopmental trajectories and investigate questions using in vivo neural measures in awake, behaving animals. This FOA seeks shorter, higher-risk R21 grant applications, whereas its companion funding opportunity seeks R01 grant applications.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

097912	Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-20-264	16-Feb-2021	275,000 USD
--------	--	--	------------	-------------	-------------

Contact Name | David Panchision

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Telephone	301-443-5288
Contact Email	panchisiond@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022 , 16-Oct-2022 , 16-Feb-2023 , 16-Jun-2023
Synopsis	<p>This Funding Opportunity Announcement (FOA) encourages research on the biology of high confidence risk factors associated with complex brain disorders, with a focus on the intracellular, transcellular and circuit substrates of neural function. For the purposes of this FOA, the term “complex” can refer to a multifactorial contribution to risk (e.g., polygenic and/or environmental) and/or highly distributed functional features of the brain disorder. Studies may be either hypothesis-generating (unbiased discovery) or hypothesis-testing in design and may utilize in vivo, in situ, or in vitro experimental paradigms, e.g., model organisms or human cell-based assays. While behavioral paradigms and outcome measures can be incorporated into the research design to facilitate the characterization of intracellular, transcellular and circuit mechanisms, these are neither required nor expected. Studies should not attempt to “model” disorders but instead should aim to elucidate the neurobiological impact of individual or combined risk factor(s), such as the affected molecular and cellular components and their relationships within defined biological process(es). This can include the fundamental biology of these factors, components and processes. The resulting paradigms, component pathways and biological processes should be disseminated with sufficient detail to enrich common and/or federated data resources (e.g., those contributing to the Gene Ontology, Synaptic Gene Ontology, FAIR Data Informatics) in order to bridge the gap between disease risk factors, biological mechanism and therapeutic target identification. The present announcement (R21 activity code) can be used for applications to develop early stage, high-risk, exploratory approaches or establish proof-of-concept where there is little or no preliminary data.</p>

069757	Research on Autism Spectrum Disorders (R01-Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PA-18-401	05-Feb-2021	Not Specified
--------	---	--	-----------	-------------	---------------

Contact Name	Lisa Gilotty, Ph.D.
Contact Telephone	301-443-3825
Contact Email	gilottyl@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Feb-2021
Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications to support research designed

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		to elucidate the etiology, epidemiology, diagnosis, treatment, and optimal means of service delivery in relation to Autism Spectrum Disorders (ASD). This program will use the NIH Research Project Grant (R01) award mechanism.			
081133	Reducing the Duration of Untreated Psychosis in the United States (R34 Clinical Trial Required)	National Institute of Mental Health/NIH/DHHS	PAR-19-235	16-Feb-2021	450,000 USD
	Contact Name	Susan T. Azrin, Ph.D.			
	Contact Telephone	301-443-3267			
	Contact Email	susan.azrin@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022			
	Synopsis	<p>Approximately 100,000 adolescents and young adults in the United States experience a first episode of psychosis (FEP) every year. The early phase of psychotic illness is widely viewed as a critical opportunity for indicated prevention, and a chance to alter the downward trajectory and poor outcomes associated with schizophrenia and related psychotic disorders. Unfortunately, numerous studies find a substantial delay between the onset of psychotic symptoms and the initiation of FEP care; in the U.S. treatment is typically delayed between one and three years. Early identification of FEP, rapid referral to evidence-based Coordinated Specialty Care (CSC) for early psychosis, and effective engagement in CSC services are essential to shortening the duration of untreated psychosis (DUP) and pre-empting the functional deterioration common in psychotic disorders. The World Health Organization advocates reducing DUP to 3 months or less. Accordingly, this Funding Opportunity Announcement (FOA) seeks planning research project grant applications that (1) identify a baseline rate of DUP in community or institutional settings; (2) map referral pathways to CSC care, (3) identify bottlenecks and gaps in the pathway to CSC care, and (4) develop and pilot test feasible strategies for substantially reducing DUP among persons with FEP. Alternatively, applicants who have already completed significant developmental or pilot work in this area are encouraged to apply to the companion R01 FOA PAR-19-236.</p>			
080146	Pilot Services Research Grants Not Involving Clinical Trials (R34 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-19-189	16-Feb-2021	450,000 USD
	Contact Name	Denise Juliano-Bult, M.S.W.			
	Contact Telephone	301-443-1638			
	Contact Email	djuliano@mail.nih.gov			
	Sponsor Website				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021</p> <p>Synopsis The purpose of this funding announcement is to encourage pilot research that is not an immediate precursor to testing a service intervention but is consistent with NIMH priorities for services research. While NIMH now requires use of an experimental therapeutics model for all intervention studies, there is recognition that some mission-relevant areas of services research do not involve clinical trials. These areas include: 1) studies to identify mutable factors that impact access, continuity, utilization, quality, value, outcomes, including disparities in outcomes, or scalability of mental health services, which may serve as targets in future intervention development 2) development and testing of new research tools, measures, or methods 3) testing the feasibility of integrating existing data sets to understand factors affecting access, quality or outcomes of care 4) pilot work on the learning mental health care system model as a means to enable practical studies of the value and effectiveness of services and treatments Studies focused on the development or preliminary testing of services interventions should be submitted under RFA-MH-18-706 (SPIN # 68982).</p>				
069759	Research on Autism Spectrum Disorders (R21-Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PA-18-400	16-Feb-2021	275,000 USD
	<p>Contact Name Lisa Gilotty, Ph.D.</p> <p>Contact Telephone 301-443-3825</p> <p>Contact Email gilottyl@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021</p> <p>Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invite applications to support research designed to elucidate the etiology, epidemiology, diagnosis, treatment, and optimal means of service delivery in relation to Autism Spectrum Disorders (ASD). This program will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</p>				
069760	Research on Autism Spectrum Disorders (R03-Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PA-18-399	16-Feb-2021	100,000 USD
	<p>Contact Name Lisa Gilotty, Ph.D.</p> <p>Contact Telephone 301-443-3825</p> <p>Contact Email gilottyl@mail.nih.gov</p> <p>Sponsor Website</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021</p> <p>Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invite applications to support research designed to elucidate the etiology, epidemiology, diagnosis, treatment, and optimal means of service delivery in relation to Autism Spectrum Disorders (ASD). This program will use the NIH R03 Small Grant Program award mechanism.</p>				
070684	<p>Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity (R21 Clinical Trial Optional)</p>	National Institute of Mental Health/NIH/DHHS	PAR-18-554	16-Feb-2021	275,000 USD
	<p>Contact Name Bettina D. Buhring, Ph.D.</p> <p>Contact Telephone 301-443-1576</p> <p>Contact Email bettina.buhring@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021</p> <p>Synopsis National Institute of Mental Health's (NIMH) invites applications for projects that test whether modifying electrophysiological patterns during behavior can improve cognitive, affective, or social processing. Applications must use experimental designs that incorporate active manipulations to address at least one, and ideally more, of the following topics: (1) in animals or humans, determine which parameters of neural coordination, when manipulated in isolation, improve particular aspects of cognitive, affective, or social processing; (2) in animals or humans, determine how particular abnormalities at the genomic, molecular, or cellular levels affect the systems-level coordination of electrophysiological patterns during behavior; (3) determine whether in vivo, systems-level electrophysiological changes in behaving animals predict analogous electrophysiological and cognitive improvements in healthy persons or clinical populations; and (4) use biologically-realistic computational models that include systems-level aspects to understand the function and mechanisms by which oscillatory and other electrophysiological patterns unfold across the brain to impact cognitive, affective, or social processing. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</p>				
070683	<p>Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity (R01 Clinical Trial Optional)</p>	National Institute of Mental Health/NIH/DHHS	PAR-18-555	05-Feb-2021	Not Specified
	<p>Contact Name Bettina D. Buhring, Ph.D.</p> <p>Contact Telephone 301-443-1576</p> <p>Contact Email bettina.buhring@mail.nih.gov</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021</p> <p>Synopsis National Institute of Mental Health's (NIMH) invites applications for projects that test whether modifying electrophysiological patterns during behavior can improve cognitive, affective, or social processing. Applications must use experimental designs that incorporate active manipulations to address at least one, and ideally more, of the following topics: (1) in animals or humans, determine which parameters of neural coordination, when manipulated in isolation, improve particular aspects of cognitive, affective, or social processing; (2) in animals or humans, determine how particular abnormalities at the genomic, molecular, or cellular levels affect the systems-level coordination of electrophysiological patterns during behavior; (3) determine whether in vivo, systems-level electrophysiological changes in behaving animals predict analogous electrophysiological and cognitive improvements in healthy persons or clinical populations; and (4) use biologically-realistic computational models that include systems-level aspects to understand the function and mechanisms by which oscillatory and other electrophysiological patterns unfold across the brain to impact cognitive, affective, or social processing. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
077196	New Computational Methods for Understanding the Functional Role of DNA Variants that are Associated with Mental Disorders (R01 (Collab) Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PA-18-907	05-Feb-2021	Not Specified

Contact Name	Alexander Arguello, PhD				
Contact Telephone	301-827-3547				
Contact Email	alexander.arguello@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022				
Synopsis	National Institute of Mental Health (NIMH) invites applications for the development of advanced computational, bioinformatic and statistical tools to determine the functional relevance of genetic variants associated with mental disorders of complex etiologies identified through genome-wide association or sequencing studies. The overarching goal of this initiative is to support the development of innovative computational methods that facilitate the elucidation of the functionality of genetic variants associated with mental illness, taking into account the added complexities and nuances of brain diseases, and to ultimately inform novel treatment development based on human biology. This FOA should be used when two or more sites are needed to complete the study. For a linked set of collaborative R01s, each site must have its own				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program Director/Principal Investigator and the set of linked applications provide a mechanism for cross-site coordination, quality control, database management, statistical analysis, and reporting. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
077195	New Computational Methods for Understanding the Functional Role of DNA Variants that are Associated with Mental Disorders (R01 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PA-18-908	05-Feb-2021	Not Specified
	<p>Contact Name Alexander Arguello, PhD Contact Telephone 301-827-3547 Contact Email alexander.arguello@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 Synopsis National Institute of Mental Health (NIMH) invites applications for the development of advanced computational, bioinformatic and statistical tools to determine the functional relevance of genetic variants associated with mental disorders of complex etiologies identified through genome-wide association or sequencing studies. The overarching goal of this initiative is to support the development of innovative computational methods that facilitate the elucidation of the functionality of genetic variants associated with mental illness, taking into account the added complexities and nuances of brain diseases, and to ultimately inform novel treatment development based on human biology. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
068701	NIMH Exploratory/Developmental Research Grant (R21 Clinical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	PA-18-350	16-Feb-2021	275,000 USD
	<p>Contact Name Pim Brouwers, Ph.D. Contact Telephone 240-627-3863 Contact Email ebrouwer@mail.nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 16-Feb-2021 , 07-May-2021 Synopsis National Institute of Mental Health (NIMH) invites applications for exploratory and high-risk research projects that fall within</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

the NIMH mission by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough or to the development of novel techniques, agents, methods, measures, models, or strategies, or to the generation of pilot or feasibility data. The preliminary work from these studies could lead to a major impact on biomedical, behavioral, or clinical mental health research, or on the delivery of mental health care. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

079331	Drug Discovery For Nervous System Disorders (R21 Clinical Trials Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-19-146	16-Feb-2021	275,000 USD
--------	---	--	------------	-------------	-------------

Contact Name	Enrique Michelotti, PhD
Contact Telephone	301-443-5415
Contact Email	michelottiel@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022
Synopsis	This Funding Opportunity Announcement (FOA) intends to support investigators who have interest and capability in the discovery of novel compounds for the prevention and treatment of nervous system disorders. This FOA is designed to stimulate research in 1) Identification, design, synthesis, and preclinical testing of compounds of candidate therapeutics, 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest, 3) Later stage lead optimization to improve efficacy and pharmacokinetics ,and 4) Initial drug metabolism and pharmacokinetics (DMPK). Emphasis will be placed on projects that provide novel approaches to identify potential therapeutic agents. The R21 grant mechanism is intended to encourage exploratory/developmental research by providing support for the early and conceptual stages of project development. High risk/high payoff projects that lack preliminary data may be most appropriate for this FOA. Applicants with preliminary data may wish to apply to the companion R01 mechanism (PAR-19-147)

079325	Drug Discovery For Nervous System Disorders (R01 Clinical Trials Not Allowed)	National Institute of Mental Health/NIH/DHHS	PAR-19-147	05-Feb-2021	Not Specified
--------	---	--	------------	-------------	---------------

Contact Name	Enrique Michelotti, PhD
Contact Telephone	301-443-5415
Contact Email	michelottiel@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022			
	Synopsis	This Funding Opportunity Announcement (FOA) supports the discovery of novel compounds for the prevention and treatment of nervous system disorders. Through this FOA NIMH and NIA wish to stimulate research in: 1) Identification, design, synthesis, and preclinical testing of compounds of candidate therapeutics; 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest; 3) Later stage lead optimization to improve efficacy and pharmacokinetics; and 4) Initial drug metabolism and pharmacokinetic properties (DMPK). Emphasis will be placed on projects that provide novel approaches for identifying potential therapeutic agents.			
083168	Clinical Studies of Mental Illness (Collaborative R01 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	PAR-19-297	05-Feb-2021	Not Specified
	Contact Name	Anjené Addington			
	Contact Telephone	301-443-6653			
	Contact Email	anjene.addington@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022			
	Synopsis	This Funding Opportunity Announcement (FOA) seeks to support collaborative clinical studies, not involving treatment development, efficacy, or effectiveness trials. Primary areas of focus include mental health genetics, biomarker studies, and studies of mental illnesses (e.g., psychopathology, neurodevelopmental trajectories of psychopathology) also when associated with HIV/AIDS. Applicants should apply to this FOA when two or more sites are needed to complete the study. Accordingly, the collaborating studies share a specific protocol across the sites and are organized as such in order to increase sample size, accelerate recruitment, or increase sample diversity and representation. In studies with a large number of sites, it is expected that one site will be submitted as a coordinating R01 for data management and/or other centralized administration. For a linked set of collaborative R01s, each application has its own Program Director/Principal Investigator (PD/PI). The collaborative R01 program provides a mechanism for cross-R01 coordination, quality control, database management, statistical analysis, and reporting.			
070493	NeuroNEXT Clinical Trials (U01 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18-528	05-Feb-2021	Not Specified
	Contact Name	Codrin Lungu, MD			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-496-9135</p> <p>Contact Email lunguci@ninds.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021</p> <p>Synopsis National Institute of Neurological Disorders and Stroke (NINDS) invites applications for exploratory clinical trials of investigational agents (drugs, biologics, surgical therapies or devices) that may contribute to the justification for and provide the data required for designing a future trial, for biomarker validation studies, or for proof of mechanism clinical studies. Diseases chosen for study should be based on the NINDS' strategic plan and clinical research interests (www.ninds.nih.gov/funding/areas/index.htm). Successful applicants will be given access to the NeuroNEXT infrastructure. Following peer review, NINDS will prioritize and order trials that are given access to the NeuroNEXT infrastructure. The NeuroNEXT Clinical Coordinating Center (CCC) will work with the successful applicant to efficiently implement the proposed study. The NeuroNEXT Data Coordinating Center (DCC) will provide statistical and data management support. The NeuroNEXT clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol. Applicants do not need to be part of the existing NeuroNEXT infrastructure. This FOA will utilize the NIH U01 Research Project – Cooperative Agreements award mechanism.</p>				
077707	Research on Chronic Overlapping Pain Conditions (R01 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PA-18-937	05-Feb-2021	Not Specified
	<p>Contact Name Michael L. Oshinsky, Ph.D.</p> <p>Contact Telephone 301-451-4460</p> <p>Contact Email michael.oshinsky@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021</p> <p>Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invites applications for epidemiological, clinical and translational research that will increase our understanding of the natural history, prevalence, biological mechanisms, psychological variables, and clinical risk factors responsible for the presence of multiple chronic pain conditions in people with pain. Recent clinical findings suggest that substantial overlap may exist between chronic pain conditions. Individuals diagnosed with one disorder often exhibit characteristics of additional chronic painful conditions or transition to other</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>diagnostic categories. A better understanding is needed of the prevalence of overlapping pain conditions, the underlying etiologies, the progression of these conditions, the evolution of these overlaps, and the therapeutic approaches best suited for treating subjects with these conditions. The main objective of this FOA is the formation of research groups with interests bridging expertise in pain mechanisms with translational and clinical expertise to address important unresolved questions about overlapping pain conditions. Applicants are encouraged to leverage existing and develop new resources pertinent to the study of these conditions. Applicants are encouraged to include researchers with complementary expertise from outside the pain field in their research teams who will enhance the breadth of research and understanding of comorbid chronic pain conditions. This FOA will use the NIH Research Project (R01) award mechanism.</p>			
070582	CREATE Bio Development Track: Nonclinical and Early-Phase Clinical Development for Biologics (U01 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18-542	12-Feb-2021	7,500,000 USD
	Contact Name	Hao Wang, Ph.D.			
	Contact Telephone	301-496-1779			
	Contact Email	CREATEinquiries@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	12-Feb-2021 , 07-May-2021			
	Synopsis	<p>National Institute of Neurological Disorders and Stroke (NINDS) invites applications for the development of therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene therapies, cell therapies, and novel emerging therapies) for disorders identified under the NINDS mission. An identified clinical candidate with sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the desired clinical application, is required for entry to this CREATE Bio Development Track. Therefore, this FOA supports Investigational New Drug (IND)-enabling studies for a therapeutic candidate and the inclusion of an optional small delayed-onset first in human Phase I clinical trial. At the end of the funding period, a successful project should have at least an IND application submitted to the U.S. Food and Drug Administration (FDA). This program will use the NIH U01 Research Project – Cooperative Agreements award mechanism.</p>			
065643	CREATE Bio Optimization Track for Biologics (SBIR-U44)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-17-457	12-Feb-2021	Not Specified
	Contact Name	Chris Boshoff, Ph.D.			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-496-1779</p> <p>Contact Email chris.boshoff@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Feb-2021 , 07-May-2021</p> <p>Synopsis National Institute of Neurological Disorders and Stroke (NINDS) invites SBIR applications for the optimization of potential therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene therapies, cell therapies, and novel emerging modalities) for disorders identified under the NINDS mission. This track supports the further characterization and optimization of therapeutic agent(s) that showed promise as evidenced by relevant, rigorous, convincing in vivo studies. Therefore, at the end of this funding period, successful projects will have delivered an optimized therapeutic candidate with demonstrated bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and should be eligible for entry into the CREATE Bio Development track. This program will use the NIH U44 Small Business Innovation Research (SBIR) Cooperative Agreements - Phase II, and Fast-Track award mechanism.</p>				
065641	CREATE Bio Optimization Track for Biologics (U01)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-17-456	12-Feb-2021	2,500,000 USD
	<p>Contact Name Chris Boshoff, Ph.D.</p> <p>Contact Telephone 301-496-1779</p> <p>Contact Email chris.boshoff@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Feb-2021 , 07-May-2021</p> <p>Synopsis National Institute of Neurological Disorders and Stroke (NINDS) invites applications for the optimization of potential therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene and cell therapies) for disorders identified under the NINDS mission. This track supports the further characterization and optimization of therapeutic lead(s) that showed promise as a potential therapeutic agent as evidenced by convincing animal proof-of-concept studies. Therefore, at the end of this funding period, successful projects will have delivered and optimized therapeutic candidate with demonstrated bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and should be eligible for entry into the CREATE Bio Development track. The CREATE Bio Development track is a later stage program focused on the development of optimized therapeutic candidates through Investigational New Drug (IND)-enabling studies</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

and submission of an IND package to the Food and Drug Administration (FDA). This program will use the NIH U01 Research Project Cooperative Agreements award mechanism.

083919	Discovery of Biomarkers and Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-19-315	22-Feb-2021	Not Specified
--------	---	--	------------	-------------	---------------

Contact Name	Mary Ann Pellemounter, PhD
Contact Telephone	301-496-1779
Contact Email	mary.pellemounter@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	22-Feb-2021 , 07-May-2021 , 22-Jun-2021 , 07-Sep-2021 , 22-Feb-2022 , 07-May-2022
Synopsis	The overarching purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and/or early evaluation of strong candidate biomarkers and biomarker signatures that can be used as tools to facilitate the clinical development of neurotherapeutics and their use in clinical practice. Specifically, the focus of this FOA is on the identification and initial biological, analytical and clinical evaluation of biomarkers and biomarker signatures for neurological and neuromuscular disorders/diseases. Although research supported by this FOA can include animal studies, it must also include preliminary human evaluation using carefully standardized human samples or datasets. The goal of this initiative is to deliver candidate biomarkers or biomarker signatures that are ready for definitive analytical and clinical validation studies.

080572	Clinical Trial Readiness for Rare Neurological and Neuromuscular Diseases (U01 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-19-220	17-Feb-2021	3,250,000 USD
--------	--	--	------------	-------------	---------------

Contact Name	Glen H. Nuckolls, Ph.D.
Contact Telephone	301-496-5745
Contact Email	glen.nuckolls@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	17-Feb-2021 , 18-Aug-2021 , 16-Feb-2022
Synopsis	This Funding Opportunity Announcement (FOA) invites researchers to submit applications for support of clinical studies that

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

address critical needs for clinical trial readiness in rare neurological and neuromuscular diseases. These studies should result in clinically validated biomarkers and clinical outcome assessment measures appropriate for use in upcoming clinical trials. Through the support of trial readiness studies, NINDS and NCATS expect to enhance the quality and increase the likelihood of success of clinical trials in these rare diseases.

100819	Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-059	22-Feb-2021	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name	Mary Ann Pellemounter, PhD
Contact Telephone	301-496-1779
Contact Email	mary.pellemounter@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	22-Feb-2021 , 04-May-2021 , 22-Jun-2021 , 07-Sep-2021 , 22-Feb-2022 , 07-May-2022 , 22-Jun-2022 , 07-Sep-2022 , 22-Feb-2023 , 07-May-2023 , 22-Jun-2023 , 07-Sep-2023
Synopsis	The purpose of this Program Announcement (PAR) is to enable clinical validation of strong candidate biomarkers for neurological and neuromuscular disorders and conditions. Specifically, the goal of this PAR is to enable the rigorous clinical validation of biomarker measurements within the clinical population of interest to establish the clinical sensitivity and specificity of the biomarker consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed and analytically validated, and 3) the research and/or clinical need and potential context of use has been identified.

100817	Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-057	22-Feb-2021	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name	Mary Ann Pellemounter, PhD
Contact Telephone	301-496-1779
Contact Email	mary.pellemounter@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	22-Feb-2021 , 04-May-2021 , 22-Jun-2021 , 07-Sep-2021 , 22-Feb-2022 , 07-May-2022 , 22-Jun-2022 , 07-Sep-2022 , 22-Feb-

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>2023 , 07-May-2023 , 22-Jun-2023 , 07-Sep-2023</p> <p>The purpose of this Program Announcement (PAR) is to enable analytical validation of strong candidate biomarkers for neurological and neuromuscular disorders and conditions. Specifically, the goal of this PAR is to enable the rigorous validation of analytical methods for biomarker measurements, which should include evaluation of the detection method, its performance characteristics, and the optimal conditions that will generate reproducibility and accuracy consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed, and 3) the research and/or clinical need and potential context of use has been identified.</p>			
100818	Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-058	22-Feb-2021	Not Specified
	Contact Name	Mary Ann Pellemounter, PhD			
	Contact Telephone	301-496-1779			
	Contact Email	mary.pellemounter@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	22-Feb-2021 , 04-May-2021 , 22-Jun-2021 , 07-Sep-2021 , 22-Feb-2022 , 07-May-2022 , 22-Jun-2022 , 07-Sep-2022 , 22-Feb-2023 , 07-May-2023 , 22-Jun-2023 , 07-Sep-2023			
	Synopsis	<p>The purpose of this Program Announcement (PAR) is to enable clinical validation of strong candidate biomarkers for neurological and neuromuscular disorders and conditions. Specifically, the goal of this PAR is to enable the rigorous clinical validation of biomarker measurements within the clinical population of interest to establish the clinical sensitivity and specificity of the biomarker consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed and analytically validated, and 3) the research and/or clinical need and potential context of use has been identified.</p>			
100816	Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-056	22-Feb-2021	Not Specified
	Contact Name	Mary Ann Pellemounter, PhD			
	Contact Telephone	301-496-1779			
	Contact Email	mary.pellemounter@nih.gov			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	22-Feb-2021 , 04-May-2021 , 22-Jun-2021 , 07-Sep-2021 , 22-Feb-2022 , 07-May-2022 , 22-Jun-2022 , 07-Sep-2022 , 22-Feb-2023 , 07-May-2023 , 22-Jun-2023 , 07-Sep-2023			
	Synopsis	The purpose of this Program Announcement (PAR) is to enable analytical validation of strong candidate biomarkers for neurological and neuromuscular disorders and conditions. Specifically, the goal of this PAR is to enable the rigorous validation of analytical methods for biomarker measurements, which should include evaluation of the detection method, its performance characteristics, and the optimal conditions that will generate reproducibility and accuracy consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed, and 3) the research and/or clinical need and potential context of use has been identified.			
070586	CREATE Bio Development Track: Nonclinical and Early-Phase Clinical Development for Biologics (U44 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18-543	12-Feb-2021	Not Specified
	Contact Name	Chris Boshoff, Ph.D.			
	Contact Telephone	301-496-1779			
	Contact Email	chris.boshoff@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	12-Feb-2021 , 07-May-2021			
	Synopsis	National Institute of Neurological Disorders and Stroke (NINDS) invites applications for the development of therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene therapies, cell therapies, and novel emerging therapies) for disorders identified under the NINDS mission. An identified clinical candidate with sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the desired clinical application, is required for entry to this CREATE Bio Development Track. Therefore, this FOA supports Investigational New Drug (IND)-enabling studies for a therapeutic candidate and the inclusion of an optional small delayed-onset first in human Phase I clinical trial. At the end of the funding period, a successful project should have at least an IND application submitted to the U.S. Food and Drug Administration (FDA). This program will use the NIH U44 Small Business Innovation Research (SBIR) Cooperative Agreement – Fast-track only.			
067277	NIH SIREN Neurologic Clinical Trials (U01 Clinical Trial Required)	National Institute of Neurological Disorders and	PAR-18-304	05-Feb-2021	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Stroke/NIH/DHHS

Contact Name	Jeremy Brown, MD
Contact Telephone	301-594-4481
Contact Email	jeremy.brown@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Feb-2021
Synopsis	National Institute of Neurological Disorders and Stroke (NINDS) invites applications for multi-center clinical trials focused on neurological emergencies. Successful applicants will collaborate and conduct the trial within the NIH SIREN Network. The NIH SIREN Clinical Coordinating Center (CCC) will work with the successful applicants to implement the proposed trial efficiently and the SIREN Data Coordinating Center (DCC) will provide statistical and data management support. The NIH SIREN hubs and their affiliated clinical sites will provide on-site implementation of the clinical protocols. The NIH SIREN Network will also be uniquely poised to collaborate with other US and international consortia necessary to conduct larger, definitive trials of promising interventions for neurological emergencies. Multi-center clinical trials in stroke treatment, recovery, or prevention supported by NINDS will be conducted in the NIH StrokeNet, and not within SIREN. Applicants do not need to be part of the existing SIREN infrastructure to apply under this FOA. This program will use the NIH U01 Research Project Cooperative Agreements award mechanism.

070628	RFA-NS-18-021 -- BRAIN Initiative: Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (UG3/UH3 Clinical Trial Required)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-18-021	23-Jan-2021 [Optional][LOI/Pre-App]	Not Specified
--------	--	--	---------------	-------------------------------------	---------------

Contact Name	Nick Langhals, PhD
Contact Telephone	301-496-1447
Contact Email	nick.langhals@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	23-Jan-2021 [Optional][LOI/Pre-App], 22-Feb-2021
Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for translational and clinical studies for recording and/or stimulating devices to treat nervous system disorders and better understand the human brain. The program will utilize a cooperative agreement mechanism to support the submission of an Investigational Device

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>Exemption (IDE) for a Significant Risk (SR) study or obtain Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, and a subsequent small clinical trial (e.g., Early Feasibility Study). The small clinical trial should provide data to answer key questions about the function or final design of a device. This final device design may require most, if not all, of the non-clinical testing on the path to more advanced clinical trials and market approval. The clinical trial is expected to provide information that cannot be practically obtained through additional nonclinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, and pursuit of regulatory approval for, and implementation of, a single small clinical trial. This FOA will use the NIH UG3/UH3 Exploratory/Developmental Phased Award Cooperative Agreement mechanism.</p>			
070629	RFA-NS-18-022 -- BRAIN Initiative: Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (U44 Clinical Trial Required)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-18-022	22-Feb-2021	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	<p>Nick Langhals, PhD 301-496-1447 nick.langhals@nih.gov Link to program URL 22-Feb-2021</p>			
	Synopsis	<p>National Institutes of Health (NIH) and its participating Institutes and Centers invite applications from small business concerns (SBCs) to pursue translational non-clinical studies and clinical studies for recording and/or stimulating devices to treat nervous system disorders and thereby better understand the human brain. The program will utilize a cooperative agreement mechanism to support the non-clinical studies necessary for the submission of an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or to obtain Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, and the subsequent small clinical trial (e.g., Early Feasibility Study). Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, and pursuit of regulatory approval for, and implementation of, a single small clinical trial. The small clinical trial should provide data to answer key questions about the function or final design of a device. This final device design may require most, if not all, of the non-clinical testing on the path to more advanced clinical trials and market approval. The clinical trial is expected to provide information that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This FOA will use the NIH U44 Small Business Innovation Research (SBIR) Cooperative Agreement – Fast-Track mechanism.</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
070636	RFA-NS-18-023 -- BRAIN Initiative: Clinical Studies to Advance Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (UH3 Clinical Trial Required)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-18-023	23-Jan-2021 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Nick Langhals, PhD</p> <p>Contact Telephone 301-496-1447</p> <p>Contact Email nick.langhals@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 23-Jan-2021 [Optional][LOI/Pre-App], 22-Feb-2021</p> <p>Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for investigators to pursue a small clinical trial to obtain critical information necessary to advance recording and/or stimulating devices to treat central nervous system disorders and better understand the human brain (e.g., Early Feasibility Study). Clinical studies supported may consist of acute or short-term procedures that are deemed Non-Significant Risk (NSR) by an Institutional Review Board (IRB), or Significant Risk (SR) studies that require an Investigational Device Exemption (IDE) from the FDA, such as chronic implants. The clinical trial should provide data to answer key questions about the function or final design of a device. This final device design may require most, if not all, of the non-clinical testing on the path to more advanced clinical trials and market approval. The clinical trial is expected to provide information that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. Activities supported by this Funding Opportunity include a small clinical trial to answer key questions about the function or final design of a device. This FOA will use the NIH UH3 Exploratory Phased Award Cooperative Agreement mechanism.</p>				
077714	Research on Chronic Overlapping Pain Conditions (R21 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PA-18-939	16-Feb-2021	275,000 USD
	<p>Contact Name Michael L. Oshinsky, Ph.D.</p> <p>Contact Telephone 301-451-4460</p> <p>Contact Email michael.oshinsky@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	<p>Synopsis</p>	<p>National Institutes of Health (NIH) and its participating Institutes and Centers invites applications for epidemiological, clinical and translational research that will increase our understanding of the natural history, prevalence, biological mechanisms, psychological variables, and clinical risk factors responsible for the presence of multiple chronic pain conditions in people with pain. Recent clinical findings suggest that substantial overlap may exist between chronic pain conditions. Individuals diagnosed with one disorder often exhibit characteristics of additional chronic painful conditions or transition to other diagnostic categories. A better understanding is needed of the prevalence of overlapping pain conditions, the underlying etiologies, the progression of these conditions, the evolution of these overlaps, and the therapeutic approaches best suited for treating subjects with these conditions. The main objective of this FOA is the formation of research groups with interests bridging expertise in pain mechanisms with translational and clinical expertise to address important unresolved questions about overlapping pain conditions. Applicants are encouraged to leverage existing and develop new resources pertinent to the study of these conditions. Applicants are encouraged to include researchers with complementary expertise from outside the pain field in their research teams who will enhance the breadth of research and understanding of comorbid chronic pain conditions. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</p>			
068924	RFA-NS-18-012 -- Translational Neural Devices (U44 Clinical Trial Required)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-18-012	23-Jan-2021 [Optional][LOI/Pre-App]	Not Specified

Contact Name	Nick Langhals, PhD
Contact Telephone	301-496-1447
Contact Email	nick.langhals@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	23-Jan-2021 [Optional][LOI/Pre-App], 22-Feb-2021

<p>Synopsis</p>	<p>National Institute of Neurological Disorders and Stroke (NINDS) invites applications from Small Business Concerns (SBCs) to pursue translational activities and small clinical studies to advance the development of therapeutic and diagnostic devices for disorders that affect the nervous or neuromuscular systems. The translational device activities, including translational bench and animal studies, are expected to lead to submission of an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) or Institutional Review Board (IRB) application for a Non-Significant Risk (NSR) study. This cooperative agreement will also support the subsequent small clinical study to collect safety and effectiveness data required to support a marketing application or to inform final device design. This FOA will use the NIHU44 Small Business Innovation Research (SBIR) Cooperative Agreements - Fast-Track award mechanism.</p>
-----------------	--

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
068913	RFA-NS-18-011 -- Translational Neural Devices (UG3/UH3 Clinical Trial Required)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-18-011	23-Jan-2021 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name Nick Langhals, PhD</p> <p>Contact Telephone 301-496-1447</p> <p>Contact Email nick.langhals@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 23-Jan-2021 [Optional][LOI/Pre-App], 22-Feb-2021</p> <p>Synopsis National Institute of Neurological Disorders and Stroke (NINDS) invites applications for translational activities and small clinical studies to advance the development of therapeutic, and diagnostic devices for disorders that affect the nervous or neuromuscular systems. The translational device activities, including translational bench and animal studies, are expected to lead to submission of an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) or Institutional Review Board (IRB) application for a Non-Significant Risk (NSR) study. This cooperative agreement will also support the subsequent small clinical trial to collect safety and effectiveness data required to support a marketing application or to inform final device design. This FOA will use the NIH UG3/UH3 Exploratory/Developmental Phased Award Cooperative Agreement award mechanism.</p>				
097476	NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-20-285	18-Feb-2021	Not Specified
	<p>Contact Name Claudia Scala Moy, PhD</p> <p>Contact Telephone 301-496-9135</p> <p>Contact Email moyc@ninds.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 18-Feb-2021 , 18-Jun-2021 , 14-Oct-2021 , 22-Feb-2022 , 20-Jun-2022 , 18-Oct-2022 , 14-Feb-2023 , 14-Jun-2023</p> <p>Synopsis This FOA encourages applications for multi-site exploratory and confirmatory clinical trials focused on promising interventions; biomarker or outcome measure validation studies that are immediately preparatory to trials in stroke prevention, treatment, and recovery; and ancillary studies designed to add scientific aims to active studies being conducted</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

within StrokeNet. Successful applicants will collaborate and conduct the study within the NIH StrokeNet. Following peer review, NINDS will prioritize studies among the highest scoring to be conducted in the NIH StrokeNet infrastructure. The NIH StrokeNet National Coordinating Center (NCC) will work with the successful applicant to implement the proposed study efficiently and the National Data Management Center (NDMC) will provide statistical and data management support. The NIH StrokeNet Regional Coordinating Centers (RCCs) and their affiliated clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol. The NIH StrokeNet network will also be uniquely poised to collaborate with other US and international consortia necessary to conduct larger, definitive trials of promising interventions for stroke treatment, prevention, and recovery. NINDS intends that all multi-center clinical trials in stroke treatment, recovery, or prevention supported by NINDS will be conducted in the NIH StrokeNet and that only in exceptional circumstances will NINDS consider funding multi-site stroke clinical trials outside of this program. Applicants do not need to be part of the existing NIH StrokeNet infrastructure to apply under this FOA. This FOA uses the bi-phasic, milestone driven UG3/UH3 cooperative agreement mechanism. Awards made under this FOA will initially support a one-year milestone-driven planning and start-up phase, with possible transition to an implementation (UH3) phase of up to 6 additional years. Only UG3 projects that meet the scientific milestones and award requirements of the UG3 phase may transition to the UH3 phase. Applications submitted in response to this FOA must address both the UG3 and UH3 phases and are expected to include plans for project management and performance milestones for each phase.

098951	Notice of Special Interest (NOSI): Administrative Supplements for Connecting Pre-mortem Clinical Information with Post-Mortem Brain Analysis	National Institute of Neurological Disorders and Stroke/NIH/DHHS	NOT-NS-21-001	26-Feb-2021	Not Specified
--------	--	--	---------------	-------------	---------------

Contact Name	Debra Babcock, PhD, MD
Contact Telephone	301-496-9964
Contact Email	dbabcock@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	26-Feb-2021 , 28-Jun-2021
Synopsis	The Lewy Body Dementias (LBD) are frequently misdiagnosed or underdiagnosed during life, and despite the development of diagnostic criteria at multiple expert consensus conferences, the gold standard for diagnosis remains post-mortem brain analysis. Improvement in diagnostic accuracy during life, and the development of good quality diagnostic biomarkers, would be greatly facilitated if comprehensive, longitudinal clinical and biological data obtained on patients during life were regularly linked with detailed post-mortem brain examination. In response to recommendations from the Alzheimer's Disease Related Dementias (ADRD) Summits convened by the NINDS in 2013, 2016, and 2019, longitudinal clinical data and biospecimens are

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

being collected from patients with LBD and shared with the research community through the Parkinson's Disease Biomarker Program (PDBP). The PDBP is an NINDS-funded resource that collects standardized clinical data and biospecimens longitudinally on patients with Parkinson's Disease (PD) and PD-related disorders (including LBD) with the goal of accelerating the pace of biomarkers research. The PDBP currently has data and biospecimens on about 1900 subjects, some of whom have gone to autopsy, though relatively little post-mortem data on these subjects is available in PDBP at this time.

072892	Career Transition Award for NINDS Intramural Clinician-Scientists (K22 Clinical Trial Required)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18-710	12-Feb-2021	Not Specified
--------	---	--	------------	-------------	---------------

Contact Name	Stephen Korn, Ph.D.
Contact Telephone	301-496-4188
Contact Email	korns@ninds.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	12-Feb-2021 , 12-Jun-2021
Synopsis	National Institute of Neurological Disorders and Stroke (NINDS) invites applications to facilitate the transition of NINDS intramural neurologist- and neurosurgeon-scientists to independent, academic faculty positions that support clinician-scientists to engage in independently funded scientific research as well as clinical activities. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. This FOA will use the NIH K22 Career Transition Award mechanism.

072904	Career Transition Award for NINDS Intramural Clinician-Scientists (K22 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18-711	12-Feb-2021	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name	Stephen Korn, Ph.D.
Contact Telephone	301-496-4188
Contact Email	korns@ninds.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	12-Feb-2021 , 12-Jun-2021

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	National Institute of Neurological Disorders and Stroke (NINDS) invites applications to facilitate the transition of NINDS intramural neurologist- and neurosurgeon-scientists to independent, academic faculty positions that support clinician-scientists to engage in independently funded scientific research as well as clinical activities. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. This FOA will use the NIH K22 Career Transition Award mechanism.			
097731	Notice of Special Interest (NOSI): Platform Trials of Thrombectomy in Acute Stroke Treatment	National Institute of Neurological Disorders and Stroke/NIH/DHHS	NOT-NS-20-095	18-Feb-2021	Not Specified
	Contact Name	Claudia Scala Moy, PhD			
	Contact Telephone	301-496-9135			
	Contact Email	moyc@ninds.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	18-Feb-2021 , 18-Jun-2021			
	Synopsis	The NINDS is issuing this Notice of Special Interest in applications to establish a master protocol to conduct platform trials for treatments of ischemic stroke due to large vessel occlusion. Master protocols should incorporate advanced clinical trial methodologies such as, but not limited to, Bayesian modeling, response adaptive randomization, shared controls, and the ability for treatment arms to enter, leave, or be combined. Master protocols must be designed to allow future addition of trial questions. Strong representation of expertise from the neurology, neurosurgery, and interventional communities is required for such a multi-disciplinary approach and will be expected of applicants.			
070119	NINDS Advanced Postdoctoral Career Transition Award to Promote Diversity in Neuroscience Research (K22-Clinical Trial Required)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18-468	12-Feb-2021	Not Specified
	Contact Name	Michelle Jones-London, Ph.D.			
	Contact Telephone	301-451-7966			
	Contact Email	jonesmiche@ninds.nih.gov			
	Sponsor Website				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Feb-2021 , 07-May-2021</p> <p>Synopsis National Institute of Neurological Disorders and Stroke (NINDS) invites applications for the NINDS Advanced Postdoctoral Career Transition Award to Promote Diversity. This opportunity provides postdoctoral fellows from underrepresented groups with strong training in neuroscience with the resources and tools that will help facilitate a transition to a stable and productive independent research position. Individuals are eligible for support under this award if they have doctoral research degrees (Ph.D., Ph.D./M.D. or equivalent) and between 2 and 5 years of postdoctoral prior research training at the time of application. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial that also meets the definition of a clinical trial, as part of their research and career development. NINDS will only accept applications to this FOA that propose human mechanistic trials/studies that meet NIH's definition of a clinical trial and that fall within the NINDS research priorities. Applicants are strongly advised to consult with NINDS Scientific/Research contact prior to submitting an application with human subjects to determine the appropriate funding opportunity. This FOA will utilize the NIH K22 Career Transition Award mechanism.</p>				
070137	NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01 Clinical Trial Required)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18-486	12-Feb-2021	975,000 USD
	<p>Contact Name Michelle Jones-London, Ph.D.</p> <p>Contact Telephone 301-451-7966</p> <p>Contact Email jonesmiche@ninds.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Feb-2021 , 07-May-2021</p> <p>Synopsis National Institute of Neurological Disorders and Stroke (NINDS) invites applications for the Faculty Development Award to Promote Diversity in Neuroscience Research. The purpose of the NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01) is to diversify the pool of independent neuroscience research investigators by providing junior faculty with research cost support, protected research time and career stage appropriate professional development mentorship in neuroscience research. Individuals from backgrounds underrepresented in biomedical research are eligible for support under this award if they have doctoral research degrees (Ph.D. or equivalent) and are in the first 3 years of a faculty tenure track or equivalent position at the time of application. This Funding Opportunity Announcement (FOA) is designed</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. NINDS will only accept applications to this FOA that propose human mechanistic trials/studies that meet NIH's definition of a clinical trial and that fall within the NINDS research priorities. Applicants are strongly advised to consult with NINDS program staff prior to submitting an application with human subjects to determine the appropriate funding opportunity. This Funding Opportunity Announcement (FOA) will utilize the NIH K01 Research Scientist Development Award - Research & Training mechanism.

070123	NINDS Advanced Postdoctoral Career Transition Award to Promote Diversity in Neuroscience Research (K22-No Independent Clinical Trials)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18-469	12-Feb-2021	Not Specified
--------	--	--	------------	-------------	---------------

Contact Name | Michelle Jones-London, Ph.D.
 Contact Telephone | 301-451-7966
 Contact Email | jonesmiche@ninds.nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 12-Feb-2021 , 07-May-2021

Synopsis | National Institute of Neurological Disorders and Stroke (NINDS) invites applications for the NINDS Advanced Postdoctoral Career Transition Award to Promote Diversity. The NINDS Advanced Postdoctoral Career Transition Award to Promote Diversity is designed to enhance the participation of highly trained early career investigators from underrepresented groups in neuroscience research. This opportunity provides postdoctoral fellows from underrepresented groups with strong training in neuroscience with the resources and tools that will help facilitate a transition to a stable and productive independent research position. Individuals are eligible for support under this award if they have doctoral research degrees (Ph.D., Ph.D./M.D. or equivalent) and between 2 and 5 years of postdoctoral prior research training at the time of application. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. This FOA will utilize the NIH K22 Career Transition Award mechanism.

071756	Disease Mechanisms of Prenatal and Pediatric Hydrocephalus (R01 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PA-18-622	05-Feb-2021	Not Specified
--------	---	--	-----------	-------------	---------------

Contact Name | Jill A. Morris, Ph.D.

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-496-5745</p> <p>Contact Email jill.morris@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021</p> <p>Synopsis National Institute of Neurological Disorders and Stroke (NINDS) invites applications for hypothesis-driven research of prenatal and pediatric hydrocephalus. This FOA intends to support hydrocephalus research projects that examine the developmental etiology (intrinsic factors including genetics) and acquired etiology (extrinsic factors including hemorrhage and infection) of prenatal and/or pediatric hydrocephalus. Studies should focus on understanding the molecular, cellular and developmental mechanisms involved in the pathogenesis of prenatal and/or pediatric hydrocephalus. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
071757	Tools to Enhance the Study of Prenatal and Pediatric Hydrocephalus (R21 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PA-18-623	16-Feb-2021	275,000 USD
	<p>Contact Name Jill A. Morris, Ph.D.</p> <p>Contact Telephone 301-496-5745</p> <p>Contact Email jill.morris@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 07-May-2021</p> <p>Synopsis National Institute of Neurological Disorders and Stroke (NINDS) invites applications that propose to develop or substantially modify existing cutting-edge tools that will advance prenatal and/or pediatric hydrocephalus research. The primary objective of this FOA is to remove barriers to hydrocephalus research that are due to scarcity of tools to investigate both the disease mechanisms and alternative therapies (non-shunt) in a rigorous manner. Applications should aim to transform the field of prenatal and/or pediatric hydrocephalus research by generating tools including animal and cell models, novel methods and innovative technologies that will be widely used throughout the neuroscience community to understand disease mechanisms and/or developing therapeutics. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</p>				
086471	NINDS Ruth L. Kirschstein National Research Service Award (NRSA) for	National Institute of	PAR-20-	11-Feb-2021	Not

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	Training of Postdoctoral Fellows (F32 Clinical Trial Not Allowed)		Neurological Disorders and Stroke/NIH/DHHS	021	Specified	
	<p>Contact Name Stephen Korn, Ph.D.</p> <p>Contact Telephone 301-496-4188</p> <p>Contact Email korns@ninds.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-Feb-2021 , 07-May-2021 , 09-Jun-2021 , 07-Sep-2021 , 14-Oct-2021 , 07-Jan-2022 , 09-Feb-2022 , 07-May-2022 , 08-Jun-2022 , 07-Sep-2022 , 11-Oct-2022 , 07-Jan-2023</p> <p>Synopsis The purpose of this award is to support outstanding scientific training of highly promising postdoctoral candidates with outstanding mentors. Candidates are eligible to apply for support from this program from ~12 months prior to the start of the proposed postdoctoral position to within 12 months after starting in the proposed postdoctoral position. This NINDS F32 seeks to foster early, goal-directed planning and to encourage applications for bold and/or innovative projects by the candidate that have the potential for significant impact. Inclusion of preliminary data is strongly discouraged; rather, this F32 seeks innovative research ideas and thoughtful plans for training and mentorship that will facilitate the development of the postdoctoral fellow into an outstanding scientist. Applications are expected to incorporate strong training in quantitative reasoning and the quantitative principles of experimental design and analysis. Support by this program is limited to the first 3 years of a candidate's activity in a specific laboratory or research environment, so as to further encourage early, thoughtful planning and timely completion of "mentored training" within a particular lab or environment. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.</p>					
086929	NINDS Postdoctoral Mentored Career Development Award (K01 - No Independent Clinical Trial Allowed)		National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-20-049	12-Feb-2021	Not Specified
	<p>Contact Name Stephen Korn, PhD</p> <p>Contact Telephone </p> <p>Contact Email korns@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p>					

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 12-Feb-2021 , 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023</p> <p>Synopsis The purpose of the NINDS Postdoctoral Mentored Career Development Award is to support the ability of outstanding, mentored postdoctoral researchers to develop a potentially impactful research project with a comprehensive career development plan that will enable them to launch an independent research program. Candidates are encouraged to apply for support from this NINDS K01 any time between the second through fourth year of cumulative mentored postdoctoral research experience, and may be supported by this NINDS K01 within the first 6 years of cumulative postdoctoral research experience. Because the completion of a strong, well-planned, thorough career development plan, in addition to development of an impactful research project, is a critical aspect of this K01, applications are strongly encouraged early in the postdoctoral eligibility window. By the end of the proposed K01 award period, the candidate should be poised to begin an independent research career with a well-developed, impactful research project and the expertise required to become a leader in the field. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent small clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing an independent small clinical trial as lead investigator, should apply to the companion FOA (PAR-20-050).</p>				
086932	NINDS Postdoctoral Mentored Career Development Award (K01 - Clinical Trial Required)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-20-050	12-Feb-2021	Not Specified
	<p>Contact Name Stephen Korn, PhD</p> <p>Contact Telephone </p> <p>Contact Email korns@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Feb-2021 , 07-May-2021 , 12-Jun-2021 , 07-Sep-2021 , 12-Oct-2021 , 07-Jan-2022 , 12-Feb-2022 , 07-May-2022 , 12-Jun-2022 , 07-Sep-2022 , 12-Oct-2022 , 07-Jan-2023</p> <p>Synopsis The purpose of the NINDS Postdoctoral Mentored Career Development Award is to support the ability of outstanding, mentored postdoctoral researchers to develop a potentially impactful research project with a comprehensive career development plan that will enable them to launch an independent research program. Candidates are encouraged to apply for support from this NINDS K01 any time between the second through fourth year of cumulative mentored postdoctoral research experience, and may be supported by this NINDS K01 within the first 6 years of cumulative postdoctoral research experience. Because the completion of a strong, well-planned, thorough career development plan, in addition to</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>development of an impactful research project, is a critical aspect of this K01, applications are strongly encouraged early in the postdoctoral eligibility window. By the end of the proposed K01 award period, the candidate should be poised to begin an independent research career with a well-developed, impactful research project and the expertise required to become a leader in the field. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent small clinical trial as part of their research and career development. Applicants not planning an independent small clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-20-049).</p>			
070144	NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01 Independent Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18-490	12-Feb-2021	975,000 USD
	Contact Name	Michelle Jones-London, Ph.D.			
	Contact Telephone	301-451-7966			
	Contact Email	jonesmiche@ninds.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	12-Feb-2021 , 07-May-2021			
	Synopsis	<p>National Institute of Neurological Disorders and Stroke (NINDS) invites applications for the Faculty Development Award to Promote Diversity in Neuroscience Research. The purpose of the NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01) is to diversify the pool of independent neuroscience research investigators by providing junior faculty with research cost support, protected research time and career stage appropriate professional development mentorship in neuroscience research. Individuals from backgrounds underrepresented in biomedical research are eligible for support under this award if they have doctoral research degrees (Ph.D. or equivalent) and are in the first 3 years of a faculty tenure track or equivalent position at the time of application. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. This Funding Opportunity Announcement (FOA) will utilize the NIH K01 Research Scientist Development Award - Research & Training mechanism.</p>			
070148	Promoting Research in Basic Neuroscience (R01 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAS-18-483	05-Feb-2021	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Robert Riddle, PhD</p> <p>Contact Telephone 301-496-5745</p> <p>Contact Email rr260c@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021</p> <p>Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for research addressing fundamental questions in basic neuroscience. Proposed projects can address any area of neuroscience within the missions of the participating institutes and should focus on understanding the development, the structure and/or the function of the normal nervous system. While fundamental basic research often generates insights relevant to disorders of the nervous system, this FOA is not intended to stimulate research that is explicitly disease-related. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
069923	NINDS Exploratory Clinical Trials (U01 Clinical Trial Required)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18-420	05-Feb-2021	Not Specified
	<p>Contact Name Peter R. Gilbert, Sc.M.</p> <p>Contact Telephone 301-496-0870</p> <p>Contact Email pgilbert@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021</p> <p>Synopsis National Institute of Neurological Disorders and Stroke (NINDS) invites applications for investigator-initiated exploratory clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must address questions within the mission and research interests of the NINDS and may evaluate drugs, biologics, and devices, as well as surgical, behavioral and rehabilitation therapies. Information about the mission and research interests of the NINDS can be found at the NINDS website (https://www.ninds.nih.gov/). This FOA will use the NIH Research Project (R01) award mechanism.</p>				
069928	NINDS Efficacy Clinical Trials (U01 Clinical Trial Required)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18-422	05-Feb-2021	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Peter R. Gilbert, ScM</p> <p>Contact Telephone 301-496-0870</p> <p>Contact Email pgilbert@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021</p> <p>Synopsis National Institute of Neurological Disorders and Stroke (NINDS) invites applications for investigator-initiated efficacy clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must address questions within the mission and research interests of the NINDS and may evaluate drugs, biologics, and devices, as well as surgical, behavioral and rehabilitation therapies. Information about the mission and research interests of the NINDS can be found at the NINDS website (https://www.ninds.nih.gov/). This FOA will utilize the Cooperative Agreement (U01) grant mechanism.</p>				
073884	<p>Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)</p>	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18-761	17-Feb-2021	750,000 USD
	<p>Contact Name Mary Ann Pellemounter, PhD</p> <p>Contact Telephone 301-496-1779</p> <p>Contact Email mary.pellemounter@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 17-Feb-2021 , 07-May-2021</p> <p>Synopsis National Institute of Neurological Disorders and Stroke (NINDS) invites applications to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological disorders that fall under the NINDS mission. Therapeutic agents may include but are not limited to small molecules, biologics or biotechnology-derived products. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the NINDS Cooperative Research to Enable and Advance Translational Enterprises for Biologics program (CREATE Bio) program for biologics, biotechnology products, Blueprint Neurotherapeutics Network for small molecules, or other translational programs. This FOA will utilize the R61/R33 Phased Innovation Award mechanism.</p>				
073885	<p>Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay</p>	National Institute of	PAR-18-	17-Feb-2021	750,000

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)	Neurological Disorders and Stroke/NIH/DHHS	762		USD
	<p>Contact Name Mary Ann Pellemounter, PhD</p> <p>Contact Telephone 301-496-1779</p> <p>Contact Email mary.pellemounter@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 17-Feb-2021 , 07-May-2021</p> <p>Synopsis National Institute of Neurological Disorders and Stroke (NINDS) invites applications to develop in vitro and/or ex vivo assays and conduct iterative screening efforts to identify and characterize potential therapeutic agents for neurological disorders. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the NINDS Cooperative Research to Enable and Advance Translational Enterprises for Biologics (CREATE Bio) program for biologics, biotechnology products, the Blueprint Neurotherapeutics Network (BPN) for small molecules, or other translational programs. This FOA will utilize the NIH R61/R33 Phased Innovation Award mechanism.</p>				
073889	Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems and/or Pharmacodynamic Markers to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-18-763	17-Feb-2021	750,000 USD
	<p>Contact Name Mary Ann Pellemounter, PhD</p> <p>Contact Telephone 301-496-1779</p> <p>Contact Email mary.pellemounter@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 17-Feb-2021 , 07-May-2021</p> <p>Synopsis National Institute of Neurological Disorders and Stroke (NINDS) invites applications for the development and validation of: 1) animal models and human tissue ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological disorder and/or 2) clinically feasible pharmacodynamic markers for therapeutics designed to treat neurological disease. The goal of this FOA is to promote a significant improvement in the translational relevance of animal models, ex vivo</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>systems, and pharmacodynamic markers that will be utilized to facilitate the development of neurotherapeutics. Ideally, models, model systems and pharmacodynamic markers proposed in applications for this FOA would have the potential to provide feasible and meaningful assessments of efficacy following therapeutic intervention that would be applicable in both preclinical and clinical settings. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) focused on enabling the exploratory and early stages of drug discovery. This FOA will utilize the NIH R61/R33 Phased Innovation Award mechanism.</p>			
079593	Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-19-171	18-Feb-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Adam L. Hartman, MD</p> <p>301-496-9135</p> <p>adam.hartman@nih.gov</p> <p></p> <p>Link to program URL</p> <p>18-Feb-2021 , 07-May-2021 , 18-Jun-2021 , 07-Sep-2021 , 14-Oct-2021 , 07-Jan-2022</p> <p>The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated prospective observational comparative effectiveness research (CER) to the National Institute of Neurological Disorders and Stroke (NINDS) (note: only prospective observational studies will be considered)). The study must address questions within the mission and research interests of the NINDS and may evaluate preventive strategies, diagnostic approaches, or interventions including drugs, biologics, and devices, or surgical, behavioral, and rehabilitation therapies. NINDS is particularly interested in pragmatic study designs that utilize a cost-effective means of prospectively collecting observational data important to current clinical practice.</p>			
100306	NINDS Ruth L. Kirschstein National Research Service Award (NRSA) for Training of Postdoctoral Fellows (F32 Clinical Trial Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-032	11-Feb-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p>	<p>Stephen Korn, Ph.D.</p> <p>301-496-4188</p> <p>korns@ninds.nih.gov</p> <p></p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-Feb-2021 , 07-May-2021 , 09-Jun-2021 , 07-Sep-2021 , 14-Oct-2021 , 07-Jan-2022 , 09-Feb-2022 , 07-May-2022 , 08-Jun-2022 , 07-Sep-2022 , 11-Oct-2022 , 07-Jan-2023 , 09-Feb-2023 , 07-May-2023 , 08-Jun-2023 , 07-Sep-2023 , 10-Oct-2023 , 07-Jan-2024</p> <p>Synopsis The purpose of this award is to support outstanding scientific training of highly promising postdoctoral candidates with outstanding mentors. Candidates are eligible to apply for support from this program from ~12 months prior to the start of the proposed postdoctoral position to within 12 months after starting in the proposed postdoctoral position. This NINDS F32 seeks to foster early, goal-directed planning and to encourage applications for bold and/or innovative projects by the candidate that have the potential for significant impact. Inclusion of preliminary data is strongly discouraged; rather, this F32 seeks innovative research ideas and thoughtful plans for training and mentorship that will facilitate the development of the postdoctoral fellow into an outstanding scientist. Applications are expected to incorporate strong training in quantitative reasoning and the quantitative principles of experimental design and analysis. Support by this program is limited to the first 4 years of a candidate's activity in a specific laboratory or research environment, so as to further encourage early, thoughtful planning and timely completion of "mentored training" within a particular lab or environment. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.</p>				
085884	Patient Activation for Self-Management of Chronic Conditions (R21 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PAR-19-382	16-Feb-2021	400,000 USD
	<p>Contact Name Karen Huss, PhD, RN, APRN-BC, FAAN, FAAAAI</p> <p>Contact Telephone 301-594-5970</p> <p>Contact Email hussk@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 16-Mar-2021 , 07-May-2021 , 16-Jun-2021 , 16-Jul-2021 , 07-Sep-2021 , 16-Feb-2022 , 16-Mar-2022 , 07-May-2022 , 16-Jun-2022 , 16-Jul-2022 , 07-Sep-2022 , 16-Feb-2023 , 16-Mar-2023 , 07-May-2023</p> <p>Synopsis The purpose of this Funding Opportunity Announcement is to encourage grant applications that address the influence of patient activation on self-management of chronic conditions.</p>				
085882	Patient Activation for Self-Management of Chronic Conditions (R01 Clinical)	National Institute of Nursing	PAR-19-	05-Feb-2021	Not

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	Trial Optional		Research/NIH/DHHS	381	Specified	
	<p>Contact Name Karen Huss, PhD, RN, APRN-BC, FAAN, FAAAAI</p> <p>Contact Telephone 301-594-5970</p> <p>Contact Email hussk@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 05-Mar-2021 , 07-May-2021 , 05-Jun-2021 , 05-Jul-2021 , 07-Sep-2021 , 05-Feb-2022 , 05-Mar-2022 , 07-May-2022 , 05-Jun-2022 , 05-Jul-2022 , 07-Sep-2022 , 05-Feb-2023 , 05-Mar-2023 , 07-May-2023</p> <p>Synopsis The purpose of this Funding Opportunity Announcement is to encourage grant applications that address the influence of patient activation on self-management of chronic conditions.</p>					
076050	Prevention Research in Mid-Life Adults (R21 Clinical Trial Optional)		National Institute of Nursing Research/NIH/DHHS	PA-18-850	16-Feb-2021	275,000 USD
	<p>Contact Name Mary C. Roary, Ph.D.</p> <p>Contact Telephone 301-594-2154</p> <p>Contact Email mary.roary@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021</p> <p>Synopsis National Institute of Nursing Research (NINR) and National Institute on Aging (NIA) invite applications for research on mid-life adults (those 50 to 64 years of age) that can inform efforts to optimize health and wellness as individuals age, and prevent illness and disability in later years. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</p>					
076049	Prevention Research in Mid-Life Adults (R01 Clinical Trial Optional)		National Institute of Nursing Research/NIH/DHHS	PA-18-849	05-Feb-2021	Not Specified
	<p>Contact Name Mary C. Roary, Ph.D.</p> <p>Contact Telephone 301-594-2154</p> <p>Contact Email mary.roary@nih.gov</p>					

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021			
	Synopsis	National Institute of Nursing Research (NINR) and National Institute on Aging (NIA) invite applications for research on mid-life adults (those 50 to 64 years of age) that can inform efforts to optimize health and wellness as individuals age, and prevent illness and disability in later years. This FOA will use the NIH Research Project (R01) award mechanism.			
070262	End-of-Life and Palliative Care Health Literacy: Improving Outcomes in Serious, Advanced Illness (R21 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PA-18-499	16-Feb-2021	275,000 USD
	Contact Name	Lynn S. Adams, Ph.D.			
	Contact Telephone	301-594-8911			
	Contact Email	adamsls@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Feb-2021 , 07-May-2021			
	Synopsis	National Institute of Nursing Research (NINR) invites applications for research focused on identification of the key barriers to effective end-of-life and palliative care (EOLPC) health literacy in diverse settings and populations, and to create novel strategies, interventions, and models of care to improve EOLPC health literacy, with the goal of improving outcomes for individuals with serious, advanced illness and their families and caregivers. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.			
070260	End-of-Life and Palliative Care Health Literacy: Improving Outcomes in Serious, Advanced Illness (R01 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PA-18-498	05-Feb-2021	Not Specified
	Contact Name	Lynn S. Adams, Ph.D.			
	Contact Telephone	301-594-8911			
	Contact Email	adamsls@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Feb-2021 , 07-May-2021			
	Synopsis	National Institute of Nursing Research (NINR) invites applications for research focused on identification of the key barriers to			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

effective end-of-life and palliative care (EOLPC) health literacy in diverse settings and populations, and to create novel strategies, interventions, and models of care to improve EOLPC health literacy, with the goal of improving outcomes for individuals with serious, advanced illness and their families and caregivers. This FOA will use the NIH Research Project (R01) award mechanism.

074459	Maternal Nutrition and Pre-pregnancy Obesity: Effects on Mothers, Infants and Children (R01 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PA-18-776	05-Feb-2021	Not Specified
--------	--	---	-----------	-------------	---------------

Contact Name	Sung Sug (Sarah) Yoon, PhD, RN
Contact Telephone	301-402-6959
Contact Email	sungsug.yoon@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021
Synopsis	National Institute of Nursing Research (NINR) and Office of Dietary Supplements (ODS) invite applications to improve health outcomes for women, infants and children, by stimulating interdisciplinary research focused on maternal nutrition and pre-pregnancy obesity. Maternal health significantly impacts not only the mother but also the intrauterine environment, and subsequently fetal development and the health of the newborn. This FOA will use the NIH Research Project (R01) award mechanism.

084550	Palliative Care in Home and Community Settings (R21 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PAR-19-320	16-Feb-2021	275,000 USD
--------	--	---	------------	-------------	-------------

Contact Name	Karen A. Kehl, PhD, RN, FPCN
Contact Telephone	301-594-8010
Contact Email	karen.kehl@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022
Synopsis	The purpose of this funding opportunity is to stimulate research aimed at determining needs and best practices for the integration of palliative care into home and community settings. Home and community in this FOA refer to the place where

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		an individual resides or lives. Home- and community-based palliative care programs ensure those with serious, advanced illness who do not require hospitalization but are not appropriate for hospice have access to high quality end-of-life and palliative care.			
084549	Palliative Care in Home and Community Settings (R01 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PAR-19-321	05-Feb-2021	Not Specified
	Contact Name	Karen A. Kehl, PhD, RN, FPCN			
	Contact Telephone	301-594-8010			
	Contact Email	karen.kehl@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022			
	Synopsis	The purpose of this funding opportunity is to stimulate research aimed at determining needs and best practices for the integration of palliative care into home and community settings. Home and community in this FOA refer to the place where an individual resides or lives. Home- and community-based palliative care programs ensure those with serious, advanced illness who do not require hospitalization but are not appropriate for hospice have access to high quality end-of-life and palliative care.			
068621	Mechanisms, Models, Measurement, & Management in Pain Research (R01 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PA-18-141	05-Feb-2021	Not Specified
	Contact Name	Martha Matocha, PhD			
	Contact Telephone	301-594-2775			
	Contact Email	matocham@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Feb-2021 , 07-May-2021			
	Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications to stimulate and foster a wide range of basic, clinical, and translational studies on pain as they relate to the missions of these ICs. New advances are needed in every area of pain research, from the micro perspective of molecular sciences to the macro perspective of			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

behavioral and social sciences. Although great strides have been made in some areas, such as the identification of neural pathways of pain, the experience of pain and the challenge of treatment have remained uniquely individual and unsolved. Furthermore, our understanding of how and why individuals transition to a chronic pain state after an acute injury is limited. Research to address these issues conducted by interdisciplinary and multidisciplinary research teams is strongly encouraged, as is research from underrepresented, minority, disabled, or women investigators. This FOA will use the NIH Research Project (R01) award mechanism.

068622	Mechanisms, Models, Measurement, & Management in Pain Research (R21 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PA-18-159	16-Feb-2021	275,000 USD
--------	--	---	-----------	-------------	-------------

Contact Name | Martha Matocha, PhD
 Contact Telephone | 301-594-2775
 Contact Email | matocham@mail.nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 16-Feb-2021 , 07-May-2021

Synopsis | National Institutes of Health (NIH) and its participating Institutes and Centers invite applications to stimulate and foster a wide range of basic, clinical, and translational studies on pain as they relate to the missions of these ICs. New advances are needed in every area of pain research, from the micro perspective of molecular sciences to the macro perspective of behavioral and social sciences. Although great strides have been made in some areas, such as the identification of neural pathways of pain, the experience of pain and the challenge of treatment have remained uniquely individual and unsolved. Furthermore, our understanding of how and why individuals transition to a chronic pain state after an acute injury is limited. Research to address these issues conducted by interdisciplinary and multidisciplinary research teams is strongly encouraged, as is research from underrepresented, minority, disabled, or women investigators. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.

077787	Biobehavioral Basis of Chronic Pain (R21 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PA-18-943	16-Feb-2021	275,000 USD
--------	---	---	-----------	-------------	-------------

Contact Name | Lois A. Tully, PhD
 Contact Telephone | 301-594-5968
 Contact Email | tullyla@mail.nih.gov
 Sponsor Website |

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022</p> <p>Synopsis The purpose of the Funding Opportunity Announcement is to encourage grant applications from the scientific community on the biobehavioral basis of chronic pain. The focus encompasses the individual phenotype, genotype, and other omic-type assessments and the associated sensory and emotional components that underpin the individual's chronic pain experience. Research relating biology and behavior is needed to better define the individual-specific burden of chronic pain and to better understand the mechanisms underlying differences in pain experiences among individuals afflicted with the same chronic illness.</p>				
077785	Biobehavioral Basis of Chronic Pain (R01 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PA-18-944	05-Feb-2021	Not Specified
	<p>Contact Name Lois A. Tully, PhD</p> <p>Contact Telephone 301-594-5968</p> <p>Contact Email tullyla@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022</p> <p>Synopsis The purpose of the Funding Opportunity Announcement is to encourage grant applications from the scientific community on the biobehavioral basis of chronic pain. The focus encompasses the individual phenotype, genotype, and other omic-type assessments and the associated sensory and emotional components that underpin the individual's chronic pain experience. Research relating biology and behavior is needed to better define the individual-specific burden of chronic pain and to better understand the mechanisms underlying differences in pain experiences among individuals afflicted with the same chronic illness.</p>				
077788	Applying a Biopsychosocial Perspective to Self-Management of Chronic Pain (R01 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PA-18-945	05-Feb-2021	Not Specified
	<p>Contact Name Martha Matocha, PhD</p> <p>Contact Telephone 301-594-2775</p> <p>Contact Email matocham@mail.nih.gov</p> <p>Sponsor Website</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022			
	Synopsis	The purpose of the Funding Opportunity announcement is to encourage grant applications from the scientific community on applying a biopsychosocial perspective to self-management of chronic pain.			
077789	Applying a Biopsychosocial Perspective to Self-Management of Chronic Pain (R21 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PA-18-946	16-Feb-2021	275,000 USD
	Contact Name	Martha Matocha, PhD			
	Contact Telephone	301-594-2775			
	Contact Email	matocham@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022			
	Synopsis	The purpose of the Funding Opportunity announcement is to encourage grant applications from the scientific community on applying a biopsychosocial perspective to self-management of chronic pain.			
077974	Addressing Caregiver Symptoms through Technological Tools (R21 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PA-19-024	16-Feb-2021	275,000 USD
	Contact Name	Augie Diana, Ph.D.			
	Contact Telephone	301-402-6423			
	Contact Email	dianaa@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022			
	Synopsis	The purpose of the Funding Opportunity announcement is to encourage grant applications from the scientific community that develop and test tools to address symptoms in caregivers. The key to this announcement is the focus on the caregiver, regardless of patient symptoms or conditions. Research is needed to enhance symptom recognition and assessment in caregivers, and to promote technological strategies to alleviate distress in caregiver symptoms. These studies are needed to advance the science related to caregiver experience of symptoms, caregiving contexts that promote these symptoms, and viable tools to address the symptoms experienced by caregivers.			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
077972	Addressing Caregiver Symptoms through Technological Tools (R01 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PA-19-023	05-Feb-2021	Not Specified
	<p>Contact Name Augie Diana, Ph.D.</p> <p>Contact Telephone 301-402-6423</p> <p>Contact Email dianaa@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022</p> <p>Synopsis The purpose of the Funding Opportunity announcement is to encourage grant applications from the scientific community that develop and test tools to address symptoms in caregivers. The key to this announcement is the focus on the caregiver, regardless of patient symptoms or conditions. Research is needed to enhance symptom recognition and assessment in caregivers, and to promote technological strategies to alleviate distress in caregiver symptoms. These studies are needed to advance the science related to caregiver experience of symptoms, caregiving contexts that promote these symptoms, and viable tools to address the symptoms experienced by caregivers.</p>				
079184	Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Required)	National Institute of Nursing Research/NIH/DHHS	PAR-19-135	25-Feb-2021	300,000 USD
	<p>Contact Name Michelle R.J. Hamlet, PhD</p> <p>Contact Telephone 301-496-9623</p> <p>Contact Email hamletm@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 25-Feb-2021 , 07-May-2021 , 25-Jun-2021 , 07-Sep-2021 , 25-Oct-2021 , 07-Jan-2022</p> <p>Synopsis The purpose of the Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools is to stimulate basic and clinical research in educational institutions that provide baccalaureate or advanced degrees for a significant number of the Nation's research scientists, but that have not been major recipients of NIH support. REAP grants create opportunities for scientists and health professional institutions otherwise unlikely to participate extensively in NIH research programs to contribute to the Nation's biomedical and behavioral research effort. REAP grants are intended to support small-scale research projects proposed by faculty members of eligible, domestic institutions, to expose undergraduate and/or graduate students at health professional schools or graduate schools to meritorious research projects,</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>and to strengthen the research environment of the applicant institution. Eligible institutions (e.g., the university or college with a unique identifier number (such as DUNS) and a unique NIH Institutional Profile File (IPF) number)) must award NIH-relevant baccalaureate or advanced degrees in health professions and have received no more than \$6 million per year of NIH support (in both direct and F&A/indirect costs) in 4 of the last 7 fiscal years. For institutions composed of multiple schools and colleges, the \$6 million funding limit is based on the amount of NIH funding received by the institution as a whole (meaning all schools and colleges within an institution). In other words, the funding for all the institution's health professional schools, graduate schools, and colleges and all the institution's non-health professional schools and colleges that are part of the institution are considered together and summed as total NIH funding when determining institutional eligibility. For institutions with multiple campuses, eligibility can be considered for each individual campus (e.g. main, satellite, etc.) only if a unique identifier number or NIH IPF number is established for each campus. For institutions that use one identifier number or NIH IPF number for all campuses, eligibility is determined for all campuses (e.g. main, satellite, etc.) together. This funding opportunity announcement (FOA) supports investigator-initiated mechanistic and/or minimal risk clinical trials addressing the mission and research interests of the participating NIH institutes. Minimal risk clinical trials are defined as those that do not require FDA oversight, do not intend to formally establish efficacy, and have low risks to potentially cause physical or psychological harm.</p>				
079185	End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) with Serious Illnesses (R01 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PAR-19-136	05-Feb-2021	Not Specified
	<p>Contact Name Lynn S. Adams, Ph.D. Contact Telephone 301-594-8911 Contact Email lynn.adams@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 Synopsis The purpose of this funding opportunity announcement (FOA) is to foster research on the unique perspectives, needs, wishes, and decision-making processes of adolescents and young adults (AYA; defined by the World Health Organization and the Centers for Disease Control and Prevention as youth between 12–24 years of age) with serious, advanced illnesses; and research focused on specific end-of-life/palliative care (EOLPC) models that support the physical, psychological, spiritual, and social needs of AYA with serious illness, their families and caregivers.</p>				
078636	Telomeres in Wellness and Disease: A Biobehavioral Approach (R21 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PA-19-073	16-Feb-2021	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name	Lois A. Tully, PhD
Contact Telephone	301-594-5968
Contact Email	tullyla@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022
Synopsis	The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research that examines the role of telomeres in wellness and disease, and to advance the incorporation of telomere studies into biobehavioral programs of research. A body of research has demonstrated the contribution of telomeres to health-related outcomes; however, additional studies are needed to achieve the full potential for incorporating telomere-guided approaches for maintaining wellness, reducing the risk and burden of disease, and for advancing symptom and self-management strategies.

078635	Telomeres in Wellness and Disease: A Biobehavioral Approach (R01 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PA-19-074	05-Feb-2021	Not Specified
--------	---	---	-----------	-------------	---------------

Contact Name	Lois A. Tully, PhD
Contact Telephone	301-594-5968
Contact Email	tullyla@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022
Synopsis	The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research that examines the role of telomeres in wellness and disease, and to advance the incorporation of telomere studies into biobehavioral programs of research. A body of research has demonstrated the contribution of telomeres to health-related outcomes; however, additional studies are needed to achieve the full potential for incorporating telomere-guided approaches for maintaining wellness, reducing the risk and burden of disease, and for advancing symptom and self-management strategies.

079344	End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) with Serious Illnesses (R21 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PAR-19-153	16-Feb-2021	275,000 USD
--------	---	---	------------	-------------	-------------

Contact Name	Lynn S. Adams, Ph.D.
Contact Telephone	301-594-8911

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email lynn.adams@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022</p> <p>Synopsis The purpose of this funding opportunity announcement (FOA) is to foster research on the unique perspectives, needs, wishes, and decision-making processes of adolescents and young adults (AYA; defined by the World Health Organization and the Centers for Disease Control and Prevention as youth between 12–24 years of age) with serious, advanced illnesses; and research focused on specific end-of-life/palliative care (EOLPC) models that support the physical, psychological, spiritual, and social needs of AYA with serious illness, their families and caregivers.</p>				
085700	Omics-guided Biobehavioral Interventions for Improved Health Outcomes: A Step Forward in Translation (R01 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PAR-19-377	05-Feb-2021	Not Specified
	<p>Contact Name Lois A. Tully, PhD</p> <p>Contact Telephone 301-594-5968</p> <p>Contact Email tullyla@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023</p> <p>Synopsis The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research that harnesses the wealth of advances in the fields of genomics and other omics (e.g., metabolomics, microbiomics, proteomics, transcriptomics, epigenomics, etc.) to incorporate these advances into translatable, personalized biobehavioral interventions for improved health outcomes.</p>				
078362	End-of-Life and Palliative Care Approaches to Advanced Signs and Symptoms (R21 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PAR-19-044	16-Feb-2021	275,000 USD
	<p>Contact Name Karen A. Kehl, Ph.D.</p> <p>Contact Telephone 301-594-8010</p> <p>Contact Email kehlka@nih.gov</p> <p>Sponsor Website</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022			
	Synopsis	The purpose of this funding opportunity announcement (FOA) is to stimulate research to examine the multi-dimensional foundations, experiences and management of complex, advanced signs and symptoms at the end of life.			
078345	End-of-Life and Palliative Care Approaches to Advanced Signs and Symptoms (R01 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PAR-19-045	05-Feb-2021	Not Specified
	Contact Name	Karen A. Kehl, Ph.D.			
	Contact Telephone	301-594-8010			
	Contact Email	kehlka@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022			
	Synopsis	The purpose of this funding opportunity announcement (FOA) is to stimulate research to examine the multi-dimensional foundations, experiences and management of complex, advanced signs and symptoms at the end of life.			
078414	Strategies to Provide Culturally Tailored Palliative and End-of-Life Care for Seriously Ill American Indian and Alaska Native Individuals (R21 Clinical Trial Optional)	National Institute of Nursing Research/NIH/DHHS	PAR-19-058	16-Feb-2021	275,000 USD
	Contact Name	Lynn S. Adams, Ph.D.			
	Contact Telephone	301-594-8911			
	Contact Email	adamsls@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022			
	Synopsis	The purpose of this funding opportunity announcement (FOA) is to encourage research that will improve and increase the use of evidence-based interventions in end-of-life and palliative care (EOLPC) for American Indian/Alaska Native (AI/AN) individuals with advanced illness and their families and communities.			
078411	Strategies to Provide Culturally Tailored Palliative and End-of-Life Care for Seriously Ill American Indian and Alaska Native Individuals (R01 Clinical Trial)	National Institute of Nursing Research/NIH/DHHS	PAR-19-057	05-Feb-2021	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

[Optional](#)

	Contact Name	Lynn S. Adams, Ph.D.			
	Contact Telephone	301-594-8911			
	Contact Email	adamsls@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022			
	Synopsis	The purpose of this funding opportunity announcement (FOA) is to encourage research that will improve and increase the use of evidence-based interventions in end-of-life and palliative care (EOLPC) for American Indian/Alaska Native (AI/AN) individuals with advanced illness and their families and communities.			

076590	Late Stage Clinical Trials for the Spectrum of Alzheimer's Disease and Age-related Cognitive Decline (R01 Clinical Trial Required)	National Institute on Aging/NIH/DHHS	PAR-18-878	05-Feb-2021	Not Specified
--------	--	--------------------------------------	------------	-------------	---------------

	Contact Name	Laurie Ryan			
	Contact Telephone	301-496-9350			
	Contact Email	ryanl@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Feb-2021 , 05-Jun-2021			
	Synopsis	National Institute on Aging (NIA) and National Institute of Nursing Research (NINR) invite applications that propose to develop and implement late stage (Phase II/III, III) clinical trials of promising pharmacological and non-pharmacological interventions in individuals with age-related cognitive decline and across the Alzheimer's disease (AD) spectrum from pre-symptomatic to more severe stages of disease. This FOA will use the NIH Research Project (R01) award mechanism.			

076587	Early Stage Clinical Trials for the Spectrum of Alzheimer's Disease and Age-related Cognitive Decline (R01 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-18-877	05-Feb-2021	Not Specified
--------	---	--------------------------------------	------------	-------------	---------------

	Contact Name	Laurie Ryan			
	Contact Telephone	301-496-9350			
	Contact Email	ryanl@mail.nih.gov			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 05-Jun-2021</p> <p>Synopsis National Institute on Aging (NIA) and National Institute of Nursing Research (NINR) invite applications that propose to develop and implement early stage (Phase I or II) clinical trials of promising pharmacological and non-pharmacological interventions in individuals with age-related cognitive decline and in individuals with Alzheimer's disease (AD) across the spectrum from pre-symptomatic to more severe stages of disease, and 2) to stimulate studies to enhance trial design and methods. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
081131	Limited Competition: Additional Sequencing for the Alzheimer's Disease Sequencing Project (U01 Clinical Trial Not Allowed) Activity Code	National Institute on Aging/NIH/DHHS	PAR-19-234	05-Feb-2021	Not Specified
	<p>Contact Name Marilyn Miller, Ph.D.</p> <p>Contact Telephone 301-496-9350</p> <p>Contact Email millerm@nia.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites applications specific to sample acquisition, genome wide association studies, whole genome sequencing, quality control checking, variant calling, and data calling that will support the generation of data for the Alzheimer's Disease Sequencing Project Follow-Up Study.</p>				
081010	Pragmatic Clinical Trial on Efficacy of Managing Reduced Iron Stores on Risk of Clinically Important Events in Older Adults with Heart Failure and Anemia (U01 Clinical Trial Required)	National Institute on Aging/NIH/DHHS	PA-19-230	05-Feb-2021	Not Specified
	<p>Contact Name Sergei Romashkan, MD, Ph.D.</p> <p>Contact Telephone 301-435-3047</p> <p>Contact Email romashks@nia.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	Synopsis This FOA invites applications for a pragmatic clinical trial to establish efficacy of managing reduced iron stores on risk of clinically important events in older adults with heart failure and anemia.				
--	---	--	--	--	--

075524	Analyses of Adherence Strategies and Data Sets from CALERIE to Explore Behavioral and Psychosocial Aspects of Sustained Caloric Restriction in Humans (R01 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PA-18-825	05-Feb-2021	Not Specified
--------	--	--------------------------------------	-----------	-------------	---------------

	Contact Name Giovanna Zappalà, Ph.D., M.P.H. Contact Telephone 301-827-6240 Contact Email Giovanna.Zappala@nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 05-Feb-2021 , 05-Jun-2021				
	Synopsis National Institute on Aging (NIA) invites applications for research projects (R01) involving secondary analyses of data in the Computerized Tracking System (CTS) database from the CALERIE (Comprehensive Assessment of Long-term Effects of Reducing Intake of Energy) trial to explore behavioral and psychosocial aspects of sustained caloric restriction (CR) in humans, including the translation of the CR adherence strategies used in the trial to promote healthy behaviors, especially for the prevention of weight gain with age. CALERIE was the first trial in humans to specifically focus on the effects of sustained CR. It demonstrated feasibility of sustained human CR (for at least two years) and favorable effects on predictors of longevity, as well as on cardiometabolic risk factors. The sustained weight loss in CALERIE has not been previously attained in any clinical study in non-obese individuals. This FOA will use the NIH Research Project (R01) award mechanism.				

091505	Translational Bioinformatics Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimer's Disease (R01 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-20-156	05-Feb-2021	Not Specified
--------	---	--------------------------------------	------------	-------------	---------------

	Contact Name Jean Yuan, Ph.D. Contact Telephone 301-496-9350 Contact Email yuanx4@mail.nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023				
--	---	--	--	--	--

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	This Funding Opportunity Announcement (FOA) enables data-driven drug repositioning and combination therapy for Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD) by developing computational methods and data resources and/or integrating computational approaches with proof-of-concept efficacy studies in cell-based models, animal models, and/or humans.			
076719	Limited Competition: Additional Sequencing for the Alzheimer's Disease Sequencing Project: Opportunity for Revision Requests for Active Cooperative Agreements (U01 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PAR-18-890	05-Feb-2021	2,500,000 USD
	Contact Name	Marilyn Miller, Ph.D.			
	Contact Telephone	301-496-9350			
	Contact Email	millerm@nia.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Feb-2021 , 05-Jun-2021			
	Synopsis	National Institute on Aging (NIA) invites revision applications to ongoing NIA-supported Cooperative Agreements in the area of the genetics of Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD). This Funding Opportunity Announcement (FOA) invites applications specific to sample acquisition, genome wide association studies, whole genome sequencing, quality control checking, variant calling, and data calling that will support the generation of data for the Alzheimer's Disease Sequencing Project Follow-Up Study. This program will use the NIH U01 Research Project Cooperative Agreements award mechanism.			
076718	Limited Competition: Renewal of, and Revisions to, the Alzheimer's Disease Genetics Consortium (U01 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PAR-18-889	05-Feb-2021	2,500,000 USD
	Contact Name	Marilyn Miller, Ph.D.			
	Contact Telephone	301-496-9350			
	Contact Email	millerm@nia.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Feb-2021 , 05-Jun-2021			
	Synopsis	National Institute on Aging (NIA) invites the NIA Alzheimer's Disease Genetics Consortium to submit revision and/or renewal			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

applications in the area of the genetics of Alzheimer's Disease. This program will use the NIH U01 Research Project Cooperative Agreements award mechanism.

082123	Cognitive Systems Analysis of Alzheimer's Disease Genetic and Phenotypic Data (U01 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PAR-19-269	05-Feb-2021	Not Specified
--------	--	--------------------------------------	------------	-------------	---------------

Contact Name	Marilyn Miller, Ph.D.
Contact Telephone	301-496-9350
Contact Email	millerm@nia.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022
Synopsis	This Funding Opportunity Announcement (FOA) invites applications that propose Artificial Intelligence (AI), Machine Learning (ML), and/or Deep Learning (DL) approaches, collectively referred to here as "cognitive systems," that lead to the identification of gene mutations/variants that cause or contribute to the risk of or protection against the development of Alzheimer's disease (AD) and Alzheimer's disease related dementias (ADRD) via analysis of a variety of genetic, genomic, and biomarker data that are currently available to the research community.

083316	Non-Invasive Neurostimulation in AD/ADRD (R01 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-19-298	05-Feb-2021	Not Specified
--------	--	--------------------------------------	------------	-------------	---------------

Contact Name	Kristina McLinden
Contact Telephone	301-827-2563
Contact Email	kristina.mclinden@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022
Synopsis	The goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies using non-invasive neurostimulation/neuromodulation in the treatment of Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). The goal of this FOA is to establish initial efficacy of neurostimulation/neuromodulation in the treatment of AD/ADRD or to refine these interventions for AD/ADRD patients. Multimodal or combination interventions are allowed, provided the focus and innovative component is neurostimulation. Applications that seek to develop devices, tools, or

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
	invasive techniques are outside the scope of this FOA.																		
083523	NIA Multi-site Clinical Trial Implementation Grant (R01 Clinical Trial Required)	National Institute on Aging/NIH/DHHS	PAR-19-302	05-Feb-2021	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>Sergei Romashkan, M.D., Ph.D.</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td>301-435-3047</td> </tr> <tr> <td style="padding-right: 5px;">Contact Email</td> <td>romashks@mail.nih.gov</td> </tr> <tr> <td style="padding-right: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="padding-right: 5px;">Deadline Dates (ALL)</td> <td>05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022</td> </tr> <tr> <td style="padding-right: 5px;">Synopsis</td> <td>This Funding Opportunity Announcement (FOA) invites applications for implementation of investigator-initiated multi-site interventional clinical trials (all phases). The trials should be hypothesis-driven, milestone-defined, and related to NIA's research mission. Information about NIA's mission can be found on the NIA website.</td> </tr> </table>					Contact Name	Sergei Romashkan, M.D., Ph.D.	Contact Telephone	301-435-3047	Contact Email	romashks@mail.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022	Synopsis	This Funding Opportunity Announcement (FOA) invites applications for implementation of investigator-initiated multi-site interventional clinical trials (all phases). The trials should be hypothesis-driven, milestone-defined, and related to NIA's research mission. Information about NIA's mission can be found on the NIA website.
Contact Name	Sergei Romashkan, M.D., Ph.D.																		
Contact Telephone	301-435-3047																		
Contact Email	romashks@mail.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022																		
Synopsis	This Funding Opportunity Announcement (FOA) invites applications for implementation of investigator-initiated multi-site interventional clinical trials (all phases). The trials should be hypothesis-driven, milestone-defined, and related to NIA's research mission. Information about NIA's mission can be found on the NIA website.																		
073071	NIA Limited Competition: Renewals of, and Revisions to, Existing Alzheimer's Disease Patient Registry Cooperative Agreement Awards (U01 - Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PAR-18-715	05-Feb-2021	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>Robin A. Barr</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td>301-496-9322</td> </tr> <tr> <td style="padding-right: 5px;">Contact Email</td> <td>BarrR@mail.nih.gov</td> </tr> <tr> <td style="padding-right: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="padding-right: 5px;">Deadline Dates (ALL)</td> <td>05-Feb-2021</td> </tr> <tr> <td style="padding-right: 5px;">Synopsis</td> <td>National Institute on Aging (NIA) invites existing Alzheimer's Disease Patient Registry cooperative agreements to submit revision and or renewal applications. The Alzheimer's Disease (AD) Patient Registry is a population-based longitudinal cohort study of AD and dementia that is linked to an HMO-medical record system or a similar record system. Potential applicants are strongly encouraged to contact their current program officer prior to submission to discuss the application. This FOA will utilize the NIH U01 Research Project – Cooperative Agreements award mechanism.</td> </tr> </table>					Contact Name	Robin A. Barr	Contact Telephone	301-496-9322	Contact Email	BarrR@mail.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	05-Feb-2021	Synopsis	National Institute on Aging (NIA) invites existing Alzheimer's Disease Patient Registry cooperative agreements to submit revision and or renewal applications. The Alzheimer's Disease (AD) Patient Registry is a population-based longitudinal cohort study of AD and dementia that is linked to an HMO-medical record system or a similar record system. Potential applicants are strongly encouraged to contact their current program officer prior to submission to discuss the application. This FOA will utilize the NIH U01 Research Project – Cooperative Agreements award mechanism.
Contact Name	Robin A. Barr																		
Contact Telephone	301-496-9322																		
Contact Email	BarrR@mail.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	05-Feb-2021																		
Synopsis	National Institute on Aging (NIA) invites existing Alzheimer's Disease Patient Registry cooperative agreements to submit revision and or renewal applications. The Alzheimer's Disease (AD) Patient Registry is a population-based longitudinal cohort study of AD and dementia that is linked to an HMO-medical record system or a similar record system. Potential applicants are strongly encouraged to contact their current program officer prior to submission to discuss the application. This FOA will utilize the NIH U01 Research Project – Cooperative Agreements award mechanism.																		
084767	Limited Competition: Renewals of, and Revisions and Resubmissions to, the Longitudinal Early-onset Alzheimer's Disease Study (LEADS) Cooperative	National Institute on Aging/NIH/DHHS	PAR-19-338	05-Feb-2021	Not Specified														

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Agreement (U01 Clinical Trial Not Allowed)					
	<p>Contact Name John K. Hsiao, M.D.</p> <p>Contact Telephone 301-496-9350</p> <p>Contact Email jhsiao@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022</p> <p>Synopsis This FOA invites revision, resubmission, or renewal applications to the Longitudinal Early-onset Alzheimer’s Disease Study (LEADS) Cooperative Agreement. Revision applications may not request funding beyond the project end date of the Parent award.</p>				
100297	Notice of Special Interest (NOSI): Integrative Studies of Neural Mechanisms Underlying Fundamental Affective Processes in Aging	National Institute on Aging/NIH/DHHS	NOT-AG-21-012	05-Feb-2021	Not Specified
	<p>Contact Name Luci Roberts, Ph.D.</p> <p>Contact Telephone </p> <p>Contact Email roberlu@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 16-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to inform applicants of NIA’s interest in research on the neural mechanisms underlying fundamental affective processes in aging. Grant applications are encouraged to 1) extend research on neural mechanisms underlying affective processes into aging models; and/or 2) seek to “reverse translate” clinical research results on affective processes in aging into model systems that support elucidation of fundamental neural mechanisms. NIA also wishes to encourage collaboration among cognitive and affective neuroscientists and/or investigators working at different levels of neurobiological and behavioral analysis.</p>				
083550	Early-Stage T1 Translational Aging Research (Bench to Bedside) for the Development of Novel Therapeutics (R33 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-19-304	16-Feb-2021	1,500,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name	Chhanda Dutta, Ph.D.
Contact Telephone	301-496-4161
Contact Email	duttac@nia.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022
Synopsis	<p>This Funding Opportunity Announcement (FOA) encourages Exploratory/Developmental Phase II (R33) grant applications to facilitate early-stage T1 translation (bench-to-bedside) of discoveries from basic and applied research in aging into novel therapeutics for the prevention and treatment of clinical conditions related to aging or multiple chronic conditions in older people (e.g., sarcopenia, hearth failure with preserved ejection fraction (HFePF), immunosenescence, pulmonary fibrosis, metabolic syndrome, chronic kidney disease). This includes the development of pharmacological strategies such as new classes of compounds (e.g., senolytics, anti-inflammatory agents, modulators of proteostasis and autophagy), natural products (or their derivatives, mimics, and synthetic equivalents), biologics, stem/progenitor cell-based therapies, and the repurposing of Food and Drug Administration (FDA)-approved drugs. Applications submitted in response to this FOA may involve novel treatment targets and/or innovative approaches for engaging known targets. The R33 mechanism is intended to provide milestone-driven support (up to 5 years) for innovative exploratory and developmental research activities originally initiated under the R21 mechanism. Awardees from NIA's R21 T1 translational aging research program are encouraged to apply to this FOA to expand upon the translation of their candidate pharmacological interventions from prior studies. Other applicants with sufficient and strong preliminary/proof-of-concept data (equivalent to that achievable under a R21) for a novel drug target, new compound(s), or for a potential new clinical indication for an FDA-approved drug for age-related conditions are also eligible to apply to this FOA. The scope of early-stage T1 translational research activities to be conducted under the R33 is expected to vary with the stage of translation of the candidate therapeutic. Nevertheless, the R33 support should advance the experimental intervention closer to human testing (if warranted). The development of non-pharmacological interventions is considered outside the scope of this FOA. Applications that focus on Alzheimer's disease or its related dementias are outside the scope of this announcement.</p>

086248	Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research: Area of Focus Basic Science (R03 Clinical Trials Not Allowed)	National Institute on Aging/NIH/DHHS	PAS-19-392	16-Feb-2021	200,000 USD
--------	--	--------------------------------------	------------	-------------	-------------

Contact Name	Lisa Opanashuk, Ph.D.
Contact Telephone	301-807-5422

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email lisa.opanashuk@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022 , 16-Oct-2022</p> <p>Synopsis This Small Research Grant (R03) will support important and innovative projects focused on basic science approaches to elucidate neurodegenerative mechanisms/pathways of Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). Proposed projects should ultimately aim to improve the prevention, diagnosis, treatment, and/or care for individuals with AD/ADRD. The program seeks (i) to facilitate the next generation of researchers in the United States to pursue research and academic careers in neuroscience, AD/ADRD, and healthy brain aging and (ii) to stimulate established researchers who are not currently doing AD/ADRD research to perform pilot studies toward developing new, innovative AD/ADRD research programs that leverage and build upon their existing expertise. Individuals from underrepresented racial and ethnic groups, as well as individuals with disabilities, are always encouraged to apply for NIH support.</p>				
100902	Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials (R01 Clinical Trial Required)	National Institute on Aging/NIH/DHHS	PAR-20-309	05-Feb-2021	Not Specified
	<p>Contact Name Laurie Ryan, Ph.D.</p> <p>Contact Telephone 301-496-9350</p> <p>Contact Email ryanl@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023 , 05-Oct-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites applications to develop and implement Phase Ib to III clinical trials of promising pharmacological and non-pharmacological interventions that may prevent, delay, or treat the symptoms of Alzheimer's disease (AD) and other age-related dementias using the Alzheimer's disease Clinical Trials Consortium (ACTC) trial coordination and management infrastructure.</p>				
075519	Analyses of CALERIE Data and Biospecimens to Elucidate Mechanisms of Caloric Restriction (CR)-Induced Effects in Humans (R01 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PA-18-823	05-Feb-2021	Not Specified
	Contact Name	Giovanna Zappalà, Ph.D., M.P.H.			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Telephone	301-827-6240
Contact Email	Giovanna.Zappala@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Feb-2021 , 05-Jun-2021
Synopsis	National Institute on Aging (NIA) invites applications for research projects (R01) involving secondary analyses of data and/or stored biospecimens from the CALERIE (Comprehensive Assessment of Long- term Effects of Reducing Intake of Energy) trial. The goal of this funding opportunity announcement (FOA) is to encourage analyses that will lead to a more detailed understanding of the effects of caloric restriction (CR) on risk factors for chronic diseases, as well as, the cellular/molecular mechanisms mediating the effects of sustained CR in humans. This FOA will use the NIH Research Project (R01) award mechanism.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

086252	Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research: Area of Focus Systems Biology (R03 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PAS-19-393	16-Feb-2021	200,000 USD
--------	---	--------------------------------------	------------	-------------	-------------

Contact Name	Alison Yao, Ph.D.
Contact Telephone	301-496-9350
Contact Email	alison.yao@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022 , 16-Oct-2022
Synopsis	This Small Research Grant Program (R03) will support important and innovative system biology projects in which more scientific insight is needed to improve the prevention, diagnosis, treatment, and care for individuals with Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). The overall goal of this R03 program is (i) to facilitate the next generation of researchers in the United States to pursue research and academic careers in neuroscience, AD/ADRD, and healthy brain aging and (ii) to stimulate established researchers who are not currently doing AD/ADRD research to perform pilot studies toward developing new, innovative AD/ADRD research programs that leverage and build upon their existing

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

expertise. Individuals from underrepresented racial and ethnic groups, as well as individuals with disabilities, are always encouraged to apply for NIH support.

086244	Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research: Area of Focus Archiving and Leveraging Existing Data Sets for Analyses (R03 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PAS-19-391	16-Feb-2021	200,000 USD
--------	--	--------------------------------------	------------	-------------	-------------

Contact Name	Partha Bhattacharyya, Ph.D.
Contact Telephone	301-496-3136
Contact Email	bhattacharyyap@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022 , 16-Oct-2022
Synopsis	This Small Research Grant (R03) will support important and innovative projects to provide needed scientific insight to improve the prevention, diagnosis, treatment, and/or care for individuals with Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). Specifically, this FOA will support archiving and leveraging existing data sets for analyses of projects covering a wide array of topics relating to AD/ADRD. The overall goal of this FOA is (i) to encourage the next generation of U.S. researchers to pursue research and academic careers in neuroscience, AD/ADRD, and healthy brain aging and (ii) to stimulate established researchers who are not currently doing AD/ADRD research to perform pilot studies developing new, innovative AD/ADRD research programs that leverage and build upon their existing expertise. Individuals from underrepresented racial and ethnic groups, as well as individuals with disabilities, are always encouraged to apply for NIH support.

101188	RFA-AG-22-001 -- Limited Competition: National Institute on Aging (NIA) Late Onset of Alzheimer's Disease (LOAD) Family-Based Study (FBS) (U24 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	RFA-AG-22-001	17-Jan-2021 [Optional][LOI/Pre-App]	12,000,000 USD
--------	--	--------------------------------------	---------------	--	----------------

Contact Name	Marilyn Miller, Ph.D.
Contact Telephone	301-496-9350
Contact Email	millerm@nia.nih.gov
Sponsor Website	
Program URL	Link to program URL

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	17-Jan-2021 [Optional][LOI/Pre-App], 17-Feb-2021			
	Synopsis	This Funding Opportunity Announcement (FOA) invites applications specific to infrastructure to support the Alzheimer's Disease Sequencing Project (ADSP) and related data collection, longitudinal follow-up, ascertainment of antecedent risk factors, and the characterization of additional relatives from families multiply affected by Alzheimer's disease and related dementias (AD/ADRD) in order to expand the existing NIA Late Onset of AD (LOAD) Family Based Study (FBS) sample set.			
075522	Exploratory Analyses of CALERIE Data and Biospecimens to Elucidate Mechanisms of Caloric Restriction (CR)-Induced Effects in Humans (R21 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PA-18-824	16-Feb-2021	275,000 USD
	Contact Name	Giovanna Zappalà, Ph.D., M.P.H.			
	Contact Telephone	301-827-6240			
	Contact Email	Giovanna.Zappala@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Feb-2021 , 16-Jun-2021			
	Synopsis	National Institute on Aging (NIA) invites applications for exploratory research projects (R21) involving secondary analyses of data and/or stored biospecimens from the CALERIE (Comprehensive Assessment of Long-term Effects of Reducing Intake of Energy) trial. The goal of this funding opportunity announcement (FOA) is to encourage analyses that will lead to a more detailed understanding of the effects of caloric restriction (CR) on risk factors for chronic diseases, as well as, the cellular/molecular mechanisms mediating the effects of sustained CR in humans. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.			
083551	Early-Stage T1 Translational Aging Research (Bench to Bedside) for the Development of Novel Therapeutics (R21/R33 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-19-305	16-Feb-2021	Not Specified
	Contact Name	Chhanda Dutta, Ph.D.			
	Contact Telephone	301-496-4161			
	Contact Email	duttac@nia.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages Exploratory/Developmental Phased Innovation (R21/R33) grant applications to facilitate early-stage T1 translation (bench-to-bedside) of discoveries from basic and applied research in aging into novel therapeutics for the prevention and treatment of clinical conditions related to aging and/or multiple chronic conditions in older people (e.g., sarcopenia, heart failure with preserved ejection fraction (HFpEF), immunosenescence, metabolic syndrome, chronic kidney disease). This includes the development of pharmacological strategies such as new classes of compounds (e.g., senolytics, anti-inflammatory agents, modulators of proteostasis and autophagy), natural products (or their derivatives, mimics, and synthetic equivalents), biologics, stem/progenitor cell-based therapies, and the repurposing of Food and Drug Administration (FDA)-approved drugs. This FOA provides support for up to two years (R21, milestone-driven exploratory phase) for preliminary, proof-of-concept studies, which is followed by up to three years of support (R33 phase) for further/expanded preclinical development of the candidate therapeutic. Applicants may request funds for the development of assays and other methodologies required for translational studies in the project budget for the R21 and/or R33 phases. Funding for the R33 phase will be contingent on successful completion of established milestones in the R21 phase. The development of non-pharmacological interventions is considered outside the scope of this FOA. Applications that focus on Alzheimer's disease or its related dementias are outside the scope of this announcement. Applications using only the R21 mechanism will not be accepted under this FOA.</p>				
087474	Research Infrastructure Development for Interdisciplinary Aging Studies (R21/R33 - Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-20-070	16-Feb-2021	1,775,000 USD
	<p>Contact Name Winifred K. Rossi</p> <p>Contact Telephone 301-496-3836</p> <p>Contact Email rossiw@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022 , 16-Oct-2022</p> <p>Synopsis This FOA invites applications that propose to develop novel research infrastructure that will advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. This FOA will use the NIH Phased Innovation Award (R21/R33) mechanism to provide up to 2 years of R21 support for initial developmental activities and up to 3 years of R33 support for expanded activities. Through this award, investigators will develop a sustainable research infrastructure to support projects that address key interdisciplinary aging research questions.</p>				
087500	Advanced-Stage Development and Utilization of Research	National Institute on	PAR-20-071	16-Feb-2021	2,495,000

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Infrastructure for Interdisciplinary Aging Studies (R33 Clinical Trial Optional)	Aging/NIH/DHHS			USD
	<p>Contact Name Winifred K. Rossi</p> <p>Contact Telephone 301-496-3836</p> <p>Contact Email rossiw@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022 , 16-Oct-2022</p> <p>Synopsis This FOA invites applications that propose to support advanced-stage development and utilization of novel research infrastructure to advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. This FOA will use the NIH Exploratory/Developmental Grants Phase II mechanism to provide support for expanded activities. Applicants are expected to have an existing research infrastructure developed, either through PA-12-064 or with other NIH or non-NIH support. Through this award, investigators will develop a mature and sustainable research infrastructure to support projects that address key interdisciplinary aging research questions.</p>				
075525	Exploratory Analyses of Adherence Strategies and Data Sets from CALERIE to Investigate Behavioral and Psychosocial Aspects of Sustained Caloric Restriction in Humans (R21 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PA-18-826	16-Feb-2021	275,000 USD
	<p>Contact Name Giovanna Zappalà, Ph.D., M.P.H.</p> <p>Contact Telephone 301-827-6240</p> <p>Contact Email Giovanna.Zappala@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 16-Jun-2021</p> <p>Synopsis National Institute on Aging (NIA) invites applications for exploratory research projects (R21) involving secondary analyses of data in the Computerized Tracking System (CTS) database from the CALERIE (Comprehensive Assessment of Long-term Effects of Reducing Intake of Energy) trial to explore behavioral and psychosocial aspects of sustained caloric restriction (CR) in humans, including the translation of the CR adherence strategies used in the trial to promote healthy behaviors, especially for the prevention of weight gain with age. CALERIE was the first trial in humans to specifically focus on the effects of</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		sustained CR. It demonstrated feasibility of sustained human CR (for at least two years) and favorable effects on predictors of longevity, as well as on cardiometabolic risk factors. The sustained weight loss in CALERIE has not been previously attained in any clinical study in non-obese individuals. This FOA will use the NIH Research Project (R01) award mechanism.			
100463	NIA Intervention Testing Program (ITP) Announces Annual Call for Compounds to Test for Anti-Aging Activity in Mice	National Institute on Aging/NIH/DHHS	NOT-AG-21-014	28-Feb-2021	Not Specified
	Contact Name	Francesca Macchiarini, Ph.D.			
	Contact Telephone	301-827-4013			
	Contact Email	francesca.macchiarini@nih.gov			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	28-Feb-2021			
	Synopsis	The National Institute on Aging (NIA) Interventions Testing Program (ITP) was established to test compounds purported to extend lifespan and/or delay the onset of disease and disability. The NIA ITP tests such compounds in mice, using a variety of measured endpoints to assess the efficacy of interventions. There are three sites that perform the testing, one at the University of Michigan, one at the University of Texas Health Sciences Center-San Antonio, and one at The Jackson Laboratory. It is anticipated that approximately 5 compounds will be accepted for study in 2021.			
100192	RFA-AG-21-027 -- MD-PhD Training Program in Alzheimer's Disease and Its Related Dementias and the Behavioral and Social Sciences (T32)	National Institute on Aging/NIH/DHHS	RFA-AG-21-027	03-Feb-2021	Not Specified
	Contact Name	Georgeanne E. Patmios			
	Contact Telephone	301-496-3136			
	Contact Email	PatmiosG@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	03-Feb-2021			
	Synopsis	NIA's MD-PhD Training Program in Alzheimer's Disease and Its Related Dementias and the Behavioral and Social Sciences is designed to help strengthen the pipeline of physician-scientist leaders dedicated to using social and behavioral science approaches to addressing the nation's challenges posed by Alzheimer's disease and its related dementias (AD/ADRD). This			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

FOA provides support to eligible domestic institutions to develop and implement effective approaches to integrated dual-degree training leading to the award of both an MD and a research doctorate degree (PhD or equivalent). This FOA invites applications from institutions with externally funded grants in the social/behavioral sciences that are relevant to the research topics proposed under this FOA. Fields of graduate training that are responsive to this FOA are economics, health economics, health services research, public policy, healthcare policy, social work, demography, sociology, social epidemiology, and psychology. Integrated medical and graduate research training programs may be built around single disciplines or may be multidisciplinary, may be flexible in structure, and should be consistent with individual institutional strengths. Proposed training programs should be flexible and adaptable in providing each trainee with the appropriate background in the social/behavioral sciences relevant to AD/ABDR research and clinical practice, yet be rigorous enough to enable graduates to function independently in both basic social/behavioral science research and clinical investigation. This Funding Opportunity Announcement (FOA) does not allow appointed Trainees to lead an independent clinical trial but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.

075498	Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PAR-18-820	05-Feb-2021	5,000,000 USD
--------	--	--------------------------------------	------------	-------------	---------------

Contact Name	Lorenzo M. Refolo, Ph.D.
Contact Telephone	301-594-7576
Contact Email	refolol@nia.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021
Synopsis	National Institute on Aging's (NIA) invites applications for pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic therapeutic agents that prevent Alzheimer's disease (AD), slow its progression or treat its cognitive and behavioral symptoms. Participants in this program will receive funding for therapy development activities such as medicinal chemistry, pharmacokinetics (PK), Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET), efficacy in animal models, formulation development, chemical synthesis under Good Manufacturing Practices (GMP), Investigational New Drug (IND) enabling studies and initial Phase I clinical testing. This program does not support research on basic mechanisms of disease, mechanisms of drug action, development of biomarkers, devices, non-pharmacological interventions (e.g., exercise, diet, cognitive training), repurposed drugs and combinations therapies, or discovery activities such as high throughput screening and hit optimization. This FOA will utilize the NIH U01 Research Project – Cooperative Agreements award mechanism.

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
070905	Underactive Bladder and Detrusor Activity in Aging (R21 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PA-18-572	16-Feb-2021	275,000 USD
	<p>Contact Name Marcel E. Salive, MD</p> <p>Contact Telephone 301-496-6761</p> <p>Contact Email saliveme@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 07-May-2021</p> <p>Synopsis National Institute on Aging (NIA) invites applications that propose basic, clinical, or translational research on underactive bladder (UAB) and detrusor underactivity (DU) and its consequences in aging and in older persons. Applications should focus on the 1) biology, etiology and pathophysiology of DU or UAB in animal models and/or older adults; 2) translation of basic/clinical research into clinical practice and health decision-making; 3) diagnosis, prevention, management and clinical outcomes of UAB in older adults; and/or 4) epidemiology and risk factors for the development of DU/UAB with advancing age. The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. Research supported by this initiative should enhance knowledge of DU/UAB and its consequences in older adults and provide evidence-based guidance in the diagnosis, evaluation, and treatment of DU/UAB in older persons. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</p>				
070904	Underactive Bladder and Detrusor Activity in Aging (R01 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PA-18-570	05-Feb-2021	Not Specified
	<p>Contact Name Marcel E. Salive, MD</p> <p>Contact Telephone 301-496-6761</p> <p>Contact Email saliveme@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021</p> <p>Synopsis National Institute on Aging (NIA) and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invite applications that propose basic, clinical, or translational research on underactive bladder (UAB) and detrusor underactivity (DU) and its consequences in aging and in older persons. Applications should focus on the 1) biology, etiology and</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>pathophysiology of DU or UAB in animal models and/or older adults; 2) translation of basic/clinical research into clinical practice and health decision making; 3) diagnosis, prevention, management and clinical outcomes of UAB in older adults; and/or 4) epidemiology and risk factors for the development of DU/UAB with advancing age. Research supported by this initiative should enhance knowledge of DU/UAB and its consequences in older adults and provide evidence-based guidance in the diagnosis, evaluation, and treatment of DU/UAB in older persons. This FOA will use the NIH Research Project (R01) award mechanism.</p>			
070906	Underactive Bladder and Detrusor Activity in Aging (R03 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	PA-18-571	16-Feb-2021	100,000 USD
	<p>Contact Name Marcel E. Salive, MD</p> <p>Contact Telephone 301-496-6761</p> <p>Contact Email saliveme@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 07-May-2021</p>	<p>Synopsis National Institute on Aging (NIA) invites pilot/feasibility projects that propose basic, clinical, or translational research on underactive bladder (UAB) and detrusor underactivity (DU) and its consequences in aging and in older persons. Applications should focus on the 1) biology, etiology and pathophysiology of DU or UAB in animal models and/or older adults; 2) translation of basic/clinical research into clinical practice and health decision-making; 3) diagnosis, prevention, management and clinical outcomes of UAB in older adults; and/or 4) epidemiology and risk factors for the development of DU/UAB with advancing age. Pilot/feasibility research supported by this initiative should enhance knowledge of DU/UAB and its consequences in older adults and provide evidence-based guidance in the diagnosis, evaluation, and treatment of DU/UAB in older persons. This FOA will use the NIH R03 Small Grant Program award mechanism.</p>			
098385	RFA-AG-21-020 -- Paul B. Beeson Emerging Leaders Career Development Award in Aging (K76 Independent Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	RFA-AG-21-020	03-Feb-2021	Not Specified
	<p>Contact Name Shahrooz Vahedi, Ph.D.</p> <p>Contact Telephone 301-496-9322</p> <p>Contact Email shahrooz.vahedi@nih.gov</p> <p>Sponsor Website </p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 03-Feb-2021 , 22-Sep-2021 [Optional][LOI/Pre-App], 22-Oct-2021 , 21-Sep-2022 [Optional][LOI/Pre-App], 21-Oct-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites early-stage physicians and other health professional investigators with a commitment to aging and/or aging-related diseases to apply for this award to advance their research and leadership skills in their specialty and in the broader field of aging and geriatrics research. The National Institute on Aging is pursuing this initiative to recruit early-stage investigators who have successfully competed for a research grant and begun to establish research programs and who, through this award, will be ready to assume leadership roles in their field of expertise and be poised to change theory, practice, and health outcomes related to the health of older individuals. Unlike other mentored K awards, candidates for this award must have received competitively awarded research support as a Program Director/Primary Investigator (PD/PI) at the faculty level or have otherwise leveraged faculty-level research support to develop an independent line of research. They must show evidence of leadership in the clinical or research domain. This FOA is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as a lead investigator should apply to the companion FOA (RFA-AG-21-021).</p>				
098057	<p>RFA-AG-21-021 -- Paul B. Beeson Emerging Leaders Career Development Award in Aging (K76 Clinical Trial Required)</p>	National Institute on Aging/NIH/DHHS	RFA-AG-21-021	03-Feb-2021	Not Specified
	<p>Contact Name Shahrooz Vahedi, Ph.D.</p> <p>Contact Telephone 301-496-9322</p> <p>Contact Email shahrooz.vahedi@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 03-Feb-2021 , 22-Sep-2021 [Optional][LOI/Pre-App], 22-Oct-2021 , 21-Sep-2022 [Optional][LOI/Pre-App], 21-Oct-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites early-stage physician and other health professional investigators with a commitment to aging and/or aging-related diseases to apply for this award to advance their research and leadership skills in their specialty and in the broader field of aging and geriatrics research. NIA is pursuing this initiative to recruit early-stage investigators who have begun to establish research programs and who, through this award, will be ready to assume leadership roles in their field of expertise and will be poised to change theory, practice, and health outcomes related to the health of older individuals. Unlike other mentored K awards, candidates for this award must have received competitively awarded research support as a Program Director/Principal Investigator (PD/PI) at the faculty level or have otherwise</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

leveraged faculty-level research support to develop an independent line of research. They must show evidence of leadership in the clinical or research domain. This FOA is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA RFA-AG-21-020.

096052	NIA Multi-site COVID-19 Related Clinical Trial Implementation Grant on Aging-Related Topics In At-risk Older Adult Populations (R01 Clinical Trial Required)	National Institute on Aging/NIH/DHHS	PAR-20-234	01-Feb-2021	Not Specified
--------	--	--------------------------------------	------------	-------------	---------------

Contact Name | Sergei Romashkan, M.D., Ph.D.
 Contact Telephone | 301-435-3047
 Contact Email | romashks@mail.nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 01-Feb-2021

Synopsis | This Funding Opportunity Announcement (FOA) invites applications for implementation of investigator-initiated multi-site clinical trials (all phases or stages) of interventions focused on specific aging-related issues to reducing transmission, risk, morbidity, mortality, severity, or complications of Coronavirus Disease 2019 (COVID-19). Applications on the following priority topics are invited: Efficacy and safety of interventions that target aging-related biological mechanisms that may influence risk or severity of COVID-19 infection among at-risk older adults Efficacy and safety of preventive and treatment interventions in older patients with differing comorbid conditions that make them especially vulnerable to adverse outcomes of COVID-19 infection Effectiveness of health and/or custodial care practices to reduce transmission risk or improve outcomes of COVID-19 infection in nursing homes or other residential settings serving at-risk older persons, including the development and testing of infection control training procedures for healthcare workers Rapid pragmatic trials in (at least two) health systems, nursing homes, or adult living facilities, ensuring replication across large pragmatic trial sites and leveraging electronic health records to promote quality improvement in physician, hospital, palliative care, and hospice practices to improve outcomes for older patients with COVID-19, especially those with cognitive impairment, Alzheimer's disease or Alzheimer's disease-related dementias (AD/ADRD), or underlying comorbidities Trials in at-risk older adults age 65 and older for whom electronic medical records are available and long-term outcomes can be tracked, and in institutions serving those populations Trials in older adults with AD/ADRD, older adults from populations with NIH-defined health disparities, and/or other vulnerable populations (e.g. incarcerated, homeless, living in institutions)

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
101480	AMENDMENT -- Genetic and Epidemiological Factors for Age-Related Traits and Diseases in the Sardinian Population (SardiNIA5)	National Institute on Aging/NIH/DHHS	NIDA-RFP-21-75N95021R00009	05-Feb-2021	Not Specified
	<p>Contact Name Eric McKay</p> <p>Contact Telephone 301-480-2406</p> <p>Contact Email eric.mckay@nih.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021</p> <p>Synopsis The National Institute on Aging (NIA) has a need for a project entitled, "Genetic and epidemiological factors for age-related traits and diseases in the Sardinian population (SardiNIA5)", to analyze both epidemiological and genetic factors in aging-related traits and conditions. We propose to extend an ongoing longitudinal study (SardiNIA) and add new traits based on the unique 'founder' population of Sardinia. This proposed SardiNIA5 project is a continued need of the SardiNIA study under Contract No. HHSN271201600005C, with a primary focus on a genetic analysis of Alzheimer/dementia based an all-island case control study (AIM I) and also encompassing an additional follow-up period to carry out sixth visits for the maximum number as possible of current SardiNIA cohort participants (AIM II). Please see the attached RFP titled "NIDA-RFP-21-75N95021R00009" for the full solicitation Additional beta.sam.gov information Notice</p> <p>Id 4ae7ece0b1f04ca3af7791e03098e1b8</p> <p>Source https://beta.sam.gov/opp/4ae7ece0b1f04ca3af7791e03098e1b8/view Note: This link might not be valid after archive date below. Archive Date 2/21/2021</p>				
086469	Aging Research Dissertation Awards to Increase Diversity (R36 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	PAR-19-394	16-Feb-2021	Not Specified
	<p>Contact Name Shahrooz Vahedi, Ph.D.</p> <p>Contact Telephone 301-496-9322</p> <p>Contact Email shahrooz.vahedi@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to provide dissertation awards in all areas of research within NIA's strategic priorities to increase the diversity of the scientific research workforce engaged in research on aging and aging-related health conditions.			
097636	Notice of Special Interest (NOSI): Basic and Translational Research on Affective, Motivational, and Social Function in Normative Aging and/or Alzheimer's Disease and Related Dementias (AD/ADRD)	National Institute on Aging/NIH/DHHS	NOT-AG-20-040	05-Feb-2021	Not Specified
	Contact Name	Janine Simmons, M.D., Ph.D.			
	Contact Telephone	301-480-8959			
	Contact Email	janine.simmons@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Feb-2021 , 16-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022			
	Synopsis	This Notice of Special Interest (NOSI) is intended to underscore NIA's continued commitment to psychological and neuroscientific research on affective, motivational, and social functions in midlife and aging. NIA supports research to further clarify the changes in and trajectories of these processes in adults who are aging normally and/or in individuals with mild cognitive impairment (MCI), Alzheimer's disease (AD), and AD-related dementias (ADRD). NIA also seeks to understand how changes in the structure and function of neurobiological and neuromodulatory systems mediate or moderate affective, motivational, and social behaviors and interact with other psychological functions, including cognition. NIA's goals are three-fold: (1) to advance understanding of normative maturational changes in affective, motivational, and social processes, their role in behavior and cognition, and their underlying integrative neural-behavioral mechanisms; (2) to elucidate how dysfunction in these processes might manifest in MCI and the early stages of AD/ADRD; and/or (3) to determine how dysfunction in these processes might account for any of the Behavioral and Psychological Symptoms of Dementia (BPSD) observed in AD/ADRD. Such studies may identify novel targets for preventative or therapeutic interventions to promote social, emotional, and cognitive well-being; facilitate adaptive function in aging; normalize social or emotional dysregulation; and/or strengthen social or emotional resilience at different stages of the life course and at different disease stages in AD/ADRD.			
101159	Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R34 Clinical Trial Optional)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-21-097	19-Feb-2021	450,000 USD
	Contact Name	William Dunty, PhD			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-443-7351</p> <p>Contact Email duntyw@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 19-Feb-2021 , 17-Jun-2021 , 19-Oct-2021 , 17-Feb-2022 , 17-Jun-2022 , 18-Oct-2022 , 17-Feb-2023 , 19-Jun-2023 , 17-Oct-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) for R34 planning grant applications focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this FOA is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and incidence of FASD and (2) interventions for FASD. It is expected that research conducted via this mechanism will consist of studies that are a pre-requisite for preparing and submitting subsequent applications for larger scale FASD prevention or intervention studies. Applicants interested in exploratory phased projects may consider FOA (PAR-21-098, the R61/R33 option).</p>				
101160	Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-21-098	19-Feb-2021	Not Specified
	<p>Contact Name William Dunty, PhD</p> <p>Contact Telephone 301-443-7351</p> <p>Contact Email duntyw@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 19-Feb-2021 , 17-Jun-2021 , 19-Oct-2021 , 17-Feb-2022 , 17-Jun-2022 , 18-Oct-2022 , 17-Feb-2023 , 19-Jun-2023 , 17-Oct-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this FOA is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and the incidence of FASD and (2) interventions for FASD. These objectives will be accomplished with the Exploratory/Developmental Phased Award (R61/R33) mechanism, clinical trial optional. The R61 phase will support pilot studies or secondary data analysis for hypothesis development and feasibility, and research testing the hypotheses can be expanded in the R33 phase. The transition to the R33 phase will be determined by NIAAA program staff after evaluation of the achievement of specific milestones set for the R61 phase. Highest priority will be given to applications with clinical trials. Applicants interested in planning clinical trials or adding to current projects may also consider FOA (PAR-21-097, the R34 option).</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
071743	Understanding Processes of Recovery in the Treatment of Alcohol Use Disorder (R21 - Clinical Trial Optional)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-18-620	16-Feb-2021	275,000 USD
	<p>Contact Name Brett T. Hagman</p> <p>Contact Telephone 301-443-0638</p> <p>Contact Email brett.hagman@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021</p> <p>Synopsis National Institute on Alcohol Abuse and Alcoholism (NIAAA) invites applications that seek to examine processes of recovery and relapse in the treatment of Alcohol Use Disorders. Applications high in innovation and significance are highly encouraged that address the following potential topics: 1) defining recovery; 2) Examining new and innovative methods to examine precipitants of relapse; 3) Understanding mechanisms of mutual help and recovery; 4) Evaluating recovery systems of care; and 5) Examining processes of extended treatment for AUD. This FOA will use the NIH Exploratory/Developmental (R21) award mechanism.</p>				
101458	Notice of Special Interest (NOSI): Alcohol-induced Tissue-specific and Organ System Diseases (R01/R21/R03)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	NOT-AA-20-024	05-Feb-2021	Not Specified
	<p>Contact Name Li Lin</p> <p>Contact Telephone 301-827-7749</p> <p>Contact Email linli@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 16-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024</p> <p>Synopsis The purpose of this Notice is to inform potential applicants of the NIAAA's special interest in research project applications studying the harmful effects of alcohol on the body's tissues, organs, and systems in diverse populations across the lifespan.</p>				
071738	Understanding Processes of Recovery in the Treatment of Alcohol Use Disorder (R01 Clinical Trial Optional)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-18-619	05-Feb-2021	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Brett T. Hagman</p> <p>Contact Telephone 301-443-0638</p> <p>Contact Email brett.hagman@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021</p> <p>Synopsis National Institute on Alcohol Abuse and Alcoholism (NIAAA) invites applications that seek to examine processes of recovery and relapse in the treatment of Alcohol Use Disorders. Applications high in innovation and significance are highly encouraged that address the following potential topics: 1) defining recovery; 2) Examining new and innovative methods to examine precipitants of relapse; 3) Understanding mechanisms of mutual help and recovery; 4) Evaluating recovery systems of care; and 5) Examining processes of extended treatment for AUD. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
072235	Mechanisms of Alcohol Tolerance (R21/R33 Clinical Trial Not Allowed)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	/PAR-18-659	16-Feb-2021	Not Specified
	<p>Contact Name Elizabeth M Powell, PhD</p> <p>Contact Telephone Elizabeth M Powell, PhD</p> <p>Contact Email elizabeth.powell3@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 07-May-2021</p> <p>Synopsis National Institute on Alcohol Abuse and Alcoholism (NIAAA) invites applications on sensitivity and tolerance mechanisms underlying the development of alcohol use disorders. The intent of this FOA is to: (1) develop hypotheses about cellular, molecular or network mechanisms that regulate sensitivity and tolerance to alcohol, and (2) develop quantitative models to predict the development of tolerance and the progression to alcohol dependence. These objectives will be accomplished with a Phased Innovation (R21/R33) mechanism, in which secondary data analysis or pilot studies can occur during the R21 phase, and research testing the hypotheses can be expanded in the R33 phase. The transition to the R33 phase will be determined by NIAAA program staff after evaluation of the achievement of specific milestones set for the R21 phase. This FOA will use the NIH R21/R33 Phased Innovation Award mechanism.</p>				
072233	Genetics of Alcohol Sensitivity and Tolerance (R01 Clinical Trial)	National Institute on Alcohol	PA-18-660	05-Feb-2021	Not

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Not Allowed	Abuse and Alcoholism/NIH/DHHS			Specified
	<p>Contact Name Hemin R. Chin, Ph.D.</p> <p>Contact Telephone 301-443-1282</p> <p>Contact Email chinh@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021</p> <p>Synopsis National Institute on Alcohol Abuse and Alcoholism (NIAAA) invites applications for novel genetic mechanisms underlying the development of tolerance and the progression to alcohol use disorder. Alcohol use disorders is complex, multifactorial, and influenced both by genetic and environmental factors. The purpose of this FOA is to stimulate and support efforts on identifying genetic, genomic and epigenetic factors contributing to the development of sensitivity and tolerance to alcohol. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
076324	Alcohol and Other Drug Interactions: Unintentional Injuries and Overdoses: Epidemiology and Prevention (R21 - Clinical Trial Optional)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-18-862	16-Feb-2021	275,000 USD
	<p>Contact Name Robert Freeman, Ph.D.</p> <p>Contact Telephone 301-443-8820</p> <p>Contact Email rfreeman@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021</p> <p>Synopsis National Institute on Alcohol Abuse and Alcoholism (NIAAA) and National Institute on Drug Abuse (NIDA) invite applications that explore whether and how alcohol and other illicit drugs or illicitly used prescription drugs interact to contribute to unintentional injuries and poisonings and how to prevent and/or reduce simultaneous use of alcohol or drugs singly or in combination. This FOA will use the NIH R21 Exploratory/Developmental Grant award mechanism.</p>				
076319	Alcohol and Other Drug Interactions: Unintentional Injuries and Overdoses: Epidemiology and Prevention (R01 - Clinical Trial Optional)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-18-863	05-Feb-2021	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Robert Freeman, Ph.D.</p> <p>Contact Telephone 301-443-8820</p> <p>Contact Email rfreeman@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL </p> <p>Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021</p> <p>Synopsis National Institute on Alcohol Abuse and Alcoholism (NIAAA) and National Institute on Drug Abuse (NIDA) invite applications that explore whether and how alcohol and other illicit drugs or illicitly used prescription drugs interact to contribute to unintentional injuries and poisonings and how to prevent and/or reduce simultaneous use of alcohol or drugs singly or in combination. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
083915	Mechanisms of Tolerance (R21/R33 - Clinical Trial Required)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-19-311	16-Feb-2021	1,775,000 USD
	<p>Contact Name Elizabeth M Powell, PhD</p> <p>Contact Telephone 301-443-0786</p> <p>Contact Email elizabeth.powell3@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022</p> <p>Synopsis This funding opportunity announcement (FOA) focuses on sensitivity and tolerance mechanisms underlying the development of alcohol use disorder. The intent of this FOA is to: (1) develop hypotheses about cellular, molecular or network mechanisms that regulate sensitivity and tolerance to alcohol, and (2) develop quantitative models to predict the development of tolerance and the progression to alcohol use disorder. These objectives will be accomplished with a Phased Innovation (R21/R33) mechanism, clinical trial required, in which secondary data analysis or pilot studies can occur during the R21 phase, and research testing the hypotheses can be expanded in the R33 phase. The transition to the R33 phase will be determined by NIAAA program staff after evaluation of the achievement of specific milestones set for the R21 phase. Applicants interested in animal studies on the mechanisms of tolerance may consider FOA (PAR-18-659) or in the genetic basis of tolerance may consider FOA (PA-18-660).</p>				
076327	Alcohol and Other Drug Interactions: Unintentional Injuries and Overdoses: Epidemiology and Prevention (R03 - Clinical Trial)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	PA-18-861	16-Feb-2021	100,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

[Optional](#)

	<p>Contact Name Robert Freeman, Ph.D.</p> <p>Contact Telephone 301-443-8820</p> <p>Contact Email rfreeman@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022</p> <p>Synopsis National Institute on Alcohol Abuse and Alcoholism (NIAAA) and National Institute on Drug Abuse (NIDA) invite applications that explore whether and how alcohol and other illicit drugs or illicitly used prescription drugs interact to contribute to unintentional injuries and poisonings and how to prevent and/or reduce simultaneous use of alcohol or drugs singly or in combination. This FOA will use the NIH R03 Small Grant Program award mechanism.</p>				
101405	<p>RFA-AA-21-001 -- Improving Health Disparities in Alcohol Health Services (R01 Clinical Trial Optional)</p>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	RFA-AA-21-001	05-Feb-2021	2,500,000 USD
	<p>Contact Name Laura E. Kwako, Ph.D.</p> <p>Contact Telephone 301-451-8507</p> <p>Contact Email laura.kwako@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 07-Jan-2024 , 05-Feb-2024 , 07-May-2024</p> <p>Synopsis This Funding Opportunity Announcement (FOA) solicits applications on health disparities and health services-related research focusing on: 1.) access to treatment; 2.) making treatment more appealing; 3.) costs; 4.) dissemination and implementation. All Applications are expected to emphasize health disparities in addition to the other four areas of focus mentioned above.</p>				
100945	<p>Notice of Special Interest (NOSI): Advances in Research for the Treatment, Services, and Recovery of Alcohol Use Disorder</p>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	NOT-AA-20-022	05-Feb-2021	Not Specified
	<p>Contact Name Brett T. Hagman, Ph.D.</p> <p>Contact Telephone 301-443-0638</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email brett.hagman@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 16-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to advance research on various topics that fall within NIAAA's Division of Treatment and Recovery Research (DTRR). DTRR's research interests are wide-ranging and encompass broad categories such as health services, behavioral therapies and mechanisms of behavioral change (MOBC), recovery, translational research, and innovative methods and technologies for alcohol use disorder (AUD) treatment and sustaining recovery. Other areas of interest include topics focusing on special-emphasis and underserved populations, including NIH-designated U.S. health disparity populations, as well as those with co-occurring disorders; and fetal alcohol spectrum disorders (FASD). In all studies, at all levels from FASD to elderly, efforts will be made to include participants that reflect the diversity of the population at large.</p>				
097916	Notice of Special Interest (NOSI): Secondary Analyses of Existing Alcohol Research Data	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	NOT-AA-20-018	05-Feb-2021	Not Specified
	<p>Contact Name Wenxing Zha, Ph.D.</p> <p>Contact Telephone 301-443-0633</p> <p>Contact Email zhaw@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 16-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023</p> <p>Synopsis The purpose of this Notice of Special Interest (NOSI) is to solicit applications to support the secondary analyses of existing data sets with the goal of enhancing our understanding of the following: 1) the patterns and trajectories of alcohol consumption, 2) the epidemiology and etiology, including genetics, of alcohol-related problems and disorders, and 3) alcohol-related health services and health systems, including access, quality, and efficiency. This Notice encourages applications proposing innovative analyses of existing alcohol research data, answering novel research hypotheses and questions, and developing and testing advanced analytical methodologies applicable to alcohol related epidemiological, behavioral and</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		genetics research.			
098270	Notice of Special Interest (NOSI): Alcohol and Aging	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	NOT-AA-20-019	05-Feb-2021	Not Specified
	Contact Name	Andras Orosz, Ph.D.			
	Contact Telephone	301-443-2193			
	Contact Email	orosza@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Feb-2021 , 16-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023			
	Synopsis	The purpose of this Notice of Special Interest (NOSI) is to promote research to improve our understanding of the effects of alcohol consumption on aging across different levels of biological organization including the molecular, cellular, tissue, organ, organism, and societal levels. The following broad research areas will be encouraged: 1) Basic and clinical research defining the effects of alcohol consumption on lifespan, health span, and age-related diseases depending on level of alcohol consumption, drinking pattern, and duration of drinking; 2) Research to inform evidence-based guidance for identifying risk for alcohol use disorder (AUD) among older adults as well as prevention, diagnosis, and treatment of AUD in this population; and 3) Research to extend the health span of older adults who drink and decrease the health care burden of age-related diseases associated with alcohol use.			
079193	NIDCD Clinical Research Center Grant (P50 Clinical Trial Optional	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-19-137	08-Feb-2021	7,500,000 USD
	Contact Name	Lana Shekim, Ph.D.			
	Contact Telephone	301-496-5061			
	Contact Email	shekiml@nidcd.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	08-Feb-2021 , 06-Jun-2021 , 06-Oct-2021			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>The National Institute on Deafness and Other Communication Disorders (NIDCD) invites applications for Clinical Research Center Grants designed to advance the diagnosis, prevention, treatment, and amelioration of human communication disorders. For this announcement, Clinical Research is defined as research involving individuals with communication disorders or data/tissues from individuals with a communication disorder. Examples of such research include but are not limited to, studies of the prevention, pathogenesis, pathophysiology, diagnosis, treatment, management or epidemiology of a disease or disorder of hearing, balance, smell, taste, voice, speech, or language. Applications may propose a clinical trial but are not required to (optional).</p>			
101080	NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 No Independent Clinical Trials)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21-086	17-Feb-2021	315,000 USD
	Contact Name	Alberto L. Rivera-Rentas, Ph.D.			
	Contact Telephone	301-496-1804			
	Contact Email	riverara@nidcd.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	17-Feb-2021 , 07-May-2021 , 17-Jun-2021 , 07-Sep-2021 , 13-Oct-2021 , 07-Jan-2022 , 17-Feb-2022 , 07-May-2022 , 14-Jun-2022 , 07-Sep-2022 , 13-Oct-2022 , 07-Jan-2023 , 14-Feb-2023 , 07-May-2023 , 13-Jun-2023 , 07-Sep-2023 , 13-Oct-2023 , 07-Jan-2024			
	Synopsis	<p>The purpose of the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01) is to support comprehensive and rigorous postdoctoral research and career development experiences in the biomedical, behavioral, or clinical sciences of promising Au.D./Ph.D. audiologists who have the potential to become productive, independent investigators in scientific health-related research fields relevant to NIDCD's mission. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA PAR-21-085 for Clinical Trial Required or for PAR-21-087 for Independent Basic Experimental Studies with Humans Required..</p>			
101078	NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 Clinical Trial Required)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21-085	17-Feb-2021	315,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
101085	<p>NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 Independent Basic Experimental Studies with Humans Required)</p>	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21-087	17-Feb-2021	315,000 USD

Contact Name	Alberto L. Rivera-Rentas, Ph.D.
Contact Telephone	301-496-1804
Contact Email	riverara@nidcd.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	17-Feb-2021 , 07-May-2021 , 17-Jun-2021 , 07-Sep-2021 , 13-Oct-2021 , 07-Jan-2022 , 17-Feb-2022 , 07-May-2022 , 14-Jun-2022 , 07-Sep-2022 , 13-Oct-2022 , 07-Jan-2023 , 14-Feb-2023 , 07-May-2023 , 13-Jun-2023 , 07-Sep-2023 , 13-Oct-2023 , 07-Jan-2024
Synopsis	The purpose of the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01) is to support comprehensive and rigorous postdoctoral research and career development experiences in the biomedical, behavioral, or clinical sciences of promising Au.D./Ph.D. audiologists who have the potential to become productive, independent investigators in scientific health-related research fields relevant to NIDCD's mission. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-21-086). Observational Studies involving humans should submit under PAR-21-087 - NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 Independent Basic Experimental Studies with Humans Required).

Contact Name	Alberto L. Rivera-Rentas, Ph.D.
Contact Telephone	301-496-1804
Contact Email	riverara@nidcd.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	17-Feb-2021 , 07-May-2021 , 17-Jun-2021 , 07-Sep-2021 , 13-Oct-2021 , 07-Jan-2022 , 17-Feb-2022 , 07-May-2022 , 14-Jun-2022 , 07-Sep-2022 , 13-Oct-2022 , 07-Jan-2023 , 14-Feb-2023 , 07-May-2023 , 13-Jun-2023 , 07-Sep-2023 , 13-Oct-2023 , 07-Jan-2024

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	Synopsis	<p>The purpose of the NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01) is to support comprehensive and rigorous postdoctoral research and career development experiences in the biomedical, behavioral, or clinical sciences of promising Au.D./Ph.D. audiologists who have the potential to become productive, independent investigators in scientific health-related research fields relevant to NIDCD's mission. This Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate ‘Independent Clinical Trial Required’ (PAR-21-085). Applicants not planning an independent clinical trial, or proposing to gain research in a clinical trial led by another investigator must apply to the companion ‘Independent Clinical Trial Not Allowed’ (PAR-21-086) FOA.</p>			
--	----------	---	--	--	--

101157	NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders (U01 - Clinical Trial Required)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21-064	10-Feb-2021	Not Specified
--------	--	---	------------	-------------	---------------

	Contact Name	Trinh T. Ly, M.D.			
	Contact Telephone	301-435-4085			
	Contact Email	trinh.ly@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	10-Feb-2021 , 10-Jun-2021 , 13-Oct-2021 , 10-Feb-2022 , 10-Jun-2022 , 11-Oct-2022 , 10-Feb-2023 , 09-Jun-2023 , 10-Oct-2023			
	Synopsis	<p>The NIDCD is committed to identifying effective interventions for the treatment or prevention of communication disorders by supporting well- designed and well- executed clinical trials. This funding opportunity announcement (FOA) supports a cooperative agreement between an NIDCD Project Scientist and an investigator to support a clinical trial that meets ANY of the following criteria: requires FDA oversight, is intended to formally establish efficacy, or has a higher risk to potentially cause physical or psychological harm. Clinical trial applications exceeding the annual direct costs of \$700,000 or more, in certain cases, may also be a criterion for this FOA. These investigator-initiated clinical trials are perceived to benefit from close interaction, oversight, and guidance resulting from a cooperative agreement. Only one clinical trial may be proposed in</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

each NIDCD Clinical Trials in Communication Disorders U01 application. Low risk clinical trials not meeting any of the criteria above are referred to the companion NIDCD Low Risk Clinical Trials in Communication Disorders (R01-Clinical Trial Required) PAR-21-063.

101155	NIDCD Low Risk Clinical Trials in Communication Disorders (R01 Clinical Trial Required)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21-063	05-Feb-2021	2,499,995 USD
--------	---	---	------------	-------------	---------------

Contact Name	Trinh T. Ly, M.D.
Contact Telephone	301-435-4085
Contact Email	trinh.ly@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024
Synopsis	The NIDCD is committed to identifying effective interventions for the diagnosis, prevention, or treatment of communication disorders by supporting well-designed and well-executed clinical trials. This funding opportunity announcement (FOA) supports investigator initiated low risk clinical trials addressing the mission and research interests of NIDCD. Clinical trials must meet ALL the following criteria: meet the budget limits of this FOA, not require FDA oversight, are not intended to formally establish efficacy and have low risks to potentially cause physical or psychological harm. This FOA also supports low risk trials determined to be Basic Science Experimental Studies involving Humans (BESH). These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. It is advisable that only one clinical trial be proposed in each NIDCD Clinical Trials in Communication Disorders R01 application. High risk clinical trials not meeting all the criteria above are referred companion U01 FOA PAR-21-064, NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders.

101297	NIDCD Early Career Research(ECR) Award (R21 Clinical Trial Optional)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PAR-21-107	26-Feb-2021	375,000 USD
--------	--	---	------------	-------------	-------------

Contact Name	Bracie Watson, Jr.
Contact Telephone	301-402-3458

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email watsonb@nidcd.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 26-Feb-2021 , 24-Jun-2021 , 28-Oct-2021 , 24-Feb-2022 , 23-Jun-2022 , 27-Oct-2022 , 23-Feb-2023 , 29-Jun-2023 , 26-Oct-2023</p> <p>Synopsis The NIDCD Early Career Research (ECR) Award (R21) is intended to support both basic and clinical research from scientists who are beginning to establish an independent research career. It cannot be used for thesis or dissertation research. The research must be focused on one or more of the areas within the biomedical and behavioral scientific mission of the NIDCD: hearing, balance, smell, taste, voice, speech, or language. The NIDCD ECR Award R21 grant mechanism supports different types of projects including secondary analysis of existing data; small, self-contained research projects; development of research methodology; translational research; outcomes research; and development of new research technology. Irrespective of the type of project, the intent of the NIDCD ECR Award R21 is for the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) to obtain sufficient preliminary data for a subsequent R01 application.</p>				
078310	Advancing Research in Augmentative and Alternative Communication (AAC) (R01 Clinical Trial Optional)	National Institute on Deafness and Other Communication Disorders/NIH/DHHS	PA-19-047	05-Feb-2021	Not Specified
	<p>Contact Name Lana Shekim, Ph.D.</p> <p>Contact Telephone 301-496-5061</p> <p>Contact Email shekiml@nidcd.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022</p> <p>Synopsis This funding opportunity announcement (FOA) seeks Research Project Grants (R01) applications on Augmentative and Alternative Communication (AAC) to advance our scientific knowledge in the evaluation and treatment of individuals with severe speech and physical impairments (SSPI). AAC is a set of tools and strategies that an individual uses to solve everyday communicative challenges. This FOA is for R01s only and encourages a range of research inclusive of basic, clinical, and translational.</p>				
078368	Advancing Research in Augmentative and Alternative Communication (AAC) (R21 Clinical Trial Optional)	National Institute on Deafness and Other Communication	PA-19-046	16-Feb-2021	275,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Disorders/NIH/DHHS					
	<p>Contact Name Lana Shekim, Ph.D.</p> <p>Contact Telephone 301-496-5061</p> <p>Contact Email shekiml@nidcd.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022</p> <p>Synopsis This funding opportunity announcement (FOA) solicits Research Project Grants (R21) applications on augmentative and alternative communication (AAC) to advance our scientific knowledge in the evaluation and treatment of individuals with complex communication needs (CCN) or with severe speech and physical impairments (SSPI). AAC is a set of tools and strategies that an individual uses to solve everyday communicative challenges. This FOA is for R21s only and encourages a range of research inclusive of basic, clinical, and translational.</p>				
070860	Cutting-Edge Basic Research Awards (CEBRA) (R21-Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PAR-18-437	10-Feb-2021	275,000 USD
	<p>Contact Name Amy C. Lossie, Ph.D.</p> <p>Contact Telephone 301-827-6092</p> <p>Contact Email lossieac@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-Feb-2021</p> <p>Synopsis The National Institute on Drug Abuse (NIDA) Cutting-Edge Basic Research Award (CEBRA) is designed to foster highly innovative or conceptually creative research related to the etiology, pathophysiology, prevention, or treatment of substance use disorders (SUDs). It supports high-risk and potentially high-impact research that is underrepresented or not included in NIDA's current portfolio. The proposed research should: (1) test an innovative and significant hypothesis for which there are scant precedent or preliminary data and which, if confirmed, would transform current thinking; and/or (2) develop, and/or adapt, revolutionary techniques or methods for addiction research or that show promising future applicability to SUD research. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.</p>				
073437	Exploring Epigenomic or Non-Coding RNA Regulation in the Development, Maintenance, or Treatment of Chronic Pain	National Institute on Drug Abuse/NIH/DHHS	PAR-18-742	11-Feb-2021	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

[\(R61/R33 Clinical Trial Optional\)](#)

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	John Satterlee Ph.D. 301-435-1020 satterleej@nida.nih.gov Link to program URL 11-Feb-2021 National Institute on Drug Abuse (NIDA) and National Center for Complementary and Integrative Health (NCCIH) invite applications for research that investigates the role of epigenetic or non-coding RNA regulatory pathways in the development, maintenance, or treatment of chronic pain. Ultimately research in the area will provide foundational knowledge that can be exploited to develop novel and non-addictive pain medications or to develop biomarkers that predict chronic pain progression or treatment response. This FOA will use the NIH R61/R33 Exploratory/Developmental Phased Award mechanism.
--	---

078460	Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PAR-19-064	08-Feb-2021	275,000 USD
--------	--	---	------------	-------------	-------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Marsha F. Lopez, PhD, MHS 301-443-6504 lopezmar@mail.nih.gov Link to program URL 08-Feb-2021 , 08-Jun-2021 , 08-Oct-2021 This Funding Opportunity Announcement (FOA) will support pilot, feasibility or exploratory research in 7 priority areas in substance use epidemiology, prevention, and health services, including: 1) responses to sudden and severe emerging drug issues (e.g. the ability to look into a large and sudden spike in opioid or synthetic cannabinoid use/overdoses in a particular community); 2) responses to emerging marijuana trends and topics related to the shifting policy landscape; 3) responses to unexpected and time-sensitive prescription drug abuse research opportunities (e.g., new state or local efforts); 4) responses to unexpected and time-sensitive medical system issues (e.g. opportunities to understand addiction services in the evolving health care system); 5) responses to unexpected and time-sensitive criminal or juvenile justice opportunities (e.g. new system and/or structural level changes) that relate to drug abuse and access and provision of health care service;6) partnerships
--	--

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>between researchers and state or local organizations to support the evaluation of new local policies, programs, or practices in response to public health emergencies (e.g., the opioid crisis); 7) research collecting and examining data on the risks and outcomes associated with substance use and COVID-19 infection in the general population and among underserved populations, such as racial, ethnic and gender minorities, individuals with low socioeconomic status, and those who are incarcerated or homeless. It should be clear that the knowledge gained from the proposed study is time-sensitive and that an expedited rapid review and funding are required in order for the scientific question to be answered (i.e. an imminent policy change will not allow for standard review and funding timeline).</p>			
101380	RFA-DA-21-015 -- Novel Approaches to Decrease Stigma of Substance Use Disorders in order to Facilitate Prevention, Treatment, and Support During Recovery (R41/R42 - Clinical Trials Optional)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-21-015	26-Jan-2021 [Optional][LOI/Pre-App]	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	<p> Julia Berzhanskaya, PhD 301-594-6140 julia.berzhanskaya@nih.gov Link to program URL 26-Jan-2021 [Optional][LOI/Pre-App], 26-Feb-2021 The purpose of this Funding Opportunity Announcement is to support research applications for commercializable products aimed at reducing stigma around substance use disorders (SUD). Phase I applications are invited to develop and evaluate feasibility of novel digital technologies, services or other interventions to reduce stigma towards SUD in clinical care, including HIV prevention and care settings, clinical training and other relevant settings, and to establish methods to measure stigma reduction. Phase II applications are invited to demonstrate efficacy in decreasing stigma towards SUD and commercialization potential of these products in clinical care, training, and/or other relevant settings, including those providing HIV prevention and care with the goal to remove barriers to SUD prevention, treatment, and support during recovery. Phase II applications focused on HIV prevention and care settings are invited to demonstrate efficacy in decreasing stigma towards SUD and improving health outcomes for people living with HIV and SUD. </p>			
101375	RFA-DA-21-016 -- Novel Approaches to Decrease Stigma of Substance Use Disorders in order to Facilitate Prevention, Treatment, and Support During Recovery (R43/R44 - Clinical Trials Optional)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-21-016	26-Jan-2021 [Optional][LOI/Pre-App]	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Julia Berzhanskaya, PhD</p> <p>Contact Telephone 301-594-6140</p> <p>Contact Email julia.berzhanskaya@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 26-Jan-2021 [Optional][LOI/Pre-App], 26-Feb-2021</p> <p>Synopsis The purpose of this Funding Opportunity Announcement is to support research applications for commercializable products aimed at reducing stigma around substance use disorders (SUD). Phase I applications are invited to develop and evaluate feasibility of novel digital technologies, services or other interventions to reduce stigma towards SUD in clinical care, including HIV prevention and care settings, clinical training and other relevant settings, and to establish methods to measure stigma reduction. Phase II applications are invited to demonstrate efficacy in decreasing stigma towards SUD and commercialization potential of these products in clinical care, training, and/or other relevant settings, including those providing HIV prevention and care with the goal to remove barriers to SUD prevention, treatment, and support during recovery. Phase II applications focused on HIV prevention and care settings are invited to demonstrate efficacy in decreasing stigma towards SUD and improving health outcomes for people living with HIV and SUD.</p>				
101411	<p>RFA-DA-21-041 -- Leveraging Big Data Science to Elucidate the Mechanisms of HIV Activity and Interaction with Substance Use Disorder (R21 - Clinical Trials Not Allowed)</p>	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-21-041	10-Jan-2021 [Optional][LOI/Pre-App]	275,000 USD
	<p>Contact Name Susan Wright, Ph.D.</p> <p>Contact Telephone 301-402-6683</p> <p>Contact Email susan.wright@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 09-Feb-2021</p> <p>Synopsis The purpose of this FOA is to attract data and computational scientists to propose novel ways to integrate data of different types and scales to allow new types of analysis through big data science approaches. It is expected that the development and application of novel computational, bioinformatics, statistical, and analytical approaches can be leveraged to reveal the effects of the interaction of the HIV virus and drugs of abuse on viral activity, latency, and disease progression, as well as new aspects of addiction biology.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
101410	RFA-DA-21-040 -- Leveraging Big Data Science to Elucidate the Mechanisms of HIV Activity and Interaction with Substance Use Disorder (R01 - Clinical Trials Not Allowed)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-21-040	10-Jan-2021 [Optional][LOI/Pre-App]	1,750,000 USD
	<p>Contact Name Susan Wright, Ph.D.</p> <p>Contact Telephone 301-402-6683</p> <p>Contact Email susan.wright@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 09-Feb-2021</p> <p>Synopsis The purpose of this FOA is to attract data and computational scientists to propose novel ways to integrate data of different types and scales to allow new types of analysis through big data science approaches. It is expected that the development and application of novel computational, bioinformatics, statistical, and analytical approaches can be leveraged to reveal the effects of the interaction of the HIV virus and drugs of abuse on viral activity, latency, and disease progression, as well as new aspects of addiction biology.</p>				
074542	Development and Testing of Novel Interventions to Improve HIV Prevention, Care, and Program Implementation (R34-Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PA-18-780	16-Feb-2021	450,000 USD
	<p>Contact Name Richard A. Jenkins, PhD</p> <p>Contact Telephone 301-443-1923</p> <p>Contact Email jenkinsri@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 07-May-2021</p> <p>Synopsis National Institute on Drug Abuse (NIDA) invites applications for formative research, intervention development, and pilot-testing of interventions. Primary scientific areas of focus include the feasibility, tolerability, acceptability and safety of novel or adapted interventions that target HIV prevention, treatment or services research. For the purposes of this FOA, "intervention" may include behavioral, social, or structural approaches, as well as combination biomedical and behavioral approaches that prevent the acquisition and transmission of HIV infection, or improve clinical outcomes for persons who are HIV infected. This FOA will use the NIH R34 Planning Grant award mechanism.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
071560	Women & Sex/Gender Differences in Drug and Alcohol Abuse/Dependence (R21 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PA-18-602	16-Feb-2021	275,000 USD
	<p>Contact Name Cora Lee Wetherington, Ph.D.</p> <p>Contact Telephone 301-435-1319</p> <p>Contact Email cwetheri@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 07-May-2021</p> <p>Synopsis National Institute on Drug Abuse (NIDA) and National Institute on Alcohol Abuse and Alcoholism (NIAAA) invite applications to (1) advance identification of male-female differences in drug and alcohol research outcomes, to uncover the mechanisms of those differences, and to conduct translational research on those differences, and (2) to advance research specific to women or highly relevant to women. Both preclinical and clinical studies are sought across all areas of drug and alcohol research. This FOA will use the NIH R21 Exploratory/Developmental Grant award mechanism.</p>				
071562	Women & Sex/Gender Differences in Drug and Alcohol Abuse/Dependence (R03 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PA-18-601	16-Feb-2021	100,000 USD
	<p>Contact Name Cora Lee Wetherington, Ph.D.</p> <p>Contact Telephone 301-435-1319</p> <p>Contact Email cwetheri@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 07-May-2021</p> <p>Synopsis National Institute on Drug Abuse (NIDA) and National Institute on Alcohol Abuse and Alcoholism (NIAAA) invite applications to (1) advance identification of male-female differences in drug and alcohol research outcomes, to uncover the mechanisms of those differences, and to conduct translational research on those differences, and (2) to advance research specific to women or highly relevant to women. Both preclinical and clinical studies are sought across all areas of drug and alcohol research. This FOA will use the NIH R03 Small Grant Program award mechanism.</p>				
071556	Women & Sex/Gender Differences in Drug and Alcohol Abuse/Dependence (R01 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PA-18-603	05-Feb-2021	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Cora Lee Wetherington, Ph.D.</p> <p>Contact Telephone 301-435-1319</p> <p>Contact Email cwetheri@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021</p> <p>Synopsis National Institute on Drug Abuse (NIDA) and National Institute on Alcohol Abuse and Alcoholism (NIAAA) invite applications to (1) advance identification of male-female differences in drug and alcohol research outcomes, to uncover the mechanisms of those differences, and to conduct translational research on those differences, and (2) to advance research specific to women or highly relevant to women. Both preclinical and clinical studies are sought across all areas of drug and alcohol research. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
077321	Developing the Therapeutic Potential of the Endocannabinoid System for Pain Treatment (R01 - Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PA-18-917	05-Feb-2021	Not Specified
	<p>Contact Name David Thomas, PhD</p> <p>Contact Telephone 301-435-1313</p> <p>Contact Email dthomas1@nida.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021</p> <p>Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for projects that will elucidate the therapeutic potential of the cannabinoids and endocannabinoid system in the development of mechanism-based therapies for pain. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
077343	Imaging - Science Track Award for Research Transition (I/START) (R03 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PAR-18-918	16-Feb-2021	150,000 USD
	<p>Contact Name Steven Grant, Ph.D.</p> <p>Contact Telephone 301-443-4877</p> <p>Contact Email sgrant@nida.nih.gov</p> <p>Sponsor Website </p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021</p> <p>Synopsis National Institute on Drug Abuse (NIDA) and National Institute of Biomedical Imaging and Bioengineering (NIBIB) invite applications to facilitate the entry of investigators to the area of neuroimaging, including both new investigators and established investigators seeking to adopt neuroimaging methodologies in their research programs, to enable the conduct of small "proof of concept" studies. The R03 is intended to support research projects that can be carried out in a short period of time with limited resources. This program will use the NIH Small Research Grant (R03) award mechanism.</p>				
094123	Substance Use/Substance Use Disorder Dissertation Research Award (R36 - Clinical Trials Optional)	National Institute on Drug Abuse/NIH/DHHS	PA-20-208	16-Feb-2021	100,000 USD
	<p>Contact Name Aria Crump, Sc.D.</p> <p>Contact Telephone 301-435-0881</p> <p>Contact Email acrump@nida.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023</p> <p>Synopsis The goal of this FOA is to support doctoral candidates from a variety of academic disciplines for up to two years for the completion of the doctoral dissertation research project. Research projects should align with NIDA funding priorities detailed here (https://www.drugabuse.gov/funding/funding-priorities) or within the NIDA Strategic Plan (https://www.drugabuse.gov/about-nida/2016-2020-nida-strategic-plan). This award will facilitate the entry of promising new investigators into the field of substance use/substance use disorder (SU(D) research, enhancing the pool of highly talented SU(D) researchers. Applications are particularly encouraged from those who can contribute to diversifying the research workforce as described in the Notice of NIH's Interest in Diversity (NOT-OD-20-031).</p>				
074442	International Research Collaboration on Drug Abuse and Addiction Research (R01 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PA-18-773	05-Feb-2021	Not Specified
	<p>Contact Name Steven Gust, Ph.D., Director</p> <p>Contact Telephone 301-443-6480</p> <p>Contact Email ipdirector@nida.nih.gov</p> <p>Sponsor Website</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021</p> <p>Synopsis National Institute on Drug Abuse (NIDA) solicits collaborative research applications on drug abuse and addiction that: Take advantage of unusual opportunities that exist outside the United States to access talent, resources, populations, or environmental conditions in other countries that will speed scientific discovery; Describe how the research will significantly advance U.S. health sciences; Demonstrate specific relevance to the NIDA mission and objectives. To determine whether your research plan is relevant to the NIDA mission and objectives, review the NIDA Strategic Plan (https://www.drugabuse.gov/about-nida/2016-2020-nida-strategic-plan). Where feasible, applications should address NIDA's international scientific priority areas (https://www.drugabuse.gov/international/research-priorities); and Include an investigator from a U.S. institution and a non-U.S. citizen partner living and working in another country. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
074449	Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R34 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PA-18-774	16-Feb-2021	450,000 USD
	<p>Contact Name Sarah Q. Duffy, Ph.D.</p> <p>Contact Telephone 301-451- 4998</p> <p>Contact Email duffys@nida.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 07-May-2021</p> <p>Synopsis National Institute on Drug Abuse (NIDA) and National Institute on Alcohol Abuse and Alcoholism (NIAAA) invite applications for pilot and preliminary research in preparation for larger-scale services research effectiveness trials. Relevant trials may test a wide range of approaches, including interventions, practices, and policies designed to optimize access to, and the quality, effectiveness, affordability and utilization of drug, tobacco, or alcohol use disorder treatments and related services, as well as services for comorbid medical and mental disorder conditions. Relevant approaches may include both those that are novel, and those that are commonly used in practice but lack an evidence base. This FOA provides resources for assessing the feasibility, acceptability, and utility of these approaches, in addition to usual trial preparation activities. This FOA will use the NIH R34 Planning Grant grant mechanism.</p>				
079379	Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study	National Institute on Drug Abuse/NIH/DHHS	PAR-19-162	05-Feb-2021	1,250,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

[\(R01-Clinical Trial Not Allowed\)](#)

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Karen Sirocco 301-451-8661 siroccok@nida.nih.gov Link to program URL 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 The Adolescent Brain Cognitive Development (ABCD) Study is collecting data on health and mental health, cognitive function, substance use, cultural and environmental factors, and brain structure and function from youth starting when they are 9-10 years-old and following them longitudinally to early adulthood. These data will be made available to the scientific community through the NIMH Data Archive. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications proposing the analysis of this public use dataset to increase knowledge of adolescent health and development. More information about the ABCD Study may be found on the ABCD Study web page (www.abcdstudy.org).
--	--

085474	Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PAR-19-368	05-Feb-2021	2,499,995 USD
--------	--	---	------------	-------------	---------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Marsha F. Lopez, Ph.D., M.H.S. 301-443-6504 marsha.lopez@nih.gov Link to program URL 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of substance using behaviors (defined as alcohol, tobacco, prescription and other substances) and related disorders, prevention of substance use and HIV, and health service utilization. This FOA encourages the analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology, trajectories of substance using behaviors and their consequences including morbidity and mortality, risk and resilience in the development of psychopathology, strategies to guide the development, testing, implementation, and delivery of high quality, effective and efficient services for the prevention and treatment of substance use disorder and HIV.
--	--

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
090993	NIDA Small Research Grant Program (R03 Clinical Trial Required)	National Institute on Drug Abuse/NIH/DHHS	PA-20-146	16-Feb-2021	100,000 USD
	<p>Contact Name Katrina L Foster, PhD</p> <p>Contact Telephone 301-827-5815</p> <p>Contact Email fosterkl@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023</p> <p>Synopsis The NIDA Small Research Grant Program supports small clinical trials that can be carried out in a short period of time with limited resources. This program supports different types of projects including pilot, feasibility, or small clinical trials with medications, behavioral interventions, immunotherapies, therapeutic devices, therapeutic digital applications, health services, prevention interventions, biomarkers, and development of research methodology. This Funding Opportunity Announcement requires that a clinical trial be proposed. The proposed project must be related to the programmatic interests of NIDA.</p>				
079380	Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R21-Clinical Trial Not Allowed)	National Institute on Drug Abuse/NIH/DHHS	PAR-19-163	16-Feb-2021	275,000 USD
	<p>Contact Name Karen Sirocco</p> <p>Contact Telephone 301-451-8661</p> <p>Contact Email siroccok@nida.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021</p> <p>Synopsis The Adolescent Brain Cognitive Development (ABCD) Study is collecting data on health and mental health, cognitive function, substance use, cultural and environmental factors, and brain structure and function from youth starting when they are 9-10 years-old and following them longitudinally to early adulthood. These data will be made available to the scientific community through the NIMH Data Archive. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications proposing the analysis of this public use dataset to increase knowledge of adolescent health and development. More</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
information about the ABCD Study may be found on the ABCD Study web page (www.abcdstudy.org).					
083682	Behavioral Science Track Award for Rapid Transition (B/Start)(R03 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PAR-19-310	16-Feb-2021	75,000 USD
	Contact Name	Holly Moore, Ph.D.			
	Contact Telephone	301-827-7376			
	Contact Email	holly.moore@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022			
	Synopsis	This Funding Opportunity from the National Institute on Drug Abuse (NIDA) will use a NIH Small Research Grant (R03) award mechanism to support studies that apply affective, cognitive and behavioral science approaches to research questions relevant to substance use disorders (SUD). With this R03 mechanism, NIDA aims to seed innovative affective, cognitive and behavioral hypotheses, models, and methods in preclinical and clinical SUD research. The B/START R03 is intended for recently-independent investigators with expertise in behavioral science as well as established investigators who are using behavioral science approaches to SUD for the first time. Studies supported by B/START are expected to produce a coherent set of preliminary findings that would inform the design of a more complete study and serve as preliminary data supporting feasibility or scientific rationale in an R01, R21 or similar application.			
100294	Notice of Special Interest (NOSI): Neuroimmune Signaling and Function in Substance Use Disorders	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-20-046	05-Feb-2021	Not Specified
	Contact Name	Roger G Sorensen, Ph.D., MPA			
	Contact Telephone	301-443-3205			
	Contact Email	rsorensen@nida.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Feb-2021 , 16-Feb-2021 , 25-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 25-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 25-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 25-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 25-Jun-2022 , 01-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 25-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 25-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 25-Jun-2023 , 07-Sep-2023			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The purpose of this notice is to encourage research project submissions examining the role of neuroimmune signaling in the CNS in relation to: the trajectory (i.e. initiation, escalation, and maintenance) of drug misuse; consequences of chronic exposure to misused drugs; abstinence and withdrawal from prolonged use; and relapse or reinstatement of drug taking at molecular, cellular, circuit, or behavioral levels.			
100467	Notice of Special Interest (NOSI): Effects of Smoking and Vaping on the Risk and Outcome of COVID-19 Infection	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-20-084	05-Feb-2021	Not Specified
	Contact Name	Raul Mandler, MD; FAAN; FANA			
	Contact Telephone	301-480-2541			
	Contact Email	mandlerr@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Feb-2021 , 16-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 07-Sep-2024			
	Synopsis	The purpose of this notice is to communicate NIDA's interest in supporting research on the effects of smoking or vaping tobacco or marijuana on the risk of acquiring COVID-19 and the clinical course of the infection.			
091370	NIMHD Exploratory/Developmental Research Grant Program (R21 - Clinical Trial Optional)	National Institute on Minority Health and Health Disparities/NIH/DHHS	PAR-20-150	16-Feb-2021	275,000 USD
	Contact Name				
	Contact Telephone	301-402-1366			
	Contact Email	GrantsInfo@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023			
	Synopsis	NIMHD invites applications to support short-term exploratory or developmental research projects that have the potential to			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

break new ground in the fields of minority health and/or health disparities or extend previous discoveries toward new directions or applications that can directly contribute to improving minority health and/or reducing health disparities in the U.S.

097934	Notice of Special Interest (NOSI): Comprehensive Care for Adults with Type 2 Diabetes Mellitus from Health Disparity Populations	National Institute on Minority Health and Health Disparities/NIH/DHHS	NOT-MD-20-026	05-Feb-2021	Not Specified
--------	--	---	---------------	-------------	---------------

Contact Name	Larissa Aviles-Santa, MD, MPH
Contact Telephone	301-827-6924
Contact Email	avilessantal@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Feb-2021 , 07-May-2021
Synopsis	The purpose of this Notice of Special Interest is to support multidisciplinary, investigative and collaborative research focused on developing and testing multi-level strategies to effectively implement recommended guidelines of comprehensive clinical care for individuals with Type 2 diabetes from health disparity populations.

100050	Notice of Special Interest (NOSI): Research on Rehabilitation Needs Associated with the COVID-19	National Institutes of Health/DHHS	NOT-HD-20-031	05-Feb-2021	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name	Theresa Cruz, PhD.
Contact Telephone	301-496-9233
Contact Email	cruzth@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Feb-2021 , 16-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023
Synopsis	The purpose of this Notice of Special Interest is to encourage applications in three areas related to the intersection of COVID-19, the associated mitigation actions, and rehabilitation: Encourage research to address the rehabilitation needs of survivors of COVID-19 Understand the impact of disruptions to rehabilitation services caused by the COVID-19 pandemic and

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		associated mitigation actions Understand the social, behavioral, economic, and health impact of the COVID-19 pandemic and the associated mitigation actions on people with physical disabilities Research applications addressing these topics are considered responsive; not all topics are expected within the same application. Applications will be directed to the National Center for Medical Rehabilitation Research (NCMRR) at NICHD.			
080193	Microbial-based Cancer Therapy -Bugs as Drugs (R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-19-193	05-Feb-2021	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Avi Rasooly, PhD 240-276-6196 rasoolya@mail.nih.gov Link to program URL 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022			
	Synopsis	The overall purpose of this funding opportunity announcement (FOA) is to stimulate the development of novel microbial-based cancer therapies, especially for conditions where conventional cancer therapies are inadequate, such as poorly vascularized, hypoxic, solid tumors, dormant or slowly dividing cells resistant to current interventions, and brain tumors. Utilizing bacteria, archaeobacteria, bacteriophages and other non-virus microorganisms, this initiative will support research projects designed to study the underlying mechanisms of the complex interactions between microorganisms, tumor, and immune system. The FOA also aims to support research into the use of microorganisms as delivery vehicles for cancer treatment and to complement or synergize with current therapies. This FOA will accept basic mechanistic and preclinical studies in cell culture and animal models in accordance with the state of the science. Applicants applying to this FOA are encouraged to address both the microbial and the tumor aspects of microbial-based cancer therapy. Complex microbial-tumor interactions are best addressed with a team approach. The purpose of this FOA is to encourage basic or applied, multidisciplinary research collaborations between investigators from areas relevant to microbial-based cancer therapy, such as microbiology, oncology, immunology, and cellular and molecular cancer biology. The proposed projects should be state of the art and aim to advance pre-clinical development of novel microbial-based anticancer therapeutic agents, or study the complex biology involved in the interplay of microbe-tumor-immune system. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research, and should apply an integrative approach to increase our understanding of biological, or translational aspects of microbial-based anticancer therapeutic agents.			
096053	Behavioral Tasks Targeting Brain Systems Relevant to Anhedonia (R01 Basic Experimental Studies with Humans Required)	National Institutes of Health/DHHS	PAR-20-235	05-Feb-2021	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Andrew Rossi</p> <p>Contact Telephone 301-443-1576</p> <p>Contact Email rossia@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages research to develop task-based behavioral measures that are shown to engage brain systems relevant to anhedonia using neuroimaging or other brain measures with similar spatial resolution. The goal is to identify behavioral tasks that can be used as quantitative tools in future studies of the functional constructs associated with anhedonia and in treatment development. This FOA is for basic science experimental studies involving human participants that fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of brain function in healthy individuals or those with disorders. These mechanistic studies are expected to be appropriate for the Basic Experimental Studies With Humans (BESH) FOAs https://grants.nih.gov/grants/guide/notice-files/NOT-MH-19-006.html since they are not intended to inform on the improvement of the health status of the individual or a group of individuals either by better understanding the mechanism of action of an intervention or a measurable improvement in health.</p>				
091413	Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-20-155	05-Feb-2021	Not Specified
	<p>Contact Name Christopher M. Hartshorn, Ph.D.</p> <p>Contact Telephone 240-781-3315</p> <p>Contact Email christopher.hartshorn@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to stimulate translation of scientific discoveries and engineering developments in imaging, data science and/or spectroscopic technologies into methods or tools that address contemporary problems in understanding the fundamental biology, potential risk of development, diagnosis, treatment,</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

and/or disease status for cancer or other disease. A distinguishing feature of each application to this FOA will be formation of an academic-industrial partnership: a strategic alliance of academic and industrial investigators who work together as partners to identify and translate a technological solution for mitigation of a cancer (or other disease-related) problem. In this sense, the FOA acts more as funding mechanism for driving translational research in imaging more than for a specific scientific or clinical research area. These partnerships are expected to solidify pre-existing collaborations or new ones that would drive the field of imaging, as a whole, further than if they had not been formed. This FOA defines innovation as likelihood to deliver a new capability to end users. This FOA will support clinical trials that test functionality, or validate performance in the chosen setting. This FOA is not intended to support commercial production, basic research projects, or clinical trials that lack translation as the primary motivation.

098071	Notice of Special Interest (NOSI): Simulation Modeling and Systems Science to Address Health Disparities	National Institutes of Health/DHHS	NOT-MD-20-025	05-Feb-2021	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name	Rada Dagher, Ph.D., M.P.H.
Contact Telephone	301-451-2187
Contact Email	rada.dagher@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023
Synopsis	The purpose of this Notice of Special Interest is to support investigative and collaborative research focused on developing and evaluating simulation modeling and systems science to understand and address minority health and health disparities.

091506	Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-20-157	05-Feb-2021	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name	Jovier D. Evans, PhD
Contact Telephone	301-443-1369
Contact Email	jevans1@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023
Synopsis	The goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies that will enhance

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). The findings are expected to advance mechanistic understanding of both biobehavioral and neurobiological pathways leading to NPS. Findings may also provide insight into novel therapeutic targets that can be advanced into interventions to treat and prevent the development of NPS in AD and/or ADRD. This FOA uses the R01 mechanism, while the companion announcement PAR-20-159 uses the R21 mechanism. High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism.</p>				
099871	RFA-MH-20-556 -- BRAIN Initiative: Pilot Resources for Brain Cell Type-Specific Access and Manipulation Across Vertebrate Species (U01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-MH-20-556	12-Jan-2021 [Optional][LOI/Pre-App]	Not Specified
	<p>Contact Name: Douglas S. Kim, Ph.D. Contact Telephone: 301-827-6463 Contact Email: douglas.kim@nih.gov Sponsor Website: Program URL: Link to program URL Deadline Dates (ALL): 12-Jan-2021 [Optional][LOI/Pre-App], 11-Feb-2021 , 19-Sep-2021 [Optional][LOI/Pre-App], 19-Oct-2021</p>				
	<p>Synopsis: This Funding Opportunity Announcement (FOA) from the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is intended to support the development of technologies, production efforts, and dissemination resources for a cell type-specific armamentarium to study brain function across species. The goal is to promote evaluation of molecular or genetic technologies and creation of pilot production and distribution resources for cell type-specific access and manipulation reagents for several vertebrate species, including in human ex vivo tissues or cells. Demonstration projects are sought that would develop reagents that: (1) enable access to molecularly defined neural cell types in a complex brain region or significant brain network of a vertebrate; (2) are easily produced, disseminated, utilized, and stored; and (3) are catalogued for users in a brain atlas. In addition to the above required features, reagents are also sought that exhibit the following qualities: (4) are applicable to both genetically tractable and less tractable vertebrate organisms; (5) exhibit high specificity and efficiency of targeting; (6) show low toxic or perturbative effects; (7) provide flexibility to deliver various reporter, sensor, and effector payloads and are compatible with other methods of access to brain cell types; and (8) are potentially usable in human ex vivo brain tissue or cells. The pilot projects should be scalable in the future. The long-term goal of a potentially scaled-up effort is to achieve near comprehensive, molecular access for monitoring and manipulation reagents in each defined cell type of vertebrate brains relevant to neuroscience research.</p>				
094931	NCCIH Natural Product Early Phase Clinical Trial Award (R33)	National Institutes of	PAR-20-217	01-Feb-2021	1,050,000

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Clinical Trial Required	Health/DHHS			USD
	<p>Contact Name Wendy Weber, N.D., Ph.D, M.P.H.</p> <p>Contact Telephone 301-402-1272</p> <p>Contact Email weberwj@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Feb-2021 , 07-May-2021 , 01-Oct-2021 , 07-Jan-2022 , 01-Jun-2022 , 07-Sep-2022 , 01-Feb-2023 , 07-May-2023</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages applications for investigator-initiated, early phase, clinical trials of natural products (i.e., botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. This FOA will provide up to 3 years support for studies to replicate the impact of the natural product on the biological signature(s) when used by humans and assess whether there is an association between the degree of the impact on the biological signature and functional or clinical outcomes in a patient population. Applications are encouraged to design studies to determine how to optimize the impact of the natural product on the biological signature by optimizing the delivery of the natural product by examining different doses or formulations. In addition, applications can be designed to combine the natural product with another treatment approach that is known to impact the same biological signature; or study the impact of the natural product in a target population that is more responsive. Clinical trials submitted under this FOA are expected to be hypothesis based, milestone-driven, and directly related to the research priorities and mission of NCCIH. This R33 funding mechanism is intended to accelerate the translation of emerging basic science findings about natural products into early stage clinical testing to determine whether continued clinical research is warranted. This FOA will not support efficacy or effectiveness trials, nor will it support trials to test natural products for the treatment or prevention of cancer.</p>				
089925	Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-20-111	09-Feb-2021	Not Specified
	<p>Contact Name Charles Cywin, PhD</p> <p>Contact Telephone 301-496-1779</p> <p>Contact Email charles.cywin@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 09-Feb-2021 , 09-Feb-2021 , 10-Aug-2021 , 10-Aug-2021 , 09-Feb-2022 , 09-Feb-2022 , 09-Aug-2022 , 09-Aug-2022 , 09-Feb-2023 , 09-Feb-2023</p> <p>Synopsis The Blueprint Neurotherapeutics Network (BPN) encourages applications from small businesses seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry to the Development stage, to advance a single development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Alternatively, projects can enter at the Development stage and progress in a shorter period to IND enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.</p>				
089937	Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-20-122	09-Feb-2021	Not Specified
	<p>Contact Name Charles Cywin, PhD</p> <p>Contact Telephone 301-496-1779</p> <p>Contact Email charles.cywin@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 09-Feb-2021 , 09-Feb-2021 , 10-Aug-2021 , 10-Aug-2021 , 09-Feb-2022 , 09-Feb-2022 , 09-Aug-2022 , 09-Aug-2022 , 09-Feb-2023 , 09-Feb-2023</p> <p>Synopsis The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
094932	NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)	National Institutes of Health/DHHS	PAR-20-218	01-Feb-2021	1,750,000 USD

Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry to the Development stage, to advance a single development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Alternatively, projects can enter at the Development stage and progress in a shorter period to IND enabling toxicology studies and phase I clinical testing. BPN awardee Institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.

Contact Name	Wendy Weber, N.D., Ph.D, M.P.H.
Contact Telephone	301-402-1272
Contact Email	weberwj@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	01-Feb-2021 , 07-May-2021 , 01-Oct-2021 , 07-Jan-2022 , 01-Jun-2022 , 07-Sep-2022 , 01-Feb-2023 , 07-May-2023
Synopsis	<p>This Funding Opportunity Announcement (FOA) encourages applications for investigator-initiated, early phase, clinical trials of natural products (i.e., botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. This FOA will provide up to three years (R61 phase) of support for milestone-driven testing of pharmacokinetics, bioavailability, and assessment of the natural product's effect (i.e., measure of mechanism of action) when used by humans on a biological signature(s). If milestones in the R61 phase are achieved, up to 3 years of additional support (R33 phase) may be awarded to replicate the impact of the natural product on the biological signature(s) when used by humans and assess whether there is an association between the degree of the impact on the biological signature and functional or clinical outcomes in a patient population. Applications are encouraged to design R33 studies to determine how to optimize the impact of the natural product on the biological signature by optimizing the delivery of the natural product by examining different doses or formulation. In addition, applications can be designed to combine the natural product with another treatment approach that is known to impact the same biological signature; or study the impact of the natural product in a target population that is more responsive. Clinical trials submitted under this FOA are expected to be hypothesis based, milestone-driven, and directly related to the research priorities and mission of NCCIH. This R61/R33 funding mechanism is intended to accelerate the translation of emerging basic science findings about natural products into early-stage clinical testing to determine whether continued clinical research is warranted. This FOA will not support efficacy or effectiveness</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>trials, nor will it support trials to test natural products for the treatment or prevention of cancer. A maximum of 5 years will be supported by the two phases of the R61/R33 award. Applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this FOA.</p>			
100289	Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-21-029	05-Feb-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Enrique L. Michelotti, Ph.D.</p> <p>301-443 5415</p> <p>michelottiel@mail.nih.gov</p> <p></p> <p>Link to program URL</p> <p>05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024</p> <p>The purpose of this Funding Opportunity Announcement (FOA) is to support investigators who have interest and capability to join efforts for the discovery of in vivo chemical probes for novel brain targets. It is expected that applicants will have, in hand, the starting compounds (“validated hits”) for chemical optimization and bioassays for testing new analog compounds. Through this FOA, NIH wishes to stimulate research in 1) discovery and development of novel, small molecules for their potential use in understanding biological processes relevant to the missions of NIMH, NIDA, NEI, and/or NIA and 2) discovery and/or validation of novel, biological targets that will inform studies of brain disease mechanisms. Emphasis will be placed on projects that provide new insight into important disease-related biological targets and biological processes. The main emphasis of projects submitted under this FOA should be the discovery of in vivo chemical probes. Applicants interested in developing cell-based chemical probes may wish to apply using the companion R21 mechanism, (PAR-21-028).</p>			
100292	Discovery of Cell-based Chemical Probes for Novel Brain Targets (R21 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-21-028	16-Feb-2021	275,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p>	<p>Enrique L. Michelotti, Ph.D.</p> <p>301-443 5415</p> <p>michelottiel@mail.nih.gov</p> <p></p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023 , 16-Feb-2023 , 07-May-2023 , 16-Jun-2023 , 07-Sep-2023 , 16-Oct-2023 , 07-Jan-2024</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support investigators who have interest and capability to join efforts for the discovery of cell-based chemical probes for novel brain targets. It is expected that applicants will have, in hand, the starting compounds (“validated hits”) for chemical optimization and bioassays for testing new analog compounds. Through this FOA, NIH wishes to stimulate research in: 1) discovery and development of novel, small molecules for their potential use in understanding biological processes relevant to the missions of NIMH, NIDA, NEI and/or NIA; and 2) discovery and/or validation of novel, biological targets that will inform studies of brain disease mechanisms. Emphasis will be placed on projects that provide new insight into important disease-related biological targets and biological processes. The main emphasis of projects submitted under this FOA should be the discovery of cell-based chemical probes. Applicants interested in developing in vivo chemical probes may wish to apply using the companion R01 mechanism, (PAR-21-029).</p>				
081385	<p>RFA-MH-20-120 -- BRAIN Initiative: Secondary Analysis and Archiving of BRAIN Initiative Data (R01 Clinical Trial Not Allowed)</p>	National Institutes of Health/DHHS	RFA-MH-20-120	27-Jan-2021 [Optional][LOI/Pre-App]	900,000 USD
	<p>Contact Name Ming Zhan, Ph.D.</p> <p>Contact Telephone 301-827-3678</p> <p>Contact Email ming.zhan@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 27-Jan-2021 [Optional][LOI/Pre-App], 26-Feb-2021</p> <p>Synopsis The BRAIN Initiative and the neuroscience field as a whole are generating massive and diverse research data across different modalities, spatiotemporal scales and species in efforts to advance our understanding of the brain. The data types are being produced through development and application of innovative technologies in high-throughput -omics profiling, optical microscopy, electron microscopy, electrophysiological recording, macroscale neuroimaging, neuromodulation, and others. The BRAIN Initiative has made significant investments in the development of an infrastructure to make data available to the research community in a useful way. This infrastructure includes data archives, data standards, and software for data integration, analysis and machine learning. This Funding Opportunity Announcement (FOA) encourages secondary analysis of the large amounts of existing data related to the BRAIN Initiative. The data do not need to be held in one of the funded</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

BRAIN Initiative data archives, but the data must be held in a data archive that is readily accessible to the research community. Support will be provided for innovative analysis of relevant existing datasets using conventional or novel analytic methods, data science techniques, and machine learning approaches. Support may also be requested to prepare and submit existing data into any of the BRAIN Initiative data archives. Investigators should not underestimate the time and effort that may be necessary to curate or harmonize data. Analyzed data, models and analytical tools generated under this FOA are expected to be deposited into an appropriate data archive. Since the BRAIN Initiative data archives are mostly making the data available to the research community through cloud-based storage, depositing the analyzed data, models and tools are expected to enhance opportunities to create a data sandbox where investigators can easily compare the results of their analysis with those from other research groups. The goal of this FOA is to promote studies that will significantly advance new discoveries and accelerate the pace of research of the BRAIN Initiative through harnessing the big data and machine learning opportunities. Awardees are expected to enhance the value of existing data, improve the overall data integration and analysis capability, and strengthen the statistical power and rigor and reproducibility of BRAIN Initiative related data.

100758	Notice of Special Interest (NOSI): Academy of Finland (AKA) – National Institutes of Health (NIH) Partnership Program	National Institutes of Health/DHHS	NOT-OD-21-021	05-Feb-2021	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

Contact Name	Sarah Scharf, MPA
Contact Telephone	301-496-4784
Contact Email	sarah.scharf@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024
Synopsis	The purpose of this Notice of Special Interest (NOSI) is to alert the community about this opportunity and disseminate knowledge and information on a program designed to foster the expansion of U.S.-Finland biomedical and behavioral research collaboration.

100331	Notice of Special Interest (NOSI): Encourage Eligible NIH HEAL Initiative Awardees to Apply for PA-20-222: Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)	National Institutes of Health/DHHS		15-Feb-2021	Not Specified
--------	---	------------------------------------	--	-------------	---------------

Contact Name	Eric M. Hudak, PhD
--------------	--------------------

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 301-496-1779</p> <p>Contact Email eric.hudak@nih.gov</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL) 15-Feb-2021 , 15-May-2021 , 15-Nov-2021 , 15-Feb-2022 , 15-May-2022 , 15-Nov-2022 , 15-Feb-2023 , 15-May-2023 , 15-Nov-2023 , 15-Feb-2024 , 15-May-2024</p> <p>Synopsis The NIH has a strong interest in the diversity of the NIH-funded research enterprise (see NIH notice NOT-OD-20-031) and encourages institutions to diversify their scientific workforce by increasing the participation of individuals from groups identified as underrepresented in the biomedical, clinical, behavioral, and social sciences. Participating institutes continue to support these efforts through ongoing programs and supplement funding opportunities. This specific notice reiterates this interest and encourages eligible grant and cooperative agreement awardees in the HEAL Initiative community to apply for administrative supplements in response to PA-20-222 (or any subsequent reissuances), Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed). This notice is part of the NIH's Helping to End Addiction Long-term (HEAL) Initiative to speed scientific solutions to the national opioid public health crisis. The NIH HEAL Initiative is a trans-NIH effort to (1) improve prevention and treatment strategies for opioid misuse and addiction and (2) enhance pain management. More information about the HEAL Initiative is available at: https://heal.nih.gov/.</p>				
100734	<p>Exploring the Scientific Value of Existing or New Sepsis Human Biospecimen Collections (R21/R33 - Clinical Trial Not Allowed)</p>	National Institutes of Health/DHHS	PAR-21-077	16-Feb-2021	Not Specified
	<p>Contact Name Xiaoli Zhao, Ph.D.</p> <p>Contact Telephone</p> <p>Contact Email xiaoli.zhao@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022 , 16-Oct-2022</p> <p>Synopsis The purpose of this funding opportunity announcement (FOA) is to support efficient collection, banking, and sharing of biospecimens and associated clinical data from critically ill patients, ultimately for use in mechanistic research on sepsis. The goals of this FOA are to determine the scientific value of existing or newly collected sepsis human biospecimen sets as testbeds for studies on human sepsis and to provide guidance on the best practices for collecting, utilizing, and analyzing human biospecimens, thus maximizing their value for the entire sepsis research community. This FOA invites applicants to submit proof of concept and scale-up studies to determine the scientific value of existing or new collections of human sepsis</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

biospecimens with associated patient health record data. The biospecimens used in this study must be linked to clinical datasets useful for sepsis endotyping/stratification and characterization of disease trajectory, and the use of contemporary cutting-edge technologies in the analysis of these biospecimens is highly encouraged. Studies should focus on: 1) assessment of the utility of existing biospecimen repositories from critically ill and septic patients for future mechanistic research; or 2) development of improved methods for de novo collection and analysis of biospecimens from critically ill patients, ultimately for mechanistic studies of sepsis. The proposed studies should be information-gathering and useful for hypothesis generation; the final results should be data and approaches that can ultimately form the basis for future mechanistic studies and biospecimen collection efforts. Mechanistic studies based on testable hypotheses already formed should be submitted to other opportunities for research grants (e.g., R01 or R35 applications). Applications to solely support novel technology development should be submitted for the Technology Development program. Interventional studies that meet the NIH definition for a clinical trial, or studies including animal models of sepsis, will not be accepted. The FOA will provide support for up to two years (R21 phase) for research planning activities and feasibility studies, followed by the possible transition to up to an two additional years of scaled-up, expanded, or confirmatory research support (R33 phase). Ideally, in the R21 phase, applicants should test new methods for biospecimen acquisition and/or verify the quality of those or existing biospecimens, and identify assays useful for future mechanistic research. The R33 phase should focus on scale-up activities to generate data useable to formulate testable hypotheses of the prediction, development, complexity, and resolution of sepsis in humans. The total project period for an application may not exceed four years. This FOA requires applicant-identified measurable R21 phase milestones, which will be used to determine whether an award transitions to the R33 phase. Transition to the R33 phase is not automatic, and NIGMS anticipates that about half of the funded R21 phase awards may progress to the R33 phase award.

100769	Addressing the Etiology of Health Disparities and Health Advantages Among Immigrant Populations (R01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-21-080	05-Feb-2021	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

Contact Name	Deborah Linares, Ph.D.
Contact Telephone	301-402-2516
Contact Email	deborah.linares@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support innovative research to understand factors

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
					uniquely associated with the immigration experience that contribute to health disparities or health advantages among U.S. immigrant populations.
078037	Innovation Corps (I-Corps™) at NIH Program for NIH and CDC Translational Research (Admin Supp Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PA-19-029	02-Feb-2021	55,000 USD
	<p>Contact Name Christie A. Canaria, Ph.D.</p> <p>Contact Telephone 240-276-5720</p> <p>Contact Email canariaca@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 02-Feb-2021</p> <p>Synopsis Through this I-Corps™ at NIH program Funding Opportunity Announcement (FOA), NIH and CDC provide administrative supplement awards to currently-funded SBIR and STTR Phase I grantees. The I-Corps at NIH program is focused on educating researchers and technologists on how to translate technologies from the lab into the marketplace. The program provides three-member project teams with access to instruction and mentoring in order to accelerate the translation of technologies currently being developed with NIH and CDC SBIR and STTR funding. It is anticipated that outcomes for the I-Corps teams participating in this program will include significantly refined commercialization plans and well-informed pivots in their overall commercialization strategies. Prospective applicants are strongly encouraged to contact Scientific/Research staff for more information about the program before applying.</p>				
100888	RFA-NS-21-005 -- Small Vessel VCID Biomarker Validation Consortium Sites (U01)(Clinical Trials Not Allowed)	National Institutes of Health/DHHS	RFA-NS-21-005	09-Feb-2021 [Optional][LOI/Pre-App]	4,000,000 USD
	<p>Contact Name Roderick A. Corriveau, Ph.D.</p> <p>Contact Telephone 301-496-5680</p> <p>Contact Email roderick.corriveau@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 09-Feb-2021 [Optional][LOI/Pre-App], 09-Mar-2021</p> <p>Synopsis The purpose of this funding opportunity announcement is to invite applications to an open competition to be one of up to 7</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

supported sites in the next phase of the NINDS small vessel vascular contributions to cognitive impairment and dementia (VCID) biomarkers consortium. The original consortium, established under RFA-NS-16-019 and RFA-NS-16-020, pursued initial stages of multi-site validation of 11 candidate imaging-based and fluid-based biomarkers. The primary objective of the next 5 years is to carry out comprehensive multi-site clinical validation of up to six of these 11 biomarkers to be selected by the NINDS in a process separate from this FOA. The focus will be validation in longitudinal studies of diverse all-comers populations that are typical in clinical settings in the United States. The network of sites will provide scientific expertise and experimental infrastructure to pursue these goals synergistically including with the Coordinating Center (RFA-NS-21-004). At the conclusion of clinical validation each biomarker will have a designated category and context of use as defined by the FDA and a finalized public protocol that describes all details needed to utilize the biomarker. The sites will drive the consortium scientifically and contribute administratively to comprehensive rigorous clinical validation of biomarkers for future clinical trials, including in large phase III trials, and for generating scientific breakthroughs in our understanding and treatment of VCID.

100890	RFA-NS-21-004 -- Small Vessel VCID Biomarkers Validation Consortium Coordinating Center (U24 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-NS-21-004	09-Feb-2021 [Optional][LOI/Pre-App]	Not Specified
--------	--	------------------------------------	---------------	--	---------------

Contact Name	Roderick A. Corriveau, Ph.D.
Contact Telephone	301-496-5680
Contact Email	roderick.corriveau@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	09-Feb-2021 [Optional][LOI/Pre-App], 09-Mar-2021

Synopsis
 The purpose of this funding opportunity announcement (FOA) is to have an open competition to support a Coordinating Center for the next phase of the NINDS small vessel vascular contributions to cognitive impairment and dementia (VCID) biomarkers consortium. The original consortium was established under RFA-NS-16-019 and RFA-NS-16-020. The goal of the next phase, under RFA-NS-21-004 (Coordinating Center) and RFA-NS-21-005 (sites), is to complete clinical validation of biomarkers initially developed during the first 5-year funding cycle of this program. The Coordinating Center will consist of: (i) an Administrative Core responsible for organizing, coordinating and administratively driving Consortium activities; and (ii) a Data Core that will coordinate, receive, collect, and share data, including de-identified clinical data. The Coordinating Center will drive the consortium administratively and contribute scientifically to validation of biomarkers with specified context of use for future clinical trials, including in large phase III trials, with general and diverse populations, and for generating scientific breakthroughs in our understanding and treatment of VCID.

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
099865	RFA-NS-21-010 -- HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)	National Institutes of Health/DHHS	RFA-NS-21-010	22-Feb-2021 [Optional][LOI/Pre-App]	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>Michael Oshinsky</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td>301-496-9964</td> </tr> <tr> <td style="padding-right: 5px;">Contact Email</td> <td>michael.oshinsky@nih.gov</td> </tr> <tr> <td style="padding-right: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="padding-right: 5px;">Deadline Dates (ALL)</td> <td>22-Feb-2021 [Optional][LOI/Pre-App], 24-Mar-2021 , 14-Jun-2021 [Optional][LOI/Pre-App], 14-Jul-2021 , 15-Sep-2021 [Optional][LOI/Pre-App], 15-Oct-2021 , 16-Jan-2022 [Optional][LOI/Pre-App], 15-Feb-2022 , 16-May-2022 [Optional][LOI/Pre-App], 15-Jun-2022</td> </tr> <tr> <td style="padding-right: 5px;">Synopsis</td> <td>The purpose of this funding opportunity announcement (FOA) is to support preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics to treat pain. The goal of the program is to accelerate the optimization and development of promising small molecule and biologic hits/leads to Phase I clinical trials and readiness for the Early Phase Pain Investigation Clinical Network (EPPIC-Net) https://heal.nih.gov/research/clinical-research/eppic-net or other Phase II clinical studies. Applicants must have a promising biologic or small molecule hit/lead, robust biological rationale for the intended approach, and identified assays for optimization of the agent. The scope of this program includes optimization and early development activities, IND-enabling studies, development of a pharmacodynamic/target engagement biomarker, assembly and filing of an Investigational New Drug (IND) application and Phase I clinical testing. This is a milestone-driven phased cooperative agreement program involving participation of NIH program staff in the development of the project plan and monitoring of research progress.</td> </tr> </table>					Contact Name	Michael Oshinsky	Contact Telephone	301-496-9964	Contact Email	michael.oshinsky@nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	22-Feb-2021 [Optional][LOI/Pre-App], 24-Mar-2021 , 14-Jun-2021 [Optional][LOI/Pre-App], 14-Jul-2021 , 15-Sep-2021 [Optional][LOI/Pre-App], 15-Oct-2021 , 16-Jan-2022 [Optional][LOI/Pre-App], 15-Feb-2022 , 16-May-2022 [Optional][LOI/Pre-App], 15-Jun-2022	Synopsis	The purpose of this funding opportunity announcement (FOA) is to support preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics to treat pain. The goal of the program is to accelerate the optimization and development of promising small molecule and biologic hits/leads to Phase I clinical trials and readiness for the Early Phase Pain Investigation Clinical Network (EPPIC-Net) https://heal.nih.gov/research/clinical-research/eppic-net or other Phase II clinical studies. Applicants must have a promising biologic or small molecule hit/lead, robust biological rationale for the intended approach, and identified assays for optimization of the agent. The scope of this program includes optimization and early development activities, IND-enabling studies, development of a pharmacodynamic/target engagement biomarker, assembly and filing of an Investigational New Drug (IND) application and Phase I clinical testing. This is a milestone-driven phased cooperative agreement program involving participation of NIH program staff in the development of the project plan and monitoring of research progress.
Contact Name	Michael Oshinsky																		
Contact Telephone	301-496-9964																		
Contact Email	michael.oshinsky@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	22-Feb-2021 [Optional][LOI/Pre-App], 24-Mar-2021 , 14-Jun-2021 [Optional][LOI/Pre-App], 14-Jul-2021 , 15-Sep-2021 [Optional][LOI/Pre-App], 15-Oct-2021 , 16-Jan-2022 [Optional][LOI/Pre-App], 15-Feb-2022 , 16-May-2022 [Optional][LOI/Pre-App], 15-Jun-2022																		
Synopsis	The purpose of this funding opportunity announcement (FOA) is to support preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics to treat pain. The goal of the program is to accelerate the optimization and development of promising small molecule and biologic hits/leads to Phase I clinical trials and readiness for the Early Phase Pain Investigation Clinical Network (EPPIC-Net) https://heal.nih.gov/research/clinical-research/eppic-net or other Phase II clinical studies. Applicants must have a promising biologic or small molecule hit/lead, robust biological rationale for the intended approach, and identified assays for optimization of the agent. The scope of this program includes optimization and early development activities, IND-enabling studies, development of a pharmacodynamic/target engagement biomarker, assembly and filing of an Investigational New Drug (IND) application and Phase I clinical testing. This is a milestone-driven phased cooperative agreement program involving participation of NIH program staff in the development of the project plan and monitoring of research progress.																		
100941	RFA-CA-21-001 -- Small Business Transition Grant For Early Career Scientists (R42 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-CA-21-001	08-Feb-2021 [Optional][LOI/Pre-App]	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>Kory Hallett, Ph.D.</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td>240-276-5882</td> </tr> <tr> <td style="padding-right: 5px;">Contact Email</td> <td>kory.hallett@nih.gov</td> </tr> <tr> <td style="padding-right: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Program URL</td> <td>Link to program URL</td> </tr> </table>					Contact Name	Kory Hallett, Ph.D.	Contact Telephone	240-276-5882	Contact Email	kory.hallett@nih.gov	Sponsor Website		Program URL	Link to program URL				
Contact Name	Kory Hallett, Ph.D.																		
Contact Telephone	240-276-5882																		
Contact Email	kory.hallett@nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Deadline Dates (ALL) | 08-Feb-2021 [Optional][LOI/Pre-App], 10-Mar-2021

Synopsis

The purpose of this Funding Opportunity Announcement (FOA) is to support early career academic scientists interested in transitioning to entrepreneurship while also supporting the transfer of technology from academic laboratories into small businesses. Both small businesses and universities are drivers of technological innovation in the United States (U.S.), often working together to advance innovative ideas into products that can benefit the U.S. population. While most NIH funding supports basic research in university laboratories, the NIH also supports innovative technology development in U.S. small businesses through its SBIR&STTR programs. As technologies transition from academic discovery to small businesses, two common challenges arise, identifying the right team with the right expertise to take the product into a small business, and funding for early stage technology development. This FOA seeks to address both challenges simultaneously by having two equally important goals: entrepreneurial mentoring support, and product development support. This FOA proposes a new and unique Fast-Track only award structure comprised of a Phase I STTR that transitions to a Phase II SBIR. An STTR award is a collaborative award made to small businesses that are working closely with a university. While both SBIR and STTR grants are only awarded to small businesses, the STTR program allows a significant amount of STTR-funded work to be conducted at a partner university site and allows the Principal Investigator (PI) to maintain his or her employment at a university during the phase I period. Therefore, awards made under this FOA will begin as a Phase I STTR to allow the candidate to complete proof of concept studies at the academic site and prepare the technology to move into the small business. After completion of the STTR phase I activities, transition to a Phase II SBIR award will only occur after demonstration that stringent criteria have been met that include a demonstration of ongoing mentoring as well as having achieved technical milestones (more information under Section V. Application Review Information). A key component of the small business transition grant is mentoring. Mentoring is not traditionally a factor in SBIR/STTR funding decisions, however here mentoring is critical to facilitate the transition from junior academic scientist to entrepreneur. Therefore, the mentoring team that supports the candidate will be a critical factor in peer review. The ideal candidate for this small business transition grant is a postdoctoral researcher who participated in technology discovery during their academic work and is now ready to move to a small business with the help of some key mentors and advisors. To be responsive to this FOA, proposed projects MUST pertain to one of the participating Organizations/Institutes listed above, and propose the development of a technology that fits into at least one of the following categories: (1) Therapeutics and Preventative Agents; (2) Imaging Technologies, Interventional Devices, and In Vivo Diagnostics; or (3) In Vitro and Ex Vivo Diagnostics and Prognostics.

088861	RFA-OD-20-010 -- Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 - Independent Clinical Trial Required)	National Institutes of Health/DHHS	RFA-OD-20-010	08-Feb-2021	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

Contact Name | Sergei Radaev, PhD
 Contact Telephone | 240-276-5630

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email sergei.radaev@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Feb-2021 , 09-Aug-2021 [Optional][LOI/Pre-App], 08-Oct-2021 , 09-May-2022 [Optional][LOI/Pre-App], 08-Jul-2022</p> <p>Synopsis The purpose of the Pathway to Independence Award in Tobacco Regulatory Research (K99/R00) is to increase and maintain a strong cohort of new and talented independent investigators conducting research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. This program will provide independent research support during this transition in order to help awardees launch competitive, independent research careers. Research projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP) as mandated by the Family Smoking Prevention and Tobacco Control Act (FSPTCA), Public Law 111-31. The awards under this FOA will be administered by NIH using funds made available through the CTP and the FSPTCA (P.L. 111-31). This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (RFA-OD-20-009).</p>				
088856	RFA-OD-20-009 -- Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 - Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-OD-20-009	08-Feb-2021	Not Specified
	<p>Contact Name Sergei Radaev, PhD</p> <p>Contact Telephone 240-276-5630</p> <p>Contact Email sergei.radaev@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Feb-2021 , 09-Aug-2021 [Optional][LOI/Pre-App], 08-Oct-2021 , 09-May-2022 [Optional][LOI/Pre-App], 08-Jul-2022</p> <p>Synopsis The purpose of the Pathway to Independence Award in Tobacco Regulatory Research (K99/R00) is to increase and maintain a strong cohort of new and talented independent investigators conducting research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing. This program is designed to</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. This program will provide independent NIH research support during this transition in order to help awardees launch competitive, independent research careers. Research projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP) as mandated by the Family Smoking Prevention and Tobacco Control Act (FSPTCA), Public Law 111-31. The awards under this FOA will be administered by NIH using funds made available through the CTP and the FSPTCA (P.L. 111-31). This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (RFA-OD-20-010).</p>				

088855	RFA-OD-20-008 -- Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 - Independent Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-OD-20-008	08-Feb-2021	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

Contact Name	Sergei Radaev, PhD
Contact Telephone	240-276-5630
Contact Email	sergei.radaev@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	08-Feb-2021 , 09-Aug-2021 [Optional][LOI/Pre-App], 08-Oct-2021 , 09-May-2022 [Optional][LOI/Pre-App], 08-Jul-2022
Synopsis	<p>The purpose of the Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01) is to provide support and protected time (three, four, or five years) for an intensive, supervised career development experience in biomedical, behavioral, and social science research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing and that will lead to research independence. Research projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP) as mandated by the Family Smoking Prevention and Tobacco Control Act (FSPTCA), Public Law 111-31. The awards under this FOA will be administered by NIH using funds made available through the CTP and the FSPTCA (P.L. 111-31). This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (RFA-OD-20-</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	011).				
088863	RFA-OD-20-011 -- Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 - Independent Clinical Trial Required)	National Institutes of Health/DHHS	RFA-OD-20-011	08-Feb-2021	Not Specified
	Contact Name	Sergei Radaev, PhD			
	Contact Telephone	240-276-5630			
	Contact Email	sergei.radaev@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	08-Feb-2021 , 09-Aug-2021 [Optional][LOI/Pre-App], 08-Oct-2021 , 09-May-2022 [Optional][LOI/Pre-App], 08-Jul-2022			
	Synopsis	<p>The purpose of the Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01) is to provide support and protected time (three, four, or five years) for an intensive, supervised career development experience in biomedical, behavioral, and social science research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing and that will lead to research independence. Research projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP) as mandated by the Family Smoking Prevention and Tobacco Control Act (FSPTCA), Public Law 111-31. The awards under this FOA will be administered by NIH using funds made available through the CTP and the FSPTCA (P.L. 111-31). This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial or proposing to gain research experience in a clinical trial led by another investigator, must apply to (RFA-OD-20-008).</p>			
092568	Research on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) (R01 Clinical Trials Not Allowed)	National Institutes of Health/DHHS	PAR-20-165	05-Feb-2021	Not Specified
	Contact Name	Vicky Whittemore, PhD			
	Contact Telephone	301-496-1917			
	Contact Email	vicky.whittemore@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
092569	Research on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) (R21 Clinical Trials Not Allowed)	National Institutes of Health/DHHS	PAR-20-168	16-Feb-2021	275,000 USD

Synopsis | This Funding Opportunity Announcement (FOA) encourages investigator(s)-initiated applications that propose to examine the etiology, diagnosis, pathophysiology and manifestations of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in diverse groups and across the lifespan. Applications that address gaps in the understanding of the environmental and biological risk factors, the determinants of heterogeneity among individuals with ME/CFS, and the common mechanisms influencing the multiple affected body systems in ME/CFS are encouraged. The NIH is particularly interested in funding interdisciplinary research that will enhance our knowledge of disease processes and provide evidence-based solutions to improve the diagnosis, treatment, and quality of life of all persons with ME/CFS. This interdisciplinary research may include the building of scientific teams to study and develop biomarkers and/or characterize the pathophysiological response of organ systems in individuals with ME/CFS. Applicants are encouraged to propose novel and innovative research that will break new ground or extend previous discoveries toward new directions.

Contact Name | Vicky Whittemore, PhD
 Contact Telephone | 301-496-1917
 Contact Email | vicky.whittemore@nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022 , 16-Oct-2022 , 16-Feb-2023

Synopsis | This Funding Opportunity Announcement (FOA) encourages investigator(s)-initiated applications that propose to examine the etiology, diagnosis, pathophysiology and manifestations of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in diverse groups and across the lifespan. Applications that address gaps in the understanding of the environmental and biological risk factors, the determinants of heterogeneity among individuals with ME/CFS, and the common mechanisms influencing the multiple affected body systems in ME/CFS are encouraged. The NIH is particularly interested in funding interdisciplinary research that will enhance our knowledge of disease processes and provide evidence-based solutions to improve the diagnosis, treatment, and quality of life of all persons with ME/CFS. This interdisciplinary research may include the building of scientific teams to study and develop biomarkers and/or characterize the pathophysiological response of organ systems in individuals with ME/CFS. The R21 Grant mechanism is intended to support innovative, high impact research projects. Such projects would either 1) generate pilot data to assess the feasibility of a novel avenue of investigation; 2) involve high risk experiments that could lead to a breakthrough in ME/CFS; 3) demonstrate the feasibility of new technologies that could have a major impact on ME/CFS research. Applications submitted under this mechanism should be limited to those with the potential for truly ground-breaking impact.

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
100780	Addressing Health Disparities among Immigrant Populations through Effective Interventions (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-21-081	05-Feb-2021	Not Specified
	<p>Contact Name: Deborah Linares, Ph.D.</p> <p>Contact Telephone: 301-402-2516</p> <p>Contact Email: deborah.linares@nih.gov</p> <p>Sponsor Website:</p> <p>Program URL: Link to program URL</p> <p>Deadline Dates (ALL): 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023</p> <p>Synopsis: The purpose of this initiative is to support research to design and implement effective interventions to enhance health advantages and reduce the health disparities among US immigrant populations.</p>				
101367	Notice of Special Interest (NOSI): Use of Human Connectome Data for Secondary Analysis	National Institutes of Health/DHHS	NOT-MH-21-175	05-Feb-2021	Not Specified
	<p>Contact Name: Yvonne Bennett, Ph.D.</p> <p>Contact Telephone: 301-222-7094</p> <p>Contact Email: yvonne.bennett@nih.gov</p> <p>Sponsor Website:</p> <p>Program URL: Link to program URL</p> <p>Deadline Dates (ALL): 05-Feb-2021 , 16-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-May-2024</p> <p>Synopsis: NIMH and participating institutes/centers (ICs) listed above are issuing this Notice of Special Interest (NOSI) to encourage secondary analyses of data from the Human Connectome Project (HCP) including the multiple datasets in the Lifespan Human Connectome projects and the Human Connectomes Related to Human Disease. Applicants beyond the groups that originally collected the data are encouraged to apply. The analyses will serve to generate and evaluate hypotheses about the complex interrelationships among: brain structure, function and connectivity; cognitive, affective, sensory and motor processes; environmental factors; life event, social and psychosocial factors; genomic data, and clinical symptoms during development, aging, or disease. Details about the “Lifespan” and “Disease” Connectomes, including neuroimaging protocols and clinical and</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

behavioral assessments, can be found at the Connectome Coordinating Facility website: <https://www.humanconnectome.org/> and at the NIMH Data Archive (NDA) www.nda.nih.gov.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

077905	Mechanisms of Disparities in Etiology and Outcomes of Lung Cancer in the U.S.: The Role of Risk and Protective Factors (R01 - Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PA-19-018	04-Feb-2021 [Optional][LOI/Pre-App]	Not Specified
--------	---	------------------------------------	-----------	--	---------------

Contact Name	Crystal Wolfrey
Contact Telephone	240-276-6277
Contact Email	Crystal.wolfrey@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	04-Feb-2021 [Optional][LOI/Pre-App], 04-Mar-2021
Synopsis	National Cancer Institute (NCI) invites applications that will support multidisciplinary research to understand the underlying causal factors and mechanisms that result in lung cancer disparities in U.S. health disparity populations. This FOA will use the NIH Research Project (R01) award mechanism. The purpose of this initiative is to promote multidisciplinary research to understand the underlying causal factors and mechanisms that result in lung cancer disparities in U.S. health disparity populations.

099075	Clinical Translation of Activated Optical Fluorescence Methods and Technologies for Sensitive Cancer Detection in Vivo (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-20-295	10-Feb-2021	2,500,000 USD
--------	--	------------------------------------	------------	-------------	---------------

Contact Name	Pushpa Tandon, PhD
Contact Telephone	240 276 5971
Contact Email	tandonp@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	10-Feb-2021 , 13-Oct-2021

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to bring a highly sensitive imaging technology capable of detecting very small (1-3 mm³) tumors in vivo to clinical utility. Through this FOA, the National Cancer Institute (NCI) solicits innovative concepts that propose a path to clinical validation for in vivo ‘intelligent’ or activated optical fluorescence agents or probes with previously demonstrated capabilities for the detection of small tumors. Current imaging techniques are in use for non-invasive cancer detection, but clinical methods are limited to detecting masses several millimeters to centimeters in size. To image small primary or metastatic tumor sites composed of 10⁶ -10⁷ cells, imaging sensitivity must be improved. This can be achieved without significant hardware advances by improving the contrast between diseased and healthy tissue captured in the image. Thus, there is a clinical need for techniques that improve image contrast between tumors and surrounding normal tissue. There are several novel optical fluorescence methods that rely on the use of specialized agents that are activated when coupled to a tumor target. These activated agents dramatically increase the contrast between small tumor cell masses and surrounding tissue. Efforts to develop activated fluorescence imaging agents have been ongoing for over a decade. These developmental successes now need to be translated for clinical use. This FOA thus supports translation of novel activated optical fluorescence agents for sensitive cancer detection in vivo. Clinical translation and validation should be the primary goals of the proposed research. The bulk of the proposed research must focus on translating improvements in imaging sensitivity to a clinical environment with the goal of demonstrating that tumor cell aggregates on the order of 1 mm³ in volume can be visualized in vivo. However, minimal research toward development of the probe in preparation for clinical validation will be accepted under this FOA. This FOA thus supports translation of already developed technologies for small tumor detection in vivo. It is not intended to support continued development of novel agents or preclinical studies. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer Moonshot SM Initiative that is intended to accelerate cancer research. Specifically, this FOA falls under the scientific priority designated by the Blue-Ribbon Panel (BRP) as “Developing Cancer Technologies” (see https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/implementation/new-technologies).</p>
----------	--

079769	Biology of Bladder Cancer (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-184	05-Feb-2021	275,000 USD
--------	---	------------------------------------	------------	-------------	-------------

Contact Name	Ron Johnson, Ph. D.
Contact Telephone	240-276-6250
Contact Email	rjohnso2@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022
Synopsis	This Funding Opportunity Announcement (FOA) seeks applications investigating the biology and underlying mechanisms of

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

bladder cancer. Bladder cancer is a significant health problem both in the United States and globally. Because of the high incidence and frequent tumor recurrence, bladder cancer exacts an outsized medical burden. While recent progress has been made in the molecular profiling of bladder cancers and identification of mutated genes, relatively little is known regarding the molecular mechanisms driving initiation, progression, and malignancy of bladder cancer. Furthermore, our understanding of biological processes of the normal bladder at the molecular, cell and organ levels is limited. Fundamental knowledge of how molecular and cellular functions of the bladder are altered in cancer will aid our understanding of bladder cancer biology and interventions. Applications that involve multidisciplinary teams and use clinical specimens or investigate both normal and cancer processes are encouraged.

070179	Using Information Technology to Support Systematic Screening and Treatment of Depression in Oncology Practices (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PA-18-493	05-Feb-2021	Not Specified
--------	--	------------------------------------	-----------	-------------	---------------

Contact Name | Gurvaneet S. Randhawa, M.D., MPH
 Contact Telephone | 240-276-6940
 Contact Email | gurvaneet.randhawa@nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 05-Feb-2021

Synopsis | National Cancer Institute (NCI) invites applications to: identify new, information technology (IT)-enabled delivery models that support systematic screening and treatment of depression in cancer patients; test the feasibility of implementing these new delivery models in a variety of oncology practice settings, especially those serving under-served populations; test the effectiveness of these new delivery models, and their components, in a variety of oncology practice settings, especially those serving under-served populations; and evaluate the sustainability and scalability of these new delivery models. This FOA will use the NIH Research Project (R01) award mechanism.

079767	Biology of Bladder Cancer (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-183	05-Feb-2021	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name | Ron Johnson, Ph. D.
 Contact Telephone | 240-276-6250
 Contact Email | rjohnso2@mail.nih.gov
 Sponsor Website |

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages applications investigating the biology and underlying mechanisms of bladder cancer. Bladder cancer is a significant health problem both in the United States and globally. Because of the high incidence and frequent tumor recurrence, bladder cancer exacts an outsized medical burden. While recent progress has been made in the molecular profiling of bladder cancers and identification of mutated genes, relatively little is known regarding the molecular mechanisms driving initiation, progression, and malignancy of bladder cancer. Furthermore, our understanding of biological processes of the normal bladder at the molecular, cell and organ levels is limited. Fundamental knowledge of how molecular and cellular functions of the bladder are altered in cancer will aid our understanding of bladder cancer biology and interventions. Applications that involve multidisciplinary teams and use clinical specimens or investigate both normal and cancer processes are encouraged.</p>				
097239	Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-20-276	05-Feb-2021	1,750,000 USD
	<p>Contact Name Melissa Rotunno, Ph.D.</p> <p>Contact Telephone 240-276-7245</p> <p>Contact Email rotunnom@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022</p> <p>Synopsis Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) along with the National Human Genome Research Institute (NHGRI) and National Institute of Dental and Craniofacial Research (NIDCR) encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate the genetic architecture of cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.). The goal of this initiative is to address key scientific questions relevant to cancer genomic and epidemiology by supporting the analysis of existing genetic or genomic datasets, in combination with other omics and environmental, clinical, behavioral, lifestyle, and molecular profiles data. Applicants are encouraged to leverage existing genetic data and perform innovative analyses of the existing data.</p>				
073406	Age-related Microbiota Changes and their Implications in Chronic Disease Prevention, Treatment and Progression (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PA-18-738	05-Feb-2021	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Gabriela Riscuta MD, CNS, MS</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021</p> <p>Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invite applications to assess the role of the microbiome in health and disease during aging. This initiative will support research projects designed to evaluate changes in the microbiota during lifetime and its influence in health and disease status in the elderly, including those from racial/ethnic minority and underserved populations and understand the underlying mechanisms of microbiota interactions in aged subjects as related to health and disease. This FOA will support basic mechanistic, preclinical studies in animal models and human clinical trial proposals in accordance with the state of the science. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
079077	<p>Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional)</p>	National Cancer Institute/NIH/DHHS	PAR-19-113	05-Feb-2021	2,000,000 USD
	<p>Contact Name Nastaran Z. Kuhn, Ph.D.</p> <p>Contact Telephone 240-276-7610</p> <p>Contact Email nas.zahir@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) will support the development and characterization of state-of-the-art biomimetic tissue-engineered technologies for cancer research. Collaborative, multidisciplinary projects that engage the fields of regenerative medicine, tissue engineering, biomaterials, and bioengineering with cancer biology will be essential for generating novel experimental models that mimic cancer pathophysiology in the context of a testable cancer research hypothesis. The projects supported by this FOA will collectively participate in the Cancer Tissue Engineering Collaborative (TEC) Research Program. The Cancer TEC Program will (1) catalyze the advancement of innovative, well characterized in vitro and ex vivo systems available for cancer research, (2) expand the breadth of these systems to several cancer types, and (3) promote the exploration of cancer phenomena with biomimetic tissue-engineered systems.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
090364	Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-20-131	05-Feb-2021	1,350,000 USD
	<p>Contact Name Joanna Watson, Ph.D.</p> <p>Contact Telephone 240-276-6230</p> <p>Contact Email Joanna.Watson@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for projects to expand, improve, or transform the utility of mammalian cancer and tumor models for translational research. With this FOA, the NCI intends to encourage submission of projects devoted to demonstrating that mammalian models or their derivatives used for translational research are robust representations of human biology, are appropriate to test questions of clinical importance, and provide reliable information for patients' benefit. These practical goals contrast with the goals of many mechanistic, NCI-supported R01 projects that use mammals, or develop and use mammalian cancer models, transplantation tumor models, or models derived from mammalian or human tissues or cells for hypothesis-testing, non-clinical research. Among many other possible endeavors, applicants in response to this FOA could propose demonstrations of how to overcome translational deficiencies of mammalian oncology models, define new uses of mammalian models or their genetics for unexplored translational challenges, advance standard practices for use of translational models, test approaches to validate and credential models, or challenge current practices for how models are used translationally.</p>				
084505	Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-325	11-Feb-2021	Not Specified
	<p>Contact Name Kelly Filipski PhD, MPH</p> <p>Contact Telephone 240-276-6841</p> <p>Contact Email Filipskikk@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-Feb-2021 , 20-Sep-2021 , 11-Feb-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative research projects designed to</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>address adverse sequelae of cancer therapies that persist and become chronic comorbidities or develop as delayed posttreatment effects. This FOA supports basic, translational, and/or clinical research projects that seek to identify the mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, or translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae. Research projects should focus on 1) mechanistic studies with translational endpoints; and/or 2) longitudinal clinical phenotyping to identify and validate clinical endpoints (biomarkers, imaging, patient-reported outcomes, or combined elements) for future use in clinical trials that will evaluate the efficacy of interventions designed to prevent or reduce specific adverse sequelae.</p>				
087000	Program to Assess the Rigor and Reproducibility of Extracellular Vesicle-Derived Analytes for Cancer Detection (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-20-053	05-Feb-2021	Not Specified
	<p>Contact Name: Sudhir Srivastava, Ph.D., M.P.H. Contact Telephone: 240-276-7028 Contact Email: srivasts@mail.nih.gov Sponsor Website: Program URL: Link to program URL Deadline Dates (ALL): 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022 , 05-Oct-2022 Synopsis: This Funding Opportunity Announcement (FOA) encourages research projects that focus on innovative research in the isolation and characterization of extracellular vesicles (EVs) and their cargo for discovery of predictive biomarkers for risk assessment, detection, diagnosis and prognosis of early cancer. This FOA will promote rigor and reproducibility research in both the isolation of EVs as well as the computational analysis of the cargo carried in these vesicles.</p>				
086487	Fundamental Mechanisms of Affective and Decisional Processes in Cancer Control (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-20-034	05-Feb-2021	Not Specified
	<p>Contact Name: Rebecca A Ferrer, Ph.D. Contact Telephone: 240-276-6963 Contact Email: ferrerra@mail.nih.gov Sponsor Website: Program URL: Link to program URL Deadline Dates (ALL): 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022 , 05-Oct-2022 Synopsis: The purpose of this Funding Opportunity Announcement (FOA) is to encourage projects to generate fundamental knowledge</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

of affective processes. Basic affective science projects should have key consequences for single (e.g., cancer screening) and multiple (e.g., adherence to oral chemotherapy regimen) event decisions and behaviors across the cancer prevention and control continuum. The FOA is expected to encourage collaboration among cancer control researchers and those from scientific disciplines not traditionally connected to cancer control applications (e.g., affective and cognitive neuroscience, decision science, consumer science) to elucidate perplexing and understudied problems in affective and decision sciences with downstream implications for cancer prevention and control.

086149	Perception and Cognition Research to Inform Cancer Image Interpretation (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-387	05-Feb-2021	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name	Todd S. Horowitz, Ph.D.
Contact Telephone	240-276-6963
Contact Email	todd.horowitz@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022 , 05-Oct-2022
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to facilitate research on the perceptual and cognitive processes underlying the performance of cancer image observers in radiology and pathology, in order to improve the accuracy of cancer detection and diagnosis.

072431	Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 - Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PA-18-677	05-Feb-2021	Not Specified
--------	--	------------------------------------	-----------	-------------	---------------

Contact Name	Tram Kim Lam, Ph.D., MPH
Contact Telephone	240-276-6967
Contact Email	Tram.Lam@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Feb-2021
Synopsis	National Cancer Institute (NCI) invites applications for epidemiologic research investigating novel and innovative hypotheses on emerging risk factors (biological, environmental, and social) and their interplay with established risk factors (e.g., viral hepatitis) associated with the development of liver cancer (hepatocellular carcinoma and other histological subtypes) in the

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
United States. This FOA will use the NIH Research Project (R01) award mechanism.					
085330	Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-360	05-Feb-2021	Not Specified
	Contact Name	Sarah Kobrin, Ph.D., MPH			
	Contact Telephone	240-276-6931			
	Contact Email	kobrins@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022			
	Synopsis	<p>This Funding Opportunity Announcement (FOA) encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting, can all affect whether a provider makes a recommendation, and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare delivery.</p>			
085257	Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-352	05-Feb-2021	Not Specified
	Contact Name	Michelle Mollica, PhD, MPH, RN, OCN			
	Contact Telephone	240-276-7621			
	Contact Email	michelle.mollica@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022			
	Synopsis	<p>This Funding Opportunity Announcement (FOA) invites applications for intervention research designed to support caregivers of adult cancer patients. Interventions supported by this FOA are intended to provide caregivers with care training, promote coping skills, and ultimately help them manage care. Outcomes of such interventions are expected to (1) optimize patient health care utilization, (2) improve caregiver well-being, and (3) improve patient physical health and psychosocial outcomes.</p>			
100261	Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-20-313	18-Feb-2021	1,025,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name	Tracy G. Lively, Ph.D.
Contact Telephone	240-276-5944
Contact Email	livelyt@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	18-Feb-2021 , 09-Jul-2021 , 08-Oct-2021 , 14-Feb-2022 , 11-Jun-2022 , 11-Oct-2022 , 14-Feb-2023 , 10-Jul-2023 , 10-Oct-2023
Synopsis	<p>Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications to support the validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA will support investigator-initiated research for both analytical, and clinical validation of assays to be used in cancer treatment, control, or prevention trials supported by the NCI. This FOA will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants should have assays that work on human samples and whose importance is well justified for development into clinical assays. As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance durability of anti-cancer responses, assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously. The UH2 phase of this FOA supports analytical validation of assays for these molecular/cellular/imaging markers, which must be achieved within 2 years before assays may undergo clinical validation. The UH3 phase of this FOA supports clinical validation of analytically validated assays for up to 3 years using well-annotated biospecimens from retrospective or prospective clinical trials or studies. This FOA may be used to validate existing assays for use in other cancer clinical trials, observational studies, or population studies. Efforts to harmonize clinical laboratory tests, including investigation into the performance and reproducibility of assays across multiple clinical laboratories, are also appropriate for this funding opportunity. Projects proposed for this FOA will require multi-disciplinary interaction and collaboration among scientific investigators, oncologists, statisticians, and clinical laboratory scientists. This FOA is not intended to support early-stage development of technology or the conduct of clinical trials but is intended for validation of assays to the point where they could be integrated into clinical trials/studies as investigational assays. Investigators responding to this FOA must address both UH2 and UH3 phases. Milestones to be accomplished in the UH2 phase for transition to the UH3 phase must be proposed by the investigators.</p>

100262	Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-20-314	18-Feb-2021	750,000 USD
--------	---	------------------------------------	------------	-------------	-------------

Contact Name	Tracy G. Lively, Ph.D.
Contact Telephone	240-276-5944

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email livelyt@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 18-Feb-2021 , 09-Jul-2021 , 08-Oct-2021 , 14-Feb-2022 , 11-Jun-2022 , 11-Oct-2022 , 14-Feb-2023 , 10-Jul-2023 , 10-Oct-2023</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the adoption and validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants to this FOA must have an assay(s) whose performance has been analytically validated in specimens similar to those for the intended clinical use of the marker(s) and assay(s). As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance the durability of anti-cancer responses, assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously. The UH3 mechanism will support the clinical validation of established assays for up to 3 years using specimens from retrospective or prospective clinical trials or studies. This FOA may be used to validate existing assays for use in other trials, observational studies, or population studies. Efforts to harmonize clinical laboratory tests, including investigation into the performance and reproducibility of assays across multiple clinical laboratories, are also appropriate for this funding opportunity. Projects proposed for this FOA will require multi-disciplinary interaction and collaboration among scientific investigators, oncologists, statisticians, and clinical laboratory scientists. This FOA is not intended to support early-stage development of technology or the conduct of clinical trials but is intended for validation of assays to the point where they could be integrated into clinical trials/studies as investigational assays.</p>				
086150	Perception and Cognition Research to Inform Cancer Image Interpretation (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-389	16-Feb-2021	400,000 USD
	<p>Contact Name Todd S. Horowitz, Ph.D.</p> <p>Contact Telephone 240-276-6963</p> <p>Contact Email todd.horowitz@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022 , 16-Oct-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to facilitate research on the perceptual and cognitive processes underlying the performance of cancer image observers in radiology and pathology, in order to improve the accuracy of cancer detection and diagnosis.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
070181	Using Information Technology to Support Systematic Screening and Treatment of Depression in Oncology Practices (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PA-18-492	16-Feb-2021	275,000 USD
	<p>Contact Name Gurvaneet S. Randhawa, M.D., MPH</p> <p>Contact Telephone 240-276-6940</p> <p>Contact Email gurvaneet.randhawa@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021</p> <p>Synopsis National Cancer Institute (NCI) invites applications to: identify new, information technology (IT)-enabled delivery models that support systematic screening and treatment of depression in cancer patients; test the feasibility of implementing these new delivery models in a variety of oncology practice settings, especially those serving under-served populations; and test the usability and potential effectiveness of the IT-specific components of these new delivery models. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</p>				
070114	NCI Transition Career Development Award (K22 Independent Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-18-467	12-Feb-2021	450,000 USD
	<p>Contact Name Sonia Jakowlew, Ph.D., Program Director</p> <p>Contact Telephone 240-276-5630</p> <p>Contact Email jakowles@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Feb-2021</p> <p>Synopsis National Cancer Institute (NCI) provides support to facilitate the transition of investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions. This goal is achieved by providing protected time through salary and research support for the initial 3 years of the first independent tenure-track faculty position, or its equivalent, beginning at the time when the candidate starts a tenure-track faculty position. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. This program will use the NIH K22 Career Transition Award mechanism.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
085337	Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-358	16-Feb-2021	275,000 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>Sarah Kobrin, Ph.D., MPH</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td>240-276-6931</td> </tr> <tr> <td style="padding-right: 5px;">Contact Email</td> <td>kobrins@mail.nih.gov</td> </tr> <tr> <td style="padding-right: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="padding-right: 5px;">Deadline Dates (ALL)</td> <td>16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022</td> </tr> <tr> <td style="padding-right: 5px;">Synopsis</td> <td>This Funding Opportunity Announcement (FOA) encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting, can all affect whether a provider makes a recommendation, and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare delivery.</td> </tr> </table>					Contact Name	Sarah Kobrin, Ph.D., MPH	Contact Telephone	240-276-6931	Contact Email	kobrins@mail.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022	Synopsis	This Funding Opportunity Announcement (FOA) encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting, can all affect whether a provider makes a recommendation, and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare delivery.
Contact Name	Sarah Kobrin, Ph.D., MPH																		
Contact Telephone	240-276-6931																		
Contact Email	kobrins@mail.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022																		
Synopsis	This Funding Opportunity Announcement (FOA) encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting, can all affect whether a provider makes a recommendation, and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare delivery.																		
085343	Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R03 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-359	16-Feb-2021	100,000 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 5px;">Contact Name</td> <td>Sarah Kobrin, Ph.D., MPH</td> </tr> <tr> <td style="padding-right: 5px;">Contact Telephone</td> <td>240-276-6931</td> </tr> <tr> <td style="padding-right: 5px;">Contact Email</td> <td>kobrins@mail.nih.gov</td> </tr> <tr> <td style="padding-right: 5px;">Sponsor Website</td> <td></td> </tr> <tr> <td style="padding-right: 5px;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="padding-right: 5px;">Deadline Dates (ALL)</td> <td>16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022</td> </tr> <tr> <td style="padding-right: 5px;">Synopsis</td> <td>This Funding Opportunity Announcement (FOA) encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting, can all affect whether a provider makes a recommendation and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare delivery.</td> </tr> </table>					Contact Name	Sarah Kobrin, Ph.D., MPH	Contact Telephone	240-276-6931	Contact Email	kobrins@mail.nih.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022	Synopsis	This Funding Opportunity Announcement (FOA) encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting, can all affect whether a provider makes a recommendation and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare delivery.
Contact Name	Sarah Kobrin, Ph.D., MPH																		
Contact Telephone	240-276-6931																		
Contact Email	kobrins@mail.nih.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022																		
Synopsis	This Funding Opportunity Announcement (FOA) encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting, can all affect whether a provider makes a recommendation and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare delivery.																		
085275	Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-355	16-Feb-2021	275,000 USD														

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Michelle Mollica, PhD, MPH, RN, OCN</p> <p>Contact Telephone 240-276-7621</p> <p>Contact Email michelle.mollica@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites applications for intervention research designed to support caregivers of adult cancer patients. Interventions supported by this FOA are intended to provide caregivers with care training, promote coping skills, and ultimately help them manage care. Outcomes of such interventions are expected to (1) optimize patient health care utilization, (2) improve caregiver well-being, and (3) improve patient physical health and psychosocial outcomes</p>				
072031	Exploratory/Developmental Grants Program for Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-18-655	18-Feb-2021	275,000 USD
	<p>Contact Name Jennifer Isaacs, Ph.D.</p> <p>Contact Telephone 240-276-6251</p> <p>Contact Email jennifer.isaacs@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 18-Feb-2021</p> <p>Synopsis National Cancer Institute (NCI) invites applications from investigators interested in conducting basic research studies into the biological/genetic causes and mechanisms of cancer health disparities. These awards will support pilot and feasibility studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models and methods that are necessary to conduct basic research in cancer health disparities. In addition, the FOA will further the development of scientific areas, providing support for early-stage exploratory projects that lead to future in-depth mechanistic studies (such as R01 projects) of the biology of cancer health disparities. This FOA will use the NIH R21 Exploratory/Developmental Research award mechanism.</p>				
072029	Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-18-654	08-Feb-2021	Not

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Allowed)		Institute/NIH/DHHS		Specified
	Contact Name	Jennifer Isaacs, Ph.D.			
	Contact Telephone	240-276-6251			
	Contact Email	jennifer.isaacs@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	08-Feb-2021			
	Synopsis	<p>National Cancer Institute (NCI) invites applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants (R01) will support innovative studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models, and methods that are necessary to conduct basic research in cancer health disparities. This FOA will use the NIH Research Project (R01) award mechanism.</p>			
100707	National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)	National Cancer Institute/NIH/DHHS	PAR-21-033	05-Feb-2021	2,499,995 USD
	Contact Name	Lori A. Henderson, Ph.D.			
	Contact Telephone	240-276-5930			
	Contact Email	hendersonlori@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024			
	Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to seek research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of the National Cancer Institute's (NCI) Division of Cancer Treatment and Diagnosis</p>			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>(DCTD) and the Office of HIV and AIDS Malignancies (OHAM, Office of the Director). Applicants are strongly encouraged to consult the NCI DCTD website and/or the OHAM website to learn more about the various program goals, research priorities, and strategies developed to fight cancer. Applications submitted to this FOA must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trial information as described in this FOA. This FOA does not accept phase III clinical trials in any area of cancer research; therefore, applications that propose phase III clinical trials will be deemed non-responsive and will not be reviewed.</p>				
100708	Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)	National Cancer Institute/NIH/DHHS	PAR-21-035	05-Feb-2021	Not Specified
	<p>Contact Name Brandy Heckman-Stoddard, Ph.D., M.P.H. Contact Telephone 240-276-7048 Contact Email heckmanbm@mail.nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 07-Jan-2024 Synopsis Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for support of investigator-initiated clinical trials related to the programmatic interests of the NCI Division of Cancer Prevention and/or the NCI Division of Cancer Control and Population Sciences that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health. Applications submitted to this FOA must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trial information as described in this FOA and the application instructions. This FOA does not and will not support clinical trials for studies of cancer diagnosis and/or oncologic therapy in patients.</p>				
100855	RFA-CA-21-004 -- Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	RFA-CA-21-004	23-Jan-2021 [Optional][LOI/Pre-App]	900,000 USD
	<p>Contact Name Tony Dickherber, Ph.D., Program Director Contact Telephone 301-547-9980</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email dickherberaj@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 23-Jan-2021 [Optional][LOI/Pre-App], 22-Feb-2021 , 27-Apr-2021 [Optional][LOI/Pre-App], 27-May-2021 , 30-Aug-2021 [Optional][LOI/Pre-App], 29-Sep-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) invites grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic or clinical cancer research. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.</p>				
100854	RFA-CA-21-003 -- Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	RFA-CA-21-003	23-Jan-2021 [Optional][LOI/Pre-App]	400,000 USD
	<p>Contact Name Tony Dickherber, Ph.D., Program Director</p> <p>Contact Telephone 301-547-9980</p> <p>Contact Email dickherberaj@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 23-Jan-2021 [Optional][LOI/Pre-App], 22-Feb-2021 , 27-Apr-2021 [Optional][LOI/Pre-App], 27-May-2021 , 30-Aug-2021 [Optional][LOI/Pre-App], 29-Sep-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic or clinical cancer research. The emphasis of this FOA is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology.</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
<p>Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer biology. Projects proposing the application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.</p>					
099631	Tobacco Control Policies to Promote Health Equity (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-20-303	16-Feb-2021	275,000 USD
	<p>Contact Name Bob Vollinger, DrPH, MSPH</p> <p>Contact Telephone 240-276-6919</p> <p>Contact Email Bob.Vollinger@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022 , 16-Oct-2022 , 16-Feb-2023 , 16-Jun-2023</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support observational or intervention research focused on reducing disparities in tobacco use and secondhand smoke (SHS) exposure in the U.S. Specifically, this FOA aims to stimulate scientific inquiry focused on innovative state and local level tobacco prevention and control policies. The long-term goal of this FOA is to reduce disparities in tobacco-related cancers, and in doing so, to promote health equity among all populations. Applicants submitting applications related to health economics are encouraged to consult NOT-OD-16-025 to ensure that the research projects align with NIH mission priorities in health economics research.</p>				
099622	Tobacco Control Policies to Promote Health Equity (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-20-302	05-Feb-2021	Not Specified
	<p>Contact Name Bob Vollinger, DrPH, MSPH</p> <p>Contact Telephone 240-276-6919</p> <p>Contact Email Bob.Vollinger@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022 , 05-Oct-2022 , 05-Feb-2023 , 05-Jun-2023</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to support observational or intervention research focused on reducing disparities in tobacco use and secondhand smoke (SHS) exposure in the U.S. Specifically, this FOA aims to stimulate scientific inquiry focused on innovative state and local level tobacco prevention and control policies. The long-term goal of this FOA is to reduce disparities in tobacco-related cancers, and in doing so, to promote health equity among all populations. Applicants submitting applications related to health economics are encouraged to consult NOT-OD-16-025 to ensure that the research projects align with NIH mission priorities in health economics research.</p>			
100856	RFA-CA-21-005 -- Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R21 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	RFA-CA-21-005	23-Jan-2021 [Optional][LOI/Pre-App]	400,000 USD
	Contact Name	Tony Dickherber, Ph.D., Program Director			
	Contact Telephone	301-547-9980			
	Contact Email	dickherberaj@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	23-Jan-2021 [Optional][LOI/Pre-App], 22-Feb-2021 , 27-Apr-2021 [Optional][LOI/Pre-App], 27-May-2021 , 30-Aug-2021 [Optional][LOI/Pre-App], 29-Sep-2021			
	Synopsis	<p>This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection, and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.</p>			
100859	RFA-CA-21-006 -- Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research	National Cancer Institute/NIH/DHHS	RFA-CA-21-006	23-Jan-2021 [Optional][LOI/Pre-App]	900,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

[\(R33 Clinical Trial Not Allowed\)](#)

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Tony Dickherber, Ph.D., Program Director 301-547-9980 dickherberaj@mail.nih.gov Link to program URL 23-Jan-2021 [Optional][LOI/Pre-App], 22-Feb-2021 , 27-Apr-2021 [Optional][LOI/Pre-App], 27-May-2021 , 30-Aug-2021 [Optional][LOI/Pre-App], 29-Sep-2021 <p>This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still require further development and rigorous validation to encourage adoption by the research community. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. Projects proposing to use existing technologies where the novelty resides in the application of the technology or the biological or clinical question being pursued, and not the technical capabilities being developed, are not appropriate for this FOA and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.</p>
--	---

100903	RFA-CA-21-007 -- Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-CA-21-007	23-Jan-2021 [Optional][LOI/Pre-App]	150,000 USD
--------	--	------------------------------------	---------------	-------------------------------------	-------------

Contact Name Contact Telephone Contact Email	Tony Dickherber, Ph.D. 301-547-9980 dickherberaj@mail.nih.gov
--	--

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	23-Jan-2021 [Optional][LOI/Pre-App], 22-Feb-2021 , 27-Apr-2021 [Optional][LOI/Pre-App], 27-May-2021 , 30-Aug-2021 [Optional][LOI/Pre-App], 29-Sep-2021			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI R01 research projects. The applicants should propose to expand upon the original research question(s) or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the adoption of these emerging technologies by appropriate research communities. As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.			
100905	RFA-CA-21-008 -- Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-CA-21-008	23-Jan-2021 [Optional][LOI/Pre-App]	150,000 USD
	Contact Name	Tony Dickherber, Ph.D.			
	Contact Telephone	301-547-9980			
	Contact Email	dickherberaj@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	23-Jan-2021 [Optional][LOI/Pre-App], 22-Feb-2021 , 27-Apr-2021 [Optional][LOI/Pre-App], 27-May-2021 , 30-Aug-2021 [Optional][LOI/Pre-App], 29-Sep-2021			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI U01 research projects. The applicants should propose to expand upon the original research question(s) or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities. As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
100913	RFA-CA-21-010 -- Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U2C Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-CA-21-010	23-Jan-2021 [Optional][LOI/Pre-App]	150,000 USD
	<p>Contact Name Tony Dickherber, Ph.D.</p> <p>Contact Telephone 301-547-9980</p> <p>Contact Email dickherberaj@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 23-Jan-2021 [Optional][LOI/Pre-App], 22-Feb-2021 , 27-Apr-2021 [Optional][LOI/Pre-App], 27-May-2021 , 30-Aug-2021 [Optional][LOI/Pre-App], 29-Sep-2021</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI U2C Resource-Related Multi-Component Projects and Centers proposing to expand upon original research question(s) from specific projects or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities. As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.</p>				
079067	Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PA-19-112	05-Feb-2021	Not Specified
	<p>Contact Name Nonniekaye Shelburne, MS, CRNP, AOCN</p> <p>Contact Telephone 240-276-6897</p> <p>Contact Email nshelburne@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021</p> <p>Synopsis This Funding Opportunity Announcement (FOA) encourages collaborative applications that will contribute to the identification and characterization of patients at risk of developing cancer treatment-related cardiotoxicity. The primary intent is to mitigate cardiovascular dysfunction while optimizing cancer outcomes. To accomplish this, methods that evaluate</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

cardiovascular risk prior to treatment and integrate evidence-based cancer treatment regimens with cardiovascular screening, diagnostic, and/or management strategies are sought. Research applications should focus on mitigation/management of adverse effects associated with anti-cancer treatments including: cytotoxic chemotherapies, targeted agents, immunomodulatory therapies and radiation (that occur during cancer treatment and/or long-term survivorship) as defined by cardiac and/or vascular specific common terminology criteria for adverse events (CTCAE).

087228	Co-infection and Cancer (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-20-062	05-Feb-2021	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

Contact Name	Tram Kim Lam, Ph.D., MPH
Contact Telephone	240-276-6967
Contact Email	lamt@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022 , 05-Oct-2022
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents – either concurrently or sequentially – and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and of co-infections that engender novel opportunities for prevention and treatment

087229	Co-infection and Cancer (R21 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-20-061	16-Feb-2021	275,000 USD
--------	--	------------------------------------	------------	-------------	-------------

Contact Name	Tram Kim Lam, Ph.D., MPH
Contact Telephone	240-276-6967
Contact Email	lamt@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022 , 16-Oct-2022
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to enhance mechanistic and epidemiologic investigations

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

addressing the roles of co-infection. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents – either concurrently or sequentially – and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and of co-infections that engender novel opportunities for prevention and treatment.

077311	Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-18-913	11-Feb-2021	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

Contact Name | Claire Zhu, Ph.D.
 Contact Telephone | 240-276-7013
 Contact Email | zhucla@mail.nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 11-Feb-2021 , 11-Aug-2021

Synopsis | National Cancer Institute (NCI) invites applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO screened arm participants, and a onetime collection of buccal cells from the control arm participants. Available data associated with the biospecimens includes demographic, diet, lifestyle, smoking, screening results, and clinical data. This FOA supports a wide range of cancer research including, but not limited to, biochemical and genetic analyses of cancer risk, as well as discovery and validation of early detection biomarkers. The proposed research project must involve use of PLCO biospecimens; additionally, it should also take advantage of the unique characteristics of the PLCO biospecimens. Research projects that do not involve the use of PLCO biospecimens will not be supported under this FOA. This program will use the NIH U01 Research Project Cooperative Agreements award mechanism.

080137	Tobacco Regulatory Science (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-OD-19-019	13-Feb-2021	900,000 USD
--------	--	------------------------------------	---------------	-------------	-------------

Contact Name | Rachel Grana Mayne, PhD
 Contact Telephone | 240-276-5899
 Contact Email | granar@nih.gov
 Sponsor Website |

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 13-Feb-2021</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to invite R01 applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). The awards under this FOA will be administered by NIH using funds that have been made available through FDA CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health.</p>				
101128	RFA-CA-21-002 -- Cellular Cancer Biology Imaging Research (CCBIR) Program (U54, Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	RFA-CA-21-002	16-Feb-2021 [Optional][LOI/Pre-App]	6,250,000 USD
	<p>Contact Name Nastaran Zahir, Ph.D.</p> <p>Contact Telephone 240-276-6333</p> <p>Contact Email nas.zahir@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 [Optional][LOI/Pre-App], 18-Mar-2021</p> <p>Synopsis The National Cancer Institute (NCI) invites applications for Cellular Cancer Biology Imaging Research (CCBIR) Centers. The Centers will develop and test enabling imaging technologies at the cellular and organ scales driven by specific fundamental questions in cancer biology. The overall purpose of the CCBIR initiative is to facilitate innovation in advanced imaging technologies that could be applied to fundamental basic and pre-clinical research problems in cancer biology. CCBIR Centers are structured to operate collaboratively between technology developers and cancer biologists at the forefront of their respective fields. CCBIR Centers will increase in experimental sophistication over time to ultimately produce an interoperable suite of state-of-the-art imaging technologies with transformative potential to study the cancer biology process(es) that defines the Center. The cadre of CCBIR Centers will form a consortium that will be expected to engage with the broader cancer research community.</p>				
086016	RFA-OD-19-028--Tobacco Regulatory Science (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-OD-19-028	13-Feb-2021	900,000 USD
	Contact Name Rachel Grana Mayne, PhD				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	240-276-5899 granar@nih.gov Link to program URL 13-Feb-2021 Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to invite R01 applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). The awards under this FOA will be administered by NIH using funds that have been made available through FDA CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health.
--	---

100482	RFA-CA-20-056 -- NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	RFA-CA-20-056	26-Feb-2021	Not Specified
--------	--	------------------------------------	---------------	-------------	---------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	Sergey Radaev, PhD 240-276-5630 sradaev@mail.nih.gov Link to program URL 26-Feb-2021 Synopsis The purpose of the NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Fellows (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of data science and cancer control science are especially encouraged to apply. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or
--	---

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

an ancillary study to a clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA (RFA-CA-20-057).

100483	RFA-CA-20-057 -- NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Required)	National Cancer Institute/NIH/DHHS	RFA-CA-20-057	26-Feb-2021	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

Contact Name | Sergey Radaev, PhD
 Contact Telephone | 240-276-5630
 Contact Email | sradaev@mail.nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 26-Feb-2021

Synopsis

The purpose of the NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of data science and cancer control science are especially encouraged to apply. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (RFA-CA-20-056).

100481	RFA-CA-20-055 -- NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Basic Experimental Studies with Humans Required)	National Cancer Institute/NIH/DHHS	RFA-CA-20-055	26-Feb-2021	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

Contact Name | Sergey Radaev, PhD
 Contact Telephone | 240-276-5630

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email sradaev@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 26-Feb-2021</p> <p>Synopsis The purpose of the NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research career development beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of data science and cancer control science are especially encouraged to apply. This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this Funding Opportunity Announcement (FOA) include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA, RFA-CA-20-056</p>				
101162	Notice of Special Interest (NOSI): Tailoring Follow-up Care for Survivors Using Risk-Stratified Pathways	National Cancer Institute/NIH/DHHS	NOT-CA-21-019	05-Feb-2021	Not Specified
	<p>Contact Name Michelle Mollica, PhD, MPH, RN, OCN</p> <p>Contact Telephone 240-276-7621</p> <p>Contact Email michelle.mollica@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Jan-2023 , 05-Feb-2023</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	<p>Synopsis</p>	<p>The purpose of this Notice is to highlight the NCI Division of Cancer Control and Population Sciences' interest in receiving applications focused on identifying important factors for defining risk-stratified survivorship care or developing and testing approaches to improve the clinical management and outcomes for adult cancer survivors using risk-stratified survivorship care pathways. Risk-stratified survivorship care describes a personalized approach to care in which cancer survivors are triaged or stratified to distinct care pathways based on the complexity of their needs and the types of providers their care requires.</p>			
--	-----------------	---	--	--	--

100910	RFA-CA-21-009 -- Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U54 Clinical Trials Optional)	National Cancer Institute/NIH/DHHS	RFA-CA-21-009	23-Jan-2021 [Optional][LOI/Pre-App]	150,000 USD
--------	---	------------------------------------	---------------	--	----------------

	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Tony Dickherber, Ph.D.</p> <p>301-547-9980</p> <p>dickherberaj@mail.nih.gov</p> <p></p> <p>Link to program URL</p> <p>23-Jan-2021 [Optional][LOI/Pre-App], 22-Feb-2021 , 27-Apr-2021 [Optional][LOI/Pre-App], 27-May-2021 , 30-Aug-2021 [Optional][LOI/Pre-App], 29-Sep-2021</p> <p>The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI U54 Resource-Related Research Projects proposing to expand upon original research question(s) from specific projects or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities. As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.</p>			
--	---	---	--	--	--

100914	RFA-CA-21-011 -- Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-CA-21-011	23-Jan-2021 [Optional][LOI/Pre-App]	150,000 USD
--------	--	------------------------------------	---------------	--	----------------

	<p>Contact Name</p> <p>Contact Telephone</p>	<p>Tony Dickherber, Ph.D.</p> <p>301-547-9980</p>			
--	--	---	--	--	--

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email dickherberaj@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 23-Jan-2021 [Optional][LOI/Pre-App], 22-Feb-2021 , 27-Apr-2021 [Optional][LOI/Pre-App], 27-May-2021 , 30-Aug-2021 [Optional][LOI/Pre-App], 29-Sep-2021</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI P01 program projects proposing to expand upon original research question(s) from specific projects or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities. As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.</p>				
100916	RFA-CA-21-012 -- Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-CA-21-012	23-Jan-2021 [Optional][LOI/Pre-App]	150,000 USD
	<p>Contact Name Tony Dickherber, Ph.D.</p> <p>Contact Telephone 301-547-9980</p> <p>Contact Email dickherberaj@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 23-Jan-2021 [Optional][LOI/Pre-App], 22-Feb-2021 , 27-Apr-2021 [Optional][LOI/Pre-App], 27-May-2021 , 30-Aug-2021 [Optional][LOI/Pre-App], 29-Sep-2021</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI P50 specialized centers proposing to expand upon original research question(s) from specific projects or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities. As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		accelerate scientific discovery.			
098641	NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-20-292	19-Feb-2021	275,000 USD
	Contact Name	William C. Timmer, Ph.D			
	Contact Telephone	240-276-6130			
	Contact Email	william.timmer@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	19-Feb-2021 , 19-Mar-2021 , 21-Jun-2021 , 20-Jul-2021 , 20-Oct-2021 , 17-Dec-2021 , 22-Feb-2022 , 21-Jun-2022 , 21-Jun-2022 , 20-Jul-2022			
	Synopsis	<p>This Funding Opportunity Announcement (FOA) supports preclinical and early phase clinical research, as well as correlative studies, directly related to advancements in cancer treatment, diagnosis, prevention, symptom management, or reduction of cancer health disparities. This includes (but is not limited to) development and testing of the following: new molecular agents or biologics for cancer treatment; management strategies for cancer-related symptoms or treatment-related toxicity; cancer screening or diagnostic tools, such as imaging techniques; cancer preventive agents or approaches; predictive and prognostic biomarkers for patient selection or stratification; clinically relevant in vivo or in vitro tumor models (including genetically engineered mouse models, patient-derived xenograft models, organoids, and cell lines); and strategies to address therapeutic outcome disparities among diverse racial/ethnic populations. In addition to novel agents, new treatment strategies may involve repurposed agents or novel combinations of interventions (including radiation), based on established mechanisms of action. Comparative oncology studies in dogs investigating strategies for treatment and diagnosis of human disease are supported as well. This FOA does not support research that focuses on basic cancer biology (such as studies of cancer-related pathways or molecular mechanisms), late-stage clinical trials, risk assessment studies, epidemiological studies, or studies of behavioral interventions. These applications will be deemed not responsive to this FOA and will not be reviewed (see below for a more detailed description of studies that are not responsive for this FOA). The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to breakthroughs in particular areas, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on cancer research (preclinical or clinical).</p>			
068218	NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08 No Independent Clinical Trials)	National Cancer Institute/NIH/DHHS	PAR-18-337	12-Feb-2021	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

	Contact Name	John O. Ojeifo, MD, PhD, MBA.			
	Contact Telephone	240-276-6186			
	Contact Email	ojeifojo@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	12-Feb-2021			
	Synopsis	<p>National Cancer Institute (NCI) invites applications for the NCI Mentored Clinical Scientist Research Career Development Awards (K08). The purpose of the NCI Mentored Clinical Scientist Career Development Award (K08) program is to prepare individuals for careers that have a significant impact on the health-related research needs of the nation. This program represents the continuation of a long-standing NIH program that provides support and protected time to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. The NCI-sponsored K08 award is specifically designed to promote career development of clinical scientists from backgrounds that have been shown to be nationally underrepresented in health-related science and for those who are committed to a career in basic biomedical, behavioral or translational cancer research, including research on cancer health disparities. The expectation is that through this sustained period of research career development and training, awardees will develop enhanced research capabilities for cancer research careers and be better prepared to compete for research project grants (e.g. R03, R21, or R01) funding. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. This Funding Opportunity Announcement (FOA) will utilize the NIH K08 Clinical Investigator Award (CIA) mechanism.</p>			

070100	NCI Transition Career Development Award (K22 Independent Clinical Trial Required)	National Cancer Institute/NIH/DHHS	PAR-18-466	12-Feb-2021	450,000 USD
--------	---	------------------------------------	------------	-------------	-------------

	Contact Name	Sonia Jakowlew, Ph.D., Program Director			
	Contact Telephone	240-276-5630			
	Contact Email	jakowles@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	12-Feb-2021			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	National Cancer Institute (NCI) provides support to facilitate the transition of investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions. This goal is achieved by providing protected time through salary and research support for the initial 3 years of the first independent tenure-track faculty position, or its equivalent, beginning at the time when the candidate starts a tenure-track faculty position. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. This program will use the NIH K22 Career Transition Award mechanism.			
079076	Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PA-19-111	16-Feb-2021	275,000 USD
	Contact Name	Nonniekaye Shelburne, MS, CRNP, AOCN			
	Contact Telephone	240-276-6897			
	Contact Email	nshelburne@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021			
	Synopsis	This Funding Opportunity Announcement (FOA) encourages collaborative applications that will contribute to the identification and characterization of patients at risk of developing cancer treatment-related cardiotoxicity. The primary intent is to mitigate cardiovascular dysfunction while optimizing cancer outcomes. To accomplish this, methods that evaluate cardiovascular risk prior to treatment and integrate evidence-based cancer treatment regimens with cardiovascular screening, diagnostic, and/or management strategies are sought. Research applications should focus on mitigation/management of adverse effects associated with anti-cancer treatments including: cytotoxic chemotherapies, targeted agents, immunomodulatory therapies and radiation (that occur during cancer treatment and/or long-term survivorship) as defined by cardiac and/or vascular specific common terminology criteria for adverse events (CTCAE).			
069612	NCI Transition Career Development Award to Promote Diversity (K22 No Independent Clinical Trials)	National Cancer Institute/NIH/DHHS	PAR-18-366	12-Feb-2021	450,000 USD
	Contact Name	Abigail Soyombo, Ph.D., M.B.A.			
	Contact Telephone	240-276-6553			
	Contact Email	abigail.soyombo@nih.gov			
	Sponsor Website				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Feb-2021</p> <p>Synopsis National Cancer Institute (NCI) invites applications for the National Cancer Institute (NCI) Career Transition Award. The purpose of the award is to assist postdoctoral fellows or individuals in equivalent positions to transition to positions of assistant professor or equivalent and initiate a successful biomedical career as an independent research scientist. To this end, the Diversity Training Branch (DTB), within the Center to Reduce Cancer Health Disparities (CRCHD) (http://crchd.cancer.gov/) invites applications from research scientists in postdoctoral positions or equivalent who are from backgrounds nationally underrepresented in biomedical, behavioral, clinical, and/or social sciences. This award will provide "protected time" through salary and research support for 3 years beginning at the time when the candidate starts a tenure-track faculty position. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by another investigator. This program will use the NIH Transition Career Development Award (K22) mechanism.</p>				
069610	NCI Transition Career Development Award to Promote Diversity (K22 Clinical Trial Required)	National Cancer Institute/NIH/DHHS	PAR-18-367	12-Feb-2021	450,000 USD
	<p>Contact Name Abigail Soyombo, Ph.D., M.B.A.</p> <p>Contact Telephone 240-276-6553</p> <p>Contact Email abigail.soyombo@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Feb-2021</p> <p>Synopsis National Cancer Institute (NCI) invites applications for the National Cancer Institute (NCI) Career Transition Award. The purpose of the award is to assist postdoctoral fellows or individuals in equivalent positions to transition to positions of assistant professor or equivalent and initiate a successful biomedical career as an independent research scientist. To this end, the Diversity Training Branch (DTB), within the Center to Reduce Cancer Health Disparities (CRCHD) (http://crchd.cancer.gov/) invites applications from research scientists in postdoctoral positions or equivalent who are from backgrounds nationally underrepresented in biomedical, behavioral, clinical, and/or social sciences. This award will provide "protected time" through salary and research support for 3 years beginning at the time when the candidate starts a tenure-track faculty position. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		existing trial, as part of their research and career development. This program will use the NIH Transition Career Development Award (K22) mechanism.			
073410	Age-related Microbiota Changes and their Implications in Chronic Disease Prevention, Treatment and Progression (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PA-18-739	16-Feb-2021	275,000 USD
	Contact Name	Gabriela Riscuta MD, CNS, MS			
	Contact Telephone				
	Contact Email				
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Feb-2021			
	Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications to assess the role of the microbiome in health and disease during aging. This initiative will support research projects designed to evaluate changes in the microbiota during lifetime and its influence in health and disease status in the elderly, including those from racial/ethnic minority and underserved populations and understand the underlying mechanisms of microbiota interactions in aged subjects as related to health and disease. This FOA will support basic mechanistic, preclinical studies in animal models and human clinical trial proposals in accordance with the state of the science. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.			
097241	Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-20-277	16-Feb-2021	400,000 USD
	Contact Name	Melissa Rotunno, Ph.D.			
	Contact Telephone	240-276-7245			
	Contact Email	rotunnom@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Feb-2021 , 16-Jun-2021 , 16-Oct-2021 , 16-Feb-2022 , 16-Jun-2022			
	Synopsis	Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) along with the National Human Genome Research Institute (NHGRI) and National Institute of Dental and Craniofacial Research (NIDCR) encourages			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate the genetic architecture of cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.). The goal of this initiative is to address key scientific questions relevant to cancer genomic and epidemiology by supporting the analysis of existing genetic or genomic datasets, in combination with other omics and environmental, clinical, behavioral, lifestyle, and molecular profiles data. Applicants are encouraged to leverage existing genetic data and perform innovative analyses of the existing data.

069273	NCI Mentored Research Scientist Development Award to Promote Diversity (Parent K01 -Independent Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-18-364	12-Feb-2021	650,000 USD
--------	---	------------------------------------	------------	-------------	-------------

Contact Name | Abigail Soyombo, Ph.D., M.B.A.
 Contact Telephone | 240-276-6553
 Contact Email | Abigail.Soyombo@mail.nih.gov
 Sponsor Website |
 Program URL | [Link to program URL](#)
 Deadline Dates (ALL) | 12-Feb-2021

Synopsis | National Cancer Institute (NCI) invites applications for the Mentored Research Scientist Development Award. The purpose of the award is to enhance the diversity of the pool of the NCI-funded cancer research workforce by supporting eligible individuals from groups that have been shown to be nationally underrepresented in the biomedical, behavioral, social and clinical sciences. This FOA provides salary and research support for a sustained period of "protected time" for intensive research career development under the guidance of an experienced mentor. The Diversity Training Branch (DTB) of the Center to Reduce Cancer Health Disparities (CRCHD), at the National Cancer Institute (NCI), invites career development award applications (K01) from individuals from backgrounds that have been shown to be nationally underrepresented in health-related sciences. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. This Funding Opportunity Announcement (FOA) will utilize the NIH Mentored Research Scientist Development Award (K01) mechanism.

069282	NCI Mentored Research Scientist Development Award to Promote Diversity (Parent K01 - Clinical Trial Required)	National Cancer Institute/NIH/DHHS	PAR-18-365	12-Feb-2021	650,000 USD
--------	---	------------------------------------	------------	-------------	-------------

Contact Name | Abigail Soyombo, Ph.D., M.B.A.
 Contact Telephone | 240-276-6553

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email Abigail.Soyombo@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Feb-2021</p> <p>Synopsis National Cancer Institute (NCI) invites applications for the Mentored Research Scientist Development Award. The purpose of the award is to enhance the diversity of the pool of the NCI-funded cancer research workforce by supporting eligible individuals from groups that have been shown to be nationally underrepresented in the biomedical, behavioral, social and clinical sciences. This FOA provides salary and research support for a sustained period of "protected time" for intensive research career development under the guidance of an experienced mentor. The Diversity Training Branch (DTB) of the Center to Reduce Cancer Health Disparities (CRCHD), at the National Cancer Institute (NCI), invites career development award applications (K01) from individuals from backgrounds that have been shown to be nationally underrepresented in health-related sciences. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. This Funding Opportunity Announcement (FOA) will utilize the NIH Mentored Research Scientist Development Award (K01) mechanism.</p>				
072438	Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R21 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PA-18-678	16-Feb-2021	275,000 USD
	<p>Contact Name Tram Kim Lam, Ph.D., MPH</p> <p>Contact Telephone 240-276-6967</p> <p>Contact Email Tram.Lam@nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021</p> <p>Synopsis National Cancer Institute (NCI) invites applications for epidemiologic research investigating novel and innovative hypotheses on emerging risk factors (biological, environmental, and social) and their interplay with established risk factors (e.g., viral hepatitis) associated with the development of liver cancer (hepatocellular carcinoma and other histological subtypes) in the United States. This FOA will use the NIH R21 Exploratory/Developmental Grant award mechanism.</p>				
087537	Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-20-074	26-Feb-2021	450,000 USD

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name	Sumana Dey, Ph.D.
Contact Telephone	240-276-5748
Contact Email	sumana.dey@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	26-Feb-2021 , 13-Jul-2021 , 26-Oct-2021 , 28-Feb-2022 , 11-Jul-2022 , 28-Oct-2022
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI R01 research projects. The applicants should propose projects that are expected to accelerate the pace of translation of NCI-supported methods/assays/technologies (referred to as "assays") to the clinic. Specifically, the focus of applications submitted in response to this FOA should be on the adaption and clinical validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") for cancer detection, diagnosis, prognosis, monitoring, and prediction of response in treatment, as well as markers for cancer prevention and control. Applications may support the acquisition of well-annotated specimens from NCI-supported or other clinical trials or observational cohorts/consortia for the purpose of clinical validation of the assay. Research projects proposed in response to this FOA encourage multi-disciplinary interaction among scientific investigators, assay developers, clinicians, statisticians, and clinical laboratory staff. Clinical laboratory scientist(s) and statistical experts are highly encouraged to comprise integral parts of the application. This FOA is not intended to support early-stage development of technology or the conduct of clinical trials, but rather the adaption and validation of assays to the point where they could be integrated into clinical trials as investigational assays/tools/devices.

101460	Notice of Special Interest (NOSI): New Approaches to Identify Neurogenesis and Study its Dynamics in Brain Aging and AD/ADRD (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	NOT-CA-21-025	22-Feb-2021	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

Contact Name	Paul C. Pearlman, Ph.D.
Contact Telephone	240-276-6429
Contact Email	paul.pearlman@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	22-Feb-2021 , 27-May-2021 , 29-Sep-2021
Synopsis	This Notice of Special Interest (NOSI) is to alert the community that the National Cancer Institute (NCI) Center for Global

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Health (CGH) is seeking to leverage ongoing Innovative Molecular Analysis Technologies (IMAT) program activities to stimulate exploratory research on technology platforms relevant for global oncology and appropriate for use in low-resource settings globally. NCI CGH is prepared to support highly meritorious R21 applications submitted to either RFA-CA-21-003 or RFA-CA-21-005, with the goal of helping drive innovation in this field and enrich the pool of investigators participating in the NCI-sponsored Affordable Cancer Technologies (ACTs) Program.

101459	Notice of Special Interest (NOSI): Leveraging Population-based Cancer Registry Data to Study Health Disparities	National Cancer Institute/NIH/DHHS	NOT-CA-21-020	05-Feb-2021	Not Specified
--------	---	------------------------------------	---------------	-------------	---------------

Contact Name	Kathy Cronin, Ph.D.
Contact Telephone	240-276-6836
Contact Email	cronink@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Feb-2021 , 16-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 16-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-May-2023
Synopsis	The National Cancer Institute (NCI) is issuing this Notice of Special Interest (NOSI) to encourage applications that efficiently use the existing cancer registry infrastructure by augmenting existing data with additional information not routinely collected by registries to study observed health disparities such as those that exist by race, ethnicity, socioeconomic status, income, insurance status, age, education level, or geographic area. The Surveillance, Epidemiology, and End Results (SEER) Program and the National Program of Cancer Registries (NPCR) are uniquely positioned to support research to assess health disparities in the United States (US) population because they contain information on all cases diagnosed within geographically defined areas. The goal of these hypothesis-driven studies should be to understand why disparities in cancer treatment and outcomes persist by identifying factors contributing to disparities and their relative importance.

070540	Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-18-530	05-Feb-2021	Not Specified
--------	--	------------------------------------	------------	-------------	---------------

Contact Name	Miguel Ossandon MS
Contact Telephone	240-276-5714
Contact Email	ossandom@mail.nih.gov
Sponsor Website	

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021</p> <p>Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invite applications to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes. This FOA specifies a partnership structure that is expected to help bridge gaps in knowledge and experience by engaging the strengths of academic, industrial, and other investigators. The partners on each application should establish an inter-disciplinary, multi-institutional research team to work in strategic alliance to implement a coherent strategy to develop and translate a solution to their chosen problem. They are expected to plan, design, and validate that the solution will be suitable for end users. Each partnership should include at least one academic and one industrial organization. Each partnership should plan to transition a technology, method, assay, device, and/or system from a demonstration of possibility to a status useful in the chosen setting. Funding may be requested to enhance, adapt, optimize, validate, and otherwise translate technologies that address problems in biology, pathology, risk assessment, diagnosis, treatment, and/or monitoring of disease status. This FOA defines innovation as likelihood to deliver a new capability to end users. This FOA will support clinical trials that test functionality, or validate performance in the chosen setting. This FOA is not intended to support commercial production, basic research projects, or straight clinical trials that lack translation as the primary motivation. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
071800	Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PA-18-629	05-Feb-2021	Not Specified
	<p>Contact Name Anne Menkens, Ph.D.</p> <p>Contact Telephone 240-276-6510</p> <p>Contact Email menkensa@mail.nih.gov</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021</p> <p>Synopsis National Cancer Institute (NCI) invites applications for research projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance. This FOA will use the NIH Research Project (R01) award</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

mechanism.

076909	Advancing Translational and Clinical Probiotic/Prebiotic and Human Microbiome Research (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PA-18-902	05-Feb-2021	Not Specified
--------	--	------------------------------------	-----------	-------------	---------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Gabriela Riscuta, MD, CNS</p> <p>240-276-7118</p> <p>gabriela.riscuta@nih.gov</p> <p></p> <p>Link to program URL</p> <p>05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021</p> <p>National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for interdisciplinary collaborations across scientific disciplines engaged in microbiome and pro/prebiotic research including, but not limited to: nutritional science, microbiology, virology, microecology and microbiome, genomics, immunology, computational biology, chemistry, bioengineering, as well as integration of omics and computational approaches in DNA technologies. The purpose of this funding opportunity announcement (FOA) is twofold: 1) to accelerate translational and clinical Phase I and II a/b safety and efficacy studies for substantiating measurable functional benefits of probiotic/prebiotic components and/or their combinations; and; 2) to understand the underlying mechanisms of their action(s), and variability in responses to these interventions. This FOA will use the NIH Research Project (R01) award mechanism.</p>
---	---

086964	NCI Small Grants Program for Cancer Research for Years 2020, 2021, and 2022 (NCI Omnibus R03 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-20-052	24-Feb-2021	100,000 USD
--------	---	------------------------------------	------------	-------------	-------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p></p> <p></p> <p></p> <p></p> <p>Link to program URL</p> <p>24-Feb-2021 , 07-May-2021 , 24-Jun-2021 , 07-Sep-2021 , 20-Oct-2021 , 07-Jan-2022 , 24-Feb-2022 , 07-May-2022 , 24-Jun-2022 , 07-Sep-2022 , 20-Oct-2022 , 07-Jan-2023</p> <p>This funding opportunity announcement (FOA) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and</p>
---	--

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.			
100927	AMENDMENT -- Computing and Data Management Services for the National Cancer Institute (NCI)	National Cancer Institute/NIH/DHHS	75N91019R00007-R	12-Feb-2021	Not Specified

Contact Name	Rachel Weiszer
Contact Telephone	240-276-5389
Contact Email	rweiszer@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	12-Feb-2021
Synopsis	<p>Pre-Solicitation Notice Request for Proposals (RFP) 75N91019R00007 TITLE IS CHANGED TO: Biomedical Computing, Analytic and Data Management Services Set Aside Status: This potential acquisition will be competed through FULL AND OPEN COMPETITION. Only qualified businesses under the size classification relative to the North American Industry Classification System (NAICS) code 541511 – Custom Computer Programming Services need apply. The Government anticipates making two (2) indefinite delivery indefinite quantity (IDIQ) contract awards under which fixed price and cost-reimbursement type task orders will be issued. The Government anticipates that at least one task order will be awarded with each base contract. Background: The National Cancer Institute (NCI) conducts and supports science to identify a person’s risk of developing cancer and to find ways to reduce that risk. Years of research have shown that the diseases of cancer occur not as a single, catastrophic event, but rather as the result of a complex and long-evolving process. The process of carcinogenesis can take decades to complete, proving time and opportunities to retard, stop, or reverse its progress. The NCI advances cancer research by generating new information about molecular processes that are vulnerable to interventions, developing effective chemoprevention agents; discovering early detection biomarkers; pinpointing mechanistically targeted nutrients; testing new screening methods and technologies; and conducting clinical trials through national networks and at the community level. The NCI studies cancer through structural, functional and computational genomics, collecting data from tissue samples from research studies, and making the data publicly available for research. Project Requirements: The goal of this acquisition is to provide non-research and development (R&D) technical support and data management services to NCI, to support a wide variety of NCI studies and projects. These services include systems design, computer programming, system documentation, and operational support to the National Cancer Institute. Computer-related support is required in eleven (11) main areas. Area 1: Project Management/Core Services Area 2: Data Management Area 3: Computer Programming Area 4: Computing Infrastructure Services Area 5: Website Development Area 6: Systems Design and Development Area 7: Reports and Manuscripts Preparation Area 8: Management of NCI Data Area 9: Evaluation of NCI Data and Projects Area</p>

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>10: Technical and Administrative Support Area 11: Statistical Methodology and Program Support The NCI intends to award two (2) Indefinite Delivery Indefinite Quantity (IDIQ) contracts with a five year ordering period. Sample Task Order #1, "Contract Initiation/Kick-Off" will be solicited as part of the Request for Proposal for the base IDIQ contracts and awarded concurrently with all base IDIQ contracts. Sample Task Order #2, "Data Computing Services" will be awarded following the award of the base IDIQ contract to one awardee. Place of Performance: The place of performance will be the Contractor's work site. Additional Information: Request for Proposal Number 75N91019R0007 will be available on or about December 16, 2020 with a due date for receipt of proposals on or about February 16, 2020. The RFP is only available electronically and must be accessed through "Contract Opportunities" at the https://beta.sam.gov/ website and the National Cancer Institute homepage at http://rcb.cancer.gov/rcb-internet/index.jsp . All information required for submission of a proposal must be contained in the electronic RFP package. It is the Offeror's responsibility to monitor the above websites for the release of this RFP and amendments, if any. All responsible sources may submit a proposal, which shall be considered by the agency. This notice does not commit the Government to award a contract. Offerors are required to submit their proposals online at the NIH electronic Contract Proposal Submission (eCPS) website (https://ecps.nih.gov/NCI/home/) ONLY. Proposals submitted in hard copy (paper) will not be accepted. Proposals submitted by email will not be accepted. Collect calls will not be accepted. Facsimile transmissions will not be accepted. This notice does not commit the Government to award a contract. POTENTIAL OFFERORS ARE RESPONSIBLE FOR DOWNLOADING THEIR OWN COPY OF THE SOLICITATION AND ANY POSSIBLE AMENDMENTS. ALL INQUIRIES SHALL BE SUBMITTED ELECTRONICALLY TO THE POINTS OF CONTACTS LISTED HEREIN.</p>			
085422	Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-363	05-Feb-2021	499,999 USD
	Contact Name	Anne Menkens, Ph.D.			
	Contact Telephone	240-276-6510			
	Contact Email	menkensa@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021			
	Synopsis	National Cancer Institute (NCI) invites applications for research projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance. This FOA will use the NIH Research Project (R01) award mechanism.			
092626	RFA-CA-20-031 -- Strengthening Institutional Capacity to Conduct Global	National Cancer	RFA-CA-20-031	05-Feb-2021	1,250,000

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Cancer Research in Low- and Middle-Income Countries (D43 Clinical Trial Not Allowed)	Institute/NIH/DHHS			USD
	<p>Contact Name Sudha Sivaram, DrPH, MPH</p> <p>Contact Telephone 240-276-5804</p> <p>Contact Email nciglobaltraining@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to establish an institutional program for mentored training in global cancer research. This program will support research training led by the United States (U.S.)-based cancer research-intensive institutions working in collaboration with institutions in low and middle-income countries (LMICs). These training programs will be built upon the US institutions' pre-existing training infrastructure and research collaborations with LMICs and will leverage these resources to expand the global cancer research workforce both in the US and in LMICs. The overarching goal of this initiative is to build capacity to conduct innovative and collaborative global research projects that will contribute to the advancement of basic, clinical, translational, and population-based cancer research in LMICs. This FOA does not allow appointed trainees to lead an independent clinical trial but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.</p>				
067494	Testing Interventions for Health-Enhancing Physical Activity (R01 - Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-18-324	05-Feb-2021	Not Specified
	<p>Contact Name Frank Perna, Ed.D., Ph.D.</p> <p>Contact Telephone 240-276-6782</p> <p>Contact Email pernafm@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021</p> <p>Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for highly innovative and promising research that tests multi-level physical activity intervention programs acting on at least two levels of the socio-ecological model and designed to increase health-enhancing physical activity: 1) in persons or groups that can benefit from</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		such activity; and 2) that could be made scalable and sustainable for broad use across the nation. This program will use the NIH R01 Research Project Grant award mechanism.			
067401	Developing Interventions for Health-Enhancing Physical Activity (R21/R33 - Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-18-307	16-Feb-2021	1,025,000 USD
	Contact Name	Frank Perna, Ed.D., Ph.D.			
	Contact Telephone	240-276-6782			
	Contact Email	pernafm@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Feb-2021 , 07-May-2021			
	Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for highly innovative and promising research aimed at developing multi-level physical activity intervention programs acting on at least two levels of the socioecological model and designed to increase health-enhancing physical activity: 1) in persons or groups that can benefit from such activity; and 2) that could be made scalable and sustainable for broad use across the nation. This FOA provides support for up to two years (R21 phase) for research planning activities and feasibility studies, followed by a possible transition to expanded research support (R33 phase) for optimizing the intervention and conducting larger-scale feasibility studies. Transition to the R33 depends on the completion of applicant-defined milestones, as well as program priorities and the availability of funds. This program will use the NIH R21/R33 Phased Innovation Award award mechanism.			
076579	Advancing Mechanistic Probiotic/Prebiotic and Human Microbiome Research (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PA-18-876	05-Feb-2021	Not Specified
	Contact Name	Dr. Roberto Flores			
	Contact Telephone	240-276-7119			
	Contact Email	floresr2@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021			
	Synopsis	National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for basic and mechanistic science that facilitates the development of effective probiotics or pre-/probiotic combinations of relevance to human health			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>and disease; and (2) determine biological outcomes for the evaluation of efficacy of pre/probiotics in appropriate test systems and animal models. This FOA encourages basic and mechanistic studies using in vitro, in vivo, ex vivo, and in silico models that focus on prebiotic/probiotic strain selectivity, interaction, and function. It will also encourage inter and multidisciplinary collaborations among scientists in a wide range of disciplines including nutritional science, immunology, microbiomics, genomics, other '-omic' sciences, biotechnology, and bioinformatics. This FOA will use the NIH Research Project (R01) award mechanism.</p>			
076806	Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-18-892	16-Feb-2021	275,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Frank M. Perna, Ed.D., Ph.D.</p> <p>240-276-6782</p> <p>pernafm@mail.nih.gov</p> <p></p> <p>Link to program URL</p> <p>16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021</p> <p>National Cancer Institute (NCI) invites applications for transdisciplinary and translational research that will identify the specific biological or biobehavioral pathways through which physical activity and/or weight control (either weight loss or avoidance of weight gain) may affect cancer prognosis and survival. Research applications should test the effects of physical activity, alone or in combination with weight control (either weight loss or avoidance of weight gain), on biomarkers of cancer prognosis among cancer survivors identified by previous animal or observational research on established biomarkers other than insulin/glucose metabolism, especially those obtained from tumor tissue sourced from repeat biopsies where available. Because many cancer survivor populations will not experience recurrence but will die of comorbid diseases or may experience early effects of aging, inclusion of biomarkers of comorbid diseases (e.g., cardiovascular disease) and of the aging process are also sought. Applications should use experimental designs (e.g., randomized controlled clinical trials (RCTs), fractional factorial designs), and will include transdisciplinary approaches that bring together behavioral intervention expertise, cancer biology, and other basic and clinical science disciplines relevant to the pathways being studied. This FOA will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.</p>			
076805	Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-18-893	05-Feb-2021	Not Specified

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name	Frank M. Perna, Ed.D., Ph.D.
Contact Telephone	240-276-6782
Contact Email	pernafm@mail.nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021
Synopsis	National Cancer Institute (NCI) invites applications for transdisciplinary and translational research that will identify the specific biological or biobehavioral pathways through which physical activity and/or weight control (either weight loss or avoidance of weight gain) may affect cancer prognosis and survival. Research applications should test the effects of physical activity, alone or in combination with weight control (either weight loss or avoidance of weight gain), on biomarkers of cancer prognosis among cancer survivors identified by previous animal or observational research on established biomarkers other than insulin/glucose metabolism, especially those obtained from tumor tissue sourced from repeat biopsies where available. Because many cancer survivor populations will not experience recurrence but will die of comorbid diseases or may experience early effects of aging, inclusion of biomarkers of comorbid diseases (e.g., cardiovascular disease) and of the aging process are also sought. Applications should use experimental designs (e.g., randomized controlled clinical trials (RCTs), fractional factorial designs), and will include transdisciplinary approaches that bring together behavioral intervention expertise, cancer biology, and other basic and clinical science disciplines relevant to the pathways being studied. This FOA will use the NIH R01 Research Project Grant award mechanism.

082214	Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-274	05-Feb-2021	Not Specified
--------	---	------------------------------------	------------	-------------	---------------

Contact Name	Gila Neta, Ph.D.
Contact Telephone	240-276-6785
Contact Email	gila.neta@nih.gov
Sponsor Website	
Program URL	Link to program URL
Deadline Dates (ALL)	05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022
Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based interventions, tools, policies, and guidelines. Conversely, there is a benefit in understanding

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>circumstances that create a need to stop or reduce (“de-implement”) the use of interventions that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. All applications must be within the scope of the mission of one of the Institutes/Centers listed above.</p>			
077667	Increasing Uptake of Evidence-Based Screening in Diverse Adult Populations (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PA-18-932	05-Feb-2021	Not Specified
	<p>Contact Name Erica S. Breslau, PhD, MPH Contact Telephone 240-276-6773 Contact Email breslaue@mail.nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 05-Feb-2021 , 07-May-2021 , 05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invite applications that seek to understand strategies to reduce disparities in the uptake of evidence-based screening (e.g. screening recommendations proven to be effective based on rigorous systematic review of scientific evidence by authoritative committees) across the adult lifespan. In this program announcement, screening is defined as a preventive service focused on detection of an undiagnosed disease in asymptomatic populations. Research supported by this initiative should enhance the screening process related to use: (1) in diverse populations, (2) in diverse clinical and community settings, and/or (3) with traditional, non-traditional and/or allied health care providers. This FOA will use the NIH Research Project (R01) award mechanism.</p>				
079335	Exploratory/Developmental Bioengineering Research Grants(EBRG) (R21 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-19-149	16-Feb-2021	275,000 USD
	<p>Contact Name Miguel R. Ossandon, Ph.D. Contact Telephone 240-276-5714 Contact Email ossandom@mail.nih.gov Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 Synopsis The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
					utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility.
079333	Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-150	16-Feb-2021	275,000 USD
	Contact Name	Miguel R. Ossandon, Ph.D.			
	Contact Telephone	240-276-5714			
	Contact Email	ossandom@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022			
	Synopsis	The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of Exploratory/Developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility.			
082215	Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-275	16-Feb-2021	275,000 USD
	Contact Name	Gila Neta, Ph.D.			
	Contact Telephone	240-276-6785			
	Contact Email	gila.neta@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022			
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based interventions, tools, policies, and guidelines. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of interventions that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. All applications must be within scope of the mission of one of the Institutes/Centers listed above.			

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
082216	Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-19-276	16-Feb-2021	50,000 USD
	<p>Contact Name Gila Neta, Ph.D.</p> <p>Contact Telephone 240-276-6785</p> <p>Contact Email gila.neta@nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based interventions, tools, policies, and guidelines. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of interventions that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. All applications must be within scope of the mission of one of the Institutes/Centers listed above.</p>				
083680	Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-19-309	16-Feb-2021	275,000 USD
	<p>Contact Name Tanya Agurs-Collins, Ph.D</p> <p>Contact Telephone 240-276-6956</p> <p>Contact Email collinsta@mail.nih.gov</p> <p>Sponsor Website </p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021 , 07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022</p> <p>Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to provide support for the development of innovative interventions that improve cancer-related health behaviors across diverse racial/ethnic populations. Specifically, this FOA is intended to stimulate research aimed at 1) testing new theories and conceptual frameworks; 2) developing and evaluating novel strategies to improve cancer-related health behaviors; 3) investigating multi-level and multi-behavioral approaches; and 4) utilizing innovative research designs, methodologies, and technologies. The cancer-related health behaviors to be targeted are diet, obesity, physical activity and sedentary behavior, smoking, sleep and circadian dysfunction, alcohol use,</p>				

NIH Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

and/or adherence to cancer-related medical regimens. Research can involve several stages of the cancer continuum and any phase of the translational spectrum.

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
080079	Quantum Leap Challenge Institutes (QLCI)	National Science Foundation	19-559	01-Feb-2021	25,000,000 USD
	<p>Contact Name</p> <p>Contact Telephone 703-292-4861</p> <p>Contact Email QLCI@nsf.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Feb-2021</p> <p>Synopsis Quantum Leap Challenge Institutes are large-scale interdisciplinary research projects that aim to advance the frontiers of quantum information science and engineering. Research at these Institutes will span the focus areas of quantum computation, quantum communication, quantum simulation and/or quantum sensing. The institutes are expected to foster multidisciplinary approaches to specific scientific, technological, educational workforce development goals in these fields. Two types of awards will be supported under this program: (i) 12-month Conceptualization Grants (CGs) to support teams envisioning subsequent Institute proposals and (ii) 5-year Challenge Institute (CI) awards to establish and operate Quantum Leap Challenge Institutes. This activity is part of the Quantum Leap, one of the research Big Ideas promoted by the National Science Foundation (NSF).</p>				
079863	Growing Convergence Research (GCR)	National Science Foundation	19-551	01-Feb-2021	1,200,000 USD
	<p>Contact Name Dragana Brzakovic</p> <p>Contact Telephone 703-292-5033</p> <p>Contact Email dbrzakov@nsf.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Feb-2021</p> <p>Synopsis Growing Convergence Research (GCR) at the National Science Foundation was identified as one of 10 Big Ideas. Convergence research is a means for solving vexing research problems, in particular, complex problems focusing on societal needs. It entails integrating knowledge, methods, and expertise from different disciplines and forming novel frameworks to catalyze scientific discovery and innovation. GCR identifies Convergence Research as having two primary characteristics: Research</p>				

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>driven by a specific and compelling problem. Convergence Research is generally inspired by the need to address a specific challenge or opportunity, whether it arises from deep scientific questions or pressing societal needs; and Deep integration across disciplines. As experts from different disciplines pursue common research challenges, their knowledge, theories, methods, data, research communities and languages become increasingly intermingled or integrated. New frameworks, paradigms or even disciplines can form sustained interactions across multiple communities.</p>			
090622	Spectrum Innovation Initiative: National Center for Wireless Spectrum Research (SII-Center)	National Science Foundation	20-557	01-Feb-2021 [LOI/Pre-App]	25,000,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p>	<p>Bevin A. Zauderer</p> <p>703-292-2428</p> <p>SII-Center@nsf.gov</p> <p>Link to sponsor website</p> <p>Link to program URL</p> <p>01-Feb-2021 [LOI/Pre-App], 01-Apr-2021</p>			
	Synopsis	<p>The worldwide growth of wireless communication, navigation, and telemetry has provided immense societal benefits including mobile broadband data, Internet of Things (IoT), mobile healthcare, and intelligent transportation systems. These and other applications including 5G and beyond wireless systems call for innovations that can circumvent the challenges of radio spectrum scarcity and interference and foster the growth of ubiquitous, high speed, low latency connectivity. Commercial applications like the above must operate in harmony with scientific uses such as research on radio astronomy, Earth and atmospheric sciences, and must not inhibit weather prediction, polar research, and other nationally vital activities, all of which are dependent upon access to the radio spectrum. The National Science Foundation (NSF) continues to support wireless spectrum research and the scientific uses of the electromagnetic spectrum through multiple programs that enable fast, accurate, dynamic coordination and usage of our limited spectrum resource. These programs have created an opportune ground to build and create a large center-based ecosystem for spectrum research, which is the target of this SII-Center program. The focus of a spectrum research SII-Center must go beyond 5G, IoT, and other existing or forthcoming systems and technologies and chart out a trajectory to ensure United States leadership in future wireless technologies, systems, and applications in science and engineering through the efficient use and sharing of the radio spectrum. The SII-Center should also seek to foster scientific and technical collaboration and grow the spectrum workforce. The establishment of an SII-Center will have a transformational impact on wireless spectrum research by serving as a connecting point for the biggest and most challenging questions in spectrum management that the nation is facing.</p>			
100371	Mid-Career Advancement (MCA)	National Science	21-516	01-Feb-2021	Not Specified

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Foundation

Contact Name					
Contact Telephone	703-292-4628				
Contact Email	MCA.info@nsf.gov				
Sponsor Website	Link to sponsor website				
Program URL	Link to program URL				
Deadline Dates (ALL)	01-Feb-2021				
Synopsis	<p>An academic career often does not provide the uninterrupted stretches of time necessary for acquiring and building new skills to enhance and advance one's research program. Mid-career scientists in particular are at a critical career stage where they need to advance their research programs to ensure long-term productivity and creativity but are often constrained by service, teaching, or other activities that limit the amount of time devoted to research. The MCA offers an opportunity for scientists and engineers at the Associate Professor rank (or equivalent) to substantively enhance and advance their research program through synergistic and mutually beneficial partnerships, typically at an institution other than their home institution. Projects that envision new insights on existing problems or identify new but related problems previously inaccessible without new methodology or expertise from other fields are encouraged. Partners from outside the PI's own sub-discipline or discipline are encouraged, but not required, to enhance interdisciplinary networking and convergence across science and engineering fields. By (re)-investing in mid-career investigators, NSF aims to enable and grow a more diverse scientific workforce (more women, persons with disabilities, and underrepresented minorities) at high academic ranks, who remain engaged and active in cutting-edge research.</p>				

101054	Mid-scale Research Infrastructure-2 (Mid-scale RI-2)	National Science Foundation	21-537	03-Feb-2021 [LOI/Pre-App]	100,000,000 USD
--------	--	-----------------------------	--------	---------------------------	-----------------

Contact Name	Brian Midson				
Contact Telephone	703-292-8145				
Contact Email	bmidson@nsf.gov				
Sponsor Website	Link to sponsor website				
Program URL	Link to program URL				
Deadline Dates (ALL)	03-Feb-2021 [LOI/Pre-App], 05-Mar-2021 [LOI/Pre-App], 20-Sep-2021				
Synopsis	NSF-supported science and engineering research increasingly relies on cutting-edge infrastructure. With its Major Research				

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Instrumentation (MRI) program and Major Multi-user Research Facility projects (Major Facilities), NSF supports infrastructure projects at the lower and higher ends of infrastructure scales across science and engineering research disciplines. The Mid-scale Research Infrastructure Big Idea is intended to provide NSF with an agile, Foundation-wide process to fund experimental research capabilities in the mid-scale range between the MRI and Major Facilities thresholds. NSF defines Research Infrastructure (RI) as any combination of facilities, equipment, instrumentation, or computational hardware or software, and the necessary human capital in support of the same. Major facilities and mid-scale projects are subsets of research infrastructure. The NSF Mid-scale Research Infrastructure-2 Program (Mid-scale RI-2) supports the implementation of unique and compelling RI projects. Mid-scale RI-2 projects may include any combination of equipment, instrumentation, cyberinfrastructure, broadly used large-scale data sets, and the commissioning and/or personnel needed to successfully complete the project. Mid-scale RI-2 projects should fill a research community-defined scientific need, or address an identified national research priority, that enables current and next-generation U.S. researchers and a diverse STEM workforce to remain competitive in a global research environment. The total cost for Mid-scale RI-2 projects ranges from \$20 million to below the threshold for a Major Facilities Project, currently \$100 million. Mid-scale RI-2 projects will directly enable advances in any of the research domains supported by NSF, including STEM education research. Projects may also include upgrades to existing research infrastructure. The Mid-scale RI-2 Program emphasizes projects that have strong scientific merit, respond to an identified need of the research community, demonstrate technical and managerial readiness for implementation, include a well-developed plan for student training in the design and implementation of mid-scale research infrastructure, and involve a diverse workforce in mid-scale facility development, and/or associated data management. Training of students in design and implementation, not just in scientific exploitation of the infrastructure, is essential.

090168	ADVANCE: Organizational Change for Gender Equity in STEM Academic Professions (ADVANCE)	National Science Foundation	20-554	04-Feb-2021	Not Specified
--------	---	-----------------------------	--------	-------------	---------------

Contact Name	Jessie DeAro
Contact Telephone	703-292-5350
Contact Email	ADVANCE@nsf.gov
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	04-Feb-2021 , 04-Feb-2021 , 22-Apr-2021 [LOI/Pre-App], 07-Oct-2021
Synopsis	The NSF ADVANCE program contributes to the National Science Foundation's goal of a more diverse and capable science and engineering workforce. In this solicitation, the NSF ADVANCE program seeks to build on prior NSF ADVANCE work and other research and literature concerning gender, racial, and ethnic equity. The NSF ADVANCE program goal is to broaden the

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
	<p>implementation of evidence-based systemic change strategies that promote equity for STEM faculty in academic workplaces and the academic profession. The NSF ADVANCE program provides grants to enhance the systemic factors that support equity and inclusion and to mitigate the systemic factors that create inequities in the academic profession and workplaces. Systemic (or organizational) inequities may exist in areas such as policy and practice as well as in organizational culture and climate. For example, practices in academic departments that result in the inequitable allocation of service or teaching assignments may impede research productivity, delay advancement, and create a culture of differential treatment and rewards. Similarly, policies and procedures that do not mitigate implicit bias in hiring, tenure, and promotion decisions could lead to women and racial and ethnic minorities being evaluated less favorably, perpetuating historical under-participation in STEM academic careers and contributing to an academic climate that is not inclusive.</p>																		
100954	Dear Colleague Letter: Broadening Participation in STEM Entrepreneurship and Innovation (BPINNOVATE)	National Science Foundation	NSF 21-023	09-Feb-2021	Not Specified														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Joshua Trapani</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>jtrapani@nsf.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>09-Feb-2021</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>The National Science Foundation (NSF), through its Science of Science program (PD 19-125Y), encourages research on broadening participation in entrepreneurship and innovation. The purpose of this Dear Colleague Letter (DCL) is to invite proposals identifying contextual factors and mitigation strategies to enhance participation and success of various populations in STEM entrepreneurship and innovation. This DCL is supported by five allied programs from five NSF Directorates and Offices, reflecting the broad support and timeliness of this "BPINNOVATE" effort.</td> </tr> </table>					Contact Name	Joshua Trapani	Contact Telephone		Contact Email	jtrapani@nsf.gov	Sponsor Website		Program URL	Link to program URL	Deadline Dates (ALL)	09-Feb-2021	Synopsis	The National Science Foundation (NSF), through its Science of Science program (PD 19-125Y), encourages research on broadening participation in entrepreneurship and innovation. The purpose of this Dear Colleague Letter (DCL) is to invite proposals identifying contextual factors and mitigation strategies to enhance participation and success of various populations in STEM entrepreneurship and innovation. This DCL is supported by five allied programs from five NSF Directorates and Offices, reflecting the broad support and timeliness of this "BPINNOVATE" effort.
Contact Name	Joshua Trapani																		
Contact Telephone																			
Contact Email	jtrapani@nsf.gov																		
Sponsor Website																			
Program URL	Link to program URL																		
Deadline Dates (ALL)	09-Feb-2021																		
Synopsis	The National Science Foundation (NSF), through its Science of Science program (PD 19-125Y), encourages research on broadening participation in entrepreneurship and innovation. The purpose of this Dear Colleague Letter (DCL) is to invite proposals identifying contextual factors and mitigation strategies to enhance participation and success of various populations in STEM entrepreneurship and innovation. This DCL is supported by five allied programs from five NSF Directorates and Offices, reflecting the broad support and timeliness of this "BPINNOVATE" effort.																		
088283	Computer Science for All	National Science Foundation	20-539	10-Feb-2021	2,000,000 USD														
	<table border="0" style="width: 100%;"> <tr> <td style="width: 20%; vertical-align: top;">Contact Name</td> <td>Jeffrey Forbes</td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>703-292-8950</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>jforbes@nsf.gov</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td>Link to sponsor website</td> </tr> </table>					Contact Name	Jeffrey Forbes	Contact Telephone	703-292-8950	Contact Email	jforbes@nsf.gov	Sponsor Website	Link to sponsor website						
Contact Name	Jeffrey Forbes																		
Contact Telephone	703-292-8950																		
Contact Email	jforbes@nsf.gov																		
Sponsor Website	Link to sponsor website																		

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 10-Feb-2021</p> <p>Synopsis This program aims to provide all U.S. students with the opportunity to participate in computer science (CS) and computational thinking (CT) education in their schools at the preK-12 levels. With this solicitation, the National Science Foundation (NSF) focuses on both research and researcher-practitioner partnerships (RPPs) that foster the research and development needed to bring CS and CT to all schools. Specifically, this solicitation aims to provide (1) high school teachers with the preparation, professional development (PD) and ongoing support they need to teach rigorous computer science courses; (2) preK-8 teachers with the instructional materials and preparation they need to integrate CS and CT into their teaching; and (3) schools and districts with the resources needed to define and evaluate multi-grade pathways in CS and CT.</p>				
068213	<p>Centers of Research Excellence in Science and Technology (CREST) and HBCU Research Infrastructure for Science and Engineering (RISE)</p>	National Science Foundation	18-509	11-Feb-2021	Not Specified
	<p>Contact Name Victor A. Santiago</p> <p>Contact Telephone 703-292-4673</p> <p>Contact Email vsantiag@nsf.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-Feb-2021</p> <p>Synopsis The Centers of Research Excellence in Science and Technology (CREST) program provides support to enhance the research capabilities of minority-serving institutions (MSI) through the establishment of centers that effectively integrate education and research. MSIs of higher education denote institutions that have undergraduate enrollments of 50% or more (based on total student enrollment) of members of minority groups underrepresented among those holding advanced degrees in science and engineering fields: African Americans, Alaska Natives, American Indians, Hispanic Americans, Native Hawaiians, and Native Pacific Islanders. CREST promotes the development of new knowledge, enhancements of the research productivity of individual faculty, and an expanded presence of students historically underrepresented in science, technology, engineering, and mathematics (STEM) disciplines. CREST Postdoctoral Research Fellowship (PRF) awards provide research experience and training for early career scientists at active CREST Centers. HBCU-RISE awards specifically target HBCUs to support the expansion of institutional research capacity as well as the production of doctoral students, especially those from groups underrepresented in STEM, at those institutions.</p>				
100712	<p>Harnessing the Data Revolution (HDR): Data Science Corps (DSC)</p>	National Science	21-523	12-Feb-2021	1,500,000 USD

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Foundation					
	<p>Contact Name Amarda Shehu</p> <p>Contact Telephone 703-292-8191</p> <p>Contact Email ashehu@nsf.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Feb-2021</p> <p>Synopsis NSF's Harnessing the Data Revolution (HDR) Big Idea is a national-scale activity to enable new modes of data-driven discovery that will allow fundamental questions to be asked and answered at the frontiers of science and engineering. In 2019, the HDR Big Idea launched three parallel efforts in pursuit of these aims: Institutes for Data-Intensive Research in Science and Engineering (I-DIRSE), HDR: Transdisciplinary Research In Principles Of Data Science Phase I (HDR TRIPODS Phase I), and Data Science Corps (DSC). The Data Science Corps is one of the components of the HDR ecosystem enabling education and workforce development by focusing on building capacity for harnessing the data revolution at the local, state, and national levels to help unleash the power of data in the service of science and society. The Data Science Corps will provide practical experiences, teach new skills, and offer learning opportunities in different settings. This solicitation prompts the community to envision creative educational pathways that will transform data science education and expand the data science talent pool by enabling the participation of undergraduate and Master's degree students with diverse backgrounds, experiences, skills, and technical maturity in the Data Science Corps. These activities are envisioned to be inherently collaborative, with a lead organization and one or more collaborating organizations.</p>				
098649	NSF Dynamic Language Infrastructure - NEH Documenting Endangered Languages (DLI-DEL)	National Science Foundation	20-603	15-Feb-2021	Not Specified
	<p>Contact Name Joan M. Maling</p> <p>Contact Telephone 703-292-8046</p> <p>Contact Email jmaling@nsf.gov</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Feb-2021 , 15-Sep-2021</p> <p>Synopsis This funding partnership between the National Science Foundation (NSF) and the National Endowment for the Humanities</p>				

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

(NEH) supports projects to develop and advance knowledge concerning dynamic language infrastructure in the context of endangered human languages—languages that are both understudied and at risk of falling out of use. Made urgent by the imminent loss of roughly half of the approximately 7,000 currently used languages, this effort aims to exploit advances in human-language technology to build computational infrastructure for endangered language research. The program supports projects that contribute to data management and archiving, and to the development of the next generation of researchers. Funding can support fieldwork and other activities relevant to the digital recording, documentation and analysis, and archiving of endangered language data, including the preparation of lexicons, grammars, text samples, and databases. Funding will be available in the form of one- to three-year senior research grants and conference proposals.

100415	Integrative Strategies for Understanding Neural and Cognitive Systems (NCS)	National Science Foundation	21-517	15-Feb-2021	Not Specified
--------	---	-----------------------------	--------	-------------	---------------

Contact Name	
Contact Telephone	703-292-5149
Contact Email	ncs@nsf.gov
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	15-Feb-2021 , 14-Feb-2022 , 15-Dec-2022 [LOI/Pre-App], 15-Feb-2023

Synopsis The complexities of brain and behavior pose fundamental questions in many areas of science and engineering, drawing intense interest across a broad spectrum of disciplinary perspectives while eluding explanation by any one of them. Rapid advances within and across disciplines are leading to an increasingly interwoven fabric of theories, models, empirical methods and findings, and educational approaches, opening new opportunities to understand complex aspects of neural and cognitive systems through integrative multidisciplinary approaches. This program calls for innovative, convergent, boundary-crossing proposals that can best capture those opportunities and map out new research frontiers. NSF seeks proposals that pursue high-value scientific and technical risks by transcending the perspectives and approaches typical of disciplinary research efforts. This cross-directorate program is one element of NSF's participation in the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative (<https://www.nsf.gov/brain/>). NSF envisions a connected portfolio of transformative, integrative projects that create synergistic links across investigators and communities, yielding novel ways of tackling the challenges of understanding the brain in action and in context. This solicitation extends the NCS program for three years, from FY2021 through FY2023, including biennial competitions for the FRONTIERS proposal class. The program focuses on four aspects of neural and cognitive systems that are current targets of converging interdisciplinary interests. NCS projects must advance the foundations of one or more of these focus areas, as described further within the solicitation:

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Neuroengineering and Brain-Inspired Concepts and Designs; Individuality and Variation; Cognitive and Neural Processes in Realistic, Complex Environments; Data-Intensive Neuroscience and Cognitive Science.				
087883	Algorithms for Threat Detection (ATD)	National Science Foundation	20-531	17-Feb-2021	3,000,000 USD
	Contact Name	Leland M. Jameson			
	Contact Telephone	703-292-4883			
	Contact Email	ljameson@nsf.gov			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	17-Feb-2021			
	Synopsis	The Algorithms for Threat Detection (ATD) program will support research projects to develop the next generation of mathematical and statistical algorithms for analysis of large spatiotemporal datasets with application to quantitative models of human dynamics. The program is a partnership between the Division of Mathematical Sciences (DMS) at the National Science Foundation (NSF) and the National Geospatial Intelligence Agency (NGA).			
085993	Ethical and Responsible Research (ER2)	National Science Foundation	19-609	22-Feb-2021	600,000 USD
	Contact Name	John N. Parker			
	Contact Telephone	703-292-5034			
	Contact Email	joparker@nsf.gov			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	22-Feb-2021			
	Synopsis	Ethical and Responsible Research (ER2) funds research projects that identify (1) factors that are effective in the formation of ethical STEM researchers and (2) approaches to developing those factors in all STEM fields that NSF supports. ER2 solicits proposals for research that explores the following: "What constitutes responsible conduct for research (RCR), and which cultural and institutional contexts promote ethical STEM research and practice and why?" Do certain labs have a "culture of academic integrity"? What practices contribute to the establishment and maintenance of ethical cultures and how can these practices be transferred, extended to, and integrated into other research and learning settings?" Factors one might consider			

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>include: honor codes, professional ethics codes and licensing requirements, an ethic of service and/or service learning, life-long learning requirements, curricula or memberships in organizations (e.g. Engineers without Borders) that stress responsible conduct for research, institutions that serve under-represented groups, institutions where academic and research integrity are cultivated at multiple levels, institutions that cultivate ethics across the curriculum, or programs that promote group work, or do not grade. Successful proposals typically have a comparative dimension, either between or within institutional settings that differ along these or among other factors, and they specify plans for developing interventions that promote the effectiveness of identified factors. ER2 research projects will use basic research to produce knowledge about what constitutes or promotes responsible or irresponsible conduct of research, and how to best instill this knowledge into researchers and educators at all career stages. In some cases, projects will include the development of interventions to ensure ethical and responsible research conduct.</p>			
100938	Understanding the Rules of Life: Microbiome Interactions and Mechanisms (URoL:MIM)	National Science Foundation	21-534	23-Feb-2021	3,000,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p>	<p>Catalina Achim</p> <p>703-292-2048</p> <p>microbiome@nsf.gov</p> <p>Link to sponsor website</p> <p>Link to program URL</p> <p>23-Feb-2021</p>			
	Synopsis	<p>The URoL:MIM program invites integrated, interdisciplinary proposals that create new knowledge in multiple disciplines to develop causal frameworks with well-designed scientific and/or computational approaches to test hypotheses about the relationships within the microbiome, and among the microbiome, the host, and the environment. Projects may develop new computational, mathematical, or experimental tools, and models, to: i) explain function and interactions in natural, experimental, and model microbiomes; ii) elucidate the chemical and molecular mechanisms that underlie communication between the host and the microbiome and among the members of the microbiome; and/or iii) comparatively analyze characteristics of microbiomes to discover emergent properties that provide insight into the behavior of living systems. URoL:MIM supports basic science research projects of different scales and scope. Projects may have a total budget of up to \$3,000,000 and an award duration of up to 5 years.</p>			
100975	National Science Foundation Research Traineeship (NRT) Program	National Science Foundation	21-536	25-Feb-2021	3,000,000 USD

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>Daniel Denecke</p> <p>703-292-8072</p> <p>ddenecke@nsf.gov</p> <p>Link to sponsor website</p> <p>Link to program URL</p> <p>25-Feb-2021 , 06-Sep-2021</p> <p>The NSF Research Traineeship (NRT) program seeks proposals that explore ways for graduate students in research-based master’s and doctoral degree programs to develop the skills, knowledge, and competencies needed to pursue a range of STEM careers. The program is dedicated to effective training of STEM graduate students in high priority interdisciplinary or convergent research areas, through a comprehensive traineeship model that is innovative, evidence-based, and aligned with changing workforce and research needs. The NRT program addresses workforce development, emphasizing broad participation, and institutional capacity building needs in graduate education. The program encourages proposals that involve strategic collaborations with the private sector, non-governmental organizations (NGOs), government agencies, national laboratories, field stations, teaching and learning centers, informal science centers, and academic partners. NRT especially welcomes proposals that include partnership with NSF Inclusion across the Nation of Communities of Learners of Underrepresented Discoverers in Engineering and Science (INCLUDES) and leverage INCLUDES project efforts to develop STEM talent from all sectors and groups in our society (https://www.nsf.gov/news/special_reports/big_ideas/includes.jsp). Collaborations between NRT proposals and existing NSF INCLUDES projects should strengthen both NRT and INCLUDES projects.</p>
---	---

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
101077	Wounded Warrior Service Dog Program (WWSDP)	Department of Defense	HU000121USU00 01	03-Feb-2021	Not Specified
	Contact Name	Rita A. Holliday, Chief, Research Support Division			
	Contact Telephone	301-295-1380			
	Contact Email	wwsdp-ggg@usuhs.edu			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	03-Feb-2021			
	Synopsis	The sponsor is seeking to provide competitive grants to support nonprofit organizations committed to training and placing assistance dogs with disabled Service Members (SMs) and Veterans.			
101275	Exits from Disability Evidence Study - to collect	Social Security Administration/DHHS	28321321R00000 010	01-Feb-2021	Not Specified
	Contact Name	Brenda Monch			
	Contact Telephone				
	Contact Email	BRENDA.MONCH@SSA.GOV			
	Sponsor Website	Link to sponsor website			
	Program URL				
	Deadline Dates (ALL)	01-Feb-2021			
	Synopsis	Exits from Disability Evidence Study - The purpose of the study is to collect information about the service, medical, and employment needs of working-age adults (i.e., 18 to 64 years of age) exiting Social Security disability programs because of medical improvement. It also serves to produce testable policy recommendations that help the study population become self-sufficient. The ultimate goal of this data gathering is to identify potential interventions and to inform policy recommendations that are likely to help Exiters and Possible Exiters achieve sustainable, substantial employment leading to self-sufficiency. ORDES is aiming to award the study contract during June 2021. Additional beta.sam.gov information Notice Id 431c9eebbf4c4bfaa6f155f120d478e8 Source https://beta.sam.gov/opp/431c9eebbf4c4bfaa6f155f120d478e8/view Note: This link might not be valid after archive date below. Archive Date 11/24/2021			
101048	Integrated Networks to Deliver	Administration on	HHS-2021-ACL-	02-Feb-2021	1,400,000 USD

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	and Sustain Evidence-Based Chronic Disease Self-Management Education Programs	Aging/DHHS	AOA-CSSG-0014		
	Contact Name	Shannon Skowronski			
	Contact Telephone	202-795-7438			
	Contact Email	shannon.skowronski@acl.hhs.gov			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	02-Feb-2021			
	Synopsis	Through this funding opportunity, the Administration on Aging (AoA), part of the Administration for Community Living (ACL), plans to award approximately 3 cooperative agreements to domestic public or private non-profit entities. The intent of these awards is to strengthen integrated networks that address the behavioral and social determinants of health of older adults and adults with disabilities, and increase the number of these individuals who participate in evidence-based chronic disease self-management education and self-management support programs. Applicants may request a total budget from \$1,100,000 to a maximum of \$1,400,000 for the three-year project period.			
101024	Empowering Communities to Address Behavioral Health and Chronic Pain through Chronic Disease Self-Management Education Programs	Administration on Aging/DHHS	HHS-2021-ACL- AOA-CSSG-0018	02-Feb-2021	300,000 USD
	Contact Name	Shannon Skowronski			
	Contact Telephone	202-795-7438			
	Contact Email	shannon.skowronski@acl.hhs.gov			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	02-Feb-2021			
	Synopsis	Through this funding opportunity, the Administration on Aging (AoA), part of the Administration for Community Living (ACL), plans to award approximately eight cooperative agreements to domestic public or private non-profit entities. This			

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		funding opportunity is designed to address behavioral health and/or chronic pain among older adults and adults with disabilities through the implementation of appropriate evidence-based self-management education and self-management support programs. Applicants may request a total budget from \$200,000 to a maximum of \$300,000 for the three-year project period. All awards are subject to the availability of federal funds.			
057648	Large Research Projects for Prevention of Healthcare-Associated Infections (R01)	Agency for Healthcare Research and Quality/DHHS	PA-17-008	05-Feb-2021	2,500,000 USD
	Contact Name	James I. Cleeman, M.D.			
	Contact Telephone	301-427-1330			
	Contact Email	james.cleeman@ahrq.hhs.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Feb-2021			
	Synopsis	Agency for Healthcare Research and Quality (AHRQ) invites applications for funding to conduct Large Research Projects (R01) that propose to advance the base of knowledge for detection, prevention, and reduction of Healthcare-Associated Infections (HAIs). The FOA describes the broad areas of HAI research for which funds are available to support Large Research Projects. This FOA will utilize the AHRQ R01 Research Project Grant award mechanism.			
057071	Developing Measures of Shared Decision Making (R01)	Agency for Healthcare Research and Quality/DHHS	PA-16-424	05-Feb-2021	1,500,000 USD
	Contact Name	Monique D. Cohen, PhD, MPH			
	Contact Telephone	301-427-1630			
	Contact Email	Monique.Cohen@ahrq.hhs.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Feb-2021 , 05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022			
	Synopsis	Shared decision making (SDM) is a collaborative process in which patients and members of their clinical team work together to make health care decisions informed by scientific evidence as well as patients' own values and			

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>preferences. SDM has proven difficult to measure, and the literature points to significant gaps and limitations in the measurement of SDM. Agency for Healthcare Research and Quality (AHRQ) invites applications to develop, test, and evaluate measures of SDM that can be used to conduct research in clinical settings. This FOA will use the Research Project (R01) award mechanism.</p>			
061542	Health Information Technology (IT) to Improve Health Care Quality and Outcomes (R21)	Agency for Healthcare Research and Quality/DHHS	PA-17-246	16-Feb-2021	300,000 USD
	Contact Name	Bryan B. Kim, Ph.D.			
	Contact Telephone	301-427-1505			
	Contact Email	HealthITFunding@ahrq.hhs.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	16-Feb-2021 , 16-Jun-2021			
	Synopsis	<p>Agency for Healthcare Research and Quality (AHRQ) invites applications for funding to conduct exploratory and developmental research grants (R21) for projects in the early and conceptual stages of development that will contribute to the evidence base of how health information technology (IT) improves health care quality and outcomes. This program will use the Exploratory/Developmental (R21) grant mechanism.</p>			
057446	AHRQ Conference Grant Program (R13)	Agency for Healthcare Research and Quality/DHHS	PA-16-453	01-Feb-2021	150,000 USD
	Contact Name	Linda Franklin			
	Contact Telephone	301-427-1904			
	Contact Email	linda.franklin@ahrq.hhs.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Feb-2021 , 01-May-2021 , 01-Aug-2021 , 01-Nov-2021			
	Synopsis	<p>Agency for Healthcare Research and Quality (AHRQ) announces its interest in supporting conferences through the AHRQ Single Year and Multiple Year Conference Grant Programs (R13). AHRQ seeks to support conferences that help to further</p>			

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		its mission to produce evidence to make health care safer, higher quality, more accessible, equitable and affordable, and to work with HHS and other partners to make sure that the evidence is understood and used (http://www.ahrq.gov/funding/policies/foaguidance/index.html . This FOA will use the conference grant (R13) award mechanism.			
100779	Advanced Nursing Education - Sexual Assault Nurse Examiners (ANE-SANE) Program	Bureau of Health Workforce/HRSA/DHHS	HRSA-21-016	17-Feb-2021	1,500,000 USD
	Contact Name	Deitra Scott			
	Contact Telephone	301-945-3113			
	Contact Email	dscott1@hrsa.gov			
	Sponsor Website	Link to sponsor website			
	Program URL				
	Deadline Dates (ALL)	17-Feb-2021			
	Synopsis	The Health Resources and Services Administration (HRSA) is accepting applications for the fiscal year (FY) 2021 Advanced Nursing Education-Sexual Assault Nurse Examiners (ANE-SANE) Program. The purpose of the ANE-SANE program is to fund advanced nursing education to recruit, train and certify Registered Nurses (RNs), Advanced Practice Registered Nurses (APRNs), and Forensic Nurses (FNs) to practice as sexual assault nurse examiners (SANEs). The program aims to increase the supply and distribution of qualified working SANEs and expand access to sexual assault forensic examinations. By expanding access to SANEs, the ANE-SANE program aims to provide better physical and mental health care treatment for survivors of sexual assault and domestic violence leading to better evidence collection and potentially higher prosecution rates.			
101337	Partnering and Communicating Together	National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention/CDC/DHHS	CDC-RFA-PS21-2104	17-Feb-2021 [Optional][L OI/Pre-App]	937,500 USD
	Contact Name	Joynecia Clements-Powell, Project Officer			
	Contact Telephone	404-639-5199			
	Contact Email	NPT@cdc.gov			
	Sponsor Website				

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 17-Feb-2021 [Optional][LOI/Pre-App], 05-Apr-2021</p> <p>Synopsis CDC announces the availability of fiscal year 2021 funds for a Notice of Funding Opportunity (NOFO) to support CDC human immunodeficiency virus (HIV) prevention efforts as part of the Administration's Ending the HIV Epidemic: A Plan for America (EHE) Initiative. In February 2019, HHS announced Ending the HIV Epidemic: A Plan for America (EHE). Accordingly, CDC seeks to increase HIV awareness among the general public, reduce new HIV infections, and improve health outcomes for people with HIV in the United States and its territories. This NOFO supports organizations who have the infrastructure but have not previously focused on HIV prevention, education, treatment, outreach and/or community engagement. The purpose of this NOFO is 1) to support the dissemination of CDC's Let's Stop HIV Together (Together) campaign via the use of digital and social media platforms and 2) disseminate Together campaign materials, messaging, and other CDC resources that support HIV prevention at inperson and virtual events. This program will support organizations to expand the reach and dissemination of Together campaign resources using a variety of vehicles including publications, meetings, conferences, media (digital and social), and other mechanisms. Recipients will prioritize health communication and mobilization efforts among populations highly impacted by HIV and in the highest burden jurisdictions.</p>				
097329	<p>Prototype development of a COVID-19 Pandemic Therapeutic Rapid Advanced Research and Development (ARD) to Large Scale Manufacturing</p>	Department of the Army	W911QY-20-S-0019	28-Feb-2021	Not Specified
	<p>Contact Name Lawrence E. Mize</p> <p>Contact Telephone 301-619-9813</p> <p>Contact Email lawrence.e.mize.civ@mail.mil</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 28-Feb-2021</p> <p>Synopsis Prototype development of a COVID-19 Pandemic Therapeutic Rapid Advanced Research and Development (ARD) to Large Scale Manufacturing. This Prototype project is a combination of an agile development activity, design, and demonstration of the technical and operational utility of a product to move forward to FDA licensure/approval. In accordance with Section III.F of announcement MCS BAA-17-01, the Government is hereby requesting formal submission</p>				

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

of preproposals to execute a formal agreement under 10 USC 2371(b), Other Transaction Authority (OTA) for the prototype project described above: Upon receipt of a preproposal submitted in response to this RPP, the next steps are as follows: The Government will evaluate the preproposal. Discussions among the parties, whether verbally or in writing, will occur as appropriate. The Government may request a full proposal from the offeror. Additional discussions will occur as necessary. Award may be made after evaluation and selection of a successful proposal. (Note: Awards are dependent upon the availability of funds.) This Request for Project Proposal (RPP) is issued to request project proposals in compliance with USC 2371(b), and is being issued for planning purposes only. It is not to be construed as a commitment by the Government to award an agreement, nor will the Government pay for the information solicited. Specific requirements are identified in the Project Description/Statement of Objectives below. Due date: The date and time set for submission of preproposals is shown above. Preproposals received after the set time will not be considered unless the Government, at any time, elects to allot further time for proposal submissions. Preproposals shall be sent by email to: lawrence.e.mize.civ@mail.mil The Government will review/evaluate the submitted preproposals and if there is Government interest, the Agreements Officer may issue a request for full proposal (RFFP) in response to this RPP. The Government may award an agreement based on the proposal submission, or may require submission of additional details. The award of Prototype agreements shall be for the development of prototypes in accordance with 10 U.S.C. 2371b for projects that are directly relevant to enhancing the mission effectiveness of military personnel and the supporting platforms, systems, components, or materials proposed to be acquired or developed by the Department of Defense, or to improvement of platforms, systems, components, or materials in use by the Armed Forces. A prototype project can generally be described as a preliminary pilot, test, evaluation, demonstration, or agile development activity used to evaluate the technical or manufacturing feasibility or military utility of a particular technology, process, concept, end item, effect, or other discrete feature. Only a warranted Agreements Officer may obligate the U.S. Government to the expenditure of funds for awards under this Announcement. Evaluation will be performed by JPEO-CBRND and HHS-ASPR-BARDA personnel, other Federal Agency Representatives, outside scientists with diverse expertise, clinicians, consumers, or combinations thereof based on evaluation and selection of the best preproposal submission, and/or subsequent full proposal submission. After evaluation and selection, an award will be made to the successful offeror(s). Subsequent awards depend upon the availability of funds and fulfillment of requirements and priorities determined to exist at the time of award. In some cases, funding priorities may change as certain scientific tasks are addressed and new mission assignments arise. Award may also be dependent upon demonstration by the offeror that they have adequately addressed the requirements. The U.S. Government does not fund preparation of proposals or support work efforts or tasks that are inferred from discussions with technical project officers. The Offeror will not be reimbursed for any costs incurred prior to the effective date of the agreement. There are certain post-employment restrictions on former Federal officers and employees as defined in 18 USC 207 and FAR 3.104-4(c). If an offeror believes a post-employment restriction or conflict of interest exists, notification should be sent to the Agreements Officer prior to initiating efforts on

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

a full proposal. The Freedom of Information Act (FOIA) (5 USC 552) provides a statutory basis for public access to official U.S. Government records. "Records" are defined to include documentation received by the U.S. Government in connection with the transaction of public business. Certain types of information submitted to the Government in a process having the potential for award of an OT are exempt from disclosure requirements of FOIA for a period of five (5) years from the date the Government receives the information. The types of information listed above may continue to be exempted, in whole or in part, from disclosure after the expiration of the five (5) year period if it falls within an exemption to the FOIA such as trade secrets and commercial or financial information obtained from a person and privileged or confidential. Offerors should mark business plans and technical information that are to be protected for five years from FOIA disclosure with a legend identifying the documents as being submitted on a confidential basis. The Government is prohibited from soliciting and awarding actions to awardees that have engaged or are suspected to have engaged in criminal, fraudulent, or seriously improper conduct. Prospective awardees shall complete electronic annual representations and certifications at <https://beta.sam.gov/>. By submission of an offer, the Offeror acknowledges the requirement that prospective awardees MUST be registered in the System for Award Management (SAM) database prior to submitting an invoice and through final payment of any contract resulting from this RPP. Offerors that are not registered should consider applying for registration immediately upon receipt of this solicitation. To remain registered in the SAM database after the initial registration, the Offeror is required to review and update on an annual basis from the date of initial registration (or subsequent updates) its information in the SAM database to ensure it is current, accurate and complete. Data submitted that cannot be disclosed to the public for any purpose, or used by the Government except for evaluation purposes, shall be marked on the title page with the below legend and mark each data sheet as follows: TITLE PAGE LEGEND: This Proposal includes data that shall not be disclosed outside the Government and shall not be duplicated, used, or disclosed--in whole or in part--for any purpose other than to evaluate this Proposal. If, however, an agreement is awarded as a result of--or in connection with-- the submission of this data, the Government shall have the right to duplicate, use, or disclose the data to the extent provided in the resulting award. This restriction does not limit the Government's right to use information contained in this data if it is obtained from another source without restriction. The data subject to this restriction are contained in sheets [insert numbers or other identification of sheets]; DATA SHEET MARKING: Mark each sheet of data it wishes to restrict with the following legend: Use or disclosure of data contained on this sheet is subject to the restriction on the title page of this proposal. Questions regarding this announcement may be submitted by email to lawrence.e.mize.civ@mail.mil within 2 days of the closing date. In accordance with 10 U.S.C. § 2371b(f), the Government may award a follow-on production contract or Other Transaction (OT) for any OT awarded under this BAA if: (1) that participant in the OT, or a recognized successor in interest to the OT, successfully completed the entire prototype project provided for in the OT, as modified; and (2) the OT provides for the award of a follow-on production contract or OT to the participant, or a recognized successor in interest to the OT. Follow-on production is anticipated to 800,000 treatments per quarter for up to 18 months. Proposals Brochures or

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

other descriptions of general organizational or individual capabilities will not be accepted as a preproposal. All preproposals will be assigned an identification number and an email will acknowledge receipt of a proposal. Generally, the Project Manager of the submitting organization should receive a decision letter or email upon completion of the evaluation. Administration: The Government will retain comments and information received in response to this RPP. Do not use Government security classification markings. All written responses must be received by midnight of the due date. Submission should be identified with a Subject Line of Responding Organization and RPP Title. Material that is advertisement only in nature is not desired. Requirements: See Attached Project Description Submissions: Preproposals should be limited to six pages (including cover sheet), and include a description of the relevant technology including supporting data, the scope of the proposed effort including a high-level Work Breakdown Structure (WBS), and a description of the proposer’s research, development, manufacturing, past performance, or other special qualifications. The preproposal must also include an anticipated rough order of magnitude (ROM) cost for the efforts described in the preproposal, including a price per dose for both the manufacturing scale quantity and the follow-on production quantity. Preproposals shall be submitted to the following email address: Lawrence.e.mize.civ@mail.mil.

PROJECT DESCRIPTION/STATEMENT OF OBJECTIVES 2.1 OBJECTIVE AREA –Treatment – COVID-19 Pandemic Therapeutic Rapid Advanced Research and Development (ARD) to Large Scale Manufacturing 2.1.1 DESCRIPTION/OBJECTIVE OF THE PROJECT: The Department of Defense and Department of Health and Human Services (HHS), seeks Offerors to perform at-scale prototype manufacturing and fill-finish of Coronavirus Disease 2019 (COVID-19) Medical Countermeasures (MCM) currently in advanced development, in order to ensure nationwide access. An outbreak of respiratory disease caused by a novel coronavirus, was first detected in China and has now spread worldwide, including the United States. The virus has been named Severe Acute Respiratory Disease Coronavirus-2 (SARS-CoV-2), and causes COVID-19. On January 30, 2020, the International Health Regulations Emergency Committee of the World Health Organization (WHO), declared the outbreak a “Public Health Emergency of International Concern” (PHEIC). On January 31, the United States Department of Health and Human Services Secretary, Alex M. Azar II, declared a Public Health Emergency (PHE) for the United States to aid the nation’s healthcare community in responding to COVID-19. On March 11, WHO publicly characterized COVID-19 as a pandemic. On March 13, the President of the United States declared the COVID-19 outbreak a national emergency. It is critical for the sponsors of COVID-19 therapeutic candidates to initiate at-scale prototype manufacturing to demonstrate the target population capability. As such, the USG will support at-scale manufacturing (through packaging and release testing) of selected MCMs, to ensure timely availability to the US population when needed.

2.1.2 STATEMENT OF OBJECTIVES (SOO): 1) Project Objectives: The objective of this prototype project is to initiate an advanced development SARS-CoV-2 MCM prototype for clinical/non-clinical development and/or manufacturing scale-up to demonstrate the capability to support sustained large scale manufacturing necessary to meet surge requirements with little advance notification, under the conditions for which the MCM is being developed. Candidate MCMs will either be direct acting antivirals or host directed therapeutics, which indirectly inhibit the

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

coronavirus lifecycle. Prior in vitro and in vivo demonstration of efficacy against SARS-CoV-2 is required. Candidate MCMs shall have at minimum, capability of obtaining Emergency Use Authorization (EUA) and/or a reasonable chance of moving to Phase 3 clinical trials by 4Q 2020 including all development plans and efforts, manufacturing, all done in support of the goal of achieving FDA approval/licensure in 2021. Offerors must have started or have completed a Phase 1 clinical study no later than August 31, 2020. The Offeror will need to demonstrate large scale manufacturing capability by completing the manufacture, release, stockpiling and distribution of up to 100,000 drug product treatment courses by December 31, 2020. Fill and release of drug product should be included within the proposed scope but can be completed in Q1/Q2 2021. A treatment course is defined by the highest dose proposed for Phase 2 clinical trials. Optional line items associated with full scale Follow-On production quantities to treat up to 800,000 people per quarter may be included in the negotiated project agreement. These option line items may be exercised at the Government's sole discretion in accordance with paragraph 2.1.4.3.

2) Performance Objectives (Required Results): The U.S. Government, in support of Operation Warp Speed, seeks Offerors to perform at-scale prototype manufacturing and fill-finish of a SARS-CoV-2 MCM. Initially at the minimum, fill/finish manufacturing shall take place in a US-based facility. Manufacturing shall occur using cGMP validated manufacturing processes for bulk drug substance and fill and finished drug product. The ramp-up capacity provides up to 100,000 treatment courses for a targeted US population by December 31, 2020, to treat the US population indicated in the Offeror's target population. A treatment course is defined by the highest dose proposed for Phase 2 clinical trials. A minimum quantity is not defined; however, the intent is "Large Scale production capability in a short period of time with little to no advance notice under the conditions for which the MCM is required". Demonstration of efficacy should be included in the performance plan with support for platform clinical trial conduct. The Offeror's proposal should include a validation plan and associated timelines. The project shall be accomplished using aggressive risk management and taking advantage of any regulatory flexibilities. A description of the manufacturing facility, quality assurance, and regulatory acceptance, including quality systems and regulatory milestones towards facility approval, is required. To assist with facility assessment, the chemical synthesis and process description should be included. It is desired that the drug substance manufacturing be US based. If this is not initially possible, a mitigation strategy including a reasonable timeline is required for transfer to the future at-scale drug substance US based manufacturing facility. The supply of and manufacture of regulatory starting materials including key chemical reagents and raw materials must be sustainable and desirably US sourced. If foreign sourced a mitigation plan is needed.

3) Regulatory Objectives: Candidate MCMs shall have at a minimum, capability of obtaining Emergency Use Authorization (EUA) and/or a reasonable chance of moving to Phase 3 clinical trials by 4Q 2020 including all development plans and efforts, manufacturing, all done in support of the goal of achieving FDA approval/licensure in 2021.

4) Project Management Objectives: Mandatory reporting requirements are described in the base agreement: Monthly progress reports should include both technical and financial status and expenditure forecast; final prototype project report; patents reports, work breakdown structure; integrated master schedule; regulatory documents, including

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

communications with the FDA, all submissions, and the PL 115-92 Sponsor Authorization Letter. Project management oversight will be comprised of an Agreements Officer's Representative (AOR) and USG Project Coordination Team (PCT), which will perform ongoing technical reviews and approvals of milestones. The Offeror shall invite the government to attend all FDA meetings with regard to this project. 5) Logistics Objectives: The USG seeks at-scale prototype manufacturing and fill-finish of a SARS-CoV-2 MCMs currently in advanced development. Production shall occur using an established manufacturing process for bulk drug substance and fill and finished drug product, with a plan that provides up to 100,000 treatment courses of drug product for a targeted US population by December 31, 2020. A treatment course is defined by the highest dose proposed for Phase 2 trials. Initially it may be considered acceptable for the drug substance and the 100,000 treatment courses to manufacture at a smaller scale provided that the scale is of sufficient manufacturing scale to properly demonstrate the process. This scale must use the same synthesis, targeted, scalable, validated process, possessing the needed potential ramp-up capacity for the at-scale manufacturing. The at-scale development and manufacturing must occur in parallel. Once finished drug product is accepted by the US Government, product will be stored and distributed by the Offeror. 6) Performance Requirements: Manufacture of the therapeutic product shall occur using an established manufacturing process for bulk drug substance and fill and finished drug product, with a ramp-up capacity plan that provides enough doses to meet the desired treatment course. The Offeror's proposal should include a validation plan and associated timelines. The project shall be accomplished using aggressive risk management and taking advantage of any regulatory flexibilities. A description of the manufacturing facility quality assurance and regulatory acceptance, including quality systems and regulatory milestones towards facility approval is required. 7) Operational Constraints/Limitations/Restrictions: Fill/finish manufacturing operations shall be based in the US. 2.1.3 PERIOD AND PLACE OF PERFORMANCE: The anticipated Period of Performance for this effort is up to two (2) years from the date of award (including options). Specific dates to be negotiated. It is anticipated that the primary place of performance will be the contractors' or subcontractors' facilities. However, this aspect can be negotiated as part of each Offerors' submission. 2.1.4 DELIVERABLES: 2.1.4.1 DATA DELIVERABLE(S): Data Deliverables required include: • Meeting minutes from all scheduled and ad-hoc meetings with the Program Office and AOR. • Monthly financial reports required for invoice approval. • All FDA communications, including minutes and submissions. • Detailed Work Breakdown Structure that enables the proposed Statement of Work. • The Offeror shall have a comprehensive Supply Chain Resiliency Program that provides for identification and reporting of critical components associated with the secure supply of drug substance, drug product, and work-in-process through to finished goods. • FDA Form 483 and the Establishment Inspection Report (EIR) if applicable • Bi-Weekly Performance meeting agendas, meeting minutes, and briefings • All required reports and documents (in contractor format) set forth in Addendum 1 to this Project Description Note: Technical data deliverables described herein shall be delivered to the Government with a minimum of Government Purpose Rights 2.1.4.2 PROTOTYPE DELIVERABLE(S): The prototype Deliverable includes the fill/finished therapeutic drug product authorized for use by the FDA, and/or demonstrated

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>manufacturing capability meeting the performance objectives. Drug product must be delivered by December 31, 2020, in the US; drug product will not be accepted until it is physically located in the US. 2.1.4.3 Follow-on Production: In accordance with 10.U.S.C. 2371b(f), and upon a determination that the prototype project for this transaction has been successfully completed, any competitively awarded prototype OTA as a result of this RPP may result in the award of a follow-on production contract or transaction without the use of competitive procedures. The Government intends to purchase sufficient quantities to treat an estimated 800,000 people per quarter with the selected MCM therapeutic for the duration of 2021. The Offeror's proposal shall include production option(s) to purchase the fill/finished drug product, based on maximum production capability, providing quantity per month, price per dose and per gram, inclusive of all direct and indirect costs, storage, and distribution to US Government designated facilities. The manufactured prototype will be successful if: • The prototype is safe and effective, as agreed to by the FDA either by licensure or under an EUA or, • The Offeror demonstrates capability of delivering up to 100,000 treatment courses of drug product for a targeted population by December 31, 2020 in the US. 2.1.5 SPECIAL REQUIREMENTS: 2.1.5.1 Export Control: Export Controls shall be in accordance with the Base Agreement. 2.1.5.2 Security and Classified Data: This project is Unclassified. 2.1.5.3 Acceptance of Deliverables: The Government will provide acceptance of all data deliverables within ten (10) calendar days of delivery. The Government will provide acceptance of all therapeutic prototype deliverables within thirty (30) calendar days of delivery and physical delivery to US soil. 2.1.5.4 Travel: The following travel situations may be approved by the Government upon request: • Travel for Face-to-face meetings with Government personnel and/or sub-contractors. • Travel to provide oversight, audits, and/or data reviews with sub-contractors. • Travel for Program review meetings or Integrated Product Team (IPT) meetings, as requested by the Government. • Travel to complete in-person FDA requested meetings. Additional non-directed travel, necessary for the completion of the contracted work, may be permitted. The Offeror shall provide a breakout of expected travel in their proposal. 2.1.6 GOVERNMENT FURNISHED PROPERTY: Government Furnished Equipment, Contractor Acquired Government Furnished Property, and Contractor Acquired Government Owned Property are subject to negotiations during the award process. The contractor should identify necessary equipment and property in white paper submissions to this RPP. 2.1.7 FUNDING CONFIDENCE LEVEL: CL-1 Highly Confident funds will be available. 2.1.8 AGREEMENTS OFFICER'S REPRESENTATIVE (AOR): Name: Kristen Herring Telephone: 202-260-1388 E-mail: kristen.herring@hhs.gov Office Symbol: HHS/ASPR/BARDA 2.1.8.1 ALTERNATE AOR: Name: Nellie Byun Telephone: 202-774-2303 E-mail: Nellie.byun@hhs.gov Office Symbol: HHS/ASPR/BARDA 2.1.9 Requiring Activity: Joint mission between the Department of Health and Human Services and Department of Defense to combat COVID-19</p>				
101327	The Kevin and Avonte Program: Reducing Injury and Death of Missing Individuals with Dementia and Developmental	Bureau of Justice Assistance/Department of Justice	O-BJA-2021-44004	17-Feb-2021	150,000 USD

Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

[Disabilities](#)

<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>800-851-3420</p> <p>grants@ncjrs.gov</p> <p>Link to sponsor website</p> <p>Link to program URL</p> <p>17-Feb-2021 , 03-Mar-2021</p> <p>The Reducing Injury and Death of Missing Individuals with Dementia and Developmental Disabilities Program supports local jurisdictions’ efforts to reduce the number of deaths and injuries of individuals with forms of dementia, such as Alzheimer’s Disease, or developmental disabilities, such as autism, who due to their condition wander from safe environments. It provides funding to law enforcement and public safety agencies to implement locative technologies to track missing individuals; and to such agencies and partnering nonprofit organizations to develop or operate programs to prevent wandering, increase individuals’ safety, and facilitate rescues.</p>
---	--

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
013641	ENTELLIGENCE Young Investigators Award Program	Actelion Pharmaceuticals US, Inc.		01-Feb-2021	100,000 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; vertical-align: top;">Contact Name</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>650-624-6900</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td>Link to sponsor website</td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>01-Feb-2021</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>ENTELLIGENCE is a program designed for basic science, translational and clinical research in the field of cardiopulmonary medicine. The ENTELLIGENCE program provides opportunities for individual young investigators to promote quality medical care and enhance patients' lives by supporting research (basic science, translational and clinical research) in the area of pulmonary hypertension (PH) related to expanding our knowledge of the pathways involved in pulmonary vascular pathobiology and ultimately, to improve treatment for patients with pulmonary hypertension. ENTELLIGENCE provides individual grants of up to \$100,000 to qualified investigators to conduct research via a 12-month mentored grant.</td> </tr> </table>					Contact Name		Contact Telephone	650-624-6900	Contact Email		Sponsor Website	Link to sponsor website	Program URL	Link to program URL	Deadline Dates (ALL)	01-Feb-2021	Synopsis	ENTELLIGENCE is a program designed for basic science, translational and clinical research in the field of cardiopulmonary medicine. The ENTELLIGENCE program provides opportunities for individual young investigators to promote quality medical care and enhance patients' lives by supporting research (basic science, translational and clinical research) in the area of pulmonary hypertension (PH) related to expanding our knowledge of the pathways involved in pulmonary vascular pathobiology and ultimately, to improve treatment for patients with pulmonary hypertension. ENTELLIGENCE provides individual grants of up to \$100,000 to qualified investigators to conduct research via a 12-month mentored grant.
Contact Name																			
Contact Telephone	650-624-6900																		
Contact Email																			
Sponsor Website	Link to sponsor website																		
Program URL	Link to program URL																		
Deadline Dates (ALL)	01-Feb-2021																		
Synopsis	ENTELLIGENCE is a program designed for basic science, translational and clinical research in the field of cardiopulmonary medicine. The ENTELLIGENCE program provides opportunities for individual young investigators to promote quality medical care and enhance patients' lives by supporting research (basic science, translational and clinical research) in the area of pulmonary hypertension (PH) related to expanding our knowledge of the pathways involved in pulmonary vascular pathobiology and ultimately, to improve treatment for patients with pulmonary hypertension. ENTELLIGENCE provides individual grants of up to \$100,000 to qualified investigators to conduct research via a 12-month mentored grant.																		
089995	Alzheimer's Association Research Grant to Promote Diversity - New to the Field (AARG-D-NTF)	Alzheimer's Association		13-Jan-2021 [LOI/Pre-App]	150,000 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; vertical-align: top;">Contact Name</td> <td></td> </tr> <tr> <td style="vertical-align: top;">Contact Telephone</td> <td>312-335-5747</td> </tr> <tr> <td style="vertical-align: top;">Contact Email</td> <td>grantsapp@alz.org</td> </tr> <tr> <td style="vertical-align: top;">Sponsor Website</td> <td>Link to sponsor website</td> </tr> <tr> <td style="vertical-align: top;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="vertical-align: top;">Deadline Dates (ALL)</td> <td>13-Jan-2021 [LOI/Pre-App], 31-Mar-2021</td> </tr> <tr> <td style="vertical-align: top;">Synopsis</td> <td>The Research Grant to Promote Diversity - New to the Field award is up to three years (minimum two years) to increase the number of scientists from underrepresented groups at academic institutions in Alzheimer's and all</td> </tr> </table>					Contact Name		Contact Telephone	312-335-5747	Contact Email	grantsapp@alz.org	Sponsor Website	Link to sponsor website	Program URL	Link to program URL	Deadline Dates (ALL)	13-Jan-2021 [LOI/Pre-App], 31-Mar-2021	Synopsis	The Research Grant to Promote Diversity - New to the Field award is up to three years (minimum two years) to increase the number of scientists from underrepresented groups at academic institutions in Alzheimer's and all
Contact Name																			
Contact Telephone	312-335-5747																		
Contact Email	grantsapp@alz.org																		
Sponsor Website	Link to sponsor website																		
Program URL	Link to program URL																		
Deadline Dates (ALL)	13-Jan-2021 [LOI/Pre-App], 31-Mar-2021																		
Synopsis	The Research Grant to Promote Diversity - New to the Field award is up to three years (minimum two years) to increase the number of scientists from underrepresented groups at academic institutions in Alzheimer's and all																		

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	dementia research.				
089994	Alzheimer's Association Research Grant - New to the Field (AARG-NTF)	Alzheimer's Association		13-Jan-2021 [LOI/Pre-App]	150,000 USD
	<p>Contact Name</p> <p>Contact Telephone 312-335-5747</p> <p>Contact Email grantsapp@alz.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 13-Jan-2021 [LOI/Pre-App], 31-Mar-2021</p> <p>Synopsis The Research Grant aims to fund investigators who are new to Alzheimer's or other dementias field of research. The purpose of this program is to provide independent investigators with unique expertise and apply their knowledge to Alzheimer's and all dementias.</p>				
071372	Treat FTD Fund – Funding for Innovative Clinical Trials for Frontotemporal Degeneration	Alzheimer's Drug Discovery Foundation		05-Feb-2021 [LOI/Pre-App]	2,000,000 USD
	<p>Contact Name Meriel Owen, PhD, Assistant Director, ADDF</p> <p>Contact Telephone 212-901-8000</p> <p>Contact Email mowen@alzdiscovery.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021 [LOI/Pre-App], 19-Mar-2021</p> <p>Synopsis Leveraging scientific advances in FTD research to develop effective medications has proven challenging. The Treat FTD Fund, a major new funding opportunity initiated by AFTD in partnership with ADDF, seeks to accelerate FTD drug development by focusing exclusively on clinical trials of FTD therapeutics. Over the next 10 years, The Treat FTD Fund</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

will award \$10 million to support clinical trials of novel or repurposed drugs to treat FTD symptoms or target disease mechanisms.

055305	Program to Accelerate Clinical Trials (PACT)	Alzheimer's Drug Discovery Foundation		05-Feb-2021 [LOI/Pre-App]	3,000,000 USD
--------	--	---------------------------------------	--	------------------------------	------------------

	Contact Name				
	Contact Telephone	212-901-8019			
	Contact Email	grants@alzdiscovery.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Feb-2021 [LOI/Pre-App], 16-Apr-2021 , 28-May-2021 [LOI/Pre-App], 30-Jul-2021 , 01-Oct-2021 [LOI/Pre-App], 03-Dec-2021			
	Synopsis	The PACT RFP supports IND-enabling studies and early-phase clinical trials that test promising pharmacological interventions and devices for Alzheimer's disease (AD) and related dementias. Both disease-modifying and symptomatic agents will be considered. This funding opportunity prioritizes diverse drug mechanisms and modes of action related to the biology of aging and other emerging therapeutic areas for dementia. For this reason, amyloid targeted approaches and cholinesterase inhibitor proposals will not be considered for this RFP.			

055304	Drug Development Program	Alzheimer's Drug Discovery Foundation		05-Feb-2021 [LOI/Pre-App]	600,000 USD
--------	--	---------------------------------------	--	------------------------------	-------------

	Contact Name	Alessio Travaglia, PhD, Scientific Program Officer			
	Contact Telephone	212-901-7998			
	Contact Email	atravaglia@alzdiscovery.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 05-Feb-2021 [LOI/Pre-App], 16-Apr-2021 , 28-May-2021 [LOI/Pre-App], 30-Jul-2021 , 01-Oct-2021 [LOI/Pre-App], 03-Dec-2021</p> <p>Synopsis The Drug Development RFP seeks to support in vivo preclinical studies that advance lead molecules developed for Alzheimer’s disease and related dementias to IND-enabling studies. The proposed studies should be structured to deliver a compound with strong potential for clinical and commercial application. This funding opportunity prioritizes novel drug mechanisms and modes of action related to the biology of aging and other emerging therapeutic areas for dementia. For this reason, amyloid targeted approaches and cholinesterase inhibitor proposals will not be considered for this RFP.</p>				
083359	Bi-Annual Grant	Alzheimer's Foundation of America		19-Feb-2021	6,000 USD
	<p>Contact Name</p> <p>Contact Telephone 866-232-8484</p> <p>Contact Email membership@alzfdn.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 19-Feb-2021 , 27-Aug-2021</p> <p>Synopsis The Bi-Annual Grant seeks proposals from AFA’s nonprofit member organizations in good standing (meaning their dues are up-to-date) for new or existing programs and services that improve the lives of those living with Alzheimer’s disease or a related dementia, and their families and caregivers. The amount to be requested is \$6,000.</p>				
044279	AAO-HNSF Bobby R. Alford Endowed Research Grant	American Academy of Otolaryngology - Head and Neck Surgery, Inc.		15-Jan-2021	30,000 USD
	<p>Contact Name</p> <p>Contact Telephone 703-836-4444</p> <p>Contact Email COREGrants@entnet.org</p> <p>Sponsor Website Link to sponsor website</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Program URL	Link to program URL
Deadline Dates (ALL)	15-Jan-2021
Synopsis	The purpose of the Bobby R. Alford Endowed Research Grant is to support innovative research in the specialty and help facilitate the career development of young investigators.

094941	AAO-HNSF Health Services Research Grant	American Academy of Otolaryngology - Head and Neck Surgery, Inc.	15-Jan-2021	10,000 USD
--------	---	--	-------------	------------

Contact Name	Erin Lambie
Contact Telephone	703-836-4444
Contact Email	COREGrants@entnet.org
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	15-Jan-2021
Synopsis	The purpose of the American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNSF) Health Services Research Grant is to foster research that will improve the effectiveness and appropriateness of medical practice. Projects supported under this program will develop and disseminate scientific information on the effects of otolaryngology services and procedures on patients' survival, health status, functional capacity, and quality of life. The award is intended to promote increased participation by otolaryngologists in the rapidly expanding area of health services research.

061449	AAO-HNSF Health Services Research Grant	American Academy of Otolaryngology - Head and Neck Surgery, Inc.	15-Jan-2021	10,000 USD
--------	---	--	-------------	------------

Contact Name	
Contact Telephone	703-836-4444
Contact Email	COREGrants@entnet.org

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 15-Jan-2021 Synopsis The Centralized Otolaryngology Research Efforts (CORE) grants program is a collaboration of several societies, foundations, and industry supporters focused on providing support for research in the field of otolaryngology-head and neck surgery. The purpose of the American Academy of Otolaryngology – Head and Neck Surgery Foundation (AAO-HNSF) Health Services Research Grant is to foster research that will improve the effectiveness and appropriateness of medical practice. Projects supported under this program will develop and disseminate scientific information on the effects of otolaryngology services and procedures on patients' survival, health status, functional capacity, and quality of life.				
009081	AAC Research Grants	American Alpine Club		17-Jan-2021	1,500 USD
	Contact Name Contact Telephone 303-384-0110 Contact Email grants@americanalpineclub.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 17-Jan-2021 Synopsis AAC Research Grants support scientific endeavors in mountains and crags around the world. Grants fund projects that contribute vital knowledge of our climbing environment, enrich our understanding of global climber impacts and support and improve the health and sustainability of mountain environments and habitats.				
100439	AACR-Exelixis Renal Cell Carcinoma Research Fellowship	American Association for Cancer Research		14-Jan-2021	120,000 USD
	Contact Name Contact Telephone 215-446-7128				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email grants@aacr.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 14-Jan-2021</p> <p>Synopsis The inaugural AACR-Exelixis Renal Cell Carcinoma Research Fellowship represents a joint effort to encourage and support postdoctoral or clinical research fellows to conduct renal cell carcinoma research and to establish a successful career path in this field. This fellowship provides a two-year grant of \$120,000 to support the salary and benefits of the fellow while working on mentored renal cell carcinoma research.</p>				
078947	Bosarge Family Foundation-Waun Ki Hong Scholar Award for Regenerative Cancer Medicine	American Association for Cancer Research		12-Jan-2021	120,000 USD
	<p>Contact Name</p> <p>Contact Telephone 215-440-9300</p> <p>Contact Email grants@aacr.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Jan-2021</p> <p>Synopsis The Bosarge Family Foundation-Waun Ki Hong Scholar Award for Regenerative Cancer Medicine represents a joint effort to encourage and support postdoctoral or clinical research fellows to conduct highly novel and provocative research in the field of regenerative cancer medicine and to establish a successful career path in this field. The research proposed for funding may be translational, clinical, or epidemiological in nature and must have direct applicability and relevance to enhancing the physiology or function of cancer survivors using regenerative medicine techniques. This award provides a two-year grant of \$120,000 to support the salary and benefits of the fellow while working on mentored research focused on regenerative cancer medicine.</p>				
071402	AADR Student Research Fellowships	American Association for Dental Research		22-Jan-2021	2,100 USD

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Anthony Jones, Awards, Fellowships and Grants Coordinator</p> <p>Contact Telephone 703-548-0066</p> <p>Contact Email ajones@iadr.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 22-Jan-2021</p> <p>Synopsis AADR Student Research Fellowships have been created to encourage dental students living in the United States to consider careers in oral health research. Proposals are sought in basic and clinical research related to oral health.</p>				
063047	Minority Fellowship Program - Dissertation Completion Fellowship (DCF)	American Association for Marriage and Family Therapy		12-Feb-2021	Not Specified
	<p>Contact Name </p> <p>Contact Telephone 703-838-9808</p> <p>Contact Email mfp@aamft.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Feb-2021</p> <p>Synopsis The American Association for Marriage and Family Therapy (AAMFT) offers a Minority Fellowship Program (MFP), providing fellowship programs to students who are committed to research about and service to ethnic minority and underserved populations. The Dissertation Completion Fellowship (DCF) provides support for doctoral students at the dissertation stage of their curriculum.</p>				
076846	Jack D. Pressman-Burroughs Wellcome Fund Career Development Award	American Association for the History of Medicine		31-Jan-2021	1,000 USD
	<p>Contact Name Jacob Steere-Williams</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone Contact Email steerewilliamsj@cofc.edu Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 31-Jan-2021 Synopsis This award and a stipend of \$1,000 is given yearly for outstanding work in twentieth-century history of medicine or medical biomedical sciences, as demonstrated by the completion of the Ph.D. and a proposal to turn the dissertation into a publishable monograph.				
084308	NP/PA Clinical Hepatology Fellowship Program	American Association for the Study of Liver Diseases		15-Jan-2021	78,000 USD
	Contact Name Contact Telephone 703-299-9766 Contact Email awards@aasld.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 15-Jan-2021 Synopsis The NP/PA Clinical Hepatology Fellowship program provides salary and benefit support for certified and licensed Nurse Practitioners (NP) or Physician Assistants (PA) pursuing a full-year of training focused on clinical care in hepatology. An award of \$78,000 will be provided for one year.				
059175	Advanced/Transplant Hepatology Fellowship	American Association for the Study of Liver Diseases		15-Jan-2021	5,000 USD
	Contact Name Contact Telephone 703-299-9766				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email awards@aasld.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Jan-2021</p> <p>Synopsis The purpose of this award is to encourage the academic career of exceptional hepatology trainees. The Advanced/Transplant Hepatology Award provides \$5,000 in travel funds to fourth year Transplant Hepatology fellows or third year GI/Hepatology dual certification program fellows in accredited US, Canadian, or Mexican programs to attend The Liver Meeting® and one additional educational meeting (approved by the Research Awards Committee).</p>				
068422	Bridge Award	American Association for the Study of Liver Diseases		15-Jan-2021	100,000 USD
	<p>Contact Name</p> <p>Contact Telephone 703-299-9766</p> <p>Contact Email awards@aasld.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Jan-2021</p> <p>Synopsis The AASLD Foundation Bridge Award supports investigators who have recently submitted an NIH R or other federally-funded equivalent award and have received competitive scores on their proposal, but were not funded, as they strengthen their proposal for resubmission to the NIH or other federal agency. Applicant must not have other federal funding or significant institutional bridge funding (greater than \$25,000, excluding PI salary support).</p>				
071751	Competitive Research Grants	American Association of Endodontists Foundation		07-Feb-2021	Not Specified
	Contact Name				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 312-266-7255</p> <p>Contact Email foundation@aae.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 07-Feb-2021</p> <p>Synopsis The Foundation for Endodontics awards grants to inspire and support clinical research and the genesis of new knowledge in endodontics.</p>				
064910	Public Policy Fellows Program (PPFP)	American Association of Immunologists		20-Jan-2021	Not Specified
	<p>Contact Name </p> <p>Contact Telephone 301-634-7178</p> <p>Contact Email jschumacher@aai.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 20-Jan-2021</p> <p>Synopsis The PPFP provides postdoctoral fellows and other junior scientists who are committed to a career in biomedical research with the opportunity to learn about and participate in the public policy and legislative activities of AAI. Up to 10 Fellows may participate annually. Each year's program commences on May 1 and runs through April 30 of the following year.</p>				
071243	Development Grants	American Neuromuscular Foundation		11-Jan-2021 [LOI/Pre-App]	50,000 USD
	<p>Contact Name </p> <p>Contact Telephone 507-538-1037</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Email foundation@neuromuscularfoundation.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 15-Feb-2021 Synopsis The AANEM Foundation is offering development grants intended as seed money to help launch research into muscle and nerve disorders by promising new researchers.				
067553	ACCF/Merck Research Fellowships in Cardiovascular Disease and Cardiometabolic Disorders	American College of Cardiology		29-Jan-2021	100,000 USD
	Contact Name Contact Telephone 800-253-4636 Contact Email resource@acc.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 29-Jan-2021 Synopsis ACCF will award three, one-year fellowships to support research in adult cardiology. Recipients receive \$100,000 each, to be used for salary support.				
021359	Distinguished Clinician Award	American College of Rheumatology		01-Feb-2021	3,000 USD
	Contact Name Contact Telephone 404-633-3777 Contact Email arp@rheumatology.org Sponsor Website Link to sponsor website Program URL Link to program URL				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL) 01-Feb-2021 Synopsis The ARP Distinguished Clinician Award is presented to an ARP member who is engaged in clinical practice and demonstrates outstanding clinical expertise in arthritis and the rheumatic diseases.				
021291	Ann Kunkel Advocacy Award	American College of Rheumatology		01-Feb-2021	3,000 USD
	Contact Name Contact Telephone 404-633-3777 Contact Email arp@rheumatology.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 01-Feb-2021 Synopsis The Ann Kunkel Award is presented to an ARP member who has provided extraordinary service to advocate for patients with arthritis and rheumatic diseases or for health professionals in rheumatology.				
021298	Distinguished Scholar Award	American College of Rheumatology		01-Feb-2021	3,000 USD
	Contact Name Contact Telephone 404-633-3777 Contact Email arp@rheumatology.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 01-Feb-2021 Synopsis The ARP Distinguished Scholar Award is presented to an ARP member who demonstrates exceptional achievements in scholarly activities pertinent to arthritis and the rheumatic diseases.				
010661	Ephraim P. Engleman Endowed Resident Research Preceptorship	American College of Rheumatology		01-Feb-2021	15,000 USD

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name	
Contact Telephone	404-365-1373
Contact Email	Foundation@rheumatology.org
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	01-Feb-2021 , 01-May-2021
Synopsis	The Ephraim P. Engleman Endowed Resident Research Preceptorship will introduce residents to the specialty of rheumatology by supporting a full-time research experience.

021331	Joan L. and Julius H. Jacobson II Promising Investigator Award	American College of Surgeons	28-Feb-2021	30,000 USD
--------	--	------------------------------	-------------	------------

Contact Name	
Contact Telephone	312-202-5000
Contact Email	jacobsonpia@facs.org
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	28-Feb-2021
Synopsis	The Joan L. and Julius H. Jacobson II Promising Investigator Award of the American College of Surgeons(ACS) recognizes outstanding surgeons engaging in research, advancing the art and science of surgery, and demonstrating early promise of significant contribution to the practice of surgery and the safety of surgical patients.

099950	Junior Investigator Research Awards	American Epilepsy Society	13-Jan-2021	50,000 USD
--------	---	---------------------------	-------------	------------

Contact Name	
Contact Telephone	312-883-3800
Contact Email	grants@aesnet.org

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Sponsor Website [Link to sponsor website](#)
 Program URL [Link to program URL](#)
 Deadline Dates (ALL) 13-Jan-2021
 Synopsis Junior Investigator Awards supports research by recently independent investigators with the intent to facilitate successful competition for subsequent longer-term support from the NIH or other sources. Proposals are welcome across the spectrum of basic, translational, and clinical epilepsy research, including studies of disease mechanisms or treatments, epidemiologic or behavioral studies, the development of new technologies, and health services and outcomes research. This award provides up to \$50,000 for one year to support the direct costs of research.

099952	Predoctoral Research Fellowships	American Epilepsy Society		13-Jan-2021	30,000 USD
--------	--	---------------------------	--	-------------	------------

Contact Name
 Contact Telephone 312-883-3800
 Contact Email grants@aesnet.org
 Sponsor Website [Link to sponsor website](#)
 Program URL [Link to program URL](#)
 Deadline Dates (ALL) 13-Jan-2021
 Synopsis AES Predoctoral Research Fellowships support predoctoral students who are pursuing dissertation research with an epilepsy-relevant theme, and who are working under the guidance of a mentor with expertise in epilepsy research. Proposals are welcomed across the spectrum of basic, translational, and clinical research. The fellowship award offers up to \$30,000 for stipend and travel support to the AES Annual Meeting for one year.

099949	Epilepsy Study Consortium Mini Grant	American Epilepsy Society		13-Jan-2021	15,000 USD
--------	--	---------------------------	--	-------------	------------

Contact Name
 Contact Telephone 312-883-3800
 Contact Email grants@aesnet.org

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 13-Jan-2021 Synopsis The Epilepsy Study Consortium is sponsoring a mini-grant of \$15,000 for epilepsy fellows to undertake a mentored research project on anti-epileptic drug therapy during their fellowship training. The award does not require past experience with research or a specific percent protected time for research but instead focuses on the mentorship and training experience for the fellow. Applicants may request funding periods of six months to one year.				
099951	Postdoctoral Research Fellowships	American Epilepsy Society		13-Jan-2021	50,000 USD
	Contact Name Contact Telephone 312-883-3800 Contact Email grants@aesnet.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 13-Jan-2021 Synopsis AES Postdoctoral Research Fellowships support postdoctoral trainees conducting research into the causes, treatment, and consequences of epilepsy under the guidance of a mentor with expertise in epilepsy research. Proposals are welcomed across the spectrum of basic, translational, and clinical epilepsy research. The fellowship award offers up to \$50,000 for stipend and travel support to the AES Annual Meeting for one year.				
099948	Research and Training Fellowships for Clinicians	American Epilepsy Society		13-Jan-2021	50,000 USD
	Contact Name Jennifer Brummet PhD Contact Telephone 312-883-3800 Contact Email grants@aesnet.org Sponsor Website Link to sponsor website				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 13-Jan-2021</p> <p>Synopsis AES Research and Training Fellowships for Clinicians provide mentored support for clinical fellows or recently appointed clinical faculty who intend to pursue a career in epilepsy research. Proposals are welcomed across the spectrum of basic, translational, and clinical research. The fellowship award provides up to \$50,000 for one year, of which \$1000 is intended as travel support to attend the AES Annual Meeting.</p>				
010205	Outstanding Investigator Awards	American Federation for Medical Research Foundation		15-Jan-2021	2,500 USD
	<p>Contact Name</p> <p>Contact Telephone 978-927-8330</p> <p>Contact Email awards@afmr.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Jan-2021</p> <p>Synopsis An Outstanding Investigator Award is presented annually to an AFMR member in recognition of excellence in biomedical research.</p>				
000596	Junior Physician-Investigator Awards	American Federation for Medical Research Foundation		15-Jan-2021	1,250 USD
	<p>Contact Name</p> <p>Contact Telephone 978-927-8330</p> <p>Contact Email awards@afmr.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 15-Jan-2021</p> <p>Synopsis Junior Physician-Investigator Awards were created to honor young AFMR investigators whose research projects complement an overall program of research, teaching and clinical medicine.</p>				
089670	Fellow Abstract Award	American Gastroenterological Association		24-Feb-2021	1,500 USD
	<p>Contact Name</p> <p>Contact Telephone 301-654-2055</p> <p>Contact Email awards@gastro.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 24-Feb-2021</p> <p>Synopsis This \$500 travel award supports recipients who are MD, Ph.D. or equivalent fellows giving abstract-based oral or poster presentations at Digestive Disease Week (DDW). The top-scoring abstracts will be designated the Fellow Abstract of the Year and receive a \$1,000 award. The Digestive Disease Week will move online as a fully virtual meeting in 2021 and no travel to the meeting is required.</p>				
089669	Student Abstract Award	American Gastroenterological Association		24-Feb-2021	1,000 USD
	<p>Contact Name</p> <p>Contact Telephone 301-654-2055</p> <p>Contact Email awards@gastro.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 24-Feb-2021</p> <p>Synopsis This travel award supports recipients who are graduate students, medical students or medical residents (residents up to postgraduate year three) giving abstract-based oral or poster presentations at Digestive Disease Week (DDW).</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		The Digestive Disease Week will move online as a fully virtual meeting in 2021 and no travel to the meeting is required.			
000229	AHNS Alando J. Ballantyne Resident Research Pilot Grant	American Head and Neck Society		15-Jan-2021	10,000 USD
	Contact Name	Betty Mulugeta			
	Contact Telephone	703-836-4444			
	Contact Email	betty@ahns.info			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Jan-2021			
	Synopsis	The American Head and Neck Society (AHNS) awards a grant to support basic, translational, or clinical research projects in head and neck oncology.			
076832	AHNS Pilot Grant	American Head and Neck Society		15-Jan-2021	10,000 USD
	Contact Name	Betty Mulugeta			
	Contact Telephone				
	Contact Email	betty@ahns.info			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Jan-2021			
	Synopsis	The purpose of this award is to support basic, translational, or clinical research projects in head and neck oncology. Clinical or translational research studies are strongly encouraged and should be specifically related to the prevention, diagnosis, treatment, outcomes, or pathophysiology of head and neck neoplastic disease.			
061460	AHNS/AAO-HNSF Young Investigator Combined Award	American Head and Neck Society		15-Jan-2021	40,000 USD

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Betty Mulugeta</p> <p>Contact Telephone 703-836-4444</p> <p>Contact Email COREGrants@entnet.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Jan-2021</p> <p>Synopsis The purpose of this award is to support a collaborative AHNS/AAO-HNSF research project by fostering the development of contemporary basic or clinical research skills focused on neoplastic disease of the head and neck among new full-time academic head and neck surgeons.</p>				
035670	AHNS/AAO-HNSF Translational Innovator Combined Award	American Head and Neck Society		15-Jan-2021	80,000 USD
	<p>Contact Name Betty Mulugeta</p> <p>Contact Telephone 310-437-0559</p> <p>Contact Email betty@ahns.info</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Jan-2021</p> <p>Synopsis The AHNS/AAO-HNSF Translational Innovator Award is a career development award of up to \$40,000 per year for 2 years. Research supported by this award should be specifically directed toward the pathogenesis, pathophysiology, diagnosis, prevention, or treatment of head and neck neoplastic disease, and may be either basic or clinical/translational in approach. Candidates are expected to devote at least 25% effort per year (based on a 40-hour work week) to the research supported by this award.</p>				
024508	Career Development Award	American Heart Association		16-Feb-2021	231,000 USD
	Contact Name				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone</p> <p>Contact Email apply@heart.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 16-Feb-2021</p> <p>Synopsis Supports highly promising healthcare and academic professionals, in the early years of one's first professional appointment, to explore innovative questions or pilot studies that will provide preliminary data and training necessary to assure the applicant's future success as a research scientist. The award will develop the research skills to support and greatly enhance the awardee's chances to obtain and retain a high-quality career position.</p>				
062105	Merit Award	American Heart Association		14-Jan-2021	1,000,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email apply@heart.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 14-Jan-2021</p> <p>Synopsis The purpose of the Merit Award is to fund investigators with stellar track records of accomplishment, demonstrated by a history of extramural funding and excellent publication records with substantial impact, who have the potential to move a field of science forward with creative approaches that are aligned with the mission of the American Heart Association: To be a relentless force for a world of longer, healthier lives.</p>				
049768	Investigator-Initiated Research Grant Program	American Institute for Cancer Research		22-Jan-2021 [LOI/Pre-App]	Not Specified

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	202-600-3004 research@aicr.org Link to sponsor website Link to program URL 22-Jan-2021 [LOI/Pre-App], 14-May-2021 The CUP has identified significant gaps in our knowledge and understanding of the mechanisms that mediate the role of diet, nutrition, body composition and physical activity in cancer development and outcomes following a cancer diagnosis. The knowledge gaps directly inform our Investigator Initiated Research Grant Program so that we can prioritize issues of greatest scientific importance and with the highest potential for translation into effective strategies for cancer prevention and improved outcomes for people living with and beyond cancer.
--	---

005022	Investigator-Initiated Research Grants	American Institute for Cancer Research		22-Jan-2021 [LOI/Pre-App]	75,000 USD
--------	--	--	--	------------------------------	------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	703-237-0159 research@aicr.org Link to sponsor website Link to program URL 22-Jan-2021 [LOI/Pre-App], 14-May-2021 The Investigator-Initiated Research Grant Program welcomes proposals for research addressing the effects of diet, nutrition, body composition and physical activity on cancer risk and outcomes. The CUP has identified significant gaps in our knowledge and understanding of the mechanisms that mediate the role of diet, nutrition, body composition and physical activity in cancer development and outcomes following a cancer diagnosis. The knowledge gaps directly inform the Investigator Initiated Research Grant Program so that the sponsor can prioritize issues of greatest scientific
--	---

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	importance and with the highest potential for translation into effective strategies for cancer prevention and improved outcomes for people living with and beyond cancer.				
035671	Seymour R. Cohen Research Grant	American Laryngological Association		19-Jan-2021	15,000 USD
	Contact Name	Maxine Cunningham			
	Contact Telephone	615-812-6170			
	Contact Email	maxine.c@comcast.net			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	19-Jan-2021			
	Synopsis	The purpose of this award is to support basic science research projects in the area of laryngology or neurolaryngology with relevance to the pediatric population, and should lead to furthering the fields of pediatric laryngology or pediatric neurolaryngology.			
061500	ALA/ALVRE Research Grant	American Laryngological Association		19-Jan-2021	10,000 USD
	Contact Name	Maxine Cunningham			
	Contact Telephone	615-812-6170			
	Contact Email	maxine.c@comcast.net			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	19-Jan-2021			
	Synopsis	The purpose of this award is to support basic, translational, or clinical research projects in laryngology (voice, airway, swallowing), outcomes, and related subjects, and should lead to furthering the fields of laryngology or neurolaryngology.			
085305	Mewaldt-King Award	American Ornithological Society		29-Jan-2021	2,500 USD

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email info@americanornithology.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 29-Jan-2021</p> <p>Synopsis The Mewaldt-King Student Research Awards supports graduate student research (Masters or Doctorate) in any area of ornithology that relates to the conservation of birds. One award of up to \$2,500 will be presented.</p>				
072240	Student & Postdoctoral Research Awards	American Ornithological Society		29-Jan-2021	2,500 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email info@americanornithology.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 29-Jan-2021</p> <p>Synopsis The American Ornithological Society (AOS) gives annual Student Research Awards of up to \$2,500 to support research in various areas of avian biology by undergraduates, graduate students, and postdocs. AOS encourages undergraduate students from any region to apply.</p>				
017881	Research Grants	American Osteopathic Association		15-Feb-2021	100,000 USD
	<p>Contact Name Gloria Dillard, MPH, Research Manager</p> <p>Contact Telephone 312-202-8006</p> <p>Contact Email gdillard@osteopathic.org</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Feb-2021</p> <p>Synopsis The AOA awards funding to researchers conducting 18 month projects rooted in osteopathic principles and practice. MD, DO and PhD researchers are eligible to apply for AOA grant funding that corresponds to RFAs in the AOA's research focus areas: Osteopathic Manipulative Medicine and Treatment on the Prevention and Management of Musculoskeletal Injuries (OMM/OMT); and Acute/Chronic Pain Management (ACPM); Impact of the Osteopathic Approach on Chronic Disease and Elderly Care; Osteopathic Manipulative Medicine (OMM) Observational & Explorative Research Studies.</p>				
061501	Clinical Investigations Grant	American Otological Society		31-Jan-2021	66,000 USD
	<p>Contact Name John S. Oghalai, MD, Executive Secretary, Research Fund</p> <p>Contact Telephone 217-638-0801</p> <p>Contact Email john.oghalai@med.usc.edu</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 31-Jan-2021</p> <p>Synopsis The purpose of the American Otological Society (AOS) Research Fund is to encourage and support academic research in sciences related to the ear.</p>				
061551	Fellowship Grant	American Otological Society		31-Jan-2021	44,000 USD
	<p>Contact Name Kristen John S. Oghalai, MD, Executive Secretary, Research Fund</p> <p>Contact Telephone 217-638-0801</p> <p>Contact Email john.oghalai@med.usc.edu</p> <p>Sponsor Website Link to sponsor website</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL Link to program URL Deadline Dates (ALL) 31-Jan-2021 Synopsis The purpose of the American Otological Society (AOS) Research Training Fellowship is to foster the academic training of students and resident physicians in sciences related to the investigation of any topic related to ear disorders.				
025077	Research Grants	American Otological Society		31-Jan-2021	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 31-Jan-2021 Synopsis The American Otological Society is committed to the non-promotional advancement of knowledge and science and to a free exchange of medical education in otology and neurotology. The American Otological Society, through its Research Foundation, is offering Research Grant Awards. All of the AOS grant awards may involve research on any topic related to ear disorders. The research need not be directly on an otological disease but may explore normal functions of the cochlea, labyrinth or central auditory or vestibular systems. However, the applicant must describe how the proposed research will benefit our understanding, diagnosis or treatment of otological disorders. Research supported by all of the grant mechanisms can relate to any aspects of the ear, hearing and balance disorders.				
087140	Society for Health Psychology (Division 38) -- Graduate Student Research Awards Program -- Research Award to Promote Inclusion	American Psychological Association		15-Jan-2021	2,000 USD
	Contact Name Contact Telephone 804-752-4987 Contact Email apadiv38.studentawards@gmail.com				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Sponsor Website [Link to sponsor website](#)
 Program URL [Link to program URL](#)
 Deadline Dates (ALL) 15-Jan-2021
 Synopsis There is one (1) award annually for \$2,000 for graduate student research in health psychology for this category. The SfHP recognizes the need to increase the number of scientists from underrepresented groups participating in research relevant to health psychology.

087141	Society for Health Psychology (Division 38) -- Graduate Student Research Awards Program -- Research Addressing Health Disparities	American Psychological Association		15-Jan-2021	2,000 USD
--------	---	------------------------------------	--	-------------	-----------

Contact Name
 Contact Telephone 804-752-4987
 Contact Email apadiv38.studentawards@gmail.com
 Sponsor Website [Link to sponsor website](#)
 Program URL [Link to program URL](#)
 Deadline Dates (ALL) 15-Jan-2021
 Synopsis There is one (1) award annually for \$2,000 for graduate student research in health psychology for this category.

018598	Biomedical Engineering Teaching Award	American Society for Engineering Education		01-Feb-2021	350 USD
--------	---	--	--	-------------	---------

Contact Name Dr. Jennifer H Choi
 Contact Telephone 530-752-9436
 Contact Email jhkchoi@ucdavis.edu
 Sponsor Website [Link to sponsor website](#)
 Program URL [Link to program URL](#)
 Deadline Dates (ALL) 01-Feb-2021

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The Biomedical Engineering Division (BED) annually awards the Biomedical Engineering Teaching Award to recognize contributions in the field of biomedical engineering education by new faculty members as evidenced by innovative teaching materials, curricula, textbooks and/or professional papers and by activity in ASEE/BED and/or other biomedical engineering organizations.			
013847	Theo C. Pilkington Outstanding Educator Award	American Society for Engineering Education		01-Feb-2021	350 USD
	Contact Name	Dr. Jennifer H Choi			
	Contact Telephone	530-752-9436			
	Contact Email	jhkchoi@ucdavis.edu			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Feb-2021			
	Synopsis	The Biomedical Engineering Division (BED) of ASEE annually awards the Theo Pilkington Outstanding Educator Award. This award is conferred by the division for significant contributions to biomedical engineering education as evidenced by the development of successful undergraduate or graduate level programs, curricula, publications as well as by membership and activities in ASEE/BED and other biomedical engineering organizations. The award consists of a commemorative plaque and a check for \$350.			
067466	ASGE Endoscopic Training Award	American Society for Gastrointestinal Endoscopy		17-Jan-2021	5,000 USD
	Contact Name	Redi Jakova			
	Contact Telephone	630-570-5618			
	Contact Email	rjakova@asge.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 17-Jan-2021</p> <p>Synopsis The ASGE Endoscopic Training Award provides Advanced Fellows or Junior Faculty with the opportunity to train outside of their home country with a premier GI endoscopist or group to advance their training. The award assists in underwriting reasonable and customary travel and living expenses for a period of one to three months.</p>				
101062	Ajinomoto Young Investigator Pilot Grant	American Society for Nutrition		22-Jan-2021	10,000 USD
	<p>Contact Name Keith Dillion, Senior Director of Corporate Affairs, VP ASN Foundation</p> <p>Contact Telephone 301-634-7050</p> <p>Contact Email awards@nutrition.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 22-Jan-2021</p> <p>Synopsis Pilot grants are stipends for preliminary or pilot phases of young investigators' research projects. These grants support an investigator's efforts to address focused research questions, obtain preliminary data to support larger grant proposals in the future, and develop a line of research that can be carried forward into an academic career.</p>				
008636	ASPET Travel Awards	American Society for Pharmacology and Experimental Therapeutics		11-Jan-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 301-634-7060</p> <p>Contact Email travelawards@aspet.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis The objective of the ASPET Travel Award Program is to encourage the career development of young scientists through</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

their participation in the ASPET Annual Meeting at Experimental Biology. Undergraduates, post-baccalaureate students, graduate students, and postdoctoral scientists are invited to apply for a travel award to help defray the cost of travel to attend the ASPET Annual Meeting at Experimental Biology0. ASPET travel awards consist of registration reimbursement.

059738	Clinical Grants	American Society for Surgery of the Hand		01-Feb-2021 [LOI/Pre-App]	40,000 USD
--------	---------------------------------	--	--	------------------------------	------------

Contact Name	
Contact Telephone	312-880-1900
Contact Email	afsh@assh.org
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	01-Feb-2021 [LOI/Pre-App], 29-Mar-2021
Synopsis	The American Society for Surgery of the Hand (ASSH) and the American Foundation for Surgery of the Hand (AFSH) have established grant funding to encourage young investigators to perform clinical research studies. The goal is to enable investigators to initiate pilot projects that will lead to subsequent funding from other sources such as the National Institutes of Health (NIH). The AFSH is committed to excellence in clinical research while maintaining the highest academic integrity and fiscal responsibility.

059739	Basic Science Grants	American Society for Surgery of the Hand		01-Feb-2021 [LOI/Pre-App]	20,000 USD
--------	--------------------------------------	--	--	------------------------------	------------

Contact Name	
Contact Telephone	312-880-1900
Contact Email	afsh@assh.org
Sponsor Website	Link to sponsor website
Program URL	Link to program URL

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Deadline Dates (ALL) 01-Feb-2021 [LOI/Pre-App], 29-Mar-2021 Synopsis These grants function similarly to the NIH Exploratory/Developmental Research Grant Program (R21). The R21 grant mechanism is intended to encourage exploratory/developmental research by providing support for the early and conceptual stages of project development.					
091770	Residents/Fellows in Radiation Oncology Research Seed Grant	American Society for Therapeutic Radiology and Oncology		26-Feb-2021	25,000 USD
Contact Name Contact Telephone 703-502-1550 Contact Email research@astro.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 26-Feb-2021 Synopsis The American Society for Therapeutic Radiology and Oncology offers Residents/Fellows in Radiation Oncology Seed Grants to fund novel projects, and support residents or fellows who are interested in radiation-oncology related basic science, or clinical research.					
100564	Residents/Fellows in Radiation Oncology Biology Seed Grant	American Society for Therapeutic Radiology and Oncology		26-Feb-2021	25,000 USD
Contact Name Contact Telephone 703-502-1550 Contact Email research@astro.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 26-Feb-2021					

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The American Society for Therapeutic Radiology and Oncology offers Residents/Fellows in Radiation Oncology Biology Seed Grants to fund novel projects, and support residents or fellows performing biological research in radiation oncology and/or cancer focused sciences. The biology-focused seed grant will support the next generation of researchers who are planning a career in basic science or translational research.			
008893	Minority Summer Fellowship Award	American Society for Therapeutic Radiology and Oncology		05-Feb-2021	5,000 USD
	Contact Name	Natalie Cain			
	Contact Telephone	703-502-1550			
	Contact Email	natalie.cain@astro.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Feb-2021			
	Synopsis	The ASTRO Minority Summer Fellowship Award introduces medical students from backgrounds that are under-represented in medicine to the discipline of radiation oncology early in their medical education. Medical students in all years are encouraged to apply; preference will be given to first- and second-year students. In an effort to promote radiation oncology as a career choice, the fellowship will provide medical students with an experience designed to expose students to clinical, basic and translational research questions in radiation oncology.			
086633	American Society of Animal Science Award for Industry Innovation	American Society of Animal Science		15-Jan-2021	Not Specified
	Contact Name				
	Contact Telephone	217-356-9050			
	Contact Email	asas@asas.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Deadline Dates (ALL) 15-Jan-2021

Synopsis The American Society of Animal Science presents the American Society of Animal Science Award for Industry Innovation to recognize excellence in development of applied technologies that enhances animal production, wellness or wellbeing.

021033	Minority Medical Student Award Program	American Society of Hematology		15-Jan-2021	Not Specified
--------	--	--------------------------------	--	-------------	---------------

Contact Name
 Contact Telephone 202-776-0544
 Contact Email awards@hematology.org
 Sponsor Website [Link to sponsor website](#)
 Program URL [Link to program URL](#)

Deadline Dates (ALL) 15-Jan-2021

Synopsis The ASH Minority Medical Student Award Program (MMSAP) provides underrepresented minority medical students with an opportunity to conduct a research project under the supervision of an ASH member, receive guidance from a career-development mentor, gain valuable knowledge of hematology, and ultimately, advance their careers. As part of the ASH Minority Recruitment Initiative, the MMSAP aims to expand the program's reach to the next generation of hematologists.

030069	Research Training Award for Fellows (RTAF)	American Society of Hematology		15-Jan-2021	70,000 USD
--------	--	--------------------------------	--	-------------	------------

Contact Name
 Contact Telephone 202-776-0544
 Contact Email awards@hematology.org
 Sponsor Website [Link to sponsor website](#)
 Program URL [Link to program URL](#)

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 15-Jan-2021</p> <p>Synopsis The ASH Research Training Award for Fellows (RTAF) is designed to encourage junior researchers in hematology, hematology/oncology, and other hematology-related training programs to pursue careers in academic hematology. The award provides each recipient with \$70,000 for a one-year period to guarantee protected time for clinical, basic, or translational research.</p>				
032661	ASH Medical Student Physician-Scientist Award	American Society of Hematology		01-Feb-2021	42,000 USD
	<p>Contact Name</p> <p>Contact Telephone 202-776-0544</p> <p>Contact Email awards@hematology.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Feb-2021</p> <p>Synopsis The ASH Medical Student Physician-Scientist Award provides an opportunity for first-, second-, and third-year medical students to gain experience in hematology research under the mentorship of an ASH member and to learn more about the specialty. Awardees must agree to spend more than 80 percent of their time during the immersive, year-long project conducting laboratory, translational, or clinical hematology research. The award provides \$42,000 of funding for a one-year period, which includes \$32,000 to support the trainee, \$4,000 for research supplies, \$4,000 for insurance and educational expenses (including one course), and \$2,000 for meeting attendance (including the ASH annual meeting).</p>				
016657	Research Training Award for Fellows (RTAF) -- Junior Investigator Award	American Society of Hematology		15-Jan-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 202-552-4928</p> <p>Contact Email awards@hematology.org</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Jan-2021</p> <p>Synopsis The ASH Research Training Award for Fellows (RTAF) is designed to encourage junior researchers in hematology, hematology/oncology, or other hematology-related training programs to pursue a career in academic hematology. The RTAF awards \$70,000 to fellows in training so they will have protected time for research and is to be used primarily for salary support for the applicant. A junior Investigator award is for those whose research has been initiated but no preliminary data has been collected.</p>				
020188	Donald W. Seldin Young Investigator Award	American Society of Nephrology		29-Jan-2021	Not Specified
	<p>Contact Name Molly Harrison</p> <p>Contact Telephone 202-640-4660</p> <p>Contact Email mharrison@asn-online.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 29-Jan-2021</p> <p>Synopsis The Donald W. Seldin Young Investigator Award is presented annually to an individual with an outstanding record of achievement and creativity in basic or patient-oriented research related to the functions and diseases of the kidney. This award is co-sponsored by the American Society of Nephrology and the Council on the Kidney in Cardiovascular Disease of the American Heart Association and is limited to individuals who are age 45 or younger on December 31 of the year during which the award is presented. The award consists of a certificate of recognition, an unrestricted grant to the laboratory of the awardee, and paid travel expenses to the meeting. The Donald W. Seldin Young Investigator Award recipient also gives a presentation during the plenary session at the annual meeting.</p>				
044274	ASPO Research Career Development Award	American Society of Pediatric Otolaryngology		15-Jan-2021	40,000 USD

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone 703-836-4444</p> <p>Contact Email ASPO@facs.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Jan-2021</p> <p>Synopsis The purpose of this award is to provide support for the research career development of otolaryngologists – head and neck surgeons who have made a commitment to focus their research endeavors on research oriented to pediatric otolaryngology (e.g. patient-oriented clinical trials, health services, outcomes research, translational research, basic science).</p>				
076833	ASPO Research Grant	American Society of Pediatric Otolaryngology		15-Jan-2021	20,000 USD
	<p>Contact Name Erin Lambie</p> <p>Contact Telephone 703-836-4444</p> <p>Contact Email COREGrants@entnet.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Jan-2021</p> <p>Synopsis The American Society of Pediatric Otolaryngology (ASPO) awards funds annually to support innovative research in pediatric otolaryngology.</p>				
020086	Research Starter Grants	American Society of Pharmacognosy		15-Feb-2021	5,000 USD
	<p>Contact Name Chair of the ASP Awards and Funds Committee</p> <p>Contact Telephone</p> <p>Contact Email afc@pharmacognosy.us</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 15-Feb-2021 Synopsis The Research Starter Grants are small research grants from \$2000 to \$5000 available for active members in the first eight years after earning their Ph.D. and in the first five years of their first independent career position. These are one-time awards and do not provide indirect costs. They are awarded preferentially to applicants who have not yet received major external funding.				
019850	Siemens Clinical Advancement Scholarship	American Society of Radiologic Technologists Education and Research Foundation		31-Jan-2021	Not Specified
	Contact Name Contact Telephone 800-444-2778 Contact Email foundation@asrt.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 31-Jan-2021 Synopsis The Siemens Clinical Advancement Scholarship assists medical imaging professionals seeking to enhance their clinical practice skills and provide excellent patient care. Scholarships are \$5,000 each.				
064856	Research Grants	American Thyroid Association		01-Feb-2021 [LOI/Pre-App]	50,000 USD
	Contact Name Contact Telephone 703-998-8890 Contact Email research@thyroid.org Sponsor Website Link to sponsor website				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Feb-2021 [LOI/Pre-App]</p> <p>Synopsis The ATA® is committed to supporting research into better ways to diagnose and treat thyroid disease. The generosity of members, patients, industry, and donors in the workplace has enabled the ATA® to fund 105 thyroid research grants totaling over \$2.8 million since the inception of the Research Fund. In addition, the ATA® rigorously manages the selection of research projects and distribution of over \$2.9 million to date generously donated to the ATA® specifically for research grants from ThyCa: Thyroid Cancer Survivors' Association, Inc. and Bite Me Cancer.</p>				
070030	Arthritis Research Grants	Arthritis National Research Foundation		17-Jan-2021	100,000 USD
	<p>Contact Name</p> <p>Contact Telephone 800-588-2873</p> <p>Contact Email</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 17-Jan-2021</p> <p>Synopsis The Arthritis National Research Foundation (ANRF) is seeking grant applications that focus on studying arthritis and related autoimmune diseases. Applicants may request up to \$100,000 in direct costs only.</p>				
077751	Psoriatic Arthritis Grant	Arthritis National Research Foundation		17-Jan-2021	100,000 USD
	<p>Contact Name</p> <p>Contact Telephone 800-588-2873</p> <p>Contact Email</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 17-Jan-2021</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	In a collaborative effort, the Arthritis National Research Foundation (ANRF) and the National Psoriasis Foundation (NPF) are seeking grant applications that focus on studying psoriatic arthritis.			
077752	Arthritis and Aging Research Grant	Arthritis National Research Foundation		15-Jan-2021	100,000 USD
	Contact Name				
	Contact Telephone	800-588-2873			
	Contact Email	grants@curearthritis.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Jan-2021			
	Synopsis	In a collaborative effort, the Arthritis National Research Foundation (ANRF) and the American Federation for Aging Research (AFAR) are seeking grant applications that focus on studying the underlying mechanisms by which aging processes contribute to the development of arthritis.			
071373	Holloway Postdoctoral Fellowships	Association for Frontotemporal Degeneration		29-Jan-2021	120,000 USD
	Contact Name	Debra Niehoff, PhD, Research Manager			
	Contact Telephone	267-758-8654			
	Contact Email	dniehoff@theaftd.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	29-Jan-2021			
	Synopsis	The AFTD postdoctoral fellowship program provides funding for the next generation of FTD researchers. By supporting talented young investigators during this critical phase of their scientific training, AFTD aims to inspire a long-standing commitment to FTD research. For the 2021-2023 award cycle, up to 3 fellowships will be funded, thanks to the generosity of the Holloway Family Fund.			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
031491	AAMI's HTM Leadership Award	Association for the Advancement of Medical Instrumentation		11-Jan-2021	2,500 USD
	Contact Name				
	Contact Telephone	703-253-8296			
	Contact Email	awards@aami.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)				
	Synopsis	AAMI's HTM Leadership Award recognizes individual excellence, achievement, and leadership in the healthcare technology management (HTM) profession.			
073435	AAMI & GE Healthcare's BMET of the Year Award	Association for the Advancement of Medical Instrumentation		11-Jan-2021	1,500 USD
	Contact Name				
	Contact Telephone	703-525-4890			
	Contact Email	awards@aami.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)				
	Synopsis	The AAMI & GE Healthcare BMET of the Year Award is given to a biomedical equipment technician (BMET) to recognize individual dedication, achievement, and excellence in the field of healthcare technology management.			
073436	AAMI Foundation & ACCE's Robert L. Morris Humanitarian Award	Association for the Advancement of Medical Instrumentation		11-Jan-2021	1,000 USD
	Contact Name				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone 703-525-4890 Contact Email awards@aami.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL)				
	Synopsis	The AAMI Foundation & ACCE's Robert L. Morris Humanitarian Award award—honoring the late humanitarian Robert Morris—recognizes individuals or organizations whose humanitarian efforts have applied healthcare technology to improving global human conditions.			
073431	AAMI & Becton Dickinson's Patient Safety Award	Association for the Advancement of Medical Instrumentation		11-Jan-2021	1,500 USD
	Contact Name Contact Telephone 703-525-4890 Contact Email awards@aami.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL)				
	Synopsis	The AAMI & Becton Dickinson's Patient Safety Award recognizes outstanding achievements by healthcare professionals who have made a significant advancement toward the improvement of patient safety.			
013387	Award for Distinguished Research in the Biomedical Sciences	Association of American Medical Colleges		22-Jan-2021	10,000 USD
	Contact Name Sandra Gordon Contact Telephone 202-828-0472 Contact Email sgordon@aamc.org Sponsor Website Link to sponsor website				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL Link to program URL Deadline Dates (ALL) 22-Jan-2021 Synopsis The Award for Distinguished Research in the Biomedical Sciences honors an individual or a team of two individuals for outstanding research in the basic or translational sciences. The 2020 awardee receives the Research Award and a prize of \$10,000.				
013386	Abraham Flexner Award for Distinguished Service to Medical Education	Association of American Medical Colleges		22-Jan-2021	10,000 USD
	Contact Name Sandra Gordon Contact Telephone 202-828-0472 Contact Email sgordon@aamc.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 22-Jan-2021 Synopsis The Abraham Flexner Award for Distinguished Service to Medical Education honors an individual or a team of two individuals whose contributions have had a demonstrable impact on advancing medical education. The awardee receives the Flexner Medal and a prize of \$10,000.				
080060	Wild Bird Health Grant	Association of Avian Veterinarians		15-Feb-2021	5,000 USD
	Contact Name Contact Telephone 720-458-4111 Contact Email office@aav.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 15-Feb-2021 , 15-Jul-2021				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Synopsis		The Association of Avian Veterinarians (AAV) is accepting pre-proposals for research projects addressing wild bird health. Grants are limited to \$5,000 US for individual projects.			
054263	Dr. Jay Brown Best Abstract Award	Association of Black Cardiologists, Inc.		15-Jan-2021	1,000 USD
Contact Name		Katrese Phelps-McCullum, Program Director			
Contact Telephone		202-600-4353			
Contact Email		cmccullough@abcadio.org			
Sponsor Website		Link to sponsor website			
Program URL		Link to program URL			
Deadline Dates (ALL)		15-Jan-2021			
Synopsis		The Dr. Jay Brown Best Abstract Award is for an abstract summarizing any problem that relates to cardiovascular disease whether it is: Clinical, Basic or Population Science.			
043710	AMD Resident Research Grant	Association of Migraine Disorders		15-Jan-2021	10,000 USD
Contact Name					
Contact Telephone					
Contact Email		info@migrainedisorders.org			
Sponsor Website		Link to sponsor website			
Program URL		Link to program URL			
Deadline Dates (ALL)		15-Jan-2021			
Synopsis		The purpose of this grant is to stimulate original resident research in migraine-related head and neck disorder projects that are well-conceived and scientifically valid, with the potential to advance the understanding of migraine disease.			
067880	APHL-CDC Infectious Diseases Laboratory Fellowship Program	Association of Public Health Laboratories		28-Feb-2021	Not Specified

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone 240-485-2778</p> <p>Contact Email fellowships@aphl.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 28-Feb-2021</p> <p>Synopsis The Infectious Diseases Laboratory (ID) Fellowship, sponsored by APHL and CDC, trains and prepares scientists for careers in public health laboratories and supports public health initiatives related to infectious diseases. The fellowship's mission is to provide a high quality training experience for the fellow while providing workforce capacity to the public health laboratory community.</p>				
057954	Audio Visual Prize	Association of Surgeons of Great Britain & Ireland		31-Jan-2021	402 USD
	<p>Contact Name</p> <p>Contact Telephone 020 7304 4770</p> <p>Contact Email dvds@asgbi.org.uk</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 31-Jan-2021</p> <p>Synopsis ASGBI offers an competition for the best video submitted for their annual meeting. Entries must be of general surgical interest, suitable for an audience of consultants and higher surgical trainees and may include topic presentations as well as operative surgery.</p>				
018455	Sir Harcourt Caughey Award	Auckland Medical Research Foundation		26-Jan-2021	17,750 USD
	Contact Name	Research Programme Manager			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone +64 9 923 1701</p> <p>Contact Email amrf@medicalresearch.org.nz</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 26-Jan-2021</p> <p>Synopsis The Sir Harcourt Caughey Award provides funds up to \$25,000 for medical graduates. There are three different categories for this Award. However, in 2021, AMRF will only be calling for applications in the following category due to Covid-19-related travel restrictions: 1. Be a graduate of New Zealand who, having trained in research overseas, is returning to New Zealand to a part-time appointment in Auckland and who has sufficient experience in research to deserve part-time support (or similar to a part-time Senior Research Fellowship) in such research.</p>				
063875	Shimadzu Prize	Australian and New Zealand Society of Nuclear Medicine		05-Feb-2021	1,520 USD
	<p>Contact Name </p> <p>Contact Telephone +61 1300 330 402</p> <p>Contact Email secretariat@anzsnm.org.au</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021</p> <p>Synopsis The Shimadzu Award will be held in conjunction with the Annual Scientific Meeting (ASM) of the Australian and New Zealand Society of Nuclear Medicine (ANZSNM). Its aim is to encourage innovative and progressive work in the field of Radiopharmaceutical Science (RPS). The Award will be provided for an oral presentation by a financial member of the ANZSNM.</p>				
098919	Postdoctoral Fellowships	Banting and Best Diabetes Centre		23-Feb-2021	Not Specified

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Rose LaBarbera</p> <p>Contact Telephone 416-978-4656</p> <p>Contact Email diabetes.bbdc@utoronto.ca</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 23-Feb-2021</p> <p>Synopsis Postdoctoral Fellowships offered by the Banting & Best Diabetes Centre (BBDC) are in-training awards for individuals who hold (or are expecting to complete) a doctoral degree (PhD) or medical degree (MD). The objective of these awards is to attract and foster young investigators to initiate and/or continue research training in the field of diabetes.</p>				
057909	Emerging Leader Award	Bay Area Lyme Foundation		15-Feb-2021	250,000 USD
	<p>Contact Name </p> <p>Contact Telephone 650-530-2439</p> <p>Contact Email award@bayarealyme.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Feb-2021</p> <p>Synopsis The Bay Area Lyme Foundation Emerging Leader Awards (ELA) recognize both established and up-and-coming researchers bringing new approaches and creative thinking to the field of Lyme disease. These grants support new and innovative projects and aim to attract aspiring new scientific talent to the field of Lyme. Two award levels are offered: a \$250,000 ELA Grant, and a \$100,000 ELA Grant.</p>				
027706	Summer Student Research Program Studentship	BC Children's Hospital Research Institute		26-Feb-2021	3,686 USD
	<p>Contact Name </p> <p>Contact Telephone 604-875-2000</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Email reseduc@bcchr.ca Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 26-Feb-2021 Synopsis BC Children's Hospital invites applications for Research Summer Studentships in any health related research area that has direct relevance to improving the health of children and families, tenable between May and August.				
004844	Ernest May Fellowship in History and Policy	Belfer Center for Science and International Affairs		15-Jan-2021	Not Specified
	Contact Name Susan M. Lynch, Program Assistant, International Security Program Contact Telephone 617-495-9858 Contact Email susan_lynch@harvard.edu Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 15-Jan-2021 , 03-Feb-2021 Synopsis The Ernest May Fellowship in History and Policy of the Harvard Kennedy School's Belfer Center for Science and International Affairs aims to help build the next generation of men and women who will bring professional history to bear on strategic studies and major issues of international affairs.				
078554	International Security Program (ISP)	Belfer Center for Science and International Affairs		15-Jan-2021	Not Specified
	Contact Name Susan M. Lynch, Program Assistant Contact Telephone Contact Email susan_lynch@harvard.edu Sponsor Website Link to sponsor website				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Jan-2021 , 03-Feb-2021</p> <p>Synopsis The International Security Program develops and trains new talent in security studies by hosting pre- and postdoctoral research fellows. The International Security Program offers fellowships in the following research areas: U.S. defense and foreign policy; grand strategy; diplomacy; nuclear, chemical, and biological–weapons proliferation; managing nuclear technology and materials; chemical and biological weapons proliferation, control, and countermeasures; terrorism; regional security, internal and ethnic conflict; and international relations theory.</p>				
099665	Early Career Research Awards	Biochemical Society		31-Jan-2021	1,340 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email awards@biochemistry.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 31-Jan-2021</p> <p>Synopsis The Biochemical Society Early Career Research Awards recognize the impact of research carried out by early career scientists i.e. those who have no more than six years postdoctoral research experience. It is expected that successful candidates will have produced international quality research outputs, and be able to demonstrate ambitions and aspirations consistent with the potential to achieve world-leading status.</p>				
089251	Medical Education Grants	Biogen, Inc.		15-Feb-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 617-914-1299</p> <p>Contact Email grantsandgiving@biogen.com</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Sponsor Website [Link to sponsor website](#)
 Program URL [Link to program URL](#)
 Deadline Dates (ALL) 15-Feb-2021
 Synopsis Biogen provides funding to an eligible institution or organization to support independent medical educational activities for HCPs and researchers. Medical education may be accredited or non-accredited.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

089255	General Grants	Biogen, Inc.		15-Feb-2021	Not Specified
--------	--------------------------------	--------------	--	-------------	---------------

Contact Name
 Contact Telephone 617-914-1299
 Contact Email grantsandgiving@biogen.com
 Sponsor Website [Link to sponsor website](#)
 Program URL [Link to program URL](#)
 Deadline Dates (ALL) 15-Feb-2021
 Synopsis Biogen provides funding to an eligible institution or organization to support a program or project that does not fit any of the other defined grant categories.

045333	Bladder Cancer Research Innovation Award	Bladder Cancer Advocacy Network (BCAN)		13-Jan-2021 [LOI/Pre-App]	300,000 USD
--------	--	--	--	------------------------------	-------------

Contact Name
 Contact Telephone 301-215-9099
 Contact Email grants@bcan.org
 Sponsor Website [Link to sponsor website](#)

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 13-Jan-2021 [LOI/Pre-App]</p> <p>Synopsis BCAN is pleased to announce two 2021 Bladder Cancer Research Innovation Awards to support the work of investigators with exceptionally novel and creative projects with great potential to produce breakthroughs in our understanding of the management of bladder cancer. Two proposals will be funded for \$300,000 at \$150,000 per year. The proposed research may be basic, translational, clinical or epidemiological and must have direct applicability and relevance to bladder cancer. Innovation, either conceptual or technological, is essential.</p>				
091333	COVID-19 Research Grants	British Society for Antimicrobial Chemotherapy		18-Jan-2021 [LOI/Pre-App]	Not Specified
	<p>Contact Name The Secretary, Grants Committee</p> <p>Contact Telephone +44 (0) 121 236 1988</p> <p>Contact Email grants@bsac.org.uk</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 18-Jan-2021 [LOI/Pre-App], 09-Apr-2021</p> <p>Synopsis BSAC is launching an open call for funding to support grant applications in response to the current coronavirus (COVID-19) public health emergency. They are specifically interested in applications from new investigators to support the acceleration of careers of research scientists in LMICs.</p>				
005671	Scholarship Scheme	British Society for Oral and Maxillofacial Pathology		31-Jan-2021	1,340 USD
	<p>Contact Name Dr Ali Khurram</p> <p>Contact Telephone</p> <p>Contact Email thebsomp@gmail.com</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	31-Jan-2021			
	Synopsis	The British Society for Oral & Maxillofacial Pathology Scholarship provides funding for scholarship projects which contribute to the advancement of oral pathology.			
058765	Innovation in Regulatory Science Award	Burroughs Wellcome Fund		12-Feb-2021	500,000 USD
	Contact Name	Kelly Rose, PhD, Program Officer			
	Contact Telephone	919-991-5120			
	Contact Email	krose@bwfund.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	12-Feb-2021			
	Synopsis	BWF's Innovation in Regulatory Science Awards provides \$500,000 over five years to academic researchers developing new methodologies or innovative approaches in regulatory science that will ultimately inform the regulatory decisions FDA and others make. This would necessarily draw upon the talents of individuals trained in mathematics, computer science, applied physics, medicine, engineering, toxicology, epidemiology, biostatistics, systems pharmacology, and food safety and nutrition to name a few.			
036762	Postdoctoral Enrichment Program for Underrepresented Minorities	Burroughs Wellcome Fund		14-Jan-2021	60,000 USD
	Contact Name	Alfred M. Mays			
	Contact Telephone	919-991-5103			
	Contact Email	amays@bwfund.org			
	Sponsor Website	Link to sponsor website			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 14-Jan-2021</p> <p>Synopsis Postdoctoral Enrichment Program (PDEP) provides a total of \$60,000 over three years to support the career development activities for underrepresented minority postdoctoral fellows in a degree-granting institution in the United States or Canada whose training and professional development are guided by mentors committed to helping them advance to stellar careers in biomedical or medical research. Generally, up to 12 awards will be granted for enrichment activities annually. This grant is meant to supplement the training of postdocs whose research activities are already supported. It is not a research grant.</p>				
059564	QuickStart Program	California Breast Cancer Research Program		14-Jan-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 888-313-2277</p> <p>Contact Email QuickStartTP@gmail.com</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 14-Jan-2021 , 18-Mar-2021</p> <p>Synopsis QuickStart is an innovative three-month program for both newly forming and experienced collaborative community-academic research partnerships. The full QuickStart program is scheduled for May 2021 to October 2021. The optional grant preparation and mock review is scheduled to take place between October 2021 to January 2022. This schedule may change as it is determined whether or not in-person sessions will be offered, or whether those sessions will be spread over a combination of in-person and online sessions, or whether those 4-days-worth of session will be completely online, or some other approach.</p>				
026080	International Postdoctoral Fellowship	Canadian HIV Trials Network		31-Jan-2021	27,300 USD
	<p>Contact Name Jacqueline Sas</p> <p>Contact Telephone 604-806-8381</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email jsas@hivnet.ubc.ca</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 31-Jan-2021</p> <p>Synopsis The CTN International Postdoctoral Fellowship's purpose is to train scientists who are committed to developing and conducting HIV treatment or prevention research studies in a resource-limited country.</p>				
062443	Other: Health System Impact Fellowships	Canadian Institutes of Health Research		09-Feb-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 613-954-1968</p> <p>Contact Email support@cihr-irsc.gc.ca</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 09-Feb-2021</p> <p>Synopsis The Health System Impact Fellowship provides highly-qualified doctoral trainees and post-doctoral fellows studying health services and policy research, or related fields, a unique opportunity to apply their research and analytic talents to critical challenges in health system and related organizations outside of the traditional scholarly setting (e.g., public, private for-profit, not-for-profit, and Indigenous health organizations that are not universities or research-focused institutes), and to develop professional experience, new skills, and networks.</p>				
001439	Clinic and Laboratory Integration Program (CLIP)	Cancer Research Institute, Inc.		01-Feb-2021	200,000 USD
	<p>Contact Name</p> <p>Contact Telephone 212-688-7515</p> <p>Contact Email grants@cancerresearch.org</p> <p>Sponsor Website Link to sponsor website</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Feb-2021</p> <p>Synopsis The Clinic and Laboratory Integration Program (CLIP) grants provide catalytic support for translational laboratory studies designed to answer new specific scientific questions that arise in the clinic, with special focus on improving immunotherapy for cancer patients.</p>				
064953	Clinician Scientist Fellowship	Cancer Research UK		26-Jan-2021	Not Specified
	<p>Contact Name Dr Marjolein Schaap</p> <p>Contact Telephone 0300 123 1022</p> <p>Contact Email fellowships@cancer.org.uk</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 26-Jan-2021</p> <p>Synopsis This Fellowship offers excellent individuals the opportunity to develop a clinical academic research career through a period of postdoctoral training. Fellowships must be hosted in a UK university or research institute. Short periods of research experience away from the host institution may be requested and must be fully justified.</p>				
024798	Visiting Professor Program	Center for AIDS Prevention Studies		20-Jan-2021	20,000 USD
	<p>Contact Name</p> <p>Contact Telephone 415-476-6256</p> <p>Contact Email vp.program@ucsf.edu</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 20-Jan-2021</p> <p>Synopsis Each year a small number of scientists are selected to participate in the Training Program for Scientists Conducting</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>Research to Reduce HIV/STI Health Disparities. This program is also known as the Visiting Professor (VP) Program. The VP Program is designed to assist investigators already conducting HIV-prevention research with minority communities to improve their programs of research and obtain additional funding for their work.</p>			
067228	Natural Sciences or Engineering International Security Fellowship	Center for International Security and Cooperation		15-Jan-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 650-723-4581</p> <p>Contact Email CISACfellowship@stanford.edu</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Jan-2021</p> <p>Synopsis The Center for International Security and Cooperation (CISAC) offers fellows support while they are; engaged in research and writing, attending seminars, and, interacting and collaborating with leading faculty and researchers. Natural scientists have the opportunity to conduct research on the scientific and technical aspects of security topics, as well as to work in collaboration with faculty members. Fellowships range from nine to eleven months, and in certain circumstances may be renewable.</p>				
026399	Baer Reintegration Scholarship	Center for Reintegration		15-Jan-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email baerscholarships@reintegration.com</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Jan-2021</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The goal of the Baer Reintegration Scholarship is to help people with schizophrenia, schizoaffective disorder or bipolar disorder acquire the educational and vocational skills necessary to reintegrate into society, secure jobs, and regain their lives.			
086052	Young Investigator Award	Children's Tumor Foundation		22-Jan-2021	Not Specified
	Contact Name				
	Contact Telephone	212-344-6633			
	Contact Email	info@ctf.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	22-Jan-2021			
	Synopsis	The Young Investigator Award (YIA), CTF's longest running award program, provides funding for two years to early-career NF researchers, helping them to get established as independent investigators. Initiated over 30 years ago, the main function of the YIA program is to serve as a 'seeding mechanism' for researchers to secure larger grants, such as from the NIH and CDMRP NFRP. Several former YIAs are now leaders in the NF research and clinical communities. In fact, CTF's 'seeding' of the NF field with new talent has been hailed as a key reason for rapid advancements in NF research in recent years.			
000218	Fellowship Awards	Childs (Jane Coffin) Memorial Fund		01-Feb-2021	Not Specified
	Contact Name				
	Contact Telephone	203-785-4612			
	Contact Email	letters@jccfund.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Feb-2021 , 12-Feb-2021			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>The Jane Coffin Childs Memorial Fund for Medical Research was established for the purpose of supporting research into the causes and treatment of cancer. The Fund has taken a broad approach to the study of cell growth and development, emphasizing the study of the basic biology and chemistry of the underlying processes. The Fund has increasingly focused its resources on the funding of three-year postdoctoral Fellowships, supporting Fellows selected by its Board of Scientific Advisers from among the best young scientists at what is often a critical stage in their careers. The JCC Fund supports between twenty-five and thirty new three-year Fellowships each year. The current Fellowship stipend levels are Year 1 \$52,000; Year 2 \$54,000 and Year 3 \$56,000.</p>			
054015	CURE Epilepsy Award	Citizens United for Research in Epilepsy		11-Jan-2021 [LOI/Pre-App]	250,000 USD
	Contact Name				
	Contact Telephone	312-255-1801			
	Contact Email	Research@CUREepilepsy.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Apr-2021			
	Synopsis	<p>The CURE Epilepsy Award will provide grants of up to \$250,000 paid over 2 years for research leading to disease-modifying breakthroughs for people living with epilepsy.</p>			
024600	Taking Flight Awards	Citizens United for Research in Epilepsy		11-Jan-2021 [LOI/Pre-App]	100,000 USD
	Contact Name				
	Contact Telephone	312-255-1801			
	Contact Email	Research@CUREepilepsy.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Deadline Dates (ALL) | 01-Apr-2021

Synopsis | The Taking Flight Award (1 year / \$100,000) seeks to promote the careers of young epilepsy investigators to allow them to develop a research focus independent of their mentor(s).

030571	CART Grants Program	Coins for Alzheimer's Research Trust Fund (CART)		15-Feb-2021	250,000 USD
--------	-------------------------------------	--	--	-------------	-------------

Contact Name | Dr. Gary A. Goforth, M.D., Vice Chairman for Research Grants

Contact Telephone |

Contact Email | gagoforth@earthlink.net

Sponsor Website | [Link to sponsor website](#)

Program URL | [Link to program URL](#)

Deadline Dates (ALL) | 15-Feb-2021

Synopsis | The goal of the fund is to encourage exploratory and developmental Alzheimer's disease research projects within the United States. This is accomplished by providing financial support for the early and conceptual plans of those projects that may not yet be supported by extensive preliminary data but have the potential to substantially advance biomedical research.

082626	John H. Rippey Grant for Laboratory Quality Assurance	College of American Pathologists Foundation		11-Jan-2021	20,000 USD
--------	---	---	--	-------------	------------

Contact Name |

Contact Telephone | 800-323-4040 ext. 7438

Contact Email | lnopars@cap.org

Sponsor Website | [Link to sponsor website](#)

Program URL | [Link to program URL](#)

Deadline Dates (ALL) |

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>This grant honors the memory of John H. Rippey, MD, an advocate of the CAP who was devoted to improving laboratory quality assurance. The CAP Foundation is repositioning the grant to provide funding for investigation of the impact of COVID-19-related tests, principally nucleic acid amplification and serologic methods, on patient outcomes, including studies related to test accuracy, timeliness, and result communication. Applicants must demonstrate how their projects support quality assurance, quality and/or process improvements in pathology, or patient safety, with the result of improved patient care.</p>			
019497	Support for Ongoing Clinical Research in Thalassemia	Cooley's Anemia Foundation, Inc.		01-Feb-2021	100,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p>	<p>212-279-8090</p> <p>info@thalassemia.org</p> <p>Link to sponsor website</p> <p>Link to program URL</p> <p>01-Feb-2021</p> <p>The Cooley's Anemia Foundation invites national and international applicants to apply for grants to support ongoing clinical research projects in thalassemia. The goal of this initiative is to support investigators from all disciplines and backgrounds (MD, RN, PhD, MPH, MSW or other disciplines) with their ongoing clinical projects to address one or more of the following areas impacting patients with thalassemia, including but not limited to: cardiac issues and iron overload; fertility, pregnancy and family planning; quality of life, psychosocial impact and/or burden of disease.</p>			
001955	Research Fellowship	Cooley's Anemia Foundation, Inc.		01-Feb-2021	50,000 USD
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p>	<p></p> <p>212-279-8090</p> <p>info@thalassemia.org</p> <p>Link to sponsor website</p> <p>Link to program URL</p>			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 01-Feb-2021</p> <p>Synopsis The Cooley's Anemia Foundation invites national and international clinical and basic science investigators (postdoctoral or junior faculty) to apply for its prestigious fellowship program. Applications should be focused on the understanding or treatment of thalassemia or a complication that is related to thalassemia. Fellowship awards are limited to a maximum of \$50,000 per year.</p>				
009507	<p>Fulbright Programs--Europe--Germany--U.S.-Germany International Education Administrators Program</p>	Council for International Exchange of Scholars	11189-GM	01-Feb-2021	Not Specified
	<p>Contact Name Aferdita Krasniqi</p> <p>Contact Telephone 212-984-5326</p> <p>Contact Email EuropeEurasia@iee.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Feb-2021</p> <p>Synopsis This group seminar is designed to familiarize U.S. higher education administrators from American universities, colleges or community colleges with Germany's higher education system, society and culture. Participants will have the chance to engage in discussions on recent challenges in German and U.S. higher education, to further their professional development and establish new partnerships. During the first days in Berlin, participants are provided with a comprehensive overview of Germany and its higher education system through presentations, discussions with experts, and campus visits. During the second part of the program, participants will travel to other destinations throughout Germany to visit further institutions of (higher) education such as research universities and universities of applied sciences. The seminar offers the opportunity to explore Germany's federal education system within the European context.</p>				
001440	<p>Career Development Awards</p>	Crohn's & Colitis Foundation of America		28-Jan-2021	Not Specified
	<p>Contact Name</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone 646-943-7501 Contact Email mmbesch@crohnscolitisfoundation.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 28-Jan-2021 , 05-May-2021 [LOI/Pre-App], 20-Jul-2021 Synopsis The goal of the Career Development Award (CDA) is to encourage a career of independent basic and/or clinical investigation in the area of Crohn's disease and ulcerative colitis research.				
000055	Research Fellowship Awards	Crohn's & Colitis Foundation of America		28-Jan-2021	174,750 USD
	Contact Name Orlando Green Contact Telephone 646-943-7501 Contact Email ogreen@crohnscolitisfoundation.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 28-Jan-2021 , 05-May-2021 [LOI/Pre-App], 20-Jul-2021 Synopsis The Crohn's & Colitis Foundation's Research Fellowship Awards are intended to support individuals in the post-doctoral phase of their career, to develop skills related to basic and/or clinical investigation in the field of inflammatory bowel disease (IBD), or Crohn's disease and ulcerative colitis.				
000628	Senior Research Awards	Crohn's & Colitis Foundation of America		28-Jan-2021	Not Specified
	Contact Name Orlando Green Contact Telephone 646-943-7501 Contact Email ogreen@crohnscolitisfoundation.org Sponsor Website Link to sponsor website				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 28-Jan-2021 , 05-May-2021 [LOI/Pre-App], 20-Jul-2021</p> <p>Synopsis Senior Research Awards provide established researchers with funds to generate sufficient preliminary data to become competitive for funds from other sources. Support will be provided for proposals relevant to Inflammatory Bowel Disease (IBD) or Crohn's disease and/or ulcerative colitis.</p>				
083322	Crohn's & Colitis Foundation/NASPGHAN IBD Young Investigator Award	Crohn's & Colitis Foundation of America		28-Jan-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 646-943-7505</p> <p>Contact Email grant@crohnscolitisfoundation.org</p> <p>Sponsor Website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 28-Jan-2021</p> <p>Synopsis This three-year grant, in partnership with the NASPGHAN Foundation and the Crohn's & Colitis Foundation, is available to research fellows or junior faculty. Applications must propose original clinical, translational, epidemiological, or basic scientific research related to pediatric inflammatory bowel disease.</p>				
063869	Litwin IBD Pioneers Initiative	Crohn's & Colitis Foundation of America		28-Jan-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 646-943-7505</p> <p>Contact Email grant@crohnscolitisfoundation.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 28-Jan-2021</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The Litwin IBD Pioneers Initiative supports innovative clinical and translational research projects with the potential to impact the treatment of IBD patients in the near future. The program encourages novel research into the diagnosis, identification of clinically relevant subsets, treatments, and cures for inflammatory bowel diseases (IBD) and funds innovative pilot research so that scientists can test their initial ideas and generate preliminary data.			
066992	Visiting IBD Fellow Program	Crohn's & Colitis Foundation of America		29-Jan-2021	Not Specified
	Contact Name	Rida Mahmood, Education Program Coordinator			
	Contact Telephone	646-943-7406			
	Contact Email	rmahmood@crohnscolitisfoundation.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	29-Jan-2021			
	Synopsis	The Crohn's & Colitis Foundation Visiting IBD Fellowship accepts qualified gastroenterology 2nd & 3rd year fellows for a one-month, (most) expenses-paid observation at a leading IBD center. This highly competitive fellow program offers fellows exposure in treating and managing IBD patients.			
007739	Grants Program	Cummings (James H.) Foundation		20-Jan-2021	Not Specified
	Contact Name				
	Contact Telephone	716-874-0040			
	Contact Email	info@jameshcummings.com			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	20-Jan-2021 , 24-Mar-2021 [LOI/Pre-App], 14-Apr-2021			
	Synopsis	The James H. Cummings Foundation provides support to nonprofit organizations in Buffalo, Toronto, and Hendersonville, North Carolina to advance medical research, science, and post-secondary medical education; to			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		provide services for vulnerable children and children with disabilities; and to assist older adults and vulnerable adults with services that help them maintain independent, healthy, and active lifestyles.			
008927	Harry Shwachman Clinical Investigator Award	Cystic Fibrosis Foundation		11-Feb-2021	390,000 USD
	Contact Name				
	Contact Telephone	301-841-2614			
	Contact Email	grants@cff.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	11-Feb-2021			
	Synopsis	The Harry Shwachman Clinical Investigator Award provides the opportunity for clinically trained physicians to develop into independent biomedical research investigators who are actively involved in cystic fibrosis-related areas. The three-year award provides salary support for up to \$100,000 per year plus \$30,000 for supplies.			
089567	Clinical Fellowships (Fifth Year)	Cystic Fibrosis Foundation		11-Feb-2021	100,000 USD
	Contact Name	Angela Minucci			
	Contact Telephone	301-841-2614			
	Contact Email	aminucci@cff.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	11-Feb-2021			
	Synopsis	The mission of the Cystic Fibrosis Foundation (CFF) is to cure cystic fibrosis (CF) and to provide all people with the disease the opportunity to lead full, productive lives by funding research and drug development, promoting individualized treatment, and ensuring access to high-quality, specialized treatment.			
008928	LeRoy Matthews Physician Scientist Award	Cystic Fibrosis Foundation		11-Feb-2021	Not Specified

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone 301-841-2614</p> <p>Contact Email grants@cff.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-Feb-2021</p> <p>Synopsis The LeRoy Matthews Physician-Scientist Award will provide up to six years of support for outstanding, newly trained pediatricians and internists (M.D.s and M.D./Ph.D.s) to complete sub-specialty training, develop into independent investigators, and initiate a research program. Support ranges from \$60,000 (stipend) plus \$10,000 (research and development) for year one, to \$100,000 (stipend) plus \$30,000 (research and development) for year six.</p>				
003252	Clinical Fellowships (Fourth Year)	Cystic Fibrosis Foundation		11-Feb-2021	200,000 USD
	<p>Contact Name Grants and Contracts Office</p> <p>Contact Telephone 301-841-2614</p> <p>Contact Email grants@cff.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-Feb-2021</p> <p>Synopsis Clinical Fellowship Awards encourage specialized training early in a physician's career and prepare candidates for careers in academic medicine.</p>				
008916	Clinical Fellowships (Third Year)	Cystic Fibrosis Foundation		11-Feb-2021	200,000 USD
	<p>Contact Name</p> <p>Contact Telephone 301-841-2614</p> <p>Contact Email grants@cff.org</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 11-Feb-2021</p> <p>Synopsis Clinical Fellowship Awards encourage specialized training early in a physician's career and prepare candidates for careers in academic medicine. This award is designed to support third year Clinical Fellowships for (pediatric and adult) physicians who have completed at least two years of CF-related fellowship training and seek support for additional fellowship training. The maximum award amount is \$100,000 in direct costs per year for up to two years.</p>				
005450	Clinical Research Award	Cystic Fibrosis Foundation		25-Jan-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 301-841-2637</p> <p>Contact Email grants@cff.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 25-Jan-2021 , 19-Mar-2021 [LOI/Pre-App], 18-Aug-2021</p> <p>Synopsis Clinical Research Awards are offered to provide support for investigator-initiated clinical research projects that have the potential to make an important contribution to the CF Foundation's mission. Research projects may address diagnosis, treatment, management of disease or symptom, or the pathophysiology of CF using clinical (observational/interventional), translational or epidemiologic study approaches. Applicants must demonstrate access to sufficient numbers of CF patients and appropriate controls. Applicants may request funding of up to \$150,000 per year, plus an additional twelve (12) percent indirect costs for single-center clinical studies; and up to \$350,000 per year, plus twelve (12) percent indirect costs for multi-center clinical studies.</p>				
089449	Research Grants	Daisy Foundation		25-Jan-2021	7,500 USD
	<p>Contact Name Bonnie Barnes</p> <p>Contact Telephone 707-996-7936</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email ErinAscher@DAISYFoundation.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 25-Jan-2021</p> <p>Synopsis The Research Grant provides awards to qualified nurses carrying out clinical research studies that directly benefit patients and/or families involving treatment of cancer and auto-immune diseases.</p>				
001443	Evidence-based Practice (EBP) Grants	Daisy Foundation		24-Feb-2021 [LOI/Pre-App]	2,500 USD
	<p>Contact Name Bonnie Barnes</p> <p>Contact Telephone 707-996-7936</p> <p>Contact Email bonniebarnes@daisyfoundation.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 24-Feb-2021 [LOI/Pre-App], 24-Apr-2021</p> <p>Synopsis Evidence-based Practice (EBP) grants will be awarded to stimulate the use of patient-focused data and/or previously generated research findings to develop, implement and evaluate changes in nursing practice in treatment of patients with cancer and auto-immune diseases.</p>				
004329	Grants Program	Drown (Joseph) Foundation		15-Jan-2021	Not Specified
	<p>Contact Name Alyssa Santino, Program Officer</p> <p>Contact Telephone 310-277-4488 x100</p> <p>Contact Email alyssa@jdrown.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 15-Jan-2021 , 15-Apr-2021 , 15-Jul-2021 , 15-Oct-2021</p> <p>Synopsis The Joseph Drown Foundation provides support in the areas of education; community, health and social services; medical and scientific research; arts and humanities; and special projects. Tax-exempt organizations, primarily in the state of California, are eligible. The Foundation makes grants for both operating support and program support, but does not make multi-year commitments. Organizations may receive funding up to four years, after which they must take a two-year hiatus.</p>				
089130	Ruth K. Broad Biomedical Research Foundation Extramural Award (Temporarily Suspended)	Duke University		01-Feb-2021	250,000 USD
	<p>Contact Name Erica Kitchen</p> <p>Contact Telephone 919-385-0032</p> <p>Contact Email erica.kitchen@duke.edu</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Feb-2021</p> <p>Synopsis The Ruth K. Broad Biomedical Research Foundation, Inc., a support corporation of Duke University, funds high priority, high potential, basic or translational research toward prevention or treatment of neurodegenerative diseases. And award of \$125,000 per year for two years is available.</p>				
086707	Grant Program	EB Research Partnership (EBRP)		15-Jan-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 664-844-0902</p> <p>Contact Email grants@ebresearch.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 15-Jan-2021</p> <p>Synopsis EB Research Partnership (EBRP), a 501(c)(3) non-profit organization, seeks to award grant funding for research with the potential to lead directly to commercially feasible products and therapies for treating and/or curing Epidermolysis Bullosa (EB).</p>				
015063	EMF/EMRA Resident Research Grant	Emergency Medicine Foundation		05-Feb-2021	10,000 USD
	<p>Contact Name Cynthia Singh</p> <p>Contact Telephone 469-499-0297</p> <p>Contact Email csingh@acep.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021</p> <p>Synopsis The Emergency Medicine Foundation awards funds to support the development of research in emergency medicine. The goals of the EMF/EMRA Resident Research Program are: to promote research within the specialty of emergency medicine, to advance emergency medical care, and to facilitate the academic growth and development of future researchers in emergency medicine and thereby invest in the future of the specialty of emergency medicine.</p>				
015061	Mid-Career Research Development Grant	Emergency Medicine Foundation		05-Feb-2021	250,000 USD
	<p>Contact Name Cynthia Singh</p> <p>Contact Telephone 469-499-0297</p> <p>Contact Email csingh@acep.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021</p> <p>Synopsis This grant is intended to provide "bridge funding" which may serve to help sustain a successful line of research that</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

has reached the end of a funding period or support a new research direction for an established mid-career investigator. The goal of this grant is to fund work that will meaningfully impact emergency care research and is intended for a broad audience, including both clinical and basic science fields researchers. EMF encourages application partnerships between research universities and community emergency departments.

069220	Early Career Research Development Grant	Emergency Medicine Foundation		05-Feb-2021	150,000 USD
--------	---	-------------------------------	--	-------------	-------------

Contact Name	Cynthia Singh
Contact Telephone	800-798-1822 x3217
Contact Email	csingh@acep.org
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	05-Feb-2021
Synopsis	The Early Career Research Development grant is designed to provide junior faculty applicants with an opportunity to participate in a well-delineated career development plan (e.g., didactics, mentored meetings, and obtaining an advanced degree) and design and develop a project that will permit them to apply for extramural funding. This grant is intended to assist the awardee in developing a path towards an independent research career and successfully compete for extramural funding. One award of \$150,000 will be given.

043140	Predoctoral Research Training Fellowship	Epilepsy Foundation of America		13-Jan-2021	30,000 USD
--------	--	--------------------------------	--	-------------	------------

Contact Name	
Contact Telephone	312-883-3800
Contact Email	grants@aesnet.org
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	13-Jan-2021

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	AES Predoctoral Research Fellowships support predoctoral students who are pursuing dissertation research with an epilepsy-relevant theme, and who are working under the guidance of a mentor with expertise in epilepsy research. Proposals are welcomed across the spectrum of basic, translational, and clinical research. Successful applicants receive up to \$30,000 over a twelve-month period of the award.			
001855	Postdoctoral Research Fellowship	Epilepsy Foundation of America		13-Jan-2021	50,000 USD
	Contact Name				
	Contact Telephone	312-883-3800			
	Contact Email	grants@aesnet.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	13-Jan-2021			
	Synopsis	AES Postdoctoral Research Fellowships support postdoctoral trainees conducting research into the causes, treatment, and consequences of epilepsy under the guidance of a mentor with expertise in epilepsy research. Proposals are welcomed across the spectrum of basic, translational, and clinical epilepsy research. The fellowship award offers up to \$49,000 for stipend and/or benefits, \$1,000 for travel support to the AES annual meeting, as well as one year of complimentary AES membership and registration for the AES annual meeting. The number of awards granted each year is contingent upon available funds.			
006961	Claude Bernard Medal and Lecture	European Association for the Study of Diabetes		15-Feb-2021	Not Specified
	Contact Name				
	Contact Telephone	49-211-758 469 0			
	Contact Email	sarah.schotten@easd.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	15-Feb-2021			
	Synopsis	The European Association for the Study of Diabetes awards a medal and lectureship in recognition of an individual's innovative leadership and lifetime achievements in diabetes research.			
058576	ECTRIMS Multiple Sclerosis Nurse Training Fellowships Programme	European Committee for Treatment and Research in Multiple Sclerosis		01-Feb-2021	Not Specified
	Contact Name	ECTRIMS Secretariat			
	Contact Telephone	+41 61 686 77 79			
	Contact Email	fellowship@ectrims.eu			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Feb-2021			
	Synopsis	The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) offers a Nurse Training Fellowships Programme for qualified/licensed nurses from anywhere in the world to provide the opportunity for them to obtain additional expertise through practical nursing experience and training in a mentored MS environment in Europe. The sponsor's aim is to enhance care and support of individuals with MS by fostering improved clinical care and education and by helping to promote best practices in nursing care for MS.			
045005	ERS Gold Medal in Asthma	European Respiratory Society		15-Feb-2021	60,500 USD
	Contact Name				
	Contact Telephone	+41 21 213 01 01			
	Contact Email	scientific@ersnet.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Feb-2021			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
<p style="text-align: center;">Synopsis The European Respiratory Society (ERS) offers this award to recognize excellence in the field of asthma research.</p>					
045002	ERS Gold Medal in COPD	European Respiratory Society		15-Feb-2021	60,500 USD
	Contact Name				
	Contact Telephone	41 21 213 01 01			
	Contact Email	scientific@ersnet.org			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Feb-2021			
	Synopsis	The European Respiratory Society (ERS) offers an award of €50,000 to a researcher who has made an outstanding contribution in any sector of respiratory medicine and who is pursuing an active research project in COPD.			
029966	Albrecht-Berblinger-Award	European School of Aviation Medicine		28-Feb-2021	12,100 USD
	Contact Name				
	Contact Telephone	+49 69 69716769			
	Contact Email	DAF.Frankfurt@t-online.de			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	28-Feb-2021			
	Synopsis	The European School of Aviation Medicine Award recognizes work that demonstrates excellence in clinical practice, education and/or administration in the field of aviation, aerospace, travel medicine and related scientific areas. Eligible candidates should have accomplished the scientific work in an EASA member state. Only manuscripts in English or German language can be accepted.			
009599	Young Investigator Award	European Society for Paediatric Infectious Diseases		31-Jan-2021	Not Specified

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Name Contact Telephone +44 (0)1506 639613 Contact Email admin@espid.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 31-Jan-2021 Synopsis ESPID will provide two awards, one for clinical research and the other one for basic research, to outstanding young investigators in the field of paediatric infectious diseases.				
089232	Discovery Research Grants	Evans (Edward P.) Foundation		01-Feb-2021	600,000 USD
	Contact Name Contact Telephone 978-494-6009 Contact Email mdl@epfoundation.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 01-Feb-2021 Synopsis The Edward P. Evans Foundation seeks to fund the discovery of new knowledge that will lead to the development of better MDS therapies and ultimately, disease cures.				
002076	Summer Student Fellowships	Fight for Sight, Inc.		15-Feb-2021	2,500 USD
	Contact Name Janice Benson Contact Telephone 212-679-6060 Contact Email janice@fightforsight.org Sponsor Website Link to sponsor website				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL Link to program URL Deadline Dates (ALL) 15-Feb-2021 Synopsis Fight for Sight funds basic or clinical research in ophthalmology, vision or related sciences by individuals with limited or no other research funding.				
004604	Transatlantic Networks of Excellence in Cardiovascular Research Program	Fondation Leducq		16-Feb-2021	8,470,000 USD
	Contact Name Contact Telephone +33 (0)1 45 00 59 65 Contact Email contact@flcq.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 16-Feb-2021 Synopsis The Fondation Leducq Transatlantic Networks of Excellence Program provides \$7,000,000 over five years to teams of researchers working collaboratively in the areas of cardiovascular and neurovascular disease.				
073832	Summer Institute for Medical Students (SIMS)	Ford (Betty) Institute		01-Feb-2021	Not Specified
	Contact Name Contact Telephone 760-773-4375 Contact Email MPE@hazeldenbettyford.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 01-Feb-2021 , 01-Mar-2021 Synopsis The Summer Institute for Medical Students program provides an inside look at the dynamics of addiction and the process of healing.				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
000277	Mentored Research Training Grants	Foundation for Anesthesia Education & Research		15-Feb-2021	250,000 USD
	Contact Name				
	Contact Telephone	630-912-2554			
	Contact Email	FAER@faer.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Feb-2021			
	Synopsis	Mentored Research Training Grants help anesthesiologists develop the skills, preliminary data for subsequent grant applications and research publications needed to become independent investigators. Grants of up to \$250,000 will be awarded for a duration of two years.			
000512	Research Fellowship Grant	Foundation for Anesthesia Education & Research		15-Feb-2021	75,000 USD
	Contact Name				
	Contact Telephone	630-912-2554			
	Contact Email	FAER@faer.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Feb-2021			
	Synopsis	Research Fellowship Grants are intended to provide anesthesiology residents and fellows with the opportunity to obtain significant training in research techniques and scientific methods. The RFG is a one-year (12-month), \$75,000 primary investigator (no co-investigators) award for anesthesiology trainees after the CA-1 year.			
065089	Boerger Research Fund in Alzheimer's Disease and	Foundation of the American Society of		19-Jan-2021	150,000 USD

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Neurocognitive Disorders	Neuroradiology (ASNR)			
	Contact Name				
	Contact Telephone	630-574-0220			
	Contact Email	rbhala@asnr.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	19-Jan-2021			
	Synopsis	The American Society of Neuroradiology funds imaging-based research that advance our understanding of Alzheimer's disease, help identify new treatment strategies, provide information to improve care for people with dementia, and further our knowledge of brain health and disease prevention. This award supports investigators at every professional stage and is specifically designed to help talented young scientists establish careers in Alzheimer's imaging research.			
023597	Comparative Effectiveness Research Award	Foundation of the American Society of Neuroradiology (ASNR)		19-Jan-2021	60,000 USD
	Contact Name				
	Contact Telephone	630-574-0220			
	Contact Email	foundation@asnr.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	19-Jan-2021			
	Synopsis	The Comparative Effectiveness Research Award in Neuroradiology was created to support investigators in the generation and synthesis of evidence that compares the benefits and harms of diagnostic imaging methods or interventions to prevent, diagnose, treat and monitor a clinical condition or to improve the delivery of care.			
007116	Postdoctoral Fellowships	French Muscular Dystrophy Association		19-Jan-2021	Not Specified

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Laurence TIENNOT-HERMENT</p> <p>Contact Telephone + 33 1 69 47 28 28</p> <p>Contact Email spcsafm@afm.genethon.fr</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 19-Jan-2021 , 30-Mar-2021</p> <p>Synopsis The Association Francaise contre les Myopathies provides Postdoctoral Fellowships for for one year, renewable for a second year, for research of neuromuscular diseases and rare genetic diseases.</p>				
007114	Scientific Call for Proposals	French Muscular Dystrophy Association		19-Jan-2021	Not Specified
	<p>Contact Name </p> <p>Contact Telephone + 33 1 69 47 28 28</p> <p>Contact Email spcsafm@afm-telethon.fr</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 19-Jan-2021</p> <p>Synopsis This International Call for Proposals, open to both French and foreign groups, aims to support research which will: increase our understanding of the neuromuscular system; and encourage the development of therapies for neuromuscular diseases and rare genetic diseases.</p>				
101276	Medical Research Call for Proposals	French Muscular Dystrophy Association		19-Jan-2021	Not Specified
	<p>Contact Name </p> <p>Contact Telephone + 33 1 69 47 28 28</p> <p>Contact Email spcsafm@afm-telethon.fr</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
<p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 19-Jan-2021</p> <p>Synopsis The objective of this international call for proposals, open to both French and foreign teams, is to support medical research projects which aim is to improve the care and management of patients, the knowledge of neuromuscular disorders and their progression, as well as the quality of life of patients affected by neuromuscular disorders</p>					
076236	General Research Grants	Friedreich's Ataxia Research Alliance		01-Feb-2021	300,000 USD
<p>Contact Name</p> <p>Contact Telephone 484-879-6160</p> <p>Contact Email info@curefa.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Feb-2021 , 01-Apr-2021 , 15-Jul-2021 , 15-Sep-2021</p> <p>Synopsis FARA supports research through funding competitive grants, promoting collaboration among scientists, advocating for public-private partnerships that support drug discovery, drug development and clinical research and hosting open forums for leading scientists to share their insights, ideas and challenges to advancing treatments for Friedreich's ataxia. The applicant may request a budget of up to \$150,000 per year for one or two years.</p>					
036254	Keith Michael Andrus Memorial Award	Friedreich's Ataxia Research Alliance		15-Jan-2021 [LOI/Pre-App]	300,000 USD
<p>Contact Name</p> <p>Contact Telephone 484-879-6160</p> <p>Contact Email info@cureFA.org</p> <p>Sponsor Website Link to sponsor website</p>					

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Jan-2021 [LOI/Pre-App], 01-Mar-2021</p> <p>Synopsis The Keith Michael Andrus Cardiac Research Award was made in honor of its namesake to remember Keith's legacy and to help advanced our understanding and treatment of the cardiomyopathy associated with FA. Proposals for this award should focus on advancing understanding and/or treatment of the cardiac involvement in FA.</p>				
000954	Research Grant Program	GBS/CIDP Foundation International		31-Jan-2021	100,000 USD
	<p>Contact Name</p> <p>Contact Telephone 610-667-0131</p> <p>Contact Email grants@gsb-cidp.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 31-Jan-2021</p> <p>Synopsis The GBS-CIDP Foundation International believes in supporting research on GBS and CIDP, funding grants for projects that contribute to the knowledge of and towards an eventual cure for GBS and CIDP. Multiple grants are awarded annually.</p>				
014009	Research Grants	Geneva Association / International Association for the Study of Insurance Economics		11-Jan-2021	11,200 USD
	<p>Contact Name</p> <p>Contact Telephone +41 44 200 49 00</p> <p>Contact Email secretariat@genevaassociation.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	Each year The Geneva Association awards one research grant intended to support a research paper on a specific theme. The theme of the 2021 research grant is The Future Face of Life Insurance.			
	Synopsis				
073959	Research Grants Program	Gerber Foundation		15-Feb-2021	Not Specified
	Contact Name				
	Contact Telephone	231-924-3175			
	Contact Email	tgf@ncresa.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Feb-2021			
	Synopsis	The Foundation's mission focuses on infants and young children. Accordingly, priority is given to projects that improve the nutrition, care and development of infants and young children from the first year before birth to three years of age. Total grant size should be no more than roughly \$20,000 (inclusive of direct costs).			
066449	Gene-Targeting Strategies for Neurofibromatosis Type 1	Gilbert Family Foundation		28-Feb-2021 [LOI/Pre-App]	1,200,000 USD
	Contact Name	Jim Goss			
	Contact Telephone	313-782-9500			
	Contact Email				
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	28-Feb-2021 [LOI/Pre-App], 31-May-2021			
	Synopsis	The Gilbert Family Foundation's (GFF) Gene Therapy Initiative is pleased to announce a Request for Proposal (RFP) for high-impact research on gene therapy strategies aimed at addressing the loss of neurofibromin 1 (NF1) gene function			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		in neurofibromatosis type 1 (NF1) patients. Proposals will be accepted for Team Science Awards defined as collaborative research amongst investigators with experience in gene-targeting strategies in or outside the NF1 field.			
065811	Ecosystem Health and Sustainable Fish Populations - Ecological and Biological Research to Inform Management	Great Lakes Fishery Trust		15-Jan-2021	Not Specified
	Contact Name	Cody Proudfoot, Grant Manager			
	Contact Telephone	517-371-7468			
	Contact Email	cproudfoot@glft.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Jan-2021			
	Synopsis	The Great Lakes Fishery Trust (GLFT) invites preliminary proposals for Great Lakes fisheries projects under its Ecosystem Health and Sustainable Fish Populations grant program. This request for proposals (RFP) process will be used for the disbursement of up to \$1.3 million in grants for the Ecological and Biological Research to Inform Management funding theme.			
077274	Faculty Scholars Program	Greenwall Foundation		11-Jan-2021	Not Specified
	Contact Name	Johanna Brownell			
	Contact Telephone	212-679-7266			
	Contact Email	jbrownell@greenwall.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)				
	Synopsis	The Greenwall Faculty Scholars Program in Bioethics is a career development award to enable junior faculty members to carry out innovative bioethics research. It supports research that goes beyond current work in bioethics to help			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		resolve pressing ethical issues in clinical care, biomedical research, and public policy, and creates a community that enhances future bioethics research by Scholars and Alumni/ae.			
101316	Grand Challenges ICODA COVID-19 Data Science Grant Programme	Health Data Research UK		19-Jan-2021	100,000 USD
	Contact Name Contact Telephone + 44 (0) 203 950 3715 Contact Email enquiries@hdruk.ac.uk Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 19-Jan-2021 Synopsis ICODA and Grand Challenges are delighted to launch the new pilot Grand Challenges ICODA COVID-19 Data Science grant programme that will focus on addressing major questions about how to reduce the harm of COVID-19 and future pandemics. The programme aims to unite data and develop processes, analytical tools and infrastructure to achieve rapid scientific progress and impact.				
000381	Emerging Research Grants	Hearing Health Foundation		26-Feb-2021	50,000 USD
	Contact Name Contact Telephone 212-257-6140 Contact Email grants@hhf.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 26-Feb-2021 Synopsis Through the Emerging Research Grants (ERG) program, Hearing Health Foundation (HHF) provides seed money to researchers working across the entire spectrum of hearing research and balance research, including many				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		underfunded areas of otology.			
000772	Postdoctoral Research Fellowships in Cardiac Electrophysiology	Heart Rhythm Society		08-Feb-2021	50,000 USD
	Contact Name	Irene Meroka			
	Contact Telephone	202-464-3400			
	Contact Email	awards@hrsonline.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	08-Feb-2021			
	Synopsis	The Heart Rhythm Society has established post-doctoral fellowships in cardiac electrophysiology encouraging and supporting research training of individuals in either basic or clinical electrophysiology. These fellowships assist awardees in initiating careers in electrophysiology research while obtaining significant research results. Each year, HRS awards Post-Doctoral Fellowships, which include: a one-year stipend, complimentary membership to the Society, and complimentary registration to the Heart Rhythm Scientific Sessions.			
001519	Postdoctoral Fellowships	Hereditary Disease Foundation		01-Feb-2021 [LOI/Pre-App]	Not Specified
	Contact Name				
	Contact Telephone	212-928-2121			
	Contact Email	grantinfo@hdfoundation.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Feb-2021 [LOI/Pre-App], 17-Apr-2021			
	Synopsis	Postdoctoral fellowships are intended to cultivate interest in Huntington's disease research by bright young scientists.			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Fellowships are granted to those who possess imagination, rigor, creativity and spirit to push forward toward a cure for HD and ensure that these discoveries can be applied to other brain diseases.

001830	Basic Research Grants	Hereditary Disease Foundation		01-Feb-2021 [LOI/Pre-App]	75,000 USD
--------	---------------------------------------	-------------------------------	--	------------------------------	------------

Contact Name	
Contact Telephone	212-928-2121
Contact Email	grantinfo@hdfoundation.org
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	01-Feb-2021 [LOI/Pre-App], 17-Apr-2021
Synopsis	The Basic Research Grants Program supports projects contributing to identifying and understanding the fundamental defects in Huntington’s disease.

081163	SWOG/Hope Foundation Impact Award	Hope Foundation for Cancer Research		15-Jan-2021 [LOI/Pre-App]	250,000 USD
--------	---	-------------------------------------	--	------------------------------	-------------

Contact Name	Johanna Horn, President & CEO
Contact Telephone	734-998-7150
Contact Email	jo@thehopefoundation.org
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	15-Jan-2021 [LOI/Pre-App], 15-Mar-2021 , 01-Jul-2021 [LOI/Pre-App], 01-Sep-2021
Synopsis	The SWOG/Hope Foundation Impact Award is a funding program that encourages novel and innovative SWOG research by supporting early and conceptual stages of these projects. The work proposed should use resources from completed SWOG trials or be directly translatable to future clinical trials in SWOG and the National Clinical Trials

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>Network (NCTN). These studies may involve scientific risk but potentially lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on cancer research. It is expected that support via this mechanism will lead to subsequent extramural support from other sources, and will be a metric of success for this grant program. In addition, publications citing SWOG and The Hope Foundation will be further metrics for success.</p>			
038087	Postdoctoral Fellowship	Hope Funds for Cancer Research		25-Jan-2021	54,000 USD
	Contact Name				
	Contact Telephone	401-847-3286			
	Contact Email	grants@hope-funds.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	25-Jan-2021			
	Synopsis	<p>The Hope Funds for Cancer Research is offering fellowships to postdoctoral scientists who propose to work on highly innovative research projects that challenge the traditional paradigms of understanding the causes, mechanisms, progression, disease markers or risk factors of the most difficult-to-treat cancers, including pancreatic, lung, liver, sarcomas, esophageal, brain, gastric, bone and ovarian cancers; and rare leukemias, lymphomas and MDS. The Trustees of the Hope Funds believe that funding research that could lead to breakthroughs in these areas and increase life expectancy in these types of cancers is at the core of its mission.</p>			
064126	Grants for Emerging Researches/Clinicians Mentorship (GERM)	Infectious Diseases Society of America		05-Feb-2021	4,000 USD
	Contact Name				
	Contact Telephone	703-299-0200			
	Contact Email				
	Sponsor Website	Link to sponsor website			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 05-Feb-2021</p> <p>Synopsis Grants for Emerging Researches/Clinicians Mentorship (GERM) was developed to provide grants to medical students to support a longitudinal mentored clinical learning and/or research project for up to a year, on infectious diseases-related topics including HIV under the mentorship of an IDSA or HIVMA member.</p>				
091301	HIVMA Clinical Fellowships	Infectious Diseases Society of America		19-Jan-2021	75,000 USD
	<p>Contact Name</p> <p>Contact Telephone 703-299-0200</p> <p>Contact Email</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 19-Jan-2021</p> <p>Synopsis The HIVMA Clinical Fellowship program supports newly trained physicians with gaining HIV clinical experience working with medically underserved patient populations. The goal of the program is to develop a diverse primary care workforce with HIV expertise and a commitment to treat persons with HIV. Expanding this group is particularly important given the shortages in the HIV clinical workforce and our ongoing efforts to end the HIV epidemic.</p>				
007366	Chapman Medal	Institute of Materials, Minerals and Mining		31-Jan-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone +44 (0)20 7451 7300</p> <p>Contact Email awards@iom3.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 31-Jan-2021</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The Chapman Medal is presented for distinguished research in the field of biomedical materials, particularly with respect to biomaterials innovation, which has produced benefits for patients and/or contributed to associated opportunities for industry. The winner will receive a medal.			
050013	Women in Science Award for Distinguished Research	International Association for Dental Research		01-Feb-2021	200 USD
	Contact Name	Effie Ioannidou, President			
	Contact Telephone				
	Contact Email	ioannidou@uchc.edu			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Feb-2021			
	Synopsis	The Women in Science Award for Distinguished Research is intended to recognize excellence by a female researcher who is the first or senior author a single research paper in Dental/Oral/ Craniofacial Research.			
050004	Student Research Fellowship	International Association for Dental Research		22-Jan-2021	2,700 USD
	Contact Name	Anthony Jones, Awards, Fellowships and Grants Coordinator			
	Contact Telephone	1-703-548-0066			
	Contact Email	ajones@iadr.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	22-Jan-2021			
	Synopsis	The AADR Student Research Fellowships, supported by several major industrial companies, as well as by AADR and IADR Group Chapters, Sections, and members, are sponsored and administered by the AADR and have been created to			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

encourage dental students living in the United States to consider careers in oral health research. Proposals are sought in basic and clinical research related to oral health.

007141	ILCF Fellowship and Young Investigator Awards	International Association for the Study of Lung Cancer		31-Jan-2021	50,000 USD
--------	---	--	--	-------------	------------

Contact Name	
Contact Telephone	1-855-464-2752
Contact Email	foundation@iaslc.org
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	31-Jan-2021
Synopsis	The International Association for the Study of Lung Cancer (IASLC) offers both Young Investigator Awards and Fellowships through the International Lung Cancer Foundation (ILCF). For investigators who are ready to begin independent research studies, ILCF offers numerous awards on an annual cycle, dependent on geographic region of applicant. These one-year awards are for \$50,000 in research funding. ILCF fellowships are Exclusive to fellows, these awards provide \$50,000 for a one-year research project. Opportunities are numerous and based on geographic region of applicant. Applications must be within the scope of the following funding priorities to be considered: the etiology, epidemiology, prevention, diagnosis, treatment, and all aspects of lung cancer and thoracic malignancies.

101425	Grand Challenge - COVID-19 Data Science Grants	International COVID-19 Data Alliance		19-Jan-2021	100,000 USD
--------	--	--------------------------------------	--	-------------	-------------

Contact Name	Health Data Research UK (London office)
Contact Telephone	+ 44 (0) 203 950 3715
Contact Email	
Sponsor Website	Link to sponsor website
Program URL	Link to program URL

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 19-Jan-2021</p> <p>Synopsis ICODA and Grand Challenges are delighted to launch the new pilot Grand Challenges ICODA COVID-19 Data Science grant programme that will focus on addressing major questions about how to reduce the harm of COVID-19 and future pandemics. The programme aims to unite data and develop processes, analytical tools and infrastructure to achieve rapid scientific progress and impact. The Grand Challenges ICODA COVID-19 Data Science grant programme will provide awards of up to US\$100,000 for studies lasting for between 6-12 months, starting in mid-March 2021 onwards. In addition, successful applicants will have access to ICODA's digital workbench, as well as technical and wider support from ICODA and its partners.</p>				
005893	Research Grant Program	International Essential Tremor Foundation		28-Feb-2021	50,000 USD
	<p>Contact Name</p> <p>Contact Telephone 913-341-3880</p> <p>Contact Email pmccartney@essentialtremor.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 28-Feb-2021</p> <p>Synopsis The IETF is requesting proposals for grants addressing the nosology, etiology, pathogenesis, treatment or other topics relevant to essential tremor (ET).</p>				
079328	ISHLT/Enduring Hearts Transplant Longevity Research Award	International Society for Heart and Lung Transplantation		08-Feb-2021	160,000 USD
	<p>Contact Name Megan Barrett</p> <p>Contact Telephone 972-490-9495</p> <p>Contact Email megan.barrett@ishlt.org</p> <p>Sponsor Website Link to sponsor website</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Program URL	Link to program URL
Deadline Dates (ALL)	08-Feb-2021
Synopsis	One of ISHLT's missions is to award research grants and establish endowments for the study of heart and lung transplantation and end-stage heart and lung disease. The organizational goal of Enduring Hearts is to promote research to improve longevity of, and quality of life for, pediatric heart transplant recipients, and ultimately reduce and eliminate pediatric heart disease.

079053	O.H. Frazier Award in MCS Translational Research	International Society for Heart and Lung Transplantation		08-Feb-2021	65,000 USD
--------	--	--	--	-------------	------------

Contact Name	
Contact Telephone	972-490-9495
Contact Email	communications@ishlt.org
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	08-Feb-2021
Synopsis	The purpose of this award is to support research utilizing MCS that would result in an increased understanding of the biologic effects, use as sole or combined therapy, insights into patient/MCS management, innovative use/application or improved outcomes for the treatment of heart failure. This is a one-year award in the amount of \$65,000.

006830	Mental Health and Wellness Research Award	International Society of Psychiatric-Mental Health Nurses		15-Jan-2021	1,500 USD
--------	---	---	--	-------------	-----------

Contact Name	
Contact Telephone	608-443-2463
Contact Email	info@ispn-psych.org
Sponsor Website	Link to sponsor website

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Jan-2021</p> <p>Synopsis The purpose of this award is to recognize and support the contributions of nursing research project or clinical inquiry project for a graduate nursing student or junior faculty member that will address research concerns related to mental health promotion and prevention, mental health policy development, community outreach, equity and social justice in nursing or health care for ethnic minority populations.</p>				
095169	Educational Grants -- Infectious Diseases (HIV/AIDS)	Janssen Biotech, Inc.		15-Jan-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email jtgrantinfo@its.jnj.com</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Jan-2021 , 15-Mar-2021 , 15-May-2021</p> <p>Synopsis Janssen provides grants to support educational activities for healthcare providers, allied healthcare providers and patients. Priority is given for activities within Janssen’s areas of scientific interest that contribute to improved knowledge, practice and performance for healthcare providers and improved health outcomes for patients, including in the area of Infectious Diseases. Grants are available for: Continuing Medical Education (CE)/Non-Accredited Continuing Education (NCE); Fellowships; and Patient Education.</p>				
081724	Therapeutic Area Contributions - Infectious Diseases Program	Janssen Pharmaceuticals, Inc.		31-Jan-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 908-218-6095</p> <p>Contact Email</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	31-Jan-2021 , 31-Mar-2021 , 31-May-2021 , 31-Jul-2021 , 30-Sep-2021 , 15-Nov-2021			
	Synopsis	Janssen Pharmaceuticals, Inc. makes charitable contributions to support therapeutic area initiatives. Applications are evaluated competitively with emphasis given to innovative programs with measurable outcomes that address disparities or unmet needs. The Infectious Diseases area of interest supports the following disease states: Hepatitis B; HIV / AIDS; Respiratory Infections; and Vaccines.			
091830	Summer Research Student Internship Program	Joslin Diabetes Center		31-Jan-2021	Not Specified
	Contact Name				
	Contact Telephone	617-309-2400			
	Contact Email	SummerStudent@Joslin.Harvard.edu			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	31-Jan-2021			
	Synopsis	The Joslin Summer Research Student Internship Program provides 10-12 weeks of practical exposure to diabetes-related biomedical research, ranging from clinically focused to basic science investigation. In addition to direct laboratory experience and interactions with Joslin investigators, students participate in didactic sessions related to diabetes pathophysiology and treatment. During the course of the program, participants present results from their research efforts to their student colleagues and Joslin research staff.			
002712	Klingenstein-Simons Fellowship Awards in the Neurosciences	Klingenstein (Esther A. & Joseph) Fund		15-Feb-2021	225,000 USD
	Contact Name				
	Contact Telephone				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email info@klingenstein.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Feb-2021</p> <p>Synopsis The Esther A. & Joseph Klingenstein Fund and the Simons Foundation announce the opening of its 2021 competition for research fellowships in the neurosciences. The Klingenstein-Simons Fellowship Awards in Neuroscience supports, in the early stages of their careers, young investigators engaged in basic or clinical research that may lead to a better understanding of neurological and psychiatric disorders.</p>				
034069	Lasker-Koshland Special Achievement Award in Medical Science	Lasker Foundation		01-Feb-2021	Not Specified
	<p>Contact Name David Keegan</p> <p>Contact Telephone 212-286-0222</p> <p>Contact Email dkeegan@laskerfoundation.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Feb-2021</p> <p>Synopsis The Lasker-Koshland Special Achievement Award in Medical Science honors scientists whose contributions to research and scientific statesmanship are of unique magnitude, and whose professional career has engendered within the biomedical community the deepest feelings of awe and respect.</p>				
010942	Lasker-DeBakey Clinical Medical Research Award	Lasker Foundation		01-Feb-2021	Not Specified
	<p>Contact Name David Keegan</p> <p>Contact Telephone 212-286-0222</p> <p>Contact Email dkeegan@laskerfoundation.org</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Feb-2021			
	Synopsis	The Lasker-DeBakey Clinical Medical Research Award is awarded for a major advance that improves the lives of many thousands of people. Each Award consists of an honorarium, a citation and an inscribed statuette of the Winged Victory of Samothrace, symbolizing victory over death and disease.			
071136	Albert Lasker Basic Medical Research Award	Lasker Foundation		01-Feb-2021	Not Specified
	Contact Name	David Keegan			
	Contact Telephone	212-286-0222			
	Contact Email	dkeegan@laskerfoundation.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Feb-2021			
	Synopsis	The Albert Lasker Basic Medical Research Award honors individuals who have made significant contributions to basic research.			
036282	LEO Foundation Awards	LEO Foundation		05-Feb-2021	100,000 USD
	Contact Name				
	Contact Telephone	+ 45 32 72 51 10			
	Contact Email	applications@leo-foundation.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-Feb-2021 , 18-Jun-2021 , 10-Sep-2021			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Synopsis		The LEO Foundation Awards constitute a global recognition and are given annually to outstanding young scientists whose work represent extraordinary contributions to dermatology research. There will be three awards of 100.000 USD, one in each of the Americas, EMEA (Europe/Middle East/Africa) and Asia-Pacific regions.			
055958	Hollis Brownstein Research Grants Program	Leukemia Research Foundation		05-Feb-2021 [LOI/Pre-App]	100,000 USD
Contact Name					
Contact Telephone		847-424-0600			
Contact Email		Grants@LRFmail.org			
Sponsor Website		Link to sponsor website			
Program URL		Link to program URL			
Deadline Dates (ALL)		05-Feb-2021 [LOI/Pre-App], 05-Apr-2021			
Synopsis		The Leukemia Research Foundation exclusively funds New Investigators - individuals beginning to establish their own laboratories that are no longer under the tutelage of a senior scientist mentor. It is difficult for them to get the level of funding they need at this critical point in their careers. The Leukemia Research Foundation is unique in the level of support it provides to highly promising scientists in this absolutely critical research niche. Providing one year grants of \$100,000 to selected New Investigator researchers, allows innovative scientists to act on their ideas, and try new procedures and experiments that will hopefully lead to significant breakthroughs.			
029379	Lupus Insight Prize	Lupus Research Alliance		19-Jan-2021	100,000 USD
Contact Name		Dr. Teodora Staeva			
Contact Telephone		646-884-6090			
Contact Email		tstaeva@lupusresearch.org			
Sponsor Website		Link to sponsor website			
Program URL		Link to program URL			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Deadline Dates (ALL) 19-Jan-2021

Synopsis The Lupus Research Alliance requests nominations for the 2021 Lupus Insight Prize recognizing and honoring significant scientific insights relevant to understanding the causes, pathogenesis, or treatment of lupus. The Prize also aims to stimulate further advances leading to improved outcomes for patients with lupus and ultimately to a cure. The Lupus Insight Prize will provide research funds to an outstanding investigator with a documented record of creativity, innovation, and productivity and who has made a novel insight and/or discovery in an area of research that is applicable to the pathogenesis or treatment of lupus and who is judged to have a high likelihood of generating further significant advances by applying the insight to lupus.

082247	Lupus Innovation Award	Lupus Research Alliance		16-Feb-2021	300,000 USD
--------	--	-------------------------	--	-------------	-------------

Contact Name Dr. Shayla Shorter, Scientific Program Manager

Contact Telephone 1-646-884-6015

Contact Email sshorter@lupusresearch.org

Sponsor Website [Link to sponsor website](#)

Program URL [Link to program URL](#)

Deadline Dates (ALL) 16-Feb-2021 , 15-Jun-2021

Synopsis The Lupus Research Alliance seeks to fund biomedical research that will discover better diagnostics, improve medical treatments and advance translational and clinical research that will ultimately lead to a cure for lupus. The Lupus Innovation Award provides support for pioneering, high-risk, high-reward approaches to major challenges in lupus research. Funding is up to \$150,000 per year for total costs for up to 2 years.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

043989	Post-Doctoral Fellowship Program	Maryland Stem Cell Research Fund		14-Jan-2021	130,000 USD
--------	--	----------------------------------	--	-------------	-------------

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone 410-715-4161</p> <p>Contact Email mscrinfo@tedco.md</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 14-Jan-2021</p> <p>Synopsis This Request for Applications, is soliciting Applications for Post-Doctoral Fellowship Grants. These Grants are for post-doctoral fellows who wish to conduct basic, translational, commercial and/or clinical research involving human stem cells. The MSCRF supports Projects involving human stem cells of all types, as defined in the Stem Cell Act. The purpose of this RFA is to fulfill the provisions of the Stem Cell Act by providing State funds to train the next generation of human stem cell researchers and expand the biotechnology community in Maryland. There is currently a need for more investment in basic, translational, commercial and clinical research to pursue the potential of stem cell therapies.</p>				

070279	Clinical Program	Maryland Stem Cell Research Fund		14-Jan-2021	650,000 USD
--------	----------------------------------	----------------------------------	--	-------------	----------------

	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email mscrinfo@tedco.md</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 14-Jan-2021</p> <p>Synopsis Stem cell research offers extraordinary promise for new medical therapies and a better understanding of debilitating human diseases, injuries and conditions. The development of new medical strategies for the prevention, diagnosis, treatment and cure of human diseases, injuries and conditions through human stem cell research is a high priority for</p>				
--	---	--	--	--	--

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>the State of Maryland. In this Request for Applications, the MSCRF is soliciting Clinical Stem Cell Research Grant Applications from organizations that wish to conduct clinical trials in the State of Maryland using human stem cells to advance medical therapies.</p>				
077673	New England Regional Fellowship Consortium	Massachusetts Historical Society		01-Feb-2021	5,000 USD
	<p>Contact Name Katy Morris Contact Telephone 617-646-0577 Contact Email fellowships@masshist.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 01-Feb-2021 Synopsis The New England Regional Fellowship Consortium, a collaboration of 30 major cultural agencies, offers fellowships for a minimum of eight weeks of research at participating institutions. Each grant will provide a stipend of \$5,000 for a minimum of eight weeks of research at participating institutions.</p>				
013299	Surgery - Breast Oncology Fellowship (Minnesota)	Mayo Clinic College of Medicine and Science		19-Feb-2021	Not Specified
	<p>Contact Name Contact Telephone 507-284-0354 Contact Email breastsurgoncfellowship@mayo.edu Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 19-Feb-2021 Synopsis The 1- to 2-year Multidisciplinary Breast Surgery Fellowship at Mayo Clinic in Rochester is designed to enhance one's knowledge of the management of breast disease, especially those cases for which treatment involves surgery.</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
013321	Surgery - Vascular Surgery Fellowship (Minnesota)	Mayo Clinic College of Medicine and Science		31-Jan-2021	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Julie Griffin, Education Coordinator 507-255-7062 griffin.julie@mayo.edu Link to sponsor website Link to program URL 31-Jan-2021 The Vascular Surgery Fellowship at Mayo Clinic's campus in Rochester, Minnesota, is a challenging training program that encompasses both open and endovascular management of arterial, venous and lymphatic diseases.			
013130	Female Pelvic Medicine and Reconstructive Surgery Fellowship (Minnesota)	Mayo Clinic College of Medicine and Science		31-Jan-2021	Not Specified
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Danette M. Anderson, Education Coordinator 507-266-0167 obgfellowships@mayo.edu Link to sponsor website Link to program URL 31-Jan-2021 The Female Pelvic Medicine and Reconstructive Surgery (FPMRS) Fellowship at Mayo Clinic's campus in Rochester, Minnesota, is a three-year subspecialty training program for obstetrics and gynecology and urology physicians who wish to specialize in urogynecology and reconstructive pelvic surgery.			
013312	Surgery - Abdominal Transplant Surgery Fellowship (Minnesota)	Mayo Clinic College of Medicine and Science		10-Feb-2021	Not Specified

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Stephanie L. Putzier, Education Coordinator 507-266-8731 rsttransplantcenterec@mayo.edu Link to sponsor website Link to program URL 10-Feb-2021 The Abdominal Transplant Surgery Fellowship at Mayo Clinic's campus in Rochester, Minnesota, provides fellows with the best possible foundation for a career in transplantation surgery. The American Society of Transplant Surgeons has accredited Mayo Clinic for training in liver and kidney transplantation.
--	---

016791	Breast Surgery Fellowship (Temporarily Suspended)	Memorial Sloan-Kettering Cancer Center		19-Feb-2021	Not Specified
--------	---	--	--	-------------	---------------

Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	Zachary Almer, MPA, Education Program Manager 212-639-7537 surfellowships@mskcc.org Link to sponsor website Link to program URL 19-Feb-2021 The Breast Surgery Service at MSKCC offers a one-year surgical fellowship to fully trained general surgeons who desire further experience in breast surgical oncology and the management of benign breast disease. Four new fellows are appointed each year.
--	--

073496	Department of Radiology - Breast Imaging Fellowship	Memorial Sloan-Kettering Cancer Center		15-Jan-2021	Not Specified
--------	---	--	--	-------------	---------------

Contact Name	Jacqueline Kurdziel, Education Coordinator
--------------	--

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone 212-639-2190 Contact Email kurdziej@mskcc.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 15-Jan-2021 Synopsis MSKCC invites applications for a one-year Breast Imaging Fellowship, which consists of consists of 32 weeks of breast imaging and 6 weeks elective.				
038045	Research Grants	Ménière's Society		15-Feb-2021	Not Specified
	Contact Name Natasha Harrington-Benton Contact Telephone +44 0 1306 876883 Contact Email research@menieres.org.uk Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 15-Feb-2021 , 15-May-2021 , 15-Aug-2021 , 15-Nov-2021 Synopsis The Ménière's Society's Research Programme supports vital research into vestibular disorders.				
058805	Investigator Studies Program (MISP) -- Surgery -- Anesthesia	Merck		22-Feb-2021	Not Specified
	Contact Name Lisa Mount Contact Telephone 267-305-1258 Contact Email lisa_mount@merck.com Sponsor Website Link to sponsor website Program URL Link to program URL				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 22-Feb-2021 , 01-May-2021 , 18-Jun-2021 , 01-Sep-2021 , 19-Oct-2021</p> <p>Synopsis The Investigator Studies Program aims to advance science and improve patient care by supporting, through the provision of drug/vaccine and/or total/partial funding, high-quality research that is initiated, designed, implemented and sponsored by external investigators. Results will be generated and properly disseminated in peer-reviewed publications.</p>				
061235	Merck MISP Oncology Grant	Merck		19-Jan-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 267-305-3871</p> <p>Contact Email oncmisp@msd.com</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 19-Jan-2021 , 10-Mar-2021</p> <p>Synopsis The Investigator Studies Program aims to advance science and improve patient care by supporting, through the provision of drug/vaccine and/or total/partial funding, high-quality research that is initiated, designed, implemented and sponsored by external investigators. Results will be generated and properly disseminated in peer-reviewed publications.</p>				
037398	Research Associateship Program (RAP)	National Academies		01-Feb-2021	Not Specified
	<p>Contact Name Attn: NRC Research Associateship Programs</p> <p>Contact Telephone 202-334-2760</p> <p>Contact Email RAP@nas.edu</p> <p>Sponsor Website Link to sponsor website</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Feb-2021 , 01-May-2021 , 01-Aug-2021 , 01-Nov-2021</p> <p>Synopsis The NRC Research Associateship Programs (RAP) promote excellence in scientific and technological research conducted by the U.S. government through the administration of programs offering graduate, postdoctoral, and senior level research opportunities at sponsoring federal laboratories and affiliated institutions.</p>				
071173	National Environmental Public Health Internship Program (NEPHIP)	National Environmental Health Association		22-Jan-2021	6,000 USD
	<p>Contact Name Reem Tariq, Project Coordinator</p> <p>Contact Telephone 303-756-9090</p> <p>Contact Email rtariq@neha.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 22-Jan-2021</p> <p>Synopsis In partnership with the Centers for Disease Control and Prevention's (CDC) Water, Food, and Environmental Health Services Branch, NEHA is offering an internship program for environmental health students for summer 2021. The purpose of this internship is to allow students to gain a firsthand perspective on the day-to-day responsibilities of environmental health professionals, make invaluable connections with those working in the field, and encourage students to consider careers working in local, state, or tribal environmental health departments following graduation. Through funding from CDC, the program will support environmental health student internships and provide a base stipend of \$6,000 for undergraduate and \$8000 for a 10-week internship through NEHA to cover lodging, food, and incidental expenses.</p>				
001547	Young Investigator Grants	National Kidney Foundation		08-Feb-2021	35,000 USD
	<p>Contact Name Kiley Thornton</p> <p>Contact Telephone 800-622-9010</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email kiley.thornton@kidney.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Feb-2021</p> <p>Synopsis The National Kidney Foundation recognizes the importance of the accomplishments of individuals who are early in their investigative careers in the advancement of our knowledge about the treatment and prevention of kidney disease. To raise awareness and create interest in the challenge of developing better treatments for kidney disease and its complications, the NKF has established a Young Investigator grant program to support clinical research studies addressing important issues for patients with kidney disease. Promising young scientists are encouraged to submit proposals for investigating clinical research questions in nephrology, or closely related fields.</p>				
018791	Nursing Education Research Grants	National League for Nursing		04-Feb-2021	30,000 USD
	<p>Contact Name</p> <p>Contact Telephone 800-669-1656</p> <p>Contact Email research@nlm.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 04-Feb-2021</p> <p>Synopsis The NLN Research in Nursing Education Grants Program supports high-quality studies that contribute to the development of the science of nursing education. The NLN-funded grants promote diversity of research topics and support investigators who demonstrate rigor and innovative approaches to advance the field of nursing education research.</p>				
040683	Junior Faculty Career Development Award (Kornfeld Scholars Program)	National Palliative Care Research Center		22-Jan-2021	180,000 USD
	Contact Name				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 212-241-7447</p> <p>Contact Email npcrc@mssm.edu</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 22-Jan-2021</p> <p>Synopsis The National Palliative Care Research Center (NPCRC) provides Junior Faculty Career Development Awards to allow junior faculty to have the protected time required to develop and conduct the pilot research necessary to be competitive for larger, extramurally funded awards. Recipients of the career development award will work with a mentor/co-mentor who has extensive palliative care research experience. The goal of the advisor is to ensure that funded junior investigators receive appropriate mentoring, that projects move forward in an efficient and timely manner, that projects continue to address the core mission of the Center, and to connect junior faculty with other investigators in the field of palliative care.</p>				
071600	Research Grants	National Pancreas Foundation		31-Jan-2021	50,000 USD
	<p>Contact Name Ms. Brooke Campbell, National Program Coordinator</p> <p>Contact Telephone 866-726-2737</p> <p>Contact Email bcampbell@pancreasfoundation.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 31-Jan-2021</p> <p>Synopsis The National Pancreas Foundation (NPF) provides support for the funding of research related to pancreatic diseases.</p>				
085042	Summer Student Research Grants	National Psoriasis Foundation		13-Jan-2021	5,000 USD
	<p>Contact Name </p> <p>Contact Telephone 503-244-7404</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email research@psoriasis.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 13-Jan-2021</p> <p>Synopsis The National Psoriasis Foundation (NPF) is seeking applications from undergraduate and medical students interested in conducting a summer of research focused on psoriatic disease or related comorbidities. The goal is to foster the development of promising young scientists who will go on to become bench researchers or clinician scientists focused on improving the lives of those living with psoriatic disease.</p>				
085049	Early Career Research Grants	National Psoriasis Foundation		13-Jan-2021	50,000 USD
	<p>Contact Name</p> <p>Contact Telephone 503-244-7404</p> <p>Contact Email research@psoriasis.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 13-Jan-2021</p> <p>Synopsis The National Psoriasis Foundation (NPF) is seeking grant applications from graduate students, postdoctoral researchers, and researchers at similar trainee-level positions interested in conducting projects focused on psoriatic disease. The goal of this award is to support scientists at this challenging early career stage and to welcome them into the collaborative community of scientists, clinicians, and patients involved with NPF research, with particular interest in fostering an increased representation of underrepresented individuals within the research community. Ultimately, recipients of this award are expected to be in a position to compete for future funding through NPF Discovery or Translational Research Grants and go on to establish successful long-term careers conducting psoriatic disease research.</p>				
018808	Discovery Research Grant	National Psoriasis Foundation		13-Jan-2021	75,000 USD

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone 503-244-7404</p> <p>Contact Email research@psoriasis.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 13-Jan-2021</p> <p>Synopsis The National Psoriasis Foundation (NPF) is seeking grant applications that encourage the advancement of innovative research into psoriasis and psoriatic arthritis. Discovery Grants fund researchers while they explore preliminary ideas and conduct proof-of-concept experiments. The goal is to stimulate the development of new research programs in the field of psoriatic disease capable of competing for long-term funding from the National Institutes of Health or other agencies.</p>				
018807	Translational Research Grant	National Psoriasis Foundation		13-Jan-2021	100,000 USD
	<p>Contact Name</p> <p>Contact Telephone 503-244-7404</p> <p>Contact Email research@psoriasis.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 13-Jan-2021</p> <p>Synopsis The National Psoriasis Foundation (NPF) is seeking grant applications that encourage the advancement of innovative research into psoriasis and psoriatic arthritis. Translational Research Grants fund research initiatives that focus on the rapid translation of basic scientific discoveries into clinical applications with a clear benefit for patients with psoriatic disease.</p>				
085055	Psoriatic Disease Research Fellowships	National Psoriasis Foundation		13-Jan-2021	50,000 USD

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone 503-244-7404</p> <p>Contact Email research@psoriasis.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 13-Jan-2021</p> <p>Synopsis The National Psoriasis Foundation (NPF) is announcing the availability of the Psoriatic Disease Research Fellowships program for the academic year 2021-22. The program provides support to eligible institutions to develop and enhance the opportunities for physicians training for research careers in academic dermatology, rheumatology, pediatric dermatology, and pediatric rheumatology. Priority consideration will be given to applications that advance psoriatic disease research.</p>				
087122	Milestones to a Cure Grant	National Psoriasis Foundation		13-Jan-2021	100,000 USD
	<p>Contact Name</p> <p>Contact Telephone 503-244-7404</p> <p>Contact Email research@psoriasis.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 13-Jan-2021</p> <p>Synopsis The National Psoriasis Foundation (NPF) is seeking grant applications from postdoctoral researchers interested in conducting projects focused on psoriatic disease. The goal of this award is to support research with an aim focused on treatment durability, remission/relapse, prevention and personalized medicine.</p>				
001639	Research Associateship Programs -- Naval Medical Research Center/Naval Health Research Center (NMRC/NHRC)	National Research Council		01-Feb-2021	Not Specified

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone 202-334-2760</p> <p>Contact Email rap@nas.edu</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Feb-2021 , 01-May-2021</p> <p>Synopsis The mission of the NRC Research Associateship Programs (RAP) is to promote excellence in scientific and technological research conducted by the U. S. government through the administration of programs offering graduate, postdoctoral, and senior level research opportunities at sponsoring federal laboratories and affiliated institutions.</p>				
058602	Research Associateship Programs -- U.S. Army Medical Research and Materiel Command	National Research Council		01-Feb-2021	Not Specified
	<p>Contact Name Dr. Ray Gamble, Program Administrator</p> <p>Contact Telephone 202-334-2787</p> <p>Contact Email rgamble@nas.edu</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Feb-2021 , 03-May-2021</p> <p>Synopsis The mission of the NRC Research Associateship Programs (RAP) is to promote excellence in scientific and technological research conducted by the U. S. government through the administration of programs offering graduate, postdoctoral, and senior level research opportunities at sponsoring federal laboratories and affiliated institutions.</p>				
001045	Research Associateship Programs -- Armed Forces Radiobiology Research Institute	National Research Council		01-Feb-2021	57,000 USD
	Contact Name Dr. Ray Gamble				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 202-334-2787</p> <p>Contact Email rgamble@nas.edu</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Feb-2021 , 01-May-2021 , 01-Aug-2021</p> <p>Synopsis The National Academies of Sciences, Engineering, and Medicine administers competitive postdoctoral and senior research awards on behalf of U.S. federal research agencies and affiliated institutions with facilities at over 100 locations throughout the U.S. and abroad. Awardees have the opportunity to: conduct independent research in an area compatible with the interests of the sponsoring laboratory devote full-time effort to research and publication access the excellent and often unique facilities of the federal research enterprise collaborate with leading scientists and engineers at the sponsoring laboratories.</p>				
058572	Research Associateship Programs -- Naval Postgraduate School	National Research Council		01-Feb-2021	Not Specified
	<p>Contact Name Dr. Ray Gamble, Program Administrator</p> <p>Contact Telephone 202-334-2787</p> <p>Contact Email rgamble@nas.edu</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Feb-2021 , 03-May-2021</p> <p>Synopsis The mission of the NRC Research Associateship Programs (RAP) is to promote excellence in scientific and technological research conducted by the U. S. government through the administration of programs offering graduate, postdoctoral, and senior level research opportunities at sponsoring federal laboratories and affiliated institutions.</p>				
058605	Research Associateship Programs -- U.S. Army Research Office	National Research Council		01-Feb-2021	Not Specified

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Dr. Eric Basques, Program Administrator</p> <p>Contact Telephone 202-334-2707</p> <p>Contact Email ebasques@nas.edu</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Feb-2021 , 03-May-2021</p> <p>Synopsis The mission of the NRC Research Associateship Programs (RAP) is to promote excellence in scientific and technological research conducted by the U. S. government through the administration of programs offering graduate, postdoctoral, and senior level research opportunities at sponsoring federal laboratories and affiliated institutions.</p>				
058596	Research Associateship Programs -- U.S. Army Research, Development & Engineering Command, NVESD (RDEC/NVESD)	National Research Council		01-Feb-2021	Not Specified
	<p>Contact Name Dr. Eric Basques, Program Administrator</p> <p>Contact Telephone 202-334-2707</p> <p>Contact Email ebasques@nas.edu</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Feb-2021 , 03-May-2021</p> <p>Synopsis The mission of the NRC Research Associateship Programs (RAP) is to promote excellence in scientific and technological research conducted by the U. S. government through the administration of programs offering graduate, postdoctoral, and senior level research opportunities at sponsoring federal laboratories and affiliated institutions.</p>				
058545	Research Associateship Programs -- National Oceanic and Atmospheric Administration (NOAA)	National Research Council		01-Feb-2021	Not Specified
	<p>Contact Name Dr. Ray Gamble, Program Administrator</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone 202-334-2787 Contact Email rgamble@nas.edu Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 01-Feb-2021 , 03-May-2021 Synopsis The mission of the NRC Research Associateship Programs (RAP) is to promote excellence in scientific and technological research conducted by the U. S. government through the administration of programs offering graduate, postdoctoral, and senior level research opportunities at sponsoring federal laboratories and affiliated institutions.				
058604	Research Associateship Programs -- U.S. Army Research Laboratory	National Research Council		01-Feb-2021	Not Specified
	Contact Name Dr. Eric Basques, Program Administrator Contact Telephone 202-334-2707 Contact Email ebasques@nas.edu Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 01-Feb-2021 , 03-May-2021 Synopsis The mission of the NRC Research Associateship Programs (RAP) is to promote excellence in scientific and technological research conducted by the U. S. government through the administration of programs offering graduate, postdoctoral, and senior level research opportunities at sponsoring federal laboratories and affiliated institutions.				
058544	Research Associateship Programs -- National Institute of Standards and Technology (NIST)	National Research Council		01-Feb-2021	Not Specified
	Contact Name Dr. Ray Gamble, Program Administrator Contact Telephone 202-334-2787				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email rgamble@nas.edu</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Feb-2021</p> <p>Synopsis The mission of the NRC Research Associateship Programs (RAP) is to promote excellence in scientific and technological research conducted by the U. S. government through the administration of programs offering graduate, postdoctoral, and senior level research opportunities at sponsoring federal laboratories and affiliated institutions. All NIST NRC Postdocs must conduct their research at an already established NIST duty station, i.e., Gaithersburg, MD; Boulder, CO; or Charleston, SC.</p>				
058542	Research Associateship Programs -- Air Force Research Laboratory	National Research Council		01-Feb-2021	80,000 USD
	<p>Contact Name Ms. Ellen M. Robinson</p> <p>Contact Telephone 703-588-8527</p> <p>Contact Email ellen.robinson.1@us.af.mil</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Feb-2021 , 03-May-2021</p> <p>Synopsis Competitive awards are available for scientists and engineers to conduct independent research in federal laboratories and affiliated institutions. Awards include attractive stipends, health insurance, professional travel, and relocation.</p>				
001033	Research Associateship Programs -- Naval Research Laboratory	National Research Council		01-Feb-2021	Not Specified
	<p>Contact Name Ms. Erica Deschak</p> <p>Contact Telephone 202-767-8323</p> <p>Contact Email erica.deschak@nrl.navy.mil</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website Program URL Link to program URL Deadline Dates (ALL) 01-Feb-2021 Synopsis The Naval Research Laboratory conducts a broad based multidisciplinary program of scientific research in advanced technological development, techniques, systems, and related operational procedures				
058592	Research Associateship Programs -- Army Aviation and Missile Research, Development, and Engineering Center (AMRDEC)	National Research Council		01-Feb-2021	Not Specified
	Contact Name Dr. Eric Basques, Program Administrator Contact Telephone 202-334-2707 Contact Email ebasques@nas.edu Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 01-Feb-2021 , 03-May-2021 Synopsis The mission of the NRC Research Associateship Programs (RAP) is to promote excellence in scientific and technological research conducted by the U. S. government through the administration of programs offering graduate, postdoctoral, and senior level research opportunities at sponsoring federal laboratories and affiliated institutions.				
070292	Research Associateship Programs -- Environmental Protection Agency Faculty Fellowship Program (EPA/FFP)	National Research Council		01-Feb-2021	Not Specified
	Contact Name Dr. Eric Basques Contact Telephone 202-334-2707 Contact Email ebasques@nas.edu Sponsor Website Link to sponsor website Program URL Link to program URL				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Deadline Dates (ALL) | 01-Feb-2021 , 01-May-2021 , 01-Aug-2021 , 01-Nov-2021

Synopsis | The National Research Council provides support to promote excellence in scientific and technological research conducted by the U.S. government through the administration of programs offering graduate, postdoctoral, and senior level research opportunities at the Environmental Protection Agency.

057928	Nephrotic Syndrome Study Network Career Development Fellowship	NephCure Kidney International		15-Feb-2021	62,500 USD
--------	--	-------------------------------	--	-------------	------------

Contact Name | Tina Mainieri, NEPTUNE Project Manager

Contact Telephone | 734-615-5020

Contact Email | NEPTUNE-STUDY@umich.edu

Sponsor Website | [Link to sponsor website](#)

Program URL | [Link to program URL](#)

Deadline Dates (ALL) | 15-Feb-2021

Synopsis | The NEPTUNE Career Development program is designed to support advanced post-doctoral and junior faculty trainees, or established investigators interested in redirecting their investigative focus, who are preparing to become independent investigators in clinical and translational research in human glomerular disease. Successful applicants will design and carry out an individually tailored program that combines a clearly defined training component with a mentored research experience that employs the resources of NEPTUNE to address a question relevant to glomerular disease.

052255	Glorney-Raisbeck Fellowship in Cardiovascular Diseases	New York Academy of Medicine		15-Jan-2021	70,000 USD
--------	--	------------------------------	--	-------------	------------

Contact Name |

Contact Telephone | 212-419-3544

Contact Email | fellows@nyam.org

Sponsor Website | [Link to sponsor website](#)

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Jan-2021</p> <p>Synopsis The Glorney-Raisbeck Fellowship Award in Cardiovascular Diseases is a one-year, \$70,000 grant awarded for research by young physician scientists in supervised programs that will develop the candidates' ability to perform independent clinical or laboratory research. Up to three Fellowships will be awarded.</p>				
058790	Glorney-Raisbeck Medical Student Grants in Cardiovascular Research	New York Academy of Medicine		15-Jan-2021	8,000 USD
	<p>Contact Name</p> <p>Contact Telephone 212-419-3544</p> <p>Contact Email fellows@nyam.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Jan-2021</p> <p>Synopsis The Glorney-Raisbeck Medical Student Grants in Cardiovascular Research are awarded to MD candidates who are either enrolled in a New York-area medical school or plan to conduct research at a New York-area institution, to pursue 10-12 week summer research projects seeking better understanding of the causes, prevention, and treatment of cardiovascular diseases.</p>				
063652	Ferdinand C. Valentine Student Research Grants in Urology	New York Academy of Medicine		15-Jan-2021	4,000 USD
	<p>Contact Name</p> <p>Contact Telephone 212-419-3544</p> <p>Contact Email fellows@nyam.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 15-Jan-2021</p> <p>Synopsis The Ferdinand C. Valentine Medical Student Research Grants in Urology are awarded to MD candidates who are either enrolled in a New York-area medical school or plan to conduct research at a New York-area institution, to pursue 10 to 12 week mentored summer research projects in urology. Up to three \$4,000 grants will be awarded each year.</p>				
064447	David E. Rogers Student Fellowship Award	New York Academy of Medicine		15-Jan-2021	4,000 USD
	<p>Contact Name</p> <p>Contact Telephone 212-419-3544</p> <p>Contact Email fellows@nyam.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Jan-2021</p> <p>Synopsis The David E. Rogers Student Fellowship Award is a national fellowship for medical and dental students in support of a 10-12 week mentored project initiated during the summer between the first and second years of medical or dental school. The Fellowship is meant to enrich the educational experiences of students through projects that couple medicine and dentistry with the needs of underserved or disadvantaged patients or populations.</p>				
100236	Rapid Testing Innovation Competition	New York City Economic Development Corporation		20-Jan-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email rapidtesting@edc.nyc</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 20-Jan-2021 , 03-Feb-2021 , 17-Feb-2021</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	<p>The success of New York City’s Test and Trace program has facilitated a safe and steady economic reopening; the City is seeking to significantly increase the availability, usability, and speed of testing to further reopen the economy in the period prior to broad distribution of a vaccine. Specifically, New York City seeks point-of-care and at-home COVID tests that can deliver results in minutes, rather than hours and that may be self-administered. There are only a handful of COVID tests that have Food and Drug Administration (FDA) Emergency Use Authorization (EUA) and are allowed in a CLIA-waived setting (“rapid tests”). However, many are in development and the FDA has recently issued guidance for at-home and over-the counter diagnostic tests.</p>			
013105	Druckenmiller Fellowship Awards	New York Stem Cell Foundation		13-Jan-2021	Not Specified
	Contact Name				
	Contact Telephone	212-787-4111			
	Contact Email	info@nyscf.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	13-Jan-2021			
	Synopsis	<p>NYSCF invites applications from postdoctoral fellows from institutions within New York, New Jersey, and Connecticut to cultivate research that will explore the basic biology and therapeutic potential of stem cells derived from humans and model organisms.</p>			
031596	Robertson Stem Cell Investigator Awards	New York Stem Cell Foundation		17-Feb-2021	1,500,000 USD
	Contact Name				
	Contact Telephone	212-787-4111			
	Contact Email	info@nyscf.org			
	Sponsor Website	Link to sponsor website			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Program URL	Link to program URL
Deadline Dates (ALL)	17-Feb-2021
Synopsis	NYSCF is soliciting applications from early career investigators for Innovator Awards to be used for exploring the basic biology and translational potential of stem cells.

088605	Research Grants	North American Spine Society		08-Feb-2021 [LOI/Pre-App]	100,000 USD
--------	---------------------------------	------------------------------	--	------------------------------	----------------

Contact Name	Karen James, Manager of Research
Contact Telephone	630-230-3691
Contact Email	KJames@spine.org
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	08-Feb-2021 [LOI/Pre-App], 10-May-2021
Synopsis	NASS research grants provide funding for promising research projects by qualified investigators in the field of spine. Research grants should focus on basic science, clinical or translational research. Basic research may focus on projects that further our understanding of the mechanisms of disease and developing novel models for prevention and/ or treatment. Clinical research may focus on projects that investigate the epidemiology, prevention, and or treatment of spine disease. Translational research may focus on projects that move findings from the 'bench to bedside'

088607	Nontraditional Nonsurgical Treatment Grants	North American Spine Society		08-Feb-2021 [LOI/Pre-App]	100,000 USD
--------	---	------------------------------	--	------------------------------	----------------

Contact Name	Karen James, Manager of Research
Contact Telephone	630-230-3691
Contact Email	KJames@spine.org

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Feb-2021 [LOI/Pre-App], 10-May-2021</p> <p>Synopsis The Nontraditional, Nonsurgical Treatment Grant is the result of a donation to research as part of a settlement of a class action lawsuit unrelated to NASS. This grant supports research of disc-related and/or neuropathic back pain by nonsurgical techniques. These funds must be used for new, nontraditional methods of nonsurgical treatment of such back and neck pain and radiculopathy. If TNF-inhibitors other than etanercept are used in research and/or treatment funded, comparison studies using perispinal etanercept in at least as many research subjects or patients should be done. Funding amount and number of grants are at the discretion of the NASS Research Project Management Committee based upon merit of applications and amount of funding available each year. It is recommended that approved grant budgets range between \$20,000-\$40,000 per year. In rare cases and at the discretion of the committee, each year may be up to \$50,000 per year.</p>				
088606	Young Investigator Grants	North American Spine Society		08-Feb-2021 [LOI/Pre-App]	100,000 USD
	<p>Contact Name Karen James, Manager of Research</p> <p>Contact Telephone 630-230-3691</p> <p>Contact Email KJames@spine.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 08-Feb-2021 [LOI/Pre-App], 10-May-2021</p> <p>Synopsis One to two Young Investigator Grants may be awarded each year. Principal investigators may be any age. MD applicants must be within five years of completion of training at the time of application; PhD applicants must be within five years of their post-doc training. Applicants may not have received previous grant funding from the NASS Research Project Management Committee. It is recommended that approved grant budgets range between \$20,000-\$40,000 per year. In rare cases and at the discretion of the committee, each year may be up to \$50,000 per year.</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
024601	Resident Research Project Grant	Orthopaedic Research & Education Foundation		21-Feb-2021	5,000 USD
	Contact Name				
	Contact Telephone	847-698-9980			
	Contact Email	grants@oref.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	21-Feb-2021			
	Synopsis	The objective of the OREF Resident Research Project Grant is to provide funding to residents who are interested in research. Grants of \$5,000 will be considered for orthopaedic surgery residents in approved orthopaedic programs to cover research expenses, but not salary or travel. All orthopaedic topics will be considered; proposals related to sports, shoulder and elbow, spine and pediatrics are encouraged.			
009972	OTA Member Full Research Grants - Clinical Research Grants	Orthopaedic Trauma Association		11-Jan-2021	80,000 USD
	Contact Name				
	Contact Telephone	847-698-1631			
	Contact Email	ota@ota.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)				
	Synopsis	The Orthopaedic Trauma Association provides Clinical Research Grants for any research issue related to musculoskeletal trauma (excluding product development). Grants provide a maximum of \$40,000 per year for up to two years.			
089474	Ann Kolker Fellowship	Ovarian Cancer Research Alliance		15-Jan-2021	51,000 USD

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone 202-331-1332</p> <p>Contact Email KolkerFellowship@ocrahope.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Jan-2021</p> <p>Synopsis The Ovarian Cancer Research Alliance offers the Ann Kolker Fellowship, providing a uniquely tailored experience that could have a real impact on health policy in Washington, DC and beyond. Working directly with OCRA's Vice President of Policy, the Fellow will play an important role in working to implement a policy agenda that seeks to eliminate ovarian cancer by translating the latest scientific and observational research into concrete policy objectives. Through both grass-roots and legislative advocacy and direct engagement, the Ann Kolker Fellow will gain important insights into both health policy advocacy and patient engagement.</p>				
002235	Program for Children with Special Health Care Needs	Packard (Lucile) Foundation for Children's Health		15-Feb-2021	Not Specified
	<p>Contact Name</p> <p>Contact Telephone 650-497-8365</p> <p>Contact Email info@lpfch.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Feb-2021</p> <p>Synopsis The Foundation funds programs and projects that will contribute to improving California's system of care for children with special health care needs and their families.</p>				
095462	Graduate Studentship Award	Parkinson Canada		01-Feb-2021	15,600 USD

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Lorena Araujo</p> <p>Contact Telephone 416-227-3382</p> <p>Contact Email lorena.araujo@Parkinson.ca</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Feb-2021</p> <p>Synopsis Parkinson Canada offers its graduate award program as a strategic initiative to encourage promising young scientists to enter the field of Parkinson's research and to invest in research training that offers promise for future work in the area of Parkinson's disease. The program offers awards for the support of projects with budgets of up to \$10,000 per year over a two-year term. For 2021, the Graduate Student Award is not available for the master's level.</p>				
026640	Basic Research Fellowship	Parkinson Canada		01-Feb-2021	39,000 USD
	<p>Contact Name Lorena Araujo</p> <p>Contact Telephone 800-565-3000 ext 3309</p> <p>Contact Email lorena.araujo@parkinson.ca</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Feb-2021</p> <p>Synopsis Parkinson Canada offers its Basic Research Fellowship program as a strategic initiative to encourage promising young scientists to enter the field of Parkinson's research and to invest in research training that offers promise for future work in the area of Parkinson's disease. Parkinson Canada intends to provide awards in the range of \$40,000 - \$50,000 per year over a two-year term.</p>				
072968	Clinical Research Fellowships	Parkinson Canada		01-Feb-2021	78,000 USD
	Contact Name Lorena Araujo				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 416-227-9700</p> <p>Contact Email lorena.araujo@Parkinson.ca</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Feb-2021</p> <p>Synopsis Parkinson Canada offers its clinical research fellowship program as a strategic initiative to encourage promising young scientists to enter the field of Parkinson's clinical research and to invest in research training that offers promise for future work in the area of Parkinson's Disease. The program offers awards in the amount of a maximum of \$50,000 per year over a two-year term.</p>				
001994	Postdoctoral Fellowships for Basic Scientists	Parkinson's Foundation		19-Feb-2021	110,000 USD
	<p>Contact Name </p> <p>Contact Telephone 212-923-4700</p> <p>Contact Email grants@parkinson.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 19-Feb-2021</p> <p>Synopsis The Postdoctoral Fellowships for Basic Scientists are two-year fellowships for young scientists, fresh from their Ph.D. training, to study at major research institutions. This program grants \$110,000 over two years.</p>				
046755	Postdoctoral Fellowships for Clinical Neurologists	Parkinson's Foundation		19-Feb-2021	140,000 USD
	<p>Contact Name </p> <p>Contact Telephone 212-923-4700</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Email grants@parkinson.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 19-Feb-2021</p> <p>Synopsis For young clinicians who have completed their neurology residency and are seeking clinical research experience, the Parkinson's Foundation offers the Postdoctoral Fellowships for Clinical Neurologists, two-year awards in the amount of \$140,000. This award includes salary support of \$65,000 per year.</p>				
077836	Melvin Yahr Early Career Award in Movement Disorders Research	Parkinson's Foundation		19-Feb-2021	50,000 USD
	<p>Contact Name</p> <p>Contact Telephone 212-923-4700</p> <p>Contact Email grants@parkinson.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 19-Feb-2021</p> <p>Synopsis The Parkinson's Foundation Melvin Yahr Early Career Award in Movement Disorders Research is a two-year award providing a total of \$50,000 for early career neurologists. Awardees will be required to prepare an application for a K-type award, such as the NIH-K23 award or others, by the end of Year 1 of this Early Career Award. Applications should be submitted before the end of Year 2.</p>				
058485	Stanley Fahn Junior Faculty Award	Parkinson's Foundation		19-Feb-2021	300,000 USD
	<p>Contact Name</p> <p>Contact Telephone 212-923-4700</p> <p>Contact Email grants@parkinson.org</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 19-Feb-2021</p> <p>Synopsis The Stanley Fahn Junior Faculty Award acts as a bridge to ensure promising early career scientists stay in the Parkinson’s research field, helping us solve, treat and end the disease. In today’s funding environment, as young scientists navigate the path from mentored to independent research, they face a “valley of death” between their scientific potential and the funding they need to make it happen. This award can stem Parkinson’s research talent loss.</p>				
088268	Assessment of Prevention, Diagnosis, and Treatment Options Program	Patient-Centered Outcomes Research Institute (PCORI)		12-Jan-2021	5,000,000 USD
	<p>Contact Name</p> <p>Contact Telephone 202-627-1885</p> <p>Contact Email pfa@pcori.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 12-Jan-2021</p> <p>Synopsis The Broad PCORI Funding Announcements (PFAs) seek investigator-initiated applications for patient-centered comparative clinical effectiveness research (CER) projects aligned with our priority areas for research. This PFA covers the following four priority areas: Addressing Disparities; Assessment of Prevention, Diagnosis, and Treatment Options; Communication and Dissemination Research, and Improving Health Systems. Applications should address needs of patients, caregivers, clinicians, and other healthcare stakeholders in making personalized clinical decisions across a wide range of conditions, populations, and treatments.</p>				
030477	Broad PCORI Funding	Patient-Centered Outcomes Research Institute (PCORI)		02-Feb-2021 [LOI/Pre-App]	3,000,000 USD
	Contact Name				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Telephone 202-827-7700</p> <p>Contact Email info@pcori.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 02-Feb-2021 [LOI/Pre-App], 04-May-2021</p> <p>Synopsis The Broad PCORI Funding Announcements (PFAs) seek investigator-initiated applications for patient-centered comparative clinical effectiveness research (CER) projects aligned with our priority areas for research. This PFA covers the following four priority areas outlined in PCORI's National Priorities for Research and Research Agenda: Addressing Disparities; Assessment of Prevention, Diagnosis, and Treatment Options; Communication and Dissemination Research, and Improving Healthcare Systems. These broad areas encompass the patient-centered comparative CER we support.</p>				
053400	Pershing Square Sohn Prize for Young Investigators in Cancer Research	Pershing Square Foundation		29-Jan-2021	600,000 USD
	<p>Contact Name Olivia Tournay Flatto, PhD, Executive Director</p> <p>Contact Telephone </p> <p>Contact Email otflatto@persq.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 29-Jan-2021</p> <p>Synopsis The Pershing Square Sohn Prize for Young Investigators in Cancer Research provides New York area-based early career scientists the freedom to take risks and pursue their boldest research at a stage when traditional funding is lacking. Prize winners each receive \$200,000 a year for up to three years. At least six grants are awarded annually.</p>				
088216	Inflammatory Bowel Disease Fellowship	Pfizer Pharmaceuticals		01-Feb-2021	80,000 USD

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name Amanda Solis</p> <p>Contact Telephone 212-733-2323</p> <p>Contact Email amanda.solis@pfizer.com</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Feb-2021</p> <p>Synopsis Pfizer Global Medical Grants (GMG) is issuing this Request for Proposals (RFP) to offer salary support for Inflammatory Bowel Disease (IBD) focused Fellowship programs. Through this grant we intend to support clinical training programs in regions where there are continued workforce challenges. Priority will be placed on programs that emphasize mentorship and patient care.</p>				
100985	Competitive Grant Program: Inflammatory and Immune-Mediated Dermatologic Disorders	Pfizer Pharmaceuticals		24-Feb-2021	175,000 USD
	<p>Contact Name Derek Warnick, Grant Officer</p> <p>Contact Telephone 212-733-2323</p> <p>Contact Email derek.warnick@pfizer.com</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 24-Feb-2021</p> <p>Synopsis Pfizer Global Medical Grants (GMG) is issuing this Request for Proposals (RFP) to support preclinical, clinical and outcomes research through a competitive grant program with the intent to increase medical knowledge in the diagnosis and management of inflammatory and immune-mediated dermatologic disorders.</p>				
101340	Competitive Grant Program: Fellowship for Inflammatory Dermatological Diseases	Pfizer Pharmaceuticals		17-Feb-2021	80,000 USD

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Name	Derek Warnick, Grant Officer
Contact Telephone	212-733-2323
Contact Email	derek.warnick@pfizer.com
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	17-Feb-2021
Synopsis	Pfizer Global Medical Grants (GMG) is issuing this Request for Proposals (RFP) to offer salary support for Fellowship programs (e.g. Dermatology, Allergy). It is Pfizer's intent to support fellowship programs at institutions with expertise in inflammatory and immune-mediated dermatological disorders and have a strong focus on clinical practice, research, and education to further the understanding of inflammatory skin diseases, such as atopic dermatitis, alopecia areata, vitiligo, and hidradenitis suppurativa. Grants will be awarded based on the strength of the requesting organization's ability to provide training and guidance to the fellow.

101092	Medical Education Grants: Advances in Atopic Dermatitis & Alopecia Areata for Community Pharmacists & Managed Care Health Care Professionals	Pfizer Pharmaceuticals	12-Feb-2021	300,000 USD
--------	--	------------------------	-------------	----------------

Contact Name	Derek Warnick, Grant Officer
Contact Telephone	212-733-2323
Contact Email	derek.warnick@pfizer.com
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	12-Feb-2021
Synopsis	Pfizer Global Medical Grants (GMG) is issuing this Request for Proposals (RFP) to support educational projects that focus on the role of community pharmacists and managed care health professionals, addressing knowledge and practice gaps specific to the overall care management of AD and AA. Individual projects requesting up to \$300,000 will

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

| be considered.

101112	Competitive Grant Program: 2020 RD US- Next Generation PET Imaging for ATTR-CM	Pfizer Pharmaceuticals		01-Feb-2021	125,000 USD
--------	--	------------------------	--	-------------	-------------

Contact Name	Amanda Stein, Grant Officer
Contact Telephone	212-733-2323
Contact Email	amanda.j.stein@pfizer.com
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	01-Feb-2021
Synopsis	GE Healthcare and Pfizer are collaborating to offer a new competitive grant opportunity focused on addressing diagnostic performance and disease stabilization using F-flutemetamol cardiac PET in subjects presenting with ATTR-CM and are treated with Tafamidis. Individual projects requesting up to \$125,000 will be considered.

101178	Medical Education Grants: Call for Independent Medical Education Grant Applications Oncology – Prostate Cancer	Pfizer Pharmaceuticals		28-Jan-2021	200,000 USD
--------	--	------------------------	--	-------------	-------------

Contact Name	
Contact Telephone	
Contact Email	
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	28-Jan-2021
Synopsis	Astellas and Pfizer (collectively, the Companies) are committed to supporting high quality, evidence-based independent medical education (IME) that seeks to improve the overall safety and quality of patient care and treatment. The intent of this Call for Grant Applications (CGA) is to encourage organizations to submit grant

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>applications for independent CME/CE certified education designed to close knowledge gaps identified in the public healthcare landscape, drive measurable improvements in knowledge, competence and performance of healthcare professionals, and advance patient health outcomes. "Independent" means that the projects funded by the companies are the full responsibility of the recipient organization. The Companies do not have influence over any aspect of the supported projects and only ask for interim and final outcomes reports including a description of the impact of the projects. Individual requests up to \$200,000 will be considered for funding.</p>			
101176	Medical Education Grant: Understanding Residual Cardiovascular Risk Related to Triglyceride-Rich Remnant Lipoproteins	Pfizer Pharmaceuticals		18-Feb-2021	150,000 USD
	<p>Contact Name Jessica Romano, Grant Officer</p> <p>Contact Telephone 212-733-2323</p> <p>Contact Email jessica.romano@pfizer.com</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 18-Feb-2021</p> <p>Synopsis Pfizer Global Medical Grants (GMG) is issuing a Request for Proposals (RFP) to support educational programs focused on understanding residual cardiovascular (CV) risk associated with triglyceride (TG)-rich remnant lipoproteins. Individual projects requesting up to \$100,000-\$150,000 will be considered.</p>				
100583	Medical Education Grants: Providing Access to Learning Resources for Tobacco Dependence Treatment	Pfizer Pharmaceuticals		13-Jan-2021	Not Specified
	<p>Contact Name Renee Yip</p> <p>Contact Telephone </p> <p>Contact Email Renee.Yip@pfizer.com</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 13-Jan-2021</p> <p>Synopsis The Pfizer Global Medical Grants (GMG) is issuing a Request for Proposals (RFP) for a project to broaden access to Mayo Clinic's educational curriculum in tobacco dependence treatment for members of organizations which demonstrate a commitment to sustainable tobacco treatment education. Ultimately, this will improve patients' awareness of the harms of tobacco and their chances of successfully stopping tobacco use.</p>				
075493	Research Starter Grants in Translational Medicine	Pharmaceutical Research & Manufacturers of America (PhRMA) Foundation		01-Feb-2021	100,000 USD
	<p>Contact Name</p> <p>Contact Telephone 202-572-7756</p> <p>Contact Email foundation@phrma.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Feb-2021</p> <p>Synopsis The PhRMA Foundation Research Starter Grant in Translational Medicine offers financial support to individuals beginning independent research careers in translational medicine at the faculty level. The program provides a research grant of \$100,000 for one year.</p>				
075494	Postdoctoral Fellowships in Translational Medicine	Pharmaceutical Research & Manufacturers of America (PhRMA) Foundation		01-Feb-2021	120,000 USD
	<p>Contact Name</p> <p>Contact Telephone 202-572-7756</p> <p>Contact Email foundation@phrma.org</p> <p>Sponsor Website Link to sponsor website</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Program URL	Link to program URL
Deadline Dates (ALL)	01-Feb-2021
Synopsis	The Postdoctoral Fellowship in Translational Medicine supports individuals engaged in multidisciplinary/collaborative research training programs that will extend their credentials in Translational Medicine.

061524	Predoctoral Fellowships in Health Outcomes	Pharmaceutical Research & Manufacturers of America (PhRMA) Foundation	01-Feb-2021	25,000 USD
--------	--	---	-------------	------------

Contact Name	Joanne Westphal
Contact Telephone	202-572-7756
Contact Email	foundation@phrma.org
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	01-Feb-2021
Synopsis	This award provides support to promising students during advanced stages of training and thesis research and for the career development of scientists prepared to engage in health outcomes research. Predoctoral Fellowships are designed for students who expect to complete their PhD requirements in two years or less from the time the fellowship begins. Fellows are expected to devote full time (including summers) to their research.

061543	Research Starter Grants in Health Outcomes	Pharmaceutical Research & Manufacturers of America (PhRMA) Foundation	01-Feb-2021	100,000 USD
--------	--	---	-------------	-------------

Contact Name	Joanne Westphal
Contact Telephone	202-572-7756
Contact Email	foundation@phrma.org

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 01-Feb-2021 Synopsis Research Starter Grants offer financial support to individuals beginning independent research careers at the faculty level. This program provides a research grant of \$100,000 for one year.				
061525	Postdoctoral Fellowships in Health Outcomes	Pharmaceutical Research & Manufacturers of America (PhRMA) Foundation		01-Feb-2021	110,000 USD
	Contact Name Joanne Westphal Contact Telephone 202-572-7756 Contact Email foundation@phrma.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 01-Feb-2021 Synopsis This award supports individuals engaged in a research training program that will extend their credentials in health outcomes research and will strengthen representation of health outcomes research in schools of pharmacy, medicine, nursing and public health.				
010211	Franco-American Medical Exchanges Grants	Philippe Foundation, Inc.		28-Feb-2021	Not Specified
	Contact Name Claire Waiss Contact Telephone 212-687-3290 Contact Email philippefoundation@fourpointsam.com Sponsor Website Link to sponsor website				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 28-Feb-2021 , 31-May-2021 , 31-Aug-2021 , 30-Nov-2021</p> <p>Synopsis The purpose of the Philippe Foundation is to encourage, assist, aid and support scientific and medical activities and research by giving grants to doctors and scientists (post-graduates) interested in exchange programs between France and the United States, specifically in medical laboratories.</p>				
080370	PKD Foundation Fellowship	Polycystic Kidney Disease Foundation (Marked for Deletion)		18-Jan-2021	120,000 USD
	<p>Contact Name</p> <p>Contact Telephone 816-931-2600</p> <p>Contact Email research@pkdcure.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 18-Jan-2021</p> <p>Synopsis The PKD Foundation's principal mission is to support basic, translational and clinical research that will benefit patients with autosomal dominant and autosomal recessive polycystic kidney disease (ADPKD and ARPKD). The Award of \$60,000 per year will be provided for two years (grant total of \$120,000).</p>				
022929	Research Medical Student Grant	Radiological Society of North America		03-Feb-2021	3,000 USD
	<p>Contact Name Brittni Cartalino</p> <p>Contact Telephone 1-630-590-7789</p> <p>Contact Email bcartalino@rsna.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 03-Feb-2021</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	This R&E Foundation grant gives medical students the opportunity to gain research experience in medical imaging while they're still in school. Recipients will define objectives, develop research skills and test hypotheses, all before even choosing a residency program. Ultimately, this experience gives students a chance to consider academic radiology as a future career option. In order to attract the brightest young researchers to radiology, the Foundation will award up to 10 additional grants for medical students who identify as minorities underrepresented in medicine (UIM).			
090603	RSNA/AUR/APDR/SCARD Radiology Education Research Development Grant	Radiological Society of North America		11-Jan-2021	10,000 USD
	Contact Name				
	Contact Telephone	630-571-7816			
	Contact Email				
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)				
	Synopsis	RSNA awards grants of up to \$10,000 to encourage innovation and improvement in health sciences education by providing research opportunities to individuals in pursuit of advancing the science of radiology education. In addition, this program will help build a critical mass of radiology education researchers and promote the careers of persons advancing the science of radiology education.			
063066	Derek Harwood-Nash International Education Scholar Grant	Radiological Society of North America		11-Jan-2021	75,000 USD
	Contact Name	Keshia Osley, Assistant Director, Grant Administration			
	Contact Telephone	630-571-7816			
	Contact Email	rmurray@rsna.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
<div style="display: flex; justify-content: space-between;"> <div style="width: 20%;"> <p>Deadline Dates (ALL)</p> <p>Synopsis</p> </div> <div style="width: 80%;"> <p>This grant funds investigators looking to affect radiology education around the world. All projects are eligible for funding as long as they are on an international scale.</p> </div> </div>					
016946	Research Resident/Fellow Grant Program	Radiological Society of North America		15-Jan-2021	Not Specified
<div style="display: flex; justify-content: space-between;"> <div style="width: 20%;"> <p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> <p>Synopsis</p> </div> <div style="width: 80%;"> <p>Brittini Cartalino</p> <p>630-590-7789</p> <p>bcartalino@rsna.org</p> <p>Link to sponsor website</p> <p>Link to program URL</p> <p>15-Jan-2021</p> <p>The RSNA Research Resident/Fellow Grant provides young investigators an opportunity to gain further insight into scientific investigation and to gain competence in research techniques and methods in anticipation of establishing a career in academic radiologic science. Recipients will devote a minimum of 50% of their time in the approved research project under the guidance of a scientific advisor/mentor.</p> </div> </div>					
044536	Fellowship Grants	Rally Foundation		11-Jan-2021	100,000 USD
<div style="display: flex; justify-content: space-between;"> <div style="width: 20%;"> <p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email</p> <p>Sponsor Website</p> <p>Program URL</p> <p>Deadline Dates (ALL)</p> </div> <div style="width: 80%;"> <p>Leigh Anna Lang</p> <p>404-847-1270</p> <p>Leighanna@RallyFoundation.org</p> <p>Link to sponsor website</p> <p>Link to program URL</p> </div> </div>					

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The Rally Foundation is administrating collaborative pediatric research awards, including a Fellowship. Fellowship Grants are available for one or two years of support. Each funded grant will be awarded up to \$50,000 per year.			
044280	Young Investigator and Independent Investigator Research Grants	Rally Foundation		11-Jan-2021	100,000 USD
	Contact Name	Leigh Anna Lang			
	Contact Telephone	404-847-1270			
	Contact Email	Leighanna@RallyFoundation.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)				
	Synopsis	Young Investigator and Independent Investigator Grants are for one or two years of support. Each funded grant will be awarded up to \$50,000 per year.			
057069	Consortium Grants	Rally Foundation		11-Jan-2021	200,000 USD
	Contact Name				
	Contact Telephone	404-847-1270			
	Contact Email	Leighanna@RallyFoundation.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)				
	Synopsis	Consortium Grants are intended to provide support to three or more institutions collaborating on a grant-supported research project. Grants are for one or two years of support. At the end of the award, recipients may apply for additional funding the next grant cycle. Each funded grant will be awarded up to \$100,000 per year.			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
017807	RSA Distinguished Researcher Award	Research Society on Alcoholism		31-Jan-2021	Not Specified														
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; border-right: 1px solid black;">Contact Name</td> <td>Debra Sharp</td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Telephone</td> <td>512-454-0022</td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Email</td> <td>DebbyRSA@sbcglobal.net</td> </tr> <tr> <td style="border-right: 1px solid black;">Sponsor Website</td> <td>Link to sponsor website</td> </tr> <tr> <td style="border-right: 1px solid black;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="border-right: 1px solid black;">Deadline Dates (ALL)</td> <td>31-Jan-2021</td> </tr> <tr> <td style="border-right: 1px solid black;">Synopsis</td> <td>This award recognizes a senior researcher who has made outstanding scientific contributions to the alcohol field.</td> </tr> </table>						Contact Name	Debra Sharp	Contact Telephone	512-454-0022	Contact Email	DebbyRSA@sbcglobal.net	Sponsor Website	Link to sponsor website	Program URL	Link to program URL	Deadline Dates (ALL)	31-Jan-2021	Synopsis	This award recognizes a senior researcher who has made outstanding scientific contributions to the alcohol field.
Contact Name	Debra Sharp																		
Contact Telephone	512-454-0022																		
Contact Email	DebbyRSA@sbcglobal.net																		
Sponsor Website	Link to sponsor website																		
Program URL	Link to program URL																		
Deadline Dates (ALL)	31-Jan-2021																		
Synopsis	This award recognizes a senior researcher who has made outstanding scientific contributions to the alcohol field.																		
017844	RSA Early Career Investigator Award	Research Society on Alcoholism		31-Jan-2021	Not Specified														
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; border-right: 1px solid black;">Contact Name</td> <td>Debra Sharp</td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Telephone</td> <td>512-454-0022</td> </tr> <tr> <td style="border-right: 1px solid black;">Contact Email</td> <td>debbyrsa@sbcglobal.net</td> </tr> <tr> <td style="border-right: 1px solid black;">Sponsor Website</td> <td>Link to sponsor website</td> </tr> <tr> <td style="border-right: 1px solid black;">Program URL</td> <td>Link to program URL</td> </tr> <tr> <td style="border-right: 1px solid black;">Deadline Dates (ALL)</td> <td>31-Jan-2021</td> </tr> <tr> <td style="border-right: 1px solid black;">Synopsis</td> <td>This award recognizes an early career investigator who has demonstrated research excellence, potential to be a future leader, and a commitment to the alcohol field.</td> </tr> </table>						Contact Name	Debra Sharp	Contact Telephone	512-454-0022	Contact Email	debbyrsa@sbcglobal.net	Sponsor Website	Link to sponsor website	Program URL	Link to program URL	Deadline Dates (ALL)	31-Jan-2021	Synopsis	This award recognizes an early career investigator who has demonstrated research excellence, potential to be a future leader, and a commitment to the alcohol field.
Contact Name	Debra Sharp																		
Contact Telephone	512-454-0022																		
Contact Email	debbyrsa@sbcglobal.net																		
Sponsor Website	Link to sponsor website																		
Program URL	Link to program URL																		
Deadline Dates (ALL)	31-Jan-2021																		
Synopsis	This award recognizes an early career investigator who has demonstrated research excellence, potential to be a future leader, and a commitment to the alcohol field.																		
017850	Henri Begleiter Excellence in Research Award	Research Society on Alcoholism		31-Jan-2021	Not Specified														
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; border-right: 1px solid black;">Contact Name</td> <td></td> </tr> </table>						Contact Name													
Contact Name																			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Contact Telephone	512-454-0022
Contact Email	DebbyRSA@sbcglobal.net
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	31-Jan-2021
Synopsis	This award is given to an individual demonstrating innovation or creativity and excellence in their research and/or to someone whose work has a major impact on the field.

070899	RPB/LCIF Low Vision Research Award	Research to Prevent Blindness		20-Jan-2021	300,000 USD
--------	--	-------------------------------	--	-------------	-------------

Contact Name	Pattie Moran, Director of Grants Administration
Contact Telephone	646-892-9566
Contact Email	pmoran@rpbusa.org
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	20-Jan-2021
Synopsis	The RPB / Lions Clubs International Foundation Low Vision Research Award (LVRA) serves as a catalyst to launch brand new lines of research which target damage to the visual system. The research should seek to answer such questions as: what happens to degraded input and how is it processed; what are the adaptive strategies in the visual pathway in response to visual impairment; how does the brain re-organize itself with visual damage; and how can the visibility of objects be enhanced? The \$300,000 LVRA is payable in two installments, \$150,000 a payment with the second payment contingent upon approval of a 14-month substantive progress report.

075392	Summer Research Experience Program in Oncology	Roswell Park Cancer Institute		31-Jan-2021	4,800 USD
--------	--	-------------------------------	--	-------------	-----------

Contact Name	c/o Adam Kisailus
--------------	-------------------

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone 716-845-2339 Contact Email education@roswellpark.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 31-Jan-2021 , 05-Feb-2021 Synopsis Through this internship experience, first-year medical or PA students will gain either first-hand research or clinical experience by working full-time on an independent clinical or scientific cancer-related research project in their area of interest.				
073243	Ernst Schering Prize	Schering (Ernst) Foundation/ Schering Stiftung		17-Feb-2021	60,500 USD
	Contact Name Dr. Katja Naie Contact Telephone +49 (0)30-20 62 29 62 Contact Email naie@scheringstiftung.de Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 17-Feb-2021 Synopsis The Ernst Schering Prize is awarded annually in the amount of 50,000 EUR to honor scientists worldwide whose pioneering basic research has yielded new, inspiring models or led to fundamental shifts in biomedical knowledge.				
090568	Postdoctoral Fellowships	Science History Institute		08-Feb-2021	45,000 USD
	Contact Name Contact Telephone 215-925-2222 Contact Email fellowships@sciencehistory.org Sponsor Website Link to sponsor website				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Program URL	Link to program URL
Deadline Dates (ALL)	08-Feb-2021
Synopsis	These fellowships reflect the Institute’s commitment to providing career-launching fellowships for recent PhDs and its support for the career diversity initiatives of the American Historical Association and affiliated scholarly societies. The 80/20 postdoctoral fellowship program will enable the Beckman Center’s postdocs to build skills and experience that can enhance their opportunities outside the academy or their work within it.

056778	Structure and Function Summer Institute (SFSI)	Scripps Research Institute		15-Feb-2021	Not Specified
--------	--	----------------------------	--	-------------	---------------

Contact Name	
Contact Telephone	858-784-2819
Contact Email	
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	15-Feb-2021
Synopsis	This NSF Research Experiences for Undergraduates (REU) Site award to Scripps Research located in La Jolla, CA, supports the training of 10 students in a 10-week program that probes the structure and function of macromolecules. This program offers its diverse participants an academic structure that integrates cutting-edge research with professional skills development and faculty mentoring.

071837	Research Grants	SENS Research Foundation		01-Feb-2021	Not Specified
--------	---------------------------------	--------------------------	--	-------------	---------------

Contact Name	
Contact Telephone	650-336-1780
Contact Email	foundation@sens.org

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
<p style="margin-left: 40px;">Sponsor Website Link to sponsor website</p> <p style="margin-left: 40px;">Program URL Link to program URL</p> <p style="margin-left: 40px;">Deadline Dates (ALL) 01-Feb-2021 , 16-Jun-2021 , 18-Aug-2021 , 01-Nov-2021</p> <p style="margin-left: 40px;">Synopsis SRF is uniquely focused on a damage repair approach to treating the diseases of aging. This approach has amazing potential to positively affect the human condition by giving people interventions and treatments that yield more years of healthy, productive life.</p>					
060678	Dr. Ernest J. Ring Academic Development Grant	SIR Foundation		15-Jan-2021	100,000 USD
<p style="margin-left: 40px;">Contact Name</p> <p style="margin-left: 40px;">Contact Telephone 703-691-1805</p> <p style="margin-left: 40px;">Contact Email grants@sirfoundation.org</p> <p style="margin-left: 40px;">Sponsor Website Link to sponsor website</p> <p style="margin-left: 40px;">Program URL Link to program URL</p> <p style="margin-left: 40px;">Deadline Dates (ALL) 15-Jan-2021</p> <p style="margin-left: 40px;">Synopsis The Dr. Ernest J. Ring Academic Development Grant program is designed to provide support to junior interventional radiology faculty members early in their academic careers to allow time for the conduct of research. The goal of this program is to have grant recipients subsequently obtain additional funding from other sources, such as National Institutes of Health (NIH) grants.</p>					
017331	Allied Scientist Training Grant	SIR Foundation		15-Jan-2021	40,000 USD
<p style="margin-left: 40px;">Contact Name Sara Myers</p> <p style="margin-left: 40px;">Contact Telephone 703-691-1805</p> <p style="margin-left: 40px;">Contact Email smyers@sirweb.org</p> <p style="margin-left: 40px;">Sponsor Website Link to sponsor website</p>					

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Jan-2021</p> <p>Synopsis The SIR Foundation Allied Scientist Training Grant is designed to provide support to trainees enrolled in graduate-level training programs that are outside the clinical realm of interventional radiology but are still considered crucial to the future of IR. The goal is to create collaborative research training environments that benefit from the unique perspectives of established scientists and interventional radiologists.</p>				
060679	Academic Transition Grant	SIR Foundation		15-Jan-2021	25,000 USD
	<p>Contact Name</p> <p>Contact Telephone 703-691-1805</p> <p>Contact Email grants@sirfoundation.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 15-Jan-2021</p> <p>Synopsis The Academic Transition Grant is designed for interventional radiologists over the age of 40 who have recently begun academic careers after spending several years in non-academic practice. The grant is intended to facilitate the establishment of a record of independent research by the investigator in order to promote a successful academic career.</p>				
077997	Leah Menshouse Springer Summer Student Program	Siteman (Alvin J.) Cancer Center		18-Jan-2021	6,200 USD
	<p>Contact Name</p> <p>Contact Telephone 800-600-3606</p> <p>Contact Email SCCsummeropportunities@wudosis.wustl.edu</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Deadline Dates (ALL) 18-Jan-2021</p> <p>Synopsis Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine invites undergraduate, graduate, and medical students to participate in the Leah Menshouse Springer Summer Opportunities Program. The Summer Opportunities Program is designed to provide students with hands-on cancer research experience for 10 weeks over the summer.</p>				
087014	High Impact Research Award	Sjogrens Syndrome Foundation, Inc.		01-Feb-2021	75,000 USD
	<p>Contact Name</p> <p>Contact Telephone 800-475-6473</p> <p>Contact Email</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Feb-2021</p> <p>Synopsis This award will support more fully developed research proposals, which should already have the necessary preliminary data and methodology in place to move forward into the next phase of the project.</p>				
059455	Pilot Research Award	Sjogrens Syndrome Foundation, Inc.		01-Feb-2021	25,000 USD
	<p>Contact Name</p> <p>Contact Telephone 301-530-4420</p> <p>Contact Email research@sjogrens.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Feb-2021</p> <p>Synopsis The Sjögren's Foundation Pilot Research Award will assist investigators in conducting feasibility studies, collecting preliminary data, or other research assistance necessary to advance their project and should help prepare them to</p>				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

pursue additional, larger forms of grant funding.

076606	Karen and Josef E. Fischer International Traveling Fellowship for Surgeons in Academic Practice	Society for Surgery of the Alimentary Tract		26-Jan-2021	5,000 USD
--------	---	---	--	-------------	-----------

Contact Name	
Contact Telephone	978-927-8330
Contact Email	admin@SSAT.com
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	26-Jan-2021
Synopsis	The goal of this Traveling Fellowship is to promote interaction and learning among SSAT Members working in academic practice environments with gastrointestinal surgeons in academic practice in other countries.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

094591	Carol and Tom DeMeester Traveling Fellowship for Surgeons within the U.S. or Canada	Society for Surgery of the Alimentary Tract		23-Feb-2021	5,000 USD
--------	---	---	--	-------------	-----------

Contact Name	
Contact Telephone	978-927-8330
Contact Email	admin@SSAT.com
Sponsor Website	Link to sponsor website
Program URL	Link to program URL
Deadline Dates (ALL)	23-Feb-2021
Synopsis	The goal of this traveling fellowship is to promote interaction and learning among SSAT members within the United

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	States or Canada. The travelling fellow will visit a University-affiliated or academic practice of his/her choosing, within the United States or Canada, for a period of 6 to 10 days, under the sponsorship of a Society member at the hosting institution. A stipend of up to \$5,000 will be provided to the Traveling Fellow, to defray reasonable costs for travel, lodging and meals.				
066849	Mentored Clinical Scientist Research Career Development Award (K08)	Society for Vascular Surgery		12-Feb-2021	Not Specified
	Contact Name	Jane D. Scott			
	Contact Telephone	301-435-0535			
	Contact Email	scottj2@nhlbi.nih.gov			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	12-Feb-2021 , 12-Jun-2021 , 12-Oct-2021			
	Synopsis	The SVS Foundation offers this award in partnership with the NHLBI as a means to facilitate the research career development of individuals pursuing a career in vascular research. This award provides financial support over and above that offered by the NHLBI K08 mechanism.			
001382	St. Baldrick's Scholars (Career Development Award)	St. Baldrick's Foundation		19-Feb-2021	330,000 USD
	Contact Name	Laura Chung, Director of Grants Administration			
	Contact Telephone	626-792-8247 x236			
	Contact Email	Laura@StBaldricks.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	19-Feb-2021			
	Synopsis	The St. Baldrick's Scholars program is a career development award aimed at helping develop the independent research			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		<p>of highly-qualified individuals still early in their careers (no more than seven years as a faculty member, post-fellowship). This is an early-career award. The Scholar award is intended to develop the independent pediatric cancer research careers of highly qualified investigators, not to support well established or senior investigators.</p>			
010754	Summer Scholars Program	Stowers Institute for Medical Research		01-Feb-2021	4,000 USD
	Contact Name	Ana Pedraza, Ph.D., Summer Scholars Program Coordinator			
	Contact Telephone	816-926-4400			
	Contact Email	studenttrainingprograms@stowers.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Feb-2021			
	Synopsis	<p>The Stowers Summer Scholars Program offers undergraduate students the opportunity to become immersed in a research topic for a full-time minimum 8-week period and experience firsthand the intellectual and collaborative spirit of research. Hands-on research for undergraduate students currently pursuing a degree in the biological and physical sciences are available during the academic year.</p>			
075167	Summer Training Program	Strong Children's Research Center		26-Feb-2021	3,000 USD
	Contact Name	Erik Abell			
	Contact Telephone	585-273-2977			
	Contact Email	scrc@urmc.rochester.edu			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	26-Feb-2021			
	Synopsis	<p>The Strong Children's Research Center's Summer Training Program provides opportunities for outstanding medical,</p>			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount														
	graduate and undergraduate students who plan to pursue a career in biomedical or clinical research. This program is created to develop fundamental skills in various research methodologies in a defined project, leading to an end-of-summer poster and, possibly, a scientific publication. The 2021 program is expected to run from June 1, 2021 through August 5, 2021, but may be subject to change depending on the COVID pandemic.																		
058379	Swedish Institute Scholarships for South Africa (SISSA)	Swedish Institute		15-Jan-2021	Not Specified														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 10px;">Contact Name</td> <td></td> </tr> <tr> <td>Contact Telephone</td> <td>+46(0)8 453 7800</td> </tr> <tr> <td>Contact Email</td> <td>si@si.se</td> </tr> <tr> <td>Sponsor Website</td> <td>Link to sponsor website</td> </tr> <tr> <td>Program URL</td> <td>Link to program URL</td> </tr> <tr> <td>Deadline Dates (ALL)</td> <td>15-Jan-2021 , 18-Feb-2021</td> </tr> <tr> <td>Synopsis</td> <td>The Swedish Institute will allocate up to 10 scholarships for South African citizens attending master's studies at a Swedish university starting in the autumn semester 2021.</td> </tr> </table>					Contact Name		Contact Telephone	+46(0)8 453 7800	Contact Email	si@si.se	Sponsor Website	Link to sponsor website	Program URL	Link to program URL	Deadline Dates (ALL)	15-Jan-2021 , 18-Feb-2021	Synopsis	The Swedish Institute will allocate up to 10 scholarships for South African citizens attending master's studies at a Swedish university starting in the autumn semester 2021.
Contact Name																			
Contact Telephone	+46(0)8 453 7800																		
Contact Email	si@si.se																		
Sponsor Website	Link to sponsor website																		
Program URL	Link to program URL																		
Deadline Dates (ALL)	15-Jan-2021 , 18-Feb-2021																		
Synopsis	The Swedish Institute will allocate up to 10 scholarships for South African citizens attending master's studies at a Swedish university starting in the autumn semester 2021.																		
098518	Clinical Research Training Scholarship in Tourette Syndrome	Tourette Association of America		01-Feb-2021	130,000 USD														
	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%; padding-right: 10px;">Contact Name</td> <td>Leo Neuringer, Program Associate</td> </tr> <tr> <td>Contact Telephone</td> <td>718-224-2999</td> </tr> <tr> <td>Contact Email</td> <td>leo.neuringer@tourette.org</td> </tr> <tr> <td>Sponsor Website</td> <td>Link to sponsor website</td> </tr> <tr> <td>Program URL</td> <td>Link to program URL</td> </tr> <tr> <td>Deadline Dates (ALL)</td> <td>01-Feb-2021</td> </tr> <tr> <td>Synopsis</td> <td>This award aims to recognize the importance of good clinical research and to encourage young investigators in clinical studies related to Tourette Syndrome.</td> </tr> </table>					Contact Name	Leo Neuringer, Program Associate	Contact Telephone	718-224-2999	Contact Email	leo.neuringer@tourette.org	Sponsor Website	Link to sponsor website	Program URL	Link to program URL	Deadline Dates (ALL)	01-Feb-2021	Synopsis	This award aims to recognize the importance of good clinical research and to encourage young investigators in clinical studies related to Tourette Syndrome.
Contact Name	Leo Neuringer, Program Associate																		
Contact Telephone	718-224-2999																		
Contact Email	leo.neuringer@tourette.org																		
Sponsor Website	Link to sponsor website																		
Program URL	Link to program URL																		
Deadline Dates (ALL)	01-Feb-2021																		
Synopsis	This award aims to recognize the importance of good clinical research and to encourage young investigators in clinical studies related to Tourette Syndrome.																		
077661	Young Investigator Award	Tourette Association of America		01-Feb-2021	160,000 USD														

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone 718-224-2999</p> <p>Contact Email leo.neuringer@tourette.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 01-Feb-2021</p> <p>Synopsis The Tourette Association of America (TAA) aims to encourage early career researchers to invest their efforts and expertise in increasing our biological understanding of Tourette Syndrome (TS), pursuing clinical research aimed at improving patient care, and developing and testing new therapies.</p>				
064015	Translational Research Institute for Space Health (TRISH) - Postdoctoral Fellowship	Translational Research Institute for Space Health	TRISH-RFA-2101-PD	28-Jan-2021	60,000 USD
	<p>Contact Name Kristin M. Fabre, PhD. Chief Scientist</p> <p>Contact Telephone 713-357-1038</p> <p>Contact Email SpaceHealth-Info@bcm.edu</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 28-Jan-2021</p> <p>Synopsis TRISH is soliciting proposals from postdoctoral researchers ready to help solve the health challenges of human deep space exploration. This postdoc program supports early-career scientists pursuing disruptive, breakthrough research with the potential to reduce risks to astronaut health and performance. Selected fellows will receive a stipend for salary support, an allowance for health insurance and funds for travel to related scientific meetings. Applicants must submit research proposals together with an identified mentor and institution.</p>				
100584	Challenges	Trinity Challenge		30-Jan-2021	Not Specified

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	<p>Contact Name</p> <p>Contact Telephone</p> <p>Contact Email questions@thetrinitychallenge.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 30-Jan-2021 , 30-Apr-2021</p> <p>Synopsis The Trinity Challenge is set across three areas designed to reflect the most pressing needs for building preparedness for resilience in health emergencies. People from across the world are encouraged to form Challenge Teams and submit applications that respond to these questions with their ideas and innovations. Successful applications will receive support from Members to develop their solutions. Applicants will benefit from the data, resources and support of The Trinity Challenge’s global coalition. Categories include: Identification; Response; and Recovery.</p>				
036310	Research Career Development Awards	Triological Society		31-Jan-2021	40,000 USD
	<p>Contact Name Gail Binderup</p> <p>Contact Telephone 402-346-5500</p> <p>Contact Email info@triological.org</p> <p>Sponsor Website Link to sponsor website</p> <p>Program URL Link to program URL</p> <p>Deadline Dates (ALL) 31-Jan-2021</p> <p>Synopsis The purpose of this award is to provide support for the research career development of otolaryngologists-head and neck surgeons whose projects have specific application in the field of otolaryngology-head and neck surgery.</p>				
026402	Taubman Prize for Excellence in Translational Medical Science	University of Michigan		01-Feb-2021	100,000 USD
	Contact Name				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone 734-615-7282 Contact Email TaubmanPrize@TaubmanInstitute.org Sponsor Website Link to sponsor website Program URL Deadline Dates (ALL) 01-Feb-2021 Synopsis This award is presented every other year to recognize work in the crucial field of translational research being conducted by the clinician-scientist who has done the most to transform laboratory discoveries into clinical applications for patients suffering from disease.				
019817	Graduate Student Research Recognition Award	Wildlife Disease Association (WDA)		26-Feb-2021	5,000 USD
	Contact Name Contact Telephone 800-627-0326 Contact Email tgrillo@wildlifehealthaustralia.com.au Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 26-Feb-2021 Synopsis This award is given to the student judged to have the best research project in the field of wildlife health or disease. The winner receives between \$2,500 to \$5,000 US to cover travel, housing, registration, and similar expenses related to the annual international WDA conference plus 1-year's WDA membership (Student or Regular Member Worldwide Online).				
019896	Terry Amundson Student Presentation Award	Wildlife Disease Association (WDA)		26-Feb-2021	350 USD
	Contact Name Tiggy Grillo, Chair Contact Telephone 800-627-0326 Contact Email tgrillo@wildlifehealthaustralia.com.au				

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	26-Feb-2021			
	Synopsis	This award acknowledges outstanding oral presentation of research findings at the annual international WDA conference.			
013027	Research Training Program - Geriatric Clinical Epidemiology and Aging-Related Research (T32)	Yale University School of Medicine		29-Jan-2021	Not Specified
	Contact Name	Ms. Robbin Bonanno, Fellowship Coordinator			
	Contact Telephone	203-688-5238			
	Contact Email	robbin.bonanno@yale.edu			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	29-Jan-2021			
	Synopsis	Yale University offers a two to three year training program in Geriatric Clinical Epidemiology and Aging-Related Research, sponsored by the National Institute on Aging.			
024768	Collaborative Research Grants	Zoos Victoria		15-Jan-2021	Not Specified
	Contact Name	Dr Michael Magrath, Senior Research Manager, Wildlife Conservation & Science			
	Contact Telephone	+61-3 9340 2752			
	Contact Email	research@zoo.org.au			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	15-Jan-2021 , 19-Mar-2021 , 21-May-2021 , 23-Jul-2021 , 17-Sep-2021 , 12-Nov-2021			

Non Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	----------------

Synopsis | Zoos Victoria welcomes collaborative research proposals. These could involve the use of Zoos Victoria resources, active collaboration with Zoos Victoria staff or independent research at one of Zoos Victoria's three properties: Melbourne Zoo, Werribee Open Range Zoo or Healesville Sanctuary.